<SEC-DOCUMENT>0001370053-21-000056.txt : 20210809
<SEC-HEADER>0001370053-21-000056.hdr.sgml : 20210809
<ACCEPTANCE-DATETIME>20210809161338
ACCESSION NUMBER:		0001370053-21-000056
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210809
DATE AS OF CHANGE:		20210809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO, INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37985
		FILM NUMBER:		211156641

	BUSINESS ADDRESS:	
		STREET 1:		10770 WATERIDGE CIRCLE, SUITE 210
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10770 WATERIDGE CIRCLE, SUITE 210
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYSBIO INC
		DATE OF NAME CHANGE:	20080828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>anab-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:c7655f00-1548-4625-8cd9-c93812026c41,g:f65e361e-f377-49d6-802f-d6fad364b94f,d:e2789247198f4cf1b60b048da420eb52--><html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:anab="http://www.anaptysbio.com/20210630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>anab-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF80LTEtMS0xLTA_07a4f7c6-9e30-4642-b781-af6c558747e3">0001370053</ix:nonNumeric><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF81LTEtMS0xLTA_b2282552-5558-4723-905e-e0c512318707">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF82LTEtMS0xLTA_778be727-15ef-48fe-9b03-78bf51661d10">2021</ix:nonNumeric><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF83LTEtMS0xLTA_eb38e083-bff9-4db7-9ee2-7990922a8265">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF84LTEtMS0xLTA_86ce3f8b-266d-497c-ac69-ad43f4bb7e4f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_0ace4234-c65a-4b90-89b7-b121fc84c601">http://www.anaptysbio.com/20210630#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_2f59a2c7-ef6d-4596-9c6c-0bde0d2eb86e">http://www.anaptysbio.com/20210630#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_48bd1fc1-422b-4ce5-9e49-3270208864cc">http://www.anaptysbio.com/20210630#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_a4aa99ec-e447-4b6c-88d1-348a79a7aa89">http://www.anaptysbio.com/20210630#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="i08c80bb1f49f4b5bafd1241939a88605_D20210101-20210630" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU2OQ_2c6af718-21cf-4692-a2d3-b58b8b1319f6">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i881cf8050b394e0682d0acff78aa7d9c_D20210101-20210630" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcxNA_0f49c841-e469-4cdb-9e94-1d8fc6721bf2">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ia309061dd36448469b328ecf3c762679_D20200101-20201231" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwMg_8efbf14a-390d-4a61-8d2e-efb73efed063">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i2fdc2c8d4dd1467f8757e49958c27417_D20200101-20201231" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ1NQ_25069077-64eb-4770-a079-0932cb57d201">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i57cbe5ce58ef4a0eb06ff307f39465a7_D20200101-20201231" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyMA_ca5315b3-0237-444d-96a1-9e4abab3f521">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ia50950aa6de04e559cb7c6cb70e4a3be_D20200101-20201231" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc3NA_1f934835-43a2-4d2e-869c-8b6ff5fa0e3d">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="anab-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4308818b5a0a4b6a9dc093c01b5bf5a2_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66483ee3f39e44a3aaf565221c3c7873_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie61ef44ef0874171870af019d2a30f6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee911f281b4c476f9c39c369d300a1b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie18fcf4f5df24767b6bbe988f6fdad48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed6ec8bf45a4cd0aa3ee9a5c90c681c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3d053c201649c798018f2b53f729cb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2278fb08662b4d1b8fd10ab11f525ee7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b1fdd751a94267ae3ebfa67f9a7b34_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3653550b703940c4a4851c44af5f43b7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863d80faf8674ff9bb6b825aac12e27b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d35a18ba42945f887b212ef18ac78b9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce013027a2041b0a49e202ddcfe2040_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc32bd3c09c4088810c227718709561_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d411a7cb224c5ebbb4ac4d0c70b7ac_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i815cd3ad41474aa89bdbc8aac7df75ff_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af639e68aed46ceaadf61c50fa22b6c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i558e5a32ec2d4a419c4b11583520ee8a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided6cc631fa347f29afdeec8dc63dfa2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdb0c2fd7a1425b88540d8ab89e49ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7208ae669f5a4129b42fd35dfa7a6c27_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4c209b6991485097f5062d7e179388_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb2028cc405d4c44936f5ed145a50dbf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4641429f60564692a060512d8c74558a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4663eb93a648168c61a81e9457dc1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142b163e653d4a9cba36852e354d5a57_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d07597b3dc4975a4fe06e498a5d3e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd7946500014e7a935d20e4d9049cab_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90cec4c950e344009abf72bee3271d18_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i357b6498c5d9488bb080175359e876e9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida9c210ea8494148835c51d4ce0d58f1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b05a125a4494bb5ab7cdbe086bdd21c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb913f721294b8fbd1c537aae3279a9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4615342e0d54465853cf7d151fdec12_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d8e92fdf0848f5a09451c6582b0d02_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i226bcfccf34e4b0bba7f77efd6749232_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd22ef257044497bb6129f2ee1efd43_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f83c27a2f24bcf960cbb189259177b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d26b66b1c74404b1a4ad9a12346650_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if46ccc6f74854042980a58a0f048852f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64512e583b524f5fbae03573f01e4425_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bf867918fb40f2ade51bfcba942241_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e42fc0c6ff14036a66064c60d7832a5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0daff577f8ae408693a9f6c34fbe73ce_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386a0a6a5d9e4bd8ad62ba1339a4e448_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfc960c533644748967278a36e67af20_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>anab:segment</xbrli:measure></xbrli:unit><xbrli:context id="i54e09947d78640e4b9eeb147c43743aa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ddd91f6523469eb8f7ad820f2b8764_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1487ca8ec2e24d4fba6469fa2aa23d66_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4217decdbe45471ca7c606434d0632c0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b92baa04c8b4070987a2e921dbaafa4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a1dc7356a94c6eb2c2452e7957ebe8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b552c03f74142c287d50400a1538790_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i593bf7da05f24f8a88e6e1f64037cce7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c0631bdcfa94b9182f6f5cfe8b439b3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c4a40293897411dad729dd8d12a9b9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6bb85d544044f74be91e6c4ded1291a_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>anab:target</xbrli:measure></xbrli:unit><xbrli:context id="if23f0b3a9c1543389445ca1f2a582eb5_I20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i443e38b29ed84f36aeff8d125942ff3c_I20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6137734596471eb3bfbea0e8c29f72_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8cde62162f4437eb22081031e78c481_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i47989d6424ad4d9ab848e3e615102bac_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedZejulaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb9fa8ebdf074b57a099e54ad0196d1d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40e9b7e255a4b9b918086d940de14a0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedZejulaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>anab:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i44529c9832924677ab0905ad04031c28_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a47cb5a3684fb9965f688e81d082de_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationFirstIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e884c92e4248ebb969f8b647ff98db_D20150401-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id039343680da47d7af05ac3697ed6412_D20151001-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d312a71cb6944cda527675f2fbd0a55_D20160701-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3GSK40974386Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f3dd66d4c24741b2a7ded6059d960e_D20160101-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91888314abeb436d827a581cdd98c07c_D20160401-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ad61a6cdfc4838b66812099ad185db_D20170401-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3GSK40974386Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d52b0d15c6a49759798e25fe838631e_D20170401-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69938c04553e464db0b8b7c7704d1867_D20171001-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97554db485364f75b7e7a0213d8a4225_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3GSK40974386Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7184beea9df1436ba28682c84638c335_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationFirstIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2aeffac54924963b1bf3dc19fca0a21_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationSecondIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7140062cc12f4f01acbb92e93e19466c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingOfBLAFirstIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4353bed79fb8420982f9675d50f0e0b6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingOfMMAFirstIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bc779cbb0dd4b988a625b412a15a49c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingOfBLASecondIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2241e34e4b2493cb520e2f1469c8282_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FirstBLAApprovalDMMRECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac11f17d0664ef6b0b60ad3b9f2d76d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FirstMAAApprovalFirstIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6011ad3b1c6b44a885a7bd57000ca6be_D20110101-20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcb6477f9a49486ab46021a396ff7561_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59da14b2fe8548e5870e1779cc0aa9d0_D20160401-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a55c463e33c4afab95cb2149af0e3ce_D20161001-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase1ClinicalTrialInitiationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa80869592e640d389371d71f073f337_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c2ff1aec104594b36f1b5f8e2a3e4a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6413c5f064d49babec39642d4b164a5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id77469bf2efe425dac416b31a411d04b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9133e4132b240e7bca2e1c95471892e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5399bd92b9e4cf693eb263ebaa5e180_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e2dfb981084eb1a6ddf8ebc09962d3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e78cb67f53f47f3b1937709b61ee528_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5641bee18d3141bda9c26e4ca72e89b6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288736d64ff04b0ab6b16af4d6d2b14a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8414801a345a4cd4ab3c203b8ec660a9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee60ae93525403795b2bac324fca5a6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ef14c2603b489b847974efac36accf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6ade6ba8d441b5a2642b21f097a179_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab16caf39c34c8eb91ade5ed0af706b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9275bf5a2daa483ba130b781fc58af8a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id13ee5fb8cf54c68859bac354f7a79d8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6704368d964ed69d2439d929ef4748_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c4a55ee9124b8bac3e70be46d12bc4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eeb2688caf9475dacc5b156e4b9ebcc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61b8a35c442e40f59ff35f5aab9e1ca4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a862142bb64348860dc4025bb374fc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e9b6fa28a604b77aa8d086a61c3002a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc0beaf432b417aa88fa1f2d048adb7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifad4b811111a4959a97b530f3e1edc30_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2efedcdd907841bdb7b475cccdb198dc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d7c88a334a4713960dc3460eb06106_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5ed2e6efa94819b8a0fb85e74275d6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8725cde7bd3b4b58934b4ecdcef2816a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6944b71b72a84436a68e5213fe6df51a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad391a709b144bd48d2872b283602f84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9067efbd18c467aad2eebbaff82cfc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3519bdb64f8b4b6d8efc1c5e46616753_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3adfb85bf6451c9575bc0e8d008d13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id81d1d57d00941ff976792c032f7c601_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b9e3d355a14ac49a01d376ea60f2a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2037e57e85fb441b94c20fe503046463_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id812dbcc01ba448783f4b7ace47357b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c66084d39744f29e968164be5da8b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9802e6239684804a3dc3860a653719b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifea2879f95c041cd895eda44820f8624_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eae37d2da574506ba4e102853287bd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3081867d37934fefb8be59e85e8c7a4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i051c714be443417780719d2eb4b53ea9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674430e3d2c341c8a6df0759fb0fbd73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12aa4229eb9f4c2fa7c9289e272467c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c3ef9e7fdb4ea2b3bfd0ac0a4f062b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454b38ab8bdc449cad61e6eb5af78756_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bdd900a94544d0bbba160586a6eb58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51217ad1af3e4ebda21a0ad07210b827_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ec26d7834be4c8abd097426fd877cb2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07640a2359445eba2a41ae90501863f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13528acc7aef4f81ae58f9b16746d0fe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b72c1bc28e426696c80f01a5640e80_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i711fd5f10f4e49a58b560bb507d95052_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45f7ba855861405cbd820fb0f83d8611_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c80bb1f49f4b5bafd1241939a88605_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d163026a6654743b9979520a3af47aa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b96a7f246684ad1800b51d91e9a69b8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i881cf8050b394e0682d0acff78aa7d9c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e188f2a2fc40cdb0ad1ad5fc3d9224_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f6372c975642c8b721a357169c41f7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i392569839eab4af895cd18151a8a634b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d6272b78fc4eaf908301d14bb663d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia309061dd36448469b328ecf3c762679_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a331153831844abb1eef1d1c1087186_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fdc2c8d4dd1467f8757e49958c27417_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d5876a7ef54861bdd2687c9d49d1e8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57cbe5ce58ef4a0eb06ff307f39465a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic24b2a7ad667476c99b89caed4bc0d88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50950aa6de04e559cb7c6cb70e4a3be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da7cac937d44fb19c0b0d2f90db8d5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i440d9f4d37024e65a225809024ed80f1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f2dd192f9145a1bcc410371db79135_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754f18c3eac04b658b8b6ed077314e68_D20180101-20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4866424e06474a119edf3063462a6832_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b08700ca1748b2afd4fa071b355893_D20180101-20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69a7ed7bd244d29905de3cacf88167f_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197e760b801d4f73b5d6e406c4027a35_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb3a9fe237f347e39f34d734ffdf3d9c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i626d95b570df4e1abdac73a6a2e718d0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib16d46e48de9476ca69ec729d02ab7f7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b921f1f24c4c54bb6d506c5e62de1f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79408e23b2ef4790851584643cf1fd31_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4c03b9afe14b17a08c26f39c61ee23_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c0c2bd7cd84e75ba87c7188ac5cb04_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1bf654bbd4e431098303b2f5ba09a92_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5753215b52c451093ff6ca5ba3c9575_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7e2add807724d19a9e8cbee0dad3919_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie04286dba40e490ebc78cc7952a23570_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3b64ce4f6404458b4b4d2e565325a2d_D20201215-20201215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-15</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c00b90fbbe46ffbed30a2f2233aea7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10455PacificCenterCourtInSanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i1767abcdc9d947d19efb733b02b78b30_I20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769956911bf34bc3babeafd4ff7c179c_D20200504-20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-04</xbrli:startDate><xbrli:endDate>2020-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerSqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib2b8bcbccfe046d982471dc4466417f9_I20210405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb17cf126b4e4598b3ace9ab2298bc16_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie2789247198f4cf1b60b048da420eb52_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjQ0_e83f0dcd-1d51-4f9a-8240-a76d9fcdf0f6">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6NDc0ODBkMjYyMzdjNDI3NTlkZGQ2YTU3OGYwMzZiZDEvdGFibGVyYW5nZTo0NzQ4MGQyNjIzN2M0Mjc1OWRkZDZhNTc4ZjAzNmJkMV8wLTAtMS0xLTA_205529f4-b830-4e24-bf2d-3fc3160163bd">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Quarterly Report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8xMzE_a48adada-b6c7-41be-91ea-d56bd8ba43fa">June&#160;30, 2021</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6YjFkZWFhZDdhYWFkNGZmMDljY2ViYThlY2FkYjVjYjgvdGFibGVyYW5nZTpiMWRlYWFkN2FhYWQ0ZmYwOWNjZWJhOGVjYWRiNWNiOF8wLTAtMS0xLTA_01098f7f-7c9a-40c2-9b0e-45104aaba450">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Transition report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjI5_43ebd00d-efab-416c-ad8c-d58fb4da7ded">001-37985</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjI3_af5a3c8c-74a2-4510-813b-38b74b512f7d">ANAPTYSBIO,&#160;INC</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.005%"><tr><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6MjE0OWZmNTgzYWFlNGFiNDk4MDExNDU1NTkxMzMyNTcvdGFibGVyYW5nZToyMTQ5ZmY1ODNhYWU0YWI0OTgwMTE0NTU1OTEzMzI1N18wLTAtMS0xLTA_59242533-5007-4368-8ea8-22f36ff0517e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6MjE0OWZmNTgzYWFlNGFiNDk4MDExNDU1NTkxMzMyNTcvdGFibGVyYW5nZToyMTQ5ZmY1ODNhYWU0YWI0OTgwMTE0NTU1OTEzMzI1N18wLTItMS0xLTA_8c88a398-bdd2-47fe-a77f-d923be90d120">20-3828755</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM4_9112eb84-4472-44c8-b635-5db8961889ff">10770 Wateridge Circle</ix:nonNumeric>, <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM1_37d6ff45-96cf-4e93-b427-75dc14bbcf17">Suite 210</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM5_a022eda9-2e45-4465-8024-7aa450302517">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM2_28639522-5582-479c-bf10-dfaceb9cbed0">CA</ix:nonNumeric> <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM0_0552f42f-c76b-4dec-93fc-3235cecccc5f">92121</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjQw_fa2aabfc-6470-4335-803f-3159d4c1f7c1">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjMw_a28dcc9d-3edd-41e7-a0ef-8318e63d2240">362-6295</ix:nonNumeric>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6OTFjNGQ5NzY1NjM2NDE3Nzk0N2JjNTlmMTNiMzQ5NDIvdGFibGVyYW5nZTo5MWM0ZDk3NjU2MzY0MTc3OTQ3YmM1OWYxM2IzNDk0Ml8xLTAtMS0xLTA_21c70154-93d5-486e-bcb1-efdd80724d53">Common Stock, $0.001 par value</ix:nonNumeric> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6OTFjNGQ5NzY1NjM2NDE3Nzk0N2JjNTlmMTNiMzQ5NDIvdGFibGVyYW5nZTo5MWM0ZDk3NjU2MzY0MTc3OTQ3YmM1OWYxM2IzNDk0Ml8xLTEtMS0xLTA_66cd6b75-5345-44f4-993b-228916e755ed">ANAB</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6OTFjNGQ5NzY1NjM2NDE3Nzk0N2JjNTlmMTNiMzQ5NDIvdGFibGVyYW5nZTo5MWM0ZDk3NjU2MzY0MTc3OTQ3YmM1OWYxM2IzNDk0Ml8xLTItMS0xLTA_e3031a3c-b833-4c0f-b136-0eaaac9af2f5">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjMz_d8e3d1c0-d8c4-42a6-bfd2-7e150b15e537">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjQy_9da0ecc7-2a90-4175-8760-52eebaddb873">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:22.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large Accelerated Filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;Filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6ODI1NDM2YjM5YTZkNDhiOTk5ZjEyY2EwMTcwZGI0NGYvdGFibGVyYW5nZTo4MjU0MzZiMzlhNmQ0OGI5OTlmMTJjYTAxNzBkYjQ0Zl8yLTAtMS0xLTA_bee65bdf-1981-458a-9a9c-3cebd98bb420">Non-accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;Reporting&#160;Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6ODI1NDM2YjM5YTZkNDhiOTk5ZjEyY2EwMTcwZGI0NGYvdGFibGVyYW5nZTo4MjU0MzZiMzlhNmQ0OGI5OTlmMTJjYTAxNzBkYjQ0Zl8yLTYtMS0xLTA_40c2d9ac-cab1-4b05-bcc2-164c18d5b04e">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6ODI1NDM2YjM5YTZkNDhiOTk5ZjEyY2EwMTcwZGI0NGYvdGFibGVyYW5nZTo4MjU0MzZiMzlhNmQ0OGI5OTlmMTJjYTAxNzBkYjQ0Zl80LTYtMS0xLTA_0e850884-8d82-4d5c-9e27-67ce4c1b536e">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjQz_e75f2d1f-250d-48b2-9ef7-6ed780322491">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August&#160;5, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i4308818b5a0a4b6a9dc093c01b5bf5a2_I20210805" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMTY5_9c880692-faee-48e5-aede-dd5d8f3c0fb2">27,433,359</ix:nonFraction> shares of the Registrant&#8217;s Common Stock outstanding. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:10.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page Number</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I. FINANCIAL INFORMATION</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_13">Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_16">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_16">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_16">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_16">, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_19">Consolidated Statements of Operations and Comprehensive Loss for the Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_19"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_19">Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_19"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_19">June </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_19">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_19">, 2021 and 2020 </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_19">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_22">Consolidated Statements of Stockholders' Equity for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_22">and Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_22">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_22">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_22">, 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_22">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_25">Consolidated Statements of Stockholders&#8217; Equity for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_25">and Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_25">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_25">June </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_25">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_25">, 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_25">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_28">Consolidated Statements of Cash Flows for th</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_28">e </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_28">Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_28">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_28"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_28">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_28">, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_28">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_31">Notes to the Unaudited Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_31">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_67">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_67">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_70">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_70">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_70">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_73">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_73">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_73">30</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II. OTHER INFORMATION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_79">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_79">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_79">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_82">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_82">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_82">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_85">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_85">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_85">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_88">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_88">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_88">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_91">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_91">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_91">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_94">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_94">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_94">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_97">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_97">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_97">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_100">Exhibit Index</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_100">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2789247198f4cf1b60b048da420eb52_103">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie2789247198f4cf1b60b048da420eb52_103">71</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="ie2789247198f4cf1b60b048da420eb52_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Consolidated Financial Statements (unaudited)</span></div><div id="ie2789247198f4cf1b60b048da420eb52_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNC0xLTEtMS0w_59cf4a31-f003-42b1-9648-b476f15e833c">332,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNC0zLTEtMS0w_33f2f357-4df5-4854-ad4a-3ee09749a198">250,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivable from collaborative partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNS0xLTEtMS0w_1496f3c3-f599-401f-bd3a-def821f47eee">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNS0zLTEtMS0w_f6c1e08e-b4ce-482d-9557-874f342fcdcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNi0xLTEtMS0w_d65013f5-031b-4722-a790-e9769a908bda">58,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNi0zLTEtMS0w_d939e4d4-f614-4bd8-bfc8-6c6b8f59e291">143,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNy0xLTEtMS0w_abd18de8-e426-4fe4-a55e-f1271ead430e">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNy0zLTEtMS0w_984e556f-7fe6-4213-839b-0d372680b60f">2,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfOC0xLTEtMS0w_70e50d64-c8e5-41ad-b7b2-ad3e44e479bc">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfOC0zLTEtMS0w_ea093a8d-241f-4160-b548-5980485866c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfOS0xLTEtMS0w_e4553571-3eaf-49ab-84b2-94ef6be3154a">398,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfOS0zLTEtMS0w_fc309f62-be9d-4e57-aed9-68a741750271">396,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTAtMS0xLTEtMA_aefd1b75-3496-4f6b-b3dd-743038947ce0">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTAtMy0xLTEtMA_782147c7-bd76-4b67-a672-70e965a95db9">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTEtMS0xLTEtNzUw_89f8b8d7-dd68-4ca5-a715-49ce5d089cbc">20,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTEtMy0xLTEtNzUz_0e1f4528-d6ea-416a-80f4-4b4e257e4aab">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTEtMS0xLTEtMA_c326d040-ecf6-4972-b2bb-e53231472080">5,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTEtMy0xLTEtMA_fc6f6b5a-8092-4776-bb59-7da8d0aa2d93">17,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTItMS0xLTEtMA_15d36c96-31ae-4f85-b20c-43772d234b4f">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTItMy0xLTEtMA_917753f3-5cf5-4b7c-b19f-950d21331410">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTMtMS0xLTEtMA_e6185ef1-d8dc-4967-ad5f-ac643fbb5c19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTMtMy0xLTEtMA_8dd3a069-8cc4-4656-b778-b236a4ad1e89">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTUtMS0xLTEtMA_164379b1-0850-4f0a-af4f-d4f562ed73e9">426,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTUtMy0xLTEtMA_cfd0fd74-ea75-4e4e-9bb8-dce67f9a4f8a">416,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTgtMS0xLTEtMA_9a4e8f92-607f-4bac-99ef-83375d4f184e">4,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTgtMy0xLTEtMA_a0aad230-0687-4ae3-a5fd-7265afe2b520">4,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTktMS0xLTEtMA_13c9dbe6-1a5b-4c23-be6f-111af68ea332">15,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTktMy0xLTEtMA_c01420cf-d8e1-4001-b61c-98f9ca70689d">15,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMjEtMS0xLTEtMA_c1986110-08cc-41ce-a46b-26ba522e27e3">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMjEtMy0xLTEtMA_f20b9924-b443-47bf-8859-179b91d8d5d9">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMjItMS0xLTEtMA_42da8e50-4739-47db-8da2-62c689c22d62">20,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMjItMy0xLTEtMA_af600110-0e5a-4b2e-8aed-9508217242a9">19,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMS0xLTEtNzU3_ce667c6f-c37e-4e6c-b677-afa07d47e8b2">20,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMy0xLTEtNzc1_e75cf819-4fd3-4955-aa25-bda4be9a40b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIy_cb3b0e4f-fdeb-4565-b4ae-dc8c2f41f79c"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIy_e7a5d0be-437b-4686-9a2f-81acfac6eb1f">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzM2_3f39eaa3-e22c-443c-a687-fcdb0b5fe730"><ix:nonFraction unitRef="shares" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzM2_aa31efac-aa02-481f-b212-38999b6d432f">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIxOTkwMjMyNTU3ODM_529c918b-b398-467c-8217-9ff798ab3bbd"><ix:nonFraction unitRef="shares" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIxOTkwMjMyNTU3ODM_5c9ce06a-efd4-4891-9402-018aeeac096c"><ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIxOTkwMjMyNTU3ODM_a0bf53be-bc56-4590-b900-898c6b3ff93a"><ix:nonFraction unitRef="shares" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIxOTkwMjMyNTU3ODM_f39ce28f-f661-4566-b6a0-4bf76d815c46">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares, issued or outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMS0xLTEtMA_c2abb0db-531e-4942-8c3e-757afaf8b046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMy0xLTEtMA_28cbf662-8057-406b-8512-5fceabd5316d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzE4_54501a9b-72b7-4d9e-ab92-87cdfa2e1630"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzE4_f5827ec5-190e-4322-9532-4b8664c7a00d">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzMy_7d793548-86dd-4ab8-8ab5-808eddd9afca"><ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzMy_b800a47e-ff06-43f8-9a1e-73fb9e756c76">500,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzU0_38b0c300-0feb-462d-9001-51b19094e9a3"><ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzU0_9db4702e-4e22-4a13-b9bc-e375b75f8a13">27,433</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzY4_dfec6ac9-ba4c-4fe2-bbd7-fbb8b41efcf2"><ix:nonFraction unitRef="shares" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzY4_e6b129a6-27af-4436-9608-17e3a05e889c">27,356</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMS0xLTEtMA_ab98971a-805f-48dc-bb98-a5923d4c4a60">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMy0xLTEtMA_e81930d9-98ef-432b-b28d-f6af01e6e286">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzUtMS0xLTEtMA_f8fb0c8c-82b1-42f6-b2bf-9030483a7034">668,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzUtMy0xLTEtMA_dd5cfb69-c592-405b-ac3c-7060ab2e3f35">660,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzYtMS0xLTEtMA_7b00d2b7-ecf4-4c7b-a8ff-a6855f9aae63">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzYtMy0xLTEtMA_ff92597e-fcf3-4976-972d-6ea816402b1b">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzctMS0xLTEtMA_6f7601c4-e5db-4348-8f3c-b7f0d31f4d61">282,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzctMy0xLTEtMA_05b98c1e-a0a9-45ef-ab26-68e4cf966fe5">263,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzgtMS0xLTEtMA_f50fb0e4-e1d6-43b0-b177-3ac3db4b72b0">385,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzgtMy0xLTEtMA_afda8b14-af95-4c99-8c84-a3c81dd8117d">396,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzktMS0xLTEtMA_90dbe814-32dd-4d39-bb9e-2de6d3cbebb4">426,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzktMy0xLTEtMA_20a351b6-4aa2-43dc-bd7b-4263d771c683">416,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See accompanying notes to unaudited consolidated financial statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_0ace4234-c65a-4b90-89b7-b121fc84c601"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_2f59a2c7-ef6d-4596-9c6c-0bde0d2eb86e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_48bd1fc1-422b-4ce5-9e49-3270208864cc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_a4aa99ec-e447-4b6c-88d1-348a79a7aa89">Collaboration revenue</span></span></span></span></span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0xLTEtMS0w_5d43ed17-d214-40ab-909d-6136f80afd97">30,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0zLTEtMS0w_c5d86cf4-6551-4730-93c9-ec56c6ee0dd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy01LTEtMS0w_efca4da4-2bca-4eb7-a713-f685c9a440ad">41,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy03LTEtMS0w_d90537b4-241c-479c-980b-a79fc7fdf487">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfNy0xLTEtMS0w_d028bc33-d510-49ad-ac9b-e32bd4b9c815">25,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfNy0zLTEtMS0w_1bab96cb-d75b-4e92-aa48-a30af3765f5d">17,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfNy01LTEtMS0w_a685b7ef-4b54-42e0-8e44-6e297ebf28e0">49,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfNy03LTEtMS0w_94eedfad-a8d2-4cec-8d47-7af00200bed6">38,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOC0xLTEtMS0w_1df034c2-f524-477e-9aff-544b0dd41c14">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOC0zLTEtMS0w_d4469d94-13cd-48b6-983f-c7af1a7d8ee7">4,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOC01LTEtMS0w_a3afd759-cc6c-4717-9908-4bd40cbb3606">10,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOC03LTEtMS0w_01325767-cda1-4e30-9bff-14e7bcc11054">8,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOS0xLTEtMS0w_45ac841b-1902-4a1e-a05d-ab1f8967870d">30,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOS0zLTEtMS0w_2d402631-fed6-4cf5-8642-e21ecb200b7b">22,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOS01LTEtMS0w_b947faf3-7922-4254-bf63-b1afe45cb1b9">60,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOS03LTEtMS0w_f6e0ec9e-09c7-4d02-9521-d7c3cd36caba">47,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTAtMS0xLTEtMA_e2b7c563-758f-4504-ba7d-bcdb16f471ba">533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTAtMy0xLTEtMA_2086a3a4-136b-4543-91b0-706041815398">22,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTAtNS0xLTEtMA_611c881c-196a-43fa-807a-9dec62ae4118">18,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTAtNy0xLTEtMA_0dcfa988-bbe5-4803-9824-45a163972537">32,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTQtMS0xLTEtMA_25dc1f24-5cf9-4fc7-9f48-780e50bad556">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTQtMy0xLTEtMA_c1062d3c-ea64-4693-b950-faa4f73093d2">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTQtNS0xLTEtMA_65abaa68-dad8-4b86-8fba-f12abee2b577">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTQtNy0xLTEtMA_deafc396-15a3-4c22-952c-05ba8988d35b">2,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTUtMS0xLTEtMA_1e52cc82-ec60-4adb-af5a-1839e5da25b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTUtMy0xLTEtMA_89b7946a-90cb-424d-a9bf-bbc57feee390">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTUtNS0xLTEtMA_26717be7-2a32-46a9-8a33-b2f56d2a7966">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTUtNy0xLTEtMA_ef5b4f2f-5227-4b4d-ae1d-a4b290dec7d6">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTYtMS0xLTEtMA_6f32a55c-2fb2-4b8a-b494-0df8f7408e1d">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTYtMy0xLTEtMA_0955ac7a-4031-4f73-8261-efd082d68807">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTYtNS0xLTEtMA_80836c6a-9299-49c5-bcd4-af4a3d697f04">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTYtNy0xLTEtMA_8e627bb2-8c14-452e-9b01-61f086ac2098">3,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjAtMS0xLTEtMA_9e3eaccb-56b7-46de-840e-31050ed8bd16">429</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjAtMy0xLTEtMA_33f836cb-4231-4952-b4e3-ede9c96b3269">21,548</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjAtNS0xLTEtMA_9d948c8e-469c-4d68-a4a0-151698619372">18,592</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjAtNy0xLTEtMA_6817df05-dcdb-4b83-b80b-258592084567">29,810</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) income on available for sale securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjMtMS0xLTEtMA_ad8d920a-7fa0-42f9-954a-71016a234ae3">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjMtMy0xLTEtMA_2df7815f-047b-40ba-ab3a-2b292d29f02f">392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjMtNS0xLTEtMA_1e1f19c5-b143-4f63-96e0-a62e8c41821a">172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjMtNy0xLTEtMA_ac97755c-5d89-47a8-af51-0ccc32a9ef26">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjUtMS0xLTEtMA_97d95552-fb2e-462f-8135-cea4569ab7fe">494</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjUtMy0xLTEtMA_6ed6f9e0-c9c5-454e-b53b-341772931f9f">21,940</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjUtNS0xLTEtMA_d7a2538a-ed00-46d1-8506-1df2287778aa">18,764</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjUtNy0xLTEtMA_376bef57-25d1-4187-aece-1570176494b2">29,395</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctMS0xLTEtMA_b1a12ee9-4875-4a46-8713-436b704d26de"><ix:nonFraction unitRef="usdPerShare" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctMS0xLTEtMA_bdf68a02-fe5a-43d6-9d17-f161fb444ad5">0.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctMy0xLTEtMA_36cd4ef6-9379-4f71-a355-0861fa9b4569"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctMy0xLTEtMA_59b4c63e-7ebb-4ce1-8807-e149adf69195">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctNS0xLTEtMA_64e02ec4-13cf-47a7-bd3c-33251cec583a"><ix:nonFraction unitRef="usdPerShare" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctNS0xLTEtMA_8d3d699a-e868-42d3-982d-e44a8835229d">0.68</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctNy0xLTEtMA_19e5f7ae-4537-4fc2-b2a2-490430b68187"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctNy0xLTEtMA_dc7b24ba-2bc8-43a5-aaba-8059a1b557a0">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtMS0xLTEtMA_fc1c0819-a01d-4b2e-b549-a4db56644cfa"><ix:nonFraction unitRef="shares" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtMS0xLTEtMA_fcbd9b68-ed94-4f21-a408-e74189b921b5">27,391</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtMy0xLTEtMA_bb3b9ebe-c3ce-4213-bcc8-bfab6654ba82"><ix:nonFraction unitRef="shares" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtMy0xLTEtMA_c387d4c1-bd8d-427a-a52e-2fd95ffede12">27,279</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtNS0xLTEtMA_97a5a81f-1ea3-489d-8403-5751bd663a40"><ix:nonFraction unitRef="shares" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtNS0xLTEtMA_c6d2af61-2ff3-4530-861c-29abedf3836a">27,377</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtNy0xLTEtMA_d4bc8a7e-4974-4e9a-a4a6-c8d33012b401"><ix:nonFraction unitRef="shares" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtNy0xLTEtMA_d5002eef-a86e-47e4-81d9-3a5caf35e1af">27,271</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See accompanying notes to unaudited consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.69pt;font-weight:700;line-height:120%">Consolidated Statement of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66483ee3f39e44a3aaf565221c3c7873_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi0xLTEtMS0w_a26f783e-2b0e-4342-9f78-7cc339cbe5c8">27,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66483ee3f39e44a3aaf565221c3c7873_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi0zLTEtMS0w_c1a79697-75fe-46ec-b10e-fd7fd22900a1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61ef44ef0874171870af019d2a30f6e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi01LTEtMS0w_0852c617-fd7e-407d-a6ff-578875c6e929">660,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee911f281b4c476f9c39c369d300a1b0_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi03LTEtMS0w_b65a8aa6-666e-4b55-ab8c-c8e2fb46d39d">4</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie18fcf4f5df24767b6bbe988f6fdad48_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi05LTEtMS0w_1a21fb74-f2c0-43e7-8d61-f6702ee45ad0">263,957</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi0xMS0xLTEtMA_5dd3e5f2-106f-4693-b470-830e4d23f5f6">396,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifed6ec8bf45a4cd0aa3ee9a5c90c681c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfNi0xLTEtMS0w_3832c2ca-f6ff-4637-9773-476dafef3b3e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3d053c201649c798018f2b53f729cb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfNi01LTEtMS0w_3125ad10-4bfc-4980-862d-24201f7d781d">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfNi0xMS0xLTEtMA_9e0e9932-ed39-4e30-a339-14769521407f">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3d053c201649c798018f2b53f729cb_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTEtNS0xLTEtMA_0a5ca650-512a-45ce-aa12-239de3eba8df">3,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTEtMTEtMS0xLTA_642badcc-27c9-4d01-b194-a23dea6965e5">3,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2278fb08662b4d1b8fd10ab11f525ee7_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTItNy0xLTEtMA_a1abfc80-9561-4ff1-8897-4910c735f676">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTItMTEtMS0xLTA_2aee6455-27aa-46d5-9ebf-fcb70f5390b8">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77b1fdd751a94267ae3ebfa67f9a7b34_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTMtOS0xLTEtMA_381bb772-6ae8-4e7a-a6a3-5834b1872dd9">18,163</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTMtMTEtMS0xLTA_073f802f-745e-4206-a9eb-e03dfd177834">18,163</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3653550b703940c4a4851c44af5f43b7_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtMS0xLTEtMA_6ecdba12-2489-4f85-9fef-23b3ffd651a4">27,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3653550b703940c4a4851c44af5f43b7_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtMy0xLTEtMA_d628d1e0-0099-4238-8a72-ecbe05de391e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863d80faf8674ff9bb6b825aac12e27b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtNS0xLTEtMA_fb7adec5-2dff-4b8a-a91d-b66851c31386">664,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d35a18ba42945f887b212ef18ac78b9_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtNy0xLTEtMA_33ac5aa4-eb95-40dc-872f-d767a0960312">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce013027a2041b0a49e202ddcfe2040_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtOS0xLTEtMA_a6e1e91f-341e-4e62-b4b0-be854db1c792">282,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc32bd3c09c4088810c227718709561_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtMTEtMS0xLTA_102519a6-a3dc-44ab-a8ed-70aa5641846d">381,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4d411a7cb224c5ebbb4ac4d0c70b7ac_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTUtMS0xLTEtMA_1d4fb29a-0ecc-49d3-8a47-2590de1c51d7">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815cd3ad41474aa89bdbc8aac7df75ff_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTUtNS0xLTEtMA_5b3d69cc-c29d-420f-8893-9d1d018d85c0">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTUtMTEtMS0xLTA_bd334241-0ae9-4cca-b544-a48c245fd946">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815cd3ad41474aa89bdbc8aac7df75ff_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTYtNS0xLTEtMA_694eb3aa-b727-4696-bbcf-f3e334581e3f">3,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTYtMTEtMS0xLTA_ed2b0c4f-0fbd-4717-b9e3-b733eb81b638">3,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive loss, net</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5af639e68aed46ceaadf61c50fa22b6c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTctNy0xLTEtMA_aa4ea82c-f5ce-4bb1-ba80-e5d0f998cf88">65</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTctMTEtMS0xLTA_6a535d5b-d134-453f-b8ea-8f89742cfdf6">65</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i558e5a32ec2d4a419c4b11583520ee8a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTgtOS0xLTEtMA_e1d9150a-15cc-4f27-a6e6-3b4b8c2b73f3">429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTgtMTEtMS0xLTA_7445c18a-c348-4829-83cf-19d563abd32b">429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided6cc631fa347f29afdeec8dc63dfa2_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktMS0xLTEtMA_3256a131-c4dc-43af-9926-0b3003b7bcf8">27,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided6cc631fa347f29afdeec8dc63dfa2_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktMy0xLTEtMA_75e95449-508e-4be4-80cb-e4bb703abf15">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdb0c2fd7a1425b88540d8ab89e49ef_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktNS0xLTEtMA_c02b6f30-e517-4526-bc4a-07a0bf002065">668,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7208ae669f5a4129b42fd35dfa7a6c27_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktNy0xLTEtMA_48c13d2f-f349-4c50-8f59-f6927dee8bdd">176</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf4c209b6991485097f5062d7e179388_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktOS0xLTEtMA_877a87dd-efe6-4cf0-8e32-e1f924c214e8">282,549</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktMTEtMS0xLTA_5732346e-21fc-47df-9fee-2463cccb9411">385,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.69pt;font-weight:700;line-height:120%">Consolidated Statement of Stockholders&#8217; Equity  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:37.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.722%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb2028cc405d4c44936f5ed145a50dbf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi0xLTEtMS0w_9840cf52-98ce-40c0-a527-1ba6790c4380">27,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2028cc405d4c44936f5ed145a50dbf_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi0zLTEtMS0w_a96a7aeb-a8ce-4301-b6d5-1d2485ed45bb">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4641429f60564692a060512d8c74558a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi01LTEtMS0w_a3deeea8-5559-41d2-8ba5-b19c256288ac">648,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4663eb93a648168c61a81e9457dc1c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi03LTEtMS0w_58cdbe2a-e019-41a5-9348-5286e78f7032">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i142b163e653d4a9cba36852e354d5a57_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi05LTEtMS0w_d7e71e3f-2f42-45db-88c6-8743b871a5b0">244,026</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d07597b3dc4975a4fe06e498a5d3e4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi0xMS0xLTEtMA_f87b9649-4a64-4245-a965-6019fd5c0177">405,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd7946500014e7a935d20e4d9049cab_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfNi0xLTEtMS0w_635475d0-725f-4bf5-974e-b01673bdf232">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90cec4c950e344009abf72bee3271d18_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfNi01LTEtMS0w_06b42e1f-d06a-405b-9b68-f92487f63172">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357b6498c5d9488bb080175359e876e9_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfNi0xMS0xLTEtMA_b23195ef-56d7-4688-aba6-74f611dc0f5e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90cec4c950e344009abf72bee3271d18_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTEtNS0xLTEtMA_4aeaabb7-c8a4-4310-bcd8-4e9adb69d599">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357b6498c5d9488bb080175359e876e9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTEtMTEtMS0xLTA_fbe71e4d-ad1e-4d49-b299-f34556facd87">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida9c210ea8494148835c51d4ce0d58f1_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTItNy0xLTEtMA_1f70a83c-2a78-4f60-9e93-35c1bd654b7a">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357b6498c5d9488bb080175359e876e9_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTItMTEtMS0xLTA_f2218469-cca3-4eb8-ae60-9e1c7ddd4c75">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b05a125a4494bb5ab7cdbe086bdd21c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTMtOS0xLTEtMA_588e40ba-14b3-405a-b98f-8295181ac534">8,262</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i357b6498c5d9488bb080175359e876e9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTMtMTEtMS0xLTA_519b4195-e9e2-4087-a006-30a2260533ab">8,262</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bb913f721294b8fbd1c537aae3279a9_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtMS0xLTEtMA_a236421b-3662-4e9d-adb8-1f2cff73f136">27,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb913f721294b8fbd1c537aae3279a9_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtMy0xLTEtMA_35178fa9-7712-4215-a8dc-560367edb6ae">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4615342e0d54465853cf7d151fdec12_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtNS0xLTEtMA_9e5315b1-67dc-442a-8af1-a9726a6c5b41">651,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d8e92fdf0848f5a09451c6582b0d02_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtNy0xLTEtMA_601375c1-a068-46b8-aded-c1401b1efa66">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i226bcfccf34e4b0bba7f77efd6749232_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtOS0xLTEtMA_aa303864-c470-4df1-ba19-ea60410ddec6">252,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd22ef257044497bb6129f2ee1efd43_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtMTEtMS0xLTA_9fc80e72-3d58-41a1-8db2-842086d72ad7">400,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares issued under employee stock plans</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3f83c27a2f24bcf960cbb189259177b_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTUtMS0xLTEtMA_1f0ec578-5c56-4822-a73e-5a08438bd48b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d26b66b1c74404b1a4ad9a12346650_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTUtNS0xLTEtMA_13d657a5-d895-4533-a073-f1fb47580e6f">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTUtMTEtMS0xLTA_3ea755b3-bedd-48b9-8652-bf50ded62dc3">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d26b66b1c74404b1a4ad9a12346650_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTctNS0xLTEtMA_b121f770-2ace-421b-95e1-352dc19f4914">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTctMTEtMS0xLTA_d90e82d9-15b2-4356-b973-75c8f9f875b9">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive loss, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if46ccc6f74854042980a58a0f048852f_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTgtNy0xLTEtMA_925fee0f-6f61-4a25-9164-39d2cdad47b8">392</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTgtMTEtMS0xLTA_7b383dc1-e10f-44d2-b81c-d33b2e00d62e">392</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64512e583b524f5fbae03573f01e4425_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTktOS0xLTEtMA_ac9e979e-42fc-4a38-9785-5db7f2df99d3">21,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTktMTEtMS0xLTA_9e1b9105-b907-4ba3-866b-9d24a54a34cf">21,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8bf867918fb40f2ade51bfcba942241_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtMS0xLTEtMA_4fe0208d-e903-451d-a132-ee585cff09cb">27,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bf867918fb40f2ade51bfcba942241_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtMy0xLTEtMA_dc1389d8-7087-4367-8e1e-0befbde4c449">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e42fc0c6ff14036a66064c60d7832a5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtNS0xLTEtMA_d1e4ca39-6309-49e0-a102-b4c479fb1d37">654,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0daff577f8ae408693a9f6c34fbe73ce_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtNy0xLTEtMA_9ac96fba-367c-447c-a457-b72d13daff2c">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i386a0a6a5d9e4bd8ad62ba1339a4e448_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtOS0xLTEtMA_4bf8cd6f-e00f-4e79-b751-8a0d841fe8e6">273,836</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc960c533644748967278a36e67af20_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtMTEtMS0xLTA_dd496feb-227a-40c8-b01f-aa4a91f6e894">381,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMy0xLTEtMS0w_4c764b84-246b-417a-bb04-2103650c110a">18,592</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMy0zLTEtMS0w_2b9c5029-62eb-4731-a602-cb35c578a2ea">29,810</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNS0xLTEtMS0w_2e8a8cff-6679-40c4-b9e9-409ad54e897b">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNS0zLTEtMS0w_1d5e21ae-5cd0-4e80-b19e-d8869281e69f">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNi0xLTEtMS0w_c49477c4-f59a-47b5-b7cc-7f91f09c4b56">7,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNi0zLTEtMS0w_46ffdc03-a8bc-412f-94c5-6cf648ff3dc4">5,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion/amortization of investments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfOC0xLTEtMS0w_eb409479-b35b-40d7-bf6a-350ffe1d5ada">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfOC0zLTEtMS0w_9692d245-1a60-4ba6-9f3d-705651be14f3">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right-of-use assets &#8211; operating</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTAtMS0xLTEtMjAzNA_0b60a7f7-5a11-4e0a-8a46-7da7482246a7">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTAtMy0xLTEtMjAzOQ_e6d1cafe-0bf4-47c8-9612-09f802d77db5">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivable from collaborative partners</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTEtMS0xLTEtMA_e5094132-d3d9-4141-a11c-847edf3b161b">642</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTEtMy0xLTEtMA_98909dbd-5a93-4896-a0e3-b771a9cd8070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTMtMS0xLTEtMA_d15ce15f-d7a7-429a-923b-8856672e6bff">3,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTMtMy0xLTEtMA_db3c1b71-ecf1-4ad7-a57d-13145e845ac5">2,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTQtMS0xLTEtMA_bc79ee66-5773-4d6a-9381-4f908023e53f">772</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTQtMy0xLTEtMA_c5375b0a-a026-474e-8314-6fa7ff23b10c">8,068</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTctMS0xLTEtODI2_227c1858-5aed-47f6-9df7-a07e41d3b784">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTctMy0xLTEtODU2_4cdd92c0-5b1d-4f82-aa6c-04ae239522b0">420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTctMS0xLTEtMA_7448acb7-8818-462e-abfe-5c2c987d2140">13,613</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTctMy0xLTEtMA_ec549815-a35c-477b-9a9e-d29d7a47aa45">34,722</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTktMS0xLTEtMA_244ba512-fce7-49e6-a547-6211d145a056">9,734</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTktMy0xLTEtMA_fe060568-4114-40a7-8892-a4a8876d6fd5">86,947</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjAtMS0xLTEtMA_9cc503c3-7287-4b8e-bcda-c52d8e568874">105,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjAtMy0xLTEtMA_a9ae8475-9c2e-4454-bc17-5ceffbb89929">173,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjEtMS0xLTEtMA_88ec64e5-d8d0-4e55-b0ab-c1c4362b0cd6">1,180</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjEtMy0xLTEtMA_a2c786b8-29a6-48f8-a8f8-38617a66ff78">170</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjItMS0xLTEtMA_94fdb3d5-72d3-49b2-b7f6-e9be0c74cb46">94,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjItMy0xLTEtMA_e27f5673-53d5-4b13-ad85-c5df90e7535f">86,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, upon the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjQtMS0xLTEtMA_69f5265d-8eb6-4ecd-bb49-31515c92dc9c">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjQtMy0xLTEtMA_23d9ff45-adb1-42a2-b61a-51d15acb53c8">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on notes payable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjctMS0xLTEtMA_060d36a1-d271-44cc-aaa5-171687ee1e39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjctMy0xLTEtMA_b10d92bb-f456-47e0-924b-8f37c9ab1c05">1,375</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzAtMS0xLTEtMA_33f1b5bb-ec7a-4839-8411-96ad41039e33">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzAtMy0xLTEtMA_7d64876a-6475-4401-a3d1-d40925378977">1,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzEtMS0xLTEtMA_896ce90c-b081-4c59-912a-8a2450ca463f">81,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzEtMy0xLTEtMA_0a79b60a-c952-4ee7-999c-015605acbe3b">50,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzItMS0xLTEtMA_c5b1e44e-48d1-4433-abb8-2291d9b2335d">250,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d07597b3dc4975a4fe06e498a5d3e4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzItMy0xLTEtMA_790640a2-ace0-42c9-9212-f11dd3f627d3">171,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzMtMS0xLTEtMA_7d0b5415-d944-441d-bdb1-e37dd23817c5">332,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc960c533644748967278a36e67af20_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzMtMy0xLTEtMA_84b2e483-6e1f-4980-8eb1-c7e87571d763">221,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzUtMS0xLTEtMA_d08bb56f-4399-4dfa-8b1c-4bf20fc592aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzUtMy0xLTEtMA_00812def-36a9-4700-90c5-5e3606ee6fe2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNDAtMS0xLTEtMjA1NA_57c366b5-407f-4111-9a2e-d2ef86807d5c">20,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNDAtMy0xLTEtMjA1Nw_5bf8ee66-d236-499c-a487-c31f0104c1b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts accrued for property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzgtMS0xLTEtMA_2085d935-74df-4224-933e-2eedc101389b">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzgtMy0xLTEtMA_3e08a92d-df8d-4902-9407-24a0dd5d18a1">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivable related to issuance of common stock, upon exercise of stock options</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="anab:ReceivablesForStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzktMS0xLTEtMA_2f30a8ca-f667-4e81-a652-945e80ca2847">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="anab:ReceivablesForStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzktMy0xLTEtMA_9d805b5d-e7da-4bcd-b46f-a95b24e78fc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AnaptysBio, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements </span></div><div id="ie2789247198f4cf1b60b048da420eb52_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNC9mcmFnOmI0YzkwOWIyMWFlZjRlYTRiYmVhZWQwNjU2MTMxYjZjL3RleHRyZWdpb246YjRjOTA5YjIxYWVmNGVhNGJiZWFlZDA2NTYxMzFiNmNfMTkyMg_775eb912-80e8-4f5f-a5e0-f368180a1773" continuedAt="ic7e33c6c5e8e4b2683a9167da7f7c6c2" escape="true">Description of the Business </ix:nonNumeric></span></div><ix:continuation id="ic7e33c6c5e8e4b2683a9167da7f7c6c2"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AnaptysBio, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We currently generate revenue from milestones and royalties achieved under our collaborative research and development arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div></ix:continuation><div id="ie2789247198f4cf1b60b048da420eb52_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTk0Mw_2671b84e-e067-4831-acac-46f78adec24b" continuedAt="i8983032b98d144d3aa3afc800e87507d" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i8983032b98d144d3aa3afc800e87507d" continuedAt="ied64e12054054abc986d4c7dff630fe7"><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkzOQ_8a51c8a0-d550-463b-a026-60e9d35ed21a" continuedAt="icb39e0088f354079a421b89acfde5e23" escape="true">Basis of Presentation </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icb39e0088f354079a421b89acfde5e23">The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2020 financial information to conform to the current year presentation of other long-term assets, operating lease right-of-use, or &#8220;ROU&#8221; asset, and operating lease liabilities on the Consolidated Balance Sheets and Consolidated Statements of Cash Flows. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities, to date there has not been any material delays in clinical operations. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="ied64e12054054abc986d4c7dff630fe7" continuedAt="i6fc65539be0641b4979a869a5dd3d53d"><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkxOA_0030f6e9-8999-4cd3-8d91-7bb80981c158" continuedAt="i06c061e166034866bf5992248a3f9132" escape="true">Basis of Consolidation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i06c061e166034866bf5992248a3f9132">The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in <ix:nonFraction unitRef="segment" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfMjU4OQ_f7ede7c2-4335-4498-ae1e-2bd2232aeb84">one</ix:nonFraction> reportable segment, and our functional and reporting currency is the U.S. dollar.</ix:continuation>  </span></div><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkxMg_dc713b07-77a9-45b2-b572-bd5575e6637a" escape="true"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkxNg_c90dc943-6347-485f-aac8-226da3e7754f" continuedAt="idd964f3badd04b6da6bd114320419650" escape="true"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with revenue recognition accounting guidance, which utilizes five basic steps to determine whether revenue can be recognized and to what extent: (i)&#160;identify the contract with a customer; (ii)&#160;identify the performance obligation; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price; and (v) determine the recognition period. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We evaluate deliverables on a contract-by-contract basis to determine whether each deliverable represents a good or service that is distinct or has the same pattern of transfer as other deliverables. A deliverable is considered distinct if the customer can benefit from the good or service independently of other goods/services either in the contract or that can be obtained elsewhere, without regard to contract exclusivity, and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contact. If the deliverable is not considered distinct, we combine such deliverables and account for them as a single performance obligation. We allocate the consideration to each deliverable at the inception of the arrangement based on the transaction price. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations may include the following: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">License Arrangements. The performance obligations under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. Licenses for multiple antibodies within a single contract are generally combined as they have substantially the same pattern of transfer to the customer. Historically, our licenses have held no value to the customer, as the antibodies were in the discovery phase and required our expertise for further development. Accordingly, licenses are not considered distinct. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and Development Services. The performance obligations under our collaboration and license agreements generally include research and development services we perform on behalf of or with our collaborators. As discussed within license arrangements above, our licenses have historically held no value without the research and development services we provide. As we generally only provide research and development services for internally generated antibodies that require a license to be utilized by a third party, our research and development services are not considered distinct. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Steering Committee Meetings. The performance obligations under our collaboration and license agreements may also include our participation on steering committees, which allows us to direct the progression of our discovery programs. As these steering committees would not occur or benefit the customer without the use of our licenses, these are not considered distinct.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="i6fc65539be0641b4979a869a5dd3d53d"><ix:continuation id="idd964f3badd04b6da6bd114320419650" continuedAt="i35194b9f556e4610be37cd7d356e2d21"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize consideration allocated to a performance obligation as the performance obligation is satisfied, and the determination as to whether consideration is recognized over time or at a point in time is made upon contract inception. For our collaboration agreements, this is generally over the period in which research and development services have been performed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and license agreements generally include both fixed and variable consideration. Fixed payments, such as those for upfront fees are included in the transaction price at contract value, while variable consideration such as reimbursement for research and development services, milestone and royalty payments are estimated and then evaluated for constraints upon inception of the contract and evaluated on a quarterly basis thereafter. Research and development services are updated for actual invoices. Given the nature of our agreements, milestones are estimated using the most likely amount and are evaluated on a quarterly basis. Upon commercialization, royalty payments will be recognized in the period incurred. </span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i35194b9f556e4610be37cd7d356e2d21">We receive royalty revenue on sales by our partners of products covered by patents or contract rights that we own and net sales of their approved drugs, where we have concluded the license is the predominant item to which the royalties relate. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of our partners&#8217; historical experience including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. As of June&#160;30, 2021, there have not been material differences between actual and estimated royalty revenues.</ix:continuation> </span></div><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTk0MA_69aa2e2a-8e12-4a59-8b46-557e35aa4e03" escape="true"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkyMw_9d9cca9b-55cf-4dbb-8632-50cd6c03bcf5" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the weighted-average o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54e09947d78640e4b9eeb147c43743aa_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RhYmxlOmQ3MGUzZTZmNWU4ZTQ3YzViZDMxNGYzZjU3ODgzNDc5L3RhYmxlcmFuZ2U6ZDcwZTNlNmY1ZThlNDdjNWJkMzE0ZjNmNTc4ODM0NzlfMy0xLTEtMS0w_fdc3fcac-74be-42b8-8177-f677d2ceb1f3">3,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12ddd91f6523469eb8f7ad820f2b8764_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RhYmxlOmQ3MGUzZTZmNWU4ZTQ3YzViZDMxNGYzZjU3ODgzNDc5L3RhYmxlcmFuZ2U6ZDcwZTNlNmY1ZThlNDdjNWJkMzE0ZjNmNTc4ODM0NzlfMy0zLTEtMS0w_2cd0f41c-29dd-4c76-bed1-3fb961dd5954">2,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1487ca8ec2e24d4fba6469fa2aa23d66_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RhYmxlOmQ3MGUzZTZmNWU4ZTQ3YzViZDMxNGYzZjU3ODgzNDc5L3RhYmxlcmFuZ2U6ZDcwZTNlNmY1ZThlNDdjNWJkMzE0ZjNmNTc4ODM0NzlfMy01LTEtMS0w_be9f43e3-fe66-4fea-bdb1-5dd40825b682">3,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4217decdbe45471ca7c606434d0632c0_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RhYmxlOmQ3MGUzZTZmNWU4ZTQ3YzViZDMxNGYzZjU3ODgzNDc5L3RhYmxlcmFuZ2U6ZDcwZTNlNmY1ZThlNDdjNWJkMzE0ZjNmNTc4ODM0NzlfMy03LTEtMS0w_afb112b3-e5f4-4311-b4f9-eab1314baac8">2,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RleHRyZWdpb246Njg0MjcwNzVlZGRhNDI5NzhlZmUyMTZhMGRlYWQ3OTZfMjE5_44140411-49c5-4a54-bf59-65972630eec5" continuedAt="i8169556c793b428d89404a979f5ea2f5" escape="true">Balance Sheet Accounts and Supplemental Disclosures </ix:nonNumeric></span></div><ix:continuation id="i8169556c793b428d89404a979f5ea2f5"><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net </span></div><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RleHRyZWdpb246Njg0MjcwNzVlZGRhNDI5NzhlZmUyMTZhMGRlYWQ3OTZfMjIx_e32391ec-4736-4559-b833-02b642287805" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b92baa04c8b4070987a2e921dbaafa4_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMS0xLTEtMS0w_f0ceb1e8-3a7f-471f-a0ce-defd028ee19f">5,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a1dc7356a94c6eb2c2452e7957ebe8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMS0zLTEtMS0w_c1b360df-9aae-4690-b5db-f97d2754e98d">5,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b552c03f74142c287d50400a1538790_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMi0xLTEtMS0w_6e423b39-fcfa-4c1f-bf4a-cc75746addfb">1,508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593bf7da05f24f8a88e6e1f64037cce7_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMi0zLTEtMS0w_289dbf33-d295-4fd0-a294-ab7ed6216712">976</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c0631bdcfa94b9182f6f5cfe8b439b3_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMy0xLTEtMS0w_59c20530-51d3-48a7-841e-2dd12a312b95">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c4a40293897411dad729dd8d12a9b9b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMy0zLTEtMS0w_e7340c4d-09ca-429c-bd4f-165f3065564e">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNC0xLTEtMS0w_2c6cb621-cd8c-455c-93b2-b3fc83983ff2">7,716</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNC0zLTEtMS0w_af931585-6848-41c1-bf51-7803308fca3d">6,728</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNS0xLTEtMS0w_81d8e9eb-0cae-4f27-b34d-cd74b2c21aff">5,228</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNS0zLTEtMS0w_e47ed5e6-0f57-46fb-8c6d-f379d99bcacc">4,945</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNi0xLTEtMS0w_b8151192-9310-47af-ba61-90edc54e7977">2,488</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNi0zLTEtMS0w_2b7b83b9-314e-4f1b-a38a-6657cd7eb085">1,783</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RleHRyZWdpb246Njg0MjcwNzVlZGRhNDI5NzhlZmUyMTZhMGRlYWQ3OTZfMjE4_819250a5-7313-4406-82a7-355bf36297a9" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMS0xLTEtMS0w_dadc21dc-7f6e-4d0c-a880-bc0566fb0ba8">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMS0zLTEtMS0w_7901d5f6-5cb3-4308-82f0-dcc65dbdf254">3,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMi0xLTEtMS0w_761eb699-b507-431d-b5ce-ec31981bd686">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMi0zLTEtMS0w_2b64edea-f2d1-44a5-98dc-6410c500dddc">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research, development and manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:AccruedResearchAndDevelopmentExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMy0xLTEtMS0w_a93bb097-7928-485d-b685-5ff6fa7db54e">11,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="anab:AccruedResearchAndDevelopmentExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMy0zLTEtMS0w_8a2a9d5b-7c98-4086-a4a0-5564c87f2cbf">10,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfNC0xLTEtMS0w_e10c842b-26f4-46f4-8a4e-a78649c0a890">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfNC0zLTEtMS0w_159fd6eb-75fc-41e2-a185-817527fac4b7">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfNS0xLTEtMS0w_992f7aa1-3c9e-4ece-805e-bd4387bab7a6">15,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfNS0zLTEtMS0w_27ab9a0b-4118-4c21-8004-22c43545d91b">15,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie2789247198f4cf1b60b048da420eb52_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTE0MTU_1d14c6b8-4b2a-437d-816d-6ac737832f9c" continuedAt="i986377af274d4a309ac3fb562ab46eb3" escape="true">Collaborative Research and Development Agreements</ix:nonNumeric></span></div><ix:continuation id="i986377af274d4a309ac3fb562ab46eb3" continuedAt="i1adea2a50ce34e1b95eaf53c4af73e2f"><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GlaxoSmithKline Collaboration </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, we entered into a Collaboration and Exclusive License Agreement (the &#8220;GSK Agreement&#8221;) with TESARO, Inc. (&#8220;Tesaro&#8221;), an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline (Tesaro and GlaxoSmithKline are hereinafter referred to, collectively, as &#8220;GSK&#8221;). Under the terms of the GSK Agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory, and commercial development to be performed by GSK. Under the terms of the GSK Agreement, GSK paid an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ib6bb85d544044f74be91e6c4ded1291a_D20140301-20140331" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNzQy_7ec55b7e-db23-4add-8445-8a86970d72ab">17.0</ix:nonFraction> million in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for <ix:nonFraction unitRef="target" contextRef="if23f0b3a9c1543389445ca1f2a582eb5_I20140331" decimals="INF" format="ixt-sec:numwordsen" name="anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfODc2_f89c7004-a149-41d0-95b1-ec3f3fb9f568">three</ix:nonFraction> specific targets. In November 2014, Amendment No.&#160;1 to the GSK Agreement was agreed by both parties to add an antibody discovery program against an undisclosed <ix:nonFraction unitRef="target" contextRef="i443e38b29ed84f36aeff8d125942ff3c_I20141130" decimals="INF" format="ixt-sec:numwordsen" name="anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTAzOQ_cfa481de-a1ba-47b2-8d52-45c00aaa3071">four</ix:nonFraction>th target for an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i5c6137734596471eb3bfbea0e8c29f72_D20141101-20141130" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTA4MQ_fc407157-d1ed-4f3c-b257-0132aed78099">2.0</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each development program, we are eligible to receive milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i443e38b29ed84f36aeff8d125942ff3c_I20141130" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTE3MQ_ab9129e1-18f0-49c5-8610-60fc026140ff">18.0</ix:nonFraction> million if certain preclinical and clinical trial events are achieved by GSK, up to an additional $<ix:nonFraction unitRef="usd" contextRef="i443e38b29ed84f36aeff8d125942ff3c_I20141130" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTI2NA_68e1030e-9d88-4339-b985-66e267cf4d58">90.0</ix:nonFraction> million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional $<ix:nonFraction unitRef="usd" contextRef="i443e38b29ed84f36aeff8d125942ff3c_I20141130" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTM5NQ_fc8b4dd8-e015-45dc-ab41-0f7292f51e1a">165.0</ix:nonFraction> million upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the GSK Agreement will terminate, with respect to each specific developed product, upon the later of the <ix:nonNumeric contextRef="i5c6137734596471eb3bfbea0e8c29f72_D20141101-20141130" format="ixt-sec:duryear" name="anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTc5MQ_b0f7b0e8-c900-444e-a8f0-b5c0aed2ead9">12</ix:nonNumeric>th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that the upfront license fees and research funding under the GSK Agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In February 2016, Amendment No.&#160;2 to the GSK Agreement was agreed by both parties to define the effective dates of the development programs of the GSK Agreement. We determined that the research and development services would be extended </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="i1adea2a50ce34e1b95eaf53c4af73e2f" continuedAt="i222564a44978429b93e68fac765d971e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through December 31, 2016. As a result, the period over which the unrecognized license fees and discovery milestones were recognized was extended through December 31, 2016 and have since been recognized in full. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer.&#160;We identified the following material promises under the GSK Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) research and development (&#8220;R&amp;D&#8221;) services, and (3) joint steering committee meetings. We considered the research and discovery capabilities of GSK for these specific programs, GSK&#8217;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the joint steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 23, 2020, Amendment No. 3 to the GSK Agreement (the &#8220;Amendment&#8221;) was agreed to by both parties to permit GSK to conduct development and commercialization of Zejula, an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, which has received U.S. approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under the Amendment, we were granted increased royalties upon sales of JEMPERLI (dostarlimab), an anti-PD-1 antagonist antibody under development by GSK for multiple oncological disorders. The Amendment also provided for a one-time, non-refundable cash payment of $<ix:nonFraction unitRef="usd" contextRef="ia8cde62162f4437eb22081031e78c481_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNDc2Mw_67424fc3-e9c0-4703-912b-516b89d9410d">60.0</ix:nonFraction>&#160;million that we received and recognized as revenue in the fourth quarter of 2020. GSK also agreed, starting January 1, 2021, to pay us a <ix:nonFraction unitRef="number" contextRef="i47989d6424ad4d9ab848e3e615102bac_D20210101-20210101" decimals="2" name="anab:NetSalesRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNDg5NQ_259e552a-0f48-4ca9-aa8e-8c53c9355afe">1</ix:nonFraction>% royalty less third-party royalty deductions on all GSK net sales of Zejula. The $<ix:nonFraction unitRef="usd" contextRef="icb9fa8ebdf074b57a099e54ad0196d1d_D20210101-20210630" decimals="-8" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNDk0Mg_9008de5a-d2c6-4bf9-bb52-0411044f28bb">1.1</ix:nonFraction>&#160;billion in cash milestone payments due under the GSK Agreement remain unchanged.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, under the terms of the Amendment, GSK has agreed to certain diligence commitments with respect to the future development of JEMPERLI, and the parties have agreed to review such commitments under regular joint review committee meetings going forward.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed this Amendment in accordance with ASC 606 and concluded the Amendment was a contract modification to the GSK Agreement. Based on our assessment, we identified the terms of the Amendment to be interrelated to the GSK Agreement&#8217;s single performance obligation, noting completion and delivery of terms under the Amendment were satisfied by both parties with the execution of the Amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the transaction price for the GSK Agreement and Amendment includes the upfront payment, research reimbursement revenue, one-time payment associated with the Amendment, and milestones earned to date, which are allocated in their entirety to the single performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We earned and recognized $<ix:nonFraction unitRef="usd" contextRef="id40e9b7e255a4b9b918086d940de14a0_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQ1NQ_fe2bd775-14e4-4d0c-8002-9d86d3b6aab1">1.3</ix:nonFraction> million in royalty revenue during the six months ended June 30, 2021 related to GSK net sales of Zejula and JEMPERLI during the period based on estimates of GSK&#8217;s sales historical experience. GSK reports sales information to us on a one quarter lag and differences between actual and estimated royalty revenues will be adjusted in the following quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earned and recognized <ix:nonFraction unitRef="milestone" contextRef="i44529c9832924677ab0905ad04031c28_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNjM0OQ_0299633c-ec1f-40e4-9feb-0928fb81853e">three</ix:nonFraction> clinical milestones totaling $<ix:nonFraction unitRef="usd" contextRef="i79a47cb5a3684fb9965f688e81d082de_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNjM3NQ_9df0fdf7-750f-45ad-8be6-0724e35b94f5">40.0</ix:nonFraction> million during the six months ended June 30, 2021. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and GSK&#8217;s efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to GSK and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTE0MTk_200cbb11-c587-4aee-a8c3-9307c59c1bc0" continuedAt="i140696cfe44f4de8b3b25f209fd22712" escape="true">Milestones recognized through June&#160;30, 2021 under the GSK Agreement are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="i222564a44978429b93e68fac765d971e" continuedAt="id3896c2ec84047c0997fa0f115dfd7b9"><div style="margin-top:18pt;text-align:center"><ix:continuation id="i140696cfe44f4de8b3b25f209fd22712" continuedAt="i0f7c6203c5124bcd849351c0ab98d898"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(JEMPERLI/Dostarlimab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-TIM-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4069889A/Cobolimab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-LAG-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK40974386)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initiated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using good laboratory practices (GLPs) </span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i36e884c92e4248ebb969f8b647ff98db_D20150401-20150630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMi0xLTEtMS0w_fd123ed8-187e-4ee0-ae75-e6df7ff64a6e">1.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="id039343680da47d7af05ac3697ed6412_D20151001-20151231" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMi00LTEtMS0w_f8b07aac-99c9-4379-8f6f-d0adc0341f08">1.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i2d312a71cb6944cda527675f2fbd0a55_D20160701-20160930" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMi03LTEtMS0w_3c9a7347-4535-4293-9099-184393ffa16a">1.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IND clearance from the FDA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie0f3dd66d4c24741b2a7ded6059d960e_D20160101-20160331" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMy0xLTEtMS0w_eca6e803-dce4-4811-a38a-6da7558ef0bb">4.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i91888314abeb436d827a581cdd98c07c_D20160401-20160630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMy00LTEtMS0w_4edf0693-be4d-41d8-8b02-2d3ab6d2c9d9">4.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i29ad61a6cdfc4838b66812099ad185db_D20170401-20170630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMy03LTEtMS0w_036a5c66-ac26-4675-8a0f-d658c6c8e84b">4.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2 clinical trial initiation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i8d52b0d15c6a49759798e25fe838631e_D20170401-20170630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNC0xLTEtMS0w_1ddd7a64-d171-453a-a730-47a0a304100a">3.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i69938c04553e464db0b8b7c7704d1867_D20171001-20171231" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNC00LTEtMS0w_32606265-55aa-4ffc-8e0f-25761bc4c4fd">3.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i97554db485364f75b7e7a0213d8a4225_D20191001-20191231" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNC03LTEtMS0w_f1a0e653-e637-470a-aefc-1e259b708ed6">3.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'19</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7184beea9df1436ba28682c84638c335_D20180701-20180930" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNS0xLTEtMS0w_edf29e8d-e4a8-443f-abc3-eab44f96a72e">5.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - second indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib2aeffac54924963b1bf3dc19fca0a21_D20190401-20190630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNi0xLTEtMS0w_7e742a4d-62ec-4a30-8137-a7c945a8f88e">5.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'19</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first BLA - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7140062cc12f4f01acbb92e93e19466c_D20200101-20200331" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNy0xLTEtMS0w_94c9cad2-4cb5-436e-869a-7a4725e6d017">10.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first MAA - first indication</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i4353bed79fb8420982f9675d50f0e0b6_D20200101-20200331" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfOC0xLTEtMS0w_caf3c0c4-dea8-45ad-baa3-821c3924593e">5.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first BLA - second indication</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i5bc779cbb0dd4b988a625b412a15a49c_D20210101-20210331" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfOS0xLTEtMS0w_8e0cfc45-0623-435e-bcdd-c49ff8a60a37">10.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">First BLA approval - first indication</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia2241e34e4b2493cb520e2f1469c8282_D20210401-20210630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMTAtMS0xLTEtNTY2_fcfdcc86-96b9-4db3-8a79-267c2e8a63e1">20.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">First MAA approval - first indication</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i8ac11f17d0664ef6b0b60ad3b9f2d76d_D20210401-20210630" decimals="-5" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMTEtMS0xLTEtNTY2_8930e691-6547-4cee-ae91-8488e67c747c">10.0</ix:nonFraction>M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></ix:continuation></div><div style="margin-top:13pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized $<ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQyOQ_1053cac0-e01c-40b9-a964-a2bd0d17fa0e">30.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQzNQ_13cc9287-0369-4e06-aa50-1ef706f9c234">41.3</ix:nonFraction> million in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> revenue under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GSK Agreement </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the three and six months ended June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively, and $<ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQ0Mw_1881dc1d-719c-4766-b8ef-ccde5d67aedf">0</ix:nonFraction> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQ0Nw_455ef548-fac4-4e2d-8bde-a105186f0816">15.0</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">six months ended June 30, 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody Generation Agreement with Bristol-Myers Squibb </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2011, we entered into a license and collaboration agreement (the &#8220;BMS Agreement&#8221;) with Celgene, now a part of Bristol-Myers Squibb (Celgene and Bristol-Myers Squibb are hereinafter referred to, collectively, as &#8220;BMS&#8221;), to develop therapeutic antibodies against multiple targets. We granted BMS the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BMS Agreement provided for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i6011ad3b1c6b44a885a7bd57000ca6be_D20110101-20111231" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfODU2MQ_25072d1f-558a-4572-b2ae-4171e7bc04cb">6.0</ix:nonFraction> million from BMS, which we received in 2011 and recognized through 2014, milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ifcb6477f9a49486ab46021a396ff7561_I20111231" decimals="INF" format="ixt:numdotdecimal" name="anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfODY1Nw_9296c673-119a-438f-aeea-b7c46e2369f6">53.0</ix:nonFraction> million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, BMS, is a customer.&#160;We identified the following material promises under the BMS Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;D services, (3) a written report documenting findings, and (4) steering committee meetings. We considered the research and discovery capabilities of BMS, BMS&#8217;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the transaction price of the BMS Agreement includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and BMS&#8217;s efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="id3896c2ec84047c0997fa0f115dfd7b9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined to relate predominantly to the intellectual property license granted to BMS and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><ix:continuation id="i0f7c6203c5124bcd849351c0ab98d898"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved through June&#160;30, 2021 under the BMS Agreement are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 <br/>(CC-90006)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of first </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using GLPs</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i59da14b2fe8548e5870e1779cc0aa9d0_D20160401-20160630" decimals="-5" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjhiMDhjMGMxOGNkZDQzNjBiYTBmMjM1MWM1MGZhYmIyL3RhYmxlcmFuZ2U6OGIwOGMwYzE4Y2RkNDM2MGJhMGYyMzUxYzUwZmFiYjJfMi0xLTEtMS0w_0748750c-6f4d-49d1-8174-077172825cec">0.5</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1 clinical trial initiation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i4a55c463e33c4afab95cb2149af0e3ce_D20161001-20161231" decimals="-5" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjhiMDhjMGMxOGNkZDQzNjBiYTBmMjM1MWM1MGZhYmIyL3RhYmxlcmFuZ2U6OGIwOGMwYzE4Y2RkNDM2MGJhMGYyMzUxYzUwZmFiYjJfMy0xLTEtMS0w_13f9c33e-f956-49ac-9150-2eebb3248bf5">1.0</ix:nonFraction>M</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'16</span></td></tr></table></div></ix:continuation><div style="margin-top:7pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  There was <ix:nonFraction unitRef="usd" contextRef="ifa80869592e640d389371d71f073f337_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTEzNTA_03cc7e6d-f9c1-48a6-8c5e-4575b63d69dc"><ix:nonFraction unitRef="usd" contextRef="i70c2ff1aec104594b36f1b5f8e2a3e4a_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTEzNTA_809f6a66-6542-4553-ba5b-ebc7fd19c32c"><ix:nonFraction unitRef="usd" contextRef="ia6413c5f064d49babec39642d4b164a5_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTEzNTA_9aa3048e-825f-4840-8c21-6ba7eeb993e5"><ix:nonFraction unitRef="usd" contextRef="id77469bf2efe425dac416b31a411d04b_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTEzNTA_b47b1241-ee76-47e9-a43b-67df7b0f9566">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue recognized under this agreement during the three and six months ended June 30, 2021 and 2020.</span></div></ix:continuation><div id="ie2789247198f4cf1b60b048da420eb52_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTIyNA_349ef4d0-22c4-4e43-8da8-2199e2aa92ca" continuedAt="i31b77a9feb504efabbcfcfc23869abcb" escape="true">Fair Value Measurements and Available for Sale Investments </ix:nonNumeric></span></div><ix:continuation id="i31b77a9feb504efabbcfcfc23869abcb" continuedAt="ie090742a4ba94bf5ad14b486d91f47e0"><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, and accounts payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="ie090742a4ba94bf5ad14b486d91f47e0" continuedAt="i00220deb953e45eb82f7ee0b7e777625"><div style="margin-top:12pt;padding-left:11.25pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTIyNQ_6aed4d91-8ef5-465a-81c1-329d19d57136" continuedAt="iad1e8ae8b1834f819402e540fd72635c" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices for</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identical&#160;Assets</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At June  30, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9133e4132b240e7bca2e1c95471892e_I20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMy0xLTEtMS0w_1b51a7a0-e370-489a-9c92-1d4902758cd4">305,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5399bd92b9e4cf693eb263ebaa5e180_I20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMy0zLTEtMS0w_7514e730-41f1-4694-98f6-f1c5ef9ed077">305,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e2dfb981084eb1a6ddf8ebc09962d3_I20210630" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMy01LTEtMS0w_d929c364-6e80-4941-81af-4c554a2b08c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e78cb67f53f47f3b1937709b61ee528_I20210630" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMy03LTEtMS0w_c9baebec-b83b-482c-879a-f187afd0093b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5641bee18d3141bda9c26e4ca72e89b6_I20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNC0xLTEtMS0w_66e4fddc-b1f6-4928-a82e-eba17e9b26f3">26,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288736d64ff04b0ab6b16af4d6d2b14a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNC0zLTEtMS0w_de579e96-1f59-428b-9306-ca631804cb62">26,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8414801a345a4cd4ab3c203b8ec660a9_I20210630" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNC01LTEtMS0w_fcad4509-77af-4ab4-abd8-7f8c9ce901f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icee60ae93525403795b2bac324fca5a6_I20210630" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNC03LTEtMS0w_5d18943f-b6b7-42de-8d5e-d181d3563050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ef14c2603b489b847974efac36accf_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNS0xLTEtMS0w_ae5cba3f-4961-4f39-809a-a53e95d55d98">45,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6ade6ba8d441b5a2642b21f097a179_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNS0zLTEtMS0w_95430902-7520-48fa-9860-56bd19f33b32">45,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab16caf39c34c8eb91ade5ed0af706b_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNS01LTEtMS0w_247f4ede-3205-49a6-a39e-4e95b9e9dbaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9275bf5a2daa483ba130b781fc58af8a_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNS03LTEtMS0w_0978b145-0b7c-4bc7-8aa0-b6287e9b51d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ee5fb8cf54c68859bac354f7a79d8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNi0xLTEtMS0w_ed906133-b141-4f84-a9cd-d5745ddadddc">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6704368d964ed69d2439d929ef4748_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNi0zLTEtMS0w_860605b4-27e6-4f72-a45a-9752c2126a5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c4a55ee9124b8bac3e70be46d12bc4_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNi01LTEtMS0w_480ac706-52dc-47bb-b32c-9505fe7c942b">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eeb2688caf9475dacc5b156e4b9ebcc_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNi03LTEtMS0w_3bdefe91-4176-4056-ad34-69384ff6666d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b8a35c442e40f59ff35f5aab9e1ca4_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNy0xLTEtMS0w_20dec6c6-b4b3-4320-9818-2024a2075d8a">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a862142bb64348860dc4025bb374fc_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNy0zLTEtMS0w_ad9a3572-7dea-4d2b-aa94-06eda454d4c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9b6fa28a604b77aa8d086a61c3002a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNy01LTEtMS0w_8e745d73-3a25-47c4-a3dc-49b55b483527">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc0beaf432b417aa88fa1f2d048adb7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNy03LTEtMS0w_e32dd7f8-7e22-4897-a5e9-59921a4183d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad4b811111a4959a97b530f3e1edc30_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfOC0xLTEtMS0w_2807a0e7-ff8b-40a7-8385-8b6bc11b6b38">11,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2efedcdd907841bdb7b475cccdb198dc_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfOC0zLTEtMS0w_e31dfed2-c25c-450f-9970-1a7306cb4d6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d7c88a334a4713960dc3460eb06106_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfOC01LTEtMS0w_9a6bef93-0386-4060-a254-aac831e07c02">11,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5ed2e6efa94819b8a0fb85e74275d6_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfOC03LTEtMS0w_45d019bb-e3ea-45e3-aea5-10807c13d67b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8725cde7bd3b4b58934b4ecdcef2816a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTEtMS0xLTEtMA_032ba3d2-23af-428f-a715-b73c2974e7b4">188,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6944b71b72a84436a68e5213fe6df51a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTEtMy0xLTEtMA_edc70327-b45b-46ce-8d48-f53b5e251bcb">188,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad391a709b144bd48d2872b283602f84_I20201231" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTEtNS0xLTEtMA_af5fb622-303d-4967-8422-59452d49947a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9067efbd18c467aad2eebbaff82cfc4_I20201231" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTEtNy0xLTEtMA_566b2aae-d8f6-4c89-bd30-50840ea13e12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3519bdb64f8b4b6d8efc1c5e46616753_I20201231" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTItMS0xLTEtMA_6f59e498-2be9-486d-b990-05962d5da101">57,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3adfb85bf6451c9575bc0e8d008d13_I20201231" decimals="-3" format="ixt:numdotdecimal" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTItMy0xLTEtMA_c9073f03-619b-4469-ad59-afaa3a885016">57,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81d1d57d00941ff976792c032f7c601_I20201231" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTItNS0xLTEtMA_a4c9b19a-118e-4597-9684-a442cc1298fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b9e3d355a14ac49a01d376ea60f2a1_I20201231" decimals="-3" format="ixt:zerodash" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTItNy0xLTEtMA_e85504c4-9add-4fc9-9566-4d867b19c131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2037e57e85fb441b94c20fe503046463_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTMtMS0xLTEtMA_b74b0905-5435-4753-a322-b2178d5e4cf7">107,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id812dbcc01ba448783f4b7ace47357b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTMtMy0xLTEtMA_951ffd4a-a5c6-4e83-9739-60b6f5eebe9d">107,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c66084d39744f29e968164be5da8b7_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTMtNS0xLTEtMA_83056ec7-59e6-4bc1-a088-da6388ac5312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9802e6239684804a3dc3860a653719b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTMtNy0xLTEtMA_0799fcc1-44d5-4e26-b6b6-a72c43f4295a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea2879f95c041cd895eda44820f8624_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTQtMS0xLTEtMA_1a3dd949-e1b1-4989-8ee2-965a5bf99a44">2,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eae37d2da574506ba4e102853287bd8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTQtMy0xLTEtMA_743d7a6a-9137-4e82-adf1-d7992d9414c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3081867d37934fefb8be59e85e8c7a4e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTQtNS0xLTEtMA_f0f3f98c-5a85-4697-9f86-20fd41b6f442">2,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i051c714be443417780719d2eb4b53ea9_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTQtNy0xLTEtMA_53c9d5ee-bc50-468d-ad18-900b0ac6e248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674430e3d2c341c8a6df0759fb0fbd73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTUtMS0xLTEtMA_15fadd48-4a1e-40f4-94a3-43627ef663fe">21,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12aa4229eb9f4c2fa7c9289e272467c6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTUtMy0xLTEtMA_bc7d190f-3f05-4a2f-a7ea-1291509e0e4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c3ef9e7fdb4ea2b3bfd0ac0a4f062b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTUtNS0xLTEtMA_08d9c6ca-a30c-4018-9bcb-d5f3812ab889">21,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454b38ab8bdc449cad61e6eb5af78756_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTUtNy0xLTEtMA_60fd1cc8-1c3e-4696-a06d-2e905a3b0f9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bdd900a94544d0bbba160586a6eb58_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTYtMS0xLTEtMA_c6d0691d-eccf-4d90-b059-ba7133abeefd">29,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51217ad1af3e4ebda21a0ad07210b827_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTYtMy0xLTEtMA_41283f4e-4ab4-410a-ac40-e9e406528fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec26d7834be4c8abd097426fd877cb2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTYtNS0xLTEtMA_8fbb0358-1214-43de-b975-03ccd955b57d">29,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07640a2359445eba2a41ae90501863f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTYtNy0xLTEtMA_25bba865-600e-4c11-bc42-30fdef8f95c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div></ix:nonNumeric><div style="margin-top:2pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="iad1e8ae8b1834f819402e540fd72635c" continuedAt="i6b78fe8efc04402e8c9c07a8eb9a39a7">(2)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b78fe8efc04402e8c9c07a8eb9a39a7">Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date.</ix:continuation> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. </span></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Other Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, accrued expenses, and receivables approximate fair value due to their short-term nature. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="i00220deb953e45eb82f7ee0b7e777625" continuedAt="i179337cf608b40a0b6ac804c88db01a0"><div style="margin-top:18pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTIzNQ_8fb02045-c649-4715-b88f-7274e643faa6" continuedAt="i550563288b914a178d4e166c30d33859" escape="true">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of June&#160;30, 2021 are as follows:</ix:nonNumeric></span></div><ix:continuation id="i550563288b914a178d4e166c30d33859"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMS0xLTEtMS0w_927595f2-6e6b-4de5-96fa-7b6454284203">5,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMS0zLTEtMS0w_9b239caa-205c-4d82-a357-0268e9f4f6c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMS01LTEtMS0w_66c00492-70b0-413c-99e2-17a7c5f02bec">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMS03LTEtMS0w_ade62162-a3de-45a7-8e00-183abafe0adc">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMy0xLTEtMS0w_217386e7-6304-4a72-932e-194f4090c940">1,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMy0zLTEtMS0w_19cb5a92-ef5f-4893-b0b5-fe694d7809ad">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMy01LTEtMS0w_3c9b35a5-7499-4aba-b676-7d2a0119abbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMy03LTEtMS0w_377ba8ec-68a7-466e-be4c-67aaa4f150c1">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNC0xLTEtMS0w_a47d3837-e724-4b49-8019-dd31da4b4d70">11,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNC0zLTEtMS0w_80ea1172-9030-4e65-8432-c984333522bb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNC01LTEtMS0w_12c3c159-ecba-4764-95bc-67b994451c56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNC03LTEtMS0w_7a781d6a-8afa-4e72-84f6-057704d6a45a">11,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711fd5f10f4e49a58b560bb507d95052_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNS0xLTEtMS0w_47e62cbc-8bef-463f-85ee-7521662e4346">45,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711fd5f10f4e49a58b560bb507d95052_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNS0zLTEtMS0w_84736511-9cf2-4522-bda7-2505dc19e4c2">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711fd5f10f4e49a58b560bb507d95052_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNS01LTEtMS0w_ac994fdf-6c62-4904-ae64-90d32282112f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711fd5f10f4e49a58b560bb507d95052_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNS03LTEtMS0w_8234d411-a9bd-454d-ab53-5aa025522a8f">45,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNi0xLTEtMS0w_2eb78add-8234-4ea3-b00e-c86fd19c3eaa">64,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNi0zLTEtMS0w_64490e11-3370-4467-9638-740ee01598bb">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNi01LTEtMS0w_e582b5be-f7af-4f53-aca2-42185e312286">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNi03LTEtMS0w_c93d0a47-d82e-4851-88fe-53c8c621da53">64,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding agency securities, <ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzQ5MQ_17e49653-9ed8-4b8d-a0d0-64c021e78968">none</ix:nonFraction> have maturity dates of less than <ix:nonNumeric contextRef="i45f7ba855861405cbd820fb0f83d8611_D20210101-20210630" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzUyNw_7c776d83-4a70-4b48-94cd-5f56dd94476f">one year</ix:nonNumeric> and $<ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzUzNA_4f5b3f30-87c8-4dd1-9f60-9e0020b90d22">5.0</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU2OQ_2c6af718-21cf-4692-a2d3-b58b8b1319f6">one</span> to <ix:nonNumeric contextRef="i1d163026a6654743b9979520a3af47aa_D20210101-20210630" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU3NQ_e3e11b04-bd30-48fe-aa75-c00e53ec8424">two years</ix:nonNumeric> as of June&#160;30, 2021.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $<ix:nonFraction unitRef="usd" contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzYzNg_54adb533-b48c-450a-b8c1-528912b02301">1.1</ix:nonFraction> million have maturity dates of less than <ix:nonNumeric contextRef="i8b96a7f246684ad1800b51d91e9a69b8_D20210101-20210630" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzY3Mg_e071d5be-42df-4caf-8929-f58902332d1a">one year</ix:nonNumeric> and $<ix:nonFraction unitRef="usd" contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzY3OQ_fc76f142-e625-47b6-8f33-ef67ca6770c2">0.5</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcxNA_0f49c841-e469-4cdb-9e94-1d8fc6721bf2">one</span> to <ix:nonNumeric contextRef="i61e188f2a2fc40cdb0ad1ad5fc3d9224_D20210101-20210630" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcyMA_c798eaf0-3c9c-4420-9142-d74fd2ef713e">two years</ix:nonNumeric> as of June&#160;30, 2021.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations have maturity dates of less than <ix:nonNumeric contextRef="i03f6372c975642c8b721a357169c41f7_D20210101-20210630" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzgzMA_6bf12f54-1ba1-473d-a43f-bbd01e5a42ef">one year</ix:nonNumeric> as of June&#160;30, 2021. </span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding U.S. Treasury securities have maturity dates of less than one year as of June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of December&#160;31, 2020 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMS0xLTEtMS0w_c304ca08-7183-413a-840e-33a201b290d0">21,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMS0zLTEtMS0w_4a43a700-cefe-4b53-9b0d-92206bac99c2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMS01LTEtMS0w_11355a4b-4944-44b7-9a25-271fe195ade4">1</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMS03LTEtMS0w_41e19594-2e5c-4341-bd8d-c63a188e61f5">21,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392569839eab4af895cd18151a8a634b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMi0xLTEtMS0w_4dc8b603-d070-462c-8811-f75d8ba9ce19">2,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392569839eab4af895cd18151a8a634b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMi0zLTEtMS0w_b1b754ca-40cf-4730-896a-e6c7737fede4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392569839eab4af895cd18151a8a634b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMi01LTEtMS0w_451555da-63b5-48bc-81ba-1b9f092d352a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392569839eab4af895cd18151a8a634b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMi03LTEtMS0w_15b15262-0400-4209-bab0-9df97816228e">2,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMy0xLTEtMS0w_a2da044e-716b-4832-9e39-277685cfd1e6">29,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMy0zLTEtMS0w_0e3ff0a6-a7a4-44ff-bbb9-8ec2786cfd20">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMy01LTEtMS0w_0368480c-13f9-44e2-bcbe-1ed2a4f05d59">1</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMy03LTEtMS0w_10cbe75f-09b2-4af3-9b80-4ec638be3ebf">29,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNC0xLTEtMS0w_b3de3fac-7beb-4627-b583-77e153e7b99d">107,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNC0zLTEtMS0w_44b6cf34-469f-4d1f-8154-eebf2ec6f887">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNC01LTEtMS0w_3493d374-374a-4fee-9089-7bd536b09870">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNC03LTEtMS0w_4305a63e-855f-47b5-b46a-0ddd3cf5d41e">107,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNS0xLTEtMS0w_90f59043-8ee4-4ba8-98e5-1d9f63a921cd">160,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNS0zLTEtMS0w_d003d1e3-7051-4646-885d-935d1454830e">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNS01LTEtMS0w_cea2e789-cf20-469a-8741-e2f4f7382128">5</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNS03LTEtMS0w_0880ca95-e8de-45b4-b826-0219d5de7aec">160,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Of our outstanding agency securities, $<ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDIxOA_f9d42527-ab0d-4de2-92db-cba5d98904bd">10.0</ix:nonFraction> million have maturity dates of less than one year and $<ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDI2Nw_592ad217-22f4-4561-b750-a0cfdff11107">11.2</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwMg_8efbf14a-390d-4a61-8d2e-efb73efed063">one</span> to <ix:nonNumeric contextRef="i9a331153831844abb1eef1d1c1087186_D20200101-20201231" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwOA_3b0791c4-c1bc-4dc9-93c5-89ee3004d4ca">two years</ix:nonNumeric> as of December&#160;31, 2020.</span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $<ix:nonFraction unitRef="usd" contextRef="i392569839eab4af895cd18151a8a634b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDM3MA_ba843bf2-acfa-4ac1-80b7-827c547c9834">1.1</ix:nonFraction> million have a maturity date of less than one year and $<ix:nonFraction unitRef="usd" contextRef="i392569839eab4af895cd18151a8a634b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQyMA_377146d0-8d43-4382-86b4-ef334de7a88f">1.3</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ1NQ_25069077-64eb-4770-a079-0932cb57d201">one</span> to <ix:nonNumeric contextRef="i41d5876a7ef54861bdd2687c9d49d1e8_D20200101-20201231" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ2MQ_c0ec87ff-8ede-4e34-924a-15e43382d649">two years</ix:nonNumeric> as of December&#160;31, 2020.</span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations, $<ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDUzNg_7f62f7d9-0bf5-4f38-bf3d-48225b265c03">29.4</ix:nonFraction> million have maturity dates of less than one year and $<ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDU4NQ_f264b752-09f6-4176-977b-c63db0b9c65d">0.0</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyMA_ca5315b3-0237-444d-96a1-9e4abab3f521">one</span> to <ix:nonNumeric contextRef="ic24b2a7ad667476c99b89caed4bc0d88_D20200101-20201231" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyNg_1d7a5746-f460-44c5-91c4-f180e0903cad">two years</ix:nonNumeric> as of December&#160;31, 2020. </span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Of our outstanding U.S. Treasury securities, $<ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDY5MA_672cea0e-a7b6-41b8-ae13-ed3b09e8d200">102.7</ix:nonFraction> million have maturity dates of less than one year and $<ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDczOQ_37780332-234d-42d0-9f37-1971296dbe65">5.0</ix:nonFraction> million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc3NA_1f934835-43a2-4d2e-869c-8b6ff5fa0e3d">one</span> to <ix:nonNumeric contextRef="i4da7cac937d44fb19c0b0d2f90db8d5a_D20200101-20201231" format="ixt-sec:durwordsen" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc4MA_c88450c0-9971-4f61-b74c-3457a8b58235">two years</ix:nonNumeric> as of December&#160;31, 2020.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTI0Mw_831dd683-9360-44db-ae0f-dc13eff436c4" continuedAt="i32ec8e8e212b4b099fb96b3f2cd094dd" escape="true">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;June&#160;30, 2021&#160;and&#160;December&#160;31, 2020, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="i179337cf608b40a0b6ac804c88db01a0" continuedAt="i5e99a2aac3294bec8458c5cc287ac57a"><ix:continuation id="i32ec8e8e212b4b099fb96b3f2cd094dd"><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:26.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy0xLTEtMS0w_d8d71ccd-464a-4b5b-9de8-0bef648afe51">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy0zLTEtMS0w_00908592-c23b-4456-a130-213987ea933b">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy01LTEtMS0w_0026b09d-403c-455e-b3d2-a3b78fe20d71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy03LTEtMS0w_afab8dd3-2b98-40fe-a1ff-6157f1d6d649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy05LTEtMS0w_f5541b16-269c-4125-85ff-1c503a5dd1eb">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy0xMS0xLTEtMA_43010616-fa54-4469-93ad-1363a1ecb161">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC0xLTEtMS0w_eb34a7c9-f731-4d5c-b260-a0766b382204">3,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC0zLTEtMS0w_5167cbeb-adff-40e5-9dd0-8892ea532b78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC01LTEtMS0w_526f5265-5d47-4d9e-afbd-09947701f9d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC03LTEtMS0w_956bfae0-eeeb-4124-ac71-e0415da87827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC05LTEtMS0w_2cf20c18-c691-4f56-b53a-c6d77e1eeb96">3,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC0xMS0xLTEtMA_9ab0d06b-90ba-4118-ba3a-2b126625654f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi0xLTEtMS0w_c3863f3f-8248-4fa2-b927-842ca6e524a1">8,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi0zLTEtMS0w_339321c0-29ca-4c0d-acc3-19b2838a56b4">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi01LTEtMS0w_2cdfe726-cc3a-4828-99f5-27e5788f4e9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi03LTEtMS0w_e730e87d-bc64-402d-9c2d-dd48917bb154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi05LTEtMS0w_e34f754d-0535-439d-88dc-a3ff8e9e8f10">8,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi0xMS0xLTEtMA_8e9fce4b-9070-4d8f-b14b-f672f36c4145">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:26.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy0xLTEtMS0w_1a620498-3d18-4e1d-93fa-8188cabec49e">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy0zLTEtMS0w_2abd80c7-fed7-4665-822a-deef8448cb3e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy01LTEtMS0w_85d696b6-144b-4bb2-abcf-6a924283d9d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy03LTEtMS0w_433c39cb-4a29-4c03-a365-1784f3ac8581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy05LTEtMS0w_b58ea019-c2ce-424a-931d-6a55f5e5556c">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy0xMS0xLTEtMA_6e55a099-87ab-4aca-90b9-8f1461186696">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC0xLTEtMS0w_ae91f651-8da0-4a81-9da3-776dd2ab0100">6,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC0zLTEtMS0w_06518870-8a6c-47f8-82f2-9e49c3fb1bf6">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC01LTEtMS0w_43990ba5-0e23-475d-88bd-6b4b68b3a560">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC03LTEtMS0w_bc61b103-e8e0-4056-9b3b-dec11a37aa20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC05LTEtMS0w_7fe9d618-0bcc-4111-99f1-c72cb7208b1e">8,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC0xMS0xLTEtMA_48b2e785-79ea-4734-a3fd-8921336d6718">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS0xLTEtMS0w_b23d3fd0-d47b-4fdb-b5f0-6da22c5175a2">35,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS0zLTEtMS0w_6219b1da-165e-4998-8404-5c980644726e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS01LTEtMS0w_a7443529-3bee-4b9c-a709-72ba83197725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS03LTEtMS0w_ee731830-31b3-46f4-9e4c-fdc43e19bf04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS05LTEtMS0w_f8c4d9c1-9660-429f-8d03-603b8954103a">35,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS0xMS0xLTEtMA_9933597d-ff0d-433e-993b-365282c916ac">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi0xLTEtMS0w_33a63beb-378c-4494-858f-79b2338c9c19">46,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi0zLTEtMS0w_ce921fe8-00e1-438a-8d0f-acbf2a2041b2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi01LTEtMS0w_1a3bf220-f7c2-4c43-8317-3d36b919c454">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi03LTEtMS0w_8a3eced7-4a3e-4cc8-864a-66eeea2f5786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi05LTEtMS0w_d7a263b2-a127-4592-8546-3efd5aea0cfb">49,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi0xMS0xLTEtMA_333156e3-0be7-4262-a66a-c156d4169f3a">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5e99a2aac3294bec8458c5cc287ac57a">As of June&#160;30, 2021 and 2020, unrealized losses on available-for-sale investments were <ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTE0Nw_055a7e92-9f38-4dd0-946d-670f7d7cdd6f"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTE0Nw_e2e0e937-0fec-4119-8389-4207e74b634f">no</ix:nonFraction></ix:nonFraction>t material, and accordingly, <ix:nonFraction unitRef="usd" contextRef="idfc960c533644748967278a36e67af20_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTE3OA_07c84060-b9ed-4fd8-948c-c4ed9d4a4064"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTE3OA_8e478822-affe-46c9-8788-55290eb1b30c">no</ix:nonFraction></ix:nonFraction> allowance for credit losses were recorded.</ix:continuation> </span></div><div id="ie2789247198f4cf1b60b048da420eb52_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfMjg5_21fc73ae-216e-4666-8ee9-d045ca3547ea" continuedAt="i7fe8fd235d374c67886650e70a6835bd" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="i7fe8fd235d374c67886650e70a6835bd"><div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the <ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfNTE_28f3959c-2714-4278-8753-7df881dc6047">500,000,000</ix:nonFraction>&#160;shares of common stock authorized</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfODk_892b420f-b7c1-4d20-bb6c-56a98c42d58a"><ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfODk_927b55a4-c5e3-42cd-8f65-3ab5de8ff28c">27,432,609</ix:nonFraction></ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of June&#160;30, 2021. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfMjky_b92c2a74-8972-41b9-a49a-7545935c009e" continuedAt="i9a69d0bc9f4e4751921b9450556a7f57" escape="true">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at June&#160;30, 2021 are as follows: </ix:nonNumeric></span></div><ix:continuation id="i9a69d0bc9f4e4751921b9450556a7f57"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued and Outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RhYmxlOjk5ZTM1ZWUxYjYwNjQzMTliNzBjZmM0N2E1NGVmOGE0L3RhYmxlcmFuZ2U6OTllMzVlZTFiNjA2NDMxOWI3MGNmYzQ3YTU0ZWY4YTRfMS0xLTEtMS0w_6c2e4c8e-6042-4fb9-b8f9-a1f5bcb0da9b">3,731,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares Reserved For:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Equity Incentive Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i440d9f4d37024e65a225809024ed80f1_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RhYmxlOjk5ZTM1ZWUxYjYwNjQzMTliNzBjZmM0N2E1NGVmOGE0L3RhYmxlcmFuZ2U6OTllMzVlZTFiNjA2NDMxOWI3MGNmYzQ3YTU0ZWY4YTRfNC0xLTEtMS0w_712a6b50-d595-40f5-8968-a0a1256f4a6e">3,192,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74f2dd192f9145a1bcc410371db79135_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RhYmxlOjk5ZTM1ZWUxYjYwNjQzMTliNzBjZmM0N2E1NGVmOGE0L3RhYmxlcmFuZ2U6OTllMzVlZTFiNjA2NDMxOWI3MGNmYzQ3YTU0ZWY4YTRfNS0xLTEtMS0w_4b770262-050e-4ac5-8915-6e82e23dff90">1,271,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RhYmxlOjk5ZTM1ZWUxYjYwNjQzMTliNzBjZmM0N2E1NGVmOGE0L3RhYmxlcmFuZ2U6OTllMzVlZTFiNjA2NDMxOWI3MGNmYzQ3YTU0ZWY4YTRfNi0xLTEtMS0w_716fdc31-56c9-46d6-9234-a326ab0780c5">8,195,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="ie2789247198f4cf1b60b048da420eb52_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI5NA_e8856edd-e3b1-4e5e-84d6-3012e10d258a" continuedAt="iad5cd1d0e13f4882a21202cd1ea2f80a" escape="true">Equity Incentive Plans </ix:nonNumeric></span></div><ix:continuation id="iad5cd1d0e13f4882a21202cd1ea2f80a" continuedAt="i2e0e36cec7c54cc2857e810a699a66f4"><div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017 and replaced our existing 2006 Equity Incentive Plan. Under the 2017 Plan, we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by <ix:nonFraction unitRef="number" contextRef="i754f18c3eac04b658b8b6ed077314e68_D20180101-20180101" decimals="INF" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNzcw_f13a2ba5-5754-4ea4-8d9f-eab677785657">4</ix:nonFraction>% of the aggregate number of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="i2e0e36cec7c54cc2857e810a699a66f4" continuedAt="i32143c631bd74b1b86f088f2f290250a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4866424e06474a119edf3063462a6832_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfOTg3_882832a1-cde5-4e2f-bb95-c9b55e1cdb6a">1,094,223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares as of January 1, 2021.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by <ix:nonFraction unitRef="number" contextRef="ia3b08700ca1748b2afd4fa071b355893_D20180101-20180101" decimals="INF" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTQ4Mg_9d5772de-4b24-4e6f-a9a4-72e14680126b">1</ix:nonFraction>% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="ib69a7ed7bd244d29905de3cacf88167f_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTY5NA_30965e25-cd50-457b-824e-be3f6b7eb8b0">273,555</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares as of January 1, 2021. The initial offering period for the ESPP began in May 2021.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees generally vest over a <ix:nonNumeric contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI3OA_5c357e28-0ea8-4a67-a09a-f62a1b454d8a">four-year</ix:nonNumeric> period while stock options granted to directors vest over a <ix:nonNumeric contextRef="i197e760b801d4f73b5d6e406c4027a35_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTg4NQ_7acd0a52-109a-414c-99ab-32f7f207eecc">one year</ix:nonNumeric> period. Each stock option award has a maximum term of <ix:nonNumeric contextRef="i197e760b801d4f73b5d6e406c4027a35_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTk0Mg_4d147af5-688a-439a-89f9-54107d958052"><ix:nonNumeric contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTk0Mg_57665e1f-5af3-4e8a-85ad-d25b2f098b69">10</ix:nonNumeric></ix:nonNumeric> years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI3Ng_c80f9e55-328d-4c75-b519-f7fccd201d16" continuedAt="ic08927d24d864ed89db5e8bb79d4b69f" escape="true">A summary of the activity related to stock option awards during the six months ended June 30, 2021 is as follows: </ix:nonNumeric></span></div><ix:continuation id="ic08927d24d864ed89db5e8bb79d4b69f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;(in</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMS0xLTEtMS0w_f81f3a15-dc2b-4b8d-8de9-022a97c2ab50">2,920,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMS0zLTEtMS0w_76c3b56d-353f-4f1a-a5f2-0b57c90cb3f3">26.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMi0xLTEtMS0w_977fb535-ce28-4c66-9cc1-3419495245b9">1,037,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMi0zLTEtMS0w_5d017608-0719-4afa-bdb2-e9002b6ba4ae">29.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMy0xLTEtMS0w_6585e16b-7e9d-4fc5-90de-6a4785b27359">77,034</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMy0zLTEtMS0w_74dce53c-2e0f-42df-bfdf-796ead05c1bf">9.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and cancellations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNC0xLTEtMS0w_4516a4a5-01a7-4363-b3dc-060dfa2feee2">149,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNC0zLTEtMS0w_96371a8f-cc71-4349-8f61-84db2b51cc1d">29.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNS0xLTEtMS0w_6e785d4e-399e-4386-98db-8481c7d4d15e">3,731,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNS0zLTEtMS0w_b3a7c5bd-3c9d-4083-afa5-f170ecbfd712">27.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNS01LTEtMS0w_d8a69119-54e6-4266-8737-472990f09542">7.51</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNS03LTEtMS0w_615b0930-e657-4210-ba96-181cea1492ae">24,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNi0xLTEtMS0w_3557722b-7af0-4bbf-a540-700d03ab7e0f">1,744,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNi0zLTEtMS0w_c8cc9cb6-ba23-423c-8354-b30331f0bc5a">27.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNi01LTEtMS0w_6dff5680-3b5e-483f-9fe9-ba9b30d405b8">5.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNi03LTEtMS0w_4e27bb93-158d-4e19-a75a-6b2b5cd1aa8a">17,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for awards issued to employees and non-employees over the requisite service period based on the estimated grant-date fair value of such awards. We record the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI4NA_4bcde887-fa0d-49b2-ab5c-4701ef44733e" continuedAt="iedec6865fdd64ae4af918e9c74f3232d" escape="true">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: </ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="iedec6865fdd64ae4af918e9c74f3232d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfMy0yLTEtMS0w_2fb3acdf-b247-424f-b0c7-cd226c965582">0.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfMy02LTEtMS0w_a7da947c-7a5b-4454-8f21-5d8e6af3dff4">1.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNC0yLTEtMS0w_4cb52a6c-4b5b-4a2c-8ebd-dc97ac292ac8">93.1</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNC02LTEtMS0w_79aa5d2a-4f6a-4554-8895-327a0a0f1a52">91.8</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNS0yLTEtMS0w_6bd47ff1-3997-41da-aa06-d2df4f35961d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNS02LTEtMS0w_d6353260-0cb1-45bd-aeec-676031333ae7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNi0yLTEtMS0w_d8327f95-38aa-41b3-a208-888b4aa46747">6.18</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNi02LTEtMS0w_02542f66-5394-4284-acfd-7e55b9e505a2">6.25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNy0yLTEtMS0w_f7ec95a9-4a94-42af-a2d4-df100e98e9d2">22.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNy02LTEtMS0w_f5c64e8f-fb0d-424a-bd27-d05c66e57a14">11.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate risk-free interest rate, expected term for employee stock-based awards, contractual term for non-employee stock-based awards, and volatility assumptions. The weighted-average expected option term for employee and </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="i32143c631bd74b1b86f088f2f290250a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-employee stock-based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted-average vesting period for all option tranches. Estimated volatility for 2021 incorporates the historical volatility of our stock price, and volatility for 2020 incorporates our stock price as well as similar entities whose share prices are publicly available. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock-based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </span></div><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI5Ng_3603c3bc-22fb-4025-8b88-22e5d63ccb46" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb3a9fe237f347e39f34d734ffdf3d9c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMi0xLTEtMS0w_f8cf106f-4711-4027-be21-e661eadb26f7">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626d95b570df4e1abdac73a6a2e718d0_D20200401-20200630" decimals="-3" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMi0zLTEtMS0w_8a53c2a1-cf4a-47ca-ae25-97994669a718">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib16d46e48de9476ca69ec729d02ab7f7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMi01LTEtMS0w_cd799aa5-3223-4ede-9f4c-f6a5d82891ff">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b921f1f24c4c54bb6d506c5e62de1f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMi03LTEtMS0w_a9f99ab5-63ad-4ad1-a08f-678678147f84">2,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79408e23b2ef4790851584643cf1fd31_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMy0xLTEtMS0w_0a9a52cc-12f5-4559-a4d9-a141b3b28212">2,255</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4c03b9afe14b17a08c26f39c61ee23_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMy0zLTEtMS0w_31ca730e-57a4-4f81-b745-d9a385bffe1e">1,783</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c0c2bd7cd84e75ba87c7188ac5cb04_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMy01LTEtMS0w_28966e4f-12f4-403f-a9bf-0fc7edc88674">4,376</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1bf654bbd4e431098303b2f5ba09a92_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMy03LTEtMS0w_69779d99-51ea-4250-a75f-f8bf6d972df5">3,612</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfNC0xLTEtMS0w_c1e37953-eda2-4a38-90da-b7cea75849c4">3,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfNC0zLTEtMS0w_09da4a92-c3ae-4351-b2d5-79fc1f415293">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfNC01LTEtMS0w_3faeadb7-8267-413d-9b3c-943c8df65deb">7,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfNC03LTEtMS0w_c4556c55-ae76-470c-a98d-0d5bf50a5394">5,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ie5753215b52c451093ff6ca5ba3c9575_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDEwOA_643cd2c5-ba3c-4217-9b10-2bf6123177b1">36.8</ix:nonFraction> million of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI3Mw_24763f26-286b-4834-9eae-bd3b6e2af40f">2.71</ix:nonNumeric> years. At June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="id7e2add807724d19a9e8cbee0dad3919_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTY0OTI2NzQ0NzcxMg_2782f152-fffd-4bf0-9304-92cb13652266">0.2</ix:nonFraction> million of unrecognized compensation cost related to the ESPP, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="ie04286dba40e490ebc78cc7952a23570_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTY0OTI2NzQ0NzcyNQ_df0d84a1-9899-429a-85ed-fe7d0871400a">0.38</ix:nonNumeric> years.</span></div></ix:continuation><div id="ie2789247198f4cf1b60b048da420eb52_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfNTAzNw_e1ec084e-4756-429b-8f59-93f8c3118358" continuedAt="i497b5286ee01466283d765c6a9d7f3a8" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i497b5286ee01466283d765c6a9d7f3a8" continuedAt="iafca0eef4df4456cbefee28d5c15405f"><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 11, 2020, we entered into an agreement to terminate our sublease (the &#8220;Sublease Termination&#8221;) with Trex Enterprises Corporation, with respect to facilities in the building at 10455 Pacific Center Court in San Diego, California (the &#8220;10455 Building&#8221;). The terms of the original sublease with Trex provided for a November 12, 2021 lease expiration. Under the Sublease Termination, we agreed to terminate the sublease agreement on December 15, 2020 with no associated penalty. We recorded a non-cash gain of approximately $<ix:nonFraction unitRef="usd" contextRef="ie3b64ce4f6404458b4b4d2e565325a2d_D20201215-20201215" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfNTg2_6c0345e5-dd9e-41dc-a5d6-5157404da2bf">0.1</ix:nonFraction>&#160;million as other income, in connection with the write-off of the lease liability and corresponding ROU asset. As of June&#160;30, 2021, there was <ix:nonFraction unitRef="usd" contextRef="i84c00b90fbbe46ffbed30a2f2233aea7_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMzI5ODUzNDg4ODM5MQ_05605aae-4226-4152-ae4a-52193c803fea"><ix:nonFraction unitRef="usd" contextRef="i84c00b90fbbe46ffbed30a2f2233aea7_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMzI5ODUzNDg4ODM5MQ_859ccf39-59ff-4b51-bf6b-0281a47fe1d1">no</ix:nonFraction></ix:nonFraction> lease liability and corresponding ROU asset related to the 10455 Building Lease. </span></div><div style="margin-top:12pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 4, 2020, we entered into a lease agreement with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121 (the &#8220;Lease Agreement&#8221;). Under the Lease Agreement, we agreed to lease approximately <ix:nonFraction unitRef="sqft" contextRef="i1767abcdc9d947d19efb733b02b78b30_I20200504" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDI0NQ_0f02fb82-01d1-45d7-b903-a523081df8c4">45,000</ix:nonFraction> square feet of space for a term of <ix:nonNumeric contextRef="i1767abcdc9d947d19efb733b02b78b30_I20200504" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDI4NA_dd0109af-35f3-449b-a515-2920de763dd2">124</ix:nonNumeric> months, beginning on April 5, 2021. The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional <ix:nonNumeric contextRef="i1767abcdc9d947d19efb733b02b78b30_I20200504" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDQyNg_bb9df583-3ec2-41ba-b6ce-52f83f61c947">five years</ix:nonNumeric>, as well as a one-time option to terminate the lease after <ix:nonNumeric contextRef="i769956911bf34bc3babeafd4ff7c179c_D20200504-20200504" format="ixt-sec:durwordsen" name="anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDQ4OQ_4f45528b-a459-41fc-b19b-46a1fc9a5c45">seven years</ix:nonNumeric> with the payment of a termination fee. The exercise of the lease option is at our sole discretion, which we currently do not anticipate exercising and as such was not recognized as part of our ROU assets and lease liabilities. The monthly base rent will be $<ix:nonFraction unitRef="usdPerSqft" contextRef="i769956911bf34bc3babeafd4ff7c179c_D20200504-20200504" decimals="2" name="anab:RentPerSquareFoot" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDU2Mg_4b25f205-b6ac-40d2-949d-cd9439ce8699">4.20</ix:nonFraction> per rentable square foot and will be increased by <ix:nonFraction unitRef="number" contextRef="i769956911bf34bc3babeafd4ff7c179c_D20200504-20200504" decimals="2" name="anab:AnnualRentIncreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDYxNg_bb2dd787-4581-4c1b-88a1-9a8f63f610ff">3</ix:nonFraction>% annually. Under the Lease Agreement, we are also responsible for our pro rata share of real estate taxes, building insurance, maintenance, direct expenses, and utilities. Upon lease commencement, on April 5, 2021, we recognized an ROU asset of $<ix:nonFraction unitRef="usd" contextRef="ib2b8bcbccfe046d982471dc4466417f9_I20210405" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMjE5OTAyMzI2OTI5OA_7660ff87-9de3-4a96-8402-675d4a7d244f">20.6</ix:nonFraction>&#160;million, with a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="ib2b8bcbccfe046d982471dc4466417f9_I20210405" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMjE5OTAyMzI2OTMxMg_87020b6c-cec5-4288-9167-91371f6b5f57">20.7</ix:nonFraction>&#160;million on the consolidated balance sheets. The ROU asset includes adjustments for prepayments, initial direct costs, and lease incentives. As of June&#160;30, 2021, we have recorded $<ix:nonFraction unitRef="usd" contextRef="ieb17cf126b4e4598b3ace9ab2298bc16_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDg0NA_631bc68f-a3c8-4e89-b20a-1ab516f04db2">0.3</ix:nonFraction>&#160;million as a security deposit in accordance with the terms of the Lease Agreement. As of June&#160;30, 2021, we also maintain the non-cancellable office lease for our facilities at 10421 Pacific Center Court in San Diego, California, which expires on August 31, 2021. </span></div><div style="margin-top:12pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our lease payments are fixed, and we recognize lease expense for leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was <ix:nonFraction unitRef="number" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTQ5NA_409eaeb6-4316-4e8f-9310-3fc03b47ab53">4</ix:nonFraction>%.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><ix:continuation id="iafca0eef4df4456cbefee28d5c15405f" continuedAt="i90fb68f33cdf4cfdb0e2ebf3a2bc457f"><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfNTAzNQ_036ea024-5dc8-4d57-8897-f1e9fda006ef" escape="true"><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following non-cancellable office lease costs are included in our consolidated statements of cash flow (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Cash Flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOmQyNDkwYWM5MTIyNTQ0ODA4ODg5YTVjOTM2ZDExYTM2L3RhYmxlcmFuZ2U6ZDI0OTBhYzkxMjI1NDQ4MDg4ODlhNWM5MzZkMTFhMzZfMi00LTEtMS0w_a3a7d5c9-4499-48cf-8493-b22816531b17">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOmQyNDkwYWM5MTIyNTQ0ODA4ODg5YTVjOTM2ZDExYTM2L3RhYmxlcmFuZ2U6ZDI0OTBhYzkxMjI1NDQ4MDg4ODlhNWM5MzZkMTFhMzZfMi02LTEtMS0w_77ffea5e-3eec-4e5d-afca-e333bda5014c">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOmQyNDkwYWM5MTIyNTQ0ODA4ODg5YTVjOTM2ZDExYTM2L3RhYmxlcmFuZ2U6ZDI0OTBhYzkxMjI1NDQ4MDg4ODlhNWM5MzZkMTFhMzZfMy00LTEtMS0w_9f826631-f063-478a-b58d-d2601203bea5">465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOmQyNDkwYWM5MTIyNTQ0ODA4ODg5YTVjOTM2ZDExYTM2L3RhYmxlcmFuZ2U6ZDI0OTBhYzkxMjI1NDQ4MDg4ODlhNWM5MzZkMTFhMzZfMy02LTEtMS0w_f61dcd88-54c7-420a-9143-39c0405261db">478</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfNTAzMg_7ee209b6-37af-46d2-b678-d4878d8027f0" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, the future minimum annual obligations for the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfMS0xLTEtMS0w_b8d61a06-7dca-481b-8a38-5724e65ed3a0">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfMi0xLTEtMS0w_1c0125df-8a9c-45c7-88d4-b2dcb3575545">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfMy0xLTEtMS0w_e2847cfb-e09d-4df3-80ef-de821741402f">2,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfNC0xLTEtMS0w_7badb4fa-4759-48eb-87f2-2d5bca6f4ea3">2,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfNS0xLTEtMS0w_4af3efa6-d538-41c6-9811-9f86ac5cf566">2,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="anab:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfNi0xLTEtMS0w_38d1921c-d2b4-4cee-9421-641c958928d7">15,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments required</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfNy0xLTEtMS0w_8c16e6d3-aa05-4ad4-a20c-e9e7e5f990fc">25,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfOC0xLTEtMS0w_caa0dc19-bc4b-47c5-955a-2cf56988b9fd">4,998</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfOS0xLTEtMS0w_3d3354aa-d893-4f4a-b143-b4af03e379d3">20,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:13pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div></ix:continuation><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i90fb68f33cdf4cfdb0e2ebf3a2bc457f">On March 25, 2020, a putative securities class action was filed in the United States District Court for the Southern District of California naming the Company and certain of its current or former officers as defendants. The complaint purports to assert claims under Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), Exchange Act Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019 (the &#8220;Class Period&#8221;). An amended complaint was filed on September 30, 2020 alleging that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab product candidate that artificially inflated our stock price. The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses. We believe that the plaintiff&#8217;s allegations are without merit and intend to vigorously defend against the claims. On May 3, 2021, a shareholder derivative complaint was filed in the same Court based on allegations substantially similar to those in the class action, and purporting to assert claims on the Company&#8217;s behalf against current or former officers and directors for alleged violation of Sections 14(a) and 20(a) of the Exchange Act, breach of fiduciary duties, unjust enrichment, waste of corporate assets and insider selling. Because the Company is in the early stages of these litigation matters, we are unable to estimate a reasonably possible loss or range of loss, if any, that may result from these matters.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; and &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this report include, among other things, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost, and timing of our product candidate development activities and ongoing and planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize antibodies, including our lead product candidate: imsidolimab for patients with generalized pustular psoriasis (&#8220;GPP&#8221;), skin toxicities associated with treatments with inhibitors of epidermal growth factor, ichthyosis, hidradenitis suppurativa, and acne;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the coronavirus (&#8220;COVID-19&#8221;) pandemic on our business and the United States (&#8220;U.S.&#8221;) and global economies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood that the clinical data generated in any study we performed, are performing, or plan to perform in a non-U.S. jurisdiction will be subsequently accepted by the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration (&#8220;FDA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or by foreign regulatory authorities outside of the jurisdiction where the study was being performed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and ability of our collaborators to develop and commercialize our partnered product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and advantages of our product candidates and approaches versus those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to execute on our strategy, including advancing our lead product candidates, identifying emerging opportunities in key therapeutic areas, continuing to expand our wholly-owned pipeline, and retaining rights to strategic products in key commercial markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for imsidolimab and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of any approved product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing, and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S., the United Kingdom, Australia, and other foreign countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our use of the net proceeds from our public offerings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors,&#8221; and elsewhere in this Quarterly Report. Moreover, we operate in a competitive </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements to conform these statements to actual results or to changes in our expectations, except as required by law.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context indicates otherwise, as used in this Quarterly Report, the terms &#8220;AnaptysBio,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to AnaptysBio, Inc., a Delaware corporation, and its subsidiaries taken as a whole, unless otherwise noted. AnaptysBio is our common law trademark. This Quarterly Report contains additional trade names, trademarks, and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited consolidated financial statements and related notes for the six months ended June 30, 2021, included in Part I, Item&#160;1 of this report and with our audited consolidated financial statements and related notes thereto for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K. This discussion and other sections of this Quarterly Report contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions, and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#8220;Risk Factors&#8221; included in Part II, Item&#160;1A of this Quarterly Report. You should also carefully read &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation (&#8220;SHM&#8221;), and replicates this natural process of antibody generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our strategy is to advance the development of our proprietary product candidates, and where applicable, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights. Our most advanced wholly-owned antibody programs, imsidolimab, rosnilimab, previously referred to as ANB030, and ANB032, are designed to modulate therapeutic targets that are genetically associated with human inflammatory disorders.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Imsidolimab, our IL-36R antibody previously referred to as ANB019, inhibits the interleukin-36 receptor (&#8220;IL-36R&#8221;), and is being developed for the treatment of multiple dermatological inflammatory diseases. We completed a Phase 1 clinical trial in healthy volunteers, which was presented at the European Academy of Allergy and Clinical Immunology in 2018, where imsidolimab was well-tolerated by all subjects, no dose-limiting toxicities were observed, and no serious adverse events were reported among any subjects in the clinical trial. In July 2020, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) granted Orphan Drug Designation for imsidolimab for the treatment of patients with GPP.  We completed an open-label, multi-dose, single-arm Phase 2 clinical trial of imsidolimab in 8 GPP patients, also referred to as the GALLOP clinical trial, where we announced positive topline data in October 2020. Six of 8 (75%) patients treated with imsidolimab monotherapy achieved the primary endpoint of improvement in the clinical global impression scale (&#8220;CGI&#8221;) on Day 29.  Two of 8 (25%) patients were considered to have not met the primary endpoint because they dropped out of the clinical trial prior to Day 29. The modified Japanese Dermatology Association Severity Index (&#8220;mJDA-SI&#8221;) score, which incorporates both dermatological and systemic aspects of GPP, decreased on average by 29% on Day 8 and 54% on Day 29. Erythema with skin pustules, which clinically defines GPP, decreased by 60% on Day 8 and 94% on Day 29.  Serum c-reactive protein (&#8220;CRP&#8221;), which is an indicator of systemic inflammation, was normal (less than 5 mg/L) for 5 of the 6 patients achieving the primary endpoint on Day 29.  Genotypic testing indicated homozygous wild-type IL-36RN, CARD14 and AP1S3 alleles for all tested patients.  We believe this suggests that imsidolimab may be broadly applicable to pustular diseases irrespective of genetic drivers.  Anti-drug antibodies were not detected as of Day 29 in any patient.  Imsidolimab was generally well-tolerated, and most treatment-emergent adverse events were mild to moderate in severity and resolved without sequelae.  No infusion or injection site reactions were observed. One patient dropped out of the clinical trial due to a diagnosis of Staphylococcal aureus bacteremia in the first week, which was a serious adverse event deemed to be possibly drug-related.  Because the patient was symptomatic prior to dosing and had a prior medical history of bacteremia, a common comorbidity of GPP, we do not believe this event is likely attributable to imsidolimab. Another patient dropped out of the study on Day 22 due to investigator reported inadequate efficacy.  One patient contracted COVID-19 during the course of the clinical trial, which was mild, unrelated to imsidolimab, and did not lead to study discontinuation. Data from the first two patients to have completed the Day 113 treatment period under this clinical trial, which we announced in September 2019, indicated sustained efficacy in these two patients through Day 113. We plan to report full data from the GALLOP clinical trial at the European Academy of Dermatology and Venereology (EADV) Congress in October 2021. While initial GPP epidemiology studies suggested at least 3,000 GPP patients in the United States, medical claims analyses conducted by IQVIA indicate approximately 37,000 unique patients were diagnosed with GPP at least once, and approximately 15,000 unique patients were diagnosed with GPP at least twice, by a physician between 2017 and 2019 using the International Classification of Diseases 10th Revision (ICD-10) billing code pertaining to GPP (L40.1). </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have most recently met with the FDA during the second quarter of 2021 for an end-of-Phase 2 meeting to review an orphan disease registration plan for imsidolimab for the treatment of GPP.  We anticipate initiating our Phase 3 registrational trials for imsidolimab for GPP, called GEMINI-1 and GEMINI-2, in the third quarter of 2021.  GEMINI-1 will enroll approximately 45 moderate-to-severe GPP patients, each undergoing an active flare at baseline, which will be randomized equally to receive a single dose of 750mg intravenous (IV) imsidolimab, 300mg IV imsidolimab or placebo.  The primary endpoint of the Phase 3 program is the proportion of patients achieving clear or almost clear skin as determined by a Generalized Pustular Psoriasis Physician&#8217;s Global Assessment (GPPPGA) score of zero or 1 at week 4 of GEMINI-1.  Patients completing the GEMINI-1 trial will subsequently be enrolled in GEMINI-2, where they will receive monthly doses of 200mg subcutaneous imsidolimab or placebo depending upon whether they are responders, partial responders or non-responders to treatment under GEMINI-1.  The objective of GEMINI-2 is to assess the efficacy and safety of imsidolimab after 6 months of monthly dosing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are conducting a global registry of GPP patients, also referred to as the RADIANCE study, which we anticipate will improve understanding of the patient journey and assist in enrollment of future GPP clinical trials.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are conducting clinical development of imsidolimab in acne, which is the most common skin disorder in the United States, with approximately 7 million patients diagnosed with moderate-to-severe disease. Moderate-to-severe acne typically presents with painful papules, pustules, nodules, cysts and scarring. A key contributing factor to the pathogenesis of acne is the immune response to p. acnes, which is associated with upregulated IL-36 cytokine activity, localized inflammation and neutrophil infiltration of the skin. Existing therapies, including isotretinoin and systemic antibiotics, provide variable efficacy for moderate-to-severe acne patients and have practical limitations to their use given potential for clinically meaningful side effects. We are conducting a Phase 2 clinical trial of imsidolimab, called ACORN, where 120 patients will be randomized equally between two dose levels of imsidolimab and placebo, for the treatment of moderate-to-severe acne, and we anticipate top-line data during the first half of 2022.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are conducting clinical development of imsidolimab in hidradenitis suppurativa, also known as acne inversa, which is a chronic inflammatory skin disease characterized by painful nodules in intertriginous areas that can progress to abscesses, sinus tracks and scarring. Current treatment options for hidradenitis suppurativa, including antibiotics, corticosteroids and anti-TNF therapy, have variable efficacy in moderate-to-severe patients, which often leads to surgery for removal of hidradenitis suppurativa nodules. Human translational studies have demonstrated elevated IL-36 cytokine expression in hidradenitis suppurativa skin biopsies, and we believe treatment of moderate-to-severe hidradenitis suppurativa with imsidolimab may lead to therapeutic benefit for this patient population. Moderate-to-severe hidradenitis suppurativa affects approximately 150,000 adults in the United States. We are conducting a Phase 2 clinical trial of imsidolimab in hidradenitis suppurativa, called HARP, where 120 patients will be randomized equally between two dose levels of imsidolimab and placebo, and we anticipate top-line data during the second half of 2022.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are conducting clinical development of imsidolimab for the treatment of skin toxicities associated with treatments with inhibitors of epidermal growth factor (&#8220;EGFRi&#8221;) and MAPK/ERK kinase (&#8220;MEKi&#8221;).  Treatment of solid tumors with EGFRi and/or MEKi is frequently limited by the occurrence of skin toxicities, including acneiform or papulopustular rash. Recent translational data has suggested that these skin toxicities are mediated by excess IL-36 signaling, leading to IL-8-mediated cutaneous neutrophilia and acneiform rash. Based on existing claims data, approximately 60,000 patients are prescribed EGFRi and/or MEKi treatments annually, and the vast majority of these patients experience skin toxicity, which in some cases leads to dose reduction and/or discontinuation of treatment. Current standard-of-care treatments are generally ineffective in patients with the most severe grades of EGFRi and/or MEKi mediated skin toxicity. We are conducting a Phase 2 clinical trial, called EMERGE, of imsidolimab in combination with EGFRi inhibitors, for the treatment of patients diagnosed with a certain baseline severity of skin toxicity, where 45 patients are randomized 2:1 between imsidolimab and placebo arms, to assess the efficacy of imsidolimab in the treatment of this indication where we anticipate an interim analysis by the end of 2021. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also conducting clinical development of imsidolimab in ichthyosis, which is a family of rare, inherited, dermatological disorders characterized by dry, scaling and thickened skin. Recent human translational studies have suggested that the underlying skin inflammation responsible for ichthyosis is mediated by dysregulated IL-36 signaling, and we believe that imsidolimab treatment may be efficacious in treatment of this condition. Approximately 6,000 patients in the United States are affected with moderate-to-severe levels of ichthyosis, and no approved therapies are available for this disease. We are conducting a Phase 2 clinical trial, called INSPIRE, of imsidolimab in patients with certain baseline severity of ichthyosis, where 24 patients are randomized 2:1 between imsidolimab and placebo arms, and we anticipate interim top-line data in 2022.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our second wholly-owned program, rosnilimab, previously referred to as ANB030, is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases. Genetic mutations in the PD-1 pathway are known to be associated with increased susceptibility to human inflammatory diseases, and hence we believe that rosnilimab is applicable to diseases where PD-1 checkpoint receptor function may be under-represented. We presented preclinical data for rosnilimab at the Festival of Biologics Annual Meeting in March 2020, including translational data demonstrating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> activity of rosnilimab in alopecia areata patient samples. We initiated a Phase 1 healthy volunteer clinical trial in the first half of 2020, which is designed to assess the safety, pharmacokinetics and pharmacodynamics of rosnilimab in single and multiple ascending dose cohorts. We anticipate top-line safety, pharmacokinetic and receptor occupancy data from this Phase 1 clinical trial during the fourth quarter of 2021. We plan to initiate a Phase 2 clinical trial of rosnilimab in alopecia areata in the fourth quarter of 2021. We continue to assess clinical development opportunities for rosnilimab in additional indications, including vitiligo and rheumatoid arthritis, and will make decisions in 2022 pending additional data.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our third wholly-owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. Mutations in the BTLA signaling pathway are associated with human inflammatory disease, and we believe ANB032 silences pro-inflammatory signaling by modulating BTLA binding to HVEM. We are conducting a healthy volunteer Phase 1 trial of ANB032, under an Australian Clinical Trial Notification (&#8220;CTN&#8221;) and anticipate top-line data from this trial during the first half of 2022. We presented preclinical data regarding ANB032 at the 2020 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting in October 2020.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to our wholly-owned antibody programs, multiple Company-developed antibody programs have been advanced to preclinical and clinical milestones under our collaborations. We have received to date approximately $205.3 million in cash receipts from collaborations. Our collaborations include an immuno-oncology-focused collaboration with GlaxoSmithKline, Inc. (&#8220;GSK&#8221;) and an inflammation-focused collaboration with Bristol-Myers Squibb (&#8220;BMS&#8221;). A Biologics License Application (&#8220;BLA&#8221;) for our most advanced partnered program, which is an anti-PD-1 antagonist antibody called JEMPERLI (dostarlimab), was approved by the FDA in April 2021 for the treatment of advanced or recurrent deficient mismatch repair endometrial cancer (&#8220;dMMREC&#8221;). This is the first AnaptysBio-generated antibody, of eight currently under clinical development, to obtain FDA approval. We earned a $20.0 million milestone payment as a result of this FDA approval. In addition, in April 2021 the European Medicines Agency (&#8220;EMA&#8221;) granted conditional marketing authorization in the European Union (&#8220;EU&#8221;) for JEMPERLI for use in women with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen, which approval makes JEMPERLI the first anti-PD-1 therapy available for endometrial cancer in Europe. We earned a $10.0 million milestone payment as a result of this approval. A second BLA submitted by GSK was accepted by the FDA during the first quarter of 2021 for JEMPERLI in pan-deficient mismatch repair tumors (&#8220;PdMMRT&#8221;). We received a $10.0 million cash milestone payment upon the FDA acceptance of GSK&#8217;s second FDA BLA for JEMPERLI and anticipate an additional $20.0 million cash milestone payment upon FDA approval of this second FDA BLA of JEMPERLI during the second half of 2021. We anticipate an additional $15.0 million and $165.0 million in milestone payments upon achievement of certain JEMPERLI regulatory and commercial milestones, respectively. JEMPERLI is currently in clinical development for various solid tumor indications, including dMMREC, PdMMRT, colorectal cancer, ovarian cancer, non-small cell lung cancer, cervical cancer, rectal cancer, clear cell sarcoma and head-and-neck squamous cell carcinoma. In June 2021, GSK disclosed peak year annual sales estimates of &#163;1-&#163;2 billion for JEMPERLI.  In October 2020, we amended our GSK collaboration to increase royalties on global net sales of JEMPERLI to 8% on annual global net sales below $1 billion and 12-25% of annual global net sales above $1 billion, add a 1% royalty rate on GSK&#8217;s global net sales of Zejula and received a one-time cash payment of $60.0 million. For more information about these collaborations, see Note 4 &#8212; Collaborative Research and Development Agreements in the accompanying notes to the consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain key information about our wholly-owned and partnered product candidates:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><img src="anab-20210630_g1.jpg" alt="anab-20210630_g1.jpg" style="height:548px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:3pt;margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to proactively monitor and assess the coronavirus (&#8220;COVID-19&#8221;) global pandemic. The full impact of the COVID-19 pandemic is inherently uncertain at the time of this Quarterly Report. Our ongoing clinical trials have been, and may continue to be, affected by the closure of offices, or country borders, among other measures being put in place around the world.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused us to modify our business practices (including but not limited to curtailing or modifying employee travel, moving to full remote work, and cancelling physical participation in meetings, events, and conferences). While we have begun to re-open our offices, we continue to allow remote work, and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, patients, and business partners.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent of the impact of the COVID-19 pandemic on our future liquidity and operational performance will depend on certain developments, including the duration and spread of the outbreak, including its variants, the availability and effectiveness of vaccines, the impact on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials, patients, and collaboration partners, and the effect on our suppliers.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Operating Results </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue from product sales. Our revenue has been derived from amortization of upfront license payments, research and development funding, milestone and royalty payments under collaboration and license agreements with our collaborators. From inception through June&#160;30, 2021, we have received $205.3 million in cash in non-dilutive funding from our collaborators.</span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research and development activities, including drug discovery efforts, preclinical and clinical development of our programs, and manufacturing. Our research and development expenses include: </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">External research and development expenses incurred under arrangements with third parties, such as contract research organizations (&#8220;CROs&#8221;), consultants, members of our scientific and therapeutic advisory boards, and contract manufacturing organizations (&#8220;CMOs&#8221;); </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Employee-related expenses, including salaries, benefits, travel, and stock-based compensation; </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies; and </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">License and sub-license fees. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have been received.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting research and development activities primarily on inflammation programs. We have a research and development team that conducts antibody discovery, characterization, translational studies, IND-enabling preclinical studies, and clinical development. We conduct some of our early research and preclinical activities internally and plan to rely on third parties, such as CROs and CMOs, for the execution of certain of our research and development activities, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> toxicology and pharmacology studies, drug product manufacturing, and clinical trials.</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have completed Phase 1 clinical trials and have ongoing Phase 2 clinical trials for imsidolimab and ongoing Phase 1 clinical trials for rosnilimab and ANB032. We expect our research and development expenses to be higher for the foreseeable future as we continue to advance our product candidates into larger clinical trials.</span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation for our executive, finance, legal, business development, human resource, and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses, and professional fees for auditing, tax, and legal services. </span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our short-term and long-term investments and is recognized when earned.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K filed with the SEC on February 25, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations - Comparison of the Three and Six Months Ended June&#160;30, 2021 and 2020 </span></div><div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue consists of both milestone payments under the collaborations, and royalty payments. We recognized $30.0 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million in milestone revenue for the three months ended June 30, 2021 and 2020, respectively, related to milestone payments associated with JEMPERLI, the anti-PD-1 antagonist antibody partnered with GSK. For the second quarter of 2021, milestone revenue reflects $20.0 million for first BLA approval in a first indication, and $10.0 million for first MAA approval in a first indication. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We recognized $40.0 million and $15.0 million in milestone revenue for the six months ended June 30, 2021 and 2020, respectively, related to milestone payments associated with JEMPERLI, the anti-PD-1 antagonist antibody partnered with GSK.   For the six months ended June 30, 2021, milestone revenue reflects $10.0 million for successful filing of the first BLA in a second indication for JEMPERLI, $20.0 million for first BLA approval in a first indication, and $10.0 million for first MAA approval in a first indication. For the six months ended June 30, 2020, milestone revenue reflects $10.0 million for successful filing of the first BLA in a first indication and $5.0 million for successful filing of the first MAA in a first indication.  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We expect that any collaboration revenue we generate will continue to fluctuate from period to period as a result of the timing and amount of milestones from our existing collaborations. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is a function of our partners' product sales and the applicable royalty rate. During the six months ended June&#160;30, 2021, we recognized $1.3&#160;million related to the net sales of GSK&#8217;s Zejula and JEMPERLI, which we estimated based on GSK&#8217;s historical sales.</span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $25.3 million during the three months ended June 30, 2021 compared to $17.9 million during the three months ended June 30, 2020 for an increase of $7.4 million, primarily due to a $4.5 million&#160;increase in clinical expenses, $1.9 million increase in salaries and related expenses, including stock compensation expense, and a $1.4 million increase in other research and development expenses, offset by a $0.4 million decrease in outside services for manufacturing expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $49.5 million during the six months ended June 30, 2021 compared to $38.9 million during the six months ended June 30, 2020 for an increase of $10.6 million, primarily due to a $7.0 million&#160;increase in clinical expenses, $3.1 million increase in salaries and related expenses, including stock compensation expense, and a $1.5 million increase in other research and development expenses, offset by a $1.0 million decrease in outside services for manufacturing expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development costs separately for each of our product candidates. We review our research and development expenses by focusing on external development and internal development costs. External development expenses consist of costs associated with our external preclinical and clinical trials, including pharmaceutical development and manufacturing. Included in preclinical and other unallocated costs are external corporate overhead costs that are not specific to any one program. Internal costs consist of salaries and wages, share-based compensation and benefits, which are not tracked by product candidate as several of our departments support multiple product candidate research and development programs. The following table summarizes the external costs attributable to each program and internal costs:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External Costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imsidolimab</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rosnilimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANB032</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Etokimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical and other unallocated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total External Costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal Costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $5.2 million during the three months ended June 30, 2021 compared to $4.7 million during the three months ended June 30, 2020 for an increase of $0.5 million, primarily due to a $0.8 million increase in personnel costs including stock compensation expense, $0.1 million increase in insurance expense, offset by a $0.4 million decrease in legal expense.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $10.7 million during the six months ended June 30, 2021 compared to $9.0 million during the six months ended June 30, 2020 for an increase of $1.7 million, primarily due to a $1.7 million increase in personnel costs including stock compensation expense, $0.3 million increase in insurance expense, offset by a $0.3 million decrease in legal expense.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase for the foreseeable future as we incur additional costs associated with being a publicly traded company, including legal, auditing and filing fees, additional insurance premiums, investor relations expenses and general compliance and consulting expenses. We also expect our intellectual property related legal expenses, including those related to preparing, filing, prosecuting and maintaining patent applications, to increase as our intellectual property portfolio expands. </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $0.1 million and $0.3 million during the three and six months ended June&#160;30, 2021, respectively, and was $1.1 million and $3.0 million during the three and six months ended June&#160;30, 2020 which primarily related to our short-term and long-term investments, the balance of which decreased during the periods as a result of funding our clinical trial programs. The decrease in interest income is also attributable to lower interest rates during the three and six months ended June&#160;30, 2021 and a decrease in investment balances as of June&#160;30, 2021.</span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $0 million and less than $0.1 million for the three and six months ended June&#160;30, 2021, respectively, and was less than $0.1 million and $0.1 million during the three and six months ended June&#160;30, 2020, respectively, which primarily related to foreign exchange transactions through our Australian subsidiary and with our foreign CROs and CMOs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception through June&#160;30, 2021, we have received an aggregate of $845.4 million to fund our operations, which included $621.0 million from the sale of equity securities, $205.3 million from our collaboration agreements and $19.1 million from venture debt. As of June&#160;30, 2021, we had $396.3 million in cash, cash equivalents and investments. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing cash, cash equivalents and investments, we are eligible to earn milestone and other contingent payments for the achievement of defined collaboration objectives and certain nonclinical, clinical, regulatory and sales-based events, and royalty payments under our collaboration agreements. Our ability to earn these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators&#8217; research and development activities. Our rights to payments under our collaboration agreements are our only committed external source of funds. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specific to our collaboration agreement with GSK, JEMPERLI is currently in clinical development for various solid tumor indications. In April 2021, we became eligible to receive additional milestones from GSK, as outlined above, following the acceptance and approval of BLA and EMA filings of JEMPERLI for the PdMMRT indication. We anticipate an additional $35.0 million and $165.0 million in milestone payments upon achievement of certain JEMPERLI regulatory and commercial milestones, respectively. Our amended GSK Agreement also includes a 1% royalty less third-party royalty deductions on GSK&#8217;s global net sales of Zejula</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that began in 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek to obtain additional financing in the future through equity or debt financings or through collaborations or partnerships with other companies. If we are unable to obtain additional financing on commercially reasonable terms, our business, financial condition and results of operations will be materially adversely affected. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services, including manufacturing, laboratory and related supplies, compensation and related expenses, legal, patent and other regulatory expenses, and general overhead costs. We have entered into agreements with certain vendors for the provision of services, including services related to commercial manufacturing, that we are unable to terminate for convenience.&#160;Under such agreements, we are contractually obligated to make certain minimum payments to the vendors with the amounts to be based on the timing of the termination and the specific terms of the agreement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and investments totaled $396.3 million as of June&#160;30, 2021, compared to $411.2 million as of December&#160;31, 2020. We believe that our existing cash, cash equivalents and investments will fund our current operating plan at least into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials and seeking regulatory approval is costly, and the timing of progress and expenses in these trials is uncertain.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the six months ended June 30, 2021 and 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,722)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,690&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,145&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,798&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,155&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the six months ended June 30, 2021 of $13.6 million was primarily due to our net loss of $18.6 million, adjusted for addbacks for non-cash expenses of $8.3 million, which includes stock-based compensation and amortization of operating right-of-use assets, and net decreases in working capital of $3.3 million. Net cash used in operating activities during the six months ended June 30, 2020 of $34.7 million was primarily due to our net loss of $29.8 million, adjusted for non-cash expenses of $6.4 million, which includes stock-based compensation and amortization of operating right-of-use assets, and net decreases in working capital of $11.3 million. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the six months ended June 30, 2021 and 2020 of $94.7 million and $86.1 million, respectively, primarily relates to the timing of our investment maturity, which was used to fund our operating expenses.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash provided by financing activities during the six months ended June 30, 2021 of $0.7 million related to the issuance of common stock upon the exercise of stock options. The net cash used in financing activities during the six months ended June 30, 2020 of $1.3 million primarily related to principal and final payments of $1.4 million made on our Term Loans, offset by $0.1 million in proceeds from the issuance of common stock upon the exercise of stock options. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with certain vendors for the provision of goods and services, which includes manufacturing services with contract manufacturing organizations and development services with contract research organizations. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement and therefore are cancellable contracts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information related to our operating leases and future minimum annual obligations, see Note 8 &#8212; Commitments and Contingencies in the accompanying notes to the consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June&#160;30, 2021, there have been no material changes surrounding our market risk, including interest rate risk, inflation risk, and foreign currency exchange risk from the discussion provided in Item 7A. Quantitative and Qualitative Disclosures About Market Risk of our Annual Report on Form 10-K filed with the SEC on February 25, 2021.</span></div><div id="ie2789247198f4cf1b60b048da420eb52_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. As of June&#160;30, 2021, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the quarter ended June&#160;30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ie2789247198f4cf1b60b048da420eb52_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We investigate these claims as they arise and accrue estimates for resolution of legal and other contingencies when losses are probable and estimable. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information related to our legal proceedings, see Note 8 &#8212; Commitments and Contingencies in the accompanying notes to the consolidated financial statements.</span></div><div id="ie2789247198f4cf1b60b048da420eb52_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Risk Factors</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our common stock involves various risks, and prospective investors are urged to carefully consider the matters discussed in the section titled &#8220;Risk Factors&#8221; prior to making an investment in our common stock. These risks include, but are not limited to, the following:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial viability. Results from our initial clinical trials may not be representative of the results we will experience in later clinical trials. If we or our collaborators are unable to complete development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The COVID-19 pandemic has had a material impact on the U.S. and global economies and could have a material adverse impact on our employees, contractors, and patients, which could adversely and materially impact our business, financial condition, and results of operations.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have only limited data regarding the safety profile of our wholly-owned product candidates when dosed in humans. Our ongoing and planned clinical trials or those of our collaborators may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to commercialize and generate revenue from our product candidates.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may not be successful in our efforts to use our technology platform to expand our pipeline of product candidates and develop marketable products.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:19pt">We have recently commenced clinical development of imsidolimab, rosnilimab and ANB032 and have a limited history of conducting clinical trials and no history of commercializing biotechnology products, which may make it difficult to evaluate the prospects for our future viability.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our product candidates may not achieve adequate market acceptance among physicians, patients, health care payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If companion diagnostics for our product candidates, for which such diagnostics are required, are not successfully, and in a timely manner, validated, developed or approved, we may not achieve marketing approval or realize the full commercial potential of our product candidates.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The manufacture of biologics is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. </span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have no products approved for commercial sale, and to date we have not generated any revenue or profit from sales of our product candidates.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We must attract and retain highly skilled employees in order to succeed.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any loss of our master cell banks or if any of our third-party manufacturers encounter other difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide product candidates for clinical trials or our products to patients, once approved, could be delayed or stopped.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We currently have no marketing and sales force. If we are unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to effectively sell or market our product candidates, if approved, or generate product revenue.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our existing collaborations, including those with GSK and BMS, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may not succeed in establishing and maintaining additional development and commercialization collaborations, which could adversely affect our ability to develop and commercialize product candidates.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The market price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery and Development of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial viability. Results from our initial clinical trials may not be representative of the results we will experience in later clinical trials. If we or our collaborators are unable to complete development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using our proprietary technology platform to develop therapeutic antibodies, including our wholly-owned product candidates, as well as other programs that are being developed by our collaborators. However, all of our wholly-owned </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and most of partnered product candidates are in the early stages of development, and, for a wide variety of reasons discussed below, may fail in development or suffer delays that adversely affect their commercial viability.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care, and other variables. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. For example, results from our initial Phase 2a clinical trial of etokimab in moderate-to-severe atopic dermatitis patients were not representative of the results we experienced in our later etokimab moderate-to-severe atopic dermatitis Phase 2b clinical trial called &#8220;ATLAS&#8221; and we ultimately discontinued development of etokimab.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our rationale for conducting clinical trials of imsidolimab in multiple indications is that we believe imsidolimab&#8217;s mechanism of action, the inhibition of IL-36R, has the potential be effective for treatment of a range of dermatological inflammatory diseases. However, it is possible that our assumptions regarding the effectiveness of imsidolimab&#8217;s mechanism of action may be incorrect and that imsidolimab may be ineffective in certain dermatological inflammatory diseases or in treating inflammatory disorders generally. If this were the case, then the results from any clinical trials of imsidolimab that we conduct are less likely to be positive. For example, top-line data from our POPLAR clinical trial of imsidolimab in PPP failed to meet the primary endpoint of the clinical trial of least-squares mean difference PPPASI improvement at week 16 (Day 113) and we do not currently plan to conduct further development of imsidolimab in PPP.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If our other ongoing or future clinical trials of imsidolimab are unsuccessful, whether for one of the reasons mentioned above or otherwise, imsidolimab may be delayed in development or fail entirely, which would have a material adverse impact on our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our current product candidates, and any other product candidates we may develop in the future, will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtaining regulatory permission to initiate clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">successful enrollment of patients in, and the completion of, our planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">receiving marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">establishing commercial manufacturing capabilities and/or making arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">enforcing and defending intellectual property rights and claims;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">achieving desirable therapeutic properties for our product candidates&#8217; intended indications;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">effectively competing with other therapies; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times, or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites, and the availability of effective treatments for the relevant disease. We may not be able to initiate our planned clinical trials if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or foreign regulatory authorities. More specifically, some of our product candidates, including imsidolimab, initially target indications that are very rare, which can prolong the clinical trial timeline for the regulatory process if sufficient patients cannot be enrolled in a timely manner.</span></div><div style="margin-top:18pt;text-indent:31.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The COVID-19 pandemic has had a material impact on the U.S. and global economies and could have a material adverse impact on our employees, contractors and patients, which could adversely and materially impact our business, financial condition and results of operations. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic and mitigation measures have had, and may continue to have, an adverse impact on global economic conditions, which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID-19 pandemic impacts our business and operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic has caused us to modify our business practices (including but not limited to curtailing or modifying employee travel, moving to full remote work, and cancelling physical participation in meetings, events and conferences). While we have begun to re-open our offices, we continue to allow some remote work, and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees and patients. In response to the COVID-19 pandemic, we initially limited our office to only those employees completing laboratory-based tasks essential to our development efforts, or &#8220;essential&#8221; employees, and are starting to allow other employees to work in our office with certain precautions in place that we believe will ensure our employees&#8217; safety and wellbeing. Certain jurisdictions have begun re-opening only to return to restrictions due to increases in new COVID-19 cases and the emergence of new variant strains of COVID-19. Even in areas where &#8220;stay-at-home&#8221; restrictions have been lifted and the number of cases of COVID-19 has declined, many individuals remain cautious about resuming activities such as preventive-care medical visits. Additionally, the emergence of new variant strains of COVID-19 in regions that have reopened has necessitated, and may in the future necessitate, renewed government restrictions.  We have implemented appropriate safety measures, following guidance from the Center for Disease Control and the Occupational Safety and Health Administration. Pursuant to updated guidance from the Equal Employment Opportunity Commission, we are engaging in limited and appropriate inquiries of employees regarding potential COVID-19 exposure based on the direct threat that such exposure may present to our workforce. We continue to address other unique situations that arise among our workforce due to the COVID-19 pandemic on a case-by-case basis. While we believe that we have taken appropriate measures to ensure the health and well-being of our employees, there can be no assurances that our measures will be sufficient to protect our employees in our workplace, and they may be exposed to COVID-19 outside of our workplace. If a number of our essential employees become ill, incapacitated or are otherwise unable to continue working during the current or any future epidemic, our operations may be adversely impacted.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A prolonged disruption or any further unforeseen delay in our operations or within any of our business activities could continue to result in reduced participation in ongoing clinical trials or delays in enrolling our planned clinical trials because we rely on contract research organizations (for non-clinical and clinical activities) (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;) to conduct our clinical trials and to manufacture our product candidates. If our CROs are unable to continue ongoing clinical trials or to enroll new patients for new clinical trials, or if our CMOs are unable to obtain sufficient quantities of reagents or manufacture adequate drug quantities, our clinical trials could be materially delayed or disrupted. We may also encounter delays from the FDA, EMA or other health authorities in our clinical development efforts. Any elongation or de-prioritization of our preclinical or clinical studies or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. Further, in reaction to the spread of COVID-19 in the United States and internationally, many patients and medical facilities are delaying or canceling elective procedures, adding further strain to health care budgets globally.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic may result in the inability of our suppliers to deliver supplies to us on a timely basis. We currently utilize third parties to, among other things, manufacture components of our product candidates and, in the future, intend to utilize third parties to conduct our preclinical and clinical studies. If either we or any third-party parties in the supply chain for materials used in the production of our product candidates are adversely impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our preclinical or clinical studies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Both the health and economic aspects of the COVID-19 virus are highly fluid, and depend in part on the emergence and spread of variant strains of the COVID-19 virus which cannot be predicted, and the future course of each is uncertain. For these reasons and other reasons that may come to light if the COVID-19 pandemic and associated protective or preventative measures expand, we may experience a material adverse effect, either directly or indirectly through our CROs, CMOs, collaboration partners or patients, on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">We have only limited data regarding the safety profile of our wholly-owned product candidates when dosed in humans. Our ongoing and planned clinical trials or those of our collaborators may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to obtain marketing approval for any of our product candidates, we must demonstrate the safety and efficacy of the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. If our product candidates are associated with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have conducted various preclinical studies of our product candidates, but we do not know the predictive value of these studies for humans, and we cannot guarantee that any positive results in preclinical studies will successfully translate to human patients. We have only completed Phase 1 and Phase 2 clinical trials with imsidolimab, and subsequent clinical trials with imsidolimab are currently ongoing. It is not uncommon to observe results in human clinical trials that are unexpected based on preclinical testing, or to observe results in later stage clinical trials that are unexpected based on early clinical trials. Many product candidates fail in clinical trials despite promising preclinical and early clinical results. In addition, top-line results of a clinical trial, which generally reflect preliminary reviews of primary efficacy and/or safety results, do not necessarily predict final results, and any top-line findings or assessments are subject to change pending the completion of final data review procedures. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some patients in our clinical trials have experienced adverse events, including serious adverse events. We reported that one patient dropped out of the GALLOP Phase 2 clinical trial for imsidolimab due to diagnosis with&#160;Staphylococcal aureus&#160;bacteremia on Day 3 post-imsidolimab administration, which was a serious adverse event deemed to be possibly drug-related. Subjects in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or in our Phase 1 or Phase 2 clinical trials. The observed potency and kinetics of our product candidates in preclinical studies may not be observed in human clinical trials. We have tested the dosing frequency and route of administration of our product candidates in preclinical studies, which will inform our dosing strategy for future clinical trials, however such dose and route of administration may not result in sufficient exposure or pharmacological effect in humans and may lead to unforeseen toxicity not previously observed in preclinical testing. If preclinical studies of our product candidates fail to provide preliminary evidence of safety to the satisfaction of regulatory authorities or do not otherwise produce satisfactory results, we may incur additional costs or experience delays in initiating and/or advancing the development and commercialization of our product candidates. Further, if clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trial, patients may drop out of our trial, or we may be required to abandon the trial or our development efforts of that product candidate altogether. We, the FDA, or other applicable regulatory authorities, or an institutional review board or ethics committee, may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such clinical trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude a product candidate from obtaining or maintaining marketing approval, undesirable side effects may </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, if any of our product candidates obtain marketing approval, toxicities associated with our product candidates may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early stage clinical testing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to commercialize and generate revenue from our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to continue to develop our product candidates, and to have the potential to achieve and sustain profitability, depends on the FDA and foreign regulatory authorities permitting us to conduct human clinical trials and, if our product candidates are safe and effective, obtaining approval from the FDA and foreign regulatory authorities to market them and subsequently successfully commercializing them, either alone or with our collaborators. The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and foreign regulatory authorities. Though we have cleared an IND and clinical trial application (&#8220;CTA&#8221;) to conduct clinical trials for imsidolimab in the United States and certain foreign jurisdictions and we have cleared an IND to conduct a clinical trial for rosnilimab in the United States, before commencing clinical trials in the United States for any other product candidate, we must submit an IND to the FDA; foreign regulatory authorities enforce similar requirements for initiation of clinical trials in other countries. An IND or foreign equivalent requires extensive preclinical studies, and there is no guarantee that the FDA or foreign regulatory authorities will allow clinical trials to proceed based on the IND or equivalent submission. For example, although we have initiated toxicology studies for our product candidates, the FDA in the United States, or other foreign regulatory authorities, as applicable, may not allow our clinical trials to proceed in the regulatory authority&#8217;s jurisdiction if we are unable to show safety margins acceptable to the particular regulatory authority in appropriate animal species in our preclinical toxicology studies.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we or our collaborators initiate and complete clinical trials for our product candidates, these product candidates will not be permitted to be marketed in the United States until approval of a BLA from the FDA is received, and will not be permitted to be marketed in other countries without marketing approval from foreign regulatory authorities. Obtaining approval of a BLA or other marketing approvals is often a lengthy, expensive and uncertain process over which the FDA and foreign regulatory authorities have substantial discretion. Other than submitting and receiving acceptance for initiation of our previous and current clinical trials in the United States and certain foreign jurisdictions, we have had only limited discussions with the FDA and no discussions with foreign regulatory authorities regarding the development plans for any of our product candidates or the designs of any of our later-stage clinical studies. We thus may not have the full benefit of the FDA&#8217;s or foreign regulatory authorities&#8217; current thinking on clinical trial designs or product development for our target indications. For example, we believe our planned Phase 3 trials for imsidolimab for GPP, GEMINI-1 and GEMINI-2, with GEMINI-1 enrolling approximately 45 moderate-to-severe GPP patients, will be sufficient to demonstrate substantial evidence of efficacy and safety of imsidolimab in GPP patients and obtain BLA approval, and we discussed these plans with the FDA in an end-of-Phase 2 meeting during the second quarter of 2021.  However, the FDA may determine, based on future clinical efficacy and safety data from our GPP studies, that we will need to conduct additional clinical trials in order to obtain approval of a BLA.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete, and are uncertain as to outcome. Product candidates, on average, take 10 to 15 years to be developed from the time they are discovered to the time they are approved and available for treating patients. The start or end of a clinical trial is often delayed or halted for many reasons, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">imposition of a clinical hold for safety reasons or following an inspection of clinical trial operations or site by the FDA or other regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">manufacturing challenges;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">insufficient supply or quality of product candidates or other materials necessary to conduct clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and CROs or failure by such CROs or trials sites to carry out the clinical trial in accordance with our agreed-upon terms;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">non-clinical or clinical sites becoming unavailable due to political, economic, or public health events, such as the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">clinical sites electing to terminate their participation in one of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inability or unwillingness of patients or medical investigators to follow clinical trial protocols;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">required clinical trial administrative actions;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">slower than anticipated patient enrollment;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changing standards of care;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">safety concerns;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">availability or prevalence of use of a comparative drug or required prior therapy; or</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">clinical outcomes or financial constraints.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical or other studies or clinical trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Moreover, regulatory authorities may determine that the clinical and other benefits of a product candidate do not outweigh the safety or other risks. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application may also cause delays in or prevent the approval of an application.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience any of the issues described above, or other similar or related issues, we may:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">not obtain marketing approval at all;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtain marketing approval in some countries and not in others;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:118%">We may not be successful in our efforts to use our technology platform to expand our pipeline of product candidates and develop marketable products.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. Our business depends on our successful development and commercialization of the limited number of internal product candidates we have in preclinical and early-stage clinical development. Even if we are successful in continuing to build our pipeline, development of the potential product candidates that we identify will require substantial investment in additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, building a commercial organization, and significant marketing efforts before we generate any revenue from product sales. Furthermore, such product candidates may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we cannot validate our technology platform by successfully developing and commercializing product candidates based upon our technological approach, we may not be able to obtain product or partnership revenue in future periods, which would adversely affect our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of our current focus on our lead product candidates, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Our understanding and evaluation of biological targets for the discovery and development of new product candidates may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">We have recently commenced clinical development of imsidolimab, rosnilimab and ANB032 and have a limited history of conducting clinical trials and no history of commercializing biotechnology products, which may make it difficult to evaluate the prospects for our future viability.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations to date have been largely limited to financing and staffing our company, developing our technology, and developing our wholly-owned product candidates and other product candidates in partnerships with our collaborators. As a company, we have only very limited experience conducting clinical trials and have not had previous experience commercializing product candidates, including submitting a BLA to the FDA. In part because of this lack of experience, we cannot be certain that planned clinical trials will begin or be completed on time, if at all, that our planned development programs would be acceptable to the FDA or other regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized. Clinical trials and commercializing our wholly-owned product candidates will require significant additional financial and management resources, and reliance on third-party clinical investigators, CROs, consultants or collaborators. Relying on third-party clinical investigators, CROs or collaborators may result in delays that are outside of our control.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">Furthermore, we may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%;padding-left:19pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%;padding-left:19pt">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">conditions imposed by the FDA or foreign regulatory authorities regarding the number, scope or design of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in enrolling research subjects in clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">high drop-out rates of research subjects;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inadequate supply or quality of clinical trial materials or other supplies necessary for the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">greater than anticipated clinical trial costs;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">poor effectiveness or unacceptable side effects of our product candidates during clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">serious and unexpected drug-related side effects experienced by participants in our planned clinical trials or by individuals using drugs similar to our product candidates;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">varying interpretations of data by the FDA and foreign regulatory authorities.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, any predictions you make about our future success or viability based on our short operating history may not be as accurate as they could be if we had a longer operating history or an established track record in conducting clinical trials or commercializing products.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as a clinical stage business, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry is highly competitive and subject to rapid and significant technological change. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical and biotechnology companies, established biotechnology companies, specialty biotechnology companies, emerging and start-up companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or approval from the FDA or foreign regulatory authorities or discovering, developing and commercializing products in our field before we do.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For GPP our competitors include marketed therapies such as secukinumab (Cosentyx; Novartis), which binds IL-17A; ustekinumab (Stelara; Janssen), which blocks IL-12 and 23 cytokine function; and acitretin (Soriatane; GSK), as well as therapies in development such as guselkumab (Janssen), which blocks IL-23 cytokine function, gevokizumab (Xoma 052) and canakinumab (Ilaris, Novartis), which binds IL-1 beta, anakinra (Kineret; Swedish Orphan Biovitrum AB), a recombinant form of the IL-1 receptor antagonist and an anti-IL-36 receptor antibody called spesolimab or BI-655130 (Boehringer Ingelheim).</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">For ichthyosis, systemically administered competitors include secukinumab (Cosentyx; Novartis), liarozole (GSK), dupilumab (Dupixent; Regeneron/Sanofi), and adalimumab (Humira; Abbvie). Various topical treatments may also be used off-label for treatment of ichthyosis related symptoms.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">For hidradenitis suppurativa, our competitors include adalimumab (Humira; Abbvie) which is approved for the treatment of moderate to severe hidradenitis suppurativa for patients 12 years of age or older.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">For acne, our competitors include retinoids and retinoid-like drugs, including tretinoin (Avita, Retin-A, adapalene (Differin) and tazarotene (Tazorac, Avage), antibiotics including clindamycin (Benzaclin, Duac) and erythromycin (Benzamycin) and isotretinoin (Amnesteem, Claravis, Accutane) and oral antibiotics including sarecycline (Seysara).</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">For our anti-inflammatory checkpoint modulator antibody programs, our competitors include CC-90006 (BMS), which is an anti-PD-1 agonist antibody developed under our partnership with BMS, a BTLA modulator antibody called LY3361237 being developed by Eli Lilly, a PD-1 agonist antibody called LY3462817 also being developed by Eli Lilly and two PD-1 agonist antibodies called PT627 and PT001 being developed by Pandion Therapeutics who is being acquired by Merck. Our competitors in moderate-to-severe alopecia areata and vitiligo include topical and oral corticosteroids, topical immunotherapy (diphencyprone, dinitrochlorobenzene, squaric acid dibutyl ester), calcineurin inhibitors (tacrolimus, pimecrolimus), light therapy, prostaglandins and janus kinase inhibitors (tofacitinib, rixolitinib) currently in development.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product is approved under a BLA. To date, several biosimilar products have been approved under the BPCIA, but no interchangeable biological products have been approved. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that if any of our product candidates are approved as a biological product under a BLA it should qualify for the 12-year period of exclusivity. However, there is a risk that the FDA will not consider any of our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, are less expensive or capture significant market share prior to or during our commercialization. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for planned clinical trials and acquiring technologies complementary to, or necessary for, our programs. In addition, the biotechnology industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our product candidates may not achieve adequate market acceptance among physicians, patients, health care payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, health care payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the efficacy and safety profile as demonstrated in planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing of market introduction of the product candidate as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the clinical indications for which the product candidate is approved;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">restrictions on the use of our products, if approved, such as boxed warnings or contraindications in labeling or a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), if any, which may not be required of alternative treatments and competitor products;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">acceptance of the product candidate as a safe and effective treatment by physicians, clinics and patients;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the potential and perceived advantages of product candidates over alternative treatments, including any similar generic treatments;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">relative convenience and ease of administration;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the frequency and severity of adverse events;</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the effectiveness of sales and marketing efforts; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unfavorable publicity relating to the product candidate.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, health care payors and patients, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If companion diagnostics for our product candidates, for which such diagnostics are required, are not successfully, and in a timely manner, validated, developed or approved, we may not achieve marketing approval or realize the full commercial potential of our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If companion diagnostics are developed in conjunction with clinical programs, the FDA may require regulatory approval of a companion diagnostic as a condition to approval of the product candidate. For example, if we use a genetic test to determine which patients are most likely to benefit from imsidolimab for the treatment of GPP by designing our pivotal clinical trial or clinical trials of imsidolimab in that indication to require that subjects test positive for specific genetic mutations as a criterion for enrollment, then we will likely be required to obtain FDA approval or clearance of a companion diagnostic, concurrent with approval of imsidolimab, to test for those genetic mutations; we may also be required to demonstrate to the FDA the predictive utility of the companion diagnostic&#8212;namely, that the diagnostic selects for patients in whom the biologic therapy will be effective or more effective compared to patients not selected for by the diagnostic. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. We do not currently have any agreement in place with any third party to develop or commercialize companion diagnostics for any of our product candidates. Companion diagnostics are subject to regulation by the FDA and foreign regulatory authorities as medical devices and require separate regulatory approval or clearance prior to commercialization.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners, or any third party, are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the development of our product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our planned clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations targeted by our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we believe genetic testing is becoming more prevalent in the diagnosis and treatment of various diseases and conditions, our product candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the companion diagnostic or the need to complete additional procedures to identify genetic markers prior to administering our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, our business would be harmed, possibly materially.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The manufacture of biologics is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing biologics is complex, highly-regulated and subject to multiple risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our manufacturer is not in compliance with FDA laws and regulations, including those governing current good manufacturing practices (&#8220;cGMPs&#8221;), the FDA may deny BLA approval until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we or our collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. Moreover, we source certain of the raw materials needed for our product candidates from outside the U.S. Although we have not experienced any material supply interruptions to date, it is possible that the COVID-19 pandemic could cause such interruptions in the future. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scaling up a biologic manufacturing process is a difficult and uncertain task, and we may not be successful in transferring our production system or the manufacturer may not have the necessary capabilities to complete the implementation and development process. If we are unable to adequately validate or scale-up the manufacturing process with our current manufacturers, we will need to transfer to other manufacturers and complete the manufacturing validation process, which can be lengthy and costly. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with contract manufacturers, we will still need to negotiate with such contract manufacturers agreements for commercial supply, and it is not certain we will be able to come to agreement on terms acceptable to us.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Needs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for commercial sale, and to date we have not generated any revenue or profit from sales of our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an early-stage biotechnology company with a limited operating history. We have no approved products. To date, our revenue has been primarily derived from our GSK and BMS research collaboration and license agreements, and we are significantly dependent on such collaborators for the successful development of product candidates in these collaborations. Our ability to generate revenue and become profitable depends upon our ability, alone or with our collaborators, to successfully complete the development of our product candidates for our target indications and to obtain necessary regulatory approvals.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses in every year except fiscal year 2014. We had $41.3 million in collaboration revenue and our net loss was $18.6 million for the six months ended June 30, 2021 and a net loss of $29.8 million for the six months ended June 30, 2020, with $15.0 million in collaboration revenue. As of June&#160;30, 2021, we had an accumulated deficit of $282.5 million.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily through our initial public offering of common stock in January 2017, our follow-on public offerings of common stock in October 2017 and September 2018, private placements of our preferred stock and the issuance of debt. We have devoted substantially all of our efforts to research and development. We have only recently initiated clinical development for three of our product candidates and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and the net losses we incur may fluctuate significantly from quarter to quarter. Our revenue has been historically derived from amortization of upfront payments, research and development funding, milestone and royalty payments under collaboration and license agreements with our collaborators. Our ability to generate future product revenue from our current or future product candidates depends on a number of additional factors, including our ability (or as applicable our collaborators&#8217; ability) to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue research and preclinical development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain existing and enter into new collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct additional preclinical studies and initiate clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approvals for the product candidates we develop or developed under our collaboration arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional executive, clinical, quality control and scientific personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and maintain supply and manufacturing relationships with third parties and ensure adequate and legally compliant manufacturing of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain coverage and adequate product reimbursement from third-party payors, including government payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieve market acceptance for our or our collaborators&#8217; products, if any.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability because of the numerous risks and uncertainties associated with product development. In addition, our expenses could increase significantly beyond expectations if we are required by the FDA or other regulatory authorities to perform studies or clinical trials in addition to those that we currently anticipate. Even if imsidolimab, or any of our other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates, is approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of any product candidate. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently only in the clinical development stages for our most advanced product candidates. In order to become and remain profitable we must, alone or with our collaborators, develop and eventually commercialize a product or products with significant market potential. This may require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, successfully developing companion diagnostics, obtaining marketing approval for these product candidates and manufacturing, marketing and selling those products for which we may obtain marketing approval. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain or expand our research and development efforts, expand our business or continue our operations. A decline in the value of our company would also cause you to lose part or even all of your investment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research and development company, our operations have consumed substantial amounts of cash since our inception. We expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we continue our discovery and preclinical development to identify new clinical candidates, and we and our collaborators conduct clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we incur additional costs associated with operating as a public company. We believe that our existing cash, cash equivalents and investments will fund our current operating plan at least into 2024. However, circumstances may cause us to consume capital more rapidly than we currently anticipate. For example, as we continue to move our product candidates through preclinical studies, submit INDs or foreign equivalents and conduct clinical development, we may have adverse results requiring us to find new product candidates. Any of these events may increase our development costs more than we expect. We may need to raise additional funds or otherwise obtain funding through collaboration agreements to continue development of our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we do not raise additional capital when required or on acceptable terms, we may need to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly delay, scale back or discontinue the development or commercialization of our product candidates or cease operations altogether;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek strategic alliances for research and development programs at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relinquish, or license on unfavorable terms, our rights to technologies or future product candidates that we otherwise would seek to develop or commercialize ourselves; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminate staff to conserve resources.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to conduct additional fundraising activities and we do not raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects. Our forecast of the period of time through which our financial resources will adequately support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#8220;Risk Factors&#8221; section. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Our future funding requirements, both short and long-term, will depend on many factors, including:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates and future product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and size of clinical trials needed to show safety, efficacy and an acceptable risk/benefit profile for any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and foreign regulatory authorities, including the potential for such authorities to require that we perform more studies or trials than those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success or failure of products sold by our collaborators, such as JEMPERLI and Zejula by GSK, and the timing thereof;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain existing and enter into new collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost to establish, maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of any approved product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of recruiting and retaining key employees;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the costs and fees associated with any delays or cancellations of forecasted manufacturing batches;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of selecting, auditing and potentially validating manufacturing sites for commercial-scale manufacturing; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates for which we may receive regulatory approval and that we determine to commercialize ourselves or in collaboration with our collaborators.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations, license agreements and royalty agreements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations, or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Growth, Operations and Macroeconomic Conditions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We must attract and retain highly skilled employees in order to succeed.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. This is especially critical as we ramp up our hiring </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">needs entering into later-stage product development of our product candidates. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan, harm our operating results and adversely affect our ability to successfully commercialize our product candidates. In particular, we believe that our future success is highly dependent upon the contributions of our senior management, particularly our President and Chief Executive Officer, as well as our senior scientists. The loss of services of any of these individuals, who all have at-will employment arrangements with us, could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates, if approved. The competition for qualified personnel in the biotechnology field is intense and, as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. In addition, certain members of our senior management team have worked together for only a relatively short period of time, and it may be difficult to evaluate their effectiveness, on an individual or collective basis, and ability to address future challenges to our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any loss of our master cell banks or if any of our third-party manufacturers encounter other difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide product candidates for clinical trials or our products to patients, once approved, could be delayed or stopped.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of biotechnology products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We and our contract manufacturers must comply with cGMP regulations and guidelines for the manufacturing of biologics used in clinical trials and, if approved, marketed products. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up and validating initial production. Furthermore, if microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Delays in raw materials availability and supply may also extend the period of time required to develop our products.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our therapeutic antibodies are manufactured by starting with cells which are stored in a cell bank. We have one master cell bank for each antibody manufactured in accordance with cGMP and multiple working cell banks and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We currently have no marketing and sales force. If we are unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to effectively sell or market our product candidates, if approved, or generate product revenue.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to obtain regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development and growing our capability to conduct clinical trials. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be vulnerable to disruption, damage and financial obligation as a result of system failures.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, any of the internal computer systems belonging to us, our collaborators or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own, in collaborators&#8217; or in third-party service vendors&#8217; operations could result in a material disruption of our drug discovery and development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our or our collaborators&#8217; regulatory approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability as a result, our drug discovery programs and competitive position may be adversely affected, and the further development of our product candidates may be delayed. Furthermore, we may incur additional costs to remedy the damages caused by these disruptions or security breaches.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations, or the third parties upon whom we depend, are vulnerable to interruption by fire, earthquake, power loss, telecommunications failure, terrorist activity, health epidemics or pandemics and other events beyond our control, which could harm our business.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">Our facilities are located in San Diego, California, which is a seismically active region, and has also historically been subject to wildfires and electrical blackouts as a result of a shortage of available electrical power. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major earthquake, fire, power </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">loss, terrorist activity, health epidemics or pandemics such as the COVID-19 pandemic or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. We maintain multiple copies of each of our antibody sequences and electronic data records, most of which we maintain at our headquarters. If our facility was impacted by a seismic or wildfire event, we could lose some of our antibody sequences, which would have an adverse effect on our ability to perform our obligations under our collaborations and discover new targets.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, integral parties in our supply chain are geographically concentrated and operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe and/or serious adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our existing collaborations, including those with GSK and BMS, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaborations with GSK and BMS to develop several of our product candidates. We have also entered into antibody generation and/or development collaborations with various collaborators, including GSK and BMS, under which we have generated therapeutic quality antibodies using our technology platform and conducted certain preclinical studies in collaboration. We are currently aware that GSK and BMS have advanced multiple antibodies generated through our collaboration into clinical trials. If our collaborators terminate any of our collaborations, we may not receive all or any of this funding, which would adversely affect our business or financial condition. Our operational obligations under each of our collaborations has ended.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are unable to predict the success of our collaborations. Our collaborators have discretion in determining and directing the efforts and resources, including the ability to discontinue all efforts and resources, they apply to the development and, if approval is obtained, commercialization and marketing of the product candidates covered by such collaborations. As a result, our collaborators may elect to de-prioritize our programs, change their strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us. Our collaborators may have other marketed products and product candidates under collaboration with other companies, including some of our competitors, and their corporate objectives may not be consistent with our best interests. Our collaborators may also be unsuccessful in developing or commercializing our products. If our collaborations are unsuccessful, our business, financial condition, results of operations and prospects could be adversely affected. In addition, any dispute or litigation proceedings we may have with our collaborators in the future could delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expense. For example, in August 2020, we served notice on GSK related to an alleged breach of our collaboration agreement in connection with GSK&#8217;s use of certain antibodies originally developed by us for the development of a drug not covered by the agreement. We subsequently settled this matter in October 2020, but</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">here can be no assurance that we will not encounter such issues under our collaborations with GSK or other parties in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not succeed in establishing and maintaining additional development and commercialization collaborations, which could adversely affect our ability to develop and commercialize product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our current licensing arrangements with GSK and BMS, a part of our strategy is to enter into additional strategic product development and commercialization collaborations in the future, including collaborations to broaden and accelerate clinical development and potential commercialization of our product candidates. We may face significant competition in seeking appropriate development partners, and the negotiation process is time-consuming and complex. Moreover, we may not succeed in our efforts to establish collaborations or other alternative arrangements for any of our other existing or future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort, and/or third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy or to be commercially viable. Even if we are successful in our efforts to establish new collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into new collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if we fail to establish and maintain additional collaborations related to our product candidates:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the development of certain of our current or future product candidates may be terminated or delayed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash expenditures related to development of certain of our current or future product candidates would increase significantly and we may need to seek additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to hire additional employees or otherwise develop expertise, such as sales and marketing expertise, for which we have not budgeted; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will bear all of the risk related to the development and commercialization of any such product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If third parties on which we depend to conduct our planned preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with adverse effects on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third party clinical investigators, CROs, CMOs and consultants to design, conduct, supervise and monitor key activities relating to, discovery, manufacturing, non-clinical studies and clinical trials of our product candidates, and we intend to do the same for future activities relating to existing and future programs. Because we rely on third parties and do not have the ability to conduct all required discovery, manufacturing, preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of discovery, manufacturing, preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs, CMOs and consultants are not our employees, and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties we contract with might not be diligent, careful or timely in conducting our discovery, manufacturing, preclinical studies or clinical trials, resulting in discovery, manufacturing, preclinical studies or clinical trials being delayed or unsuccessful, in whole or in part.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely completely on third parties to manufacture our nonclinical, clinical and future commercial drug supplies of any approved products.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource the manufacture of our product candidates. We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. If we were to experience an unexpected loss of supply of our product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, our business would be harmed, and we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, we may be required to manufacture additional supplies of our product candidates to the extent our estimates of the amounts required prove inaccurate, we suffer unexpected losses of product candidate supplies, or we are required to have fresh product candidate supplies manufactured to satisfy regulatory requirements or specifications. Any significant delay or discontinuation in the supply of a product candidate, or the raw material components thereof, due to the need to replace a contract manufacturer or other third-party manufacturer, could considerably harm our business and ability to generate revenue and delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delays in our preclinical or clinical development could lead to delays or cancellations of forecasted manufacturing batches, which would typically result in significant fees owed by us to the manufacture and an uncertainty as to when the manufacturer will have the availability for a new time slot to manufacture the batch, which could lead to further delays in the development of the product candidate and have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails additional risks, including the possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the agreement by the manufacturer at a time that is costly or inconvenient for us. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected product candidates could be significantly delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on a small number of suppliers for the raw materials necessary to produce our product candidates. The loss of these suppliers, or their failure to supply us with these raw materials, would materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on the availability of key raw materials for our product candidates from a small number of third-party suppliers. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials. We do not have any control over the availability of raw materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and good clinical practices for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and foreign regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers or manufacturing process;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending BLAs or supplements to approved BLAs.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human Services&#8217; Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including promotion of our products for unapproved (or off-label) uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the government. Additionally, comparable foreign regulatory authorities will heavily scrutinize advertising and promotion of any product candidate that obtains approval outside of the United States.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, engaging in the impermissible promotion of our products for off-label uses can also subject us to false claims litigation under federal and state statutes, which can lead to civil and criminal penalties and fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. These false claims statutes include the federal False Claims Act, which allows any individual to bring a lawsuit against a biotechnology company on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the lawsuit, the individual will share in any fines or settlement funds. Such False Claims Act lawsuits against biotechnology companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements regarding certain sales practices promoting off-label drug uses involving fines in excess of $1.0 billion. This growth in litigation has increased the risk that a biotechnology company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid and other federal and state health care programs. In addition, we may incur liability from claims initiated under the Lanham Act or other federal and state unfair competition laws with respect to how our products are marketed and promoted. Furthermore, the off-label use of our products may increase the risk of product liability claims. If we do not lawfully promote our approved products, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">harmed, and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">We plan to seek Orphan Drug Designation for imsidolimab and certain of our other product candidates, and we may not be able to obtain or maintain Orphan Drug Designation or obtain the benefits associated with Orphan Drug status, including market exclusivity.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regulatory authorities in some jurisdictions, including the United States and the European Union (&#8220;EU&#8221;) may designate biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a biologic as an Orphan Drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. We received Orphan Drug Designation from the FDA for imsidolimab for our GPP indication in 2020 and plan to seek Orphan Drug Designation for imsidolimab in other indications and for certain of our other product candidates. Generally, if a biologic with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the biologic is entitled to a period of marketing exclusivity, which precludes the FDA with respect to the United States or the EMA with respect to the EU from approving another marketing application for a drug containing the same active moiety for the same indication for that time period. The applicable period is seven years in the United States and ten years in the EU. The EU exclusivity period can be reduced to six years if a biologic no longer meets the criteria for Orphan Drug Designation or if the biologic is sufficiently profitable so that market exclusivity is no longer justified. Orphan Drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In addition, the Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Also, regulatory approval for any product candidate may be withdrawn and other candidates may obtain approval before us.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not been granted Orphan Drug Designation for imsidolimab for any indication other than GPP, and there can be no assurance that any of our other product candidates will be designated as an orphan drug. For example, we may seek FDA Orphan Drug Designation for imsidolimab for the treatment of other indications, which will likely require that we demonstrate to FDA that each such indication is a distinct disease from psoriasis generally (a non-rare disease) or that use of imsidolimab may be appropriate for the treatment of such other indication but not appropriate for use in the general psoriasis population.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we obtain Orphan Drug Designation for imsidolimab in indications other than GPP, or for any of our other product candidates, we may not receive Orphan Drug exclusivity, and such exclusivity, if obtained, may not effectively protect the candidate from competition because different drugs or biologics can be approved for the same condition and only the first biologic with an Orphan Drug Designation to receive regulatory approval for a particular indication will receive marketing exclusivity. Even after a drug or biological with Orphan Drug Designation is approved, the FDA can subsequently approve another biologic containing the same active moiety (which in the case of an antibody is the principal molecular structure) for the same condition if the FDA concludes that the later biologic is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Any drugs we develop may become subject to unfavorable third-party reimbursement practices and pricing regulations.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and extent of coverage and adequate reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar health care management organizations or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only at limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services, because CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly examining the medical necessity and reviewing the cost effectiveness of medical drug products. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific drug products on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We or our collaborators may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement and the timing of achieving a reimbursement determination will be.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics, including our product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce health care costs may cause such organizations to limit both coverage and level of reimbursement for new products approved, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on health care costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the health care market.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to CMS and private payors, professional organizations such as the American Medical Association can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, some of our target indications, such as GPP, are rare diseases with small patient populations. In order for therapeutics that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such therapeutics must be higher, on a relative basis, to account for the low volume of sales. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare legislative reform measures may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;) was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhanced remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, (i) subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for follow on biologic products, (ii) proscribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and therapeutic biologics that are inhaled, infused, instilled, implanted or injected, (iii) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (iv) established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs and therapeutic biologics, apportioned among these entities according to their market share in certain government healthcare programs, (v) established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs and therapeutic biologics to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs and therapeutic biologics to be covered under Medicare Part D, which has since been increased to 70% by the Bipartisan Budget Act of 2018 (&#8220;BBA&#8221;), (vi) expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability, (vii) expanded the entities eligible for discounts under the Public Health program (viii) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research and (ix) established a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been judicial and Congressional efforts to repeal, replace or change certain aspects of the ACA, including measures taken during the former presidential administration. The Tax Cuts and Jobs Act of 2017, or the Tax Reform Act, among other things, included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In November 2020, the United States Supreme Court held oral arguments on the Fifth Circuit U.S. Court of Appeals decision that held that the individual mandate is unconstitutional. In June 2021, the Supreme Court held that the petitioners in the case did not have standing to challenge the individual mandate and remanded the case for dismissal. However, it is uncertain whether there will be additional efforts to challenge, repeal or replace the ACA or how healthcare measures of the Biden administration will impact the ACA and our business.  Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans and the medical device excise tax, and effective January 1, 2021, also eliminates the health </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurer tax. The BBA, among other things, also amended the ACA, effective January 1, 2019, by increasing from 50% to 70% the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In addition, CMS published a final rule that would give states greater flexibility, effective January 1, 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021 was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in 2013 and will remain in effect through 2030, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through December 31, 2021, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the former presidential administration&#8217;s budget proposal for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increased patient access to lower cost generic and biosimilar drugs. In particular, on July 24, 2020 and September 13, 2020, the former presidential administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration's proposals. The FDA also released a final rule in September 2020 providing guidance for states to build and submit importation plans for drugs from Canada. The former presidential administration and the Biden Administration both issued executive orders intended to favor government procurement from domestic manufacturers. In addition, the former presidential administration issued an executive order specifically aimed at the procurement of pharmaceutical products, which instructed the federal government to develop a list of &#8220;essential&#8221; medicines and then buy those and other medical supplies that are manufactured, including the manufacture of the API, in the United States. It is unclear whether this executive order or something similar will be implemented by the Biden Administration.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in November 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The CMS also issued an interim final rule implementing former President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. In December 2020, CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. It is unclear to what extent these new regulations will be implemented and to what extent these or any future legislation or regulation by the Biden administration will have on our business, including our ability to generate revenue and achieve profitability. We expect additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of cost containment measures or other health care reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business entails a significant risk of product liability, and our ability to obtain sufficient insurance coverage could have an adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other health care laws and regulations, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state health care laws and regulations include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal health care program such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any health care benefit program or making false statements relating to health care matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Program, with specific exceptions, to report to CMS annually information regarding payments and other transfers of value to physicians and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information was initially made publicly available on a searchable website in September 2014 and is disclosed on an annual basis; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA, among other things, amended the intent standard of the federal Anti-Kickback Statute and criminal health care fraud statutes to a stricter standard such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures. For example, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual health care practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals. Still other states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain pricing information, including information pertaining to and justifying price increases. Some states further require pharmaceutical companies to implement compliance programs and/or marketing codes. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, the collection and use of health data in the EU and the UK is governed by the General Data Protection Regulation (&#8220;GDPR&#8221;), which became fully applicable in May 2018 and has been incorporated into the UK&#8217;s data protection laws following Brexit. The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and new rights for individuals. The GDPR is complex, and guidance, interpretation and application under the GDPR are still developing. Failure to comply with the GDPR may result in substantial fines and other administrative penalties of up to the greater of &#8364;20 million or 4% of worldwide revenue. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. The pending EU ePrivacy Regulation is also expected to establish new requirements applicable to the handling of personal data and imposes penalties for non-compliance. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the European Economic Area to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws. For example, in July 2016, the European Commission adopted the EU-U.S. Privacy Shield Framework (the &#8220;Privacy Shield Framework&#8221;), which replaced the prior U.S. Safe Harbor scheme. On July 16, 2020, the Court of Justice of the European Union issued a decision, known as Schrems II, that declared the Privacy Shield Framework invalid. The Schrems II decision also resulted in substantial additional compliance obligations for companies that implement standard contractual clauses to ensure a valid basis for the transfer of personal data outside of Europe. The European Commission has also published draft updates to its standard contractual clauses that impose substantial additional obligations on the companies that wish to use the clauses as the basis for their data transfers. Additionally, California enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;), which became effective on January 1, 2020, and the California Privacy Rights Act (&#8220;CPRA&#8221;), which modifies the CCPA and creates additional obligations beginning on January 1, 2022. The CCPA and CPRA provide California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used, and provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The costs of compliance with, and other burdens imposed by, the GDPR, CCPA and other U.S., EU and worldwide laws may impose onerous requirements on our business and, if our efforts to comply with such laws are not successful, our business could be adversely affected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in significant part on our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; ability to establish, maintain and protect patents and other intellectual property rights and operate without infringing the intellectual property rights of others. We have filed numerous patent applications both in the United States and in foreign jurisdictions to obtain patent rights to inventions we have discovered. We have also licensed from third parties rights to patent portfolios. Some of these licenses give us the right to prepare, file and prosecute patent applications and maintain and enforce patents we have licensed, and other licenses may not give us such rights. The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors, licensees or collaborators. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent rights are highly uncertain. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. In the past, we have not always been able to obtain the full scope of patent protection we have initially sought in our patent applications, and as described above and as is typical for most biotechnology patent prosecution, we have been required to narrow or eliminate patent claims as part of the patent prosecution process. In addition, some patent applications that we or our licensors have filed have not resulted in issued patents because we or our licensors have abandoned those patent applications as changes in business and/or legal strategies dictated.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors, licensees, or collaborators were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications on or before March 15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of the patent. However the applicable authorities, including the FDA and the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) in the United States, and any equivalent foreign regulatory authority, may not agree with our assessment of whether such extensions are available and may refuse to grant extensions to our patents or may grant more limited extensions than we request. If this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors, licensees or collaborators may not be able to prevent third parties from practicing our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; inventions in all countries outside the United States or from selling or importing products made using our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors, licensees or collaborators have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us and our licensors, licensees or collaborators to stop the infringement of our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or marketing of competing products in violation of our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; proprietary rights generally. Proceedings to enforce our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; efforts and attention from other aspects of our business, could put our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents at risk of being invalidated or interpreted narrowly and our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors, licensees or collaborators. We or our licensors, licensees or collaborators may not prevail in any lawsuits that we or our licensors, licensees or collaborators initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications and the enforcement or defense of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;AIA&#8221;) was signed into law. The AIA includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, future and recent past changes in the patent laws in the U.S. and abroad could impact or could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications and the enforcement or defense of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; issued patents, which could have an impact on our business and financial conditions.  For example, over the past decade, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have rendered decisions in several patent cases such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Association for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., Mayo Collaborative Services v. Prometheus Laboratories, Inc., and Alice Corporation Pty. Ltd. v. CLS Bank International, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; ability to obtain patents in the future, these type of changes in the patent laws have created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; ability to obtain new patents or to enforce existing patents and patents that we and our licensors, licensees or collaborators may obtain in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors, licensees or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have an adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we collaborate with various collaborators on the development and commercialization of one or more of our product candidates and because we rely on third parties to manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our wholly-owned technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future may be granted rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. Our existing collaborative research and development programs may require us to share trade secrets under the terms of our research and development collaborations or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may infringe our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or misappropriate or otherwise violate our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; intellectual property rights. In the future, we or our licensors, licensees or collaborators may initiate legal proceedings to enforce or defend our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; intellectual property rights, such as the litigation we initiated in August 2020 to enforce our rights under our collaboration with GSK, to protect our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; trade secrets or to determine the validity or scope of intellectual property rights we own or control. Also, third parties may initiate legal proceedings against us or our licensors, licensees or collaborators to challenge the validity or scope of intellectual property rights we own or control. These proceedings can be expensive and time-consuming, and many of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors, licensees or collaborators. In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents do not cover the technology in question. Furthermore, an adverse result in any litigation or administrative proceeding could put one or more of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents at risk of being invalidated, held unenforceable or interpreted narrowly.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, despite our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; efforts, we or our licensors, licensees or collaborators may not prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the United States. In addition, litigation and administrative proceedings could result in substantial costs and diversion of management resources, which could harm our business and financial results.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings regarding patent and other intellectual property rights in the pharmaceutical industry including opposition, derivation, reexamination, inter partes review or interference proceedings, or other preissuance or post-grant proceedings. Such proceedings may be provoked by third parties or by us or our licensors, licensees or collaborators to protect or enforce our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents or patent applications. Additionally, third-party preissuance submission of prior art to the USPTO or other foreign jurisdictions may jeopardize the issuance or scope of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications. An unfavorable outcome in any such proceedings could require us or our licensors, licensees or collaborators to cease using the related technology, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors, licensees or collaborators a license on commercially reasonable terms or at all, and we could be forced to stop commercializing our product candidates. Even if we or our licensors, licensees or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors, licensees or collaborators.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial costs, and it may distract our management and other employees. We could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of shares of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we breach the license agreements related to our product candidates, we could lose the ability to continue the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our licensors, licensees and collaborators, to develop, manufacture, market and sell our product candidates and use our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; wholly-owned technologies without infringing the proprietary rights of third parties. A third party may hold intellectual property, including patent rights that are important or necessary to the development of our products. As a result, we are a party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the future. For example, we have in-licensed the rights to certain intellectual property relating to SHM under our in-license agreement with the Medical Research Council, which is the subject of issued patents and pending patent applications in certain countries. If we fail to comply with the obligations under these agreements, including payment and diligence terms, our licensors may have the right to terminate these agreements, in which event we may not be able to develop, manufacture, market or sell any product that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all, or cause us to lose our rights under these agreements, including our rights to intellectual property or technology important to our development programs.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us and our licensors, licensees or collaborators; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights, or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may initiate legal proceedings against us or our licensors, licensees or collaborators alleging that we or our licensors, licensees or collaborators infringe their intellectual property rights or that we or our licensors, licensees or collaborators may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, reexaminations, post-grant reviews, inter partes reviews or derivation proceedings in the United States or other jurisdictions. These proceedings can be expensive and time-consuming, and many of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors, licensees or collaborators.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources from our business. An unfavorable outcome could require us or our licensors, licensees or collaborators to cease using the related technology, to cease developing or commercializing our product candidates or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors, licensees or collaborators a license on commercially reasonable terms or at all. Even if we or our licensors, licensees or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors, licensees or collaborators. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our inability to protect our confidential information and trade secrets would harm our business and competitive position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened, and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The market price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions with respect to our products or our competitors&#8217; products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of preclinical studies and clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments with respect to our existing collaboration agreements and announcements of new collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes, breaches and terminations of our manufacturing agreements, collaborations agreements or other important agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to in-license or acquire additional product candidates or products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, our insiders or our other stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the biotechnology sector; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the stock market in general, and the Nasdaq Global Select Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. We are currently subject to securities litigation, which is described in Item 1, &#8220;Legal Proceedings.&#8221; This or any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">future securities litigation could result in substantial costs and a diversion of our management&#8217;s attention and resources. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have broad discretion in the use of the net proceeds from our public offerings and may not use them effectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of the net proceeds from our public offerings, and you will be relying on the judgment of our management regarding the application of these proceeds. Our management might not apply the net proceeds from our public offerings in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from our public offerings in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The market price of our common stock is volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been, and may in the future be, the target of this type of litigation. We are currently subject to securities litigation, which is described in Item 1, &#8220;Legal Proceedings.&#8221; Regardless of the outcome, these matters or future litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, divert management&#8217;s attention, and affect our ability to attract and retain additional executive management and qualified board members.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and the Nasdaq Global Select Market. Our management and other personnel devote a substantial amount of time to these compliance initiatives. In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time consuming. We intend to continue to invest resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these and future requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal controls on an annual basis. If we have material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We have only recently compiled the systems, processes and documentation necessary to comply with Section&#160;404 of the Sarbanes-Oxley Act. We will need to maintain and enhance these processes and controls as we grow, and we may require additional management and staff resources to do so. Additionally, even if we conclude our internal controls are effective for a given period, we may in the future identify one or more material weaknesses in our internal controls, in which case our management will be unable to conclude that our internal control over financial reporting is effective. Regardless of compliance with Section&#160;404, any failure of our internal control over financial reporting could have a material adverse effect on our reported operating results and harm our reputation. Internal control deficiencies could also result in a restatement of our financial results.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. We also have registered all shares of common stock that we may issue under our equity incentive plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions in our restated certificate of incorporation and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors so that not all members of our board are elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;) may discourage, delay or prevent a change in control of our company. Section 203 of the DGCL imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trial results or operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We plan to use potential future operating losses and our federal and state net operating loss (&#8220;NOL&#8221;) carryforwards to offset taxable income from revenue generated from operations or corporate collaborations. However, our ability to use NOL carryforwards could be limited as a result of additional issuances of equity securities.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to use our current year operating losses to offset taxable income from any revenue generated from operations or corporate collaborations. To the extent we have taxable income, we plan to use our NOL carryforwards to offset income that would otherwise be taxable. However, under the Tax Reform Act of 1986, the benefits from the use of our NOL carryforwards may be impaired or limited under Section 382 of the Internal Revenue Code of 1984, as amended (the &#8220;Code&#8221;), if we incur a cumulative ownership change of more than 50%, as interpreted by the U.S. Internal Revenue Service, over a three-year period. In September 2015, we completed a Section 382 and 383 ownership change analysis through December 31, 2014 and determined that there was an ownership change in 2007 that may limit the utilization of approximately $5.3 million and $5.4 million in federal and state NOLs, respectively, and $0.2 million in both federal and state research tax credits. We extended the analysis period of the study through December 31, 2018, noting an additional ownership change during fiscal 2017 that may limit the utilization of federal and state NOLs. Our use of federal NOL carryforwards could be limited further by the provisions of Section 382 of the Code depending upon the timing and amount of additional equity securities that we have issued or will issue. State NOL carryforwards may be similarly limited. Any such disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation, and any increased liabilities could adversely affect our business, results of operations, financial condition and cash flow.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The legislation significantly changes U.S. tax law by, among other things, lowering the corporate income tax rates. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. Additionally, the Tax Reform Act will no longer allow deductions for compensation in excess of $1 million for certain employees, even if paid as commissions or performance-based compensation. We may be subject to these limitations as provided for under Section 162(m) of the Code in the future. The Tax Reform Act also limits the amount taxpayers are able to deduct for federal NOL carryforwards generated in taxable years beginning after December 31, 2017 to 80% of the taxpayer&#8217;s taxable income. The law also generally repeals all carrybacks. However, any NOLs generated in taxable years after December 31, 2017 can be carried forward indefinitely. Losses arising in taxable years beginning before December 31, 2017 may still be carried back two years and are subject to their current expiration period. As of December 31, 2020, we have federal NOLs of approximately $248.4 million, which expire beginning December 31, 2028 through December 31, 2037, if not used to reduce income taxes payable in the future. </span></div><div style="margin-top:18pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are a smaller reporting company and may elect to comply with reduced public company reporting requirements applicable to smaller reporting companies, which could make our common stock less attractive to investors.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company,&#8221; meaning that we are not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent company that is not a &#8220;smaller reporting company,&#8221; and have either: (i) a public float of less than $250 million or (ii) annual revenues of less than $100 million during the most recently completed fiscal year and (A) no public float or (B) a public float of less than $700 million. As a &#8220;smaller reporting company,&#8221; we are subject to reduced disclosure obligations in our SEC filings compared to other issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Until such time as we cease to be a &#8220;smaller reporting company,&#8221; such reduced disclosure in our SEC filings may make it harder for investors to analyze our operating results and financial prospects.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If some investors find our common stock less attractive as a result of any choices to reduce future disclosure we may make, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div id="ie2789247198f4cf1b60b048da420eb52_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie2789247198f4cf1b60b048da420eb52_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults upon Senior Securities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ie2789247198f4cf1b60b048da420eb52_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie2789247198f4cf1b60b048da420eb52_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, below. </span></div><div id="ie2789247198f4cf1b60b048da420eb52_100"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.611%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anaptysbio-firstamendmentx.htm">First Amendment to Lease Agreement.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-6302021x10qxexx311.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-6302021x10qxexx311.htm">f 2002.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-6302021x10qxexx312.htm">Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-6302021x10qxexx312.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-6302021x10qxexx312.htm">2002.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-6302021x10qxexx321.htm">Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="anab-6302021x10qxexx322.htm">Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Report Instance Document - The Instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Calculation Linkbase Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Label Linkbase Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Presentation Linkbase Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File -  (formatted in Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ie2789247198f4cf1b60b048da420eb52_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AnaptysBio, Inc.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Hamza Suria</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hamza Suria</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dennis Mulroy</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dennis Mulroy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>anaptysbio-firstamendmentx.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib26193e8798247afa551a41ba152e1cc_1"></div><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:144.65pt;padding-right:144.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO LEASE AGREEMENT</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.1pt;padding-left:59pt;padding-right:5.7pt;text-align:justify;text-indent:35.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO LEASE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is effective as of April&#160;5, 2021 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WATERIDGE PROPERTY OWNER, LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware limited partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANAPTYSBIO, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), with reference to the facts set forth in the Recitals below.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:144.62pt;padding-right:144.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:59.05pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.26pt">Landlord and Tenant are parties to that certain Lease Agreement dated May 4, 2020 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), for certain Premises consisting of approximately 45,057 rentable square feet, commonly referred to as Suite 210 (sometimes referred to as Suite 2B) of the Building located at 10770 Wateridge Circle, San Diego, California 92121, as more specifically described in the Lease. Except as otherwise defined herein, all capitalized terms used herein shall have the meanings ascribed to them in the Lease.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:59.05pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:2.87pt">Landlord and Tenant have agreed to make certain modifications to the Lease as more fully provided below in this Amendment.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:144.65pt;padding-right:144.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDMENT</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:59.05pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">NOW, THEREFORE, in consideration of the Recitals above, the mutual covenants and conditions below, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:58.95pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.8pt;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As of the Amendment Effective Date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Outline of Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; attached to the Lease as Exhibit &#8220;A-I&#8221; is hereby deleted in its entirety and replaced with the outline attached to this Amendment as  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit &#8220;A-I&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (where the Premises is identified as Suite 2B). As shown in such Outline of Premises, the portions of the Building listed below have been either added to or excluded from the Premises, as set forth below&#59; provided, however, that the parties have agreed that the rentable square footage of the Premises (and, accordingly, the rent payable under the Lease) shall not change as a result of such additions and exclusions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:58.95pt;padding-right:5.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.42pt;text-decoration:underline">Elevator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The elevator serving the Premises (shown on the Outline of Premises as &#8220;ELEV B&#8221;), including the portion thereof which is located on the ground floor of the Building (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Elevator B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), shall be deemed to be part of the Premises for all purposes under the Lease, except that Landlord shall maintain the service contract for Elevator B, the costs of which shall be included in Operating Expenses. Any required repairs to Elevator B shall be completed by Landlord&#8217;s contractor and the cost thereof shall be reimbursed by Tenant (outside of Operating Expenses) within ten (10) business days after Landlord&#8217;s written request.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:59pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.75pt;text-decoration:underline">Stairwell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The east stairwell, including the portion thereof which is located on the ground floor of the Building, shall be deemed to be part of the Premises for all purposes under the Lease, except that Landlord shall provide janitorial services to such stairwell, the costs of which shall be included in Operating Expenses. Any required repairs to such stairwell shall be completed by Landlord&#8217;s contractor and the cost thereof shall be reimbursed by Tenant (outside of Operating Expenses) within ten (10) business days after Landlord&#8217;s written request.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:58.95pt;padding-right:5.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.42pt;text-decoration:underline">IDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The intermediate distribution frame located on the second floor of the Building, adjacent to Elevator B (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Second Floor IDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), shall be excluded from the Premises. Landlord shall have the right to enter the Premises during Tenant&#8217;s normal business hours upon at least 24 hours&#8217; prior verbal or written notice to Tenant (except in the event of an emergency) in order to access the Second Floor IDF for maintenance, repairs and all other purposes</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib26193e8798247afa551a41ba152e1cc_4"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:58.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as deemed reasonably necessary or desirable by Landlord, and Tenant shall have no access to or rights to use the Second Floor IDF.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:59pt;padding-right:5.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.75pt;text-decoration:underline">Janitor&#8217;s Closet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The janitor&#8217;s closet located within the Premises contains a water heater and related piping and equipment which serves other portions of the Building (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Water Heater</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Accordingly, the Common Water Heater shall be excluded from the Premises. Landlord shall have the right to enter the Premises during Tenant&#8217;s normal business hours upon at least 24 hours&#8217; prior verbal or written notice to Tenant (except in the event of an emergency) in order to access the Common Water Heater for maintenance, repairs and all other purposes as deemed reasonably necessary or desirable by Landlord, and Tenant shall have no access to or rights to use the Common Water Heater.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:59pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.75pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless otherwise specifically defined in this Amendment, terms with initial capital letters in this Amendment shall have the same meaning as such terms have in the Lease.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:59pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.75pt;text-decoration:underline">No Construction Against Party Drafting Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Landlord and Tenant acknowledge and agree that each of them, and their respective professional advisors, have reviewed this Amendment and that the provisions of this Amendment shall not be construed against either party. The rule of construction that ambiguities are to be construed against the party drafting the agreement shall not apply to the interpretation of this Amendment and is waived.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:59pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.75pt;text-decoration:underline">Counterpart Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Amendment may be executed in multiple counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which together shall constitute one instrument.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:59pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.75pt;text-decoration:underline">Continued Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as specifically modified by this Amendment, all of the terms, conditions and provisions of the Lease shall remain in full force and effect.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:225.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">signatures on following page</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib26193e8798247afa551a41ba152e1cc_7"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.05pt;padding-left:63pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have executed this Amendment on the dates below to be effective as of the Amendment Effective Date.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.628%"><tr><td style="width:1.0%"></td><td style="width:34.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LANDLORD&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:77.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">WATERIDGE PROPERTY OWNER, LP,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:77.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">a Delaware limited partnership</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.1pt;padding-left:77.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">By&#58; HSRE-BPI I GP, LLC</font></div><div style="padding-left:99.05pt;padding-right:9.65pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a Delaware limited liability company, its general partner</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:100pt;padding-right:-18.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Steven Bollert</font></div><div style="padding-right:-18.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Steven Bollert</font></div><div style="padding-left:100pt;padding-right:-18.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">Authorized Signatory</font></div><div style="padding-left:100pt;padding-right:-18.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%;text-decoration:underline">May 11, 2021</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TENANT&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:77.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">ANAPTYSBIO, INC                                   a Delaware corporation</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.8pt;padding-left:77.45pt;padding-right:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:173%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:173%;text-decoration:underline">&#47;s&#47; Eric Loumeau</font></div><div style="padding-right:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> Eric Loumeau</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:1.8pt;padding-left:77.45pt;padding-right:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:173%">Its&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:173%;text-decoration:underline">Chief Operating Officer</font></div><div style="margin-top:1.8pt;padding-left:77.45pt;padding-right:17.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:173%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:173%;text-decoration:underline">May 6, 2021</font></div></td></tr></table></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib26193e8798247afa551a41ba152e1cc_10"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.6pt;margin-top:4.05pt;padding-left:206.6pt;padding-right:206.6pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:225%">EXHIBIT &#8220;A-I&#8221; OUTLINE OF PREMISES</font></div><div style="padding-left:75.57pt;padding-right:75.57pt;text-align:center"><img alt="image_1.jpg" src="image_1.jpg" style="height:770px;margin-bottom:5pt;vertical-align:text-bottom;width:384px"></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">1</font></div></div></div><div id="ib26193e8798247afa551a41ba152e1cc_13"></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:66.87pt;padding-right:66.87pt;text-align:center"><img alt="image_3.jpg" src="image_3.jpg" style="height:849px;margin-bottom:5pt;vertical-align:text-bottom;width:428px"></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">1208202&#47;56335209v.2</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>anab-6302021x10qxexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ida95c54ed31f41a89b5033648211c8ce_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">I, Hamza Suria, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of AnaptysBio, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control&#160;over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially&#160;affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;9, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Hamza Suria</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hamza Suria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>anab-6302021x10qxexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i023d762ee44d443bb26121a9ef0ccd18_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">I, Dennis Mulroy, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">1. I have reviewed this quarterly report on Form 10-Q of AnaptysBio, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control&#160;over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially&#160;affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;9, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Dennis Mulroy</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dennis Mulroy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>anab-6302021x10qxexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3324cd12d8c14c3f856ffab81c5f3b83_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 18 U.S.C. SECTION 1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Hamza Suria, Chief Executive Officer of AnaptysBio, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58; </font></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2021 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;9, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Hamza Suria</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hamza Suria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>anab-6302021x10qxexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icded31d05066497abdc6004a89b3b999_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 18 U.S.C. SECTION 1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Dennis Mulroy, Chief Financial Officer of AnaptysBio, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58; </font></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2021 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;9, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Dennis Mulroy</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dennis Mulroy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>anab-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c7655f00-1548-4625-8cd9-c93812026c41,g:f65e361e-f377-49d6-802f-d6fad364b94f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:anab="http://www.anaptysbio.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.anaptysbio.com/20210630">
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.anaptysbio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofStockholdersEquity" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statement of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.anaptysbio.com/role/DescriptionoftheBusiness">
        <link:definition>2101101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsandSupplementalDisclosures" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures">
        <link:definition>2107103 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsandSupplementalDisclosuresTables" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables">
        <link:definition>2308302 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails">
        <link:definition>2409403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails">
        <link:definition>2410404 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandDevelopmentAgreements" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements">
        <link:definition>2111104 - Disclosure - Collaborative Research and Development Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandDevelopmentAgreementsTables" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables">
        <link:definition>2312303 - Disclosure - Collaborative Research and Development Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandDevelopmentAgreementsDetails" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails">
        <link:definition>2413405 - Disclosure - Collaborative Research and Development Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestments" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments">
        <link:definition>2114105 - Disclosure - Fair Value Measurements and Available for Sale Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsTables" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables">
        <link:definition>2315304 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2416406 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails">
        <link:definition>2417407 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails">
        <link:definition>2418408 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.anaptysbio.com/role/StockholdersEquity">
        <link:definition>2119106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables">
        <link:definition>2320305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>2421409 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>2422410 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans">
        <link:definition>2123107 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables">
        <link:definition>2324306 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansNarrativeDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails">
        <link:definition>2425411 - Disclosure - Equity Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansOptionActivityDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails">
        <link:definition>2426412 - Disclosure - Equity Incentive Plans - Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails">
        <link:definition>2427413 - Disclosure - Equity Incentive Plans - Summary of Weighted Average Assumptions used to Estimate Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails">
        <link:definition>2428414 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingencies">
        <link:definition>2129108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>2330307 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2431415 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails">
        <link:definition>2432416 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails">
        <link:definition>2433417 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" abstract="false" name="RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" abstract="false" name="RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anab_FirstBLAApprovalDMMRECMember" abstract="true" name="FirstBLAApprovalDMMRECMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember" abstract="true" name="AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_EmployeeStockPurchasePlan2017Member" abstract="true" name="EmployeeStockPurchasePlan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" abstract="true" name="A10770WateridgeCircleSanDiegoCalifornia92121Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_NetSalesRoyaltyPercent" abstract="false" name="NetSalesRoyaltyPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="anab_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" abstract="false" name="RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_AvailableforsaleDebtSecuritiesRemainingMaturity" abstract="false" name="AvailableforsaleDebtSecuritiesRemainingMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember" abstract="true" name="A10455PacificCenterCourtInSanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_FirstMAAApprovalFirstIndicationMember" abstract="true" name="FirstMAAApprovalFirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" abstract="false" name="RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_Phase3ClinicalTrialInitiationFirstIndicationMember" abstract="true" name="Phase3ClinicalTrialInitiationFirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" abstract="false" name="RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_AccruedResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_Phase1ClinicalTrialInitiationMember" abstract="true" name="Phase1ClinicalTrialInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" abstract="false" name="SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" abstract="false" name="RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anab_Phase2ClinicalTrialInitiationMember" abstract="true" name="Phase2ClinicalTrialInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_FilingOfBLASecondIndicationMember" abstract="true" name="FilingOfBLASecondIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_AnnualRentIncreasePercent" abstract="false" name="AnnualRentIncreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="anab_InVivoToxicologyStudiesMember" abstract="true" name="InVivoToxicologyStudiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" abstract="true" name="AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_Phase3ClinicalTrialInitiationSecondIndicationMember" abstract="true" name="Phase3ClinicalTrialInitiationSecondIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" abstract="false" name="CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="anab_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" abstract="false" name="RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anab_RentPerSquareFoot" abstract="false" name="RentPerSquareFoot" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType"/>
  <xs:element id="anab_ReceivablesForStockOptionsExercised" abstract="false" name="ReceivablesForStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_CommercialAndCorporateObligationsMember" abstract="true" name="CommercialAndCorporateObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_AnaptysBioGeneratedZejulaMember" abstract="true" name="AnaptysBioGeneratedZejulaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_FilingOfMMAFirstIndicationMember" abstract="true" name="FilingOfMMAFirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" abstract="false" name="LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anab_EquityIncentivePlan2017Member" abstract="true" name="EquityIncentivePlan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" abstract="false" name="RevenueRecognizedMilestoneMethodMilestonePaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="anab_FilingOfBLAFirstIndicationMember" abstract="true" name="FilingOfBLAFirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_ClearanceOfInvestigationalNewDrugFromFDAMember" abstract="true" name="ClearanceOfInvestigationalNewDrugFromFDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" abstract="false" name="RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" abstract="false" name="CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anab_CollaborationAndExclusiveLicenseAgreementMember" abstract="true" name="CollaborationAndExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember" abstract="true" name="AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member" abstract="true" name="AnaptysBioGeneratedAntiLAG3GSK40974386Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anab_GlaxoSmithKlineMember" abstract="true" name="GlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>anab-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c7655f00-1548-4625-8cd9-c93812026c41,g:f65e361e-f377-49d6-802f-d6fad364b94f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a8da02cd-0c6c-481f-970e-9a484ca561fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_25102bbb-92b4-40c7-b942-4cd71b3c8fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8da02cd-0c6c-481f-970e-9a484ca561fa" xlink:to="loc_us-gaap_AccountsPayableCurrent_25102bbb-92b4-40c7-b942-4cd71b3c8fd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b3dd12e5-6b47-4a8e-a43e-ce1541358dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8da02cd-0c6c-481f-970e-9a484ca561fa" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b3dd12e5-6b47-4a8e-a43e-ce1541358dff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e49ffa60-e39f-4a4e-b3df-bc5ba6760700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8da02cd-0c6c-481f-970e-9a484ca561fa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e49ffa60-e39f-4a4e-b3df-bc5ba6760700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_39c30073-e08e-4b89-88a3-767e5718fa38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e4fe93b9-c318-43b6-a07d-8b62d17167c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39c30073-e08e-4b89-88a3-767e5718fa38" xlink:to="loc_us-gaap_LiabilitiesCurrent_e4fe93b9-c318-43b6-a07d-8b62d17167c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_48f94404-a065-4746-930a-432d42e0417d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39c30073-e08e-4b89-88a3-767e5718fa38" xlink:to="loc_us-gaap_StockholdersEquity_48f94404-a065-4746-930a-432d42e0417d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ad13aed8-3d40-42a4-87f1-cf0fb92d3fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39c30073-e08e-4b89-88a3-767e5718fa38" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ad13aed8-3d40-42a4-87f1-cf0fb92d3fa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2b431974-ac30-4880-99ec-24a41796d646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_4d46f04f-087f-4057-bb99-b0f9526e6910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b431974-ac30-4880-99ec-24a41796d646" xlink:to="loc_us-gaap_ReceivablesNetCurrent_4d46f04f-087f-4057-bb99-b0f9526e6910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b47a9959-78aa-4f4c-8715-e6bd3a443579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b431974-ac30-4880-99ec-24a41796d646" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b47a9959-78aa-4f4c-8715-e6bd3a443579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_530b364f-3765-42c6-bf22-9b99d164eee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b431974-ac30-4880-99ec-24a41796d646" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_530b364f-3765-42c6-bf22-9b99d164eee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_48e7cad6-70ac-4dc8-9777-b1995c451b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b431974-ac30-4880-99ec-24a41796d646" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_48e7cad6-70ac-4dc8-9777-b1995c451b3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_53381209-1fd8-4cea-b6a5-ecb5972de046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b431974-ac30-4880-99ec-24a41796d646" xlink:to="loc_us-gaap_RestrictedCashCurrent_53381209-1fd8-4cea-b6a5-ecb5972de046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8f3611ec-7c69-4357-850a-6c946c79248e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fc30d466-bab3-4dfb-abfc-7fa2d94ffe78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f3611ec-7c69-4357-850a-6c946c79248e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fc30d466-bab3-4dfb-abfc-7fa2d94ffe78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_217285c9-7b90-4f78-9f45-5e3712ee9a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f3611ec-7c69-4357-850a-6c946c79248e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_217285c9-7b90-4f78-9f45-5e3712ee9a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fbad85a6-58e9-4391-8c56-335e82a70319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f3611ec-7c69-4357-850a-6c946c79248e" xlink:to="loc_us-gaap_AssetsCurrent_fbad85a6-58e9-4391-8c56-335e82a70319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_815cf4c8-b7d9-4113-b516-1895aecbbba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f3611ec-7c69-4357-850a-6c946c79248e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_815cf4c8-b7d9-4113-b516-1895aecbbba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_99d65c6b-68f7-439b-b8ba-7bdf08c404e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f3611ec-7c69-4357-850a-6c946c79248e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_99d65c6b-68f7-439b-b8ba-7bdf08c404e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e6dddbc6-fb18-449b-9ab0-d80103aab9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f3611ec-7c69-4357-850a-6c946c79248e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e6dddbc6-fb18-449b-9ab0-d80103aab9d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b5edfbb-69eb-4d41-80d4-651193bf72e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e043bc3a-704f-426f-86b4-f73ec58b6be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6b5edfbb-69eb-4d41-80d4-651193bf72e0" xlink:to="loc_us-gaap_CommonStockValue_e043bc3a-704f-426f-86b4-f73ec58b6be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_553a22f3-565a-4b21-91af-3aa883033ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6b5edfbb-69eb-4d41-80d4-651193bf72e0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_553a22f3-565a-4b21-91af-3aa883033ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8eb84a41-ac6a-4e3a-8cbd-a90f0aff0c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6b5edfbb-69eb-4d41-80d4-651193bf72e0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8eb84a41-ac6a-4e3a-8cbd-a90f0aff0c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f7d6e558-961e-4653-b198-a46b1241b7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6b5edfbb-69eb-4d41-80d4-651193bf72e0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f7d6e558-961e-4653-b198-a46b1241b7a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5b4a1eae-c62e-4828-8e1f-3255c9b00246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6b5edfbb-69eb-4d41-80d4-651193bf72e0" xlink:to="loc_us-gaap_PreferredStockValue_5b4a1eae-c62e-4828-8e1f-3255c9b00246" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_96cf65d6-f856-4e93-ba5c-4e59308b71c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f578527a-6ce8-423f-bc31-c4b99b96b8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_96cf65d6-f856-4e93-ba5c-4e59308b71c8" xlink:to="loc_us-gaap_NetIncomeLoss_f578527a-6ce8-423f-bc31-c4b99b96b8ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c7746af8-5ef8-415a-88c0-84f1ee60dea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_96cf65d6-f856-4e93-ba5c-4e59308b71c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c7746af8-5ef8-415a-88c0-84f1ee60dea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b10214d8-9622-40b2-8bbe-0a655a01c530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d49fc160-4bf6-4226-a114-52c837bd9261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b10214d8-9622-40b2-8bbe-0a655a01c530" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d49fc160-4bf6-4226-a114-52c837bd9261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_30d4daa9-7665-426c-abf4-e550d240af8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b10214d8-9622-40b2-8bbe-0a655a01c530" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_30d4daa9-7665-426c-abf4-e550d240af8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9f938df4-22bd-448b-b102-20c9e3db67f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7637621b-7c62-47af-bf6a-a9d41c47de83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9f938df4-22bd-448b-b102-20c9e3db67f3" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7637621b-7c62-47af-bf6a-a9d41c47de83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b534880e-569c-45ef-8072-c38b46fbc01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9f938df4-22bd-448b-b102-20c9e3db67f3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b534880e-569c-45ef-8072-c38b46fbc01c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bae17d77-32e4-484b-a476-b89d40bea8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a41f3e9a-27dc-404d-9bd4-9d9a41c10017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bae17d77-32e4-484b-a476-b89d40bea8a4" xlink:to="loc_us-gaap_OperatingExpenses_a41f3e9a-27dc-404d-9bd4-9d9a41c10017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aa9824a-30a6-4176-be76-4167114fffec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bae17d77-32e4-484b-a476-b89d40bea8a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aa9824a-30a6-4176-be76-4167114fffec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e494c8d5-136e-4800-a8a0-f7ed7bf4245c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9926c214-9f90-4e52-9592-df658ad48baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e494c8d5-136e-4800-a8a0-f7ed7bf4245c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9926c214-9f90-4e52-9592-df658ad48baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0de98de1-11d0-44e9-8297-b99ff4420402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e494c8d5-136e-4800-a8a0-f7ed7bf4245c" xlink:to="loc_us-gaap_OperatingIncomeLoss_0de98de1-11d0-44e9-8297-b99ff4420402" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6181690b-3caa-476a-b6f1-993f8ac23890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_19ea6f86-eefa-4114-b6b2-eef6cf41be79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6181690b-3caa-476a-b6f1-993f8ac23890" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_19ea6f86-eefa-4114-b6b2-eef6cf41be79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_95a0e5a3-b44d-4eb3-9bf2-0a8b3f12dedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6181690b-3caa-476a-b6f1-993f8ac23890" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_95a0e5a3-b44d-4eb3-9bf2-0a8b3f12dedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc4749ca-5a04-4b66-aa1b-0cc63c701c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6181690b-3caa-476a-b6f1-993f8ac23890" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc4749ca-5a04-4b66-aa1b-0cc63c701c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1232534-befb-4e9a-a8de-cfb0625e1f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a38df8df-7a25-4f3e-9355-174b68f1468f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1232534-befb-4e9a-a8de-cfb0625e1f3b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a38df8df-7a25-4f3e-9355-174b68f1468f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b85fc820-2218-40c9-8a39-40bf604a47db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1232534-befb-4e9a-a8de-cfb0625e1f3b" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b85fc820-2218-40c9-8a39-40bf604a47db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e4ce39f9-010a-4af8-83c5-b23fd01b2b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_us-gaap_NetIncomeLoss_e4ce39f9-010a-4af8-83c5-b23fd01b2b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_60845bb2-79db-468b-8297-8ff0cb6d4555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_60845bb2-79db-468b-8297-8ff0cb6d4555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_5971ec90-0dfb-4b0e-a1ed-1258a89e033d" xlink:href="anab-20210630.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_5971ec90-0dfb-4b0e-a1ed-1258a89e033d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_5c2093e4-258c-4128-a1c8-a9845a271c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_5c2093e4-258c-4128-a1c8-a9845a271c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9b9fdebc-427c-4d07-9e16-d727e2a60150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9b9fdebc-427c-4d07-9e16-d727e2a60150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_fe340fde-8797-4a8d-ae09-7d32a371e94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_fe340fde-8797-4a8d-ae09-7d32a371e94d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7544b73a-8b2d-4b36-a1a8-137a9cae6d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7544b73a-8b2d-4b36-a1a8-137a9cae6d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6f19f38a-3729-49e1-af3c-bf701e59e8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6f19f38a-3729-49e1-af3c-bf701e59e8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_af726888-7cf8-4d25-ad36-8a782f86637c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96e2c325-b331-4b23-96c9-6f16529f8cbf" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_af726888-7cf8-4d25-ad36-8a782f86637c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df8276d6-22a2-47cc-9e7b-2ebcdff0322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63a7ebdc-5f52-4176-97a5-213ccdb43ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df8276d6-22a2-47cc-9e7b-2ebcdff0322e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63a7ebdc-5f52-4176-97a5-213ccdb43ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_037f2dda-978f-4d13-9bf4-72112a6bf2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df8276d6-22a2-47cc-9e7b-2ebcdff0322e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_037f2dda-978f-4d13-9bf4-72112a6bf2a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35c4168c-94be-498d-8f5d-26fffbde8df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_df8276d6-22a2-47cc-9e7b-2ebcdff0322e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35c4168c-94be-498d-8f5d-26fffbde8df5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5dbeba49-50eb-43c3-a317-4d3d3abaaa7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_24ed3b32-2252-47d8-8894-98878cf75ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5dbeba49-50eb-43c3-a317-4d3d3abaaa7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_24ed3b32-2252-47d8-8894-98878cf75ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6611f2ab-b4ce-44a3-ac92-16ea17fc157e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5dbeba49-50eb-43c3-a317-4d3d3abaaa7f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6611f2ab-b4ce-44a3-ac92-16ea17fc157e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_54eac4bd-92cc-4d8e-9dc0-047bae2118e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ab5530c4-ac5c-45fd-8a04-88eb3ed6d475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_54eac4bd-92cc-4d8e-9dc0-047bae2118e6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ab5530c4-ac5c-45fd-8a04-88eb3ed6d475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ae469a62-7dda-4384-9247-cb79f31acdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_54eac4bd-92cc-4d8e-9dc0-047bae2118e6" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ae469a62-7dda-4384-9247-cb79f31acdfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_40c18ded-5cb3-4550-8908-b63763ff4460" xlink:href="anab-20210630.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_54eac4bd-92cc-4d8e-9dc0-047bae2118e6" xlink:to="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_40c18ded-5cb3-4550-8908-b63763ff4460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c833ecc2-8859-4e3f-be11-58c505885fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_54eac4bd-92cc-4d8e-9dc0-047bae2118e6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c833ecc2-8859-4e3f-be11-58c505885fb2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_95d55668-e034-474b-90e6-25fb9dc03771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8824d87c-d9c5-44e6-8277-41692a61ae7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_95d55668-e034-474b-90e6-25fb9dc03771" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8824d87c-d9c5-44e6-8277-41692a61ae7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8953ea9f-9f3f-4f86-aac5-7e3f62a5838a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_95d55668-e034-474b-90e6-25fb9dc03771" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8953ea9f-9f3f-4f86-aac5-7e3f62a5838a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dee7058c-e6f0-4970-8e34-b70651a02ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_95d55668-e034-474b-90e6-25fb9dc03771" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dee7058c-e6f0-4970-8e34-b70651a02ea0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_35e8da9b-7921-4265-9633-0c7e6d432069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_105598dd-b227-449b-84e5-b3b9af06be34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_35e8da9b-7921-4265-9633-0c7e6d432069" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_105598dd-b227-449b-84e5-b3b9af06be34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9c410f48-5331-46dd-91f9-ffd332d7e2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_35e8da9b-7921-4265-9633-0c7e6d432069" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9c410f48-5331-46dd-91f9-ffd332d7e2f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_22436a05-d634-476f-ad73-ba30fb47a97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5c30b30a-e488-48ff-8aab-efb2f985ae3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_22436a05-d634-476f-ad73-ba30fb47a97f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5c30b30a-e488-48ff-8aab-efb2f985ae3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7fd59d5b-fa0c-42db-933e-63c62fe7116c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_22436a05-d634-476f-ad73-ba30fb47a97f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7fd59d5b-fa0c-42db-933e-63c62fe7116c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a8221af6-5f70-40de-b053-45a8c3509846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_22436a05-d634-476f-ad73-ba30fb47a97f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a8221af6-5f70-40de-b053-45a8c3509846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1e66901f-6b5d-4f6b-bebc-aa851d6c1399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_22436a05-d634-476f-ad73-ba30fb47a97f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1e66901f-6b5d-4f6b-bebc-aa851d6c1399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_cb59ae09-a260-4c05-b5a0-d75c18f75ff2" xlink:href="anab-20210630.xsd#anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_22436a05-d634-476f-ad73-ba30fb47a97f" xlink:to="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_cb59ae09-a260-4c05-b5a0-d75c18f75ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d89c11fe-b767-4045-acd0-7d4d0f441367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_22436a05-d634-476f-ad73-ba30fb47a97f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d89c11fe-b767-4045-acd0-7d4d0f441367" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>anab-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c7655f00-1548-4625-8cd9-c93812026c41,g:f65e361e-f377-49d6-802f-d6fad364b94f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedStatementofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="extended" id="i041aef1e45054efda3b69b4153e86620_ConsolidatedStatementofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a794ebd1-5a52-48ee-b51d-c7b7ce0826d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a794ebd1-5a52-48ee-b51d-c7b7ce0826d4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e3f7b8bb-049e-47e3-9660-9aa1b0926950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_SharesOutstanding_e3f7b8bb-049e-47e3-9660-9aa1b0926950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2caed36f-b972-4400-a3be-ba17ecec4f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_StockholdersEquity_2caed36f-b972-4400-a3be-ba17ecec4f38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55759a0e-642d-4696-9f6a-d9a396ae3580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55759a0e-642d-4696-9f6a-d9a396ae3580" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ad72369-336d-4d41-8ddc-72bfd60bb050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ad72369-336d-4d41-8ddc-72bfd60bb050" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_f938fe36-ae3c-4e41-9699-5cd74b07038e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_f938fe36-ae3c-4e41-9699-5cd74b07038e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43f3e5cc-b552-48eb-92dc-1b8f2a686ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43f3e5cc-b552-48eb-92dc-1b8f2a686ddb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_159cbd71-355e-4694-a386-b8172103d600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_NetIncomeLoss_159cbd71-355e-4694-a386-b8172103d600" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_124ad108-769e-450f-9c12-7517cc698914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d5b5ba7-27d8-4b8c-ae57-6b932d0ccc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5ae93d8d-e01a-495a-9782-11e9cbf63737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a794ebd1-5a52-48ee-b51d-c7b7ce0826d4" xlink:to="loc_us-gaap_StatementTable_5ae93d8d-e01a-495a-9782-11e9cbf63737" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1aadc066-b949-43b8-a324-59af97fac231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5ae93d8d-e01a-495a-9782-11e9cbf63737" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1aadc066-b949-43b8-a324-59af97fac231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1aadc066-b949-43b8-a324-59af97fac231_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1aadc066-b949-43b8-a324-59af97fac231" xlink:to="loc_us-gaap_EquityComponentDomain_1aadc066-b949-43b8-a324-59af97fac231_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1aadc066-b949-43b8-a324-59af97fac231" xlink:to="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f2e8aa2-4ecc-4e81-a9de-5a0ed7e74c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:to="loc_us-gaap_CommonStockMember_4f2e8aa2-4ecc-4e81-a9de-5a0ed7e74c33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b6ce241a-4183-405b-804d-0adf34a1e0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b6ce241a-4183-405b-804d-0adf34a1e0ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e7bbdf7a-0ff2-458f-805e-cb4cc5572c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e7bbdf7a-0ff2-458f-805e-cb4cc5572c9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_24413715-39ee-4a6b-aaef-6acb53ae0247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:to="loc_us-gaap_RetainedEarningsMember_24413715-39ee-4a6b-aaef-6acb53ae0247" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" id="i6c4bcf4ab7d646f0a55642f8a2377ee9_SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38c3c95d-d8c7-4507-979a-e8baf3a32795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_794cefe6-f380-4034-b0e6-c61517cfdf70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38c3c95d-d8c7-4507-979a-e8baf3a32795" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_794cefe6-f380-4034-b0e6-c61517cfdf70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bbce3ca5-63ec-4906-be95-dd8921d06bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38c3c95d-d8c7-4507-979a-e8baf3a32795" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bbce3ca5-63ec-4906-be95-dd8921d06bdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bc4beb2-c79c-4940-9a7f-9c37246265ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bbce3ca5-63ec-4906-be95-dd8921d06bdb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bc4beb2-c79c-4940-9a7f-9c37246265ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7bc4beb2-c79c-4940-9a7f-9c37246265ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bc4beb2-c79c-4940-9a7f-9c37246265ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7bc4beb2-c79c-4940-9a7f-9c37246265ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ff102319-8e99-4af6-9df8-c62f9ffde6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bc4beb2-c79c-4940-9a7f-9c37246265ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ff102319-8e99-4af6-9df8-c62f9ffde6a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_509df54d-9636-412d-8a34-fbd664cf66f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ff102319-8e99-4af6-9df8-c62f9ffde6a2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_509df54d-9636-412d-8a34-fbd664cf66f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails" xlink:type="extended" id="i9febfd952dcf4613a28a60e37ca074d8_BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_735143d7-c8c1-444f-adad-78e9094f2be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_735143d7-c8c1-444f-adad-78e9094f2be4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6842345e-8997-497b-ac33-f214c837c089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6842345e-8997-497b-ac33-f214c837c089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c269a07e-657a-434c-97dd-fc7eac800da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c269a07e-657a-434c-97dd-fc7eac800da5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ddd4ebe6-d849-48ee-85f7-2e4e6ca15bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ddd4ebe6-d849-48ee-85f7-2e4e6ca15bbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a068ca7-725f-474a-8f96-7efb64d23518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ddd4ebe6-d849-48ee-85f7-2e4e6ca15bbf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a068ca7-725f-474a-8f96-7efb64d23518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a068ca7-725f-474a-8f96-7efb64d23518_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a068ca7-725f-474a-8f96-7efb64d23518" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a068ca7-725f-474a-8f96-7efb64d23518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a068ca7-725f-474a-8f96-7efb64d23518" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LaboratoryEquipmentMember_d8e9c080-6cdf-4ade-a2b8-20016ffde2cb" xlink:href="anab-20210630.xsd#anab_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:to="loc_anab_LaboratoryEquipmentMember_d8e9c080-6cdf-4ade-a2b8-20016ffde2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_8a042124-8d4a-4973-9514-45d825921340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:to="loc_us-gaap_OfficeEquipmentMember_8a042124-8d4a-4973-9514-45d825921340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_46c7cf1e-a127-4c54-8da4-a2e0fa992e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_46c7cf1e-a127-4c54-8da4-a2e0fa992e74" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#CollaborativeResearchandDevelopmentAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="extended" id="i78f7030cbcd043f4b679039de382df13_CollaborativeResearchandDevelopmentAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_e3a4fa62-c008-454c-b482-0e8a201eff59" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_e3a4fa62-c008-454c-b482-0e8a201eff59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_62d4a2d6-af65-46bc-8289-d7e1dd69fb46" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_62d4a2d6-af65-46bc-8289-d7e1dd69fb46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_2d8a2eb2-cd65-4b9a-b423-c58226147301" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_2d8a2eb2-cd65-4b9a-b423-c58226147301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_49acf7b5-699f-437e-ace7-a46eef719c06" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_49acf7b5-699f-437e-ace7-a46eef719c06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_205d275b-e172-4d2c-b6a6-171353e6ac27" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_205d275b-e172-4d2c-b6a6-171353e6ac27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_7e41d3e3-53df-4bb5-b81c-d7aba68fd27f" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_7e41d3e3-53df-4bb5-b81c-d7aba68fd27f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees_4dd81d58-a3c4-49c0-8bcc-9370cb934224" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees_4dd81d58-a3c4-49c0-8bcc-9370cb934224" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_NetSalesRoyaltyPercent_a4f7fe31-6379-4e59-8a0e-9c7821a14afd" xlink:href="anab-20210630.xsd#anab_NetSalesRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_NetSalesRoyaltyPercent_a4f7fe31-6379-4e59-8a0e-9c7821a14afd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_49769616-29c1-4858-a657-665926f9b487" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_49769616-29c1-4858-a657-665926f9b487" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee3755e5-dc51-4fca-8dd5-0ddfe65080e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee3755e5-dc51-4fca-8dd5-0ddfe65080e4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5185a841-2cca-446b-9b0d-d0df0e5931fc" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5185a841-2cca-446b-9b0d-d0df0e5931fc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_74d27dd6-1544-4788-8ca0-0f5d3d187f82" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_74d27dd6-1544-4788-8ca0-0f5d3d187f82" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_d03a8dff-f3c4-4f91-b27c-03f7a9c92dee" xlink:href="anab-20210630.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_d03a8dff-f3c4-4f91-b27c-03f7a9c92dee" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3c11a35-1faa-4215-bb22-a91427ebc184" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:to="loc_srt_CounterpartyNameAxis_d3c11a35-1faa-4215-bb22-a91427ebc184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3c11a35-1faa-4215-bb22-a91427ebc184_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d3c11a35-1faa-4215-bb22-a91427ebc184" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3c11a35-1faa-4215-bb22-a91427ebc184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af16da50-a26f-4d79-9ea6-427567f4fd61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d3c11a35-1faa-4215-bb22-a91427ebc184" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af16da50-a26f-4d79-9ea6-427567f4fd61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_GlaxoSmithKlineMember_f1e4299a-38be-4f60-a460-c9a0a642825d" xlink:href="anab-20210630.xsd#anab_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af16da50-a26f-4d79-9ea6-427567f4fd61" xlink:to="loc_anab_GlaxoSmithKlineMember_f1e4299a-38be-4f60-a460-c9a0a642825d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_BristolMyersSquibbMember_0c9c22cb-d9fc-4c10-8d0d-8c0a1ead68f1" xlink:href="anab-20210630.xsd#anab_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af16da50-a26f-4d79-9ea6-427567f4fd61" xlink:to="loc_anab_BristolMyersSquibbMember_0c9c22cb-d9fc-4c10-8d0d-8c0a1ead68f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e2c80993-a149-4788-ace1-266c8ffa2e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e2c80993-a149-4788-ace1-266c8ffa2e94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2c80993-a149-4788-ace1-266c8ffa2e94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e2c80993-a149-4788-ace1-266c8ffa2e94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2c80993-a149-4788-ace1-266c8ffa2e94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9f3882f-ef53-495c-9e69-61a8ddae2d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e2c80993-a149-4788-ace1-266c8ffa2e94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9f3882f-ef53-495c-9e69-61a8ddae2d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9f3882f-ef53-495c-9e69-61a8ddae2d1c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_InVivoToxicologyStudiesMember_48420659-20ed-402d-bd3a-614a77402086" xlink:href="anab-20210630.xsd#anab_InVivoToxicologyStudiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_InVivoToxicologyStudiesMember_48420659-20ed-402d-bd3a-614a77402086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_680a348d-ee54-4d4a-9f2d-1266570e06e5" xlink:href="anab-20210630.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_680a348d-ee54-4d4a-9f2d-1266570e06e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember_921775ae-cfd5-4b4f-8427-d0e0a67a296f" xlink:href="anab-20210630.xsd#anab_Phase2ClinicalTrialInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_Phase2ClinicalTrialInitiationMember_921775ae-cfd5-4b4f-8427-d0e0a67a296f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationFirstIndicationMember_c08004e8-be1e-46e5-8570-328a3d60baad" xlink:href="anab-20210630.xsd#anab_Phase3ClinicalTrialInitiationFirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_Phase3ClinicalTrialInitiationFirstIndicationMember_c08004e8-be1e-46e5-8570-328a3d60baad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationSecondIndicationMember_177c864a-db8b-4682-8b03-d39af545f590" xlink:href="anab-20210630.xsd#anab_Phase3ClinicalTrialInitiationSecondIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_Phase3ClinicalTrialInitiationSecondIndicationMember_177c864a-db8b-4682-8b03-d39af545f590" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfBLAFirstIndicationMember_7074ad11-725d-496b-8557-29b6bc058dc0" xlink:href="anab-20210630.xsd#anab_FilingOfBLAFirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FilingOfBLAFirstIndicationMember_7074ad11-725d-496b-8557-29b6bc058dc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfMMAFirstIndicationMember_9dca1feb-2de4-4b58-9fc3-cb5acf3fe019" xlink:href="anab-20210630.xsd#anab_FilingOfMMAFirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FilingOfMMAFirstIndicationMember_9dca1feb-2de4-4b58-9fc3-cb5acf3fe019" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfBLASecondIndicationMember_014ca1b5-8f7f-4a5c-a2c2-812551a3bca4" xlink:href="anab-20210630.xsd#anab_FilingOfBLASecondIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FilingOfBLASecondIndicationMember_014ca1b5-8f7f-4a5c-a2c2-812551a3bca4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember_68c7908c-595b-4959-8dc0-fe0e5af1bf69" xlink:href="anab-20210630.xsd#anab_Phase1ClinicalTrialInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_Phase1ClinicalTrialInitiationMember_68c7908c-595b-4959-8dc0-fe0e5af1bf69" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FirstBLAApprovalDMMRECMember_117519ee-0842-46ef-8696-ceea1c8e4181" xlink:href="anab-20210630.xsd#anab_FirstBLAApprovalDMMRECMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FirstBLAApprovalDMMRECMember_117519ee-0842-46ef-8696-ceea1c8e4181" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FirstMAAApprovalFirstIndicationMember_a29e051a-cb3c-4467-86d6-13434862c26b" xlink:href="anab-20210630.xsd#anab_FirstMAAApprovalFirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FirstMAAApprovalFirstIndicationMember_a29e051a-cb3c-4467-86d6-13434862c26b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CollaborationAndExclusiveLicenseAgreementMember_bcc10e56-b7bc-4a45-a8b7-558980ee11e6" xlink:href="anab-20210630.xsd#anab_CollaborationAndExclusiveLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9f3882f-ef53-495c-9e69-61a8ddae2d1c" xlink:to="loc_anab_CollaborationAndExclusiveLicenseAgreementMember_bcc10e56-b7bc-4a45-a8b7-558980ee11e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f1167502-58b3-4126-9d59-1f7806b0a9ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:to="loc_srt_ProductOrServiceAxis_f1167502-58b3-4126-9d59-1f7806b0a9ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1167502-58b3-4126-9d59-1f7806b0a9ac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f1167502-58b3-4126-9d59-1f7806b0a9ac" xlink:to="loc_srt_ProductsAndServicesDomain_f1167502-58b3-4126-9d59-1f7806b0a9ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f1167502-58b3-4126-9d59-1f7806b0a9ac" xlink:to="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember_df132be3-498e-4b5c-bd61-8398fd69ea4f" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember_df132be3-498e-4b5c-bd61-8398fd69ea4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember_6b602bad-853e-40b9-888a-931739d23bab" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember_6b602bad-853e-40b9-888a-931739d23bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member_f5e6628f-9e45-447a-a3d2-5fb1f593eedf" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member_f5e6628f-9e45-447a-a3d2-5fb1f593eedf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_7b798c91-85b5-4ed1-a84f-24a3c261d18d" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_7b798c91-85b5-4ed1-a84f-24a3c261d18d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedZejulaMember_05cebf16-7084-43c8-a563-c6030f8a4da6" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedZejulaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedZejulaMember_05cebf16-7084-43c8-a563-c6030f8a4da6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i5be7fa0b65e9401fa6b75f6a7532f24d_FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037ed61c-68b7-41db-b930-326b27522d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_29783967-7e64-4ef3-af7d-1ae4bb802e2c" xlink:href="anab-20210630.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037ed61c-68b7-41db-b930-326b27522d26" xlink:to="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_29783967-7e64-4ef3-af7d-1ae4bb802e2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a14c5745-3bce-472c-8b2a-9e1767fe21ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037ed61c-68b7-41db-b930-326b27522d26" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a14c5745-3bce-472c-8b2a-9e1767fe21ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037ed61c-68b7-41db-b930-326b27522d26" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_246c7b5c-8acc-4903-838e-4c9d69e17612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_246c7b5c-8acc-4903-838e-4c9d69e17612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_246c7b5c-8acc-4903-838e-4c9d69e17612_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_246c7b5c-8acc-4903-838e-4c9d69e17612" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_246c7b5c-8acc-4903-838e-4c9d69e17612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ac5b2f3-22c1-4072-979e-c8b68858d296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_246c7b5c-8acc-4903-838e-4c9d69e17612" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ac5b2f3-22c1-4072-979e-c8b68858d296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_52969d21-088c-48ac-9b79-b0d0707949ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ac5b2f3-22c1-4072-979e-c8b68858d296" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_52969d21-088c-48ac-9b79-b0d0707949ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdd711a5-9f69-492b-8a30-4eeede7815a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdd711a5-9f69-492b-8a30-4eeede7815a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cdd711a5-9f69-492b-8a30-4eeede7815a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdd711a5-9f69-492b-8a30-4eeede7815a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cdd711a5-9f69-492b-8a30-4eeede7815a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdd711a5-9f69-492b-8a30-4eeede7815a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b52ac12b-eb20-45f2-b89b-833155e792a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b52ac12b-eb20-45f2-b89b-833155e792a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d05459ca-6de6-4420-8001-d07b007b722b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d05459ca-6de6-4420-8001-d07b007b722b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_143cddd4-1d16-4642-a448-0ddf057787e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_143cddd4-1d16-4642-a448-0ddf057787e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_9d29281e-a119-4b51-b512-45579c32c0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_9d29281e-a119-4b51-b512-45579c32c0dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9d29281e-a119-4b51-b512-45579c32c0dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9d29281e-a119-4b51-b512-45579c32c0dc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9d29281e-a119-4b51-b512-45579c32c0dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_692fb6a1-316d-4741-9c81-bbe85427ec46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9d29281e-a119-4b51-b512-45579c32c0dc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_692fb6a1-316d-4741-9c81-bbe85427ec46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_64e4f97e-ed57-45db-9b71-3807c0b1356f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_692fb6a1-316d-4741-9c81-bbe85427ec46" xlink:to="loc_us-gaap_MoneyMarketFundsMember_64e4f97e-ed57-45db-9b71-3807c0b1356f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_f5b1c902-ccb9-45ab-b9e2-137ee8345cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_692fb6a1-316d-4741-9c81-bbe85427ec46" xlink:to="loc_us-gaap_MutualFundMember_f5b1c902-ccb9-45ab-b9e2-137ee8345cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_186a726d-d60a-4df4-a8d3-d6f5231eeb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_186a726d-d60a-4df4-a8d3-d6f5231eeb09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_186a726d-d60a-4df4-a8d3-d6f5231eeb09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_186a726d-d60a-4df4-a8d3-d6f5231eeb09" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_186a726d-d60a-4df4-a8d3-d6f5231eeb09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_186a726d-d60a-4df4-a8d3-d6f5231eeb09" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f4fbdc81-f7b2-40c9-9265-8f054c5c84f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f4fbdc81-f7b2-40c9-9265-8f054c5c84f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6b1fc44f-830f-4b70-8748-b82c60e804ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6b1fc44f-830f-4b70-8748-b82c60e804ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2ef9d4b5-abb0-4e1f-aa21-e5b39c93cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2ef9d4b5-abb0-4e1f-aa21-e5b39c93cb1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_672645d5-77f1-4d97-997b-a16924d92426" xlink:href="anab-20210630.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_672645d5-77f1-4d97-997b-a16924d92426" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="extended" id="ia7f4dff260754dfc88a31cfca42c99fe_FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_856f4a9f-fc07-4320-82ea-70b252db93c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_856f4a9f-fc07-4320-82ea-70b252db93c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d2faf32-4018-4a5b-bf51-700a164885ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d2faf32-4018-4a5b-bf51-700a164885ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a3d998cb-4f16-4f59-9543-b65652081d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a3d998cb-4f16-4f59-9543-b65652081d7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ab686b0-0667-47db-8239-e7f48eb0e6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ab686b0-0667-47db-8239-e7f48eb0e6db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_adac4926-8ce2-4894-bf99-5795cd9c9886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_adac4926-8ce2-4894-bf99-5795cd9c9886" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_70b6c816-1534-4c2c-b5c4-8ee955acc3da" xlink:href="anab-20210630.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_70b6c816-1534-4c2c-b5c4-8ee955acc3da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_65466fb4-0704-471c-9544-e9d286e34a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_65466fb4-0704-471c-9544-e9d286e34a39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8a135449-dc25-452c-9e9f-9bc2b84ba8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8a135449-dc25-452c-9e9f-9bc2b84ba8e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a135449-dc25-452c-9e9f-9bc2b84ba8e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a135449-dc25-452c-9e9f-9bc2b84ba8e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a135449-dc25-452c-9e9f-9bc2b84ba8e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a135449-dc25-452c-9e9f-9bc2b84ba8e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_151384f4-ac49-4347-8bb4-193afab0883a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_151384f4-ac49-4347-8bb4-193afab0883a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2b6aa384-3597-48b6-89a4-4cbc2a24db6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2b6aa384-3597-48b6-89a4-4cbc2a24db6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_acfdfd8c-e9c2-47c7-ba1d-546394f733f2" xlink:href="anab-20210630.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_acfdfd8c-e9c2-47c7-ba1d-546394f733f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7a62b5e5-4639-4e2c-9c1f-253593d5c67b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7a62b5e5-4639-4e2c-9c1f-253593d5c67b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5512fdd5-0a84-4e63-b8ca-5322fc920e1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:to="loc_srt_RangeAxis_5512fdd5-0a84-4e63-b8ca-5322fc920e1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5512fdd5-0a84-4e63-b8ca-5322fc920e1c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5512fdd5-0a84-4e63-b8ca-5322fc920e1c" xlink:to="loc_srt_RangeMember_5512fdd5-0a84-4e63-b8ca-5322fc920e1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a3253eb-9266-476e-968b-31f6e9b42455" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5512fdd5-0a84-4e63-b8ca-5322fc920e1c" xlink:to="loc_srt_RangeMember_7a3253eb-9266-476e-968b-31f6e9b42455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_54e7f2a8-530f-419e-bd3b-d0fb22181407" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a3253eb-9266-476e-968b-31f6e9b42455" xlink:to="loc_srt_MinimumMember_54e7f2a8-530f-419e-bd3b-d0fb22181407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e4f6b02-7d5f-4697-a9ae-b25955faa8bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a3253eb-9266-476e-968b-31f6e9b42455" xlink:to="loc_srt_MaximumMember_7e4f6b02-7d5f-4697-a9ae-b25955faa8bb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="extended" id="ia874b03a4bef43ada0e97deab559382e_FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b730a75f-2b2b-4c3c-b5d2-f5c516baca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b730a75f-2b2b-4c3c-b5d2-f5c516baca1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_beb12d23-260e-49bc-bbb2-275416e27c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_beb12d23-260e-49bc-bbb2-275416e27c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_12a4e7f4-0883-4d31-a79b-94601a4ff2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_12a4e7f4-0883-4d31-a79b-94601a4ff2f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_735bc676-c378-424d-9fc4-f46e0e5ca1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_735bc676-c378-424d-9fc4-f46e0e5ca1fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_51ce7d74-92ca-41f0-acd4-104ef1df0abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_51ce7d74-92ca-41f0-acd4-104ef1df0abe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5e276bb8-e734-4d7a-aaa3-4363a4776d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5e276bb8-e734-4d7a-aaa3-4363a4776d9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_5d08dff0-40e5-4eaf-a206-2a804b95c775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_5d08dff0-40e5-4eaf-a206-2a804b95c775" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6850f58a-badc-4a39-ac60-0e3751077509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6850f58a-badc-4a39-ac60-0e3751077509" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66cc0807-1f54-420a-b9bf-f36e7d5e9c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66cc0807-1f54-420a-b9bf-f36e7d5e9c69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0fce348b-5242-465f-9d4a-e66e95c39e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66cc0807-1f54-420a-b9bf-f36e7d5e9c69" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0fce348b-5242-465f-9d4a-e66e95c39e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0fce348b-5242-465f-9d4a-e66e95c39e2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0fce348b-5242-465f-9d4a-e66e95c39e2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0fce348b-5242-465f-9d4a-e66e95c39e2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0fce348b-5242-465f-9d4a-e66e95c39e2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_33d741d8-3da3-4645-97b3-f6668acf2129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_33d741d8-3da3-4645-97b3-f6668acf2129" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_cbe524d8-0a33-4573-aa39-866c52f80f61" xlink:href="anab-20210630.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_cbe524d8-0a33-4573-aa39-866c52f80f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_46ad75fd-128f-468e-9c0a-ade74abb0ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_46ad75fd-128f-468e-9c0a-ade74abb0ebd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" id="i0fb76770d1854a3b8ded7bd542b1a7d6_StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3accb53a-2f34-481b-83d0-c0f0e34980c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3accb53a-2f34-481b-83d0-c0f0e34980c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef5323dd-e9ab-407e-9685-a80f01bbb272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3accb53a-2f34-481b-83d0-c0f0e34980c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef5323dd-e9ab-407e-9685-a80f01bbb272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb38c514-a0ba-4af9-bfea-77225ce0c992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb38c514-a0ba-4af9-bfea-77225ce0c992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a04e0f4b-d040-4da1-845e-10f06eec01fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a04e0f4b-d040-4da1-845e-10f06eec01fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a949e09b-ecc7-461b-a58c-b93137426f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a949e09b-ecc7-461b-a58c-b93137426f82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3b8db3a3-94a7-45d6-b425-d293aea1757b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a949e09b-ecc7-461b-a58c-b93137426f82" xlink:to="loc_us-gaap_PlanNameAxis_3b8db3a3-94a7-45d6-b425-d293aea1757b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3b8db3a3-94a7-45d6-b425-d293aea1757b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3b8db3a3-94a7-45d6-b425-d293aea1757b" xlink:to="loc_us-gaap_PlanNameDomain_3b8db3a3-94a7-45d6-b425-d293aea1757b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc497386-f340-470b-9292-95a38aee48f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3b8db3a3-94a7-45d6-b425-d293aea1757b" xlink:to="loc_us-gaap_PlanNameDomain_cc497386-f340-470b-9292-95a38aee48f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member_9af4efb1-fa3e-4db1-b939-a80c336df30f" xlink:href="anab-20210630.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cc497386-f340-470b-9292-95a38aee48f6" xlink:to="loc_anab_EquityIncentivePlan2017Member_9af4efb1-fa3e-4db1-b939-a80c336df30f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_680dddd2-4010-47ff-b16a-82873999c60e" xlink:href="anab-20210630.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cc497386-f340-470b-9292-95a38aee48f6" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_680dddd2-4010-47ff-b16a-82873999c60e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended" id="i8676f36bdaa1407fa4e55395ec02972e_EquityIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_7ab27c61-1586-4f69-917a-edf31b1b0d4d" xlink:href="anab-20210630.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_7ab27c61-1586-4f69-917a-edf31b1b0d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_4ece2065-af1a-4fcd-8a5b-e0e7573164c9" xlink:href="anab-20210630.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_4ece2065-af1a-4fcd-8a5b-e0e7573164c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e72be019-6bb6-4071-b49f-b3a38f4d5cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e72be019-6bb6-4071-b49f-b3a38f4d5cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ef7b5168-ab34-4e16-97c1-c0759d1b309a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ef7b5168-ab34-4e16-97c1-c0759d1b309a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c8e26d18-a8ed-4bdb-9354-81e2a9bfe374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c8e26d18-a8ed-4bdb-9354-81e2a9bfe374" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cb89118b-5561-42bf-b9d9-3cc52d745307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cb89118b-5561-42bf-b9d9-3cc52d745307" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9c7b6cd-9b02-451f-91b7-a346ecc9c805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9c7b6cd-9b02-451f-91b7-a346ecc9c805" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fada1b22-5386-4d2b-bfaf-91ee531c1a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:to="loc_us-gaap_PlanNameAxis_fada1b22-5386-4d2b-bfaf-91ee531c1a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fada1b22-5386-4d2b-bfaf-91ee531c1a27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fada1b22-5386-4d2b-bfaf-91ee531c1a27" xlink:to="loc_us-gaap_PlanNameDomain_fada1b22-5386-4d2b-bfaf-91ee531c1a27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c0f28515-4af2-4381-8584-f4087ec094c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fada1b22-5386-4d2b-bfaf-91ee531c1a27" xlink:to="loc_us-gaap_PlanNameDomain_c0f28515-4af2-4381-8584-f4087ec094c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member_f6987c8b-16f6-41c1-b579-9aa4518f12cd" xlink:href="anab-20210630.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c0f28515-4af2-4381-8584-f4087ec094c5" xlink:to="loc_anab_EquityIncentivePlan2017Member_f6987c8b-16f6-41c1-b579-9aa4518f12cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_c971067b-ee7f-4245-a429-70cb04d2e296" xlink:href="anab-20210630.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c0f28515-4af2-4381-8584-f4087ec094c5" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_c971067b-ee7f-4245-a429-70cb04d2e296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42841bf4-39bf-4795-94ae-1e78c55c4496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:to="loc_us-gaap_AwardTypeAxis_42841bf4-39bf-4795-94ae-1e78c55c4496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42841bf4-39bf-4795-94ae-1e78c55c4496_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_42841bf4-39bf-4795-94ae-1e78c55c4496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42841bf4-39bf-4795-94ae-1e78c55c4496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90142eeb-f617-4dd0-9bd4-98cb9f74a7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_42841bf4-39bf-4795-94ae-1e78c55c4496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90142eeb-f617-4dd0-9bd4-98cb9f74a7c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e1d66722-e5f7-47e3-95d0-bccda7a85935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90142eeb-f617-4dd0-9bd4-98cb9f74a7c0" xlink:to="loc_us-gaap_EmployeeStockMember_e1d66722-e5f7-47e3-95d0-bccda7a85935" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1bf6b534-1dcb-43cb-9fa5-35048b011b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90142eeb-f617-4dd0-9bd4-98cb9f74a7c0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1bf6b534-1dcb-43cb-9fa5-35048b011b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:to="loc_srt_TitleOfIndividualAxis_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bc63cb1-bb3d-4d8b-8f1b-05369e2b096e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bc63cb1-bb3d-4d8b-8f1b-05369e2b096e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_d550edaa-67a6-4a6a-ae04-cfdb91758a1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bc63cb1-bb3d-4d8b-8f1b-05369e2b096e" xlink:to="loc_srt_DirectorMember_d550edaa-67a6-4a6a-ae04-cfdb91758a1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails" xlink:type="extended" id="i596165b8be55445da1883db222d42595_EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a24cf705-5656-401b-8d07-9ea1f1488ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a24cf705-5656-401b-8d07-9ea1f1488ea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7ad533c9-e538-4f54-ba3f-8e8dd8399341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7ad533c9-e538-4f54-ba3f-8e8dd8399341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e56d2e68-2443-4341-af78-f0d44a392101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e56d2e68-2443-4341-af78-f0d44a392101" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b2c177e-24e8-4fdf-ab92-e2fc2aa8103f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b2c177e-24e8-4fdf-ab92-e2fc2aa8103f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_738c6be7-5305-489a-b2a3-89dcb489d024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_738c6be7-5305-489a-b2a3-89dcb489d024" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e692918-516f-4753-99c1-be32467448d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e692918-516f-4753-99c1-be32467448d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_21ed6578-d79a-48a6-992b-1bee78a4d339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e692918-516f-4753-99c1-be32467448d5" xlink:to="loc_us-gaap_AwardTypeAxis_21ed6578-d79a-48a6-992b-1bee78a4d339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21ed6578-d79a-48a6-992b-1bee78a4d339_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_21ed6578-d79a-48a6-992b-1bee78a4d339" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21ed6578-d79a-48a6-992b-1bee78a4d339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1affdf7c-5ec4-4ec9-a9ad-4ebeae1ef9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_21ed6578-d79a-48a6-992b-1bee78a4d339" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1affdf7c-5ec4-4ec9-a9ad-4ebeae1ef9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7b171d22-4a16-431a-82d7-92baae015e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1affdf7c-5ec4-4ec9-a9ad-4ebeae1ef9ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7b171d22-4a16-431a-82d7-92baae015e28" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i7c7d16c99e1642c4870f26eb779da316_EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_74a7ea9b-955c-4bd1-97ac-92b1bc6e5b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_a47901f6-e971-4b1f-ad5b-5d0abab8005f" xlink:href="anab-20210630.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_74a7ea9b-955c-4bd1-97ac-92b1bc6e5b41" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_a47901f6-e971-4b1f-ad5b-5d0abab8005f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df08195e-88ff-4860-81a9-f7fa75f5167b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_74a7ea9b-955c-4bd1-97ac-92b1bc6e5b41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df08195e-88ff-4860-81a9-f7fa75f5167b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f472b95b-d20d-4a13-9975-9c4dc417f240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df08195e-88ff-4860-81a9-f7fa75f5167b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f472b95b-d20d-4a13-9975-9c4dc417f240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f472b95b-d20d-4a13-9975-9c4dc417f240_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f472b95b-d20d-4a13-9975-9c4dc417f240" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f472b95b-d20d-4a13-9975-9c4dc417f240_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8fa51fec-625e-42f0-8359-97c6db53a8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f472b95b-d20d-4a13-9975-9c4dc417f240" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8fa51fec-625e-42f0-8359-97c6db53a8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83b7c3af-689d-41c4-88b6-8fc2e00ddcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8fa51fec-625e-42f0-8359-97c6db53a8a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83b7c3af-689d-41c4-88b6-8fc2e00ddcde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db02ddca-371f-44ae-abf9-2560cb02b13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8fa51fec-625e-42f0-8359-97c6db53a8a4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db02ddca-371f-44ae-abf9-2560cb02b13a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i66c6e0960c524077b0e0811ddef52b31_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5f9c45ed-dfd1-4673-a116-80e3b23d5741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5f9c45ed-dfd1-4673-a116-80e3b23d5741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_49e76f70-94ff-4fa3-b3fd-e8683f928f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_OperatingLeaseLiability_49e76f70-94ff-4fa3-b3fd-e8683f928f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_b70cc561-b6ed-4ee4-bb58-a20fab41fa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_b70cc561-b6ed-4ee4-bb58-a20fab41fa94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_c1dd84a6-6dca-40e2-b758-72431415bcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_c1dd84a6-6dca-40e2-b758-72431415bcc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_7c16394a-b69e-4708-8111-246c9d518c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_7c16394a-b69e-4708-8111-246c9d518c9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_44ab747a-bc6d-4bcf-86db-1a62aa64f7e3" xlink:href="anab-20210630.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_44ab747a-bc6d-4bcf-86db-1a62aa64f7e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RentPerSquareFoot_9eb1e810-31d0-4ceb-b59a-7d551a631680" xlink:href="anab-20210630.xsd#anab_RentPerSquareFoot"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_anab_RentPerSquareFoot_9eb1e810-31d0-4ceb-b59a-7d551a631680" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnnualRentIncreasePercent_da87f6ef-c181-4c6b-949a-ece21e723dc4" xlink:href="anab-20210630.xsd#anab_AnnualRentIncreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_anab_AnnualRentIncreasePercent_da87f6ef-c181-4c6b-949a-ece21e723dc4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_673c4f0a-0947-4e02-af09-36405c5e01ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_673c4f0a-0947-4e02-af09-36405c5e01ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_f089ba3a-b1e8-4c84-ac13-2a6b21e21227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_SecurityDeposit_f089ba3a-b1e8-4c84-ac13-2a6b21e21227" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5889cb9b-2a51-4ef7-b5c2-1d92dee46548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5889cb9b-2a51-4ef7-b5c2-1d92dee46548" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7ace680d-051a-4c33-ab6c-2e6bbcd61292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7ace680d-051a-4c33-ab6c-2e6bbcd61292" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_dc12a6ff-8a7b-47e2-868b-983c5e0038f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7ace680d-051a-4c33-ab6c-2e6bbcd61292" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_dc12a6ff-8a7b-47e2-868b-983c5e0038f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc12a6ff-8a7b-47e2-868b-983c5e0038f2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_dc12a6ff-8a7b-47e2-868b-983c5e0038f2" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc12a6ff-8a7b-47e2-868b-983c5e0038f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_454f2696-af1d-43f0-b166-a66c332caae5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_dc12a6ff-8a7b-47e2-868b-983c5e0038f2" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_454f2696-af1d-43f0-b166-a66c332caae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember_1146b94a-a606-48e5-92a3-896fafe82121" xlink:href="anab-20210630.xsd#anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_454f2696-af1d-43f0-b166-a66c332caae5" xlink:to="loc_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember_1146b94a-a606-48e5-92a3-896fafe82121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_38244c65-097b-4a3f-989d-5ef44c870c95" xlink:href="anab-20210630.xsd#anab_A10770WateridgeCircleSanDiegoCalifornia92121Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_454f2696-af1d-43f0-b166-a66c332caae5" xlink:to="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_38244c65-097b-4a3f-989d-5ef44c870c95" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CollaborationRevenueMember_50271531-9625-4c2a-8247-1cc5066e7d9f" xlink:href="anab-20210630.xsd#anab_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="loc_anab_CollaborationRevenueMember_50271531-9625-4c2a-8247-1cc5066e7d9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>anab-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c7655f00-1548-4625-8cd9-c93812026c41,g:f65e361e-f377-49d6-802f-d6fad364b94f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_fb85a70e-e6f4-449f-9fa8-d8d9d98c946c_verboseLabel_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and corporate obligations</link:label>
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_label_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Corporate Obligations [Member]</link:label>
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_documentation_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Corporate Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember" xlink:href="anab-20210630.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommercialAndCorporateObligationsMember" xlink:to="lab_anab_CommercialAndCorporateObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e978da5e-6590-4f63-b386-16d8a930cd23_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2eb47773-3745-4a34-aebc-e19d170a10d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_bf294448-2a84-4435-aec3-6b093ed7667e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember_a1b85464-6192-4627-8aa6-3006e4382fa9_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-PD-1 (JEMPERLI/Dostarlimab)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember" xlink:to="lab_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d10b9311-1384-49cd-b1c8-fa43d9c594fb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cc76964-f552-439c-a8ab-46264b989a4b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_ec95ba80-90e7-46d7-9d7c-3393b18b93db_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_78dcb1e3-df59-4d80-9a73-5a8d649c2d31_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_875cc567-70a4-4801-ba61-65b9e789ce70_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8b813ca8-6cb7-49b6-b590-e716c46aa054_terseLabel_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in number of shares available for issuance</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_label_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_documentation_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:href="anab-20210630.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:to="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_97512cf9-99e4-4e22-9b7c-29e67e70b86e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c02f1556-ae8d-440c-8a20-34caf69f5e2a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d4a47f09-c5f8-43b2-a6ec-390f28f348d6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8d4206e1-cccc-4e77-8236-48833485bd83_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a7befe62-a1e9-4609-b35f-a48c2b1aa921_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3654ddfd-51d3-4d3f-9ff1-a7e3417822af_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_314e9e36-ed61-4517-a8b3-583b10a20f6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_78c89d1d-351d-4101-b1e5-c68a3d5ae047_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7d1fc990-40a4-4602-abfa-2b2e064e6143_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7cea1a71-bbf7-4fde-a912-1db57287d4dc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_87aa79ed-2bc2-479b-a881-70ef43bf91a2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d6c19d6d-913a-4733-a674-fa1901b105f3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f3b7c5a-e6d2-4269-ad8e-fa5cd529cde5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_d04939f4-327b-41c2-85cf-62be68db8898_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaborative partners</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ffc83647-55dd-47b9-b1d6-6989a7a7821d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_76eb9d5f-87c7-4464-a189-cfaaf2321ff2_terseLabel_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research, development and manufacturing expenses</link:label>
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:href="anab-20210630.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54683dde-d68a-42e4-80f6-32a2b59a2c63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_fc2d6585-b2f8-4046-930d-0140d4d57e58_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c9a85b21-a2f1-46f2-b484-ef10a2ed5f2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_354be30c-6a10-4633-bea8-2f964e614b58_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fdd7f89a-7918-42b7-b893-6f6da4bf0582_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a65d4bc5-0277-425d-b217-e1a566976d2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ebc2a67-9adb-42d0-ba92-6771f329aea2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3240b2b1-160c-4f97-87e8-9e963c2559d2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, upon the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a9eb66f3-3b61-459c-b729-885b17eab72d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a5051062-19ad-4707-8164-0b254093130a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future award grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5acb1148-ed5d-4186-a196-87733df4bfd7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationFirstIndicationMember_f674f3d9-1533-4270-872a-de021df0c215_terseLabel_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical trial initiation - first indication</link:label>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationFirstIndicationMember_label_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial Initiation - First Indication [Member]</link:label>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationFirstIndicationMember_documentation_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial Initiation - First Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationFirstIndicationMember" xlink:href="anab-20210630.xsd#anab_Phase3ClinicalTrialInitiationFirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase3ClinicalTrialInitiationFirstIndicationMember" xlink:to="lab_anab_Phase3ClinicalTrialInitiationFirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5ad09ebd-d4d2-4a07-823a-85dc3a4015b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_27173a03-a1a8-41a5-a1f0-dc1943bc272d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued and Outstanding:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bcee7f33-4b50-4bac-abf6-e05aaa29fb24_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d66695a1-0a5f-4cf5-bbc2-10764adce0f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures and cancellations (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_f08f747e-15a0-4700-a539-fa8c665a17e2_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e64ffdf1-9a48-49b2-b1e0-a06cd122aca5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4243eb9e-ca7d-4712-b60e-aebc35a963ae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2b399c52-3110-4723-9b9b-cc179f0149ac_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5244afc8-dc29-4e5d-8cb8-e6d41cb67abb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9975b86b-27d0-48b5-b735-8fafce3e928a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments required</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_c1a13fa6-3133-456f-aef3-b9f792b3a1bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_974a8f32-9e0a-4e19-8e05-def362462a06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_FilingOfBLASecondIndicationMember_1f9d0e0c-72ca-49c2-b49a-4e3673916764_terseLabel_en-US" xlink:label="lab_anab_FilingOfBLASecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of the first BLA - second indication</link:label>
    <link:label id="lab_anab_FilingOfBLASecondIndicationMember_label_en-US" xlink:label="lab_anab_FilingOfBLASecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of BLA - Second Indication [Member]</link:label>
    <link:label id="lab_anab_FilingOfBLASecondIndicationMember_documentation_en-US" xlink:label="lab_anab_FilingOfBLASecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of BLA - Second Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfBLASecondIndicationMember" xlink:href="anab-20210630.xsd#anab_FilingOfBLASecondIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FilingOfBLASecondIndicationMember" xlink:to="lab_anab_FilingOfBLASecondIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9bb7d9f2-6935-40a5-b232-3aeb8573ed87_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_506336af-1f06-462a-9c95-d96f10d1833c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eddc3568-19a7-40b7-9e06-d7dd59f142c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_03e686d3-016e-4a1c-84a3-0ada597903b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_603bc945-da7a-4b9a-abb2-6e33eabdbacd_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_860d1442-db95-4073-b403-e02e598e3a2c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70b16452-8fbd-46d4-82e5-940577d91457_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ac92c264-3bc1-4d2c-8197-243f31460d60_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_16379cdb-5470-4e69-bc58-22716494dd30_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_466bf7bd-4fea-48d2-aa09-0641d4eb8f56_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_35d6005a-f7a1-4234-a7f5-8d68c8868a67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_77a501e7-cd9a-4bc3-8c85-f850fc8183a7_terseLabel_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="anab-20210630.xsd#anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6c3efa56-e80c-4812-83cc-b5c883d062eb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8c46747e-1d48-4130-ac68-e377c8fdc372_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f52100f5-794c-4942-8598-8f6b5626c201_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_GlaxoSmithKlineMember_52d97435-caf0-4465-9a7e-2b0c8cd119b3_terseLabel_en-US" xlink:label="lab_anab_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_anab_GlaxoSmithKlineMember_label_en-US" xlink:label="lab_anab_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GlaxoSmithKline [Member]</link:label>
    <link:label id="lab_anab_GlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_anab_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GlaxoSmithKline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_GlaxoSmithKlineMember" xlink:href="anab-20210630.xsd#anab_GlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_GlaxoSmithKlineMember" xlink:to="lab_anab_GlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_648e157d-009b-4bdc-aba5-d12aebdb0b58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7184941c-ef68-4733-b9c1-45e6bd69a65f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_NetSalesRoyaltyPercent_0095e8f1-1a8c-4a37-a556-26ea3d435cf0_terseLabel_en-US" xlink:label="lab_anab_NetSalesRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percent on net sales</link:label>
    <link:label id="lab_anab_NetSalesRoyaltyPercent_label_en-US" xlink:label="lab_anab_NetSalesRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Royalty, Percent</link:label>
    <link:label id="lab_anab_NetSalesRoyaltyPercent_documentation_en-US" xlink:label="lab_anab_NetSalesRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_NetSalesRoyaltyPercent" xlink:href="anab-20210630.xsd#anab_NetSalesRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_NetSalesRoyaltyPercent" xlink:to="lab_anab_NetSalesRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_63acdffc-4c8b-402e-82b6-30ce1551b540_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_946f9c47-9996-4015-b68a-2777d5dac6ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) income on available for sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b7b73eaa-5b30-43d5-9c25-ab317c897ca3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72fea274-9281-4c1d-8171-e85374700681_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_85d5228a-5d06-42fb-a250-75d805b51f1b_terseLabel_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IND clearance from the FDA</link:label>
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_label_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearance Of Investigational New Drug From FDA [Member]</link:label>
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_documentation_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearance Of Investigational New Drug From FDA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:href="anab-20210630.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:to="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RentPerSquareFoot_1ce129ef-3a51-42bf-ad3b-ef0fd124ca9e_terseLabel_en-US" xlink:label="lab_anab_RentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base rate (usd per sqft)</link:label>
    <link:label id="lab_anab_RentPerSquareFoot_label_en-US" xlink:label="lab_anab_RentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Per Square Foot</link:label>
    <link:label id="lab_anab_RentPerSquareFoot_documentation_en-US" xlink:label="lab_anab_RentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Per Square Foot</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RentPerSquareFoot" xlink:href="anab-20210630.xsd#anab_RentPerSquareFoot"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RentPerSquareFoot" xlink:to="lab_anab_RentPerSquareFoot" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e6151fee-3960-4e74-af64-033f1f028605_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2f8439ee-082f-4490-89b9-6a372ca5c9b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_00e2c5c4-cecb-4830-b23d-b47003b23bc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5b0e9207-1c5f-4af6-9503-f21f8ad3692c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_caa0173d-224b-4842-97ba-df7f95a6cdc1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_e7ba27fc-956d-411e-880c-e1cf673dac99_terseLabel_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments outstanding, maturity date range (in years)</link:label>
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_label_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities, Remaining Maturity</link:label>
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_documentation_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:href="anab-20210630.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:to="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c3fb1c28-616f-485e-8e36-ff0eaab2a1c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_36b40f99-0969-41e1-b89d-4e932792b5d3_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payments per target</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9efe0803-104e-4df6-9457-0474532fcbbb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1dbe387c-ca7f-4fd4-930a-a17ebb1b943b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2cc0442-711f-45a5-8ac1-bcee16e759e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6b9168bb-42f5-48d3-80fd-6f247d0be4a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6b68edee-9fd2-43c2-8ee7-4f25a30d9013_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_42971d13-edc5-40d9-8303-4b208e5d7323_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e6916703-e40e-44ca-be22-86d0b2c0e693_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f878d834-838a-465b-8759-5b540f1e402b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_775c0ecb-b320-4cfa-8932-59c202f960f5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_426869a8-952e-43a4-990a-87d2c800b8e1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c455fc9e-5c56-4fd4-8ce1-ad584ee41c02_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2ba4ebda-ecd8-43e2-ab3a-3918a7f3d511_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_11d4da29-295f-42de-b0f1-0b942709e846_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_605845fc-71f0-411f-8eae-809018912ae9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_c8685098-383d-4a2b-9f4e-8e1f83b47a1d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9bbf61db-cf8c-4858-810f-dcb80a92ffa8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_26bb487b-863a-476a-ae22-cc72015b7ded_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased property (sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ff68e4cb-8a1f-4978-ae0d-5806f5e9de86_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_12dd32b9-84e9-41e1-9286-523f31bd222c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_fc02bd34-3259-4714-8991-c064e61f8c83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other&#160;Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cdc11ff1-5cf3-43f2-91d8-c05b8f2746dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0e022f1-febe-4383-9bb7-31553ab55248_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_f012f9be-f468-472f-8fbd-a81e413b7cd7_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2a7ff5c4-4c68-4120-af2a-1390abf89526_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_cf88c6c8-f2c5-4fff-a910-ded26fd90c8b_terseLabel_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments at fair value</link:label>
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</link:label>
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:href="anab-20210630.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:to="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_90c2a6a9-9ded-4674-95ff-b219509f2c9b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e0c1520f-6733-4114-b8f6-8f72cb8ad748_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1f0bc6e9-199f-4e8d-a38d-fe644d4679b9_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_84e63742-bcac-4b21-ad64-671e8abf672e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11d23b0b-3003-4870-94df-bd36a7279430_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a43432e5-5867-4fe7-8cbd-f3d130f528be_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e43ad67a-8624-4488-a76f-f81bac37a381_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_466e946f-33d4-4fa3-8d85-b4976d83c96d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2dc2d5f9-06d3-46f2-b3de-2a164459ce51_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_78645f9d-033f-401e-93dd-59bd11ce8fe7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9ec6ffd1-29db-4462-bdec-c3de518cbbf5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_7dfc2c26-b7e0-495f-af82-f313c775036f_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director Stock options</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0dc91a55-5445-4574-8cbc-95fafbbb736f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_70f944e5-006a-4bf1-bc60-d23cc267431f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationSecondIndicationMember_99d03c77-56a3-42a5-9ee2-c2ea7e7ec471_terseLabel_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationSecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical trial initiation - second indication</link:label>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationSecondIndicationMember_label_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationSecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical Trial Initiation - Second Indication [Member]</link:label>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationSecondIndicationMember_documentation_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationSecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical Trial Initiation - Second Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationSecondIndicationMember" xlink:href="anab-20210630.xsd#anab_Phase3ClinicalTrialInitiationSecondIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase3ClinicalTrialInitiationSecondIndicationMember" xlink:to="lab_anab_Phase3ClinicalTrialInitiationSecondIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9bee6d3a-820d-44c9-b9a6-bbd4aba3ed83_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_11bf7066-0812-44a5-bcd8-c8c243479514_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2f7d24d4-598d-4400-be0e-c097aee5d7d7_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="anab-20210630.xsd#anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e61dbf01-27a8-4e41-ba52-e4e64a858a8f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_e63b2e1f-4c80-4391-87d4-63631cb6b693_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_ReceivablesForStockOptionsExercised_df8e8163-6222-4a54-92f7-a51545725f93_terseLabel_en-US" xlink:label="lab_anab_ReceivablesForStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable related to issuance of common stock, upon exercise of stock options</link:label>
    <link:label id="lab_anab_ReceivablesForStockOptionsExercised_label_en-US" xlink:label="lab_anab_ReceivablesForStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables for Stock Options Exercised</link:label>
    <link:label id="lab_anab_ReceivablesForStockOptionsExercised_documentation_en-US" xlink:label="lab_anab_ReceivablesForStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables for Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ReceivablesForStockOptionsExercised" xlink:href="anab-20210630.xsd#anab_ReceivablesForStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_ReceivablesForStockOptionsExercised" xlink:to="lab_anab_ReceivablesForStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_0a9fb1ec-7289-40e9-b2c1-3a0e59058810_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_10093885-9335-4e91-a548-ffb51618124e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1065a6a0-d02e-4157-ae4a-215c3802c631_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_55b36da9-e79d-430f-ae2d-e6d385f7b1ee_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Accounts and Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_97f2bc54-5eff-493a-bfed-5bbf55c28814_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination term</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:href="anab-20210630.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:to="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_BristolMyersSquibbMember_79193fcf-a090-455a-9d70-16dd49f32841_terseLabel_en-US" xlink:label="lab_anab_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene Corporation</link:label>
    <link:label id="lab_anab_BristolMyersSquibbMember_label_en-US" xlink:label="lab_anab_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_anab_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_anab_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_BristolMyersSquibbMember" xlink:href="anab-20210630.xsd#anab_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_BristolMyersSquibbMember" xlink:to="lab_anab_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b2c65e9c-0053-4259-8b7d-53a0f061b352_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c738f7d-73a2-44c4-a9c0-317a6e2a1908_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7e1517d4-ef41-4c91-8c48-8f5cc45aa88d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_54482f7b-9f61-44b9-9226-9dcb8253766e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7adc67ce-7ca1-45cc-b586-090b54a0e030_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_4091dec5-1a43-4629-98f5-df09f2f22fc4_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent upon preclinical and clinical trial events (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c348cb92-9921-4fa8-a8e3-21c22d1fe8d4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9dfb56c1-90ca-4be1-be54-6bb20457252f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8d82299b-1f11-4f44-9d7c-7a354f74047b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs in Cash Flow Statement</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f9696f2e-3d5b-451c-aa98-f2f3a4e96068_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ba497521-6c6b-4608-8b17-3bde80fbc981_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnnualRentIncreasePercent_462e2086-ea21-4a0d-90e0-33ba7d454f7e_terseLabel_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in annual rent</link:label>
    <link:label id="lab_anab_AnnualRentIncreasePercent_label_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Increase, Percent</link:label>
    <link:label id="lab_anab_AnnualRentIncreasePercent_documentation_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Increase, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnnualRentIncreasePercent" xlink:href="anab-20210630.xsd#anab_AnnualRentIncreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnnualRentIncreasePercent" xlink:to="lab_anab_AnnualRentIncreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a30a205a-3fcd-4a09-9fda-2b7629ab4703_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d44a6e98-af80-4382-bab2-cfb9cdfc99af_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_cb3f6c99-1084-4f39-ac75-670321e034b1_terseLabel_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_documentation_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="anab-20210630.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_65b43f37-4558-4250-9db8-3a30fce468de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets &#8211; operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_a9266890-f3a8-4e11-b063-8f26e5b3d173_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaborative partners</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_bc60aa23-b55e-4f00-af21-64952b80d027_terseLabel_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_4ee76e6f-850a-4960-b7d0-24a1a7462911_verboseLabel_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_label_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan, 2017 [Member]</link:label>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_documentation_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan, 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member" xlink:href="anab-20210630.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EquityIncentivePlan2017Member" xlink:to="lab_anab_EquityIncentivePlan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_21d74210-e6f5-4a9f-b625-44af0b259ff7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8e13c3e0-c0bb-4c5a-bab0-c9f0356a8532_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_d5844abd-4845-432d-828b-4006b05219cd_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion/amortization of investments, net</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a0f01d79-d854-415f-bfb6-d9a0e1aa8d9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Market Prices for Identical&#160;Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_40980e5c-4bac-42a2-9066-c5a0192b96c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa4db3cc-c01b-4b5a-b6c6-b1844da95cee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b931c4a5-2ed8-4c3b-ba61-50f4ab9fc347_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_21ef99b2-4e06-4cac-b551-ab1fcfa4193b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_a38f3b1c-a418-4773-9c2c-abce01aab426_terseLabel_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital shares reserved for future issuance, increase (in shares)</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_label_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Increase</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_documentation_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:href="anab-20210630.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:to="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CollaborationAndExclusiveLicenseAgreementMember_a878f546-098d-4bc0-830e-65c984d2261c_terseLabel_en-US" xlink:label="lab_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment</link:label>
    <link:label id="lab_anab_CollaborationAndExclusiveLicenseAgreementMember_label_en-US" xlink:label="lab_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Exclusive License Agreement [Member]</link:label>
    <link:label id="lab_anab_CollaborationAndExclusiveLicenseAgreementMember_documentation_en-US" xlink:label="lab_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Exclusive License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:href="anab-20210630.xsd#anab_CollaborationAndExclusiveLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:to="lab_anab_CollaborationAndExclusiveLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e7a42308-b712-41f8-afc1-3efa32da17e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_15282847-ac60-447e-94fe-0f5d47f54619_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of outstanding research and development targets</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ac094020-bf96-4417-9f6a-ed05bd24a0b1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_bdc6dd86-ac85-456a-a263-5dbcfd3adc9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e68543f9-9cc8-45d7-b245-4e450ed2e363_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Available for Sale Investments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7cd2f4ca-3608-4246-b11c-08b7a0f327d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_200a1059-8ac9-45df-aee0-0b3d22bbf44a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60679096-0c81-42e5-9076-4752f551736d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0f1e234c-4ea6-43a2-befe-f25f98326b1a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_861c7b97-1731-470e-bc65-42bd1b387bda_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6628b12f-6a68-4234-8790-22c40e146749_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_971e38ad-63b6-4854-82c2-7535a877d2dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_e952612d-0828-4d7b-b3a6-9225562fef5b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_34c2cc7d-7fbe-4a9a-8d35-7a59759a45f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7db7ee4b-7c6b-41fe-9184-f696234d1415_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_FilingOfMMAFirstIndicationMember_3bf538fb-20e6-4d58-a123-efbaa81a410c_terseLabel_en-US" xlink:label="lab_anab_FilingOfMMAFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of the first MAA - first indication</link:label>
    <link:label id="lab_anab_FilingOfMMAFirstIndicationMember_label_en-US" xlink:label="lab_anab_FilingOfMMAFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of MMA - First Indication [Member]</link:label>
    <link:label id="lab_anab_FilingOfMMAFirstIndicationMember_documentation_en-US" xlink:label="lab_anab_FilingOfMMAFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of MMA - First Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfMMAFirstIndicationMember" xlink:href="anab-20210630.xsd#anab_FilingOfMMAFirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FilingOfMMAFirstIndicationMember" xlink:to="lab_anab_FilingOfMMAFirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5aef89b5-63b5-4cfa-8b89-081da710d89c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_9d35d414-580f-4ad0-8198-dc2385e7924f_terseLabel_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_264d0830-c708-4158-b18c-ce111cb215c2_verboseLabel_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_label_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, 2017 [Member]</link:label>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_documentation_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member" xlink:href="anab-20210630.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EmployeeStockPurchasePlan2017Member" xlink:to="lab_anab_EmployeeStockPurchasePlan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1927767d-2f87-4c2f-be7e-92d61cf5320f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_72af8562-39fb-4477-8a74-e74a7389e0da_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_cf4ceb84-a09e-40c0-8d46-861bbe99ad3b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_0ef5197e-8a1c-4e7a-b8e7-835937ef35fd_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-PD-1 (CC-90006)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:to="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member_6420c813-c1ac-472c-8a36-67ac5c0ad334_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-LAG-3 (GSK40974386)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio Generated Anti-LAG-3 (GSK40974386) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio Generated Anti-LAG-3 (GSK40974386)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member" xlink:to="lab_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2296af82-170d-4518-be9f-891b37a766b6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c716968f-8aef-404d-aa58-814571d084e7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fa45704a-9581-43f9-a180-139289354437_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9827dece-89f0-42d6-a1e7-dab881bf3b26_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52a6b51c-23ca-4054-b83a-e0889bc61ff1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5b206219-31ea-45d5-915c-c8c12d9da47c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Subject to Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c1c8f415-31d9-489b-aae1-d024bb2b1c46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures and cancellations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_607c539d-5248-454e-9774-d69d42d1f6d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_92f710b2-68a3-4d94-ae46-149008102db9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b902e637-01e2-4659-bd6a-cfc4750f9677_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bc1378b4-c295-4c99-8533-dfb006516ce6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_LaboratoryEquipmentMember_a0bc7ab7-244c-4d1c-a7b9-70e78a8c15b5_terseLabel_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_anab_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_anab_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LaboratoryEquipmentMember" xlink:href="anab-20210630.xsd#anab_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LaboratoryEquipmentMember" xlink:to="lab_anab_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_16dfd538-2bcc-4b46-8912-513d9c324474_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1f7ba64b-b6ed-4f04-bd6b-7b216600c882_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33c79ce2-d01c-4e35-a30a-78015abc6499_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_dcd7ea23-078a-4238-90b5-51492a7dc995_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_363ec043-fc02-4d7e-8ec1-807131d11d32_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d10d3f5b-815e-451c-b54f-dc241eff6181_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c872b869-6f6e-4f27-a218-a980bfd18c21_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_31995ed9-0d6f-4c68-8e7a-cfec1e688781_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b65f0d58-befa-4dca-a552-715e97ecd7bf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_779cd391-a37f-4df8-a8f8-4573e2b73135_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_74528058-1787-458d-ab30-649835db377b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBioGeneratedZejulaMember_0946b8a7-7a64-4c36-9530-81223b49c542_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedZejulaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-generated Zejula</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedZejulaMember_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedZejulaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-generated Zejula [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedZejulaMember_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedZejulaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio-generated Zejula</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedZejulaMember" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedZejulaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedZejulaMember" xlink:to="lab_anab_AnaptysBioGeneratedZejulaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f744d734-dddb-43d0-9d42-997645842356_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e5fa50b9-4d65-47be-89fb-67d0940484dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_bd15537c-e758-4427-8eae-511a6c6f4b70_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2bfa809f-4453-459c-a124-db360208e9d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercisable, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_b41c7569-c725-44b6-80a6-4a703f416bdc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research And Development Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9325807d-a811-494d-aea1-8c7c1105317c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_213fd388-334d-49a4-a962-7b1869b5e2c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_f0b3151b-a7df-4cdf-a0e6-d22d35853e04_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_2135b488-c056-4d65-83d5-683b3e43177d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a3aa6327-70ec-4a5f-aa49-2e2689fbbf3d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_df407c84-9094-49e2-b1fc-9564aecf2751_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_975bc224-5466-4cb7-9773-e7f691c53aea_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_214bd42e-494d-4004-9e7e-ba8539b4567f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_d22d987d-61c4-4067-b1f7-d6b433798906_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_be9da37b-3619-4644-8fc0-5e9ab77c0054_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3dda28cf-6626-42b2-a055-4073276b77ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6b3f2e13-ff3b-4169-a235-6ec2c119bc61_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a1b3f025-0181-488f-8fbf-08e8b77c3819_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7a3ad1aa-fb20-46ac-91b8-83f554814376_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 500,000 shares authorized, 27,433 shares and 27,356 shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_12af674a-5201-42cf-82e2-5bfc969e2fa8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_51212a1b-9214-4b11-bbf2-fe45ecf0837a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b02b7c2-f5ad-4f31-8973-0afe8c70cdd4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period remaining for amortization of unrecognized compensation cost (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_c1384b4b-e8ce-4afa-8aa0-8826ee32d50d_verboseLabel_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 clinical trial initiation</link:label>
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_label_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Trial Initiation [Member]</link:label>
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_documentation_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Trial Initiation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember" xlink:href="anab-20210630.xsd#anab_Phase1ClinicalTrialInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase1ClinicalTrialInitiationMember" xlink:to="lab_anab_Phase1ClinicalTrialInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_FirstBLAApprovalDMMRECMember_ed60fda3-1045-4e44-a4ee-6f4e44f5ae54_terseLabel_en-US" xlink:label="lab_anab_FirstBLAApprovalDMMRECMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First BLA approval - first indication</link:label>
    <link:label id="lab_anab_FirstBLAApprovalDMMRECMember_label_en-US" xlink:label="lab_anab_FirstBLAApprovalDMMRECMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First BLA Approval - dMMREC [Member]</link:label>
    <link:label id="lab_anab_FirstBLAApprovalDMMRECMember_documentation_en-US" xlink:label="lab_anab_FirstBLAApprovalDMMRECMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First BLA Approval - dMMREC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FirstBLAApprovalDMMRECMember" xlink:href="anab-20210630.xsd#anab_FirstBLAApprovalDMMRECMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FirstBLAApprovalDMMRECMember" xlink:to="lab_anab_FirstBLAApprovalDMMRECMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7c5ae392-b768-4888-b1ba-0be7df9f722d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_FirstMAAApprovalFirstIndicationMember_d6ba1446-8c27-43e6-aa84-447847fa2dc8_terseLabel_en-US" xlink:label="lab_anab_FirstMAAApprovalFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First MAA approval - first indication</link:label>
    <link:label id="lab_anab_FirstMAAApprovalFirstIndicationMember_label_en-US" xlink:label="lab_anab_FirstMAAApprovalFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First MAA Approval - First Indication [Member]</link:label>
    <link:label id="lab_anab_FirstMAAApprovalFirstIndicationMember_documentation_en-US" xlink:label="lab_anab_FirstMAAApprovalFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First MAA Approval - First Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FirstMAAApprovalFirstIndicationMember" xlink:href="anab-20210630.xsd#anab_FirstMAAApprovalFirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FirstMAAApprovalFirstIndicationMember" xlink:to="lab_anab_FirstMAAApprovalFirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_576b9eff-a1fc-467a-bebf-4e1dba1b9188_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_203604b2-7277-4b74-87a2-216d861c84ba_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee received</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_label_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:to="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bd9293d5-bf8d-4a80-81af-e606000af313_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_bbedf73f-c986-4981-b503-29ab446b6268_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a3b28f82-7f09-481d-ae36-1ac30dad190e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ac00f8ef-944e-46e9-bbcf-f6a84e135e19_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f9a06ce1-8eca-4566-8917-cfea829a82a9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_36ca1162-b0ee-4f47-91d0-fe1faae92173_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Assumptions used to Estimate Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_f90ef6f9-e03e-4c6a-9be4-6664547f927c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_21f2c3e2-ff34-49c5-9895-c3c201b3a5e6_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c4bf95ba-ff1a-4277-9ffa-df66eda4a0cf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a4bcfeb0-c0d6-44cf-9347-9e2188cec388_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_28b53d38-dc8b-403f-ad97-d2b93b172ade_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of tenant improvements and certain equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e1c018b-d7fc-42b9-8b14-81b56aad1a25_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2643e4d5-fd14-4d20-aa41-c416412eaa37_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_570597a1-8f0a-4411-b099-a6543aa89f6b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2346d974-b17e-4712-b2ab-cb92e28a5c0f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_12b685bc-6ae9-46c7-92ca-a0e6e4f1c08c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_b53f5cfa-d457-444d-87b3-dc6996fefd5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss and Fair Values in a Loss Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_a1479b22-3524-4fb8-ac91-001e87eca663_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3e7ae0bf-6366-4bcc-81f8-5e0b95767025_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4083ea82-79de-4186-9d54-b16d315db435_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7702f791-7472-4388-80fe-793527ebc911_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_6d13c933-aa86-407a-8730-23a1d4872585_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_75a39e20-df22-4361-9ea1-41e686bbb097_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ddb9aeba-3ea0-4525-add7-b92c83632776_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_3eb9ca80-9de5-4294-bb07-c483e6bbc5ac_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_511a137e-22c4-4bcc-a667-aafd6efa6c8e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_41958039-5253-452b-ba91-c3c1b78b8fb8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d367afec-d701-404a-9647-21582c5f5a3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f85ef69c-1fb0-47ee-8726-3bba2a2c4700_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_93db0be4-5826-494a-b285-0f8635bac45f_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment earned</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_label_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_documentation_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:href="anab-20210630.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:to="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eddc5fdf-1242-4173-8f3e-fbd0383d9fda_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_3834d578-3d3e-446f-b809-6be117014649_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dd3a28e8-68c6-4a07-a53b-29e435d766ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3d1f6a0b-ea6b-4b7e-bd70-f75d7486d2d3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8e12d147-e338-4371-94da-798ec5a33fae_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_22425f82-8ae1-4ec9-82f4-721615813ffa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7c2ce30-fac5-4dd6-8b28-db90702d15a9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_046088bb-5b14-4e1f-98d7-f8e208cdb16e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8fb8a6e0-2a54-4d60-803d-4f32c14e02ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_3a9b18b6-39a7-4cd6-b620-9bd8242570c6_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f0c1a208-883e-4352-a8b5-c7d2cb3411a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember_fc492fd9-1625-43e4-8502-5c09da41ca61_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-TIM-3 (GSK4069889A/Cobolimab)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember" xlink:to="lab_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d086b62b-a641-47ce-b3cf-d88730689259_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_39e0c2e2-0096-446b-87bd-2f53692e25a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c2e36083-c0a3-42a8-8205-d0d6afa58372_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_59c97b69-e864-4fe9-8ef9-30b11aebc5d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_FilingOfBLAFirstIndicationMember_b78e7436-940a-4fd4-82a0-6d251e2617c7_terseLabel_en-US" xlink:label="lab_anab_FilingOfBLAFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of the first BLA - first indication</link:label>
    <link:label id="lab_anab_FilingOfBLAFirstIndicationMember_label_en-US" xlink:label="lab_anab_FilingOfBLAFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of BLA - First Indication [Member]</link:label>
    <link:label id="lab_anab_FilingOfBLAFirstIndicationMember_documentation_en-US" xlink:label="lab_anab_FilingOfBLAFirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filing of BLA - First Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfBLAFirstIndicationMember" xlink:href="anab-20210630.xsd#anab_FilingOfBLAFirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FilingOfBLAFirstIndicationMember" xlink:to="lab_anab_FilingOfBLAFirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_54c70eef-0510-4f18-a8cb-70da1c481b76_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3411ecfc-3740-4f62-9c9c-e246f8b2deda_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_96a41976-0fec-481a-a482-ec80ca704ad7_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones achieved, amount</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7da7853a-21d7-4297-8a6f-cae9c72723fe_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_23ee7fa1-ff8d-4ae8-9b25-6c76b19e32d1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a81a0eec-7066-4886-86c9-d173e7d34f21_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_17d3b3ff-d37b-4413-aa2c-b11ae1596225_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdae312b-7884-4c05-8be9-e868642039cb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ff2fd8a-e3b9-43f3-8ffe-41ee0b2ba0ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_34d9d8c8-40f9-43d8-807a-72cad29df6d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_dfca7f80-6bf8-4970-b9ee-0b09920c3bea_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e053b07-c553-4078-b26f-256b085a7c31_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d686cc5d-4f34-4a12-b164-dcd7babe2a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e5f4ef17-5668-4acc-af22-d3f1d3fc5a0c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f9a09d4e-a1b1-4911-81c6-a2e125a65e9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_caea1774-05a7-4067-98e1-573b3262fc88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bb51e0e9-1664-4a3f-b1fb-68c08749b162_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2519f5bd-d7bc-46c8-809f-33acef7585f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b218f1a0-723e-499d-8ee2-207411cf1f7f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research and Development Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d926faf4-5c9d-4e80-82e1-2bd9acd5af18_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cd2303a5-972a-4f14-8251-04e546093fc4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_954edb38-397c-469b-82b3-81621b02c62d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6a97b24f-f914-4860-8ee6-37fd1467a7f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_b5a3b63f-9ac7-48fb-9cc5-28c25ad9dfb9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_33b8128f-20e5-4459-9820-56ff343102b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d546c10b-2fa3-4e6c-a857-5306972acfd3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_db218d73-1871-481f-abc8-bfec7ab37ca7_terseLabel_en-US" xlink:label="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreement</link:label>
    <link:label id="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_label_en-US" xlink:label="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10770 Wateridge Circle, San Diego, California 92121 [Member]</link:label>
    <link:label id="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_documentation_en-US" xlink:label="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10770 Wateridge Circle, San Diego, California 92121</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:href="anab-20210630.xsd#anab_A10770WateridgeCircleSanDiegoCalifornia92121Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:to="lab_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_67fe55b8-8bf1-47da-8070-e55ef93ad8a9_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e92bffa6-38b0-434b-a73a-aaf18817c56a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_87d0dc3e-80a1-43ae-872e-9295f850dcdc_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement term following first commercial sale or expiration of the last to expire patent (in years)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b111f790-e916-4fc5-b903-1c13954897f7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_f197e384-2594-4b79-ba8a-baf5a471efd1_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones achieved during period</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79d38e6e-db5c-43c5-bd10-587fa9c41696_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d9f1391c-2ca0-4f4b-9fd8-f9e7bd4017b0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_a8e6f72a-9aa2-4c79-b4cd-25ab7b691f45_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8a444a78-ca6c-4d59-b155-b2ef67538451_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8efb07ea-f83d-4d1e-8df2-3832f8ecf6f8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_35cb6b92-fd9d-4c95-aa1e-2f223ebf502b_terseLabel_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2 clinical trial initiation</link:label>
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_label_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2 Clinical Trial Initiation [Member]</link:label>
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_documentation_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2 Clinical Trial Initiation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember" xlink:href="anab-20210630.xsd#anab_Phase2ClinicalTrialInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase2ClinicalTrialInitiationMember" xlink:to="lab_anab_Phase2ClinicalTrialInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees_dd8a32de-bf2a-4ac4-9b01-5de2bef93212_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition multiple deliverable arrangements upfront fee receivable</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees_label_en-US" xlink:label="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Upfront Fees</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Upfront Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" xlink:to="lab_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_352eb023-cbd1-4ed6-bad7-6e2294016f12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a9093c5c-7583-4edc-b17c-f03ed1b95d37_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_537ac0c7-8653-4214-9e92-f6bc38fc0272_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7403bcbe-edd1-4080-80a9-d300ac697140_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_696e105e-f86a-40ab-927e-814d0eb3b5ee_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_d3d2fd1f-cbaf-4dc1-bdc2-40704822a670_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Milestones Achieved</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d880f604-fa85-4319-8ed7-fa24ea56bdce_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ff05c5d3-459e-4ba7-8dbe-bbfcdb81b9ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ef9e01b5-91db-4969-858a-2f7917228c0c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1aee1368-9a1a-4084-a4a4-c0d459c517ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8c8e886f-7e5d-4398-b2dd-df6b0bf6c8f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_096426b4-fdfa-4980-be62-e63ff93dbc29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_621bc4d5-85a9-4ed4-982b-3d88f87e8e5e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Annual Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_990241f1-0537-40a6-9887-51aef392cf4f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_41f2b4c2-db8b-46c2-832e-269fe7fcc96c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4c1cb4ae-cd94-40bb-93ce-86b6f1292415_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_fc2d5adc-b6d3-4a71-8601-1db0e6df13df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 Months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f930693f-5954-4878-a38b-f63fafc613a7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6176128a-8756-498c-9f5d-fc428f5f3cc3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_84837cc5-7722-40f4-9203-0b090589bdd3_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_57595971-8436-44b8-bdf4-2f9ccb378cbc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_833533c6-12e2-4387-9b01-2a521d99c764_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ec5e3c5c-2134-443e-9b04-a92031ae759b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_d67682d9-0818-4e25-b747-9565cd757157_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ce6a915-4fce-49e3-aef8-8cae014e43cf_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_b691a82b-dcea-4b8a-b224-627dc9996e22_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_dd251ee8-6fec-4331-8609-8aaf25e4d82c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_673e72a7-84a9-487c-aad0-191c581a7104_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8f5876db-e0d3-4ac2-b688-9be66226ee48_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember_b56e0ded-282a-406f-9996-c961a01963e5_terseLabel_en-US" xlink:label="lab_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10455 Building</link:label>
    <link:label id="lab_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember_label_en-US" xlink:label="lab_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10455 Pacific Center Court in San Diego, California [Member]</link:label>
    <link:label id="lab_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10455 Pacific Center Court in San Diego, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember" xlink:href="anab-20210630.xsd#anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember" xlink:to="lab_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_14ebf058-73df-4b6c-8f60-d5be2bf978bf_terseLabel_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initiated in vivo toxicology studies using good laboratory practices (GLPs)</link:label>
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_label_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Vivo Toxicology Studies [Member]</link:label>
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_documentation_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Vivo Toxicology Studies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_InVivoToxicologyStudiesMember" xlink:href="anab-20210630.xsd#anab_InVivoToxicologyStudiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_InVivoToxicologyStudiesMember" xlink:to="lab_anab_InVivoToxicologyStudiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anab_CollaborationRevenueMember_label_en-US" xlink:label="lab_anab_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_anab_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_anab_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CollaborationRevenueMember" xlink:href="anab-20210630.xsd#anab_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CollaborationRevenueMember" xlink:to="lab_anab_CollaborationRevenueMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>anab-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c7655f00-1548-4625-8cd9-c93812026c41,g:f65e361e-f377-49d6-802f-d6fad364b94f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:type="simple" xlink:href="anab-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a65a08dd-7aec-4478-bc46-a7585d6646a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_DocumentType_a65a08dd-7aec-4478-bc46-a7585d6646a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_cb5dcde2-5782-4f3e-9f66-7010f9b22afa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_DocumentQuarterlyReport_cb5dcde2-5782-4f3e-9f66-7010f9b22afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c047d419-82d6-4ea2-bfef-1ed677a37c17" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_DocumentPeriodEndDate_c047d419-82d6-4ea2-bfef-1ed677a37c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3d92ccbb-6a9d-4673-a744-0593900a2233" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_DocumentTransitionReport_3d92ccbb-6a9d-4673-a744-0593900a2233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_62a6025c-a46b-45b2-ad0a-d773318e133a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityFileNumber_62a6025c-a46b-45b2-ad0a-d773318e133a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_43a504ed-daaa-4e6d-b80b-23b3d53ff1f8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityRegistrantName_43a504ed-daaa-4e6d-b80b-23b3d53ff1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_02270379-8b10-4496-95b6-82eda42a7803" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityIncorporationStateCountryCode_02270379-8b10-4496-95b6-82eda42a7803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4b9c8325-3694-404f-8b41-1400d704035a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityTaxIdentificationNumber_4b9c8325-3694-404f-8b41-1400d704035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ee10e2ce-88b6-4cc6-9259-5419b0dabe7b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityAddressAddressLine1_ee10e2ce-88b6-4cc6-9259-5419b0dabe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_6a61ceb2-8716-4851-b6e1-4fdd72546232" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityAddressAddressLine2_6a61ceb2-8716-4851-b6e1-4fdd72546232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a8386fd5-04da-4ba9-9b30-f7fa81c4534f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityAddressCityOrTown_a8386fd5-04da-4ba9-9b30-f7fa81c4534f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_45d08267-d5ec-40a1-8c20-6124096dac51" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityAddressStateOrProvince_45d08267-d5ec-40a1-8c20-6124096dac51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3724c091-6f29-46af-8214-7efd3e04f360" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityAddressPostalZipCode_3724c091-6f29-46af-8214-7efd3e04f360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6c6a6d13-14bd-4b21-9e32-ea94419b8cd8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_CityAreaCode_6c6a6d13-14bd-4b21-9e32-ea94419b8cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d31d9f41-9a39-4fa6-b851-870f9a4793e3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_LocalPhoneNumber_d31d9f41-9a39-4fa6-b851-870f9a4793e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7a115fef-3af4-45e9-97a0-0581c69f691f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_Security12bTitle_7a115fef-3af4-45e9-97a0-0581c69f691f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_984753b0-3475-4abf-be5d-9d74dbb61136" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_TradingSymbol_984753b0-3475-4abf-be5d-9d74dbb61136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bb1d01a7-47c1-4fb8-bed4-4236a040524a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_SecurityExchangeName_bb1d01a7-47c1-4fb8-bed4-4236a040524a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_566e515c-6ff8-461d-8a39-d74a968109d5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityCurrentReportingStatus_566e515c-6ff8-461d-8a39-d74a968109d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_681acf05-4c8b-42a5-b89f-0de7b8d8c0ee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityInteractiveDataCurrent_681acf05-4c8b-42a5-b89f-0de7b8d8c0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_959f5b54-67cb-40b0-852f-3b6cc6ae923b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityFilerCategory_959f5b54-67cb-40b0-852f-3b6cc6ae923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_be007623-be18-4042-adb0-679aec44121d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntitySmallBusiness_be007623-be18-4042-adb0-679aec44121d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a96902b3-4a4d-4176-8adc-0db57a907ebe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityEmergingGrowthCompany_a96902b3-4a4d-4176-8adc-0db57a907ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4cd76aae-6a8e-4c5a-8804-ce50157f46b3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityShellCompany_4cd76aae-6a8e-4c5a-8804-ce50157f46b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4fba25cc-30d2-41ad-bf6f-c44cbbb692a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4fba25cc-30d2-41ad-bf6f-c44cbbb692a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_49efd658-be8b-4b72-8221-923b9c58b9a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_EntityCentralIndexKey_49efd658-be8b-4b72-8221-923b9c58b9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3e1a09ea-8d49-4d99-ae09-39658af58782" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_CurrentFiscalYearEndDate_3e1a09ea-8d49-4d99-ae09-39658af58782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_353f366a-ca0f-4a32-a712-680f8c0f9889" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_DocumentFiscalYearFocus_353f366a-ca0f-4a32-a712-680f8c0f9889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7bc9e358-5f8a-4508-bb85-06f749baee83" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7bc9e358-5f8a-4508-bb85-06f749baee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6370794b-70a3-4196-a3d8-fdb647137360" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_83c436ea-3117-4b38-bc65-24eda9ea9247" xlink:to="loc_dei_AmendmentFlag_6370794b-70a3-4196-a3d8-fdb647137360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6197176e-0a9a-4b0d-8d7e-cbbfbb4f77b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6197176e-0a9a-4b0d-8d7e-cbbfbb4f77b4" xlink:to="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d6edfa03-5671-43f6-abea-2042d4a842a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d6edfa03-5671-43f6-abea-2042d4a842a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f260d57-a36b-49c7-9709-96a25fb1b57f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6edfa03-5671-43f6-abea-2042d4a842a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f260d57-a36b-49c7-9709-96a25fb1b57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_4bda099f-7eef-4674-992e-5c9ca7028734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6edfa03-5671-43f6-abea-2042d4a842a9" xlink:to="loc_us-gaap_ReceivablesNetCurrent_4bda099f-7eef-4674-992e-5c9ca7028734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0339952a-a2fb-4ea3-ba27-0a2adb385bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6edfa03-5671-43f6-abea-2042d4a842a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0339952a-a2fb-4ea3-ba27-0a2adb385bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5831a51-f3a4-4196-b844-8de3f0c5e8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6edfa03-5671-43f6-abea-2042d4a842a9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5831a51-f3a4-4196-b844-8de3f0c5e8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_cdb7bd51-558c-4d43-b349-796ca701ea7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6edfa03-5671-43f6-abea-2042d4a842a9" xlink:to="loc_us-gaap_RestrictedCashCurrent_cdb7bd51-558c-4d43-b349-796ca701ea7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4ce3fbad-a605-4371-96ab-f07c9a9e3ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6edfa03-5671-43f6-abea-2042d4a842a9" xlink:to="loc_us-gaap_AssetsCurrent_4ce3fbad-a605-4371-96ab-f07c9a9e3ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_664fd1ae-4d9c-45e9-b385-e16bfbff8f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_664fd1ae-4d9c-45e9-b385-e16bfbff8f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0995e71e-1e5d-42d3-9646-e2cc0241daec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0995e71e-1e5d-42d3-9646-e2cc0241daec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a3fc12f3-3c34-421c-96c0-c2c93aeb2a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a3fc12f3-3c34-421c-96c0-c2c93aeb2a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1a03d301-ab9e-4f84-a254-ad7060a7e28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1a03d301-ab9e-4f84-a254-ad7060a7e28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6bb826a9-9983-4ad7-9918-23e5fbae4ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6bb826a9-9983-4ad7-9918-23e5fbae4ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5cf8d4e9-32b5-4a33-be51-f865ae2c22c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b333a5a4-d278-4e4f-bc45-184c2103c6e2" xlink:to="loc_us-gaap_Assets_5cf8d4e9-32b5-4a33-be51-f865ae2c22c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75875161-9424-435f-94f8-9cdb649e75ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6197176e-0a9a-4b0d-8d7e-cbbfbb4f77b4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75875161-9424-435f-94f8-9cdb649e75ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_43e73f7b-3e72-491b-9db4-9775223bf757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75875161-9424-435f-94f8-9cdb649e75ed" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_43e73f7b-3e72-491b-9db4-9775223bf757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e940026a-366f-4dfb-9008-c5d178ebc9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43e73f7b-3e72-491b-9db4-9775223bf757" xlink:to="loc_us-gaap_AccountsPayableCurrent_e940026a-366f-4dfb-9008-c5d178ebc9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8d296292-5eb3-475b-92eb-c01620c2e15b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43e73f7b-3e72-491b-9db4-9775223bf757" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8d296292-5eb3-475b-92eb-c01620c2e15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e4d2a2f0-3ddf-4a14-8deb-1b235027a34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43e73f7b-3e72-491b-9db4-9775223bf757" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e4d2a2f0-3ddf-4a14-8deb-1b235027a34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_228e67a2-a465-428d-9e72-376c74e93c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43e73f7b-3e72-491b-9db4-9775223bf757" xlink:to="loc_us-gaap_LiabilitiesCurrent_228e67a2-a465-428d-9e72-376c74e93c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_365fd602-989d-4ded-a6fb-b6678491601d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75875161-9424-435f-94f8-9cdb649e75ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_365fd602-989d-4ded-a6fb-b6678491601d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5efa1009-0134-4474-bdb4-bc6dfd942ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75875161-9424-435f-94f8-9cdb649e75ed" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5efa1009-0134-4474-bdb4-bc6dfd942ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e64c7264-bd97-43ee-8a15-587e18002c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5efa1009-0134-4474-bdb4-bc6dfd942ddd" xlink:to="loc_us-gaap_PreferredStockValue_e64c7264-bd97-43ee-8a15-587e18002c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3e7825f9-06d8-4394-a284-3d72574448cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5efa1009-0134-4474-bdb4-bc6dfd942ddd" xlink:to="loc_us-gaap_CommonStockValue_3e7825f9-06d8-4394-a284-3d72574448cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1c48d52e-a7e7-4187-bfb3-832eecd53c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5efa1009-0134-4474-bdb4-bc6dfd942ddd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1c48d52e-a7e7-4187-bfb3-832eecd53c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb13d26d-173d-4f1f-a800-d324fb28bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5efa1009-0134-4474-bdb4-bc6dfd942ddd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb13d26d-173d-4f1f-a800-d324fb28bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_76bff2b3-8b69-4e69-9e6f-acf5f7a734c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5efa1009-0134-4474-bdb4-bc6dfd942ddd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_76bff2b3-8b69-4e69-9e6f-acf5f7a734c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7cf84e6f-abb7-4c62-bb7c-3acafcb2ce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5efa1009-0134-4474-bdb4-bc6dfd942ddd" xlink:to="loc_us-gaap_StockholdersEquity_7cf84e6f-abb7-4c62-bb7c-3acafcb2ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b2d4f987-423e-4e3c-b126-ba62cda6aa72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75875161-9424-435f-94f8-9cdb649e75ed" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b2d4f987-423e-4e3c-b126-ba62cda6aa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6630db0f-d26d-47c3-b3c6-637413273d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6630db0f-d26d-47c3-b3c6-637413273d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8a0ec211-f7d7-4cc3-83fb-20df5dc7585a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8a0ec211-f7d7-4cc3-83fb-20df5dc7585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_29d4f313-4e0f-463f-ad2a-f7cb180f023e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_29d4f313-4e0f-463f-ad2a-f7cb180f023e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_caf768e5-76b5-4a06-ba19-a7908d785ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_caf768e5-76b5-4a06-ba19-a7908d785ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_50e6466a-bd1d-403b-b2b0-02f73011c7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_50e6466a-bd1d-403b-b2b0-02f73011c7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f8dcacb1-4a09-441c-a2ce-4eca46adf42a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f8dcacb1-4a09-441c-a2ce-4eca46adf42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e2e8d736-4446-4d98-8aa6-1fe895938b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:to="loc_us-gaap_CommonStockSharesIssued_e2e8d736-4446-4d98-8aa6-1fe895938b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_52a1695a-a594-4172-bcd3-759b3db280f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_712c1b9d-beed-444e-b02b-2a2c69075a6b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_52a1695a-a594-4172-bcd3-759b3db280f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3bbe0c0f-ab5b-43a2-a26b-8960b11692c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3bbe0c0f-ab5b-43a2-a26b-8960b11692c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_22a1c2e1-db14-4066-b2ee-ba90eb463a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_OperatingExpensesAbstract_22a1c2e1-db14-4066-b2ee-ba90eb463a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8000f62d-31f0-4551-b277-7a9e4ca0152d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_22a1c2e1-db14-4066-b2ee-ba90eb463a18" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8000f62d-31f0-4551-b277-7a9e4ca0152d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e077fcc8-3bbb-4a05-af34-aa0e4a59b31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_22a1c2e1-db14-4066-b2ee-ba90eb463a18" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e077fcc8-3bbb-4a05-af34-aa0e4a59b31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5dce130e-dec8-4da0-9585-9f7bc3c5efb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_22a1c2e1-db14-4066-b2ee-ba90eb463a18" xlink:to="loc_us-gaap_OperatingExpenses_5dce130e-dec8-4da0-9585-9f7bc3c5efb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_95153dde-dd5e-40e0-a45e-d9dbec546a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_OperatingIncomeLoss_95153dde-dd5e-40e0-a45e-d9dbec546a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e2fc021-fade-423e-8c49-9a76b219aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e2fc021-fade-423e-8c49-9a76b219aba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d41de0f7-f65a-4f1c-a34f-f86b5bb84f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e2fc021-fade-423e-8c49-9a76b219aba8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d41de0f7-f65a-4f1c-a34f-f86b5bb84f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_aa8e46ce-05ea-4ed1-afab-b44268e2c622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e2fc021-fade-423e-8c49-9a76b219aba8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_aa8e46ce-05ea-4ed1-afab-b44268e2c622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e96bfe72-2a39-4fbe-9b28-6e8efdb3975a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4e2fc021-fade-423e-8c49-9a76b219aba8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e96bfe72-2a39-4fbe-9b28-6e8efdb3975a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1321d327-07f3-43f1-b7ae-a554a3ca2299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_NetIncomeLoss_1321d327-07f3-43f1-b7ae-a554a3ca2299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bf9d59ba-10f0-4477-9bae-ee32f2838d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bf9d59ba-10f0-4477-9bae-ee32f2838d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9db482c5-b7b7-4c03-bbbd-0d9cc6f4cc15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9db482c5-b7b7-4c03-bbbd-0d9cc6f4cc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_c71343e3-5ff1-4797-8b89-25f1006b595e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_c71343e3-5ff1-4797-8b89-25f1006b595e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ca071f0b-1db1-4a3e-8222-02ed876ca6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_c71343e3-5ff1-4797-8b89-25f1006b595e" xlink:to="loc_us-gaap_EarningsPerShareBasic_ca071f0b-1db1-4a3e-8222-02ed876ca6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8a9e146a-6528-45b6-b1e1-a03a6ba543b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_c71343e3-5ff1-4797-8b89-25f1006b595e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8a9e146a-6528-45b6-b1e1-a03a6ba543b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_5acb1ea2-7422-4911-80aa-81aa683b587f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_5acb1ea2-7422-4911-80aa-81aa683b587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_47f736f1-8d39-41cb-aa59-b375fb7ba373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_5acb1ea2-7422-4911-80aa-81aa683b587f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_47f736f1-8d39-41cb-aa59-b375fb7ba373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b119d690-96d3-4e4c-8b24-1ab19efbd104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_5acb1ea2-7422-4911-80aa-81aa683b587f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b119d690-96d3-4e4c-8b24-1ab19efbd104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_c97ee7b1-bd1a-483b-bb88-fe5f1ec0f393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_61402fc9-8cbc-4b3e-ab1e-40c2188bc633" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_c97ee7b1-bd1a-483b-bb88-fe5f1ec0f393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedStatementofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_46cb68f9-bbd7-438d-b836-3c91f22a61e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5ae93d8d-e01a-495a-9782-11e9cbf63737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_46cb68f9-bbd7-438d-b836-3c91f22a61e5" xlink:to="loc_us-gaap_StatementTable_5ae93d8d-e01a-495a-9782-11e9cbf63737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1aadc066-b949-43b8-a324-59af97fac231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5ae93d8d-e01a-495a-9782-11e9cbf63737" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1aadc066-b949-43b8-a324-59af97fac231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1aadc066-b949-43b8-a324-59af97fac231" xlink:to="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f2e8aa2-4ecc-4e81-a9de-5a0ed7e74c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:to="loc_us-gaap_CommonStockMember_4f2e8aa2-4ecc-4e81-a9de-5a0ed7e74c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b6ce241a-4183-405b-804d-0adf34a1e0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b6ce241a-4183-405b-804d-0adf34a1e0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e7bbdf7a-0ff2-458f-805e-cb4cc5572c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e7bbdf7a-0ff2-458f-805e-cb4cc5572c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_24413715-39ee-4a6b-aaef-6acb53ae0247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5350e821-9aa2-465e-bc84-224475428dfd" xlink:to="loc_us-gaap_RetainedEarningsMember_24413715-39ee-4a6b-aaef-6acb53ae0247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a794ebd1-5a52-48ee-b51d-c7b7ce0826d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5ae93d8d-e01a-495a-9782-11e9cbf63737" xlink:to="loc_us-gaap_StatementLineItems_a794ebd1-5a52-48ee-b51d-c7b7ce0826d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a794ebd1-5a52-48ee-b51d-c7b7ce0826d4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e3f7b8bb-049e-47e3-9660-9aa1b0926950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_SharesOutstanding_e3f7b8bb-049e-47e3-9660-9aa1b0926950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2caed36f-b972-4400-a3be-ba17ecec4f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_StockholdersEquity_2caed36f-b972-4400-a3be-ba17ecec4f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55759a0e-642d-4696-9f6a-d9a396ae3580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55759a0e-642d-4696-9f6a-d9a396ae3580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ad72369-336d-4d41-8ddc-72bfd60bb050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ad72369-336d-4d41-8ddc-72bfd60bb050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_f938fe36-ae3c-4e41-9699-5cd74b07038e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_f938fe36-ae3c-4e41-9699-5cd74b07038e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43f3e5cc-b552-48eb-92dc-1b8f2a686ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_43f3e5cc-b552-48eb-92dc-1b8f2a686ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_159cbd71-355e-4694-a386-b8172103d600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_NetIncomeLoss_159cbd71-355e-4694-a386-b8172103d600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_124ad108-769e-450f-9c12-7517cc698914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_SharesOutstanding_124ad108-769e-450f-9c12-7517cc698914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d5b5ba7-27d8-4b8c-ae57-6b932d0ccc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9adad4ff-095b-4f8a-863e-3e04f9c6e133" xlink:to="loc_us-gaap_StockholdersEquity_3d5b5ba7-27d8-4b8c-ae57-6b932d0ccc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="anab-20210630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4e4ce7a7-97c3-4c6a-9397-a33dbeb26e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4dc04892-8919-4ae3-b3c9-6729668530fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4e4ce7a7-97c3-4c6a-9397-a33dbeb26e4e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4dc04892-8919-4ae3-b3c9-6729668530fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_22c36574-8b3d-47f5-bd99-faeb3e5c5183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4dc04892-8919-4ae3-b3c9-6729668530fc" xlink:to="loc_us-gaap_NetIncomeLoss_22c36574-8b3d-47f5-bd99-faeb3e5c5183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9ce146d-7c99-4243-957c-3e143054815c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4dc04892-8919-4ae3-b3c9-6729668530fc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9ce146d-7c99-4243-957c-3e143054815c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d115fdc8-5d6d-40fa-b9bb-bedf35881d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9ce146d-7c99-4243-957c-3e143054815c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d115fdc8-5d6d-40fa-b9bb-bedf35881d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_86b5780d-2958-4b82-aa75-c203118ef4ec" xlink:href="anab-20210630.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9ce146d-7c99-4243-957c-3e143054815c" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_86b5780d-2958-4b82-aa75-c203118ef4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_a60a412e-5fdf-4cae-8009-f276fffc97f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9ce146d-7c99-4243-957c-3e143054815c" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_a60a412e-5fdf-4cae-8009-f276fffc97f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d4e746b7-9d57-4eb8-aabf-07c58d84369b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9ce146d-7c99-4243-957c-3e143054815c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d4e746b7-9d57-4eb8-aabf-07c58d84369b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1d7ba28a-fd6a-4492-9bec-5aedeb81b924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b9ce146d-7c99-4243-957c-3e143054815c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1d7ba28a-fd6a-4492-9bec-5aedeb81b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_5d866f09-6e64-424d-bb72-21a1db7ccf26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1d7ba28a-fd6a-4492-9bec-5aedeb81b924" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_5d866f09-6e64-424d-bb72-21a1db7ccf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520638db-d041-43b7-a4ca-0f79423e58d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1d7ba28a-fd6a-4492-9bec-5aedeb81b924" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520638db-d041-43b7-a4ca-0f79423e58d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8eaa1437-f904-4463-8c29-b8264e931961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1d7ba28a-fd6a-4492-9bec-5aedeb81b924" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8eaa1437-f904-4463-8c29-b8264e931961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_80a9a468-783b-47bf-9903-020cee41f7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1d7ba28a-fd6a-4492-9bec-5aedeb81b924" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_80a9a468-783b-47bf-9903-020cee41f7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3ef37d0f-987b-4ed2-b91f-fd3fe6f52bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4dc04892-8919-4ae3-b3c9-6729668530fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3ef37d0f-987b-4ed2-b91f-fd3fe6f52bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_431522fb-96ac-4748-8b06-a0779e6e45a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4e4ce7a7-97c3-4c6a-9397-a33dbeb26e4e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_431522fb-96ac-4748-8b06-a0779e6e45a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c92f3706-6535-4c37-b47e-73211113e173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_431522fb-96ac-4748-8b06-a0779e6e45a8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c92f3706-6535-4c37-b47e-73211113e173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_176cf137-4921-4010-9669-7cc5d8a5db44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_431522fb-96ac-4748-8b06-a0779e6e45a8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_176cf137-4921-4010-9669-7cc5d8a5db44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_580b3b22-ddd9-4220-a136-d2f9a6326a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_431522fb-96ac-4748-8b06-a0779e6e45a8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_580b3b22-ddd9-4220-a136-d2f9a6326a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1dd5e0df-26cf-434c-8bfa-87a519184ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_431522fb-96ac-4748-8b06-a0779e6e45a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1dd5e0df-26cf-434c-8bfa-87a519184ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33a87b7b-055c-4918-a036-ea31cd8e0143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4e4ce7a7-97c3-4c6a-9397-a33dbeb26e4e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33a87b7b-055c-4918-a036-ea31cd8e0143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_185d6b9c-c2d2-4ad1-93ff-4cf6c5056122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33a87b7b-055c-4918-a036-ea31cd8e0143" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_185d6b9c-c2d2-4ad1-93ff-4cf6c5056122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_4943da69-6daf-44ce-b5b3-43c9260c3f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33a87b7b-055c-4918-a036-ea31cd8e0143" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_4943da69-6daf-44ce-b5b3-43c9260c3f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb04062c-b07e-4e86-81a2-f0bbb9e75c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33a87b7b-055c-4918-a036-ea31cd8e0143" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb04062c-b07e-4e86-81a2-f0bbb9e75c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6ed2761f-8bb4-4fb5-9e62-de113248142c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4e4ce7a7-97c3-4c6a-9397-a33dbeb26e4e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6ed2761f-8bb4-4fb5-9e62-de113248142c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59e711be-fcb8-4436-b33b-a1978893458b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4e4ce7a7-97c3-4c6a-9397-a33dbeb26e4e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59e711be-fcb8-4436-b33b-a1978893458b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_712482ee-1f53-49d6-b872-0d9cf172231d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4e4ce7a7-97c3-4c6a-9397-a33dbeb26e4e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_712482ee-1f53-49d6-b872-0d9cf172231d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_132da883-8f5d-46d5-8780-f74d3ede17fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4e4ce7a7-97c3-4c6a-9397-a33dbeb26e4e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_132da883-8f5d-46d5-8780-f74d3ede17fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c49f3ce6-da2f-4cd0-af05-287cd4aeaa06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_132da883-8f5d-46d5-8780-f74d3ede17fa" xlink:to="loc_us-gaap_InterestPaidNet_c49f3ce6-da2f-4cd0-af05-287cd4aeaa06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1c5a7d6c-a0fd-4310-a829-e1de00b70019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_132da883-8f5d-46d5-8780-f74d3ede17fa" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1c5a7d6c-a0fd-4310-a829-e1de00b70019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4c2b92dd-823f-402b-8aa3-592f632928d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1c5a7d6c-a0fd-4310-a829-e1de00b70019" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4c2b92dd-823f-402b-8aa3-592f632928d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4d3e99b1-6648-4168-b10e-48ee4d464b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1c5a7d6c-a0fd-4310-a829-e1de00b70019" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4d3e99b1-6648-4168-b10e-48ee4d464b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ReceivablesForStockOptionsExercised_1c548d3b-4751-4a81-838c-b6d741d3a7f4" xlink:href="anab-20210630.xsd#anab_ReceivablesForStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1c5a7d6c-a0fd-4310-a829-e1de00b70019" xlink:to="loc_anab_ReceivablesForStockOptionsExercised_1c548d3b-4751-4a81-838c-b6d741d3a7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="anab-20210630.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_044c3a4d-b8c7-4807-92e1-1edc8293fe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_62835d8f-a194-4edb-b50d-3324a17cc906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_044c3a4d-b8c7-4807-92e1-1edc8293fe0f" xlink:to="loc_us-gaap_NatureOfOperations_62835d8f-a194-4edb-b50d-3324a17cc906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="anab-20210630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_253e141d-1dc3-45c8-830d-9f815981e22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2134340a-c2ce-469d-8531-bdc1251ea2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_253e141d-1dc3-45c8-830d-9f815981e22b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2134340a-c2ce-469d-8531-bdc1251ea2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="anab-20210630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b15840c7-8d54-4bfe-82b6-f885256fc143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_18212836-4a62-4eef-98ed-e2d0d1f3d1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15840c7-8d54-4bfe-82b6-f885256fc143" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_18212836-4a62-4eef-98ed-e2d0d1f3d1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ab664954-8f8c-45c1-b7c4-2a2b8d1f0d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15840c7-8d54-4bfe-82b6-f885256fc143" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ab664954-8f8c-45c1-b7c4-2a2b8d1f0d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_53080b2b-ce9c-4ebd-9fe6-62322fb789e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15840c7-8d54-4bfe-82b6-f885256fc143" xlink:to="loc_us-gaap_UseOfEstimates_53080b2b-ce9c-4ebd-9fe6-62322fb789e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_05d0398a-6af9-404f-b622-20282e19d85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15840c7-8d54-4bfe-82b6-f885256fc143" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_05d0398a-6af9-404f-b622-20282e19d85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_c01b539a-e4d6-44a2-8885-ebbcd6dff683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b15840c7-8d54-4bfe-82b6-f885256fc143" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_c01b539a-e4d6-44a2-8885-ebbcd6dff683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="anab-20210630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa9273ad-e3aa-49ee-8030-b1be5450b652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_98136024-95fa-486d-889a-b2c2cbe2bb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa9273ad-e3aa-49ee-8030-b1be5450b652" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_98136024-95fa-486d-889a-b2c2cbe2bb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_918bd596-0db9-46cf-a9d3-2f4cba33a8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_9bbbe05f-3534-41aa-8983-e783c811d521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_918bd596-0db9-46cf-a9d3-2f4cba33a8af" xlink:to="loc_us-gaap_NumberOfReportableSegments_9bbbe05f-3534-41aa-8983-e783c811d521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75252441-316d-4b91-a70f-922b71151ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bbce3ca5-63ec-4906-be95-dd8921d06bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75252441-316d-4b91-a70f-922b71151ca5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bbce3ca5-63ec-4906-be95-dd8921d06bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bc4beb2-c79c-4940-9a7f-9c37246265ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bbce3ca5-63ec-4906-be95-dd8921d06bdb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bc4beb2-c79c-4940-9a7f-9c37246265ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ff102319-8e99-4af6-9df8-c62f9ffde6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7bc4beb2-c79c-4940-9a7f-9c37246265ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ff102319-8e99-4af6-9df8-c62f9ffde6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_509df54d-9636-412d-8a34-fbd664cf66f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ff102319-8e99-4af6-9df8-c62f9ffde6a2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_509df54d-9636-412d-8a34-fbd664cf66f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38c3c95d-d8c7-4507-979a-e8baf3a32795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bbce3ca5-63ec-4906-be95-dd8921d06bdb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38c3c95d-d8c7-4507-979a-e8baf3a32795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_794cefe6-f380-4034-b0e6-c61517cfdf70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38c3c95d-d8c7-4507-979a-e8baf3a32795" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_794cefe6-f380-4034-b0e6-c61517cfdf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures" xlink:type="simple" xlink:href="anab-20210630.xsd#BalanceSheetAccountsandSupplementalDisclosures"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ee6d91c3-e8ea-41a6-ae1d-fc00d9474203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_45f9a14c-e792-4ca4-bf05-149f45ea6db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ee6d91c3-e8ea-41a6-ae1d-fc00d9474203" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_45f9a14c-e792-4ca4-bf05-149f45ea6db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables" xlink:type="simple" xlink:href="anab-20210630.xsd#BalanceSheetAccountsandSupplementalDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_289b705f-a1f7-4fe1-a769-13515a9caeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d9582653-a671-495a-a009-b9f3592704a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_289b705f-a1f7-4fe1-a769-13515a9caeea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d9582653-a671-495a-a009-b9f3592704a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_75fcb452-b459-437d-92ba-ccf6ae7b805c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_289b705f-a1f7-4fe1-a769-13515a9caeea" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_75fcb452-b459-437d-92ba-ccf6ae7b805c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f116473e-ea6f-45bf-b960-cbca4f7bb01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ddd4ebe6-d849-48ee-85f7-2e4e6ca15bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f116473e-ea6f-45bf-b960-cbca4f7bb01c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ddd4ebe6-d849-48ee-85f7-2e4e6ca15bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a068ca7-725f-474a-8f96-7efb64d23518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ddd4ebe6-d849-48ee-85f7-2e4e6ca15bbf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a068ca7-725f-474a-8f96-7efb64d23518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5a068ca7-725f-474a-8f96-7efb64d23518" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LaboratoryEquipmentMember_d8e9c080-6cdf-4ade-a2b8-20016ffde2cb" xlink:href="anab-20210630.xsd#anab_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:to="loc_anab_LaboratoryEquipmentMember_d8e9c080-6cdf-4ade-a2b8-20016ffde2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_8a042124-8d4a-4973-9514-45d825921340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:to="loc_us-gaap_OfficeEquipmentMember_8a042124-8d4a-4973-9514-45d825921340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_46c7cf1e-a127-4c54-8da4-a2e0fa992e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a8a862b-630e-4c8c-bc66-ecc03aadb454" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_46c7cf1e-a127-4c54-8da4-a2e0fa992e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ddd4ebe6-d849-48ee-85f7-2e4e6ca15bbf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_735143d7-c8c1-444f-adad-78e9094f2be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_735143d7-c8c1-444f-adad-78e9094f2be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6842345e-8997-497b-ac33-f214c837c089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6842345e-8997-497b-ac33-f214c837c089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c269a07e-657a-434c-97dd-fc7eac800da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d7fa8f0-ec0b-4439-81c3-c05f0a05d081" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c269a07e-657a-434c-97dd-fc7eac800da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0365295d-1929-4b8b-8b43-62acdbda8fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_806f33b7-f040-455b-87e8-e3cbbf9aa3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0365295d-1929-4b8b-8b43-62acdbda8fb3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_806f33b7-f040-455b-87e8-e3cbbf9aa3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_06aa45f0-3685-4e29-a558-015e6583ff9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0365295d-1929-4b8b-8b43-62acdbda8fb3" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_06aa45f0-3685-4e29-a558-015e6583ff9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_0eea2e1b-7245-4364-b7a9-96c8990c1b3a" xlink:href="anab-20210630.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0365295d-1929-4b8b-8b43-62acdbda8fb3" xlink:to="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_0eea2e1b-7245-4364-b7a9-96c8990c1b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9ef06551-ca75-428f-bdd9-55e931a5c35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0365295d-1929-4b8b-8b43-62acdbda8fb3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9ef06551-ca75-428f-bdd9-55e931a5c35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cf3d0813-cab8-45cb-af93-ea5f60cd98e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0365295d-1929-4b8b-8b43-62acdbda8fb3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cf3d0813-cab8-45cb-af93-ea5f60cd98e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements" xlink:type="simple" xlink:href="anab-20210630.xsd#CollaborativeResearchandDevelopmentAgreements"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_8781511d-329f-4683-8466-38d2b922f008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c6bd7590-f3f0-483a-b8fd-65b34f3ddc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_8781511d-329f-4683-8466-38d2b922f008" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c6bd7590-f3f0-483a-b8fd-65b34f3ddc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables" xlink:type="simple" xlink:href="anab-20210630.xsd#CollaborativeResearchandDevelopmentAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_9fee7f24-ead8-48b9-8b33-4d5dba0b137b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ba93f939-0abf-4196-8153-e2fb33e1ab85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_9fee7f24-ead8-48b9-8b33-4d5dba0b137b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ba93f939-0abf-4196-8153-e2fb33e1ab85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#CollaborativeResearchandDevelopmentAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_0553a2e7-ed91-4780-b1d5-cb2de467fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_0553a2e7-ed91-4780-b1d5-cb2de467fa28" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3c11a35-1faa-4215-bb22-a91427ebc184" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:to="loc_srt_CounterpartyNameAxis_d3c11a35-1faa-4215-bb22-a91427ebc184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af16da50-a26f-4d79-9ea6-427567f4fd61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d3c11a35-1faa-4215-bb22-a91427ebc184" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af16da50-a26f-4d79-9ea6-427567f4fd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_GlaxoSmithKlineMember_f1e4299a-38be-4f60-a460-c9a0a642825d" xlink:href="anab-20210630.xsd#anab_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af16da50-a26f-4d79-9ea6-427567f4fd61" xlink:to="loc_anab_GlaxoSmithKlineMember_f1e4299a-38be-4f60-a460-c9a0a642825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_BristolMyersSquibbMember_0c9c22cb-d9fc-4c10-8d0d-8c0a1ead68f1" xlink:href="anab-20210630.xsd#anab_BristolMyersSquibbMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af16da50-a26f-4d79-9ea6-427567f4fd61" xlink:to="loc_anab_BristolMyersSquibbMember_0c9c22cb-d9fc-4c10-8d0d-8c0a1ead68f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e2c80993-a149-4788-ace1-266c8ffa2e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e2c80993-a149-4788-ace1-266c8ffa2e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9f3882f-ef53-495c-9e69-61a8ddae2d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e2c80993-a149-4788-ace1-266c8ffa2e94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9f3882f-ef53-495c-9e69-61a8ddae2d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9f3882f-ef53-495c-9e69-61a8ddae2d1c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_InVivoToxicologyStudiesMember_48420659-20ed-402d-bd3a-614a77402086" xlink:href="anab-20210630.xsd#anab_InVivoToxicologyStudiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_InVivoToxicologyStudiesMember_48420659-20ed-402d-bd3a-614a77402086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_680a348d-ee54-4d4a-9f2d-1266570e06e5" xlink:href="anab-20210630.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_680a348d-ee54-4d4a-9f2d-1266570e06e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember_921775ae-cfd5-4b4f-8427-d0e0a67a296f" xlink:href="anab-20210630.xsd#anab_Phase2ClinicalTrialInitiationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_Phase2ClinicalTrialInitiationMember_921775ae-cfd5-4b4f-8427-d0e0a67a296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationFirstIndicationMember_c08004e8-be1e-46e5-8570-328a3d60baad" xlink:href="anab-20210630.xsd#anab_Phase3ClinicalTrialInitiationFirstIndicationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_Phase3ClinicalTrialInitiationFirstIndicationMember_c08004e8-be1e-46e5-8570-328a3d60baad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase3ClinicalTrialInitiationSecondIndicationMember_177c864a-db8b-4682-8b03-d39af545f590" xlink:href="anab-20210630.xsd#anab_Phase3ClinicalTrialInitiationSecondIndicationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_Phase3ClinicalTrialInitiationSecondIndicationMember_177c864a-db8b-4682-8b03-d39af545f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfBLAFirstIndicationMember_7074ad11-725d-496b-8557-29b6bc058dc0" xlink:href="anab-20210630.xsd#anab_FilingOfBLAFirstIndicationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FilingOfBLAFirstIndicationMember_7074ad11-725d-496b-8557-29b6bc058dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfMMAFirstIndicationMember_9dca1feb-2de4-4b58-9fc3-cb5acf3fe019" xlink:href="anab-20210630.xsd#anab_FilingOfMMAFirstIndicationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FilingOfMMAFirstIndicationMember_9dca1feb-2de4-4b58-9fc3-cb5acf3fe019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FilingOfBLASecondIndicationMember_014ca1b5-8f7f-4a5c-a2c2-812551a3bca4" xlink:href="anab-20210630.xsd#anab_FilingOfBLASecondIndicationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FilingOfBLASecondIndicationMember_014ca1b5-8f7f-4a5c-a2c2-812551a3bca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember_68c7908c-595b-4959-8dc0-fe0e5af1bf69" xlink:href="anab-20210630.xsd#anab_Phase1ClinicalTrialInitiationMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_Phase1ClinicalTrialInitiationMember_68c7908c-595b-4959-8dc0-fe0e5af1bf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FirstBLAApprovalDMMRECMember_117519ee-0842-46ef-8696-ceea1c8e4181" xlink:href="anab-20210630.xsd#anab_FirstBLAApprovalDMMRECMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FirstBLAApprovalDMMRECMember_117519ee-0842-46ef-8696-ceea1c8e4181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_FirstMAAApprovalFirstIndicationMember_a29e051a-cb3c-4467-86d6-13434862c26b" xlink:href="anab-20210630.xsd#anab_FirstMAAApprovalFirstIndicationMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ce19b872-0a29-46a1-98e3-45f68e1cc035" xlink:to="loc_anab_FirstMAAApprovalFirstIndicationMember_a29e051a-cb3c-4467-86d6-13434862c26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CollaborationAndExclusiveLicenseAgreementMember_bcc10e56-b7bc-4a45-a8b7-558980ee11e6" xlink:href="anab-20210630.xsd#anab_CollaborationAndExclusiveLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d9f3882f-ef53-495c-9e69-61a8ddae2d1c" xlink:to="loc_anab_CollaborationAndExclusiveLicenseAgreementMember_bcc10e56-b7bc-4a45-a8b7-558980ee11e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f1167502-58b3-4126-9d59-1f7806b0a9ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:to="loc_srt_ProductOrServiceAxis_f1167502-58b3-4126-9d59-1f7806b0a9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f1167502-58b3-4126-9d59-1f7806b0a9ac" xlink:to="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember_df132be3-498e-4b5c-bd61-8398fd69ea4f" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember_df132be3-498e-4b5c-bd61-8398fd69ea4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember_6b602bad-853e-40b9-888a-931739d23bab" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember_6b602bad-853e-40b9-888a-931739d23bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member_f5e6628f-9e45-447a-a3d2-5fb1f593eedf" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member_f5e6628f-9e45-447a-a3d2-5fb1f593eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_7b798c91-85b5-4ed1-a84f-24a3c261d18d" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_7b798c91-85b5-4ed1-a84f-24a3c261d18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnaptysBioGeneratedZejulaMember_05cebf16-7084-43c8-a563-c6030f8a4da6" xlink:href="anab-20210630.xsd#anab_AnaptysBioGeneratedZejulaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9de4a154-ce1e-448d-9291-6ac270e0a701" xlink:to="loc_anab_AnaptysBioGeneratedZejulaMember_05cebf16-7084-43c8-a563-c6030f8a4da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_4f089d31-f257-4917-94f6-cb4367729772" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_e3a4fa62-c008-454c-b482-0e8a201eff59" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_e3a4fa62-c008-454c-b482-0e8a201eff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_62d4a2d6-af65-46bc-8289-d7e1dd69fb46" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_62d4a2d6-af65-46bc-8289-d7e1dd69fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_2d8a2eb2-cd65-4b9a-b423-c58226147301" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_2d8a2eb2-cd65-4b9a-b423-c58226147301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_49acf7b5-699f-437e-ace7-a46eef719c06" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_49acf7b5-699f-437e-ace7-a46eef719c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_205d275b-e172-4d2c-b6a6-171353e6ac27" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_205d275b-e172-4d2c-b6a6-171353e6ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_7e41d3e3-53df-4bb5-b81c-d7aba68fd27f" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_7e41d3e3-53df-4bb5-b81c-d7aba68fd27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees_4dd81d58-a3c4-49c0-8bcc-9370cb934224" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees_4dd81d58-a3c4-49c0-8bcc-9370cb934224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_NetSalesRoyaltyPercent_a4f7fe31-6379-4e59-8a0e-9c7821a14afd" xlink:href="anab-20210630.xsd#anab_NetSalesRoyaltyPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_NetSalesRoyaltyPercent_a4f7fe31-6379-4e59-8a0e-9c7821a14afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_49769616-29c1-4858-a657-665926f9b487" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_49769616-29c1-4858-a657-665926f9b487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee3755e5-dc51-4fca-8dd5-0ddfe65080e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee3755e5-dc51-4fca-8dd5-0ddfe65080e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5185a841-2cca-446b-9b0d-d0df0e5931fc" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5185a841-2cca-446b-9b0d-d0df0e5931fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_74d27dd6-1544-4788-8ca0-0f5d3d187f82" xlink:href="anab-20210630.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_74d27dd6-1544-4788-8ca0-0f5d3d187f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_d03a8dff-f3c4-4f91-b27c-03f7a9c92dee" xlink:href="anab-20210630.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_8de9ea61-7c93-4fe8-bf35-017b936b2894" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_d03a8dff-f3c4-4f91-b27c-03f7a9c92dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestments"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f837e360-d3b7-4b98-95cc-6893a9e5e1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bd4f579d-a1c1-4010-8512-7e18bead0a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f837e360-d3b7-4b98-95cc-6893a9e5e1c4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bd4f579d-a1c1-4010-8512-7e18bead0a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_31191334-4b49-495f-b208-ae93155388e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_992ccc23-8def-4e94-a548-02411257dcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_31191334-4b49-495f-b208-ae93155388e5" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_992ccc23-8def-4e94-a548-02411257dcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c7dbf569-813c-4f0e-aca3-e3dd2eb09f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_31191334-4b49-495f-b208-ae93155388e5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c7dbf569-813c-4f0e-aca3-e3dd2eb09f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_3268b3e6-8c6a-4c8f-87c8-f6776b1be55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_31191334-4b49-495f-b208-ae93155388e5" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_3268b3e6-8c6a-4c8f-87c8-f6776b1be55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1332b433-b51c-434e-958f-23ce84893697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1332b433-b51c-434e-958f-23ce84893697" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_246c7b5c-8acc-4903-838e-4c9d69e17612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_246c7b5c-8acc-4903-838e-4c9d69e17612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ac5b2f3-22c1-4072-979e-c8b68858d296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_246c7b5c-8acc-4903-838e-4c9d69e17612" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ac5b2f3-22c1-4072-979e-c8b68858d296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_52969d21-088c-48ac-9b79-b0d0707949ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ac5b2f3-22c1-4072-979e-c8b68858d296" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_52969d21-088c-48ac-9b79-b0d0707949ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdd711a5-9f69-492b-8a30-4eeede7815a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdd711a5-9f69-492b-8a30-4eeede7815a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdd711a5-9f69-492b-8a30-4eeede7815a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b52ac12b-eb20-45f2-b89b-833155e792a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b52ac12b-eb20-45f2-b89b-833155e792a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d05459ca-6de6-4420-8001-d07b007b722b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d05459ca-6de6-4420-8001-d07b007b722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_143cddd4-1d16-4642-a448-0ddf057787e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50bdb949-ecd1-4160-bdf5-0d3c092f57e2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_143cddd4-1d16-4642-a448-0ddf057787e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_9d29281e-a119-4b51-b512-45579c32c0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_9d29281e-a119-4b51-b512-45579c32c0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_692fb6a1-316d-4741-9c81-bbe85427ec46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9d29281e-a119-4b51-b512-45579c32c0dc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_692fb6a1-316d-4741-9c81-bbe85427ec46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_64e4f97e-ed57-45db-9b71-3807c0b1356f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_692fb6a1-316d-4741-9c81-bbe85427ec46" xlink:to="loc_us-gaap_MoneyMarketFundsMember_64e4f97e-ed57-45db-9b71-3807c0b1356f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_f5b1c902-ccb9-45ab-b9e2-137ee8345cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_692fb6a1-316d-4741-9c81-bbe85427ec46" xlink:to="loc_us-gaap_MutualFundMember_f5b1c902-ccb9-45ab-b9e2-137ee8345cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_186a726d-d60a-4df4-a8d3-d6f5231eeb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_186a726d-d60a-4df4-a8d3-d6f5231eeb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_186a726d-d60a-4df4-a8d3-d6f5231eeb09" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f4fbdc81-f7b2-40c9-9265-8f054c5c84f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f4fbdc81-f7b2-40c9-9265-8f054c5c84f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6b1fc44f-830f-4b70-8748-b82c60e804ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6b1fc44f-830f-4b70-8748-b82c60e804ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2ef9d4b5-abb0-4e1f-aa21-e5b39c93cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2ef9d4b5-abb0-4e1f-aa21-e5b39c93cb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_672645d5-77f1-4d97-997b-a16924d92426" xlink:href="anab-20210630.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b841dde5-0678-4d45-978e-a2b881e1100c" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_672645d5-77f1-4d97-997b-a16924d92426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037ed61c-68b7-41db-b930-326b27522d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2fb09f2b-e5e5-48f4-956d-6a248ec01fb2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037ed61c-68b7-41db-b930-326b27522d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_29783967-7e64-4ef3-af7d-1ae4bb802e2c" xlink:href="anab-20210630.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037ed61c-68b7-41db-b930-326b27522d26" xlink:to="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_29783967-7e64-4ef3-af7d-1ae4bb802e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a14c5745-3bce-472c-8b2a-9e1767fe21ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_037ed61c-68b7-41db-b930-326b27522d26" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a14c5745-3bce-472c-8b2a-9e1767fe21ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_20ed3536-f36a-44f6-a2ea-30f2c837bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_20ed3536-f36a-44f6-a2ea-30f2c837bf5e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8a135449-dc25-452c-9e9f-9bc2b84ba8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8a135449-dc25-452c-9e9f-9bc2b84ba8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a135449-dc25-452c-9e9f-9bc2b84ba8e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_151384f4-ac49-4347-8bb4-193afab0883a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_151384f4-ac49-4347-8bb4-193afab0883a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2b6aa384-3597-48b6-89a4-4cbc2a24db6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2b6aa384-3597-48b6-89a4-4cbc2a24db6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_acfdfd8c-e9c2-47c7-ba1d-546394f733f2" xlink:href="anab-20210630.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_acfdfd8c-e9c2-47c7-ba1d-546394f733f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7a62b5e5-4639-4e2c-9c1f-253593d5c67b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f683b5c-0b39-4ed0-ad96-98324a6ff4a4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7a62b5e5-4639-4e2c-9c1f-253593d5c67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5512fdd5-0a84-4e63-b8ca-5322fc920e1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:to="loc_srt_RangeAxis_5512fdd5-0a84-4e63-b8ca-5322fc920e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a3253eb-9266-476e-968b-31f6e9b42455" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5512fdd5-0a84-4e63-b8ca-5322fc920e1c" xlink:to="loc_srt_RangeMember_7a3253eb-9266-476e-968b-31f6e9b42455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_54e7f2a8-530f-419e-bd3b-d0fb22181407" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a3253eb-9266-476e-968b-31f6e9b42455" xlink:to="loc_srt_MinimumMember_54e7f2a8-530f-419e-bd3b-d0fb22181407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e4f6b02-7d5f-4697-a9ae-b25955faa8bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a3253eb-9266-476e-968b-31f6e9b42455" xlink:to="loc_srt_MaximumMember_7e4f6b02-7d5f-4697-a9ae-b25955faa8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b19b8149-f057-4e74-8945-d226b1665760" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_856f4a9f-fc07-4320-82ea-70b252db93c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_856f4a9f-fc07-4320-82ea-70b252db93c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d2faf32-4018-4a5b-bf51-700a164885ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d2faf32-4018-4a5b-bf51-700a164885ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a3d998cb-4f16-4f59-9543-b65652081d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a3d998cb-4f16-4f59-9543-b65652081d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ab686b0-0667-47db-8239-e7f48eb0e6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ab686b0-0667-47db-8239-e7f48eb0e6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_adac4926-8ce2-4894-bf99-5795cd9c9886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_adac4926-8ce2-4894-bf99-5795cd9c9886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_70b6c816-1534-4c2c-b5c4-8ee955acc3da" xlink:href="anab-20210630.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_70b6c816-1534-4c2c-b5c4-8ee955acc3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_65466fb4-0704-471c-9544-e9d286e34a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c06628f1-da50-476c-94de-5b198297a717" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_65466fb4-0704-471c-9544-e9d286e34a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ee28d317-273d-44cd-b3ff-41500883845d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66cc0807-1f54-420a-b9bf-f36e7d5e9c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ee28d317-273d-44cd-b3ff-41500883845d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66cc0807-1f54-420a-b9bf-f36e7d5e9c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0fce348b-5242-465f-9d4a-e66e95c39e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66cc0807-1f54-420a-b9bf-f36e7d5e9c69" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0fce348b-5242-465f-9d4a-e66e95c39e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0fce348b-5242-465f-9d4a-e66e95c39e2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_33d741d8-3da3-4645-97b3-f6668acf2129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_33d741d8-3da3-4645-97b3-f6668acf2129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_cbe524d8-0a33-4573-aa39-866c52f80f61" xlink:href="anab-20210630.xsd#anab_CommercialAndCorporateObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_cbe524d8-0a33-4573-aa39-866c52f80f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_46ad75fd-128f-468e-9c0a-ade74abb0ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c26ca4d-1207-4f48-9e4d-5f00f8944bb4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_46ad75fd-128f-468e-9c0a-ade74abb0ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_66cc0807-1f54-420a-b9bf-f36e7d5e9c69" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b730a75f-2b2b-4c3c-b5d2-f5c516baca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b730a75f-2b2b-4c3c-b5d2-f5c516baca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_beb12d23-260e-49bc-bbb2-275416e27c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_beb12d23-260e-49bc-bbb2-275416e27c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_12a4e7f4-0883-4d31-a79b-94601a4ff2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_12a4e7f4-0883-4d31-a79b-94601a4ff2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_735bc676-c378-424d-9fc4-f46e0e5ca1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_735bc676-c378-424d-9fc4-f46e0e5ca1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_51ce7d74-92ca-41f0-acd4-104ef1df0abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_51ce7d74-92ca-41f0-acd4-104ef1df0abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5e276bb8-e734-4d7a-aaa3-4363a4776d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5e276bb8-e734-4d7a-aaa3-4363a4776d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_5d08dff0-40e5-4eaf-a206-2a804b95c775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_5d08dff0-40e5-4eaf-a206-2a804b95c775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6850f58a-badc-4a39-ac60-0e3751077509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0de42a3f-4843-4193-9823-1087f6241902" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6850f58a-badc-4a39-ac60-0e3751077509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="anab-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d9a8996e-9267-4aef-9400-91f0492d9052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0dd59df4-5853-4002-a853-69f1d60d6973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d9a8996e-9267-4aef-9400-91f0492d9052" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0dd59df4-5853-4002-a853-69f1d60d6973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="anab-20210630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_88de6bdb-7f23-411b-a226-6181429933ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_8dfe4588-f753-43a3-b848-f8cc1b3503cd" xlink:href="anab-20210630.xsd#anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_88de6bdb-7f23-411b-a226-6181429933ec" xlink:to="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_8dfe4588-f753-43a3-b848-f8cc1b3503cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d19441a9-da07-4b6a-a689-38f79332adfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_029895a7-1f0f-4ab6-af18-41688daf1411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d19441a9-da07-4b6a-a689-38f79332adfe" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_029895a7-1f0f-4ab6-af18-41688daf1411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eb9d41c4-34f4-4db5-b939-a1ac50459dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d19441a9-da07-4b6a-a689-38f79332adfe" xlink:to="loc_us-gaap_CommonStockSharesIssued_eb9d41c4-34f4-4db5-b939-a1ac50459dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_242d7eb6-0863-4af2-989b-4d7f985586d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d19441a9-da07-4b6a-a689-38f79332adfe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_242d7eb6-0863-4af2-989b-4d7f985586d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_882ee9a5-6932-4c84-9dce-e7c8fdd80ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a949e09b-ecc7-461b-a58c-b93137426f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_882ee9a5-6932-4c84-9dce-e7c8fdd80ff3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a949e09b-ecc7-461b-a58c-b93137426f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3b8db3a3-94a7-45d6-b425-d293aea1757b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a949e09b-ecc7-461b-a58c-b93137426f82" xlink:to="loc_us-gaap_PlanNameAxis_3b8db3a3-94a7-45d6-b425-d293aea1757b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc497386-f340-470b-9292-95a38aee48f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3b8db3a3-94a7-45d6-b425-d293aea1757b" xlink:to="loc_us-gaap_PlanNameDomain_cc497386-f340-470b-9292-95a38aee48f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member_9af4efb1-fa3e-4db1-b939-a80c336df30f" xlink:href="anab-20210630.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cc497386-f340-470b-9292-95a38aee48f6" xlink:to="loc_anab_EquityIncentivePlan2017Member_9af4efb1-fa3e-4db1-b939-a80c336df30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_680dddd2-4010-47ff-b16a-82873999c60e" xlink:href="anab-20210630.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cc497386-f340-470b-9292-95a38aee48f6" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_680dddd2-4010-47ff-b16a-82873999c60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a949e09b-ecc7-461b-a58c-b93137426f82" xlink:to="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3accb53a-2f34-481b-83d0-c0f0e34980c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3accb53a-2f34-481b-83d0-c0f0e34980c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef5323dd-e9ab-407e-9685-a80f01bbb272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3accb53a-2f34-481b-83d0-c0f0e34980c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef5323dd-e9ab-407e-9685-a80f01bbb272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb38c514-a0ba-4af9-bfea-77225ce0c992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb38c514-a0ba-4af9-bfea-77225ce0c992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a04e0f4b-d040-4da1-845e-10f06eec01fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c3041dff-9eea-482c-a4cc-6425964cd724" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a04e0f4b-d040-4da1-845e-10f06eec01fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27510f85-457c-4123-bb50-a8c05e8c07eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a7e6377d-9ef1-40b7-8c70-c24148c5d449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27510f85-457c-4123-bb50-a8c05e8c07eb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a7e6377d-9ef1-40b7-8c70-c24148c5d449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd343dd4-c19d-4411-872a-c079996f2034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2be62899-36a5-4872-9a17-52f15e01751c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd343dd4-c19d-4411-872a-c079996f2034" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2be62899-36a5-4872-9a17-52f15e01751c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_88a93b19-f08f-4014-b4dd-c137b3ed76e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd343dd4-c19d-4411-872a-c079996f2034" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_88a93b19-f08f-4014-b4dd-c137b3ed76e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3be5f67d-b534-45df-bc08-0e771ffb605e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd343dd4-c19d-4411-872a-c079996f2034" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3be5f67d-b534-45df-bc08-0e771ffb605e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4eacd824-5533-4a12-9733-f63932ec30f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4eacd824-5533-4a12-9733-f63932ec30f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fada1b22-5386-4d2b-bfaf-91ee531c1a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:to="loc_us-gaap_PlanNameAxis_fada1b22-5386-4d2b-bfaf-91ee531c1a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c0f28515-4af2-4381-8584-f4087ec094c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fada1b22-5386-4d2b-bfaf-91ee531c1a27" xlink:to="loc_us-gaap_PlanNameDomain_c0f28515-4af2-4381-8584-f4087ec094c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EquityIncentivePlan2017Member_f6987c8b-16f6-41c1-b579-9aa4518f12cd" xlink:href="anab-20210630.xsd#anab_EquityIncentivePlan2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c0f28515-4af2-4381-8584-f4087ec094c5" xlink:to="loc_anab_EquityIncentivePlan2017Member_f6987c8b-16f6-41c1-b579-9aa4518f12cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_c971067b-ee7f-4245-a429-70cb04d2e296" xlink:href="anab-20210630.xsd#anab_EmployeeStockPurchasePlan2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c0f28515-4af2-4381-8584-f4087ec094c5" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_c971067b-ee7f-4245-a429-70cb04d2e296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42841bf4-39bf-4795-94ae-1e78c55c4496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:to="loc_us-gaap_AwardTypeAxis_42841bf4-39bf-4795-94ae-1e78c55c4496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90142eeb-f617-4dd0-9bd4-98cb9f74a7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_42841bf4-39bf-4795-94ae-1e78c55c4496" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90142eeb-f617-4dd0-9bd4-98cb9f74a7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e1d66722-e5f7-47e3-95d0-bccda7a85935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90142eeb-f617-4dd0-9bd4-98cb9f74a7c0" xlink:to="loc_us-gaap_EmployeeStockMember_e1d66722-e5f7-47e3-95d0-bccda7a85935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1bf6b534-1dcb-43cb-9fa5-35048b011b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90142eeb-f617-4dd0-9bd4-98cb9f74a7c0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1bf6b534-1dcb-43cb-9fa5-35048b011b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:to="loc_srt_TitleOfIndividualAxis_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bc63cb1-bb3d-4d8b-8f1b-05369e2b096e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_13a9094f-8f3f-4bee-a6a5-6d0ce32ee0c2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bc63cb1-bb3d-4d8b-8f1b-05369e2b096e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_d550edaa-67a6-4a6a-ae04-cfdb91758a1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0bc63cb1-bb3d-4d8b-8f1b-05369e2b096e" xlink:to="loc_srt_DirectorMember_d550edaa-67a6-4a6a-ae04-cfdb91758a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81b4007f-4ed2-473d-bf0d-d27a35adc8b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_7ab27c61-1586-4f69-917a-edf31b1b0d4d" xlink:href="anab-20210630.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_7ab27c61-1586-4f69-917a-edf31b1b0d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_4ece2065-af1a-4fcd-8a5b-e0e7573164c9" xlink:href="anab-20210630.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_4ece2065-af1a-4fcd-8a5b-e0e7573164c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e72be019-6bb6-4071-b49f-b3a38f4d5cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e72be019-6bb6-4071-b49f-b3a38f4d5cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ef7b5168-ab34-4e16-97c1-c0759d1b309a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ef7b5168-ab34-4e16-97c1-c0759d1b309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c8e26d18-a8ed-4bdb-9354-81e2a9bfe374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c8e26d18-a8ed-4bdb-9354-81e2a9bfe374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cb89118b-5561-42bf-b9d9-3cc52d745307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cb89118b-5561-42bf-b9d9-3cc52d745307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9c7b6cd-9b02-451f-91b7-a346ecc9c805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0c88c23-117a-4f77-8c67-ab1113f88844" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9c7b6cd-9b02-451f-91b7-a346ecc9c805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlansOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a788f99f-aa59-4b61-a5b4-54950d6bfe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56003fa1-b897-43e4-a746-45446e7119c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a788f99f-aa59-4b61-a5b4-54950d6bfe8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56003fa1-b897-43e4-a746-45446e7119c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6f1383e3-585e-40c1-8881-f8266067528b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56003fa1-b897-43e4-a746-45446e7119c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6f1383e3-585e-40c1-8881-f8266067528b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b23ad4ad-c7d8-4d49-b1b5-4e0d4e37972c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56003fa1-b897-43e4-a746-45446e7119c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b23ad4ad-c7d8-4d49-b1b5-4e0d4e37972c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_42077da5-d305-4c5f-9d0b-8be1e38c4015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56003fa1-b897-43e4-a746-45446e7119c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_42077da5-d305-4c5f-9d0b-8be1e38c4015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_524383a8-fb1d-468c-8ad3-0aedfc042f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56003fa1-b897-43e4-a746-45446e7119c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_524383a8-fb1d-468c-8ad3-0aedfc042f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_544c2e44-b1f9-4340-9749-0097852014c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_56003fa1-b897-43e4-a746-45446e7119c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_544c2e44-b1f9-4340-9749-0097852014c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5ef005d8-b960-4ad6-99ae-fe6a5692eb93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a788f99f-aa59-4b61-a5b4-54950d6bfe8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5ef005d8-b960-4ad6-99ae-fe6a5692eb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a67a8246-525b-4813-ae32-eeb03ea6a89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a788f99f-aa59-4b61-a5b4-54950d6bfe8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a67a8246-525b-4813-ae32-eeb03ea6a89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7293910e-0f79-46fe-9436-ca9f05a2f737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a67a8246-525b-4813-ae32-eeb03ea6a89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7293910e-0f79-46fe-9436-ca9f05a2f737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_305edf56-e124-4794-865b-547e80f19740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a67a8246-525b-4813-ae32-eeb03ea6a89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_305edf56-e124-4794-865b-547e80f19740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dcebe47f-2bf5-4bb5-994d-965f03f43057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a67a8246-525b-4813-ae32-eeb03ea6a89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dcebe47f-2bf5-4bb5-994d-965f03f43057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c29b0c98-06ba-43f6-8219-ddf437aab557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a67a8246-525b-4813-ae32-eeb03ea6a89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c29b0c98-06ba-43f6-8219-ddf437aab557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_809e333a-a937-47eb-a48e-c6b50a151b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a67a8246-525b-4813-ae32-eeb03ea6a89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_809e333a-a937-47eb-a48e-c6b50a151b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_56b99fa0-6968-4ffd-ac63-c08b8e3d2acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a788f99f-aa59-4b61-a5b4-54950d6bfe8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_56b99fa0-6968-4ffd-ac63-c08b8e3d2acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cb3fde65-07b9-4c24-9b3b-0dd3dc9da015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a788f99f-aa59-4b61-a5b4-54950d6bfe8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cb3fde65-07b9-4c24-9b3b-0dd3dc9da015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8d6a212c-a0ab-4aba-aab3-11e54ab4a0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cb3fde65-07b9-4c24-9b3b-0dd3dc9da015" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8d6a212c-a0ab-4aba-aab3-11e54ab4a0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d50dced7-e7f2-49b7-b4a9-f92ffc2ab800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cb3fde65-07b9-4c24-9b3b-0dd3dc9da015" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d50dced7-e7f2-49b7-b4a9-f92ffc2ab800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ad7316fe-fdbd-4d21-81e1-50d655b95c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cb3fde65-07b9-4c24-9b3b-0dd3dc9da015" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ad7316fe-fdbd-4d21-81e1-50d655b95c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_eb8ed048-a771-417e-9e20-525729ce4b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cb3fde65-07b9-4c24-9b3b-0dd3dc9da015" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_eb8ed048-a771-417e-9e20-525729ce4b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7b1f30f-dd95-4d5e-9e92-cc0783040bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e692918-516f-4753-99c1-be32467448d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7b1f30f-dd95-4d5e-9e92-cc0783040bce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e692918-516f-4753-99c1-be32467448d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_21ed6578-d79a-48a6-992b-1bee78a4d339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e692918-516f-4753-99c1-be32467448d5" xlink:to="loc_us-gaap_AwardTypeAxis_21ed6578-d79a-48a6-992b-1bee78a4d339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1affdf7c-5ec4-4ec9-a9ad-4ebeae1ef9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_21ed6578-d79a-48a6-992b-1bee78a4d339" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1affdf7c-5ec4-4ec9-a9ad-4ebeae1ef9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7b171d22-4a16-431a-82d7-92baae015e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1affdf7c-5ec4-4ec9-a9ad-4ebeae1ef9ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7b171d22-4a16-431a-82d7-92baae015e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e692918-516f-4753-99c1-be32467448d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a24cf705-5656-401b-8d07-9ea1f1488ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a24cf705-5656-401b-8d07-9ea1f1488ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7ad533c9-e538-4f54-ba3f-8e8dd8399341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7ad533c9-e538-4f54-ba3f-8e8dd8399341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e56d2e68-2443-4341-af78-f0d44a392101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e56d2e68-2443-4341-af78-f0d44a392101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b2c177e-24e8-4fdf-ab92-e2fc2aa8103f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b2c177e-24e8-4fdf-ab92-e2fc2aa8103f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_738c6be7-5305-489a-b2a3-89dcb489d024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90f223be-bd76-4238-98e4-12339dba4e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_738c6be7-5305-489a-b2a3-89dcb489d024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4b7a5d1-37a3-4fc8-a57e-90889a2151e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df08195e-88ff-4860-81a9-f7fa75f5167b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4b7a5d1-37a3-4fc8-a57e-90889a2151e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df08195e-88ff-4860-81a9-f7fa75f5167b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f472b95b-d20d-4a13-9975-9c4dc417f240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df08195e-88ff-4860-81a9-f7fa75f5167b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f472b95b-d20d-4a13-9975-9c4dc417f240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8fa51fec-625e-42f0-8359-97c6db53a8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f472b95b-d20d-4a13-9975-9c4dc417f240" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8fa51fec-625e-42f0-8359-97c6db53a8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83b7c3af-689d-41c4-88b6-8fc2e00ddcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8fa51fec-625e-42f0-8359-97c6db53a8a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83b7c3af-689d-41c4-88b6-8fc2e00ddcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db02ddca-371f-44ae-abf9-2560cb02b13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8fa51fec-625e-42f0-8359-97c6db53a8a4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db02ddca-371f-44ae-abf9-2560cb02b13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_74a7ea9b-955c-4bd1-97ac-92b1bc6e5b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df08195e-88ff-4860-81a9-f7fa75f5167b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_74a7ea9b-955c-4bd1-97ac-92b1bc6e5b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_a47901f6-e971-4b1f-ad5b-5d0abab8005f" xlink:href="anab-20210630.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_74a7ea9b-955c-4bd1-97ac-92b1bc6e5b41" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_a47901f6-e971-4b1f-ad5b-5d0abab8005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="anab-20210630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e0faf9b-2ef4-4f4f-b63f-fd1717cd333d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_92088d6c-a904-466f-8bb2-465e0cf7e960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e0faf9b-2ef4-4f4f-b63f-fd1717cd333d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_92088d6c-a904-466f-8bb2-465e0cf7e960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="anab-20210630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00bee5b8-c210-423c-b095-307136d6ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_83d8007d-3675-4670-8610-a47b434dae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00bee5b8-c210-423c-b095-307136d6ff0c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_83d8007d-3675-4670-8610-a47b434dae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_62ba4a3d-fffb-48d7-bf98-4c68ee23ab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00bee5b8-c210-423c-b095-307136d6ff0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_62ba4a3d-fffb-48d7-bf98-4c68ee23ab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b9d5022-8b72-444c-b181-0451695b2864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7ace680d-051a-4c33-ab6c-2e6bbcd61292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1b9d5022-8b72-444c-b181-0451695b2864" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7ace680d-051a-4c33-ab6c-2e6bbcd61292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_dc12a6ff-8a7b-47e2-868b-983c5e0038f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7ace680d-051a-4c33-ab6c-2e6bbcd61292" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_dc12a6ff-8a7b-47e2-868b-983c5e0038f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_454f2696-af1d-43f0-b166-a66c332caae5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_dc12a6ff-8a7b-47e2-868b-983c5e0038f2" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_454f2696-af1d-43f0-b166-a66c332caae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember_1146b94a-a606-48e5-92a3-896fafe82121" xlink:href="anab-20210630.xsd#anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_454f2696-af1d-43f0-b166-a66c332caae5" xlink:to="loc_anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember_1146b94a-a606-48e5-92a3-896fafe82121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_38244c65-097b-4a3f-989d-5ef44c870c95" xlink:href="anab-20210630.xsd#anab_A10770WateridgeCircleSanDiegoCalifornia92121Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_454f2696-af1d-43f0-b166-a66c332caae5" xlink:to="loc_anab_A10770WateridgeCircleSanDiegoCalifornia92121Member_38244c65-097b-4a3f-989d-5ef44c870c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7ace680d-051a-4c33-ab6c-2e6bbcd61292" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5f9c45ed-dfd1-4673-a116-80e3b23d5741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5f9c45ed-dfd1-4673-a116-80e3b23d5741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_49e76f70-94ff-4fa3-b3fd-e8683f928f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_OperatingLeaseLiability_49e76f70-94ff-4fa3-b3fd-e8683f928f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_b70cc561-b6ed-4ee4-bb58-a20fab41fa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_b70cc561-b6ed-4ee4-bb58-a20fab41fa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_c1dd84a6-6dca-40e2-b758-72431415bcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_c1dd84a6-6dca-40e2-b758-72431415bcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_7c16394a-b69e-4708-8111-246c9d518c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_7c16394a-b69e-4708-8111-246c9d518c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_44ab747a-bc6d-4bcf-86db-1a62aa64f7e3" xlink:href="anab-20210630.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_44ab747a-bc6d-4bcf-86db-1a62aa64f7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_RentPerSquareFoot_9eb1e810-31d0-4ceb-b59a-7d551a631680" xlink:href="anab-20210630.xsd#anab_RentPerSquareFoot"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_anab_RentPerSquareFoot_9eb1e810-31d0-4ceb-b59a-7d551a631680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_AnnualRentIncreasePercent_da87f6ef-c181-4c6b-949a-ece21e723dc4" xlink:href="anab-20210630.xsd#anab_AnnualRentIncreasePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_anab_AnnualRentIncreasePercent_da87f6ef-c181-4c6b-949a-ece21e723dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_673c4f0a-0947-4e02-af09-36405c5e01ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_673c4f0a-0947-4e02-af09-36405c5e01ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_f089ba3a-b1e8-4c84-ac13-2a6b21e21227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_SecurityDeposit_f089ba3a-b1e8-4c84-ac13-2a6b21e21227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5889cb9b-2a51-4ef7-b5c2-1d92dee46548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4570078-ccd6-485b-b08f-4499da10bd6f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5889cb9b-2a51-4ef7-b5c2-1d92dee46548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28b02ea0-0914-4eea-87a4-d78fffbb9807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f2455841-2e5a-48fc-acd3-74f9e5e1ab9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28b02ea0-0914-4eea-87a4-d78fffbb9807" xlink:to="loc_us-gaap_OperatingLeaseCost_f2455841-2e5a-48fc-acd3-74f9e5e1ab9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bd2cd85a-af0d-465a-b1eb-58654b7362b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28b02ea0-0914-4eea-87a4-d78fffbb9807" xlink:to="loc_us-gaap_OperatingLeasePayments_bd2cd85a-af0d-465a-b1eb-58654b7362b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c5da9592-ad87-42fe-8d86-bb989ee7ee7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28b02ea0-0914-4eea-87a4-d78fffbb9807" xlink:to="loc_us-gaap_OperatingLeaseLiability_c5da9592-ad87-42fe-8d86-bb989ee7ee7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="simple" xlink:href="anab-20210630.xsd#CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a3493967-a37a-43aa-a85b-cdad1f47b3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a3493967-a37a-43aa-a85b-cdad1f47b3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dd7630b0-8f36-4dc7-8d55-e4277b5f03d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dd7630b0-8f36-4dc7-8d55-e4277b5f03d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_044c8969-5e66-4b56-9e4e-07ff10e78764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_044c8969-5e66-4b56-9e4e-07ff10e78764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e142b271-7adf-4577-ab1a-2231ed63b8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e142b271-7adf-4577-ab1a-2231ed63b8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_17e7a26e-2388-4706-a45c-32e19389c96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_17e7a26e-2388-4706-a45c-32e19389c96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_89815021-ee36-4745-aabd-8ed58880128a" xlink:href="anab-20210630.xsd#anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_89815021-ee36-4745-aabd-8ed58880128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d823d91c-9505-4c67-9cc5-82517361e196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d823d91c-9505-4c67-9cc5-82517361e196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3a6ab3d0-9f1b-4644-ae40-32b097827fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3a6ab3d0-9f1b-4644-ae40-32b097827fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_531a1a7e-52c2-4685-bfaf-65a10361fcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_139eac6c-862b-4c8a-8f40-8d8577011896" xlink:to="loc_us-gaap_OperatingLeaseLiability_531a1a7e-52c2-4685-bfaf-65a10361fcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>anab-20210630_g1.jpg
<DESCRIPTION>PIPELINE CHART
<TEXT>
begin 644 anab-20210630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 8^!\H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#Y-M_@[X!^(7QJ^-NH^*O _AOQ+J$7BBTMX[O6-)M[N5(
MAH.DL$#R(2%!9CC.,L3WK>_X9A^#G_1)O W_ (3=G_\ &JTO!'_)5OCE_P!C
M=:_^H_H]=U7=!+E1QS;YF>9_\,P_!S_HDW@;_P )NS_^-4?\,P_!S_HDW@;_
M ,)NS_\ C5>F45I9$79YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_
M\)NS_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\
M";L__C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS
M_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L_
M_C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C
M5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>
MF446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F4
M46079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446
M079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F44607
M9YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079Y
MG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_
M ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS
M#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P
M_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS#\'/
M^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P_!S_
M *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS#\'/^B3>
M!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P_!S_ *)-
MX&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS#\'/^B3>!O\
MPF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P_!S_ *)-X&_\
M)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS#\'/^B3>!O\ PF[/
M_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_
M /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-
M4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5
M'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\
M#,/P<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,
M/P<_Z)-X&_\ ";L__C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P
M<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_
MZ)-X&_\ ";L__C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)
M-X&_\)NS_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X
M&_\ ";L__C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_
M\)NS_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\
M";L__C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS
M_P#C5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L_
M_C5>F446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C
M5>F446079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>
MF446079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F4
M46079YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446
M079YG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F44607
M9YG_ ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079Y
MG_PS#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_
M ,,P_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS
M#\'/^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>F446079YG_ ,,P
M_!S_ *)-X&_\)NS_ /C5'_#,/P<_Z)-X&_\ ";L__C5>F446079YG_PS#\'/
M^B3>!O\ PF[/_P"-4?\ #,/P<_Z)-X&_\)NS_P#C5>"^/_\ @J5\*?ASXXU_
MPKJ7A_QC/J&BW\VGW$EK96C1-)$Y1BA:Y4E<J<9 ..PKOOV?_P!N_P"%?[1F
MO#0= O-0TCQ"X9H-)URW6":X5068QE'=&( )VAMV 3C -1!QJ?!J544J=^?0
M[S_AF'X.?]$F\#?^$W9__&J/^&8?@Y_T2;P-_P"$W9__ !JO3**NR)NSS/\
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M3=G_ /&J/^&8?@Y_T2;P-_X3=G_\:KTRBE9#NSS/_AF'X.?]$F\#?^$W9_\
MQJC_ (9A^#G_ $2;P-_X3=G_ /&J],HHL@NSS/\ X9A^#G_1)O W_A-V?_QJ
MC_AF'X.?]$F\#?\ A-V?_P :KTRBBR"[/,_^&8?@Y_T2;P-_X3=G_P#&J/\
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M_&J/^&8?@Y_T2;P-_P"$W9__ !JI_'7[0GP^^'/PUMO'VM>);./PM>(KV5[
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M_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=GF?\
MPS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^-5Z9119!=GF?_#,/
MP<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=GF?\ PS#\
M'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^-5Z9119!=GF?_#,/P<_Z
M)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=GF?\ PS#\'/\
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M (U1_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=GF?\ PS#\'/\ HDW@;_PF[/\
M^-4?\,P_!S_HDW@;_P )NS_^-5Z9119!=GF?_#,/P<_Z)-X&_P#";L__ (U1
M_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=GF?\ PS#\'/\ HDW@;_PF[/\ ^-4?
M\,P_!S_HDW@;_P )NS_^-5Z9119!=GF?_#,/P<_Z)-X&_P#";L__ (U1_P ,
MP_!S_HDW@;_PF[/_ .-5Z9119!=GF?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_
M!S_HDW@;_P )NS_^-5Z9119!=GF?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S
M_HDW@;_PF[/_ .-5Z9119!=GF?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_H
MDW@;_P )NS_^-5Z9119!=GF?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW
M@;_PF[/_ .-5Z9119!=GF?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;
M_P )NS_^-5Z9119!=GF?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_P
MF[/_ .-5Z9119!=GF?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )
MNS_^-5Z9119!=GF?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_
M .-5Z9119!=GF?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^
M-5Z9119!=GF?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5
MZ9119!=GF?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^-5Z9
M119!=GF?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z911
M9!=GF?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^-5Z9119!
M=GF?_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=G
MF?\ PS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^-5Z9119!=GF?
M_#,/P<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=GF?\
MPS#\'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^-5Z9119!=GF?_#,/
MP<_Z)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=GF?\ PS#\
M'/\ HDW@;_PF[/\ ^-4?\,P_!S_HDW@;_P )NS_^-5Z9119!=GF?_#,/P<_Z
M)-X&_P#";L__ (U1_P ,P_!S_HDW@;_PF[/_ .-5Z9119!=GF?\ PS#\'/\
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ME9//H_BFUOEN91(L1D*^<LCL"560%&=BI52" 3EO[6WP%\6>"/VHH/C/X?\
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MP< D[UN=UJG)\?/IVY=.^EM[WZ^1A0Y?8TU/X>37OS:]M>UK>8OQR^+7Q/\
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MZ3/#IEUJ>CS-:2F5;JV_>H8R"A>*5=P7 R6P #BO'?%%K^T/9?LH^'_CW/\
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M2^&O'6N*%UZU27[)96TMT\@N6F2)T.U)&+1L4(*]1WC#W]IAYRW<7]]_=O\
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MV!9%C^^1B,?+C '>?"G]G&?Q-^UMX,\:?"OX6^,?@UX&T-EN-7D\6"2TEN9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&?\ !3SQ9X(\'K-IGA<Z.V+ SO*NUK:"?:6<LS .<@DD^]8'@'X#^$OV@/\
M@HE\:=%\;6L^IZ%8M<7W]GQ7,ENDTHDBC0NT;*V%$C$ $<X[9!49NI*FH+XH
MREKTY?Z_K<J4534W/[+BM/[RNOS_ *V/T=;XJ>"H_" \5MXOT%?"Q.T:X=3@
M%D3NVX\_=LSNXZ]>*VM#U[3/%&DVVJ:-J-IJVF7*[X+VQG6:&5?574E6'N#7
MY2?L9?LN^$?B]\4_C)X-\5MJ.I^$O"-[/%INE#4)H84N'FEA6Y*HPS(L< &<
M\YY!P,=__P $Y_'FK>!?V4?CGJ%I-)<GPV]S?V$#C<J2K:,V0/0F-21TX-)5
ME[-U&M.3G7I>UO7]+?)^QESJFGKS<K]6FU_7]/[]USXO>!/"_B"/0=9\:^'=
M)UR3;LTR^U6"&Y;=]W$3.&.>W'-;'B;Q;H?@G1I=7\0ZSI^@Z3$562_U.ZCM
MH$+$!09'(49) '/)-?C?\%O ?@?XA_!GQ#JWBSX3_%_X@^/]<GNI+?Q=X?TF
M:[L[>;D*P=9E65M^6D\Q6.20.F3Z[XFNO'B_\$K_ !#H_P 0='UO1]5T76K6
MPM(]?M);>X>T%Q;O$0)0&9%WL@/3"8[4I5)1@VUJN5^6K2MZJX*"E-*.SNO/
M1-W]'8_1VQ^+?@;4O$%KH-GXS\/7>N74*7%OID&JP/<S1,@D5TB#[F4H0P(&
M"#GI3?%'Q@\!^!]6BTOQ'XV\.^']3E :.RU35K>VF<$X!".X)!/M7R'^RY^S
MWX*^$G[,NF_&^/0Y=5^)L/A>[UI-6N[F:5PS6\C(B1%O+&(]J [=V">>:\O_
M &+_ -CGP+^U'\#?$GCKX@R:AK?C37-3NX5UAK^426;J!^]V*P5W+,6/F!@1
MMP!S6DN=5)4XK6*N_OLDOU;L9QY7",Y/23LONNV_+[S] /C'XLU3PO\ "W5M
M=\-ZSX4TC48DA>VU+QE=/#I"!I$!,TB$$ JQ"D'EBOK5SX8>([_Q!\-]$UG7
M=4\.ZE?SVOG76H>%[AI=*D.3EX)'))CP.I/8U\D_M#? Q?V=?^"<OC;P7'XF
MU+Q1!:FUECN-15%\D->V^8XE7[L>X%@I9B"QYQ@!^D3^!X_^"9_@V#XB^)]8
M\+>%;K2X(;F?0607=T3(Q6W3=&^0Y'(P. <D+FIE-155IWLX_BG_ %YEQ@Y*
MG?KS?AR_Y_(^J] ^-_PY\5ZXNBZ)X_\ "^L:PQ95T_3]9MI[@E<[@(T<MQ@Y
MXXQ7B7[9W[4GBO\ 9U\3_"S3O#>GZ/>P>*M1EM+UM4AED:-%>W4&+9*F#B9O
MO!N@_'X-_:RNO#*_"?X<ZW\._@IK7PQTBQO(HK+QAJUO!87VHD0EXR5C)DE)
M""03EB,CC[U?0G_!2^9[CQ-^S7+*V^234Y'9CW)>R)-6GS3A_C47YK?^O^"%
MDK^<)/T:3/T1KXQ_:V_:T^*_PG_:!\)?#/X9^&_#GB"]\0:9'<P0ZQ')YKSM
M-,FP.+B)%7;$#\W?/-?9U?FA^WEI_BW5OV]OA-9^!-4M-%\7S:- NF:A?*&A
M@F^T76&<&.0$8S_ WTK.HW[2E'6SE9VWV95-+V=63MI&ZOZHZGQS^U]^UA\"
M=)C\4?$WX-^%X/":3I!/+IMU\ZLQPN7CNY_+!/&YDQD@9R0#]!>-OCYK>I^&
M_A=XE\#>)?ASX=T?Q7&MS-!\0K^6UNIXG\DB.S$; /*N]U8'(W%/6O@KXL:I
M\9?%WQDT_P"!7[1OQ8_X1[P]?2PW,>I6.E6QLKPEOW)WQI ?++!EW29".H++
MQD>K?\%"_!.F?#:X_9>\*Z,DB:7H]\]E;"5MSE$>R4%CW8XR3ZDU5*7,H-[2
MFDO3K?Y]"9)<SBMU"3?W-JWRZGZ)Z]XBTKPKI-QJFMZG9Z/IENNZ:]O[A((8
MAZL[D*!]37-M\:_AY'INEZBWCSPRNGZI,;>PNSK%N(KN0$ I$^_$C LO"DGD
M>M?$G[?4,OQ<_:X^"WP>UC4;BS\'7ZQWEU#;2;#+)+-+&3SQN"0[5)SM\QL=
M3GS#]MS]FWP=^SO\5O@VO@2.ZTC1=9U4-/HKWTUQ"D\4UN//7S79@S+(%//\
M QBE3FYN+MI*7+]V[_R"I#DO%;J/,_N;5OU/K6T_:Q\1+^W%X@^#^H6^A6?@
MO3-,^WG4I$D2Z4BUBF)>1I?+"@NW\ X Y[U]#^%_B/X2\;Z7=:GX=\4:+K^F
MVN1<7FEZA#<PPX&3O=&(7 YY-?G)X[^#^A?'+_@J?XG\+>)_M$N@2:?!<WEG
M;S/#]J6.P@98F="&"EMI.#GY>W6M/]FOX=Z-\)?^"CGQ+^''AV*:V\'7&A2Q
M-IK7$CCRWCMI=FXL6.TR, Q)8 GGG-11E*<(1>\HR:?FK[^NWRN76C&,I-;+
MDO\ -1V^;O\ /[OHOX,_MV^$/C%\;/%G@R*ZTG1=+TN1+/2KZ]U2'S-;N#*Z
M'[, VUU(52H0L2&!XSBO=O&/Q4\%_#N2"/Q7XOT'PS)<#="NL:G!:&0>JB1A
MG\*_./\ 81^ 7@/6?VL/B]#>:%YT?@?6/,\/K]LN%^Q-'=S*AXD'F8$:?ZS=
MG'/>H/BT-;_9W_:<^)?C3XL_!<?%WP7X@N UAK5];K<P:?:[B8U1GCDC1E3"
M;&V-^[!!QR2%1NE1?\R;N_73YO7R20IT_P!Y52^RTK?G;NE]]V?IWX?\2:3X
MLTF#5-#U2RUG3)QF*]T^X2>&0>JNA(/X&M&OC_\ X)]^(O@1JVG^+!\(/[9T
MK4+N<7FIZ%KL[>; NY@C1QJ[1>6-VT,A+8VASG%?8%=36B??^OF<]]6NQYY\
M=/\ D4_#_P#V.?A7_P!/^GU]%U\Z?'3_ )%/P_\ ]CGX5_\ 3_I]?1=<5;XC
MKI?"%%%%8&P4444 %%%% !1110 4444 %%%% 'S[X(_Y*M\<O^QNM?\ U']'
MKNJX7P1_R5;XY?\ 8W6O_J/Z/7=5WP^%'%/XF%%%%:$'RQ_P48^-7C/X#_ [
M2_$'@;6?[#U>;78+.2X^RPW&86AG9EVRHZ]44YQGCKUKQ/Q$O[<'@SX8S_$.
M;XG>%=;T>STX:O+IUO8V_GM;^7YC9!L8QE4R2 X/!QFNU_X*Z?\ )M&B?]C/
M;?\ I-<UQEM^SG^V!\4/AGI_A[5OC%X5@\$ZKIL,4EK;0!)Q:-&N(R8[)&/R
MX4CS!GD$FN)<\O;<M[IJW9>[U^?ZG7+EC[+FM9IW[OWO\OT/7OV?_P#@H)X'
M\=?#/P?J'C_5;3PGXJUJZGT[[,MO.UM+-"4WR"0(RQ(5EC;]XP"[CR0":]B^
M%O[3GPQ^-%OK]QX.\5P:K;:"BR:G<26\]K%;(0Q#L\R(I7$;G<"1A2<U^<'[
M7'[+^A_!O4OV<?A;8W,NIQ7U[<Q:AJ#H(GNYI[FU61]H/R#!"J,G"JN23DGZ
M'_X*.>%])^"?[)%QI7P]\.Z;X4TW6-9L[/5%T6R2V\Z$1R,/-,8&[+1QJ6;.
M<X/6MZE9JG*M;KRJW>Z5_37_ (8QITKU%2\K_+5_?9?\.>X:3^W7\!]<\6IX
M;L_B1IKZH\OD(9(9X[9WS@!;EHQ"<GH0^#VKU[QEXVT'X>^&KWQ#XDU:UT71
M;-0\]]>2!(T!( &>Y)(  Y)( Y-?#7QH_9C^#^A?\$^3KFG>'M(MM3L_#UGJ
M=KXEBA07EQ<N(CEIOO.)&<KL)*C>, 8&/ /CIXOUKQC^R+^ROIGB6[NO[(U&
M]NH[]W<DR1V\ZP0.6]1"[XSS5SYHSE17Q*48^7O-K\+/\!0Y9J-7[+4GY^ZK
M_BNO1_(_0*W_ &\O@/=>$KSQ+#\0;:32;.XCMIV%C=^=&[[MF8/*\W:=K?/M
MVY&,UV/C3]I+X;_#N_\ "=GXD\3Q:3-XJC\W2#/;3^7.GR'<SA"L0 D4DR%<
M9YZ&OAW_ (*A?L__  S^&'P7\':KX3\,Z3X9U:'5$TY/[-MUA>ZMS!(S&4KS
M*P,:'>V6^8\\UD?M^>'8O%^O_LKZ%."T&J645E(%."5D:S0X.1CAC6<92G)P
MCOSJ/WQ;_1?\'<)148J3_E<ON:7]=_(^Z_A]^U=\)_BEI/B35/#?C*UO--\-
MQK+JUY<03VL-JC;MK,\R("#L;!!/2N>\)_MW_ ?QMXHM?#VD?$.SEU6ZE\B"
M.YL[JVCDDS@*)98EC))X'S<D@#.:Y?\ :FT7X%_L_P#[.^IV_B+P%:)X4OKN
MWB_L'PXITU]2NE!,0D>!HV;:$+%G)X7."<"OC#]NC6O'GB/X$_#2[UWX8:%\
M,/"%K=1V^AZ;'J?VS4A&;<E =JJJ1;%&58;]P7('-/VGO6W2<4_GY]/):^II
M&GS)7T;3:^7EU\WH?I7\1/VBOAU\)?%FC>&_%_B>WT'5]7B:>SCNH91$T:DA
MF:8(8XP,'EV7I6#X*_;&^"_Q"_MW^P_B#I<PT2%KF_:Z$EHL<*G:T@,RH'0$
M@;DW#YEYY&?C[]N3PWI_CC]J[]FW1-:@^VZ9J4-K!=P.Q_?1M=*'4GK@C(/?
MFL'XQ_ 7P'_P\R^'O@^U\+Z7I_A;4+&WOKK1[.U2&TE>-+AL&) %VMY";AC#
M<YSDT0<Y.*=O>G*'IR]?\_T,GR\KDND8R?SZ'WM\'OVEOAG\?)M0A\!^*[?7
MKBP :XM_)FMYD4G&_P N9$8KD@;@",G&:].K\Y/A+X3T?X>_\%7_ !5HGAK3
MK?0]&_L=F73]/C6&!-]G;R,JQJ H7>=V ,9K]&ZUC)3IPJ+JOU:_0F47&<H]
MK?<TG^H4444Q!1110 4444 %%%% 'G'[1_B[5O 7P$\?^(]"N_L.LZ7HMU=V
M=SY:2>5*D9*MM<%3@CH017DO[+_[2TMS^QSIOQ5^+7B/<(I;A=0U;["!A?M;
M0Q?NK:/W1?E3W/<UZ%^U]_R:W\5/^Q<O?_135\3:'_RAQU3_ *ZM_P"G=*YI
M5'#VLET4?QDT=,::J>QB_M3:?I8^O;[]O#X"Z;>:5:W/Q'T^.;4H8KB ?9[A
ME5)%#(96$>(20P.)2I /(%>L^+/B'X:\"^#[CQ5KVN66F>'8(EG;4II1Y11L
M;2I&=Q;(VA<ELC&<U^:7C3X"^ M)_P""6^E^+[;PSIZ>+)(K34'USR%^VM))
M=A&4RXW;-C%=F=O .,C-9'[3VJ7.H_LI_LDZ!J%W./#NI11MJ'S'GRT@C0D_
M[,<LN/\ ZU:R<E*5-?$I1CY:_P"7X^1E!*2C-_"XR?G[JO\ C^'F>Y_M;?M_
MZ/-\#X=>^!/Q%M3KT&NP6EX/L \];=H9F)\B[ASL+*GSA<9&,]17JFI_%RYC
M^,OPBTB\^-'_  CMWKFC65U-X'_X1477]LNXD+2?;@F+?<01M! 'EY_BKYQ_
MX*@_ 'X9?##X*>#]3\)^%](\,ZO%JL>GQMIL"PO<VY@D9O,*_P"M(*1G>^6Y
MZ\G+_B=_R?A^RW_V+&E_SN:FB[U>7_IY%??%O3\[.ZOWW*JK]US?].Y/_P F
M6_\ FK.Q]Y?%?XW>!?@=HL6J^.?$MGX>LYF*PB?<\LQ&,B.) SOC(SM4XR,U
MF_"']I#X:_'I;K_A!/%MGKTUJ-TUJ$D@N$7.-YAE5'VYXW;<<]:^,OB)X?TK
MXN?\%5-/\,^/+.#5/#^FZ.ATW2[_ .>WN2MJ9P"AX8>8TC%3D-Y>"".*^F/!
M_P"RW\&/AY\>KKQGX<@MM"\8):;O[%TZ^6VM[>)D9&D%I'MPK@'.X%,KD $9
MITI.45.>SYK?*ZU^[7L14CRMPCNK?C9_K;U-/XE_MI?!;X0^*)O#OBKQU:V&
MM0?ZZSM[2YNVA. =LA@C<(V"#M8@\]*L?$;]J3P3X/\ V?\ 4OBMI6L6>OZ&
ML#?V?);,[1W-T01' Q16:,E\*=RC;_%C%?*WP]^)%KXTN/BU;?L\?!C3Y=#U
M"69/$/CCQAKTI@NI2LC,6B<R2LI!=@$?^,%E7(SY[^QQI%AKO_!.WX[P:E96
M^H0V\U_=0QW42RK%,EA$R2*&!PZD AAR" 16#J2E1J2V<8J7WO6R?ELWOV.E
M4XJK"/>7+_P]O/=+;N?57[$?[8EC^TGX7N++6=3M4^(,+7-[=:19V4T<5K:"
M8)%MD9=C<,G\9;GGVZ3]D'XD?\+'T/Q//_PN/_A</V2^6+[7_P (O_8?V#*D
M^5LVKYN>N[\*\S_X)=>#M M?V8]+\20:'IL/B*ZN+ZVN-7CM(UNYHA.<1O,!
MO91M7"DXX'I7C7_!.?6M2\-_LT_M!ZOH^[^UK W%U9[5+'SDLY&3 ').X#BN
MBI-4N9M?#33_ "_3=[WOK;0YZ<'55EUG;_TK]5Z6\U<^Q?B%^VI\$_A;XHD\
M.>)/']C9ZS$_ES6UO!/=^0^<%)&AC=8V!ZJQ!'>NV\1?&SP/X7^&$GQ%OO$5
MJW@J.*.8ZQ9J]U$4=UC4J(E9F^=@. <'KC!KXD_X)M_L^?#+XJ?L^Z[X@\7>
M&]+\7Z_J>K7-K?7>K0BXGMU"(0J.V6C8AR^]2&)?KP,> ?#?4;FU_8O_ &H_
M#%I=RWWA72-6TYM,F:3<AWWP5BO^\L43''7-9U)3I1:E\7*I>6KCI_Y-N:4X
M0JSC;;FY7WZZK[G^9^BU]^WA\!=-O-*M;GXCZ?'-J4,5Q /L]PRJDBAD,K"/
M$)(8'$I4@'D"O=K6ZAOK6&YMIH[BWF021S1,&1U(R&4C@@CG(K\M?&GP%\!:
M3_P2WTOQ?;>&=/3Q9)%::@^N>0OVUI)+L(RF7&[9L8KLSMX!QD9K[L_8YFDN
M/V6/A:\KM(_]@6J[G))P$  _  #\*Z%O4B]XM+[U<YND)K:2?X6_S/8Z***!
MA1110 4444 %%%?(O[87PW\._%S]HS]G;PIXLT[^U= U"77?M-GY\D/F;+2.
M1?GC96&&13P1T]*EWNHQZ_Y-_H7&*E=OHF_N5SZZHKY2\5_L!_#_ ,'^&M2U
M;X21ZK\./'%G"UQI^JZ7K-VX:5 62.9)I75XV(PP(Z$_2J7P7^.6B?&/Q]\#
M-=U7PK'<>-=:\*:E+_;T-_)&ED\,BQ742VPRCB21"0S'*@ "B,N:7+U_X$GI
M_P" N][?/8F2Y8\W3_@I:_?IO\MSZZHKYMU[]JKQCJWC?Q-HOPN^#M]\2=,\
M,7C:;J^K_P!O6VF)'=J 9(H8Y06E*@X)&.>!Q@G>\7_M56?A'X2>&_%D_@KQ
M,GB+Q'>+IFE^"[VS-KJ<UZ2P\IE<?*OREO,Y&T@@'.*GG3CSK;3\=K=[]"G%
MJ7*_/\-[]K>?GV/=**\-^$/[1FM^,/B%<> ?'_P[O/AGXR_L_P#M:SLYM2AU
M&WO;4.$9H[B(!=ZL1E,9 .:YG5?VN/%7B#Q%KMO\+/@YJWQ)\/:!=R6.IZ\N
MJP:=$9XS^]2U252UR5Y'RXR0 ,@@EN25O.[^YV?W/1^8E%RO;I^NWKIKZ:GT
MQ17SYX-_;$T/QYXG^&MII6CSIHGC07]J+^]F\F?3M2M5#26,\&PX<C.#OYQP
M#D&NPU'XZ16O[0$'PRM]*6X2#0)/$&K:S)=^7'IT0DV1H4V$,7//++A1GFJ;
M2MYW_!-O\%?S5FM&A6>OE;\7;\]/)W3U3/4Z*^5_^&S/%VO:?<^+?!_P-\0>
M*OA=;O(3XHCU.WM[FXAC8B2>WL''FRIP2O(S@]""!L?$3]LVS\.ZA\-[7P?X
M3NO'[^/],GO=#2RNUMY)94\K9"P="J B1B[LP$8C;(/2IYD_\NNS:TWU2=N]
MM"G%IZ_\#HM]M+J_;J?2%%>'^!_V@/$NH?%/P[X$\<_#]? NJZYH5QJ]M_Q.
MX]0_?0S[)+7,<2J6$967<K$8;&,@UTG@_P",S>,_C;X[\"6>BXL/"-O9FZUO
M[5D275PAD$"Q;.-J#);?U(&WO5[M)=;_ (-I_BK>MNZ(Z-]K?C:WYK^DSTRB
MBB@ HHHH **** "BO+?VIO\ DVOXH_\ 8MZA_P"D[UX+\)/^"?\ \ ?$7P=\
M':_JO@HKJ5]H=I>W5^-:OHR)7@1WDP)PJ_,2>F!Z8K/F=Y=HV_'F_P#D2^5)
M1=]7?\+?YGV917P_\&?VD;OX*_LM^,O$NIW=SX_\,^%?&<WA_1M4N;LB:[TO
M[1%'',9@K^;L\Q\8'S! HP,5[%9_M/:QX?\ ASXD\>?$CX<7WP_\-V2POI"R
M:G#?7^K^<<11BVC ,,K$H/+=N"_)PK$5S1MS+:R?WI-+ULUIZVO87+)/E>]V
MON;3^5UOTTO:Y[]17S3I?[67C#0M=T3_ (6;\&-6^'7A37+J*QL?$,FKV]^D
M4TI A6[BC :V#$@9<G#'![D7_'G[4OB.W^)&N^#/AE\*]1^)]_X<6,Z[=1ZK
M!IMM9M(N]8D>4'S9-O)08/UYPG))7_K3>_:UUOW7<.5_U_6I]#T5\9_';XM:
M3\;_ (7?L_>+]'@N;.VO/B=H\<MG>ILGM9HY)XY8I%[,KJ1[\'O7L'AG7/#T
M_P"UUXVTFW\,?9O$T'AFPGNO$7]H2/\ :H&E<)!]G(V)L()W@Y.<&J6KMYM?
M=!2O^/W:Z[!)<L>;R3^^3C;\/OTTW/;**^/=)_;N\8>+O#.N:_X4^!6K^(=*
M\.W=U;ZW>1ZW!#%;K"[9,&^,/</Y:AV1$^7<HR<YKK_&7Q=\&?$!OV=O%#>%
MI=<C\4:RDVBW$]^]K)I,S6SL9&C3*S, &0HQVYR<\5$)JHHRCLW'_P FV^_I
MT\T$HN+DGTYO_)=_NZ_DSZ3HKPSXP?M):KX-^(5K\/O 7P_OOB9XW>Q_M.ZT
M^WU"+3[>RM2VU7EN)055F(.%QSZ\C.;8_MF^'8?@WXA\:^(/#^K:%K'A_4_[
M"U+PJ56>]74B5"6\1! D#[U*N, C)[4*<9)M?UK;3OKIIUT#E::C_6U]>VFN
MO34^A:*^88_VMO'/A+Q!X<C^)WP1U#P#X:U_4H=*M-<C\06NI>7<3$B(30Q*
M&B![DGCD<FK/P/\ ^3SOVDO^N7AS_P!(I*N/O.R\_P +:?B@MI)]K?BTOZ]#
MZ5HHHIDA1110 4444 %%%% !1110 45\&?L__LA_"3XZZA\6?$/CCPG_ &WK
M$?C[6+1+G^TKNWQ$LBLJ[8I47@LW.,\U<\+^'].^#?QH^+_PO\ ZK<W7P\3X
M?SZM=:+->/>1Z+J.6C6*-W9F3?&=Y4DDY!/ %<TJKC34Y+5QYDO^W>>WW?B;
M^SYJCA%Z*7*__ N7\_P/N>BOS^_9_P#VL_$'PG_9@\"Z@OPBUW6?ASH=C%;:
MQXN2\A@\EO,(=X+5AYD\:%@I?*KN##/&:^F/B]^TDG@2^\*Z#X1\+7WQ$\9^
M*+=[S2M%L;B.U1K9%#-/-/)\L*88 $@Y/%=,K1;2UL[>?W;ZI77DF]D81O))
MOJK_ -/;2]GYGM-%>#_"/]I36_%GQ,N/AY\0/AS>?#3QC_9IU>TM9-4AU*WN
M[4/L9EGB 7<">5QT!Y]>0M?VQO&_BZ._\0^ O@7K/C;X<VEQ- OB*UUJVANK
MH0L4D>"Q93)(-RG: <MZ \5',M//7\;?+70I1;OY:?-JZ]=-=#ZGHKQ3XF?M
M,0^"],\'6VA^#];\4>./%\7G:3X0,8L;M45 \C71E&+94W!6+9P?4 D1_"/]
MHO5O%WCJ;P)X_P#A_??#+QL;-M1L["XOXM0M;^V5@KM#<Q *SJ6&Y,9 (//.
M*6LG%;Z_AO;O;K835HJ73_/8]OHJOJ$T]O8W,MK;_:[F.-FBM]X3S7 )"[CP
M,G R>F:^*M(7XI7G[;7PCUCXFW&GZ=+J6DZTUAX5TES+#I$:0H#OFSB65]PW
M,!@;  2. D[U%#O?\$W\]OEUZ7'[L'/T_%I?J?;M%%%4(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **^,OBG\"_!'Q[_ &[I]%\=Z)_;NF6G@&&[A@^USV^V47SKNW0NA/#,
M,$XYK)^(GP7\%_LF_%GX.W?P?DN?"^N^(/$\&DZCX;CU.XNH=3TZ0,)Y9(I9
M&/[H!2&! !8'KBHA)RY+Z<SLO_ G'\U\D7./*Y*/V5=_^ J7Y/[S[CHKX,^&
M?Q=\6> OCA^T/IG@?X9ZE\2=<F\4_;)H+>]BT^UMH%A"Y>XE!!D8YVQJ"S;6
M/&.?I+P/^U!X5\7? &Z^+%W%>:'HVGPW#:G9729N+2:!BLL.!]YMPPO3.Y>
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M\QO%'C2]D_8VO4U#7KKQ3X<\+_%.+3=$URX)GGO-,@G5HW+C/FXRX!'4  <
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M\#_&[18M*\<>&K+Q#9PL7A^T K)"3C)CE0AT)P,[6&<#-<E\*_V/_@]\%/$
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M<^??VBOV3O\ A?WQ.^&?B_\ X2G^PO\ A"[S[7]C_L[[1]L_?0R[=_FIY?\
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M_)V[-O\ LXQ4'B#X;>$?%NAVFBZYX6T76M&M HM]/U#3H9[>$*,*$C=2JX
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M?]@77_\ T5%7TE69=>&='OM<L-:N=*L;C6;!)([349;9&N+=) !(L<A&Y P
MR 1G'--?'&7:_P",6OU)>L7'O;\&G^AIT444P"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /C+
MXI_ OP1\>_V[I]%\=Z)_;NF6G@&&[A@^USV^V47SKNW0NA/#,,$XYKV_X3_L
MC_"+X(:TVL>#/!%GI6K$%5OIIIKN>($8(C>=W,>02#M(R"0:],7PSHZ^(FU\
M:58C76MA9MJ@MD^U& -N$1EQNV;OFVYQGG%:53"*A%);Z_C)O\G8J<G.3;VT
M_!)?FKGS#^R7&H^-/[2CA0'/B] 6QR0(.!^I_.O)/ACX^\1_##]B;XX^)_"2
M9U_3_%NLO;R>4)/(!N(E>;:>#Y:,S\@CY>01FON72?"^C:!>:E>:7I%AIMWJ
M<WVB^N+2V2*2[EQCS)64 NV.-S9--T3PCH7AFPNK'2-%T_2K*ZFDN+BVL;6.
M&.:63_6.ZJ &9NY/)[UBJ;4%%/:'+_Z1_P#(^NI:FN?F:NN?F_\ 2M/_ "8_
M,#]H[0?A#_PSQ?:C#\9?$GQG^(%_:0SV5C=>)7U 6D@*//,UM%_J$2,2'$WW
M<8ZBO6O'EG\'_&WQ(MWNOB+XE^ WQ*B\,:;-#XG35(]-L=9M'A4H5<R;9@F-
MI7=&21CYPIQ]DZ5\&?A_H5GJUIIO@7PUI]IJT;0ZC!:Z1;Q)>H>JS*J 2 Y.
M0V14_B#X3^"/%NDZ?I>N>#?#^LZ9IZ".RL]0TN">&V4 *%C1T(0  #"@<"KY
M-9.V[3[6LI+2WK\]5VM*EHE)WLFK]]8O6_IMTW/B+^WOB)\=?V6?V@?!?_"4
M0_%)/#[P0:-XOL+ 0#6(X]D\\**F5D=!'M!4L27'+9!/-74/P.U;X*+KFH_M
M._%S6(+VQ6&?P;#XRBGU&=W 1K06+Q;F)8E,,-A'.[;S7Z0:-HNG>'=,M].T
MFPM=,T^W79#:6<*PQ1KZ*B@ #Z"N?MOA'X%L_%+>)K?P7X=@\2,YD.L1Z5 M
MX6/5O.";\^^:3IW;OK=)/Y*S?;7\'WNRHSLEY-M?.VG?2W_ 1-\+]!M_"OPU
M\*Z-:1:C!:Z?I=K:Q1:P4-XB)$JJLY3Y?,  #;>,YQQ7S'\:_P!I73OB1\2-
M7^$NA?$G0?AIH>E-Y'BGQ;J6J6]K=L2<-9:>DKC,G#*\V"(^<?, &^PZ\ZO_
M -G#X2ZK?7%[>_"[P7>7ES(TT]Q<>'[1Y)9&)+.S&/+,2223R2:TJWJSYGMK
M==_7R[]]+Z73BG:G&RT:M9]O^#V[>MFD^!,OPQT_P1;>'/A5J^@:EX>T55A,
M6@ZC%>+"S9;,C(S'>QW,2QRQR:]&KG/!OPW\(_#F&ZA\)^%M%\,173*]Q'HV
MGPVBS,H(4N(U7<0"<9]371UI*3D[LSBK*P4445)04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#!AX?_ /EI1_PF_CK_ *(;XY_\&'A__P"6E>X?VQ_TR_\ 'O\ ZU']L?\
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MTR_\>_\ K4?VQ_TR_P#'O_K4>UD'LXGA_P#PF_CK_HAOCG_P8>'_ /Y:4?\
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MWQS_ .##P_\ _+2C_A-_'7_1#?'/_@P\/_\ RTKL?^&B/#G_ #Y:I_WZC_\
MCE'_  T1X<_Y\M4_[]1__'*/JN,_D8>WPW\YQW_";^.O^B&^.?\ P8>'_P#Y
M:4?\)OXZ_P"B&^.?_!AX?_\ EI78_P##1'AS_GRU3_OU'_\ '*/^&B/#G_/E
MJG_?J/\ ^.4?5<9_(P]OAOYSCO\ A-_'7_1#?'/_ (,/#_\ \M*/^$W\=?\
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M&^.?_!AX?_\ EI1_PF_CK_HAOCG_ ,&'A_\ ^6E=C_PT1X<_Y\M4_P"_4?\
M\<H_X:(\.?\ /EJG_?J/_P".4?5<9_(P]OAOYSCO^$W\=?\ 1#?'/_@P\/\
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M_1#?'/\ X,/#_P#\M*['_AHCPY_SY:I_WZC_ /CE'_#1'AS_ )\M4_[]1_\
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MP_\ _+2C_A-_'7_1#?'/_@P\/_\ RTKV?_A+;/\ YYS_ /?*_P"-'_"6V?\
MSSG_ .^5_P :.:IV#EI]SQC_ (3?QU_T0WQS_P"##P__ /+2C_A-_'7_ $0W
MQS_X,/#_ /\ +2O9_P#A+;/_ )YS_P#?*_XT?\);9_\ /.?_ +Y7_&CFJ=@Y
M:?<\8_X3?QU_T0WQS_X,/#__ ,M*/^$W\=?]$-\<_P#@P\/_ /RTKV?_ (2V
MS_YYS_\ ?*_XT?\ "6V?_/.?_OE?\:.:IV#EI]SQC_A-_'7_ $0WQS_X,/#_
M /\ +2C_ (3?QU_T0WQS_P"##P__ /+2O9_^$ML_^><__?*_XT?\);9_\\Y_
M^^5_QHYJG8.6GW/&/^$W\=?]$-\<_P#@P\/_ /RTH_X3?QU_T0WQS_X,/#__
M ,M*]G_X2VS_ .><_P#WRO\ C1_PEMG_ ,\Y_P#OE?\ &CFJ=@Y:?<\8_P"$
MW\=?]$-\<_\ @P\/_P#RTH_X3?QU_P!$-\<_^##P_P#_ "TKV?\ X2VS_P">
M<_\ WRO^-'_"6V?_ #SG_P"^5_QHYJG8.6GW/&/^$W\=?]$-\<_^##P__P#+
M2C_A-_'7_1#?'/\ X,/#_P#\M*]G_P"$ML_^><__ 'RO^-'_  EMG_SSG_[Y
M7_&CFJ=@Y:?<\8_X3?QU_P!$-\<_^##P_P#_ "TH_P"$W\=?]$-\<_\ @P\/
M_P#RTKV?_A+;/_GG/_WRO^-'_"6V?_/.?_OE?\:.:IV#EI]SQC_A-_'7_1#?
M'/\ X,/#_P#\M*/^$W\=?]$-\<_^##P__P#+2O9_^$ML_P#GG/\ ]\K_ (T?
M\);9_P#/.?\ [Y7_ !HYJG8.6GW/&/\ A-_'7_1#?'/_ (,/#_\ \M*/^$W\
M=?\ 1#?'/_@P\/\ _P M*]G_ .$ML_\ GG/_ -\K_C1_PEMG_P \Y_\ OE?\
M:.:IV#EI]SQC_A-_'7_1#?'/_@P\/_\ RTH_X3?QU_T0WQS_ .##P_\ _+2O
M9_\ A+;/_GG/_P!\K_C1_P );9_\\Y_^^5_QHYJG8.6GW/&/^$W\=?\ 1#?'
M/_@P\/\ _P M*/\ A-_'7_1#?'/_ (,/#_\ \M*]G_X2VS_YYS_]\K_C1_PE
MMG_SSG_[Y7_&CFJ=@Y:?<\8_X3?QU_T0WQS_ .##P_\ _+2C_A-_'7_1#?'/
M_@P\/_\ RTKV?_A+;/\ YYS_ /?*_P"-'_"6V?\ SSG_ .^5_P :.:IV#EI]
MSQC_ (3?QU_T0WQS_P"##P__ /+2C_A-_'7_ $0WQS_X,/#_ /\ +2O9_P#A
M+;/_ )YS_P#?*_XT?\);9_\ /.?_ +Y7_&CFJ=@Y:?<\8_X3?QU_T0WQS_X,
M/#__ ,M*/^$W\=?]$-\<_P#@P\/_ /RTKV?_ (2VS_YYS_\ ?*_XT?\ "6V?
M_/.?_OE?\:.:IV#EI]SQC_A-_'7_ $0WQS_X,/#_ /\ +2C_ (3?QU_T0WQS
M_P"##P__ /+2O9_^$ML_^><__?*_XT?\);9_\\Y_^^5_QHYJG8.6GW/&/^$W
M\=?]$-\<_P#@P\/_ /RTH_X3?QU_T0WQS_X,/#__ ,M*]G_X2VS_ .><_P#W
MRO\ C1_PEMG_ ,\Y_P#OE?\ &CFJ=@Y:?<\8_P"$W\=?]$-\<_\ @P\/_P#R
MTH_X3?QU_P!$-\<_^##P_P#_ "TKV?\ X2VS_P"><_\ WRO^-'_"6V?_ #SG
M_P"^5_QHYJG8.6GW/&/^$W\=?]$-\<_^##P__P#+2C_A-_'7_1#?'/\ X,/#
M_P#\M*]G_P"$ML_^><__ 'RO^-'_  EMG_SSG_[Y7_&CFJ=@Y:?<\8_X3?QU
M_P!$-\<_^##P_P#_ "TH_P"$W\=?]$-\<_\ @P\/_P#RTKV?_A+;/_GG/_WR
MO^-'_"6V?_/.?_OE?\:.:IV#EI]SQC_A-_'7_1#?'/\ X,/#_P#\M*/^$W\=
M?]$-\<_^##P__P#+2O9_^$ML_P#GG/\ ]\K_ (T?\);9_P#/.?\ [Y7_ !HY
MJG8.6GW/&/\ A-_'7_1#?'/_ (,/#_\ \M*/^$W\=?\ 1#?'/_@P\/\ _P M
M*]G_ .$ML_\ GG/_ -\K_C1_PEMG_P \Y_\ OE?\:.:IV#EI]SQC_A-_'7_1
M#?'/_@P\/_\ RTH_X3?QU_T0WQS_ .##P_\ _+2O9_\ A+;/_GG/_P!\K_C1
M_P );9_\\Y_^^5_QHYJG8.6GW/&/^$W\=?\ 1#?'/_@P\/\ _P M*/\ A-_'
M7_1#?'/_ (,/#_\ \M*]G_X2VS_YYS_]\K_C1_PEMG_SSG_[Y7_&CFJ=@Y:?
M<\8_X3?QU_T0WQS_ .##P_\ _+2C_A-_'7_1#?'/_@P\/_\ RTKV?_A+;/\
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MP_\ _+2C_A-_'7_1#?'/_@P\/_\ RTKV?_A+;/\ YYS_ /?*_P"-'_"6V?\
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M1_PF_CK_ *(;XY_\&'A__P"6E?05%'M9![.)\^_\)OXZ_P"B&^.?_!AX?_\
MEI1_PF_CK_HAOCG_ ,&'A_\ ^6E?05%'M9![.)\^_P#";^.O^B&^.?\ P8>'
M_P#Y:4?\)OXZ_P"B&^.?_!AX?_\ EI7T%11[60>SB?/O_";^.O\ HAOCG_P8
M>'__ ):4?\)OXZ_Z(;XY_P#!AX?_ /EI7T%11[60>SB?'WQN\;>,?^$2T5KO
MX-^,]/AC\6^&I?-GOM#969=<L66,!-28[I& C4D!0SJ69%W,/L&O-/V@X[&7
MP'I2ZA<7%K;_ /"6^&&62VMUF8RC7; Q(59T 5I BLV255F8*Y4(WI=9RDY.
M[+C%1T04445)04444 %%%% !1110 4444 %%%% 'BGPQ_P"2G?'3_L<+;_U'
MM'KTBO-_AC_R4[XZ?]CA;?\ J/:/7I% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !114=S<Q6=O+<3R)#!$A>221@JHH&223T %)M)78
M]]$245\GZ+\=?C[\?;6;Q#\&_!_@S0? WG/'I^K_ !#N+OSM7C4E?/A@MAF.
M,D'!<\C!'MZ;\!OC#XM\;:QXE\(_$+P@OA/QKX=\A[AK"8W&FW\$P;RY[:4@
M'&48%&Y7C)SD"DF_+K_7^6_D*7N_U_7IVN>QT5RC_%CP/'XP7PF_C+P^OBEC
MM&AMJD OB<9QY&_?G'M5GQ)\1O"?@VXD@U_Q/HVASQVK7SQZEJ$5NRVZL$:8
MAV&(PS*I?H"0,\U-^H=;'145D^%_%NA^-M'BU;P[K.GZ_I4I(COM+NH[F!R.
MH#H2IQ]:RM$^+'@?Q-XDN?#NC^,O#^J^(+7=Y^E6.J03746W[VZ)7++COD<4
M^MNHKJU^AU=%<KXF^+'@CP3)=)XB\8^']!>U,(N%U/5(+8P^;O\ *W[W&W?Y
M<FW/WMC8S@U%XN^,7@+X?RP1>*?&_ASPU).@DA35]6M[4R*>C*)'&1P>1Z4K
MHHZ^BO'?CK\;+OX?>'?A[J_A=M+UBT\3>*]*T1KF0F>%K2ZD*M)$T;@%L8*M
MDK[&M?6_BI#X,^(NN1>*?%_@?0O!MCI5M<A+[4Q;ZI;SR3.GF7 D81K;MA51
MN"7#"FOU:^:2?Y-">GW)_)MK]#TNBN(\)_'3X;^/M872?#'Q!\*^(]59&D6Q
MTG6K:ZG*K]Y@D;EL#N<<5<\0?%CP/X2U^UT/7/&7A_1M;N]OV?3=0U2""YFR
M<#9&[AFR>F!1V\Q75F^QU=%9GB3Q-H_@[1[C5]?U:QT/2;< S7VI7*6\$0)P
M"TCD*.2!R:\I\(_'P^-OVC;KP9HMWHNL^#?^$0A\0VFK:;)Y[33/=O 0LJR&
M-H\+V7.<\]J%[TE%>?X)O\DQOW8N3VT_%I?FT>TT5P/Q^\?ZA\*_@GXX\8:3
M#;7&IZ'I%S?VT5XK-"\D:%E#A64E<CG# ^]>$:3XF_;+U+PS8^((-.^">H6E
MS:1WR:?;OJT5S,C('$:L[>6KD'&6.T'OBES+6^RM?YW_ ,F.VWG?\+?YH^M:
M*\L^ O[0?A_XY> O"^LQ2V^C:[K-E+=/X=N+I#=Q&&8P7!5.&>-)5*^8% .5
MS@G%>@Z?XETC5M4U/3;'5;*]U'2V1+^SM[A))K1G7<@E0'*%E^8!@,CD5<HN
M+:?]="4[FE17(Z+\8/ ?B3Q--X;TGQMX=U3Q%!N\W2++5K>:[CV_>W0JY<8[
MY'%<#'^U!X=D_:>N?A&^IZ'!)!HR7@N'U2/SYKYYMHLEBR,2+&/,*\L0P. !
MDS'WG%+KM\E<;]U.3V6_S=CVRBL.U\=^&KWPW=>(K?Q#I4_A^U$IN-6BO8FM
M81$2)2\H;:NPJP;)^4J<XQ7G?Q ^-%]X>^+OP8\.:*--U#0?'$VH"YO3NE;R
MH;,W$3P.CA<,<9)# J>,=:%J[(.C?:[^[<]@HKDO&7Q>\"?#FXBM_%GC7P[X
M8GE7='%K.JP6C..>0)'4D<'\JNWGQ"\+:?I^GW]UXET>VL=1C>6RNIK^)(KI
M$B:5VC8MAPL:LY*Y 52QX&:5U9OHA^1T%?)5?4'A?Q9H?CC18-8\.:SI^OZ1
M.6$6H:7=1W,$A5BK;9$)4X((.#P017R_7U62IKVB?E^I\_FGV/G^@4445].>
M"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$'PM-X5_X2=/$NCOX;P&_MA;^(V>"P4'SMVS!) Z]2!6^#GD<BGMHQ"T444
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MUM<])HIL<BR(KHP=&&0RG((]13J8@HHHH **** "BDW#<5R-P&2._P#GBEH
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M4 %%%% 'E7[2W_).M(_['/PG_P"I#IU>JUY5^TM_R3K2/^QS\)_^I#IU>JT
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M?M!_]C3:_P#IMM:\Y^&?P_\ VMOA3\/] \(:3-\%[C3-%M$LK>6];5VF9$&
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M\'/#<5WIRWW@W5-%O=0D>2012I:1[91$=F22?N[@H/<BJA?F3EWA]SE+F_\
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M-^Q;LG'E>;\^-NW.[OFNEKFOAO'XK@\#Z3%XX.CMXJ2(K?-H)E-D6#$*8_-
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M'%I5U<OJ=G/<QEHIY=P\L1N5)$8W,H8*S9&3M_M"?L:Z9XD\,65Q\'] \(>
MO&EG-(JW<=@MA!<VLT,D%Q!,;>(LP*29&0<%>V377:Y\#=>U/X6_!SPW%=Z<
MM]X-U31;W4)'DD$4J6D>V41'9DDG[NX*#W(JH.4I<T^C@O+EN^9_*+2^5]R)
M)1C:/52?SLK?-R3?SL<)\*IOB2W[<7Q=6];PRWAA+'31=+&;DW8M_+N39"+/
MR;\[_-SQTV=ZI>%/V@O%MQ\)?AGHWP\\'>%K?QSXPN-4^R69C>RT33K>UN)!
M-<21QL9#G*?*IRS.Q_V3ZI8_"_QIX>_:<UKQOI=[H<W@GQ)I=K:ZO:WGG#4(
M9K9)A";?:/+*DR#=O.>N!QSYWIO[,'C_ ,'_  Y^'-QX5U[0+/XE>"9]2,']
MH)--I-];WDSM)!*5595^4QL&49#(1CG(R5U&*=[?CN_^!?K;;4U;4IR?>W_I
M"7X/1>>^AHZ_\1/B/H_AKP7%\3O WA,:_)X\T[24N+<F]L)X9,D7MHKMYD$J
M'<J^9R"I."&XS_\ A='Q^\>^+/B%I7P\\+>"GL?"6OSZ=_:'B&>YC%[&L4;K
M;Q)&Y/G_ #DF1]L>'0 9#&MRZ^#?Q=\<:+X9N/'GBGP[J&N6/C#3]?DT_2;=
M[?3["TM]P>&W=D,TKN3NS*0,G *@9/F_P_T7XU7'COXW7'PM\0>$K6RN?'-U
M;7EIXJM)W-JPMK<_:;9X3\SD. 4D&W]VISR:?O<THOLWI;M22?WN7E?R%I92
M7DM?6HW^%OEYG8>+/VL_$=U\#?!_C'PUI?A?PU?:U<3V6HWGCO65M=.T6Y@+
MI+"X5EFN':2-U58E)PI9L"O#_'7[3_C7X^?LG_&:QBE\&W>I^&WMH=2UC07O
M!I]Y8S9)^RB4"02JRA3O^0C=CM7KGBC]COQ5X;T#X8R^ ]4\,>)/$/A%-0%U
M%\0+&26PU&:]=99[K;%N:*42!BN,_*P&[@[J^E_LE?$G6/"_QRL_&'B3PS<:
MK\0]/LEMI]'MI8(+*X@1U$1C*_ZE1Y2A\ER Q(SU)7:J7\]NZM:WDU?[[-W+
MIRC&4&NC7K:_7S2:^:NE;4G^)7[3WC[X<S^$O ,U]\+]&^(UQI!U75]8\3:K
M-8:!;1^:4BC@#E9I7<*> ?EVDD8/&GX5_;09O@]XZUS6;30_$'BSPA<6]E)#
MX,U-;S3-5FN2JVK6\^241W;:P?+)M.<]*S?B1^R]\0_'L_ACQQ=V7PNUWXCV
MVE?V/K&C^)M)EU#0;B-9F>*6!G0S0R*&.<##%L' '.OX7_9#U"\^#_C7P]XD
ME\(>&_$/B62WN(3X!\/PZ?8Z5+;D26Y7"K+<A91O/G-W*@*,YKWO?OY[?XM.
M7SY=NE]]3&"C%4TNR_+6_E?YVM8\_P#B=K'QNN/'7P.M_BIX=\*6UA/XZL;F
MTOO"=U.XM7$<H^S7*3=7(8D/&2O[MAW%?<5?*5Y\%/C_ /$+Q9\/]1\?>*O!
M3Z;X2\1VVJ"R\/PW,/VZ*-75IYC(K?O_ )@%C3;'\[DGA:^K:UCI3:_O-_+E
MBOT_SUN1+6:?]U+YWD_U_P M#MO#O_(&M_\ @7_H1K2K-\._\@:W_P"!?^A&
MM*O.E\3.^/PH****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#RK]I;_DG6D?]CGX3_\ 4ATZO5:\
MJ_:6_P"2=:1_V.?A/_U(=.KU6@ HHHH **** "BBB@ HHHH **** "BBB@#Q
M3X8_\E.^.G_8X6W_ *CVCUZ17F_PQ_Y*=\=/^QPMO_4>T>O2* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M&\9>,-(^'_A/5O$NOW?V#1-)MGO+RZ\IY/*B0;F;:@+-@#HH)]J^>[?_ (*7
M_LV75Q'"GQ*17D8(#)HNHHH)..6:W  ]R0!7<_ME?\FH_%K_ +%J^_\ 1+5X
MQX7_ &Q);_X7Z/X=@_9S^+^OS2:/!9+'?>%5BTV\/DJOSS/(RB%O[Q4C!SBH
MYG>6E[6T[WYO\NW4IV2C?K?7M;E_S[GU_H^L6/B'2;+5-+O(-0TV]A2XMKNU
MD$D4T;@,KHPX92""".N:N5^;&M>-?B)^R5X"^$OPNUOQW%\%=#ET>YO[OQB/
M#Q\0HE_)=R2#2T7YD58XW'S\]!@XY/O>C_M&>)/ 7[)_C#Q_JOB_PC\7+_19
M/(TK6?#3>7'?&0Q1P"]A7"P3>9*"Z(<!2.AYK67+[SAJDWYWUMTZWV6E]UH3
M&]XQ>[M^*OUU_P MGJ?5E%?%_CK7?VD?V=/!T?Q5\7_$7P[XWT*UEMY?$'@V
M'08[.*RMY)$23['=H?,E=-XQYH (!)#'@]%XP\3?%_XF?M,>*/A]X%^(=KX%
M\.:?H>EZT=2;1K?49T,C3*T422  B7@L[L=OE+M'S-22NTNK=O2RN_PN]+WL
M[7>A-]'+I^>J6GS:WMN?1?AOXB>'_%_B#Q+H>DZA]KU3PW<QVFJP>3(GV>62
M,2HNYE"OE&!RA(YQUXKHZ^<O"/Q.\>ZUXD_:+TRSU?29[OPI?6UMH#>(0MM8
MV8:PCE9KB2&/>4#LSDG)[ J.GS-XJ_:O\:?"OQ5X4N[;]IWP?\7+J_U>TL[[
MP7I?AR".W$,KA)&BO8"S93.079<]2#]TJ'ORA!;R47_X$E\_\N_4<O=C*3Z.
M7_DOX?Y]NA^DU<YXL^(GA_P/J7ARPUO4/L5WXAOQI>F1^3))]HN2C.$RBD+\
MJ,<M@<=:^%OB-^U'X[D^.OC/PSJ7QPT?X$7>C:F]KH?AG7?"8NK/6+10#%=3
MZA(,1)*<_=(P.F2*^A/B-\6/&&A+^SR8=8TD3^*_$%M8ZY+H.VZL+V)[.:1Q
M;R2(6\IG165AAL8YZY(?O(PDMI.*_P# G]WZKJN@ZG[MRB]TI/\ \!7]>3[]
M3Z(HK\\_B-^U'X[D^.OC/PSJ7QPT?X$7>C:F]KH?AG7?"8NK/6+10#%=3ZA(
M,1)*<_=(P.F2*^[O .J7^M^"-!U#5+G2;S4KJQAFN;G09VFL)9&0%GMW8 M$
M2<J3S@BB'OP51;.WX_A\MUUL$O<GR/?7\/ZWV9O4444 %%%% !1110 5\E5]
M:U\E5]1DG_+SY?J>!FOV/G^@4445]0>"%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7MGPZ_Y$W3_P#MI_Z,:O$Z]L^'7_(FZ?\ ]M/_ $8U>1F?\%>OZ,]' _Q'
MZ?Y'24445\R>X%%%% !1110 4444 %%%% !5/6-8L/#VEW>IZK?6VF:;:1M-
M<7EY,L4,,:C+.[L0%4#J2<5<KR#]K[_DUOXJ?]BY>_\ HIJQK3]G3E-=$V:4
MX^TG&#ZLT_\ AI[X.?\ 16? W_A26?\ \=KOCKFG#1?[8.H6HTG[/]K^W^<O
MD>3MW>;YF=NS;\V[.,<U\,^'/'WP@30-+2;]C'QM>3"VB#W2?"RS=96V#+AB
MWS GG/?->N_MA>-="\/_  U\)_#R74]/\&V?C:^M](DFO;A+"&PTN/;)><DA
M4'DJ(0N0,S*!6L_=ND];I+MKIK_6UR(>\TVM+-OO9:O\#Z /C#05\+_\)*=;
MTX>'/LWVS^V/M<?V3R,;O-\[.S9CG=G&.]<OHO[07PN\2:E!IVD_$GPAJFH3
ML$BM++7;6:61B< *BR$DY]!7R)I_C[0!^S'^TC\+]#\0:9X@TWPE87]QHEUI
M=['=0OI5U&\T,:NC$$PL7B('W0$'I7T%#^R/\&_&GPQL]/O/AMX8M&OM,B5[
M[3])M[6[C9HA^\29$#*X)SG/7KFHYF[RBM$HOS][FT[75K/S'9*T9/6[7W6U
M^=[KR/93XFT<>(QX?.K6(U\VOVX:5]I3[4;?=L\[RL[O+W?+NQC/&<TOB+Q+
MI'A#1[C5M>U6RT32K?;YU]J-PEO!%N8*NYW(498@#)Y) KXATG6-2TOX._ G
MXX:E>37M[X*U"?P_X@U*;YI+K29+F2R>=VZN$9(I,G).6;UKV;X\1K\7?CA\
M-?A9$5GTFRD/C/Q"HSC[/;.%LXCS@B2=LD>D6>E7>[2C_-;Y;W_\ U]4T#7+
M=RZ*_P ]K?\ @6GS3/HE6#*"#D'D$5R.F_&'P%K'B=O#=AXW\.7WB)69#I%M
MJUO)=AE&6'DAR^0.HQQ7G'[8%Y?W7@'PWX3LM0N=(A\9^);#PY?7]H=LL5I,
MS&8*W\)=(S'G_;]Z/%'[$OP=UWP)+X<T[P1H_AJX6%4L]<TFRCBU*TE3!CF6
MY \QG5@#EF.['.<U"DW>26B=O/9-_@U;N^V[=DK1;U:O^+7YI_\ !N>[45\V
M^)_BA\8-:^(&J_#_ .$>G^%]0E\(VEG'K?B;QU-<".>YEB#K%''; $OLVNS?
M=RQ&!QGD)/VMOB?K-]X.\+:%X)T.+XA7FM:IX=US2]4NI1:6ES;6Z3)<1S)D
MF I(LA&TLPRBG.&+YT_AU[>:O:_I>VOFGMJ+E:5W_P -I>WW)_EOH?8-%?.O
MPU_:*\4:7HOQ7@^+NDZ1INO?#J-+R_G\,O*UG>6TENT\;0K-\P.U2OS'D]EK
MSSQ3^T+^TGX,\(Z1XZUCP1X$M/".LWME%'8Q7-U+J6E0W,T:(USEECD.'"_N
M\89@2, BFI)R45UM_P"3;??^@FFDV_/\-_T^]6/LVBOGF\^+GQ3U_P#:'\3>
M"/"VF^%8?"OAB33;K5=6UD7/G_99XB\D<*QMAYOE<J3M50H!W$BO&9/V]_%F
MJ1WOC+2+_P"$=OX&M99FC\,:MXH\GQ1>V\;LN]$W"..1P-RQ.N[MSD&H]I'1
MO^O/_+O9O97+]G+\OQU_+\UW/NRBOB[XG?MK^)O^%GOX>\$ZG\./#&EPZ78Z
MI%=?$F\NK-M6CN81,IM7CQ&H4$(=[?>SV!QUGQX_:I\7?#/P+\,KB'2?#7A+
MQ#XPWBXO?%M])<:-I3I$KF-Y[3=O,F[Y&!"X!)[XIRLFVNMOGL)0<FDNJO\
M*U_R/J6N6\9?%3P5\.9+6/Q9XOT'PO)=AFMTUG4X+0S!<;B@D9=P&1G'3(KC
MOV;_ (F>*?B=X/O;WQ3#X7N+BUNO(@UKP7JJWVE:DFT$R1?,9(BK$HR2<Y7(
MX-</\8O!?A[Q[^UQ\+M+\3:#IGB+3/\ A&M;E^QZM9QW4.\2V>&V2*1D9.#C
MN:<N92C%=?\ Y%R_0E6Y92?3_-+]3W#P?\1O"?Q"AFF\*^*-%\2Q0D"631]0
MANUCSG&XQL<=#U]*Z*OE7XT?"'PA\$?'GPK\?> = L?!VKMXHL] O;?0+9+2
M'4+*\+1R1RPQ@*^TA7!(R-A/88V/^&DO$W_#'=Q\5_L.D_\ "11M(!:^3+]D
M^6_-L/E\S?\ <&?O]?;BA24HM]G9^MD_U7X^K;B^91[V_%M?H_ZT/I*J&E:_
MIFO&\&FZC::B;*X:TNA:SK+Y$ZXW1/M)VN,C*GD9%>%_%CXL_%.'XVZ;\.?A
MMI7A>XN;SP__ &W)J'B7[0(+4+<^4^[R6W/D%0J@ [B26P,5P^L?M#>*?!'A
M?Q)>>%?!OAN[UQ_BD?"HL;:!K--0WA 9I7#G$['&96!& ,J<5,9J5O.]O_ U
M#[KNP.-E?^OA<OR1]=T5\_\ PC^,'Q*C^+6O?#[XM:1X8L]0M]%7Q#8:GX5E
MN&M9+7S?*>-Q.-V]6Y)^4>W>O+_$7[3/[0-]\,=;^+OA/P3X+/PUAMY[O3['
M5;FY.LS6B;@MXP5EBV$#S/+!#;> 2<$DJD8QYNEK^FK6OS37R;V5RHP<I<JW
MNE]ZO^37WKJ['VA7,^,OB?X.^'?V?_A*_%FA^&/M&?)_MG4H;3S<==OF,,_A
M5WP?K4VO^#]$U:Y1$N+VP@NI$B!"AGC5B%!).,GC)-?-?[-'P7\&?&CP5)\5
M?B!X;TWQKXL\67EU<RR>(+1+Q+&!+B2.&TACE#+$L:H!@#.2V3TQI)2C-P[;
M_P!??]WH9QE&4%/O8^H]+U6RUS3[>_TV\M]0L;A!)#=6LJRQ2*>C*RD@CW%6
MJ^4=%71/V4/CEXVTG14FLOAW<>#)_&4N@VYW0V%S;3>7*;=2<1B5&'R# +)Q
M@  ;/P_^(7[27BAM-UC4? _@BW\,>(;22>PBMM1G-[HQ:%GMGOMY"S(6\M6$
M W#>3CC%9J:DE)+_ (&LE;YN+M][L6XN+:;_ *LG^"DK^>BN?2BL&&001G''
MM2U\3_LS?%;QC\'_ -D#Q%XR\7V>CZS:6>HW@T2QT9YQ=7=U)J,T3Q3-("!N
MN7 0J#A#E@2*[JS^,GQR^&OB3PM=?%KPSX+3P;XBU*#21/X5N;I[S2+B<[8/
MM(F^212Y5"T? ))R> :C)2DHKK;TN]EZ_P":[H)1Y5)]G+UM'=_U\KGT?H?B
M#2_$VG)J&CZE::M8.[QK=6,ZS1%D8HZAE)&5964CL00>15^O@OX%^//CIX5^
M!+:QX'\'>%=3\&:#J&L374&L7LZZGJRK?W$DAM!&/+C"@L@\W)+(V%QC/H/Q
M6_;0N4N?!FD_#^^\$Z+J'B'0(O$KZO\ $?538:?:VTI BB 4J\LK'>,(?EV9
M((/&<:BE%2[V_%-_DG]Q4J;C*2Z)O\';]5]Y]9T5\;1?MJ^*[WP*D6E:?X0\
M1^/;/Q5I_ARZ&@ZD;S1[Y;M',4]M.K[HP64@A]Q38V0>*^H_AP/&(\'6'_"?
M-H;>*_G^V?\ "-K,+$?.=@C\XES\FW)/?/:MH^\FUT_R3_)HR>ED_P"M6OS3
M(_%'Q8\$>"=6MM+\1>,?#^@:G= -!9:IJD%M-*"< HCN&8$\<#K6GXH\8:#X
M)TA]5\1:WIV@:6C*K7VJ7<=M I/0%W(7)[<U\]?&#X1_ [X7:+XP\4^/O#UO
MXVUSQ5?RS0QZM;1WVK7EQ(H2*QT_""10H"JBIRH^9FP-P\[^$_P=?Q!\2/A=
M\._BM80>(H_!_P //[4&C:B1=6JW<]XT($B."LC10HL8W C@X[&LHRE*T;:_
MA\+DUZI+\5LM])*,5S=/_ME%?)M_\/K;[*M/%VA:AX;'B&UUK3[G0&A-P-5A
MNHWM3$!DR>:#MV@ _-G%4O!OQ(\)?$6&YF\*>*-%\3PVS!)Y-&U"&[6)CR Q
MC8[2<'K7S#X1^ 'A/Q!\6/BU\*'BNK'X>:=J>A^*HO#MC*([-Y98I3+;/&5(
M^SN\*.8UVC*C& ,&_P" ?"'@G4OVL['4_@_X>TW0]!\,:7>Z?XIU;0;5;;3;
MVXEV>19H(P(Y98F5I'('RY52<\"HRYI)6WO^"N_Q]W[GU2)E'E3[JWXO3YV=
M_P .C9]33ZSI]KJEIILU];0ZC=I)+;6<DRK-,D>WS&1"<L%WID@<;AGJ*N5\
MD:!\,+[P!^V=X$O]<\6ZIXT\2:QX9UA[W4K_ &Q1*L<MJ(XK>W3Y((EWL=HR
M26)))-?6]5'6"EWO^#:_04O=DX]O\D_U"BBBF(**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "F2S)!$\LKK'&@+,[' 4#DDGL*?7S
MW^TYIW_"Q/'OPI^%NH7%Q;^%?$][>W>M1V\C1&]@LX!(MHSJ00DCN"P')"'D
M5,F]$MW_ %^"U*5NIZMX7^+_ ($\;ZM+I?ASQKX=U_4X03)9:7JL%S,@'!)1
M')&/<5J^*_&GA_P'I)U3Q+KNF^'=,#K&;W5KR.UAWGHN^0@9..!FO!OCI^R;
M\,(_A/KFH>&_">C^!_$>@V,NIZ3X@\/VD=C=VEQ ADC<RQA68909W$\$GKS4
MFI?#^P^.'PW\#?%/7?!X^(OB2'PO#-8>#=6F@BTR2YN8XGDD99495D[;FW!5
M'"[L&I<G:5OLVOZ.]K6UO[K5O1Z[)\NJ\[V]5;_-:^OS^@-#U[3?$VDVVJ:/
MJ%KJVF72>9!>6,ZS0RK_ 'E=20P]P:I>+?''ASP#IJZCXG\0:7X<T]G$0N]6
MO8[6(N>BAY& R<'C/:OG;]A>%=!MOB9X>OM';P7XC@\0G4+SP1&BBUT6*>)/
M)6W=&9)8W$;-O3:-P8!% &?3/BI\%_AQXD\4Q_$+XC1V>J:=H>E26B6?B0PR
M:19HSAY+DQ2KM$IPJEV.-J@  \U4WRI2Z-)O7;2_S[?B**NVGT=O76W_  3T
M32?%&C:]H,>N:9J]CJ.BR1F9-2M+E);9D&<L)%)4@8/.<<&J7@_XB>%?B%;W
M%QX5\3:/XE@MW\N:71[^*[6)L9VL8V(!QV-?"*^$;+4O"MS::%I%UX7^$'Q.
M^)6DV.G:*%DM//T]86:YF2(X,4-S) "JC;E,' ! KU_XA?!OPI\-OC]\,+?P
M/IL?@./QE9ZQX;U4^&8TLO,A%DTT4H55V^=&Z95RI.3SG&*5Y6<K>5NM^52L
M_G)1^]M:6'RI/EOW?R3:^^T6_P $W>Y]"Z;\6/!&M>*9O#.G^,O#]]XDA9EE
MT>VU2"2\0K]X-"KEP1WR.*W]6UG3]!LC>:G?6VG6@=(C<7<RQ1AW<(B[F(&6
M=E4#N6 ')KXS^,WP+^%OA:U\$?"_X:>%=-7XLQWMA<V6K:?;H-0TVW@F1YM0
MO[F-0P5D5Q\_^L=P%4X^7H/VT/A??WMOI_C+5O%NJ7UC9>)M"31_#<(6WL;(
MM>V\<LL@7FXE;,FUG.$#D =RT[\OG+EO\TKK[[>J>O1)JUWVC>W7KIVZ7_3:
M_P!<44451(4444 %4-+\/Z7H<E_)INFVFGR7]PUW=O:P+$;F<@*99"H&]R%4
M%CDX4>E7Z* "BBB@ HHHH **** .V\._\@:W_P"!?^A&M*LWP[_R!K?_ (%_
MZ$:TJ\Z7Q,[H_"@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /*OVEO^2=:1_V.?A/_P!2'3J]
M5KRK]I;_ ))UI'_8Y^$__4ATZO5: "BBB@ HHHH **** "BBB@ HHHH ****
M /%/AC_R4[XZ?]CA;?\ J/:/7I%>;_#'_DIWQT_['"V_]1[1Z](H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .!^/W@'4/BI\$_''@[29K:WU/7-(N;"VEO&984DD0JI<JK$+D\X4GVKI?!
M6BS^&_!N@Z3<M&]S86%O:RM$24+)&JDJ2 <9'&0*V:*%I>W6WX7M^;!ZV\K_
M (V_R1XM\=/"/QGU35(;WX9^(/!]UI<UH;._\)^.M.>33Y26)\]9H!YV[!"F
M-LH0,\&O,_ /[$$S_"[XK:+XROM"TG6/B(8)+FS\#Z>;72=(D@4>2UM&^&=A
M(/,9FV[CQQU/UK14J*2:[Z?C??U7RZ:#N^92[:_U_7J?(&L_L]_M#_%W2++P
M%\3_ !]X,?X<0SP-J%]X?L+A=8UR&)U<13B3$,.\J"QBZ$=&&0?9O"_PEU;0
M_P!I+QI\0)+BQ.AZSH.G:7;6\;N;A)+=YF<NI3:%(D7!#$\'(%>LT5=W=/JK
MOYM6?X$<JLUTT^5FG^:_K0^7O&?[)NO^-M$_:'TJ77;'2X_B-?6=YI=Q!OE:
M 000KLN$*@;6>'!"ELHQ^E>6^+OV2OVAOB)X/TG0-0U/X1^#])T6^L[Z#2/!
MVFW5M!J302HRBYD:/,84!F"QH06P"!P5^\Z*4?<<6NG+_P"2[?D5+WHN+Z\W
M_DVY\M_%KX2_M >*-5U?2++4OA3X]\#:A=//!#\0M#F>[TR-^/)C2W7RI@@S
MM=P&/\1[U9TK]DO4_"/@?X ^&-(UNVU&W^'>O+JNH7=_NA:Y0Q7 <0HBL!^\
MG^5&( 4?>)'/TW11'W$DNZ?_ (#JOZZ]127->_5-??O_ %TZ'RW\6OA+\?\
MQ1JVKZ18ZE\*?'O@74+IYX(?B%H<SW>F1OQY,:6Z^5*$&=KN Q_B/>O8?V??
MA''\"/@WX7\"1ZG)K']CVQB>]DC$?FNSM(Y5!]U=SMM7)P,#)ZUZ'11'W8N*
MZV_"]OS^?4<O>ES/^K_U_D%%%% !1110 4444 %?)5?6M?)5?49)_P O/E^I
MX&:_8^?Z!1117U!X(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>V?#K_D3=/_[:
M?^C&KQ.O;/AU_P B;I__ &T_]&-7D9G_  5Z_HST<#_$?I_D=)1117S)[@44
M44 %%%% !1110 4444 %<)\=_ E_\4/@SXU\(Z5-;6^I:UI-Q8V\MXS+"LDB
M%5+E58A<GG )]J[NBHG%5(N$MF5&3A)26Z/EW2]/_;"TG3+2QA;X'M#:PI C
M2'6"Q55"@G ZX%=#9_L]ZG\2/BHOB[XQZ5X1\36EGX<M=+T_1XH6O;.*\8B2
M^N!%<1X3,BHD9RS;%Y()Q7T#15[RYI:O?[TU^39*]V/*M%_P4_T/D_X_?L8M
MK?\ I'P=TOPEX)GU#1=1T#6[00'3[:\MKB(>4Y6WA8,\<JJP)7H2,]!5B#P5
M^UCK7A]/"^H>(_A5X6TF2U%D^LZ!;:C<ZA;Q[-FZ))BL9?'<D8/(Q7U116?L
MU9I[/I]_^;^\OG=TUNO^!_DON//--^!OAK3?@:OPJ2!I?#7]D-I#"3!D=&0J
MTA./OEB7S_>.:XW]EWX&^)_A3:^(-7\>ZOI_B#QIJYM;1[[33(8EL;2W6&V3
M]X =YP\CX !:0U[K16GVY5.LM_Z^;^]D?84.B_K]%\TCA_C1\*;'XS?#^_\
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M!]2\5^+_ !YKEGKWC[Q7);MJ#Z5&\5A:0P(4AMK=7.XJNYSO8!FW<C/)\_\
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M%_Z$:TJ\Z7Q,[H_"@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /*OVEO^2=:1_P!CGX3_ /4A
MTZO5:\J_:6_Y)UI'_8Y^$_\ U(=.KU6@ HHHH **** "BBB@ HHHH **** "
MBBB@#Q3X8_\ )3OCI_V.%M_ZCVCUZ17F_P ,?^2G?'3_ +'"V_\ 4>T>O2*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY
M*KZUKY*KZC)/^7GR_4\#-?L?/] HHHKZ@\$**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI_Y%_P#K4?\ "8_].G_D7_ZU'-/L%H=S$_LV\_Y])_\ OVW^%']FWG_/I/\
M]^V_PK;_ .$Q_P"G3_R+_P#6H_X3'_IT_P#(O_UJ.:?8+0[F)_9MY_SZ3_\
M?MO\*/[-O/\ GTG_ ._;?X5M_P#"8_\ 3I_Y%_\ K4?\)C_TZ?\ D7_ZU'-/
ML%H=S$_LV\_Y])_^_;?X4?V;>?\ /I/_ -^V_P *V_\ A,?^G3_R+_\ 6H_X
M3'_IT_\ (O\ ]:CFGV"T.YB?V;>?\^D__?MO\*/[-O/^?2?_ +]M_A6W_P )
MC_TZ?^1?_K4?\)C_ -.G_D7_ .M1S3[!:'<Q/[-O/^?2?_OVW^%']FWG_/I/
M_P!^V_PK;_X3'_IT_P#(O_UJ/^$Q_P"G3_R+_P#6HYI]@M#N8G]FWG_/I/\
M]^V_PH_LV\_Y])_^_;?X5M_\)C_TZ?\ D7_ZU'_"8_\ 3I_Y%_\ K4<T^P6A
MW,3^S;S_ )])_P#OVW^%']FWG_/I/_W[;_"MO_A,?^G3_P B_P#UJ/\ A,?^
MG3_R+_\ 6HYI]@M#N8G]FWG_ #Z3_P#?MO\ "C^S;S_GTG_[]M_A6W_PF/\
MTZ?^1?\ ZU'_  F/_3I_Y%_^M1S3[!:'<Q/[-O/^?2?_ +]M_A1_9MY_SZ3_
M /?MO\*V_P#A,?\ IT_\B_\ UJ/^$Q_Z=/\ R+_]:CFGV"T.YB?V;>?\^D__
M '[;_"C^S;S_ )])_P#OVW^%;?\ PF/_ $Z?^1?_ *U'_"8_].G_ )%_^M1S
M3[!:'<Q/[-O/^?2?_OVW^%']FWG_ #Z3_P#?MO\ "MO_ (3'_IT_\B__ %J/
M^$Q_Z=/_ "+_ /6HYI]@M#N8G]FWG_/I/_W[;_"C^S;S_GTG_P"_;?X5M_\
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MO_X^O^-'_".ZC_S[_P#CZ_XUVU%'MI![*)Q/_".ZC_S[_P#CZ_XT?\([J/\
MS[_^/K_C7;44>VD'LHG$_P#".ZC_ ,^__CZ_XT?\([J/_/O_ ./K_C7;44>V
MD'LHG$_\([J/_/O_ ./K_C1_PCNH_P#/O_X^O^-=M11[:0>RB<3_ ,([J/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /*OVEO^2=:1_P!CGX3_ /4ATZO5:\J_:6_Y)UI'_8Y^$_\ U(=.KU6@
M HHHH **** "BBB@ HHHH **** "BBB@#Q3X8_\ )3OCI_V.%M_ZCVCUZ17F
M_P ,?^2G?'3_ +'"V_\ 4>T>O2* "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y5^TM_R3K2/^QS\)_P#J0Z=7JM>5?M+?\DZTC_L<_"?_ *D.G5ZK0 44
M44 %%%% !1110 4444 %%%% !1110!XI\,?^2G?'3_L<+;_U'M'KTBO-_AC_
M ,E.^.G_ &.%M_ZCVCUZ10 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'4>B_"GXP6W@SPC\:_%?CG7KI=$T#QGJ,0FO)9)S;0*(!'!$O) W/M5%XRW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'E7[2W_).M(_['/PG_ .I#IU>JUY5^
MTM_R3K2/^QS\)_\ J0Z=7JM !1110 4444 %%%% !1110 4444 %%%% 'BGP
MQ_Y*=\=/^QPMO_4>T>O2*\W^&/\ R4[XZ?\ 8X6W_J/:/7I% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M87/S;8RV\JFX@!@*YFQ^&/B>\_X)SZ[X2@\/7T/B:6SU%TT>:V:&Y=OM\LH
MC8!MS+R!C+;ACK7V+10X?N^1/HU][;_4<9N,_:>:?W)+]#YMU"XU'XI_$S]G
M;Q='X.\0:38VYUB6\MM:TQX9],8VGEI]H7!$19E.TD_-D8ZUPOQJ^!_BGXF:
MI^TEI^D:3>0S:O'X=NM-FP;5=0>U3S)(X+AEV>9\@0-R%8KNXK[,HHG!2O;3
M_A[_ *$TW[-);V27W.Y^>?PN^'6K^-OBEX,C;3_VDYCHNKP:E?2_$G7(8='M
M#"2V^/="_P!J.X% J!"0^=R@YKZB_9I\.ZCX?NOBT^HZ7=::=0\=:C>6[75N
MT7VF%DA"2IN WH=I 89!QUXKVJBKC[NW9K[W%_\ MJ)E[WX?@I?_ "3/%/VC
MO!GBJ>]\%_$'P-IL>N^*?!E[-,-%DF6'^TK*XC\JY@21N%DVA&4GC*=#P*X+
M5/VB_B=\7X8/"OPY^%/CCP#KMU+&EYXH\::3%:66E0AU\V6(.76Y? 957;SD
M-C%?5%%2HV>^E[V_KH_\^Y7-Y:[?U]_^9\8?'#P!XHU3_AI9;/0-7U$ZK;>&
MTT^2&QD<W[18\WRMJXD*_P 6S.WOBO8?A=X;U'3_ -H[XT:K=:7=6UCJ%OHB
M6E]-;LD5SY=M('$;D8?:QP0"<$\U[=12Y%:P-W5OZZ?Y'Q?X4^'WB2R_9O\
M@7I+>&M5@OM,\?6]W=V)L)5EM+=;ZY8RR)MRD85E.X@#!!Z&M;P[\0/&G[-V
MO>.O"(^$'B_QS>:UXEOM;T/5M @233KI+MPZI=W)(^S,C$HQ93@*#TQGZZHI
MQBXMM/>]_FH?_(+\1RES;K_ATY/_ -O:/@OXWV/BSQ!\7/$UK\0_A[\5/&>F
M7EO:+X<T;P-J,B^'E4P+YL=W+&T91_M!D!ED&2H!VA0N=/X:?#_Q5I_[*_P!
MT.Z\*:S8ZOHGCJUEU#3I;*3S;2&.]N2TKC'$05E/F'Y2&!SS7W#11&/+:W1Q
M?_@+NO\ @_H*3<DT^S7WQ<7_ $OQZ9_B*-YO#^IQQHTDCVLJJBC)8E#@ >M?
M''[/_P"TMKGPV^"O@SP3/\!/B_>>(-)TR*Q9O^$9,%G),JX_UTD@V(3_ !,O
M'I7VO11RN[:>]OPO_F',K*ZVO^-O\C\\OB#^S;\0=/T'PE\1-9M/%Z^()M8U
M?6?$]A\,M1CAUJP-\L0C2V?!$XC2!(W13EMW!(&:Z?X$_ /_ (6==>/;C6-/
M^,":'K'AJ3P^E]\7=5B>\D:23?B*T$7F1K&R*XD,H!+<(>H^YJ*E4XI<JVLT
MO)-6M??;Y]VRO:2T?6][^=^:_P!_R[=SXZ^%7PO\>?&3X;_%35_'6FSZ#XVU
MOP^/!.GKJD+Q;(8+8K), 1GRYKJ263=SE0I&1BO"-%^$/B3Q%I^D^ K[1OVF
M7UI#;6MY8ZIXCMXO"\*HR;F2[:&2-XD #*HC8G:%'(S7Z>45:5IJ;\K^JN[^
M5VVWZZ6)YO=Y%YV^:2MYV227H?%&K?#7QM;^'_$_B'2_"E]K.H^'/B[-XJ@T
M.YC,#ZM9K&L9> N &.'9T89!*'&3Q76Z-XL\2?M)_'+X<:W;?#/Q;X"\,^"Y
M;V_O-3\9:>NGW-Q-+;- EO!%O9F0[]S-T^3'!QGZJHI4X^S2CNE;[U%1O_Y*
MG;OY:!*7-=][_<VW;_R9J_;SU/@'X-?&#Q9H?[/-]X%TGX.>)_%E_K=WK=MI
M&J:=!%+I$_FWMPC&\G+C[/M<N"'&"J@@X;CV'X6_"?6_AW\</A?87=I<7]GX
M?^&#:+<:Q' YM?M2W-L/+$I& Q"N54G.T=.M>W_"OX9Z7\(?!EOX9T>>[N;"
M&XN;E9+YU>4M//).X)55& TC <= ,Y/-==2I1]GRMZM6_",HK[N9LJI+G<K;
M-M_?)2_]M7XGS+X,\':U9_"W]I"VDT._@O-8U_7I[&%K1UDO4DM46-XAC,@8
MC"E<YQ@5\S7?P;\5?#?5K76]7L?CI;:5K^@:*8_^%070CEAN(+"*&6"^M67>
MKJ8R0Y.,/MQG-?IG14QI\MK=HQ^44U^-[_(?M+MWZN3_ / FG^%K?,^(O@I\
M'=?\*^-O@YJ5QX>\8Q02Z[XAU:[E\67J:I?6PFLDBBENIHH46%Y=F=C%B"Q&
M\G@>JZ=X'UJ[^+'[1[1Z3<P0Z_I.FV^GW4T#1PWDHL9HV"2$!7VL54D$XXS7
MT113J4U4@X/:S7RM8F$G"7,M]_\ R;F_,\:_9#UB_P!0_9^\(:;JOAG7?"FI
MZ!80:)=66OV36LKR00QHTL8/WHF/W6[X/'%<G\1&\7_ 'XU:Y\1-!\&:KX_\
M'>*[.UBUW3O#Z++J=C=VP,<4\4)(\Y'C8*5!R"F<@<'Z1HK6HY5)^TO9_G??
M[_P=NQG!*$>3I_5OZZGRS-XS^*7[35QJ5CHO@[7OAAX 31]0MKO_ (3"RBMK
M_6+J:W:.&%8&W-#$C-O,@8;L 9ZBO-]+\3?$'QUX'^!O@Z;X0>+M E\&^)-%
MBU[4M3LMEN/LP,>^V"EFEB."[2D*B  ;FW U]W45$8\LE+SB_5Q;:_-_AYWN
M4N:+7DU\I*S_ "_K2WBOPQ\.ZCI_[2WQJU>YTNZMK#4(=$6TOI;=DBN?+MI
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
MJ_:6_P"2=:1_V.?A/_U(=.KU6O*OVEO^2=:1_P!CGX3_ /4ATZO5: "BBB@
MHHHH **** "BBB@ HHHH **** /%/AC_ ,E.^.G_ &.%M_ZCVCUZ17F_PQ_Y
M*=\=/^QPMO\ U'M'KTB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^2J^M:^2J^HR3_EY\OU/ S7['S_0****^H/!"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KVSX=?\B;I__;3_ -&-7B=>]? UK&Q\&RF_
MCC#37;R1EX]Y*;47/ ./F5N/:O(S32@GYGHX#6K;R-:BNM_M#0_[L'_?@_\
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M<E176_VAH?\ =@_[\'_XFC^T-#_NP?\ ?@__ !-'M'_*PY%W.2HKK?[0T/\
MNP?]^#_\31_:&A_W8/\ OP?_ (FCVC_E8<B[G)45UO\ :&A_W8/^_!_^)H_M
M#0_[L'_?@_\ Q-'M'_*PY%W.2HKK?[0T/^[!_P!^#_\ $T?VAH?]V#_OP?\
MXFCVC_E8<B[G)45UO]H:'_=@_P"_!_\ B:/[0T/^[!_WX/\ \31[1_RL.1=S
MDJ*ZW^T-#_NP?]^#_P#$T?VAH?\ =@_[\'_XFCVC_E8<B[G)45UO]H:'_=@_
M[\'_ .)H_M#0_P"[!_WX/_Q-'M'_ "L.1=SDJ*ZW^T-#_NP?]^#_ /$T?VAH
M?]V#_OP?_B:/:/\ E8<B[G)5UOA+_D&R?]=3_P"@K1_:&A_W8/\ OP?_ (FM
M'3IK2:%FLPHBW8.Q-HS@=L?2LZDFXVL7"*3W+5%%%<QT!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!Y5^TM_R3K2/^QS\)_^I#IU>JUYI^T'
MJU]HO@/2KC3[RXL+A_%OABV:6VE:-FBEUVPBEC)4@E7C=T9>C*S Y!(KTN@
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M ")NG_\ ;3_T8U>1F?\ !7K^C/1P/\1^G^1TE%%%?,GN!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !76^$O\ D&R?]=3_ .@K7)5UOA+_ )!LG_74
M_P#H*UC5^$UI_$;=%%%<1UA1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@DT1)QD<@@D=1G((!'WHW7G?RM)Q_/\ -!+W7;TMYW2E_7HSTJBBB@ HHHH
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MVM%%%(84444 %?)5?6M?)5?49)_R\^7ZG@9K]CY_H%%%%?4'@A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%>+:M^V5\'M#U:\TV]\7^1>
MV<[V\\7]F7C;)$8JPR(2#@@\@XKO8/BMX3NM!T36K;6[>[TO6KN.PL+JV#2I
M-.Y(6/Y0=IRI!W8P1SBL85J517A)/T??;[S25*I#XHM?(ZRBBBMC,**** "B
MBH+V]M]-LY[N[GCMK6!&EEFF8*D: 9+,3P  ,Y-)M15WL&Y/169X:\2:=XPT
M"PUK2+G[9IE]$L]O<!&3S$/0X8 C\17"_$3]I/X<?"?Q NB>*O$7]E:FT*W
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MM:Z/X<UZ^BLKV58;.\@\J69BZ(5"-R2>% ZU[E\/?B]\;?$GC'3=.\4_L_\
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M?:LNLZOXMU"*X,BVOD"TM(8A';VP^=]VP;R7^7<7)VBAQ=10YNB3?^)):?\
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M? \2_';XC?9_CE/X2^S^*KW0=)T.[T&QTR!+N)3=0%[B6$J%>X7&9%#$[M@
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M HHHH \J_:6_Y)UI'_8Y^$__ %(=.KU6O*OVEO\ DG6D?]CGX3_]2'3J]5H
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M[Y[5XSJ/[(OB;4?!Y\'/\7M3'@^UV_V;I7]DP P;'#1K-*&#3JN/NG:,@'C
MI3A7]Q13TOU_O.U]=?=MNI>=GJ73G1<I.=M;=/+6VG?T\KF1\>OC3XL\'_%&
M\TZ\\;3?"_PU%# =,OCX8&J6VINR;I \O)0JWR[57.!GTS2^)7[4-_:R>$]$
M?XBZ#X*-YHRZG?\ BC2]+EUB"XE,A016L>TX7*.6,@!'3J.?8?'7PA\::YKU
MQ?\ AGXIZAX8M;V-$O=-N-,AU*V9E4+NA69OW.0,D+D$\UAQ?LN-X4TS1F\
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M&%;GCHK_ ('G7[,O_)OW@#_L#P?^@U0\._\ )T7C3_L6M,_]'7-=K\,O!?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?H?]Z#_O^?\ XJCVJ[,/9ON<E176_P!GZ'_>@_[_ )_^*H_L_0_[T'_?\_\
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M'_>@_P"_Y_\ BJ/[/T/^]!_W_/\ \51[5=F'LWW.2HKK?[/T/^]!_P!_S_\
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MH93\Q&<\9KHZKJI]MOO_ ,_Q\R;*SCWW^[_+\/(9'"D42Q1HL<:KM55&  .
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA4/-"\:ENF2I S7SQX%\'_M%_#_P?H_AO3I?A?-8Z7;):PR73:BTK*HP"Q4
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M\0>/_'UO9ZJMQ!# 3K\4=U#:I&I"Q6L;(2&=B3A<LS-QZ5Y OA.[L?@GX/\
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M<>U+0 45G:]XBTGPKIKZCK>IV>CZ?&R(]W?W"01*S,%4%W( )8@ 9Y) K1H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /*OVEO^2=:1_P!CGX3_ /4ATZO5:\J_:6_Y)UI'
M_8Y^$_\ U(=.KU6@ HHHH **** "BBB@ HHHH **** "BBB@#Q3X8_\ )3OC
MI_V.%M_ZCVCUZ17F_P ,?^2G?'3_ +'"V_\ 4>T>O2* "BBB@ HHHH ****
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MO?!OXQ?#7QUXFUOX+^(?"+Z+XGO6U2_\.^-;:X\FUO651+/;RVWSGS-H)5N
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MXDCN+<QF9&D0EY"PCRC84*N1R2#S/Q'_ &/?BK\7-4N=*\577PKU'2YI0O\
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MI\"_BIX=^.[_ !$\>ZGX,EAN/#C:'_9/A6VFMH;#;<)+&(0ZYD4_O"S.006
M ('%03E*T_/_ -(T^?-VZWUY;()N*C>'E_Z5JO2U[>5M+W9X]\$?CYXU^!/[
M*<.L^)8O"M]<:MXEN=*\.*;Z6TB%Q)>W1NI+^XF^2.)'61E((RB@$ACFNY\
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M?BO7)F>]\0:S)JTUZT9.4MU9458X4 4+&BJORC.2,UZ%XF^$GQLT7Q='X^\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KVSX=?\ (FZ?
M_P!M/_1C5XG7MGPZ_P"1-T__ +:?^C&KR,S_ (*]?T9Z.!_B/T_R.DHHHKYD
M]P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAI?A_2]#DOY--T
MVTT^2_N&N[M[6!8C<SD!3+(5 WN0J@L<G"CTJ_10 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50;P_I<FN1ZVVFV
MC:S';M:)J)@4W"P,P9HA)C<$+*K%<X) /:K]%'F 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !76^$O^0;)_P!=3_Z"M<E76^$O^0;)_P!=3_Z"
MM8U?A-:?Q&W1117$=84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.2HKK?\ A$K/_GI/_P!]+_A1_P (E9_\])_^^E_PH]K$/9R.2HKK?^$2L_\
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M)6?_ #TG_P"^E_PH]K$/9R.2HKK?^$2L_P#GI/\ ]]+_ (4?\(E9_P#/2?\
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MK-N^<@GH!Z>U9U*D91LBX0<7=EJBBBN8Z HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \J_:6_P"2=:1_V.?A/_U(=.KU6O*OVEO^2=:1_P!C
MGX3_ /4ATZO5: "BBB@ HHHH **** "BBB@ HHHH **** /%/AC_ ,E.^.G_
M &.%M_ZCVCUZ17F_PQ_Y*=\=/^QPMO\ U'M'KTB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^2J^M:^2J^HR3_EY\OU/
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M8GVGX9_$+2?BOX"T3Q=H9F.E:M;K<0K<)LE3)(9'7)PRL"IP2,@\FO+OB/\
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MX8_\E.^.G_8X6W_J/:/7I%>;_#'_ )*=\=/^QPMO_4>T>O2* "BBB@ HHHH
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M0?#'3/#.H376?&K:-._BAHIG9B9.!$\FUBFXL2!C# @8]$\"?LM^,?#O@?\
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M_HST<#_$?I_D=)1117S)[@4444 %%%% !1110 4444 %%%% "=>*YWP!\/=
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M$KRM*6N_X;_F8:_ SP0L'DC1,1_\)$?%>W[7/_R%"VXW'W_4YV?<_P!FMYO
MNAMXX7Q@;+/B-=..E"\\U_\ CU,@D,>S=L^^,[MN[MG'%;U8/A76-;U9M9&M
M>'_[ %KJ$MM8G[:ES]MM5"[+GY!^[WY;]VW(V\]:$ELNG^2C^5EZ>2$[N[?7
M_-R_/7U\V<5KG[+_ ,,?$O@31?!NI>%H[GP[HUXU_I]L;RX5[>=G=V=91().
M6=C@MCGIP,3^)?V;?AMXQ\+:[X=UKPM!J6CZWJCZW>P3SS%GO7 #3H^_?$Q
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MPE_R#9/^NI_]!6N2KK?"7_(-D_ZZG_T%:QJ_":T_B-NBBBN(ZPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\
M:>&8O&7A/5M$F(5+ZW>'<PSM8CY6_ X/X5\1^"]?B\(7FM>!_&5O+_8%[-Y%
MZBG]Y8W"G"W$?TXSZC!YQ@_>U>%?M$? 23Q\H\0:!'&NNPIMGMSA1>(.G/\
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MK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !T:7!Y;L>%Z9/U+7Q-6I*K-SF[M]3]2HT:>&IQHT8J,5LD)2TE+6)L%%%%
M!1110!Y5^TM_R3K2/^QS\)_^I#IU>JUY5^TM_P DZTC_ +'/PG_ZD.G5ZK0
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MBBB@#Q3X8_\ )3OCI_V.%M_ZCVCUZ17F_P ,?^2G?'3_ +'"V_\ 4>T>O2*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY
M*KZUKY*KZC)/^7GR_4\#-?L?/] HHHKZ@\$**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O;_ (8SR6?@VR\B1H/,:1W\MBNYMY&3CJ< #Z 5XA7MGPZ_Y$W3_P#M
MI_Z,:O(S3^"O7]&>C@?XK]/\CK?[3O/^?N?_ +^-_C1_:=Y_S]S_ /?QO\:K
M45\Q9'NW99_M.\_Y^Y_^_C?XT?VG>?\ /W/_ -_&_P :K4460799_M.\_P"?
MN?\ [^-_C1_:=Y_S]S_]_&_QJM119!=EG^T[S_G[G_[^-_C1_:=Y_P _<_\
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M;_&JU%%D%V6?[3O/^?N?_OXW^-']IWG_ #]S_P#?QO\ &JU%%D%V6?[3O/\
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MXW^-']IWG_/W/_W\;_&JU%%D%V6?[3O/^?N?_OXW^-']IWG_ #]S_P#?QO\
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M]JOOVH/C-X;O[72[^R^&7@V=K];[4+=[<:M?CY8Q'&X!*)C.2/7U%?3E%%,
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M/*S\NS./FKX\^!GBC1_",_[%=_KFJV6C6+>&M<@%SJ%PD$9D=(U1-S$#<S$
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M7P]_;(\+>.?&NF>&+_PIXV\"WVL;AI$_C#0VL+?4V W;8)-[9)7Y@&VY&.Y
MJGXF_;D\ >%_%FHZ7)I7BK4-#TJ\_L_5/&&G:,\^AZ=< [6CFN0V058@':I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >5?M+?\DZTC_L<_"?_J0Z=7JM>5?M+?\ ).M(_P"QS\)_^I#I
MU>JT %%%% !1110 4444 %%%% !1110 4444 >*?#'_DIWQT_P"QPMO_ %'M
M'KTBO-_AC_R4[XZ?]CA;?^H]H]>D4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %9UOX;TBUUZ[UR'2K*'6KN%+>X
MU*.W1;F:)"2B/(!N95+-@$X&3CK6C7SQ\0/VHO%%O\1M<\$?"SX2:I\4=9\/
M>4-:N3JMOI%C:/(@=(EGF!$DFUE)4#@$<GG"NKI=1VT;Z'NMSX;TB\URRUJX
MTJRGUFQCDAM=1DMT:XMXY,>8D<A&Y5;:N0" <#/2H+'P9X?TO2KW3++0M-L]
M-OI99[NS@LXTAN))23*\B 89G))8D$L3SFO-O@9^T-)\5M<U_P *>(_!^I?#
M[Q]H$<,VH^']1FCN%\J7(2:"XC^6:,E2-P Y[5[%5.-EY?U^OXDIZ^?]?I^!
MR?AWX1^!O!\FGR:#X+\/:(^G&9K)M.TJ"W-J90!,8RB#87"J&VXW!1G.*V]+
M\-Z1H=YJ5WINE66GW6I3?:;Z>UMTB>ZE"A1)*R@%VV@#<V3@ 5HT4AG&M\%_
MA\WBI_$Y\">&3XEDD,KZR='M_MC.>K&;9O)]\U?7X;^$5\'_ /")+X6T4>%=
MK)_88TZ'[#M+%B/(V[,%B21CJ2:Z.BE;2W0?6_4YWP[\.?"?@^XAN-!\+Z+H
MD\-H-/BET[3X;=H[8.7$"E%!$8=BVP<9).,U1N?@YX!O/%R>*KCP/X;G\4)(
MLJZW)I-NUZKCHPG*;P1V.:["BJOK?J3Y&;)X;TB;Q!#KTFE63ZY#;M:1:FUN
MAN8X68,T2RXW!"P!*@X) --L_"NBZ?J&K7UKH]A;7NK%#J-S#;(DEZ578IF8
M#,F%^4;LX''2M2N ^%_Q?M/BSI/BN]T?3;F+^P=;O="\JZ9%:XFMMJLPP2%5
MF) R>@!.,X$Z6:[)OY75_P 6BM='W:7SL[?@F:5_\(? FJ:#I6AWO@KP[>:)
MI+!].TVXTJ![:S8=##&4VQD>J@5LGPKHC:U=ZP='L#J]W;+97%_]E3SYK=22
ML+R8W,@+,0I.,D\<U5\!ZQKGB#P?I6H^)?#W_"*:[<0A[S1?ML=Y]DDR?D\Z
M,!9.,<@8YK>JI)W:?]="4[I-?UU.1\(_!_P%\/\ 4KC4/"_@CPYX;U"X7;-=
M:1I-O:RRC.<,\: D9]377444O(84444 %%%% !7R57UK7R57U&2?\O/E^IX&
M:_8^?Z!1117U!X(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>V?#K_D3=/_ .VG
M_HQJ\3KVSX=?\B;I_P#VT_\ 1C5Y&9_P5Z_HST<#_$?I_D=)1117S)[@4444
M %%%% !1110 4444 %%%% !1145U/]EMI9O+DE\M"_EQ+N=L#. .Y-)M)78T
MKNR.7\$?#/2_ .L^+M3T^>[FG\3ZI_:UXMRZLL<ODQQ;8]J@A=L2G!+')//:
MN&\4?LK>%?%VL^)[^]U/6E3Q)K.F:SJEE%-"()VL5 B@(,1;R6*JSC=N)489
M1D5Y]>?M_:9IVIZ?IMW\$OC/:ZCJ!D%G:3>$U26YV+N?RT,^7VKR=H.!R:]Z
M^%_Q"_X6?X/M]?\ ^$:\1>$O.DDC_LOQ18?8KY-K%=S1;FP#C(.>12C9V<?L
MI?<K6^ZR^X<KJ]^M_P ;W_4V/%7AFP\:>&-6T#5(O.TW5+26RN8^[1R(48#W
MP37#_"_X Z+\*M:35;'5]:U6]70;+P[YFK3Q2%K:U:1HF.R-<O\ O2">A"KP
M#DGTVD)P":-(OF_K9K\F_O$]5RO^MG^B^X\^\2?!'0O$7Q.T[QZMWJ&DZ_;:
M=/I%RVGR1I'J-I)R(KA61MP1LLA4J03U(XK;^&?P_P!.^%/P_P! \(:3-=7&
MF:+:)96\MZRM,R(, N5503] /I7.>&/CKIGC+P)X9\6:/X?\0W^GZ[J?]F1P
MV]DLDUJ?.DB:><*Y"0JT9+."< CCM7I5.*23Y?ZZ_P#MS?S"5V]=_P"E^EOD
MC!\0>$_^$@UKP]J/]LZMIO\ 8]R]S]DT^Z\JWO=T31^7<I@^8@W;@N1AE4]J
MA^)'@2P^*'@'Q!X1U6:YM]-UJREL;B6S95F6.12K%"RL V#QD$>U=)12E%2B
MXO9C4G%J2W15TO3X])TRTL869H;6%($:0@L550H)P.N!7.-\-=,;XJIX_,]W
M_;*Z,=#$&]?L_D&83;MNW=OW#&=V,=N]<9\;/VEM+^"7B+0-!F\'>,?&>K:U
M;W%U;V?A#2UOY5CA*!V=#(K 9D7D CUQ5+X7_M:>%OB5XR@\)7F@>+/ 'BFZ
MA>XLM(\:Z0VG37L:<N8<LRN5')&<XR<8!Q2E[2?,M7K^J?Z_B3R\D>6VFGZ-
M?H:FJ_LR^#]=\$>./"NHMJ-WIGBW6)-=NW-P$FMKIVC96@=%&S8T2,N=W(.2
MP.*Y3P1^Q3X6\&_$#0?&]QXQ\=>+/$^C&98=0\3ZW]N:2"2)XVMW#1@>6 [,
M H4[NY'%?0E84WC?18/&UKX1>] \0W-A)JD5GL8DVT<B1M)NQM'S2*,$Y//'
M!J(Q2:2]%\E_DONWT*=Y)W\V_G_P7]_F>%']@WP,U\\+^*/';^#6F\W_ (03
M_A(I1H0&[=Y8MP-VS=SMWX_#BM;QI^QIX5\4^+=0U_2?%?C?P#)JD@EU2P\&
MZZVGV>HR!0I>:(*PR5&"5VYR2>3FO?**.6-K6#FE=NYA^!_!.C?#GPCI7AGP
M]9+I^BZ9 +>UMU8MM4>K$DL222222223UKP&\_82TA_%'B/7=-^+OQ8\.W.O
MZA)J5]#H?B2.TA>9SG[JP<@#"C))"J!GBO4?B%^T!X4^&7Q$\%^#-9DN1J_B
MJ5HK1H$5HK?!5%:=BP**\CK&I .7.*])IM*H_:/7=7^Z_P"@:P7)Z/\ .WZG
M,?#7P-_PK?P;8>'O^$@UWQ3]D\S_ (FOB6]^V7TVYV?]Y+M7=C=M''"J!VKC
M-;_9I\,:]XVU'Q1<7^K)J%]KNE^()8XYHA$+BPB,4*J#&3L93E@223T*]*[[
MQMXTT;X=^$]3\2^(+P:?HVFPF>ZN2C/L0$#.U02>2!@#O3-6\7#2_$GA[2%T
M?5K]=9\[&HV=KYEI9>7'OS<R9'EA_NKP<MQQ5-WES/?_ (-U^*3^0K63[.__
M  ?S_$HO\--,D^*B^/S/=_VPNC'0Q!O7[/Y!F$V[;MW;]PQG=C';O7G6I?LA
M^%+WP#X/\+VVO>)]';PGJ$VI:7K6EWZ0:A%)*\C2J9!'M*-YK*1M!P ,]<^Y
M5@^%?%G_  E3:R/[&U;2/[-U"73\ZK:^0+K8%/GP<G?"V[Y7XS@\<5*2TBNF
MOXW_ /2G<'?5OKI^%ORT/,/B-^R/X.^)NM>(-9U#4O$&GZUJUU87T6I:3?+;
M7&FW%I$\44MJZIE&*2.&W;@<Y &!3?A'^R3X8^#_ ,09?&UCXC\6^(/$MSI[
MZ;>W_B/5?MTE[&SHZM*60'<GEJJ[2H SD'K7M]%$8J#YH_UI;\M DW)6?]6/
M";/]C?P+;^%_%7AJXOO$&H>']<U,:O!I]UJ1V:+="1Y!)IY55: [W+'YFSWR
M"<S_  W_ &2O#'@+7I-;U3Q)XO\ B-JWV6:QM[KQQK+:D;2"4!9HXEVJJAP,
M$X)(R,X)%>I:;XWT75O%VL^&+2]$VMZ/!;W%]:A&'DI/O\HEB-IW>6_ )(P,
M]16[24(I62TM;\+?EIZ:%2<KV>^_WZ_\'\3Y@N?^">WP]NK)M-E\2>.)M"AE
MBETO0[C73/8Z.R2*^;2*1&"$A2A+;CM=@",YKZ?HKC?AC\5-)^*UCKMUI%O>
M6\>C:S=Z'<"]1%+3V[!79-K-E"3P3@^H%4OY%Z_DK_D0_P"9^GYO_,\\^)'[
M'_A/QYXJOO$NE^(O%_PZUS4O^0G=^!]9;3O[1P, SIM9&(_O!03W)KC=-_X)
MZ^#/#_A'Q+X/T3Q;XLT?P?XEMH8]6TVWNH'DGGBD5EG6:2)BA8!E=0-K!AP,
M5[UI/Q,TO6?B9XA\#PP7:ZMHEE:7]S-(BB!X[@R! A#%BP\ILY4#D8)[4KGX
MR:!8_$[5/!%W]HM+_3-!'B*ZOYPBV:6IE:,Y??N# J2<K@#G/:LN6FE;H[_<
MKM_)6;^1IS3OYJWWNUOGJOO/,/"?[&<?A'7-'U&'XU_&+4(=,N(9TTW4/%8D
MLYEC8$121B$;HR!M*Y&02*]1^-7PETWXY?#?5O!6LZEJFEZ7J8C6XGT>9(K@
MJKJ^P,Z.NTE0""IR"17E&A?MW>!=9U[2K>?PWXVT/PYJ]RMKIOC'6- >WT6]
M=SB+RYRV<.?NED ]<"OH?4=0M=(T^YOKVXCM+.UB::>XF8*D<:@EF8GH  23
M[5<N65/WOA_J]_PW)CS1G[N_]6L?/WA/]C./PCKFCZC#\:_C%J$.F7$,Z:;J
M'BL26<RQL"(I(Q"-T9 VE<C()%.\3?L-^ /$_BS4M4DU7Q7I^AZK>?VAJG@[
M3]9>#0]0N"=S236P7)+, 3M8 D=.M5]"_;N\"ZSKVE6\_AOQMH?AS5[E;73?
M&.L: ]OHMZ[G$7ESELX<_=+(!ZX%;'Q/_;%\(?#'QC?^'/[!\6^++K28TEUJ
MY\+Z.U];:,C#<&NI PV?)\V!N( Z=J3<=)-]_P!+W_!N_DQVEK%?UNE^J5O-
M&7XT_8GT3Q;\2-:\:V7Q)^)'@[5-5B@@F@\*ZY'86ZPPH$CB55@+;% )"EB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?@'2OAU^TE\('\)?!SQ5\&]&\3:K/I6I2ZUXE,TFN6\D!+PRVAGE=0,YW;@
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MY+%LD!0W'##)S]-T[_NU%[IO[K*WZ]OU9O.ZVLE\[O\ X']:(HHHJ"@HHHH
M*^2J^M:^2J^HR3_EY\OU/ S7['S_ $"BBBOJ#P0HHHH **** "BBB@ HHHH
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MGB;[78S[D9/WD7E+NQNW#GAE![5[G6NBBDNG^=_Z_!)&;OS-L**** "BBB@
MHHHH **** "BBB@ HHHH *ZWPE_R#9/^NI_]!6N2KK?"7_(-D_ZZG_T%:QJ_
M":T_B-NBBBN(ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
MJ_:6_P"2=:1_V.?A/_U(=.KU6O*OVEO^2=:1_P!CGX3_ /4ATZO5: "BBB@
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M*]1_X9W\1_\ /[I?_?V3_P"-T?\ #._B/_G]TO\ [^R?_&Z/K^&_G0?5*_\
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MZ7_W]D_^-T?\,[^(_P#G]TO_ +^R?_&Z/K^&_G0?5*_\C/+J*]1_X9W\1_\
M/[I?_?V3_P"-T?\ #._B/_G]TO\ [^R?_&Z/K^&_G0?5*_\ (SRZBO4?^&=_
M$?\ S^Z7_P!_9/\ XW1_PSOXC_Y_=+_[^R?_ !NCZ_AOYT'U2O\ R,\NHKU'
M_AG?Q'_S^Z7_ -_9/_C='_#._B/_ )_=+_[^R?\ QNCZ_AOYT'U2O_(SRZBO
M4?\ AG?Q'_S^Z7_W]D_^-T?\,[^(_P#G]TO_ +^R?_&Z/K^&_G0?5*_\C/+J
M*]1_X9W\1_\ /[I?_?V3_P"-T?\ #._B/_G]TO\ [^R?_&Z/K^&_G0?5*_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIX&:_8^?Z!1117U!X(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(5;!X!SDGCZ)^.GP/D^+B>']2T?Q/>^"?&7ARXDN='\06,"3F!I$V21R1/\
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M5@Y49077FLNMFE9-W[WOOHUJ849KFA-_W;OINV]/2W;T/(OV,_\ DU7X6_\
M8!MO_0:\=\9?''XHCPSK8\-:Y9IKP^+@\)V#ZA91-;I9,% AD"J&*@G)8'S,
M=&K6\&?LJ_'7X>^%=*\-Z!^TU]@T72X%M;2U_P"$!L)/*C48"[GE+'ZDDUVM
MK^RS-'9K%<>+?M-P?'T?CJ2?^S0F]E"@V^T2X&2N?,'3/W*VG^\K\[TBVO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=;X2_Y!LG_74_\
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M:*** "ODJOK6ODJOJ,D_Y>?+]3P,U^Q\_P! HHHKZ@\$**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH [;X2_P#(R7/_ %Z-_P"AI7K5>2_"7_D9+G_KT;_T
M-*]:KY7,?X[]$>_@OX1P/QB^.W@;X!Z'9:QX\US^PM.O+G[)!-]DGN-\NUGV
M[84<CY58Y(QQ7+_"_P#;'^#?QF\11Z#X1\<V>HZS*"8K*>WN+22; R1&)XTW
MD $X7)P">QK,_:/_ .2F? #_ +')O_3==U2_;JT/2YO@'J7B.:WA'B'PY=V>
MI:'??=G@O%N8@@C?J"^=N/\ :]A7D0D]92V4K>>T7?S^+;K:QZ3BFU!;M7\M
MY+Y+3<^AJHWVN:=IE]I]E>7]M:WFH2-%9V\TJK)<.J%V6-2<L0JLQ Z $U\=
M?M,_'7QSI/Q4U'PSX;^)P\*R:?96\\.@^$?!LGB;5KAY$+-]J\Q%AM^0-BJY
M8K\QQD5QK>)OB-^T)J'[*WC&'QK#X1U35I=3B9(-%AN$BN88;@33A9&_Y:Q)
MY?EDX0L6'(IQES:I:72^^ZO^'KW0G'E3;_E;_"]OU^_K8_06BOS]_: _:;^(
MV@^-O'4GAGXH)&?#%S*D7A7PEX)?6X/+B0/_ ,3#4)E187ZB01%A&.Y8&OMW
MX9^*9O''PY\+>([F%+>XU;2[6_EAC)*HTL2N5&>P+4Z<O:0YUMI^-[>71^G4
M52+IR47Y_A:_YHA^(7Q2\*_"FRTN[\5ZQ%H]OJ>H0Z7:221N_FW,N=B?(IQG
M!^8X48R2*ZNO@3]K#XS?"7Q5^T!K?@CXE^*5T'1?#7AFYLK4"PN;HMJM_& 9
MAY*/@P0A,;L?-*V.AKHM,_:>\9^//V4_A7XA\":S8Q>-+_Q/8>%M1GOK<2V\
MLNYHY#(I4,$D CE^7:X#X!!J*=3GC=:W:2MYRY?SL[]I+YU4AR/731W^2YM/
ME]S3/MFN3U3XJ^$])T_2+^;7+:6RU;5%T6RN+3=<1RWC.T8AW1A@#O1U). "
MI!(KQ+X<:K\7?#WQC\4?"WQA\0;/Q5)?>&&UW1?$L.@PV<MA*9C 4,",4=48
MJXW$EL8)ZBO'OV=]:^('PO\ @+X NCXX_M.SU_XBII(L_P"R+>'[/;M?W:72
M;\,7\YU\S/!3.U3BJC+F<%TE;_TM0:^3OKMU5]B9+EA)]5_\@YW^>FGJG8^^
MJP=)\<Z)KGBK7O#=C>^?K6A"W;4;7RG7R!.A>+YBH5MRJ3\I.,<XKYPM]8^/
M'QM\1>,/$?@'QYH'@_0/#VMW.B:9X;U#1ENX]6:V?9+)=W/^LA#ON \H$A<<
M9Y,'Q?\ CEX\\*:?^T:]AK"6=SX1TO1[C1UCMX9%LYIXBTQ!>/\ > M_ST!Q
MV J?:+D4WM:_G:UT_FNF_>Q:IMS]FM[V^=[/\?\ @7/K2BOE+5/$7QS^#?B#
MPAXO\9^--$\3^%/$.LVFDZGX7LM'2W71OM3B.)[:YSYD^QV4,9 ,@G"\_+Y5
M^T!^TW\1M!\;>.I/#/Q02,^&+F5(O"OA+P2^MP>7$@?_ (F&H3*BPOU$@B+"
M,=RP-#J**N_._E:S?KNMKBA!U+<O6UOG>WY/<^])-<TZ/6H='>_MEU::![J.
MQ,JB9X595:0)G)4,Z@G&,L*O5\5^'E\<?$7]L#X9>+H?&B:-9ZK\/HM:FTB/
M2(9E%J9K8W%D)6.[$DC!_-^\FW:,@UP/Q'_;:O\ 4/B=XQM%^.NE_"*T\.ZK
M/IECX=F\&3ZP^H^2=K27-PJ,(U>16 $1R%/(R!ERFH64]'[W_DLN6_GZ;[Z6
MU%&//K';W?\ R97MY?EYWT/T2KGM ^(&@>*/$WB/P_IE_P#:=7\.RPPZI;^3
M(GV=Y8_,C&YE"ME.?E)QT.#7RKX7^/WQ(_:J;P?HOPX\2Z;\.'F\.#7]<U_^
MS5U-O-^TR6H@MH)L+L,D$C$OA@"HX((/3?LCV7BK3OC1\?;;QI<V-_XCBU#2
M$N+W38S%#<J++$<H0D["R;69<X#%@.,5I&[DT^B?SM)1_P _^&(>R[Z?*ZOK
M^'ET>I]2T444 %%%% !1110 4444 %%%% !1110!XW\6OVP/A'\"_%*>'/&_
MBW^Q-9>V2[6V_LV[N,Q,6"MNBB=>2C<9SQ6I\/?VG/AA\5O"VM^(O"GBZUU?
M2]%A:YU%HX98YK:-59B[P.@DQA&P=O.TXS7B/CKXS?\ "G?VRO%UQ_P@OC3Q
MQ]N\(Z5'Y7@W2/[0DM]MQ=G=*-Z[0<X!YR0:H32:U\5M:^+'Q5D^'^N?#K0E
M^']YH4<?B6U2TU'59L/*99( 2RK$J!5+'G?P3@@<KJ25&53>RG\N7FM?O>R7
M3?R.A4TZBAYQ^?-RW]+7;^1]>^'M>L/%6@Z;K6ES_:M,U&VCN[6?8R>9%(H9
M&VL 1D$'! -:%?$'PW\2_&CX9^&?@/XDU7Q5I-WX(\22Z3X>D\&PZ4@-C!-;
MA8;@7>[S))?D4L.%!<@ @5>_:>^.?C?1OBQJGA?PQ\3QX8;3;.":#0O"/@V3
MQ-JURTBEF^U>8BPVW0;%5RQ4[CC(KJK.-.32Z-KS5M?GHT]+_F<]*+J13?9/
MRU=OS[GVC17PEXP_:H^)>J?LT_"?QI;W\W@VTUPW0\3>,-+\.C5CI?D,R1L;
M5FVJLK*Q9CG;C [ U)OVV-6\*_L_SZK'\4_"GC>^NO$%OHMEXP72)[:2P@EC
M9Y)[_350,KJ(I0@C#*^%/.&S$I*+DG]EV^]I?+5];=]C10;47WO\K7O^3VN?
M?%8?C7QOH/PY\,7_ (B\3:K;:+HEBGF7%Y=/M1!G 'J220 HR22  2:^/?V8
MOVMV\0_&;2? 5Q\9+'XT6NO6UQ)%?KX6ET&ZTZXA3S!&4*+'+&Z+)R/F##TK
MZT^(G@GPIXRTNQF\86EO=:;H=Y'K437D[10030!BLTGS!6506.'RO&2.!ARO
MRJ2Z_P">O];>9$;<SBU_73^OP.8^#W[3WPP^/ES>VW@3Q;;:Y=V:B2>U,$UM
M,J$XWB.9$9ER0"R@@$@$\BNR\<^.M#^&WAFZ\0^([[^SM'MGBCEN/*DEVM)(
ML2#:BLQR[J.!QG)XYKPGP;>0?M!_M&:'\2O#6G?9_!'A/3[W3H/$TD/EMXAN
M)RJ,D&<,UM!L;$A^5G8[,@%CM_MR?\FS>)O^OO2__3C;4UJH.V[7XRM^*U7J
M%O><;_U;]'H>]5@ZQXYT3P_XFT#P]?WOD:QKQG73K;RG;SS"GF2_,%*KA>?F
M(SVR:^1M8\8?M!>*K'XS>)O#GQ&TG0M%\":_J4>GZ5-H$%S+J45O&LIMY9B1
MY<8'RJRJ7)9MS8"FO3=>^*WBSQ1JWP)M]$U=?#B^.](O[F\,=G'<+'-_9RS0
MN%D!.(Y&W;0PW8PQ(K.,^:"FETB[=;23:\M;/KZE./++E;_F5_\ #H_S/7]>
M^*GA/PUX)O?%][KEL?#5FYCGU&TW7,:,)?)9<1!B2)/E( ."#GH:ZI6#*".A
MYKX)^#.L>/\ X0?L)^+?%4/CC^T+M-1N/[*3^R;>+^SV&JR17!R0PE\UB[_.
M/DW8'0&J/Q[_ &G/B-H?C'QO+X:^**1MX9GE2/PKX2\$OK<'EQ('/]H:A,J+
M"_42"(L(QW+ TG44=^U_P3?F]^B+5-R;4>[7W.R\C[WOM<T[3+[3[*\O[:UO
M-0D:*SMYI562X=4+LL:DY8A59B!T )K/\*^.=$\;-K*Z+>_;3H^H2Z5??NGC
M\FZC"EX_F4;L;E^9<@YX-?)/Q>7QQ\5OB-^RYXDT7QHG@Z;7+>:Z2WCTB&\6
MUN&T]YYI 9""P>,F':>%^\.:WM5^/WQ!C\/^*M+T6\LKKQ9J7Q-G\&:!<ZC;
MH+?3K?8LF]U0+YGEHLA&[))(SN Q6C;C-TVM5=6\^:$5Y:N7ZMJUGGI*,91>
MC2=_E-O[E'_).]SZVHKX^\6^,_C1^SCJ$=AXP^(5E\1=,\2:5JJZ=JRZ#!IM
MUI6HV]G)<Q?NXRR2Q,L3#Y@3NQG@8.?X5\??'GPO9_!;QWXM\=Z/X@\/^-;W
M3=+U#PO;:%%;BT%U%F.X6X#;WDX!8?*@9B%4J!A1DI2Y5W2]')M)?AZ:I[!)
M<JN^S?RCJW_79GVC7*7'Q2\*VOQ*M?A_+K$2>,+K3VU2'2_+?<ULK;2^[;L'
M(/REMQ )Q@$UU$TR6\3RR.L<:*69F.  .237Y6Z]^U=\,K[4M;^+47BH#XHV
M_C.'4],T?^S[G<^CVZ&S%F9O+,2F6WDFE)W8W.!P:7.E44&_7[TOUOYI,I0;
M@Y+Y>NK_ $MY-H_56J6M:UI_AO2KK4]5OK?3=-M4,L]W=RK%%$@ZLS,0 /K7
MS7\1/&_Q,^(WQUT#PE\+_'FG^%?#.K^#/[??5KC2(M0>/-P%CEA1RN7965<.
MVP*6.W=BO+_BUXH^(?Q$_8=^*UCXE\2VL?B3PAK=SHVJ:E9Z;'LUBW@D3&4S
MB$OYB,60#&S ')H<GRMVU5]/27*_N?SMLF.G&,IQC?1M+[X\R^]?*^Y]I:OX
MZT/0O$OA_0+Z^\G5M?,XTVW$3M]H\F/S)/F52JX7GYB,]LUOU\N?$[XJ>-/V
M>;3X80ZSXG_X2XII6NWNN7']G06?]JFUL6N(1L56\G! 7Y",XR<]*U_@SHG[
M0-SJGA?Q=XH^(/AW7O#NMPBZU/PJFC"T&EQR1%XQ:7*;GF96* B7 (W<DX-6
MFG-Q73KTUO;SUL_UL8K^'&;ZJ]OS^ZZ_2Y[=X5\<Z)XV;65T6]^VG1]0ETJ^
M_=/'Y-U&%+Q_,HW8W+\RY!SP:WJ^._&'QV^)=IX,\3W&@ZM:RZ[;_%F+PMIR
MWMO$L!LVDB5;>0K&2$)<@R &0 G#9Q75>'-=^+_P<^,G@[0?B%XXTWXA^'/&
MSW5K#-;Z-'ILNDWD4+3K&@C8^9"RHZ[GRV0"<=XIS4XJ71VU\W&,OQYE\]+O
M1O24>5R\K_<I-?A;[M;=%]-51M]<TZZU>\TJ"_MIM3LXXY;FSCE4RPI)N\MG
M0'*AMC8)Z[3Z5^='C+]L'XF:%J%SXKTSXEP^*+.SU4077AGPWX)DG\/10_:/
M*VMK,RQR-P1^\0$%^%RI!/J&GWGBWX9_M/\ [0?CN^\8OJ>@:!H%GJUWH$>D
MP(U[";>Z>U@$V=R>1M;YQS)N^;I4^T2@JDM%K^"OTO>_2UUYENFTW#=Z+[Y*
M/X?JO,^U:9-*L$3R.=J(I9CZ =:_-'P[^WYJ6CS:3XLU3X\:'XHGN9H#J/PX
MM_!ES9P6T4CJ)4M]0:/<TD:DD&0["0>3Q7T!:ZY\<OCGK'C/Q+X)\:Z)X4\,
M:!JUYHNG>%[S1TNQK#6QV2/<W)(> .^0/*Z#&1D9).;4&X[V;]+6[;[K:Y"B
MKJ[TT\KWOWVV>]CZ2\!^.]#^)GA+3O$_AJ^_M+0]11I+6Z\F2+S%#%2=LBJP
MY4CD#I2Z3XYT37/%6O>&[&]\_6M"%NVHVOE.OD"="\7S%0K;E4GY2<8YQ7D7
M["&X?LD_#D.NU_L<V5SG!^TR\5POQN^.7CSPE#^T3_8>L+!/X4M=#DT-6M8'
M%M)< >;G<AWAC_?SCMBMJS5*;BNER::=1+I>WXM'UK17S!X6U_XS?#?X^>!]
M"\>^-M)\9Z#XXM;YOL=CHJ6*Z/<V\(FV0N&+RQD$KND)/'0&NW_;*US4/#W[
M,_CJ[TVXDLYWM([:2ZB.&A@EFCBF<'L5C=SGVJ)-J',M_P!;VU?Z[6UV'!*<
MDNCM]S,_6_VZO@1X=\72>&K[XCZ;'JL<OD2>7#/+;H^<$-<)&8A@C!R_'?%>
MX:?J%KJ]A;7UC<PWME<QK-!<V\@DCEC895U8'#*0001P0:YOPK\-_"/A7P#9
M>$-)T73HO"ZVRVZ:?Y"-#.FWDNI&)"P&23DMR3FOE'P3\8K']FWX->.M$TNZ
ML;>&#QYJ7AKP9_:]XL-C#NVR9EF=@%MX':;<2<G9M'S,!0Y<K<7J[772^JC:
MW=N2MJ$5SI2CHF[=[:-WOY).^A]::7\2O#.N>.M:\&V&KPW?B71;>&ZU"PB5
MB;9)<^7O;&T,=I.W.X @D $$UOBA\7/!_P %O"[^(O&NNVV@:0L@B$TX9FD<
MY(1$0%W; )VJ"< GH#7RS^S#J7P\\)_M2>*M*T'Q[H?BB]U?PSISS:M#JD$T
MNM:F9[N2ZD&QSNDP0Q1<[$VC 4"OI[XC:)X&L[K2O'WC065J?""SW%IJNH7#
M1PV/FJ$=\%@A8@!06!()^7!/*;:I1FVNMWTTDUI\EUMW\AJSJ.-GTMWUBG^;
M_34@^$/QY\ _'G2;K4O ?B6V\06UK(([A8TDAEA8]-\4BJZ@X."5P<'&<&N=
MT/\ :\^#WB7XDMX"TSQYIUWXI$QMUM%641R2@X,:3E!$[YXVJY).0!Q7C^_4
M_&"?&KXZ:-HL_AG1[OP3/IF@>=;F&[U@11RS#4I(^&0,2B1!QO**"=N0*C^*
MW@S0= _X)U:4VEZ?;0-HVA:7JVF21( T5Z#!()D8<[V=CDCEMY]::;WDK)6N
MNNKE^D;VMUL[-,.6[48N_->SZ:*/ZRM?RNMSV#XE?MA?!WX0^+AX7\6^.+/2
M]=PI>S6WGN##NP5\UHHV6,D$'#D<$'H<UZFOB+2G\/C75U.S;1#;?;!J0G7[
M/Y&W=YOF9V[-O.[.,<UXE\0/$7@/X%:7JVA:%X8B\1^//'D\]^GA&V)N+G6;
MJ5<223>86$5N,'<[XC158*,_*<S2?V4=+C_9[\%>#_&M]>:Q#X5TR9[C2;:Z
M:+3;RX;]X/.B',RPN,1JQV]25/&,Y3E&E.3WC]VSNO.UOG?H.$8U)P2T4OOZ
M6?E?_AF['O'@_P 7Z1X^\+Z9XCT"\&H:-J<"W-I="-T$L;=&VN PS[@5LUXS
M^QG_ ,FJ_"W_ + -M_Z#7LU=52/)-Q71F$)<T5+N%%%%06%%%% !1110 444
M4 %=;X2_Y!LG_74_^@K7)5UOA+_D&R?]=3_Z"M8U?A-:?Q&W1117$=84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >5?M+?\ ).M(_P"QS\)_
M^I#IU>JUY5^TM_R3K2/^QS\)_P#J0Z=7JM !1110 4444 %%%% !1110 444
M4 %%%% 'BGPQ_P"2G?'3_L<+;_U'M'KTBO-_AC_R4[XZ?]CA;?\ J/:/7I%
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M^[U;XE_%N^^(6MPZ3?:5HTAT6WTZTTW[5"8I9_L\+?O9=K$;BPX)'H1W>K?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDEB37TY\*/V7]+D_9!\*_"'XDZ7!JD,.G(NH6L<QQ%.9#-^[E0@AD=L!E/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[^(_^?W2_P#O[)_\;H_X9W\1_P#/[I?_ ']D_P#C='_#1'B/_GRTO_OU)_\
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M;H_X9W\1_P#/[I?_ ']D_P#C='_#1'B/_GRTO_OU)_\ '*/^&B/$?_/EI?\
MWZD_^.4?\*?D'^P>8?\ #._B/_G]TO\ [^R?_&Z/^&=_$?\ S^Z7_P!_9/\
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M6WG_ #S@_P"^6_QH_>!^[#_A$KS_ )Z0?]]-_A1_PB5Y_P ](/\ OIO\*/\
MA+;S_GG!_P!\M_C1_P );>?\\X/^^6_QH_>!^[#_ (1*\_YZ0?\ ?3?X4?\
M")7G_/2#_OIO\*/^$MO/^><'_?+?XT?\);>?\\X/^^6_QH_>!^[#_A$KS_GI
M!_WTW^%'_")7G_/2#_OIO\*/^$MO/^><'_?+?XT?\);>?\\X/^^6_P :/W@?
MNP_X1*\_YZ0?]]-_A1_PB5Y_ST@_[Z;_  H_X2V\_P"><'_?+?XT?\);>?\
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M[8")RS(X*K(49EP"RJRAD+!U]+H **** "BBB@ HHHH **** "BBB@ HHHH
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MCZYJZ20?"&#2] \02:'JNU-46=S"4,S0?,RG*O\ *7QSU %?7%>"_LN>9O\
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MIZ;?>SVOXT_&ZQ^#^FVD::/J?B?Q+J:3'2M!TFW9Y;IHPI=F?&R&)-Z%Y'(
M!X#'BK7P"^(%_P#%;X+^#?&&J06UMJ.M:;%>SPV:LL2,XR0H9F./J376>)O^
M1;U;_KTE_P#0#7EG[&?_ ":K\+?^P#;?^@TH;S3Z<OX\W^02VA;K?\+?YGLU
M=MX=_P"0-;_\"_\ 0C7$UVWAW_D#6_\ P+_T(UE6^$UI?$:5%%%<9U!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^$-%CT1-/\*Z)8)H9E;2EMM.AC&GF4$2F#:H\HN&8-LQG)SG-*G[B5]URO\
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M31O'(BR1N"K(PR&!Z@CTJKHNBZ=X;TFUTO2;"UTO3+2,16]G90K##"@Z*B*
M% ] *H>+/'/AOP#I:ZEXG\0:7X<TYG$:W>K7L=K"7/10\C 9.#QGM7!?"7XP
M7WQ%^*7Q2T!AITNB^&;C3DTR\L=Q:XCN+43%W?>5?D_*5 &/7K0M6TO7\O\
M,71-_P!?U8]9KMO#O_(&M_\ @7_H1KB:[;P[_P @:W_X%_Z$:QK?";4OB-*B
MBBN,Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]XH^R;\ZMXFOS>W\Y9V;,DI W8W8&    *ZBF[)Z$H****0PHHHH **** .
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MH'NF7;MVF4IN(V\8STXKH=)T>PT'2[73-,L;;3M-M8EAM[.TB6*&&-1A41%
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M^0-;_P# O_0C7$UVWAW_ ) UO_P+_P!"-85OA-J7Q&E1117&=04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]>C?^AI7K5>2_"7_ )&2Y_Z]&_\ 0TKUJOE<Q_COT1[^"_A!1117F'<%%%%
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M6%;X3:E\1I4445QG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5?M+?\
MDZTC_L<_"?\ ZD.G5ZK7E7[2W_).M(_['/PG_P"I#IU>JT %%%% !1110 44
M44 %%%% !1110 4444 >.?"FQDN?B5\=64J /&-L.3_U+VC5Z;_9,W]Y/S/^
M%>%^$/ .N^*OBU\<;O3/B5XH\'6Z>+;6)K'1+;2I(9&'A_2"9";NRG?<0P7
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M_,_X4?V3-_>3\S_A7 ?\*;\7?]%V^('_ ( ^'O\ Y54?\*;\7?\ 1=OB!_X
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MV^('_@#X>_\ E50!W_\ 9,W]Y/S/^%']DS?WD_,_X5P'_"F_%W_1=OB!_P"
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MXYO[.H=G]YQO_#._B/\ Y_=+_P"_LG_QNC_AG?Q'_P _NE_]_9/_ (W79?\
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M_$?_ #^Z7_W]D_\ C==E_P *;\7?]%V^('_@#X>_^55'_"F_%W_1=OB!_P"
M/A[_ .55']K8GNON#^SJ'9_><;_PSOXC_P"?W2_^_LG_ ,;H_P"&=_$?_/[I
M?_?V3_XW79?\*;\7?]%V^('_ ( ^'O\ Y54?\*;\7?\ 1=OB!_X ^'O_ )54
M?VMB>Z^X/[.H=G]YQO\ PSOXC_Y_=+_[^R?_ !NC_AG?Q'_S^Z7_ -_9/_C=
M=E_PIOQ=_P!%V^('_@#X>_\ E51_PIOQ=_T7;X@?^ /A[_Y54?VMB>Z^X/[.
MH=G]YQO_  SOXC_Y_=+_ ._LG_QNC_AG?Q'_ ,_NE_\ ?V3_ .-UV7_"F_%W
M_1=OB!_X ^'O_E51_P *;\7?]%V^('_@#X>_^55']K8GNON#^SJ'9_><;_PS
MOXC_ .?W2_\ O[)_\;H_X9W\1_\ /[I?_?V3_P"-UV7_  IOQ=_T7;X@?^ /
MA[_Y54?\*;\7?]%V^('_ ( ^'O\ Y54?VMB>Z^X/[.H=G]YQO_#._B/_ )_=
M+_[^R?\ QNC_ (9W\1_\_NE_]_9/_C==E_PIOQ=_T7;X@?\ @#X>_P#E51_P
MIOQ=_P!%V^('_@#X>_\ E51_:V)[K[@_LZAV?WG&_P##._B/_G]TO_O[)_\
M&Z/^&=_$?_/[I?\ W]D_^-UV7_"F_%W_ $7;X@?^ /A[_P"55'_"F_%W_1=O
MB!_X ^'O_E51_:V)[K[@_LZAV?WG&_\ #._B/_G]TO\ [^R?_&Z/^&=_$?\
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M=_$?_/[I?_?V3_XW79?\*;\7?]%V^('_ ( ^'O\ Y54?\*;\7?\ 1=OB!_X
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M(P7R23\V>M<U_P ,9_"C_HE7P_\ _"=M/_C-=)_PIOQ=_P!%V^('_@#X>_\
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M#W_RJH ]5HKRK_A3?B[_ *+M\0/_  !\/?\ RJH_X4WXN_Z+M\0/_ 'P]_\
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MWQ _\ ?#W_RJH_X4WXN_Z+M\0/\ P!\/?_*J@#U6BO*O^%-^+O\ HNWQ _\
M 'P]_P#*JC_A3?B[_HNWQ _\ ?#W_P JJ /5:*\J_P"%-^+O^B[?$#_P!\/?
M_*JC_A3?B[_HNWQ _P# 'P]_\JJ /5:*\J_X4WXN_P"B[?$#_P  ?#W_ ,JJ
M/^%-^+O^B[?$#_P!\/?_ "JH ]5HKRK_ (4WXN_Z+M\0/_ 'P]_\JJ/^%-^+
MO^B[?$#_ , ?#W_RJH ]5HKRK_A3?B[_ *+M\0/_  !\/?\ RJH_X4WXN_Z+
MM\0/_ 'P]_\ *J@#U6BO*O\ A3?B[_HNWQ _\ ?#W_RJH_X4WXN_Z+M\0/\
MP!\/?_*J@#U6BO*O^%-^+O\ HNWQ _\  'P]_P#*JC_A3?B[_HNWQ _\ ?#W
M_P JJ /5:*\J_P"%-^+O^B[?$#_P!\/?_*JC_A3?B[_HNWQ _P# 'P]_\JJ
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M7S_0^LR'_E[\OU"BBBOD3ZP**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O1/"?\
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ME9@<@D5Z77E7[2W_ "3K2/\ L<_"?_J0Z=7JM !1110 4444 %%%% !1110
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MS\/9+^2:>TE612?/6XMEMPD+*&9C)A0N>U?4.N>.=%^'/_!0RRA\0W4VG_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOSVQG_L>^&]4\'_&_P#:$T;6/$LOB^^L]0T>,ZQ<*JSS1_8B8Q-MX,JH55F
M&XJ6P"<5%."E%R?9M?*:C_F.52TE&/=7^<7+_(]+^./[3>E_ WQ'X>T&;P9X
MS\:ZOK=O<75M9^#M+2_E2.$QB1G0R*P&95Y (]<<51^%G[4W_"TO&5MX>_X5
M#\5/"/GQR2?VKXJ\,_8K&/8I;:\OFM@G& ,<D@5Y_P#M+?\ "Q/^&J/A1_PK
M#_A&/^$G_P"$=UO_ )&[[3]B\GS+/?\ \>_S[_NX[=<UZ5\(?^&AO^$ID_X6
ME_PK+_A&_LS[/^$0_M'[9Y^5V9^T?)LQOSWSCWHII.FI2W?-^#DE^7WA4<E4
M<8[+E_%1;_/[CN/A;\3M+^+?A>37M'M[RVLTO[O3RE\B))YEO.\$APK,-I:,
MD<YP1D \5%\+_BOI'Q:LO$%UI%O>VT>BZW=Z#<"^1%+3V[!9&3:[90D\$X/J
M!7FO[$LBGX,ZA$&!DA\5:]'*F>4;^TISM8=C@@X/J*J?L3QD^$_B7<C#6]U\
M0]>F@D4@K(GV@+N!'495A^%)15VO[M_G>/\ FRI2:6G\[7RM/_)'>V_[0OA*
M;X[7?PD=[RW\6P627Z>;!BWGC9-^U) 3\X4$E6 .%8C.#4OQ ^/GA3X;_$+P
M9X)U22[E\0^+)S!86]I!O5 #@R2L2 BYX'4G!P#@U\L?&3_BF_VE/B;\1(P?
M-\"S>$M8FV#YC9NMY;78R.P@N)'/_7,9J3QA<-X\^/\ X8^();S+"3XFV/A?
M2'QP;6PL[T2NI]&NIKCIU$:U=."E*%]KV?I>*T_\"7W/Y*K)P52W177KRN33
M^2;^:7K]/_'']H+PI^S[I>AW_BI[KRM7U%-/A6SC5W3*EGG<,RXAC52SL,[1
MV->E*P90RD$$9!'>O@GXY_%33?''[1WC'3M7^&WQ"^(GA#P[H%SX3MY/!.@_
MVE!%?WD:-?.[[E"2I$88P 20=Y(&16SX+_:HUG1OV$]0O[BSU-?BCH!'@V/2
M+NU9-2DU-BL5H3 <N96C>.4KC)*N!FL^5NCSI7>C2[W=E_[:_P#M]=BN;]\J
M;=EL_5*_Y73[<K[GTE\'_P!H3PE\<-6\7Z?X:DNFG\,:@VGW1N415GPS*)X2
MK-OA9HY%#G&3&W'%>F5^<GPG^*-A\)?B]\'FT_X:_$KP+X=?2(_!&OZGXS\/
M'3[2YD9M]G/Y@<KYIN6ER6Q\LS8K]&ZTJ4U!)IW6J^[3\5:7E>QG3J<[:>FS
M^3_R=UYVOU"BBBL#<**** .DTC_D'Q?C_,U<JGI'_(/B_'^9JY7LT_@7H>-4
M^-^H4445H9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >5?M+?\DZTC_L<_"?\ ZD.G5ZK7E7[2W_).
MM(_['/PG_P"I#IU>JT %%%% !1110 4444 %%%% !1110 4444 >*?#'_DIW
MQT_['"V_]1[1Z](KS?X8_P#)3OCI_P!CA;?^H]H]>D4 %%%% !1110 4444
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MWX7\1:3XDM;:8VT\^D7T5TD4H )C9HV(5@"#M//(K=H **** "BBB@ HHHH
M*\7KVBO%Z^2S_P#Y=?/]#ZS(?^7OR_4****^1/K HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *]$\)_\B_:_\"_]#->=UZ)X3_Y%^U_X%_Z&:]?+/XS]/U1Y.9?P
M5Z_HS7HHHKZ<^:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBD,**** "BBB@ KQ>O:*\7KY+/_ /EU\_T/K,A_Y>_+]0HHHKY$^L"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KT3PG_R+]K_P+_T,UYW7HGA/_D7[7_@7_H9K
MU\L_C/T_5'DYE_!7K^C->BBBOISYH**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ34WS);VW_[AM6M_B:?E8\=UKX;^(]<^+&A_ JR^+GCS1?#.B>&7\07VMIK
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MH6I7S^&DN$_X1V*R"RJ;/[*5^_Y:E!-N#!B#R0<_:_P-_P"2)_#[_L7M/_\
M2:.O'O$W[ 'P\\2WFNQG7?&6F^&]9,\UQX2L=;9=&6YEW%KI+5E91(';>N24
M#*IV\8KW6Q\$V^E_#NW\(6-_?6=K;:6NE07\3)]JB18A$L@)0IY@ !R4QD?=
MQQ4RJ+V<E%;VLNUN;2_7?]=VRE!^UBY/;FN^]W'6W39Z=-MDC\\OB9\4!\7O
M$'QLU-?AG\3_ !3)J0BT'P=XB\)^'&O;"UCTZ9I(YX[@,I):]5G;:&^55&<\
M5ZMXB^+?B?X^Z%^S9/X9\8:AX"U#Q5=ZA8:Z]D2&AGALI!<PF(MM+JZ2>7Y@
M.QBC[21BOK+X8?#K2/A'\/M!\':$)O[)T:U6U@:X8-+(!U=R  79B68@ $L>
M!7S%\7OV2]*NOB]X"MM/A\2W7AS7O%6K:_JS6<SI%HUU)IS!9X)8D5K?=,D;
M LQS)C'7%5>"7LMTK6\[/73^\KM]VD*2GK5V;4M.UXZ:]>6R2\FRK<0^+?V>
M_&7CKX>Q_$CQ/XWT/4OA_J?B/3[KQ)?_ &G5=)NK?$987"A6\M_,!7IM:/CN
M3F:-HOBSP/\ "?X,>,+WXF>,O$&N^-O$OAAM2COM7D-I##(C%[>")<;8W#*'
MW%C(4#-S7NG@#]DGPEX#T?Q; ^L^)O%.N>*-/?2M1\4>)M4-]JC6I1E$*2LN
MU%7<2 $Y(&[=M&.FU'X#Z!J?@KP#X8EO-26P\%WFGWNGR)+&)97LUVQ"8[,,
M"/O;0I/8BB-11DFW?6%WW2G)O\'%>=A3A*46EII.ROU<8I?BI/RN<7^R?_Q^
M?&K_ +*+JG_H$%==\7OB3X)^"LUMXFU?2_M_B[4X_P"R=+M-)L%N-9U3!,@M
M8 !O90QW$$A%)R2,\[_P]^&.E_#63Q0^F3WDY\0ZU<:[=?:W1MD\P0,L>U5P
M@V# .3UY->:_&;]D/2/C-\2;'QQ-X_\ 'W@_7++3_P"S(&\):Q'8JD)=G;!\
MEGRQ(W?-@[5XXK'?V:VM&*?RBD[?E^-GL;6:]H^[DU\Y-J_Y_AIN>*^._AWX
MBT(^%/'/Q!AL]/UWQM\4M!O-7TBUF$UIIMK#%)#9V[28'F.I$9=Q\I<\<#GV
M+XV^6?VH?V>1!L_M#[3K?F8QO^R_V>V_/^SO\K\<59T']C_P_:^"_%7A7Q1X
MU\=_$K1O$*0K+%XTUTWS6;1,S));,$0Q/N8-N'=$].;OPB_90\-?"/Q!>^(A
MXC\6^,_$TUF=/@UOQ?JYU"ZLK8D$PP$JJHN0#T)]\<5KS12<>BU7_@"BEKVY
M=6]UYF7+)Z]U;_R:3;_\FT71I=#C?B?XF@\>:;K?P"^#.BV2,T$FE^(-6M;5
M8=&\-6LP(G0; %DNV61ML"=&8LY7:03]JGX'>"]%_9O\;:V-$AOM>\/^!+C1
M-.U2]S+-;VT4#A0F?E1CDY=0&.<$X  S- _X)XZ/X3L6LM#^-OQHT6R:5YS;
M:=XK2WB,CL6=]B6X&YF))..2:]WU_P"$FG^*/@S=_#?5=7UC4--O-'.BW.JW
M-RLFHS1F+RVE>5D(:4CDL5P22<5E4_@M1?O/?S=G^"N[>K-87]JG->ZORNG]
M[LG\D;O@7_D2/#W_ &#K?_T4M;E5-)TV+1]+L["%G:&UA2!&D(+%54*"< <X
M%6ZNM)3J2DMFV11BX4XQ>Z2"BBBLC4**** .DTC_ )!\7X_S-7*IZ1_R#XOQ
M_F:N5[-/X%Z'C5/C?J%%%%:&84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E7[2W_).M(_['/PG_P"I
M#IU>JUY5^TM_R3K2/^QS\)_^I#IU>JT %%%% !1110 4444 %%%% !1110 4
M444 >*?#'_DIWQT_['"V_P#4>T>O2*\W^&/_ "4[XZ?]CA;?^H]H]>D4 %%%
M% !7+ZI\5/!>BZ;J^HZCXOT&PT_1[D66I7=UJ<$<5E<';B&9V8"-SN7Y6(/S
M#CFNHK\U_C-)##\'?VEY+FQDU2V7XM:>TMC%")GN%$MAF-4/#EAP%/7.*CF]
M]0\O_;X1_P#;K_(IJT'+^OAE+_VT^U_^&J/@M_T5_P !_P#A367_ ,=KN&\:
M>'EU+3=/.NZ8+_4X?M%C:F\C\V[BX/F1)NRZ\CE01S7Q.OQ$^"S,!_PPWX\&
M3C)^$=EC_P!"K-_;N\'W&K_'KX:S>'H?L6K>%_"6I>(='AA'E*DUC+!.D>T<
M %8V3;T^;VJ[J+BYZ)MW?9*+DW^!-F[J.^EO5R27YGWY?7UMIEG-=WEQ%:6L
M*&26>=PB1J.2S,> !ZFL34OB/X2T7PFGBG4/%&BV'AAPC+K5SJ$,=DP8[5(F
M9@AR2 .>2:^9_P!K3QE:?'#X(^#?#6B3L^G^.[*37[MHGP1I=I:_;) 2.1ND
M%M%_VT->8_$"YT^S_P""5?PXN-6$;:5%%X>DNQ+'YB&$7L)?<N#N&W.1@Y]*
M6J<HRT:E&/\ X$VF_DTUZIBNFHRCK>,I?<DTO5_JC[$T7]HWX3^)-4MM,TGX
MH>#-4U*Y<1P6=EX@M)II6/1519"6/L!5_P 8?&[X=?#W5ETOQ5X^\+^&M3:)
M9A9:QK-M:3&,D@/LD<-M)!P<8X-?"WQ8^*W[&?Q)^&_B+PU\//!FB^(_&^I6
M4MOHUAX5\$36FH-=LI$+1RBVCVA7*L3NZ \-T,>O7>F^!OVCM/LOBI\)==^.
M.M0?#30[:[ATCPS#K\MO=I),)II%D.$W,"-XZFJWLMM?O]V3T].77U0-I;:_
MIK%?CS?@S[K\)_'3X;^/M872?#'Q!\*^(]59&D6QTG6K:ZG*K]Y@D;EL#N<<
M5FZA^TQ\(-)O[FQOOBMX(LKVUE:&>VN/$5G')%(I(9&4R95@000>017E?[-_
MB+X;^)/'\R>&/V:?$?PEU6WLI)EU[7/ =MHL;+N16A2>,EB[;L[.X5O2OEWX
M;_$GX3^ ]+^)%UX\_9P\0?$%[/QAKD]UXNM? UIJ=DD(NW.UKN9AC8.H/"YI
M/223[-_<TOU_ :NTWYI?>F_T/TI\,>+=#\;:1%JOAW6=/U_2Y21'?:7=1W,#
MD=0'0E3^=2:'XETCQ-%=R:/JMEJT=I<R6=P]C<),(9XSB2)RI.UU/!4\CN*^
M5OV'_##WGC3XA_$;P[X%F^&/PP\50V#:#X?FV1&Y9%D\R]-M&Q2WWAD4*O!
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M4?V-B^R^\/[8PO=_<>445ZO_ ,*HTC_GXO?^^T_^(H_X51I'_/Q>_P#?:?\
MQ%']C8OLOO#^V,+W?W'E%%>K_P#"J-(_Y^+W_OM/_B*/^%4:1_S\7O\ WVG_
M ,11_8V+[+[P_MC"]W]QY117J_\ PJC2/^?B]_[[3_XBC_A5&D?\_%[_ -]I
M_P#$4?V-B^R^\/[8PO=_<>445ZO_ ,*HTC_GXO?^^T_^(H_X51I'_/Q>_P#?
M:?\ Q%']C8OLOO#^V,+W?W'E%%>K_P#"J-(_Y^+W_OM/_B*/^%4:1_S\7O\
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MN+JW_P"$M\,*L=M.L+"4Z[8")RS(X*K(49EP"RJRAD+!U]+H **** "BBB@
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M_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%?*>VJ?S/[SZKV-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
MPDFK_P#04O?_  (?_&C_ (235_\ H*7O_@0_^-9U%'MJG\S^\/8T_P"5?<:/
M_"2:O_T%+W_P(?\ QH_X235_^@I>_P#@0_\ C6=11[:I_,_O#V-/^5?<:/\
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MA#P!<^+I=*@TRQO#->ZPBVMRZW%RZX5(2(P5@Y.6R_*J DG*44I?%_G;\_\
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MPG_R+]K_ ,"_]#->OEG\9^GZH\G,OX*]?T9KT445].?-!1110 4444 %%%%
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M_!DF@Z_IVLZ[X@UV"*/3;6.T<2D6%PKG[2SLNQ2@& V2 ,[;7A_P=XCUR_\
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MMRQ( 2, '<,L.M*Z6_\ 7]?@-)O8]PHJOI]_;ZI86U[:2K/:W,2S12J<AT8
MJ1[$$58JFFG9DIJ2N@HKA?%'Q;T_PO\ %;P3X"ELKF?4O%,5]/!<IM$,*6L:
MN^[G)8EU  &.I)&,'7\-ZYXAU3Q!XEM-6\,_V+I=A<QQ:5J7V^.X_M2(QAGE
M\M1NAVN2FU\D[<]#26NO]:.WY_KV&]/Z\K_U_P $Z.BO+_VDOC1<_ /X5W?B
MZR\/?\)5>1WEI90:5]M%GYTD\Z0K^]*.%P7!Y&/<=:\?US]J[XW> ]*N=?\
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M^0,>?2O2-!^'?B&S_:^\6>-IM/V>&+[PC8:7;WWG1G?<QW,SNFP-O&%=3DJ
M<\&G"/(U!OX92]'^Z2;7E*5_F^X3ES*4TMXQ]?XCLO51M?R1\R?!F3PQ\=_V
MC/ _BKX,_!N\^%>A>#KJ]@\4ZU<Z=;:.9RT+(+ VT#D2MO*EBW*8&<=_T$KY
MP\=_"7Q;X!_:8T#XJ?#;2FU33O$072?'6APW4-N)X5&+?4%$K*K2Q=" =S+@
M*/F8U]'U2?[N/SOZ_P"6S5M/^WN8)?Q'\K>G^:U3^72Q^9GP?^,7[*'@L^/M
M,^+UAX5N/&2^--;DD?5O",FI3^2;Q_+S,MM(",9P-W'H*]0_9UN->\/VGQF\
M8? SX>7,_@G7]5T\>$_#^J.-)LFE$6R]U!$E(*6Y)0[4&YO+"JHQA?>OV4OA
MWXA^&O@KQ58>(]/_ +.N[[Q=K&J6\?G1R[[:>Y9XGRC,!N4@X.".X%9W[:?P
MO\7?%KX.1Z-X1M(]9EBU6UO-2\.S:@U@FMV*%O-LC.K+Y>\E3DL!\G6LE>%.
M'?E@G;I\-[[O2VO7?K:UVYZDNW-)Z^KM9Z)7Z>3L]&[^::'^T]\7/ WQV\$^
M!OB8OPNUFS\67<EA"O@/4[AK[390F]7GBG.60],JH'?(X5EN/V@/VB/''CCX
MK:1\.O"7@632O VL2VG]H^()KM&OHUB5Q;11QMS/W,C,J8=!@8)/E_AG]FWX
MC3_&+X4>*-*_9V\*?"/PWX;UV.74+33M:M+W59HV5E:=[A=H:%!C]V"7+-G#
M?P_47P*^&WB/P;KWQON=8T[['#XD\5W&I:4WGQO]HMVMH45\*QV99&&'P>.E
M.5U!M;I2MYN\.7\Y6[VUV8DUSI=+QO\ ^3W_ "C^'>Y-\-/VL/ WB?X.^"/&
MWB[Q%H/@"?Q+9-<QZ?KNKP6I+HQCE$9D92ZAQU Z%<X)Q6'^TI\-_A=\1O@-
M\0O'L?A;PCXGU*;PK?75EXF73[6[F?9:.8I([G:Q.W VLK<8&*C_ &=_V9]%
MA_9S^'OAKXK?#[P_J_B+0K2>%K?6[&TU(VI>=W*HY#J PV$[3V&>E>C_ !7^
M'XN_V?\ QGX,\(:/:VK7'AR^TS2]*L4CMH5=[=TCB0?*B#<P'8#/:GC(KEJJ
M"[VM\[?H7A&U4I<[TTO?Y'&_LM_!;X>^'_A/\-O$^E^!/#.F^)7\/64K:S::
M/;Q7C/):IYC&94#DMN;)SSDYZUD>#_VCO$OB#]D?QC\4KBQTI/$&C1:T]O;1
M0RBU8V<TR1;U,A8Y$2[L.,DG&*];^"OA[4/"/P=\#:'JUO\ 9-4TW0[*SNH-
MZOY<L<"(Z[E)4X8$9!(]#7QY<?"C]HCPI\'_ (D?!/0? NBZEH&I/JT^F^-'
MUR%?-MKIWE^R_9& ;SV,C)O=EC4MDDA<MIC).56JJ?:5NU[JWX7M_F8X.*5.
MDY]XW]+._P"-CU;XF?M+>/O#EO\  6#PMX=T;7-:^(UL_P!HM;MI((HIC9),
MKK('.R)'<L^1(Q1"%^8@UR_A_P"/W[27B;6O&GPXLO!O@#_A9GA.2&YO]8FN
MKM-!DM)XA);I#'GSWF?$@RQ5%V<]<5VEQ\(?%TGB_P#9<O5TG-KX+LKF'7I/
MM,/^AL^EB!1C?F3,@V_N]WKTYKJ/AS\.?$.@_M,_&?Q9?:?Y&@>(;+18=,O/
M/C;[0UO#,LPV!BR[2ZCY@,YXS3KVC*IR:_%;Y/W?ZZHFFW[*#ENHQOZN5G?Y
M:^6YQ=C^V;<7W[*?@_XG6GA-M4\6^)[R+0]/\-6]R(TGU1IW@,8E;.V/=%(V
M3G@8SWJ#3?CE\<?A5XW\(6/QI\+>#9/#'BS4H]'M=8\%75SNTR\E!\F*YCN,
M[][#;NCPHP3D\ \?X)_9:^(L/[%_@'PLD-CX=^)W@WQ"WB73K35)EGM&GCOK
MB2..5X68;7BF/W2<$C..<;MYX=^.7[2OC'P-9_$#X=:1\+O!?A?6[?7[YCKL
M6JW6JW%ODPI (AB*/><L).<8P3@@U[OMWVYOER:7MY_%YZ+YW42C%Q3V4K/J
MY)RM?R:Y==M7\M_PW\9_C-\2/CAXQ\+>%M&\'6?A/P?XCCL-5U;6?M7GSV;P
MPR>7;)&Y!N%!E)9]J8>( 9#9^FZ\6^ OP\\0>"_B/\:]4UG3_L=AXB\3)J&E
MR^=&_P!H@%I#&7PK$K\R,,, >.F*]IK*/\.">]DWWNTK_B-_'-]+NWI=V_ *
M\7KVBO%Z^2S_ /Y=?/\ 0^LR'_E[\OU"BBBOD3ZP**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O1/"?_ "+]K_P+_P!#->=UZ)X3_P"1?M?^!?\ H9KU\L_C/T_5
M'DYE_!7K^C->BBBOISYH**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>/&UY_PAWP[E^!OB_0M1TNVAL-<U?6(X[31K2.&((\MK< N+K+* J*%R&SN
M!->'Z>OB;X7^$_V7)'\&:GJFO:;K_B*>3PZ\?V:]DC*7;,427;\_E,9$4XWD
M* ?F!K6<(QNHO2ZU[J[U_K0SC4DX\TEJDW;L[-V_K7[T?4?PM_:R\'?$M?$L
M-UI_B#P%JWARS_M+4]'\:::=.O(+/!/VG9N8&/@\@Y'&0,C/.^#?VY/!WC'Q
M7H6E'PCX\T'2O$%PMKHWBC7/#[VNDZE(XS$L,Q8D^8 2N5&?:N#6^^)GQO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5XO7M%>+U\EG__ "Z^?Z'UF0_\O?E^H4445\B?6!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ*C8O=-!1110 4444 %%%% !1110 4444 =)I'_(/B_'^9JY5/2/^0?%^/\
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M?UH.^K2\OQ5PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_D>=45Z+_P *A_ZBW_DM_P#9T?\ "H?^HM_Y+?\ V=']DXW^3\5_F']JX/\
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MV3C?Y/Q7^8?VK@_Y_P '_D>=45Z+_P *A_ZBW_DM_P#9T?\ "H?^HM_Y+?\
MV=']DXW^3\5_F']JX/\ G_!_Y'G5%>B_\*A_ZBW_ )+?_9T?\*A_ZBW_ )+?
M_9T?V3C?Y/Q7^8?VK@_Y_P '_D>=45Z+_P *A_ZBW_DM_P#9T?\ "H?^HM_Y
M+?\ V=']DXW^3\5_F']JX/\ G_!_Y'G5%>B_\*A_ZBW_ )+?_9T?\*A_ZBW_
M )+?_9T?V3C?Y/Q7^8?VK@_Y_P '_D>=45Z+_P *A_ZBW_DM_P#9T?\ "H?^
MHM_Y+?\ V=']DXW^3\5_F']JX/\ G_!_Y'G5%>B_\*A_ZBW_ )+?_9T?\*A_
MZBW_ )+?_9T?V3C?Y/Q7^8?VK@_Y_P '_D>=5Z)X3_Y%^U_X%_Z&:7_A4/\
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MH&L1ZEKGA6XDMM#N;)AJ*R2VY*P/ NXB4$[2@R<@CFOH+_A'_P#IX_\ '/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#V<.R+G]KW?_ #U_\='^%']KW?\ SU_\='^%4Z*/:3[L/9P[(N?VO=_\]?\
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M !T?X4?VO=_\]?\ QT?X53HH]I/NP]G#LBY_:]W_ ,]?_'1_A1_:]W_SU_\
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MS5]3\6:Q>>'Y/#Z7"1WME?P*08\,NUU,F 6)3:I+$9!6O0O@3^TEK7Q*\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7HGA/_D7[7_@7_H9KSNO1/"?_ "+]K_P+_P!#->OEG\9^
MGZH\G,OX*]?T9KT445].?-!1110 4444 %%%% !1110 4444 %%%% !1110
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MX\9QS3AK5@O\7X0D_P#@DU':E)_X?QE%?\ ]+^$/PQ^+O@GQ'=7_ ([^-O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O%Z]HKQ>ODL
M_P#^77S_ $/K,A_Y>_+]0HHHKY$^L"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZU[_ #"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/I,GQ%*A[3VLK7M^IQ=%=I_PJC5_^?BR_P"^W_\ B*/^%4:O_P _%E_WV_\
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M_P#/Q9?]]O\ _$5U>B>$[S3=+AMI9(6=-V2C$CEB?3WKT\OP>(I56YP:5O\
M(\W'XS#U*24)IN_^9'16E_8-Q_?C_,_X4?V#<?WX_P S_A7O^QGV/!]M#N9M
M%:7]@W']^/\ ,_X4?V#<?WX_S/\ A1[&?8/;0[F;16E_8-Q_?C_,_P"%']@W
M']^/\S_A1[&?8/;0[F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'L9]@]M#N9M%:7
M]@W']^/\S_A1_8-Q_?C_ #/^%'L9]@]M#N9M%:7]@W']^/\ ,_X4?V#<?WX_
MS/\ A1[&?8/;0[F;16E_8-Q_?C_,_P"%']@W']^/\S_A1[&?8/;0[F;16E_8
M-Q_?C_,_X4?V#<?WX_S/^%'L9]@]M#N9M%:7]@W']^/\S_A1_8-Q_?C_ #/^
M%'L9]@]M#N9M%:7]@W']^/\ ,_X4?V#<?WX_S/\ A1[&?8/;0[F;16E_8-Q_
M?C_,_P"%']@W']^/\S_A1[&?8/;0[F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'L
M9]@]M#N9M%:7]@W']^/\S_A1_8-Q_?C_ #/^%'L9]@]M#N9M%:7]@W']^/\
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M9]@]M#N9M%:7]@W']^/\S_A1_8-Q_?C_ #/^%'L9]@]M#N9M%:7]@W']^/\
M,_X4?V#<?WX_S/\ A1[&?8/;0[F;16E_8-Q_?C_,_P"%']@W']^/\S_A1[&?
M8/;0[F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'L9]@]M#N9M%:7]@W']^/\S_A1
M_8-Q_?C_ #/^%'L9]@]M#N9M%:7]@W']^/\ ,_X4?V#<?WX_S/\ A1[&?8/;
M0[F;16E_8-Q_?C_,_P"%']@W']^/\S_A1[&?8/;0[F;16E_8-Q_?C_,_X4?V
M#<?WX_S/^%'L9]@]M#N9M%:7]@W']^/\S_A1_8-Q_?C_ #/^%'L9]@]M#N9M
M%:7]@W']^/\ ,_X4?V#<?WX_S/\ A1[&?8/;0[F;16E_8-Q_?C_,_P"%']@W
M']^/\S_A1[&?8/;0[F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'L9]@]M#N9M%:7
M]@W']^/\S_A1_8-Q_?C_ #/^%'L9]@]M#N9M%:7]@W']^/\ ,_X4?V#<?WX_
MS/\ A1[&?8/;0[F;16E_8-Q_?C_,_P"%']@W']^/\S_A1[&?8/;0[F;16E_8
M-Q_?C_,_X4?V#<?WX_S/^%'L9]@]M#N:6D?\@^+\?YFKE5[&W:UM4B<@LN<[
M>G4FK%>K!6BDSRIN\FT%%%%60%%%% !1110 4444 %%%% !117@G[2GQZ?P#
M"/#>A2A=>N8]T]PO6TC/3'^VW;T'/<&O.S#'T<MP\L37>B^]OHEYGK97EF(S
M?%1PF%5Y/[DNK?DO^!N=E\3/CSX<^&N^UED.I:N!Q8VS#*G_ *:-T3]3[5\U
M^,OVF/&'BEY([:[&B6;<"&P^5L>\GWL_0@>U>0-=2W4SRRR-+*Y+,[G)8GJ2
M:4,:_ ,UXHS',I.,9^SI_P L7;[WN_R\C^CLIX,RW*XIU(^TJ=Y?HME^+\S2
MNM8N;Z9YKB>2>5SEGD<L3]2:2.\/'-9^33UZU\5*">K/M?912LD;=O?'CFM>
MTU!EQ\WZUS$+'(KV3]FG3]/UGXA&SU/3[;486LY)$6YC#A'5E(8 \="12PF7
M?VABZ>$B^5S=KOS/ S6K# X6IBI1NH*]CF[35&X(?CZUN6.N3PD%9"/QJ?XU
M1Q6?Q4UN&&-(8D,(6.-0JJ/)3H!7,6\V.]>%F6">!Q57#J5W"3C?:]G:YX5.
M,,9AJ>(Y;*<4[>JN>K^&?B1J&ES)MG8J/X2<BO;_  ;XYMO$T:QL1'=8^[G[
MWTKY-M;@JPYKN/!^MS:?J-O-$V'5P1SQUKZ#AOBK'9)B(QE-RI7UB^WEV9\3
MG614,13<X*TNY]244R&430I(OW74,/Q%/K^PHM22:V/QG;0****8@HHHH **
M** /*OVEO^2=:1_V.?A/_P!2'3J]5KRK]I;_ ))UI'_8Y^$__4ATZO5: "BB
MB@ HHHH **** "BBB@ HHHH **** /%/AC_R4[XZ?]CA;?\ J/:/7I%>;_#'
M_DIWQT_['"V_]1[1Z](H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O.O\ A87B#_H(?^08_P#XFO1:\7KY?.ZU2E[/V<FK
MWV=NQ]/DM&G5]I[2*=K;J_<Z/_A87B#_ *"'_D&/_P")H_X6%X@_Z"'_ )!C
M_P#B:YRBOF/KF)_Y^2^]GTWU/#?\^X_<CH_^%A>(/^@A_P"08_\ XFC_ (6%
MX@_Z"'_D&/\ ^)KG**/KF)_Y^2^]A]3PW_/N/W(Z/_A87B#_ *"'_D&/_P")
MH_X6%X@_Z"'_ )!C_P#B:YRBCZYB?^?DOO8?4\-_S[C]R.C_ .%A>(/^@A_Y
M!C_^)H_X6%X@_P"@A_Y!C_\ B:YRBCZYB?\ GY+[V'U/#?\ /N/W(Z/_ (6%
MX@_Z"'_D&/\ ^)H_X6%X@_Z"'_D&/_XFN<HH^N8G_GY+[V'U/#?\^X_<CH_^
M%A>(/^@A_P"08_\ XFC_ (6%X@_Z"'_D&/\ ^)KG**/KF)_Y^2^]A]3PW_/N
M/W(Z/_A87B#_ *"'_D&/_P")H_X6%X@_Z"'_ )!C_P#B:YRBCZYB?^?DOO8?
M4\-_S[C]R.C_ .%A>(/^@A_Y!C_^)H_X6%X@_P"@A_Y!C_\ B:YRBCZYB?\
MGY+[V'U/#?\ /N/W(Z/_ (6%X@_Z"'_D&/\ ^)H_X6%X@_Z"'_D&/_XFN<HH
M^N8G_GY+[V'U/#?\^X_<CH_^%A>(/^@A_P"08_\ XFC_ (6%X@_Z"'_D&/\
M^)KG**/KF)_Y^2^]A]3PW_/N/W(Z/_A87B#_ *"'_D&/_P")H_X6%X@_Z"'_
M )!C_P#B:YRBCZYB?^?DOO8?4\-_S[C]R.C_ .%A>(/^@A_Y!C_^)H_X6%X@
M_P"@A_Y!C_\ B:YRBCZYB?\ GY+[V'U/#?\ /N/W(Z/_ (6%X@_Z"'_D&/\
M^)H_X6%X@_Z"'_D&/_XFN<HH^N8G_GY+[V'U/#?\^X_<CH_^%A>(/^@A_P"0
M8_\ XFC_ (6%X@_Z"'_D&/\ ^)KG**/KF)_Y^2^]A]3PW_/N/W(Z/_A87B#_
M *"'_D&/_P")H_X6%X@_Z"'_ )!C_P#B:YRBCZYB?^?DOO8?4\-_S[C]R.C_
M .%A>(/^@A_Y!C_^)H_X6%X@_P"@A_Y!C_\ B:YRBCZYB?\ GY+[V'U/#?\
M/N/W(Z/_ (6%X@_Z"'_D&/\ ^)H_X6%X@_Z"'_D&/_XFN<HH^N8G_GY+[V'U
M/#?\^X_<CH_^%A>(/^@A_P"08_\ XFC_ (6%X@_Z"'_D&/\ ^)KG**/KF)_Y
M^2^]A]3PW_/N/W(Z/_A87B#_ *"'_D&/_P")H_X6%X@_Z"'_ )!C_P#B:YRB
MCZYB?^?DOO8?4\-_S[C]R.C_ .%A>(/^@A_Y!C_^)H_X6%X@_P"@A_Y!C_\
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M4\-_S[C]R.C_ .%A>(/^@A_Y!C_^)H_X6%X@_P"@A_Y!C_\ B:YRBCZYB?\
MGY+[V'U/#?\ /N/W(Z/_ (6%X@_Z"'_D&/\ ^)H_X6%X@_Z"'_D&/_XFN<HH
M^N8G_GY+[V'U/#?\^X_<CH_^%A>(/^@A_P"08_\ XFNS\/\ B+4+[1[>>>XW
MRMNRVQ1T8CL/:O*:]$\)_P#(OVO_  +_ -#->IEV)KSJM3FWIW?='F9AAZ,*
M2<8):]EYG1_VO=_\]?\ QT?X4?VO=_\ /7_QT?X53HKZ'VD^[/G_ &<.R+G]
MKW?_ #U_\='^%']KW?\ SU_\='^%4Z*/:3[L/9P[(N?VO=_\]?\ QT?X4?VO
M=_\ /7_QT?X53HH]I/NP]G#LBY_:]W_SU_\ '1_A1_:]W_SU_P#'1_A5.BCV
MD^[#V<.R+G]KW?\ SU_\='^%']KW?_/7_P ='^%4Z*/:3[L/9P[(N?VO=_\
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MI/NP]G#LBY_:]W_SU_\ '1_A1_:]W_SU_P#'1_A5.BCVD^[#V<.R+G]KW?\
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M]%I>GW-Y.VR"WB::1O15!)/Y"OS$\2>*KOQEXHU/6[UBUS>W#S,"<[<GA1[
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M:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ;E&/*FKQ<7\+6FVAWG[.'QP\0ZUXIM?"FM3-K-K<QR>5<S#,T.U2WS-_$I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<#^T)\5?$/@6V\,^&_!&GV>I>/O%U\VGZ2FHLPM+54C,D]U-MY*1(,[1RQ(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>+U[17B]?)9__P NOG^A]9D/_+WY?J%%
M%%?(GU@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** /*OVEO\ DG6D?]CGX3_]2'3J]5KRK]I;_DG6D?\
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M_GVP_M#"_P#/Q'%T5VG_  JC5_\ GXLO^^W_ /B*/^%4:O\ \_%E_P!]O_\
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M_GVP_M#"_P#/Q'%T5VG_  JC5_\ GXLO^^W_ /B*/^%4:O\ \_%E_P!]O_\
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M_GVP_M#"_P#/Q'%T5VG_  JC5_\ GXLO^^W_ /B*/^%4:O\ \_%E_P!]O_\
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M_P"%'L9]@]M#N9M%:7]@W']^/\S_ (4?V#<?WX_S/^%'L9]@]M#N9M;'A_\
MY>/^ _UJ'^P;C^_'^9_PJ_I=A)8^;YA4[L8VD]LUM1ISC--HQK5(2@TF7Z**
M*](\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*OVEO^2=:
M1_V.?A/_ -2'3J]5KRK]I;_DG6D?]CGX3_\ 4ATZO5: "BBB@ HHHH ****
M"BBB@ HHHH **** /%/AC_R4[XZ?]CA;?^H]H]>D5YO\,?\ DIWQT_['"V_]
M1[1Z](H **** "BN7^)OQ*T#X0^!=8\7^)[T6&B:7"9IY,;F;D!41?XG9B%5
M>Y(%?/EY^U_\3])TUO%>I?LV>*++X<I&+J35SK-H^IQ6V,F5]-'[Q2!DE2W
M!)-*Z^[[OF]AV=K_ -?);L^JZ*R/"/BS2?'GA?2O$>A7B:AHVJ6T=W:748($
MD3J&4X/(X/0\CH:UF.%)JI7C=2Z$Q:DDUU%HKS/]G7XT?\+^^%]KXQ_L?^PO
M/O+NT^Q?:OM&WR)WAW;]B9W;-V-O&<<]:],HV'U:[77W:!16%X\\4?\ "$^!
M_$/B+[-]M_LG3KB_^S>9Y?F^5&S[-V#MSMQG!QGH:X_PK\5?$/C?P'\,/%.B
M>"_MMIXLAM+O4T_M6./^Q;::W\TRY=0;C:Q5-JA2=V>,8I+WKVZ6_&]OR?IU
M!Z)-];_A:_YKUZ'IM%%% !117F7QY^-'_"D='\+W_P#8W]M?VYXCL/#_ )?V
MKR/)^TN5\[.QMVW&=O&?44=4N[2^;=E^(=&^R;^Y79Z;1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7%_\+7U?_GWLO^^'_P#BZ[2O%Z^:SG$5</[/V4K7O^A])D^'I8CVGM8W
MM;]3M/\ A:^K_P#/O9?]\/\ _%T?\+7U?_GWLO\ OA__ (NN+HKYK^T<7_S\
M9])_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'
M%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+H
MH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#X
MNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA
M_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][
M+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_
M )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +
M7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71
M_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__
M ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_
MWP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\
M^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:
M^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[
M3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_
MY]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_
M9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\
M/QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'
M%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+H
MH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#X
MNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA
M_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_ )][
M+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +7U?_
M )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71_P +
M7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__ ,71
M_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_WP__
M ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\^]E_
MWP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:^K_\
M^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[3_A:
M^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_Y]H[
M3_A:^K_\^]E_WP__ ,71_P +7U?_ )][+_OA_P#XNN+HH_M'%_\ /QA_9^%_
MY]H[3_A:^K_\^]E_WP__ ,775Z)XLO-2TN&YECA5WW9"*0.&(]?:O(*]$\)_
M\B_:_P# O_0S7IY?C,15JM3FVK?Y'FX_!X>G23A!)W_S.I_MZX_N1_D?\:/[
M>N/[D?Y'_&LVBO?]M/N>#[&'8TO[>N/[D?Y'_&C^WKC^Y'^1_P :S:*/;3[A
M[&'8TO[>N/[D?Y'_ !H_MZX_N1_D?\:S:*/;3[A[&'8TO[>N/[D?Y'_&C^WK
MC^Y'^1_QK-HH]M/N'L8=C2_MZX_N1_D?\:/[>N/[D?Y'_&LVBCVT^X>QAV-+
M^WKC^Y'^1_QH_MZX_N1_D?\ &LVBCVT^X>QAV-+^WKC^Y'^1_P :/[>N/[D?
MY'_&LVBCVT^X>QAV-+^WKC^Y'^1_QH_MZX_N1_D?\:S:*/;3[A[&'8TO[>N/
M[D?Y'_&C^WKC^Y'^1_QK-HH]M/N'L8=C2_MZX_N1_D?\:/[>N/[D?Y'_ !K-
MHH]M/N'L8=C2_MZX_N1_D?\ &C^WKC^Y'^1_QK-HH]M/N'L8=C2_MZX_N1_D
M?\:/[>N/[D?Y'_&LVBCVT^X>QAV-+^WKC^Y'^1_QH_MZX_N1_D?\:S:*/;3[
MA[&'8TO[>N/[D?Y'_&C^WKC^Y'^1_P :S:*/;3[A[&'8TO[>N/[D?Y'_ !H_
MMZX_N1_D?\:S:*/;3[A[&'8TO[>N/[D?Y'_&C^WKC^Y'^1_QK-HH]M/N'L8=
MC2_MZX_N1_D?\:/[>N/[D?Y'_&LVBCVT^X>QAV-+^WKC^Y'^1_QH_MZX_N1_
MD?\ &LVBCVT^X>QAV-+^WKC^Y'^1_P :/[>N/[D?Y'_&LVBCVT^X>QAV-+^W
MKC^Y'^1_QH_MZX_N1_D?\:S:*/;3[A[&'8TO[>N/[D?Y'_&C^WKC^Y'^1_QK
M-HH]M/N'L8=C2_MZX_N1_D?\:/[>N/[D?Y'_ !K-HH]M/N'L8=C2_MZX_N1_
MD?\ &C^WKC^Y'^1_QK-HH]M/N'L8=C2_MZX_N1_D?\:/[>N/[D?Y'_&LVBCV
MT^X>QAV-+^WKC^Y'^1_QH_MZX_N1_D?\:S:*/;3[A[&'8TO[>N/[D?Y'_&C^
MWKC^Y'^1_P :S:*/;3[A[&'8TO[>N/[D?Y'_ !H_MZX_N1_D?\:S:*/;3[A[
M&'8TO[>N/[D?Y'_&C^WKC^Y'^1_QK-HH]M/N'L8=C2_MZX_N1_D?\:/[>N/[
MD?Y'_&LVBCVT^X>QAV-+^WKC^Y'^1_QH_MZX_N1_D?\ &LVBCVT^X>QAV-+^
MWKC^Y'^1_P :/[>N/[D?Y'_&LVBCVT^X>QAV-+^WKC^Y'^1_QK2TR\>\MV=P
MH(;'R_05S=;V@_\ 'F__ %T/\A710J2E.S9A6IQC"Z1I4445Z!YP4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^GS\_P!/E?=A1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTOKNDR3Y;W\K?.*?X:^MM.K7UQ>7D&GVD]U=3QVUK C2RS3.$2-%&69F/
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M,A_Y>_+]0HHHKY$^L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %>B>$_^1?M?^!?^AFO.Z]$\)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)">.%^('Q \#:Z-,327?P9K2:>LL"2/( Y\IF;YG/\6.!Q7O%%#UM?IM^/\
MF_O$M+VZGBGP[_97TKP7I?B72]<\=>._B?H_B"T%E=:;X^UO^TX$C^;/EKY:
M["V[D^PZ8K@U_P""=O@-H5TFY\;?$J]\$*V%\#W'BJ4Z,(PV5B$04/L!Z#S,
M^]?4]%/K?^OZU8=+?U_6A3T;1K#P[I%EI6EV<.GZ;90I;VUI;1A(H8D4*J*H
MX"@   >E7***&VW=B2LK(****0PHHHH **** "O%Z]HKQ>ODL_\ ^77S_0^L
MR'_E[\OU"BBBOD3ZP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZI;K%C.\R$[0N.<YQ7ROX=^"7@3XJ?M<?&^\\8^%=+\3RVFF:':VRZK;)<)
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MO@5\2/C;JVD:3XU^*]Y\+-%^'6HZ5%?I/H\M];WD+3+&81(UPWE*/GP?F/)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O1/"?\ R+]K_P "_P#0S7G=>B>$_P#D7[7_ (%_Z&:]?+/XS]/U1Y.9?P5Z
M_HS7HHHKZ<^:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "F30QW$+Q2HLL3J59'&58'J".XI]
M%+?1C.0\)_![P%X"U2?4_#/@CPYX=U*=2DMYI.DV]K-(I.2&>- 2">>34GBK
MX3^"/'6J6FI>)?!OA_Q#J-F,6UWJNEP7,T/.?D=T)7D \&NKHJN9W3OJB;*U
MC.O/#FDZC?Z9?7>EV5U>Z6S/87,UNCR6C,A1C$Q&4)0E25QD$CI2VGA_2]/U
M;4-4M=-L[;4]0$8O+V&!$FN1&"L8D<#<^T$@9)P"<5H44AG(2?![P%-8_8I/
M!'AQ[/[+)8_9VTFW,?V>242R0[=F/+:0!RO0L-Q&>:OI\/?"T?A%?"J>&M'3
MPPJ",:(MA$+(*&W!1#MV8W?-C'7FN@HIW8K*]S/L_#VE:?JM_J=KIEG;:EJ
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MM/)*UO5J4_+5%2M-*%[*SU\V_P ERQ?WZGS9^T)\'=%^./[;7@3PWXDGO_\
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M?^%4:O\ \_%E_P!]O_\ $4?\*HU?_GXLO^^W_P#B*SO^%A>(/^@A_P"08_\
MXFC_ (6%X@_Z"'_D&/\ ^)HY\K_DG^'^8<F9_P \?Q_R-'_A5&K_ //Q9?\
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M?Q_R-'_A5&K_ //Q9?\ ?;__ !%'_"J-7_Y^++_OM_\ XBL[_A87B#_H(?\
MD&/_ .)H_P"%A>(/^@A_Y!C_ /B:.?*_Y)_A_F')F?\ /'\?\C1_X51J_P#S
M\67_ 'V__P 11_PJC5_^?BR_[[?_ .(K._X6%X@_Z"'_ )!C_P#B:/\ A87B
M#_H(?^08_P#XFCGRO^2?X?YAR9G_ #Q_'_(T?^%4:O\ \_%E_P!]O_\ $4?\
M*HU?_GXLO^^W_P#B*SO^%A>(/^@A_P"08_\ XFC_ (6%X@_Z"'_D&/\ ^)HY
M\K_DG^'^8<F9_P \?Q_R-'_A5&K_ //Q9?\ ?;__ !%'_"J-7_Y^++_OM_\
MXBL[_A87B#_H(?\ D&/_ .)H_P"%A>(/^@A_Y!C_ /B:.?*_Y)_A_F')F?\
M/'\?\C1_X51J_P#S\67_ 'V__P 11_PJC5_^?BR_[[?_ .(K._X6%X@_Z"'_
M )!C_P#B:/\ A87B#_H(?^08_P#XFCGRO^2?X?YAR9G_ #Q_'_(T?^%4:O\
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M^%']@W']^/\ ,_X5O44?5X!]8F8/]@W']^/\S_A1_8-Q_?C_ #/^%;U%'U>
M?6)F#_8-Q_?C_,_X4?V#<?WX_P S_A6]11]7@'UB9@_V#<?WX_S/^%']@W']
M^/\ ,_X5O44?5X!]8F8/]@W']^/\S_A1_8-Q_?C_ #/^%;U%'U> ?6)F#_8-
MQ_?C_,_X5I:9:/9V[(Y4DMN^7Z"KE%7&C&#NB)5I35F%%%%;&(4444 %%%%
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M3[8>')M/\'>'=/L]1T5_LDK:EJ5O,LK"?RLDE95C5HD"!BK+G)8 1?MFZ/\
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MH **** "BBB@ HHHH **** "M[0?^/-_^NA_D*P:WM!_X\W_ .NA_D*Z</\
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M"!F4%L XR0/<5$N51<I;/?Y7_+4J/,Y*,=_\[?GH<E\&?V:?AG^SW%?)\/\
MPE:^'WOL"YN%EEN)Y%'(4RS.[[0>=N[&><5U%C\.?#NF^/M4\;6^FB/Q/J=E
M#I]W?^=(3);Q,S1IL+;%P6)RJ@GN3@5H>%/$5MXP\+Z/KUFDL5GJEG#?0I.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7=C=G&1G'45-:+E1E'=VE][E*WX-%4)*-92V5X_<HQO^*93^!O\ R1/X??\
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M[J 7^O1-#.(I;42#:;AGW KNQR HQU;&_:(_:-O_ (M_LJ_%N'3_ (<_$;P
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M,. M/PSKGCW7O^">/@?Q_I_B76[OQEX;"^([B7^T9C)JL-M=2FXMIV+$S(\
M<!7R"53TKR?XN>-O"G@GXH?$SPUHOQ;\??" ZYJ4[ZI\/1X0^VSZW<.N'N-+
MNDWBW2X[-D$DY( V@?2_P9\2:-^R/^Q+X%D^*SS>'K:QL$@O();26XDCEG=W
M6!XXU8AOGVG( !X.*B#?U?FB[->SM_B2=WYWE:ZW[I#FO]HY9*]^>_\ A=K+
MRLKJ_P!S?2[-\2[CXU?M%?#72/"FM7MMX1TSP]_PFNJO8W#Q+>"Y416%M-M.
M&4AI92AR#L7TKZ1KY3_X)W?"&X^'_P )M2\2ZEI][IM]XJOFN+*SU3)N[/28
MLQV%L^1D;8\L!V$G:OJRMY)1]U*W7SUUL_.*M%^AE&[;;=^GW:77DW=KR85X
MO7M%>+U\=G__ "Z^?Z'U^0_\O?E^H4445\B?6!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5Z)X3_P"1?M?^!?\ H9KSNO1/"?\ R+]K_P "_P#0S7KY9_&?I^J/
M)S+^"O7]&:]%%>6_&_X]V7P=_L/2[71-0\8>,_$,SP:-X9TC;]HNBB[GD9F(
M6*% 1ND;A<C@\X^GZV/FNEV>I45\[^"OVHO%</CK0O"WQ9^$M_\ "NY\13-:
MZ+J UJVU:QNK@*6\B2:$+Y4C '8I!W8/3%?1%4XN*N2I)NQX;\1/V(?@?\5?
M%DOB7Q-\/K&\UN9_,GNK>XN+3SWSDO(L,B+(Q/5F!)[UZ#>?"#P;>:1X6THZ
M!:VVF>%[Z'4M'L[+=;0V=Q$&$;JD94$ ._RG*G/(-=C124G%))Z+8;BFVVM]
M/OW^\P/%W@30_'B:0FNV/VY=)U&#5K(>=)'Y5U"28Y/D8;L$GY6RI[@T>)O
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M@/\ #W]I[Q9\7?$WQ7O+[5?$>@>)[[3;:W?6;BT7PY9P8%N\2)(JKN0>;YC
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M_P!G_P#:B\$:Y9Z3#IW@Z?3-2TO1?#^LW=]I^E7C(X?RY97+LW)#JQV[]W'
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MQKM(BWK(Q;   Z9P*^MJ**'*Z^;_ !=[?>V$8\MDNR7W:7^ZP4445)84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>+U[17B]?)9_P#\NOG^A]9D/_+WY?J%%%%?(GU@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>B>$_^1?M?^!?^AFO.Z]$\)_\ (OVO_ O_ $,UZ^6?QGZ?
MJCR<R_@KU_1FO1117TY\T%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5O:#_P >;_\ 70_R%8-;V@_\
M>;_]=#_(5TX?XSFQ'\,TJ***]0\L**** "BBB@ HHHH **** "BBB@ HHHH
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M=KDIM?).W/0UT='9@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6=_;W@C_GE9?^ )_^(K1KQ>O S7%RPO)R
MQ3O?=7['O97A(XKGYI-6ML[=SU?^WO!'_/*R_P# $_\ Q%']O>"/^>5E_P"
M)_\ B*\HHKP/[6J?\^X?=_P3W_[)I_\ /R7W_P# /5_[>\$?\\K+_P  3_\
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M_B*\HHH_M:I_S[A]W_!#^R:?_/R7W_\  /5_[>\$?\\K+_P!/_Q%']O>"/\
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M9?\ @*/_ (FC[%X=_P"?"R_\!1_\36;11SQ_D7W![-_SO[S2^Q>'?^?"R_\
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M"[+_ ,!T_P */^$;TC_H%V7_ (#I_A6E11[&G_*ON#VU3^9_>9O_  C>D?\
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M%'*NP<S[D/V.W_YX1_\ ? H^QV__ #PC_P"^!4U%'*NP<S[D/V.W_P">$?\
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M%5(&!NKVK5/@_HFJ?$_PIXZ:2ZMM3\-6%WIME:6[(MJ8K@1A]R;-V0(EV[6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT[_U<CF26FNJ7X-OUV_IW1[)\-_BCX3^+WAF+Q#X,UZS\1:/(QC^U64FX*X
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MA[PWXP\-^%M1U#[/KWB,7)TNT\F1OM'V= \WSJI5-JL#\Q&<\9KHZ^<?C?\
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M"WRX.<5[?H'B#3/%6BV>KZ+J-KJVE7D8EMKVRF66&9#T974D$?2N8^&/P?\
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M9_,*\7KVBO%Z^1S_ /Y=?/\ 0^MR'_E[\OU"BBBOD3ZP**** "BBB@ HHHH
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M:&U*QT[X=_#S6/A?\1WU4:/IMK=>)X_#Y.B+(UG$S.;DR9"@DJ25X8$5Y;\
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M*-)\2_ _]I37_ UQX_\ %/Q \,7WA$^)(4\5WHO+NVNDNO*=8Y BX1E(P@
M/;O7C>K>#_B)\1/V6=>_: /QT\9:'XHO=(N];@T72-0$.B6=NH?%HMNH!$BH
MNSS=P97YY(R?MV3X8Z6_Q8C^(7GW?]M)HK:$+?>GV;R#.)MQ7;NW[AC.[&.W
M>OSH^(GP=G\9-XJ\'Z7\'OC9X>US5KBX,?A:TU93X"BO'8E;S[1A5*@D3;0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?YH*^./!/PG_ &J/@_)XGTOP5<_!^Y\.ZEX@U'6K9M>?57NU%S.T@5S$BH"
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M71;/3?#=O)%INEV8D\UTB:7]Y(7<*Q9QD8QDC&/8/'7@O2?B/X-UKPMKMO\
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M06^2164$C##D]*?IOP-^./Q5\;^$+[XT^*?!L?ACPGJ4>L6NC^"K6YW:G>1
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M_P#7,_S%;U>IA_@/+Q'\0****Z3F"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?BOXH::-.TBZ^'^K:1)$MA- 422[EE>!XDCCVF4. 3T^[R1Z[X=_Y/X\>_\
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M?E^H4445\B?6!1110 4444 %%%% !1110 4444 %%%% !6OX3_Y&"U_X%_Z
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MF'^ \O$?Q HHHKI.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*OVEO^2=:1_V.
M?A/_ -2'3J]5KRK]I;_DG6D?]CGX3_\ 4ATZO5: "BBB@ HHHH **** "BBB
M@ HHHH **** /&?A7:RS_$SXZ,B[A_PF-L.H_P"A>T>O3/[/N/\ GG_X\/\
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MJ&ZM\_S7ZL[O^S[C_GG_ ./#_&C^S[C_ )Y_^/#_ !KA/^$D^-__ $3SX?\
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M_P#Y&C_^*H_X5[X@_P"@?_Y&C_\ BJT_^$D^-_\ T3SX?_\ A>7W_P IJ/\
MA)/C?_T3SX?_ /A>7W_RFH_L/#?S2^]?Y!_;F)_EC]S_ ,S,_P"%>^(/^@?_
M .1H_P#XJC_A7OB#_H'_ /D:/_XJM/\ X23XW_\ 1//A_P#^%Y??_*:C_A)/
MC?\ ]$\^'_\ X7E]_P#*:C^P\-_-+[U_D']N8G^6/W/_ #,S_A7OB#_H'_\
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MFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23XW_]$\^'_P#X7E]_\IJ
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M_P IJ/\ A)/C?_T3SX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\
M*:C_ (23XW_]$\^'_P#X7E]_\IJ /5:*\J_X23XW_P#1//A__P"%Y??_ "FH
M_P"$D^-__1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\ T3SX?_\ A>7W_P IJ/\
MA)/C?_T3SX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23
MXW_]$\^'_P#X7E]_\IJ /5:*\J_X23XW_P#1//A__P"%Y??_ "FH_P"$D^-_
M_1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\ T3SX?_\ A>7W_P IJ/\ A)/C?_T3
MSX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23XW_]$\^'
M_P#X7E]_\IJ /5:*\J_X23XW_P#1//A__P"%Y??_ "FH_P"$D^-__1//A_\
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M_P#1//A__P"%Y??_ "FH_P"$D^-__1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\
MT3SX?_\ A>7W_P IJ/\ A)/C?_T3SX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\
M^'__ (7E]_\ *:C_ (23XW_]$\^'_P#X7E]_\IJ /5:*\J_X23XW_P#1//A_
M_P"%Y??_ "FH_P"$D^-__1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\ T3SX?_\
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MFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23XW_]$\^'_P#X7E]_\IJ
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M_P IJ/\ A)/C?_T3SX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\
M*:C_ (23XW_]$\^'_P#X7E]_\IJ /5:*\J_X23XW_P#1//A__P"%Y??_ "FH
M_P"$D^-__1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\ T3SX?_\ A>7W_P IJ/\
MA)/C?_T3SX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23
MXW_]$\^'_P#X7E]_\IJ /5:*\J_X23XW_P#1//A__P"%Y??_ "FH_P"$D^-_
M_1//A_\ ^%Y??_*:@#U6BO*O^$D^-_\ T3SX?_\ A>7W_P IJ/\ A)/C?_T3
MSX?_ /A>7W_RFH ]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23XW_]$\^'
M_P#X7E]_\IJ +7[0>FS:MX#TJ"![='7Q;X8N";FYC@7;'KMA(P#2,H+%4(5
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M (UG44>VJ?S/[P]C3_E7W'7^#=<U&ZU25)K^ZF40DA9)F89W+SR:[+[9<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#S3]H/4YM)\!Z5/ EN[MXM\,0$7-M'.NV37;"-B%D5@&"N2K@;D8*ZE
M656'I=>5?M+?\DZTC_L<_"?_ *D.G5ZK0 4444 %%%% !1110 4444 %%%%
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MUP/_ *$M=S7#>!O^0M-_UP/_ *$M=S7U67?P/FSY?,/X[] HHHKU#S HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "NDTC_D'Q?C_,US==)I'_(/
MB_'^9KKPWQOT.3$_ O4N4445Z1YH4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI.N^)-6LF\ 3>(XK2SE3^R9;)+C+2>2S!A>!@4^;  !4D'-9_@/]O#P#X_\
M$_A32[;0/&>E:?XI*0Z1XAU;0GM]+N[EES]F28L=T@(93@%,J<,1@GQ+X<_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;E)^NJ:UWV[LB,DW-I:-KYI02?EOTV_ ^7/A7X7/[6WQ"^"EG\1M4U35;/\
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M<>?;:;KNH"ZATU<L3%:C8ICC);)!+9(SG.2?4JTJ24YN2Z_AY?+8(1Y8\O\
M7K\]PHHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\7KVBO%Z^2S_ /Y=?/\ 0^LR'_E[\OU"BBBOD3ZP****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Z+P-_P A:;_K@?\ T):[FN&\#?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MXO7M%<Y_PJ'_ *BW_DM_]G7SN;X2MBO9^QC>U^WEW/H<IQ5'"\_MI6O;OY]C
MSJBO1?\ A4/_ %%O_);_ .SH_P"%0_\ 46_\EO\ [.OG?[)QO\GXK_,^A_M7
M!_S_ (/_ "/.J*]%_P"%0_\ 46_\EO\ [.C_ (5#_P!1;_R6_P#LZ/[)QO\
M)^*_S#^U<'_/^#_R/.J*]%_X5#_U%O\ R6_^SH_X5#_U%O\ R6_^SH_LG&_R
M?BO\P_M7!_S_ (/_ "/.J*]%_P"%0_\ 46_\EO\ [.C_ (5#_P!1;_R6_P#L
MZ/[)QO\ )^*_S#^U<'_/^#_R/.J*]%_X5#_U%O\ R6_^SH_X5#_U%O\ R6_^
MSH_LG&_R?BO\P_M7!_S_ (/_ "/.J*]%_P"%0_\ 46_\EO\ [.C_ (5#_P!1
M;_R6_P#LZ/[)QO\ )^*_S#^U<'_/^#_R/.J*]%_X5#_U%O\ R6_^SH_X5#_U
M%O\ R6_^SH_LG&_R?BO\P_M7!_S_ (/_ "/.J*]%_P"%0_\ 46_\EO\ [.C_
M (5#_P!1;_R6_P#LZ/[)QO\ )^*_S#^U<'_/^#_R/.J*]%_X5#_U%O\ R6_^
MSH_X5#_U%O\ R6_^SH_LG&_R?BO\P_M7!_S_ (/_ "/.J*]%_P"%0_\ 46_\
MEO\ [.C_ (5#_P!1;_R6_P#LZ/[)QO\ )^*_S#^U<'_/^#_R/.J*]%_X5#_U
M%O\ R6_^SH_X5#_U%O\ R6_^SH_LG&_R?BO\P_M7!_S_ (/_ "/.J*]%_P"%
M0_\ 46_\EO\ [.C_ (5#_P!1;_R6_P#LZ/[)QO\ )^*_S#^U<'_/^#_R/.J*
M]%_X5#_U%O\ R6_^SH_X5#_U%O\ R6_^SH_LG&_R?BO\P_M7!_S_ (/_ "/.
MJ*]%_P"%0_\ 46_\EO\ [.C_ (5#_P!1;_R6_P#LZ/[)QO\ )^*_S#^U<'_/
M^#_R/.J*]%_X5#_U%O\ R6_^SH_X5#_U%O\ R6_^SH_LG&_R?BO\P_M7!_S_
M (/_ "/.J*]%_P"%0_\ 46_\EO\ [.C_ (5#_P!1;_R6_P#LZ/[)QO\ )^*_
MS#^U<'_/^#_R/.J*]%_X5#_U%O\ R6_^SH_X5#_U%O\ R6_^SH_LG&_R?BO\
MP_M7!_S_ (/_ "/.J*]%_P"%0_\ 46_\EO\ [.C_ (5#_P!1;_R6_P#LZ/[)
MQO\ )^*_S#^U<'_/^#_R/.J*]%_X5#_U%O\ R6_^SH_X5#_U%O\ R6_^SH_L
MG&_R?BO\P_M7!_S_ (/_ ".<\#?\A:;_ *X'_P!"6NYJ'1?ARVBW+SI?BX9D
MV!6AV#J#G.X^GI6Q_8-Q_?C_ #/^%>]@\)6HTN2<;,\+&8JC6J\T)71FT5I?
MV#<?WX_S/^%']@W']^/\S_A7=[&?8XO;0[F;16E_8-Q_?C_,_P"%']@W']^/
M\S_A1[&?8/;0[F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'L9]@]M#N9M%:7]@W'
M]^/\S_A1_8-Q_?C_ #/^%'L9]@]M#N9M%:7]@W']^/\ ,_X4?V#<?WX_S/\
MA1[&?8/;0[F;16E_8-Q_?C_,_P"%']@W']^/\S_A1[&?8/;0[F;16E_8-Q_?
MC_,_X4?V#<?WX_S/^%'L9]@]M#N9M%:7]@W']^/\S_A1_8-Q_?C_ #/^%'L9
M]@]M#N9M%:7]@W']^/\ ,_X4?V#<?WX_S/\ A1[&?8/;0[F;72:1_P @^+\?
MYFLW^P;C^_'^9_PK6L;=K6U2)R"RYSMZ=2:Z</"497:.;$5(RC9,L4445WG
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!!#_R#'_\ $USE%'US$_\ /R7WL/J>&_Y]Q^Y'1_\ "PO$'_00_P#(,?\
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M#V<.R+G]KW?_ #U_\='^%']KW?\ SU_\='^%4Z*/:3[L/9P[(N?VO=_\]?\
MQT?X4?VO=_\ /7_QT?X53HH]I/NP]G#LBY_:]W_SU_\ '1_A1_:]W_SU_P#'
M1_A5.BCVD^[#V<.R+G]KW?\ SU_\='^%']KW?_/7_P ='^%4Z*/:3[L/9P[(
MN?VO=_\ /7_QT?X4?VO=_P#/7_QT?X53HH]I/NP]G#LBY_:]W_SU_P#'1_A1
M_:]W_P ]?_'1_A5.BCVD^[#V<.R+G]KW?_/7_P ='^%']KW?_/7_ ,='^%4Z
M*/:3[L/9P[(N?VO=_P#/7_QT?X4?VO=_\]?_ !T?X53HH]I/NP]G#LBY_:]W
M_P ]?_'1_A1_:]W_ ,]?_'1_A5.BCVD^[#V<.R-G2;Z>ZN665]RA,XP!W%:]
M8.@_\?C_ /7,_P Q6]7I4&Y0NSS:Z49V04445T'.%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'FG[0=Y#8^ ]*EGL+?44;Q;X8B$-RT@56?7;!%D'ENIW1LPD4$[
M2R+N5UW*?2Z\J_:6_P"2=:1_V.?A/_U(=.KU6@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW\;;G7=3DN=%\7^(O$L<=OIEHP_<VLMC*266'H?+5=P[G@B_\-?V8_BCX;^
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MV[GL5%%%!04444 %>+U[17B]?)9__P NOG^A]9D/_+WY?J%%%%?(GU@4444
M%%%% !1110 4444 %%%% !1110 5K^$_^1@M?^!?^@&LBM?PG_R,%K_P+_T
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MF*WJP=!_X_'_ .N9_F*WJ]3#_ >7B/X@4445TG,%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[)W^1639)'\^[<JW?^%G>-/^B%^//_ _P]_\M: /2**\W_X6=XT_Z(7X\_\
M _P]_P#+6C_A9WC3_HA?CS_P/\/?_+6@#TBBO-_^%G>-/^B%^//_  /\/?\
MRUH_X6=XT_Z(7X\_\#_#W_RUH ](HKS?_A9WC3_HA?CS_P #_#W_ ,M:/^%G
M>-/^B%^//_ _P]_\M: /2**\W_X6=XT_Z(7X\_\  _P]_P#+6C_A9WC3_HA?
MCS_P/\/?_+6@#TBBO-_^%G>-/^B%^//_  /\/?\ RUH_X6=XT_Z(7X\_\#_#
MW_RUH ](HKS?_A9WC3_HA?CS_P #_#W_ ,M:/^%G>-/^B%^//_ _P]_\M: /
M2**\W_X6=XT_Z(7X\_\  _P]_P#+6C_A9WC3_HA?CS_P/\/?_+6@#TBBO-_^
M%G>-/^B%^//_  /\/?\ RUH_X6=XT_Z(7X\_\#_#W_RUH ](HKS?_A9WC3_H
MA?CS_P #_#W_ ,M:/^%G>-/^B%^//_ _P]_\M: /2**\W_X6=XT_Z(7X\_\
M _P]_P#+6C_A9WC3_HA?CS_P/\/?_+6@#TBBO-_^%G>-/^B%^//_  /\/?\
MRUH_X6=XT_Z(7X\_\#_#W_RUH ](HKS?_A9WC3_HA?CS_P #_#W_ ,M:/^%G
M>-/^B%^//_ _P]_\M: /2**\W_X6=XT_Z(7X\_\  _P]_P#+6C_A9WC3_HA?
MCS_P/\/?_+6@#TBBO-_^%G>-/^B%^//_  /\/?\ RUH_X6=XT_Z(7X\_\#_#
MW_RUH ](HKS?_A9WC3_HA?CS_P #_#W_ ,M:/^%G>-/^B%^//_ _P]_\M: /
M2**\W_X6=XT_Z(7X\_\  _P]_P#+6C_A9WC3_HA?CS_P/\/?_+6@#TBBO-_^
M%G>-/^B%^//_  /\/?\ RUH_X6=XT_Z(7X\_\#_#W_RUH ](HKS?_A9WC3_H
MA?CS_P #_#W_ ,M:/^%G>-/^B%^//_ _P]_\M: /2**\W_X6=XT_Z(7X\_\
M _P]_P#+6C_A9WC3_HA?CS_P/\/?_+6@#TBBO-_^%G>-/^B%^//_  /\/?\
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M^V']H87_ )^(Z&BN>^V_$7_HB/C/_P &.@?_ "SH^V_$7_HB/C/_ ,&.@?\
MRSH_L[%_\^V']H87_GXCH:*Y[[;\1?\ HB/C/_P8Z!_\LZ/MOQ%_Z(CXS_\
M!CH'_P LZ/[.Q?\ S[8?VAA?^?B.AHKGOMOQ%_Z(CXS_ /!CH'_RSH^V_$7_
M *(CXS_\&.@?_+.C^SL7_P ^V']H87_GXCH:U_"?_(P6O_ O_0#7#_;?B+_T
M1'QG_P"#'0/_ )9U>T37/B#INJ0W,OP0\:LB;LA-1T GE2/^@G[UO1R_%1JQ
M;INR:,:V/PLJ4DIJ[3/;J*\\_P"%C>-O^B&>._\ P/\ #_\ \M:/^%C>-O\
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M_P#RUH]C/L'MH=ST.BO//^%C>-O^B&>._P#P/\/_ /RUH_X6-XV_Z(9X[_\
M _P__P#+6CV,^P>VAW/0Z*\\_P"%C>-O^B&>._\ P/\ #_\ \M:/^%C>-O\
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M'>'O_EK1_P +D\7?]$)^('_@=X>_^6M 'JM%>5?\+D\7?]$)^('_ ('>'O\
MY:T?\+D\7?\ 1"?B!_X'>'O_ ):T >JT5Y5_PN3Q=_T0GX@?^!WA[_Y:T?\
M"Y/%W_1"?B!_X'>'O_EK0!ZK17E7_"Y/%W_1"?B!_P"!WA[_ .6M'_"Y/%W_
M $0GX@?^!WA[_P"6M 'JM%>5?\+D\7?]$)^('_@=X>_^6M'_  N3Q=_T0GX@
M?^!WA[_Y:T >JT5Y5_PN3Q=_T0GX@?\ @=X>_P#EK1_PN3Q=_P!$)^('_@=X
M>_\ EK0!ZK17E7_"Y/%W_1"?B!_X'>'O_EK1_P +D\7?]$)^('_@=X>_^6M
M'JM%>5?\+D\7?]$)^('_ ('>'O\ Y:T?\+D\7?\ 1"?B!_X'>'O_ ):T >JT
M5Y5_PN3Q=_T0GX@?^!WA[_Y:T?\ "Y/%W_1"?B!_X'>'O_EK0!ZK17E7_"Y/
M%W_1"?B!_P"!WA[_ .6M'_"Y/%W_ $0GX@?^!WA[_P"6M 'JM%>5?\+D\7?]
M$)^('_@=X>_^6M'_  N3Q=_T0GX@?^!WA[_Y:T >JT5Y5_PN3Q=_T0GX@?\
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MA[_Y:T >JT5Y5_PN3Q=_T0GX@?\ @=X>_P#EK1_PN3Q=_P!$)^('_@=X>_\
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MD\7?]$)^('_@=X>_^6M 'JM%>5?\+D\7?]$)^('_ ('>'O\ Y:T?\+D\7?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1.jpg
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M2GHZW?CPP8.\G!Q=3TV<90@&C)&IH,$YJK ';V_ORY<OAX2$,&T(H4,([.S
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M @(";MZ\*1 (E*H@7:6OW7J!JIP1 OCWZ!Z!HW-!SMWC.WX#4)!SM^50\KJ
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M=' %@#,'=UA86;^LJ6\.H5WH8T(BA(;"C\N7=W%VEE>?,+>P\ _L!2#K;I;
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M=EBU:I6=G9VAU';NM"BF6/OOWW_/IJ9RN=RHB2][>GL!D,ED +A<KDZW1DE
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MI T"P@>=/;1CY*NSZ)>-#74/[MZT[Z+;BJ.J0^^+AH:&&E\0.CDF9#.GBQH
M<"B9&8>R-^6"HBKJ&GB@:NH;**ETJ+^['FP@0DCH$*Q20>_ I_1V*-B2\\>3
M!8[.A;GW3NY.H%N&O12KV"'HF2'7SJ4F_[8B.&*8J*0H)6G3F-BY+<=A"OJ,
M<,6*%4P;HGW(,2&;L>1Q -CQ320R64F]6"R6VO YE76-? [LK<WS*ZI=[73K
M*0.2=)O0$5BE@OKT$6U)14EARX3:2CU",S/^R[IZP<K6+FS(2"M;>[U8USXS
M!WFN/GIM[L@@HWQ#2$U-34I*6KER)=.&$)10WR@&<+:H7BJ50B:UY(&22FU-
M>5P.*FKJZQH:A@9X M!I-"$10H*&$!4T)F8.\HQX?N+90SN-]0TA+"SLTJ5+
M3%M!4 )=?2+E8:TU#[9\3KU$5ML@EDDE#8UB2B8UXZ*O3S<S$Y-.4)CWJZ^P
M<Z?R6T9W7&$<$!4T/H:_/./LH5;^# T?<DS(<D(=S.Y4-N;7B"FIU-J$TR"5
MVIKS+4S,)!+I?UD/!_EUAA1KK[R"R$A(I9@U"S$Q&#8,,AFV;$%^\[TF AL@
M*FB4?!X[DFD3= @Y)F0Y=F:\JD:I.9=C9V%:5M/@8FLIJFTHJJJCI!(N()7)
M=*I5[ B?Z-X=@P:!HA 1@8\^PC//H']_K%Z-NW=16<FT<80G("IHE*S[.Y=I
M$W0+J4W(?GH*3&W-3$KK)*8FW >BNNJ&1AX'76PL7>RL+]Y[J-.IV2&$-!()
M<A7^&D4B%!=#]SD%"*I#5)!@H$1&1B8E)3%M!:$MW*U-BVK%8JD,%$RYG*XV
M%LZVEM4-X@?E5=7U#3J=FDU".'0H:FLQ8  ^_!!SYR(X&-.GP\:&:;,(3;!*
M!9^/F4M4D* 6WM[>.3DY3%M!: <3+D=&4;;F?#,3GJBNL4XL 73NP,4F(>3Q
MD)*"=]Z!5 I+2VS8@,\_9]HFH^7LV;/=NW?OTJ4+ISWH_JQ2P8]_W3=^YGRF
MS" 8* $! <G)R4Q;06@548/4VI0GI<#C<DIJ&^Y7U)AP.5UM+1VL+?F/,O3J
M"'8XR\CA\S%E"B(CT95D7]05@8&!-V[<4+V_7'X2$A)8HH)D+4C0@%FS9L7'
MQS-M!:%5+I74V9C U=JTN+J^JXU%>4V=J*Y1)).9\CA]N[OI=&HVK0@![-T+
M%Q=X>R,K"SU[XN!!I@TR*G[^^6<.AR-705-3TVO7KE$J0U208-"$A(087_8X
MHT%*45PNI[)1EE_=8,;C5M0V.%B:N=I9F9N:-$JEYGS=KMG8M")\\  +%B U
M%1]\   ;-V+J5-R[!QTOBCL)4Z=.W;QY,WW]V6>???KII\S:HSI$!0G:PMO;
M^_+ERR$A^LO&3F@7.E+>!!CFP5B4)YN$\,(%C!L'?_^FET.&P-T=A85P=674
M+&-@Y\Z=M J:F)B(Q6*FS5$#HH)ZQKBCSJ.CHU-24H@0$IK!IJU1#P^DI4%>
M=Z.P$-G9Y+!0*[S\\LL ^'R^@:K@\$DSB H2.@Z))B0HA4TKPK P^/@@-!3E
MY5B\&&?.8/Y\LB_:<3P\FK(3-38V,FN)6CRN*=$K;-(<@]G(-72,>#D(P,O+
MBQP3$EK")B$$D)B((T=P[AQ,3#!_/OKW9]H@8^#^_?L KEV[IL]).1S.Z=.G
M ?3OWY_/Y].-8K$X/3V]MK96*!36U-186EJV\3A],7S2#**"!"T2'1V=FIH:
M&1G)M"'& \?PTYZ0ZA-&SN#!@__^^V\ >OZ/YG X%$45%!1<NW:M5Z]>KJZN
ME965%RY<\/;V]O'QH>^V\2Q]0<X%]0E=F-?HWQ!^__WWI*2D??OV,6T(@46P
M8T5(JD_HC L7+@!8M6H5([-WZ];-TM(R+2VM2Y<NZ>GI_O[^KNVY/A$5).B4
MEUYZ:<V:-4Q;06 7[!!"4GU"9]35U0&8.Y>Q2NBVMK;^_OY__?67BXL+44$"
MXP@$ CL[NYR<'"\O+Z9M(; %=GB-DNH31HV;FYM,)G-V=FZ[&^,J.'.0)_VE
M_ZD)^H0.HF#:"@*+8(<0TI#J$PS1;KI1#6@V[,.'#YV<G%J[*V\$60L2=(]0
M*"25* B*L,E91BK%D"&0R3!H$!H:D)R,F!B2=[N#T +3]O\RA\.A5,[OSH&J
M'TW:*'&G\:J+'E/_BS:URO4U,Z\UFUL;D]DE*8O>$'1)6%C8I4N7F+:"P!;8
M)(0 Q&)LWXZ+%V%JBM&C05R<.XS6A7#]WWDS!WFV\2:NHF9H]G;/E!!J@"X^
M!^@!=KTAZ(QITZ;%QL:2( H"#3N$4 .OT88&5%2@:U=LWX[<7+SQ!AP<=&>@
MX<+4BK!=.5243$5A4+=4.FM%A0@AFTE.3DY)25FY<B73AA!8@6%ZC=;5(2@(
M__L?W-TQ9PZ>?19)23AS1K]&&R<']K>J<V/'L?<M4KY27/=W[M\'MX<+G[>P
M:BKI3*M.,UEJHY%N5WUIVQ(5=4ZS\6G#Y/\ZN7F5/,A1'$JIY8K?[X.LV_G9
MMY\>-E;>D\W"K".$0N'2I4N9MH+ %M@AA-V[HWMWI*0T>8W2].^/L#!45L+6
MMGG___Y#1 3>> -3IV+N7"Q>C+ P%!:2Q*1:(7C@\';[*+X7H\/*H17D[^:#
MQDQJUJ*TFR)[?_GNT,8?M&(&7UIO:6E96UO;1A]+2TM?7U^M3%?R0.V2ZVZ^
M?FZ^?O0UX_]K3$&"*%@.15'GS__GXM+-TU/53VEW[MS9MFW;_/GSS<W-93+9
M^O7K7WSQ12<G)_IN>GIZ2DK*N''C1H\>O7W[]ALW;KSZZJOR9PW3:[2B L[.
MD,EP]"A&C6IZELNF[X7 !,W>T]?]G=OR75YIX_BW%G10#[B4S*$FVZGJCE5#
M<=?V/I!965D-&## J?J.4_5=GJQ#:="5?CNM!8$H]>+IM) @"C9SZ=*EHT>/
MJOO4].G3"PL+WWWWW:RLK!$C1BC>JJFIF3=OWI]__OG22R^%A87U[-E3\2Z;
MQ&/H4-368L  ?/@AYLY%<#"F3X>-C9*>$1'8O1LOO !75X2'8\8,6%JB2Q>]
M6TQHCNJ;;*Q]%]; ,+ZTODOES5I3AQ*;'A66'HLVIK8]R-=[+SP3\TF)=8]*
M\VZ.U7<M&\OU8"2 Z+<6:O"4L4*"*%A+1L:5@P</:?#@[[__GIR<#.#0H4.)
MB8F*M[IV[9J:FKIOW[YITZ8U-#2<.'%"\2X[MD9I>#RDI#1YC5I:8L.&5KU&
MG9QP_#A.GT9X.,1B^/MCV3+]VDK0)AT_J=+B*9=+18:ZC]C6Y9=;>36:6*G[
M8*.)58F-GU/5[7J^0,91]5-INQ:V)I-C7GNG96,G/""D"0D)R<[.9MH*0G.N
M7[^Q;]\^S9RV^'R^J:EI[]Z]Z6O%6SUZ].#S^:M6K?+S\[M___[ @0,5[[))
M" 'P^9@Z%5.G-KVLK45K!0JN7L7__H?B8ER[AA]^0& @QHS1FYF$CJ/=TRDM
M#C5V[%BU1C.75 /00 5I9!QNK:F#H#:OW$K5PZJ'=L':^NEU6F<9FM#04%*)
M@CU0%'7APL4C1X[(Y%5IU<'7UW?!@@7RU!PRF8RC<+*6EI:6GIX^:=(D .[N
M[FYN;HK/LDP(/_D$^_=#(@$ B03Y^<I3K#UX@ 4+D)J*#SX @(T;,74J[MTC
MQ0L)6D$M83"1U-28.75DNEHS)_N:;-7[SWDN$,#J^3$=F90 (#HZ.BDIB0@A
M&Z HZLR9,R=/GE)LY/'44*B\O+S,S$P[.SMY2Z]>O:RLFCZAUM75>7EY_???
M?_3+S,S,M]YZ2]Z334)X_CPV;<+:M9@S!VO78O]^6+7R*?O"!8P;!W__II=#
MAL#='86%:"^G<R>$HB@.25.G2R8/?UIIN[IQA*JO\.IKJP%<^?=4NST);2,4
M"M]]]UT23<@&KEZ]UDP%APP9[.KJHOH(?#[?R\M+(!"</W]^P8(%T='1BA$R
M4JET^_;M\C?#BHH*M@IA3@Y>?!&C1R,X&$Y.6+,& P="*E6RSO/P0%H:Y,OG
MPD)D9Y/8"3:@'Q<89K?R5)Q=72-5=^D4.'01E17W?79<VHG]:DU!:(9 (.C;
MMR\)HF #Z4_F3HF,C!PR9+!:'^)=75V+BXL7+UY\Z]:MC1LWAH>'*]ZE*.J=
M=]X)"PNC7Y:5E2G>99/7J*=G4_B$OS_2T@# U!2%A4IZAH7!QP>AH;A\&8L7
M(S04'WQ ]D4-#GFU!PUJ/M!A SK27=9ZM-(LWW<!P%N?_<BT(<8 \1UE(4.'
M#E57!0$4%!0,'SY\T*!!)T^># \/+R\OKZFID=_MTZ=/;FZN7/\<GLQ$QJ85
M87@X;M_&IY]B_'A$12$U%7?OMKK.2TS$D2,X=PXF)I@_'_W[Z]?63H%,(N&:
M*/\-H75+KE[-7D(%+=ET\C)/UEAMSLPZOE>O7B4E)8HM6=>;/I >.'  *CB.
MJBZ62K/8M-N_#5PJ,N1&[OCQJY??^9_\%I>2!00$<"F9H@_JCA^_5''J3DAT
M='1<7-R\>?.8-H30Q+//#HN(B-#@0(>.%'1T=#QRY B HJ*BL6/'RL\(34Q,
M[MZ]^]QSSP&X??OVCAT[%B]>+'^634)H8H*S9Y&5A3Y]L'$C3I_&)Y^TNLYK
M:$!8&$:-PO;M^.LO^/F17*/:(N/,<:7MVMV.;#2Q=JR^JS<A_&+LRC\  "
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M6M+!\O;V]L'!P3=OWCQX\&!F9J;&)?9(9AG#IO&M$28'+UI,65US^G-2FX)
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MJ U:N SQP:6> #@>_PGO6*#N@FOJM=.$"1,*"PM5VZ>]O?W"A0M]?'R0_P(
MZ'0ZD:A+Z0#5KU^_>_?NV=O;]XK),HI9$*Z1T![RX19; =AZ_*<2CVDU@^SP
M#@?"")DI@W<44#OT]/14/E]FPX8-%R]>-#,S<W=W1]ZQLK+2T]-3[5DT@T @
MF)B8O'GSAD0B85[8\_YC6CXW&MU3 F9!+<0U"JEP<.%4EE_Z-4'*4G99[C*W
M 0!6,]$F2"+4\A\%O9.=G5U>7AYJ>=T$   @ $E$053>46@=9 L4F4S&Y_.?
M/W]N86%A;FZ.K2L=N!<V,S.#65#+)6W\B<IO<(S^$>] (*@'<G%Q4=,V%#T
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M8P;>@727XL:\=75UV"K+P&>$NL1OZ;H]G\]]^>0A ,#9S0L T'^@W8_A\P$
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MD%NESW=%CYK@ P!X6_+BF_F3/O1Q ,!??_VEILB[@V]FCJRFJ'1P568U!0!
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M\?&VMK:JC4%CS,S,D(-^_?IA[@3>$4(0!.%&A05E4!$1$145%;_^^FMQ<?&
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MZZ*B(C5UOF[=NEFS9J$K*.KJZH*"@JY=NX8V0";(*&[,6U=7Y^?GIZ9XU(1
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MU*BH*+5&I2;(\HF,C PRF8RY:"H^B5"G1Q%1/>.[0&A_1M>M'^7:,P*I/9%
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MMV[=IDV;NG7K1CT<-6I4>'BXDR9"D4BD5"K]_/QR<W,K?!,D0OZRT.;#N!V
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M4(;RY,F31HT:^?O[6[@F)25%+I>GI*2XNKIR8$O"UX0Q0B >!2_T@@IN7P+
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M$X-$2) (^0PEU@ LD,OE(2$A3$=1$9LW;]9H-/GY^?GY^6JU6J/19&=G&U]
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MM%]MC;9Y8/JBHJG+MIB<7#QA '50<GE<:7A24 ;LI[A%2.\." #<8W;AA']
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M@4!0VN93Y57<(I1X>TJ\/6UR1P#@E?)F.PLN7+A@Y94*A<+/SP]9$&P"8X0
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M=^_>I29AWKU[E^F(RB"3R5!0!NRD>+L6!Q?J!0"[HFN-FIT.DY*2\O3I4X%
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MKW)A_Q?"_@A-L#G@DR=/2B02>M^)KEV[AH>''SITB-FH2D)!&7",XG\)CA^
M8?/'! "W'3]^_-MOOZ4?BL7B9LV:I:2DF)2;818*RH##%'>-[KRRC]DX ,!A
MQ&*QR9F\O#R]7L](,*5!01EPF.)$6"VH.K-Q (##].K5*R(B@GZHU6IOWKP9
M%!3$7$1FR&2R(4.&,!T%\ (FRP#P3I\^?=+2TA8L6'#ITJ7(R,AWWWUWWKQY
M3 ?U"A24 4="K5$ /EJU:M7Y\^?/GCU;N7+EW;MW^_O[,QW1*U!0!AQ)8/P
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M!?I%@4%(A # ,/2+ K.0" & 82@H \Q"(@0 )J&@## .B1  F(1^46 <$B$
M, D%98!Q2(0 P"04E '&(1$" &-04 ;8 (D0 !B# 4)@ R1" & ,"LH &R 1
M @ S4% &6 *)$ "8@7Y18 DD0@!@!@K* $L@$0(  U!0!M@#B1  &(!U], >
M2(0 P  ,$ )[(!$"  -04 ;8 XD0 !Q-+I=CX02P!Q(A #A:1$0$^D6!/9 (
M <#19#(9%DX >R 1 H!#*12*X.!@7U]?I@,!*(9$"  .A77TP#;%B7!@0-C
M@#!F0P$ /L *0F";XD2X\\H^9N,  #Y0*I5)24DH* .L4IP(JP559S8. . #
M3),!%BI.A(]N/60V#@#@ ZE4.F[<.*:C 'A%<2*LV[P^LW$  !_(9#(4E &V
M>3E9AMDX (#SY'(Y^D6!A8H3871:#+-Q  #GH: ,L!/6$0* @V"F#+ 3$B$
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M1& I/; *BFX#@(.@H QP'A(A %B"?E'@/"1" + $!66 \Y ( ?C.\D +"LH
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ML P%98"?D @!H!AFR@ _8;(,<-#%DW_X^E=+4SP\O7\[(21-\9#IB)P "LH
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M9++^(M0",7.8=JY<N9*1D7'APH7KUZ_+9#)+2\MY\^:EIZ=KF/]00J%0(!!
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M @ =O=DL,[OO='SC +@C_1O>X?S+C1LWGCQYTJ-'#W=W=\B"BHJ+BQ4GC0$
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M&AD9&1<71\S6"NA)Q**B(L4NP89<1,S+RX-M,@!@"[?N$[C4^"9X87&"AV<
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M!$ OH!,OT(7N1;>#@H*F3IW*X_'&C1LG$ @2$A(.'#B =9@F D:$ .@%')P
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MOU.G3EY>7JT/_B,(DIV=[>KJJH^G8P(2(0#MP.?S(R,C=;^/6"S^[KOO5%Q
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M4DT0.SL[!$$(_K,#Z)7:<X1J*ZBM7+DR/#Q<,1>N7;LV(B("VSA-XS@0)$(
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MK:V/CP\NA7),WH\__JCZ@J%#AW[VV6<3)DQ _T00A$:C*?YG<_'B19E,AM8
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M:M4J=W?WS,S,[HP4%Q=OW+BQNU>5E9555%24E)04%14EU#WCW]^[3#6I1TJ
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MK(:&AC-GSL3%Q1%S58BND(5.O+Q45E92J51865%!06'3IDU)24F5E950!0$
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M_T%P!;TD+80B>W)^?GY,)K.QL;&QL9'%8NGHZ(A6Q)4H#U76[ A)5545IH(
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M1'6W$0@$ B&'((\0@4 @$'+-1R%$K2<0" 0"(9_\QR/LR]51\V'SX+\^.R-
MR[\(! *!X$-!VA.0&IV=G=*> @*!0""D#]HC1" 0"(1<\__::#CE!>_M5@
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2L EL# 2(  A$! Q$!_\0
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M'7?^8YTO_P"+KZ'HH_MK'_\ /S\(_P"0>QAV/GC_ (5/^T[_ -'7?^8YTO\
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M)W_)K'P;_P"Q,T;_ -(8:]5K]!. **** "BBB@ HHHH **** "BBB@ HHHH
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MRJJ"Q5 20 ,YP!TKH*_4SS HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $NTNO;R7_?Z?S_])9C6^!GZ14445^H'FA1110 4444 %%%% !1110 4444
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M.[Y6R0">YR&Z<8Q71.DHQ4HLXZ5>4YN$U9HZZBBBN<[ HHHH **** "BBB@
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MZW_AN'_J@'QS_P#",_\ MU?"YE5Q6/G91M!;*Z^]Z[_D=M-1@O,^F**^9_\
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ME_-TQO3UKU\IPM:GC:<I1TU[=F959)P:1^MU%%%?HQYX4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>?^*?VA?A9X&UVZT3Q)\2_
M!_A_6K7;]HT[5->M;:XAW*'7?&\@9<JRL,CD,#T->@44 >5?\-8_!#_HLGP_
M_P#"HL?_ ([2']K#X($$?\+D^'_/_4T6/_QVO5J* /#=3_: ^ FK73SS_&GP
M.2V!M'BK3]H ';+Y%6M#_:1^ ^@1S);_ !F\!OYK;F:7Q58LV!T&?,Z#G\S7
MM%%6YR:LV9JG"+YDM3RK_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\
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M*^U/6SLW?:U^:R61\<-"\%P?$323J6C_  \T[4-4L[B:;6_&=A',)S&T*K$
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MRA_Z3B#GD[X.?^*/Y3/=:***^U/("BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KXC_;N_P"3I_V.O^QS'_I=I=?;E?$?[=W_ "=/^QU_V.8_]+M+KV\E
M_P!_I_/_ -)9C6^!GZ14445^H'FA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '@O[0?[0:^#EE\,>&7-SXGGQ')+$-
MWV3=T ]9#D8';.3V%>Y6&_[!;>;N\SRUW;NN<#.?>OD.+7]*^%G[3>OWWB[1
MV,%U=O+:7L@)^S*[$K.J]&!'!(Y7G'((K["1UD174AE89!'0B@"#4MW]G76Q
M_*;RFP_/RG!YXY_*O'OA1KOB*X\=MH^N^*]$U.2UT_[0FDV<MR+N")A$B,ZR
M@%T)1SYDFY]S$!L9%>S7"[H)!N=,J1NC^\..H]Z\2^!UQI>F>);K0O#VA^(-
M.TV.%[FZOO$ MH+B^G+!1+)&?]+DD(5LR3A3C;]X,I !4NO&>CQ_&"YM[CX@
M&RO8[Z#3;7P_<7<RB262YB:1C&DI#%E2.*,%5"@R,0?,;/OE>377BN[T/Q5=
MZ1;:9J"V]YKENTFN1W6G_P!G1%GB#6[!YO-61EP-@C+L\@*G!!'K- !1110
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M$C.(PQ(FSMR<],X[5E?L]^.&^-WP+T+PKX \;ZMX*\9>&-,BM[DMIL<]M(5
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MO_L<$_\ 2W5:^ZP.*J5Y24^APSBH['Z"4445[!D%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445YWXR^-VD^&/$O\ PC.E
MZ1K/C7Q6HC>?1?#=NDLMI&X8I)<2RO'!;A@IVB65&;^$-@X /1**^;? /[2/
MBQ/$?Q)_X3+X<^+;31])\0PVD<MA%8ZB-'@;2["8Q2QVLS7$IWS/,6CCF"B<
M+N^3"^_>%_%&D>-?#]CKF@:E:ZQH]]&);:^LY1)%*O3*L..H(/H00>10!J44
M44 >=7'A'XAR7$K1>-M!CC+$JC>&&8J,\ G[6,_7%=9>6DG_  BOV/4M52VN
M7MUMY=2@BCB E("^8D<N]%)<Y56WC) .[OY5\1(M4M/B7J%YX4G\5R:FVFVP
MU6#0+?37A2)7F,)8WF"TAW2X6,DX SC*Y]&L;+2OB+\.M/BO)I=<TK4[&"4W
M,P,$MP"JNLI\O:8WSAOEV[6Z8Q7#3:<IPBG?7=NS]-?OTT/J\93J1I8?$5IQ
M<'RM\L(J<;J_O)12?5QO*TEKM>W)>'_@E<6(L6NOB%XCU>&VO%N_*,=A$DK)
M/YJHSQVPEVY !42 $ KPIVU-XT\.:+X[^*6EZ+J?AK1M5BM=-:]NKO4X?,F$
M;.R1Q0#H/G!9B<@  8RV1X]X5TBT\,:UIM]9^)%EBC\3?V>GA.77=3:_7-\8
MRS_Z9L=ER9F1K?:8P=Q/,A^@/B'X3\-ZW;VVI:[>3:--8GR[?5K34)+":'S6
M5?+$J,I(=M@V'(8[>"<5S4K5*32BE:VC=[KU>W];'M8YSP>.A*=:4N932E&F
MH-2>FD8M<SU6J=NSE:Q@_"[1=.\&^-_%_ARST'1M*:*.UU"*YT> PB>UE>X6
M%)E)/[R,PR@L#A@P("\@<7\3/B;X?U+QU;V2^./#6@W&FQW5I?:)XQ@,EO*P
MEBV2B/SHP'&W*,<DH[8XKT?X70>#+0ZW;>%=275KV*YVZI=37TEY=/*N4'FR
MR,S$#:RCG:-K 8P1537/BBFD>-%TH>!/$6HZKY,I@NK.WM&62!63>RNTZE4+
M%.&"Y...*N44J"CS)*_2[Z[:6.:C6<LTJ5G3E.:BOB<8._(DY-5%-6>]NBLU
M:QTGP_U@:_X0T^^75=(UM9 ZB^T)=MG(%=E C&]\;=NT_,>5/3H.BK#\%^+(
M/&_AV#5[>SN]/622:%K2_14GA>*5XG5U5F (9#QGZX/%>%_%'QWXKMO&?B'0
M[;7Y=*N+-&U"QA@N[&-IMZV]O91!7.\QM<S2-*9 !\JJ#A@#T3KQH4HS>M^W
MIYGCX7*:N:8^KAXM4W%MM2>WO6MHK.S=M$EZ'T5=V<%_;26]U!'<V\@VO%*@
M9&'H0>#6/_P@/AC_ *%S2?\ P!B_^)K<3=L7=C=CG'3-.KJ<8RW1X,*U6DK4
MYM>C:,'_ (0'PQ_T+FD_^ ,7_P 37*?%+5?AA\%O FI>,O&=AI.C>&]-\K[5
M>_V3Y_E^9*D2?)%&SG+R(.%.,Y/ )KTFO#/VTO#6F^,_@+-X?UBV^V:1JWB3
MPW87EOO9/-@EURQ21-RD,N58C*D$9X(K*:A3BY..QJL5B&[>TE][/*O^'A/[
M'?\ T-6D_P#A)7__ ,B4?\/"?V._^AJTG_PDK_\ ^1*]O\+^&M-\&>&M)\/Z
M/;?8](TFTAL+.WWL_E01($C3<Q+-A5 RQ)..2:TZ^.?$$+Z4/Q_X!U\^(_Y^
MR^]_YGS[_P /"?V._P#H:M)_\)*__P#D2N0^+O\ P4*_9)'PU\0C3&M/&>I-
M:LMMH5CH-U82W4I(" 7$ENBPX)#&3.Y0I*JS!5/UC14OB"#5G07W_P#VI<*V
M*IR4X5I)K5.[T?WGP/\  ?X1ZUJ'Q5\*_&3]H^UU*?Q-?V%K;>'(-8F\VUT:
M="PB6:,C,,Q79)&KYVR22,Y,YRGWQ5/6-&L?$.EW.FZG:0WUA<H8YK>= R.I
M[$&O-+/5M0^"5U!IFO74^I>!96V6>O7#%Y=+).$@NF/6+G"S'IPK]FKY?$8B
MIB9\]1^GDNQ] J-/-8\U"*C7ZQ6BGYQ727>"T?V-?=/5Z*16#J&4AE(R"#D$
M4M<Q\\%%%% &9X:\4:-XST6VUCP_JUCKND7.[R-0TVY2XMY=K%&VR(2K8964
MX/!!':M.L#X4_"OP_P#"_P )Z7X+\':>ND:#8^;]EM&GEF$>^1Y7^>1F<Y=W
M/)/7 P,58U[QOX5\-:G/INH>*M(BU&V(%S9QSF6:V7;N+RHBEHHPI#-(X"J"
M"2 17?3P5;$7EAX.4;V_X?S(<U'23.BM-*NKZ,R0Q;T!VD[@.?Q/O4DFA7T4
M;R-!A$!8G>O '7O5#XF:4]C\*M;2;[2[QO#<HVGJ'>-DEC97(*M\JE0S?*V%
M#'!Z5Q/PEU'7-,UV^TB>XU"]\-ZE:ZIJVGSW\<44\C-=K))-)"L*M"DCW$AB
MRY+(&)5<"OIZ>14GAO:57)2M=K3?[CF=9\UEL=M1117Q)V!1110 4444 %9G
MB7Q1HW@S1;G6/$&K6.A:1;;?/U#4KE+>WBW,$7=(Y"KEF51D\D@=ZTZYGXD_
M#;PY\7O!6H^$O%NG?VMX>U'R_M5GY\D/F>7(LJ?/&RN,.BG@CI@\9%7#EYES
M[=;"?D=-1114#"BBB@ HHHH **** "OA[]OC_DYW]C__ +' _P#I;IE?<-?#
MW[?'_)SO['__ &.!_P#2W3*]?*?]\AZ2_P#2695?@9^@-?$/_!-C_DYW]LO_
M +'!/_2W5:^WJ^(?^";'_)SO[9?_ &."?^ENJU]CE?QR]#CJ;(]U^('Q5^)M
MKXM\2V&D6216FD6UW>116EM:O+NC"?95N));KB"?,K.PCC9!& &Y+5]'UY=X
MJ^ .C^+-!\3:9->SV;ZM)=36^I6D:)>V+W"%9PLN/WB-G[D@(VX4Y"J%]1KZ
M,P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ7X
MO?M7^%_@=>ZLOBKP]XQMM)TQ8FGU^V\/SS:9^\4$8N%&TX+!3TPW'6O:J^8_
MC5^QUK?Q=^,EKX^7XG7%FFG*G]E>']5T2#5=-TYP@5Y8X)7">8Q&[S"I8'&"
M-JX .H^+7[6G@OX?_ 0?$&WU[3+2ZUG2);[PQI^OR_8I=3FVJ(E$,K)(4#RQ
M%R/NHVXD#!K/^%?QH^ ?PL\(0:/;?&KP#J%]([7>J:O-XFL1<:I?/@S74Q\X
MY=V'3)"J%1<*B@7_ (^_L\Q_&'X$76BZ_8:-XY\>Z9ILCZ1K&IZ5;H6OEV2
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M#L/#>EZ[X@BOC>^%_#Z07E]&-)T^V,D$EQ=72VR[K=HRKQM)NB9U=0Z!?<?
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MN=C14-E?6VIVD-W9W$5W:S*'CG@<.CJ>A5AP1[BIJ#S6G%M-:A1110(****
M/+-6\-ZG\)]1N=?\(V<NH^'IV\S4_"ML.4).6N;->@?J6B& _)&&Z^@^'/$F
MF>+=&MM6T>\BO]/N5W1S1'(/8@CJ&!R"IP0000"*TJ\U\1>#M4\%:W<^*O!,
M"S?:9/.UGP[NVQZAQS-#GB.X_)9. V#AJ6Q]%&K3S6*IXB2C67PS>BEVC-]'
M_+/Y3T]Z/KGA[_D,6_\ P+_T$UP%WX3\6:;K^LQ6$VN7,%SJ$]W$+37;:V0"
M1R^U8WC9AC..3SC.!TKI/A;XQTOQU%8ZMI$YFMG+HZ.I26&100\4B'E'4\%3
M7G_Q?T[PSJ#:[+?2^"[.*]FN+,ZFOAB:]U*!HT'G3AXVSF'(+3<)&P&X@C%?
MHG#O^Z2_Q/\ )'R>-I5*%9TJL7&4=&GHTSV+XKR1Q?#[6'ETQM7C5$)ME>1,
M?O%_>EH@9%$?^L)0%P$.T$XKS+X;?8$\36UEI^N:1XNL['1;_P F]T*:=XM/
M:2:)Y$G,D\^^29CD,\@8"%@JX+$>O^*=7N_#_AJ6_P!/LI=6F@,1\B)6DD>,
MNHD90H)8A"S  $DC '->?:'XOUSQ1XKA?4=/ET^PGT[4;FTMU6ZMY;>&.9(8
M_M<4@"EIA^\3*JR;'5=X+M7T-?\ A3]'^1QQW1K4445^-GK!1110 4444 %%
M%% !1110 4444 %%%% !1110 5\*_MN1WFA_M8?LZ.EQ!+I_B?Q5H2S0- PE
M@ETN_D\MEDWX*N-9E#*4R#"A#<D5]U5\/?M\?\G._L?_ /8X'_TMTRO8RG_>
MXKNG^3?YHRJ_"?77PN_9S^&OP5UG6M6\$>#]/\/:CK#9O+BV#%G&XML7<3Y:
M9.=B;5X'' Q\T?\ !-C_ ).=_;+_ .QP3_TMU6OMZOB'_@FQ_P G._ME_P#8
MX)_Z6ZK7V66R<JDG)WT..ILCZ<\0:/8W6A>.KJWU_5[3P2EQ=?VUIMM:1OYN
M%!O?LLA^=48F42  MO$OEE6P3[-&5,:E,;,#;MZ8[8KP_P")H\,>'-)\8I=_
M$)=+\.S17-[K'AVWFM3=,#&6N(H&<AHC,-VX<G<[%&C)R/<5544*H"J!@ #
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MLD6SED\L6UQ'&+@1I+;A'",BJ29&8_-@U[_7T9@%%%% !1110 4444 %%%%
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M-Z11DLS7$A8L6).#QSG[W"826&DVW>YPRES'NU%%%>H9A1110 4444 %%%%
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M8G9E5\>A*,/PH.?%8&MA96:YHVNI+6+C>W,GVOH[V:>C2::+M%%%!YP4444
M%%%% !1110 4444 %%%% !7PS^W5I=G%^US^R#J*6D":A<>+8K>:[6)1+)%'
M?Z>T:,^,E5,LI4$X!D<C[QS]S5\1_MW?\G3_ +'7_8YC_P!+M+KV\E_W^G\_
MR9C6^!GZ14445^H'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7DR_NYW>_FG!A5V"2>5/9AV'#84!FV<>F5\S7NZCYM]+^MM?^#YG0M@HHHK
MH*J:MI%CKMA+9:C:0WUI+C?!<('0X.0<'N" 0>Q%6Z*"HRE"2E%V:/CW]H*R
M^*WACQE'#X>U36K#P7%:,D%^+LR&)6FM4</*,-N\R6/8LCEV6.7!V[P/-+76
M/'$>J&*Y^)OB;4&1-N+2Z,;HQYP69V'1#D8':O;?V[=7U7PC\/M0\32-?_\
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M5=T;R%0P0JW(^M: "BBB@ HHHH **** /!O!T3S^/_C7'&YCSXVMS(XBD?\
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M  C^B%V^56P!@9/&."#G%>\T %%%% 'QWXL_Y2>1_P#9'A_Z>C7OU> ^+/\
ME)Y'_P!D>'_IZ->_5^;9]_OK]$>A0^ ****^=.@**** "BBB@ HHHH ****
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M_(S_ .W5^IZ^4_[I'Y_F%%%%?$'L!1110 4444 %%%% !1110 4444 %%%%
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M\@FHXIQMNM^QS5U[MS]&:***_1#@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#F/B-H&H^*/"UQI>G0:%=FY8)/;>([)KNSFBYW*T:LN3TZY''0UY[\
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MYTZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XO\ "/\
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M?\GJ?LU_]S+_ .FU:^T*_-.+HJ.967\J_4]C*Y.6%BWY_F%%%%?%'K!1110
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M1Z9J-W]H/E0M?-YLC,<1 (QMFD9BHC8=?IF@ HHHH **** "BBB@#RKX-_\
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M9A+>3ZVPAC/EJVP,01O?"@XR1D5]15^;Y]%K&7:T:1Z%#X HHHKYPZ HHHH
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M1KF_B!KI\/\ AR6YCN9;6?=^[DB5" 55G._<K?)M1BV 6P#M^;%7%7DD#/S
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M ,=K\3_AOX.T"^\)_!Z:YT/3;B:^\0^'8;N26TC9KB.75=?CE20D?.KI!"K
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M#WAO2=*'QX^,$(L;2*V$>F>)S:6J;$"XAA\MO*C&/E3<VT8&3C-:7_#'<_\
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MI1<(Z?-]3EKPISFY.6K2\NB/;?\ AH+X7?\ 12?"'_@]M?\ XY1_PT%\+O\
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M$'QX\!>(/V2-2M_^$J\(:;K=]X'EC_L#3]1MXOL]P]@1]FB@WEEVL=BQ\D8
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M:QJUGJ,&DOX736P(O[*T^W^TS2J3]FW/!(H24K\L>_&UP3]UU\#?&G]I&/\
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M 4444 %%%% !1110 5\<_MG_ /)T_P"R#_V.:?\ I=IE?8U?'/[9_P#R=/\
ML@_]CFG_ *7:971A_P"(COP/^\1^?Y,_3FBBBO8/K#E?#OPST#PAXBOM7T.V
MDTDWZM]JT^TF9+&65G#&?[.#Y:S$YS(JAFW'<6.,)X4\6ZOJFJ7NE:]X8NM!
MO[<&2.XBE%W87<60 T5P%4@\C*2I&^0V%91N/5T4 %%>83?#_P 2_#^66[\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?D!X,_:B\4_M$_MA?!/5]<L-+T6_7Q'HVE7$FA?:85O;4:I!.D,R23
MNK*DHWC 'S8)SM3;^O\ 7QC\=]/B\0?MZ_#N/4&GN8= TWPYJNF0-.XBM;J7
MQ;96TLRH#MW/"Y0Y!R O=%(Z\,TI6:/4R^48U+-;_@?J#1117JGTX4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'E7P;_P"2B_';_L<[;_U'M&KU6O*O@W_R47X[?]CG;?\ J/:-7JM
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MVW_J/:-7JM>5?!O_ )*+\=O^QSMO_4>T:O5: "BBB@#XJ^)'_*3&#_LD2_\
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M@FMXV8JVZ10R-"2N[(^]N%>K5TGHA1110 4444 %%%% !1110 4444 %%%%
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M#$\D8=7V[L@'S-N"S9ZL/&\FST\!!RFY7V/W*KPC_@GM_P >/[0O_98O$/\
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MI_8VJ0WGE>=Y>[Y-VW.5(ZX/K67J'AWPSJ,NO22Z7>;M8AN8) =0++;+<_\
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M++Z$Y%=Q72>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'E7P;_Y*+\=O^QSMO\ U'M&KU6O*O@W_P E%^.W
M_8YVW_J/:-7JM !1110!^<?[3?\ REJ^"W_8F3?^@ZO7U37RM^TW_P I:O@M
M_P!B9-_Z#J]?5->7BOC7H?-9E_&7I^K"BBBN,\D**** "BBB@ HHHH ****
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M4NY;X7&A>$K:3[9,7@>!I%1XE/E-"Q <.#YC<#G,?_#(/[0?_1UG_F.M/_\
MCM93PKO[C^\Y:N6._P"Z>GG_ ,!'JE%>5_\ #(/[0?\ T=9_YCK3_P#X[7.?
M$3_@G[\8OBOX.U#PKXJ_:<_M30;_ ,O[3:?\(!9P^9LD61/GCG5AAT4\$=,'
MC-0L+/JT9++*M]6OQ_R/0/\ @EQ_R8G\,O\ N)_^G2[KZJKRK]ESX%_\,U_
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ML&4@RD-Y>-\?RR/E\91_MFO,Q2]Y,^<S)?O%+Y?U]X4445Q'CA1110 4444
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MJ"/I"O'?B1_RDQ@_[)$O_IY:O8J\K$M\]CYC,6_;6"BBBN0\L**** "BBB@
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MWO /[ 7QC^%_A.R\,^%_VFUTK0[-I6M[-/A]92+&9)6E?!><G!=V.,X&<#
M%?=%%/DC:UBO94VN7E5O0^./^&0?V@_^CK/_ #'6G_\ QVJFK?LB_M(0Z5>R
M:9^U';WFI)"[6MO=^ K""&64*=B/(K.44M@%@CD DA6Q@_:5%+V</Y43]7H_
MR+[D?G'_ ,,R?MY?]%I^'_\ X#+_ /*NC_AF3]O+_HM/P_\ _ 9?_E77Z.44
M>SA_*@^KT?Y%]R/SC_9W_8#^.G@W]L3P_P#&SXF^+_!_B*6V^T?VA)I<TRW$
MV[3Y;2+9&+2*/C='GE>%)Y/7]'***M*VB-DDE9!1113&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >5?!O_DHOQV_['.V_P#4>T:O5:\J^#?_ "47X[?]
MCG;?^H]HU>JT %%%% 'YZ?M.?$"_^'7_  4D\*7=GH0UNWU+P%INBWCF]6W^
MPPW7B P"YP5)EVR/$OEK@G?G("DU],5\(_\ !3EKJ/\ ;$TR70K2_OO'=OX
MTZ\\*P:9:RW4QU&#77G+"%%8.%MXKIR)%*?+DC(6ONZO,Q2]Y,^<S**512[A
M1117$>.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YQ^TG_P F
MZ?%/_L5=5_\ 226O1Z\X_:3_ .3=/BG_ -BKJO\ Z22U4?B1I3^->IH?\$N/
M^3$_AE_W$_\ TZ7=?55?*O\ P2X_Y,3^&7_<3_\ 3I=U]55[Q]N%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?M)_\FZ?%/\ [%75?_226O1Z\X_:3_Y-T^*?_8JZK_Z22U4?B1I3^->IH?\
M!+C_ ),3^&7_ '$__3I=U]55\J_\$N/^3$_AE_W$_P#TZ7=?55>\?;A1110
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MOJFOE;]IO_E+5\%O^Q,F_P#0=7KZIKR\5\:]#YK,OXR]/U84445QGDA1110
M4444 %%%% !17%>%?'>KZ_\ $GQUX:O/"E[I&E>'_L/V#7IR_D:OY\)DE\K,
M:K^Y8!&VN_)YV]*[6FU8IIQT84444B0HHHH **** "BBB@ KSC]I/_DW3XI_
M]BKJO_I)+7H]><?M)_\ )NGQ3_[%75?_ $DEJH_$C2G\:]30_P""7'_)B?PR
M_P"XG_Z=+NOJJOE7_@EQ_P F)_#+_N)_^G2[KZJKWC[<**** "BBB@ HHHH
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M_P"DDM>CUYQ^TG_R;I\4_P#L5=5_])):J/Q(TI_&O4T/^"7'_)B?PR_[B?\
MZ=+NOJJOE7_@EQ_R8G\,O^XG_P"G2[KZJKWC[<**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^==%^$?P<_:$\8_$74M=^$?AN\U+1
MO$+Z+<:M?644T^H2QV\#M*3L! 'FA "2?W>>.!7T57R_XCU'QO\ LP_%CQCX
M@TSP)K7Q&^&7C*[CU>X@\+1K<:IH^I"&.";%LS*9H95AC?*'*L'XY&0!OCW]
MF_X!_ RY\*>,K;X1Z1'>0>)M)M+>\T]3 ]C//>1107. <$)*\9(]/7I7U%7R
M?>^-/&'[6WBGPGH=A\-?%?@'X=Z1K-IKNMZQXVL1I]S?-:2K/;VEM;%B[!ID
MC9I&P J$=2,_6% !1110!Y5\&_\ DHOQV_['.V_]1[1J]5KRKX-_\E%^.W_8
MYVW_ *CVC5ZK0 4444 ?G'^TW_REJ^"W_8F3?^@ZO7U37R'^V6=8TW_@IE\+
M?$&D+9O_ &/X7TL7B7F[FVO-9GTQ_+"XS(/[0##) &W)SC:WUY7EXKXT?-YE
M_%3\@HHHKC/("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\X_:
M3_Y-T^*?_8JZK_Z22UZ/7BO[:/C#_A!_V6/B3J/V3[;Y^E-IGE>;Y>W[6RVN
M_.#]SS]^,<[<9&<BH:R2-:2;J12[H[/_ ()<?\F)_#+_ +B?_ITNZ^JJ^5?^
M"7'_ "8G\,O^XG_Z=+NOJJO>/M@HHHH **** "BBB@ KYR\1?MS^#;#Q%JFE
M>&O"'C_XDQZ5<-::AJ?@GPW+J%C;3*</&9LJK,O?9N_2O=O%]U-9>$]:N+=S
M'/#93R1N.JL(V(/YUXK^R)XU\!Z#^S)\*M*LO$F@6TL7AG3WN+9-0A5UN'MT
M>8NN[(<R,Y;/.XG- 'HOP=^.'@[X[^&YM9\'ZH;V*VF-M>6EQ"]O=64XZQ3P
MN \;#W&#U!(YKO*^>M,_LBS_ &WH[S09[1E\2> KF?5392*RW$UG?VL=O))M
MX+A+R5 QYV@#H!7T+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<KH/Q,T'Q"/%[6U
MQ)''X5U"33=4DFC*K%*EO%</C^\HCGC.1[CM755\;ZUK'Q:^&>O?&W1-*^"&
MM>,='\6:W<:C8:WI^KV42%)=.M;;!B>0/PT#'G'7I0!]/7_Q2\+:;X7\/^(I
M]63^Q-?N+&UTR\BBDD2YDO'1+4#:I($C2( Q  W9) KJJ^#],\6?$?7?AG\%
M?AC?_ SQKHEQH&L^%$O=;G6VEL8X["[M6FE8QRE@NV%CG' ZU]X4 %%%% 'E
M7P;_ .2B_';_ +'.V_\ 4>T:O5:\J^#?_)1?CM_V.=M_ZCVC5ZK0 4444 ?F
MA^VA;0ZI_P %)/AOI0TC^U=5O?"^BOI[[8O]$:V\0/>W$^YV&W%I:W:Y7+'?
MM .XU]>5\K?M-_\ *6KX+?\ 8F3?^@ZO7U37EXKXT?-YE_%2\@HHHKC/("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\#_ &\?#NH>*/V2?B)9
MZ9;_ &FYBM(+YTWJF(;>YAGF;+$#Y8HI&QU.W !) /OE><?M)_\ )NGQ3_[%
M75?_ $DEJX.TDS6D^6I%KNC0_P""7'_)B?PR_P"XG_Z=+NOJJOE7_@EQ_P F
M)_#+_N)_^G2[KZJKW3[8**** "BBB@ HHHH JZHADTR\06JWQ:%P+5R LWRG
MY"3P >G/'-?"DWPGMYQG4?V ]%C'<Z;K>AM^6&0_I7W;J-_#I6GW5[<,5M[:
M)II& R0J@D\?05^><_[:?A_]J_4;BQNOBSI/P.^%22-%)"VIQ0^)=<0'!!?)
M6QA/L6D8#J W !W?['>O_"9_VA/%?ASP?\#)OACXTTG17&JZA!=6]U;QQM/#
M_HCO;S2(LK,%?8<-B)NF*^V:\:_9W\4? NQT>+P1\'/$'A&YM[&!KIM*\/:C
M#<3[ 55IY0K,[G<R!I'R267)Y%>RT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7AOP
M\\5^*O'%M\><:C+<7FF^(;S1="M(PD?V-8M/MC&%; .YI97?<Q/WAT KW*OG
M+QYX&^*/PD^*6O\ C_X3:3IOC;2/$_DR^(/!6HWXT^5KR*-8EN[.X8&-6:)(
MU='&#Y:D')X /-KOX??%7X(^"?AOXXU;XQ^,]6OFUGP]:^(?#.M/:3VY%Y=V
M]O<PJR1!OE:<X(8_=ZGK7VM7S#::1\8_VA_&7A5O'_@6Q^%7@+P[JD&N3:8V
MMQ:KJ.KW<!WVJ%H1Y<4*2[9&!)9C&@& 3CZ>H **** /*O@W_P E%^.W_8YV
MW_J/:-7JM>5?!O\ Y*+\=O\ L<[;_P!1[1J]5H **** /SC_ &F_^4M7P6_[
M$R;_ -!U>OJFOE;]IO\ Y2U?!;_L3)O_ $'5Z^J:\O%?&O0^:S+^,O3]6%%%
M%<9Y(4444 %%%% !1110!SFA_$3P]XD\8^)O"NG:A]HU[PU]E_M6T\F1?LWV
MB,R0_.RA7W("?D)QT.#71UFV/AK2-+UG4]7L]*LK35=4\K[??06Z)/=^6NV+
MS9 -S[%)"[B< X&*TJ;MT*=N@4444B0HHHH **** "BBB@ KSC]I/_DW3XI_
M]BKJO_I)+7H]><?M)_\ )NGQ3_[%75?_ $DEJH_$C2G\:]30_P""7'_)B?PR
M_P"XG_Z=+NOJJOE7_@EQ_P F)_#+_N)_^G2[KZJKWC[<**** "BBB@ HHHH
MS_$.I-H_A_4[]8UE:UM99PC=&*H6P?RKQN'XJ:)>_!CX5>-M;\(6-U-XW;0K
M=K.**-UM9=1$0SEU^94:7ZD"O9=>TPZUH6HZ>)/)-W;20>81G;N4KG'?&:^*
M=:_9K^,WASX:^"M#O/V@?!L?A;PG<Z9+I4NI^&EMD#V13[*KRBX^;F-01G+8
M- 'TE9W_ (;\)?'S2_!^E>#-*TZ^U/PU?:NVN6<,4,H2"ZM(C;E5C!96-RKY
MWX!C'RG.1ZG7S+\$?!WQ%U?XYQ>-_&_Q"\"^,;?3_#=YHUK#X3@>&53<75I,
M7D!D<%?]%QP1RW>OIJ@ HHHH **** "BBB@ HHJMJ,D\6GW3VOD_:5B9HOM+
M%8M^#MWD9(7.,D=J +-%>6_#']H#2/B-=1:<NEZM;:H9I;=I[/3KF^TAWC4L
M[1:G%$;9XS@@%G1MPVE%?Y*]2H **** "BBH+^::VL;B6WMS=SQQL\=NKA#*
MP&0H8\#)XR>.: )Z*\]\(?'KP/XPUQ?#L>O6>E^,1(\$OA35+F*#58943S'0
MV^XL^$RV^/<A4;E9EYKT*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OES6O#7C7]IWXM>/-,C^(_B'X=_#SP9?Q:'%;>#IDM-0U.^-K#<SRR
MW+*S)&@N(T5%'S88D@U]1U\N'PM^T)\,OB#\1+KP-X?\ Z_X9\2Z^=<@.L:O
M=6UY&6M+:!D8)"4 _P!'R.3]Z@".TTGQ]^RKX\\'17GQ#UKXF?#+Q-JT.@3Q
M>+#'-JND7<^1;3)=(J^=$\@6-D<?+O4C/-?4]?(_C*U_:,^*5]X,T;Q'\,_"
MFEZ+9>*]&UF]U32_$QG>&&TOH9Y"L4D*%B5C/ .?K7UQ0 4444 >5?!O_DHO
MQV_['.V_]1[1J]5KRKX-_P#)1?CM_P!CG;?^H]HU>JT %%%% 'YQ_M-_\I:O
M@M_V)DW_ *#J]?5-?&7[?6OZ=X+_ &\_"WBS4UOH+;P]X-T6_?5+&5E_LZ$^
M)/)N99%1PTD;6TUQ 459"WV@?)C++]FUY>*^),^;S)?O4_*W]?>%%%%<9Y 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G'[2?_)NGQ3_[%75?
M_226O1Z^>_\ @H!J5YI/[(7Q"GL;J>SF>*T@:2WD,;&.2]@CD0D'[KH[(PZ%
M6(.035P5Y)&U%<U2*\T>F_\ !+C_ ),3^&7_ '$__3I=U]55\J_\$N/^3$_A
ME_W$_P#TZ7=?55>Z?:A1110 4444 %%%% &%X\CO9? _B)-,#-J3:=<+;!/O
M&7RFV8]]V*^>OAY\(/#GQ]_8V^!^AQO93>&[.ST'4;FTN;87$-VMLB&>VD0D
M#+,'1B<X;.0:^G+NZAL;6:YN)!%!"C222-T50,DGZ 5\MM^S]J.F,OBSX'?'
M*;X:>%O%TJ:FFDW&EVVKZ1/+<X=9;..=D,)E+!]J-@EN%'2@"SX6^$'@?X-_
MME^&K7X?^&]-\,IJ?@?5I-7L]*@6&,JE]I_V>5E7C)9IE!] ?2OJ&O%O@K\'
M].^%/B_5KSQ'X\N/'WQ5\0VBS7FIZLT,%R]E X4);6D>!#;(\PR$!&^4;CDJ
M![30 445@^/M3U+1/ OB/4=&MS>:O::;<W%E;B)I3+.D3-&FQ>6RP VCDYP*
M -ZBO&?#O[0(\5^/K/0+#2]3AAN=;:UCEU'P]J%GNL5TMK@S;YHD56^TJ8N>
MH& N2&KV:@ HHHH *RO%GV'_ (1;6?[4N4LM,^Q3?:KF58V6&+8=[D2*R$!<
MG#*5XY!'%:M8OC:^U+2_!FO7NCVHOM7M["XFL[4J6$TZQL8TP.3E@!CWH ^?
M_@9\0;KQYXXTF7P_\5CJO@B&.18=,UHZ2+_5P(F"&&WM;>&2VB3AP9/G8(08
MD7YC]-5\Z>![GPW8^.? 5UX9^(LOCN^UMYUOX;JYM[IF@%I-(UVL:(&M2LJQ
M1D+L0>>49=S+CZ+H **** "L_P 06GV_0=2MO/2U\ZVEC\^0N%CRI&X['1L#
M.?E=3QPRGD:%<]\1-0ATGX?^)KZXTV/6;>VTNZFDTV50R7:K$Q,3 @@A@-I&
M#UZ4 >/? _5?%1UO3=(\,Q^$M0^&-F)?M.L:-H$^DV\KE6VBR+7<WVDF3:7E
MVB,@MB1WR!]!5\W^ OA+:_"?QMX#U5'\+ZDNNSRV:#1M$BT]+5S93SB2T:)C
MNBV0NFR3>2) P<;<-](4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5^?GQW\,_#G6OC;X]U9/A3\1O$]GH4\1\7^+?#/B6>UAL9C;QRE8;43J
M9C'"T;.(ERN>A[_H'7RO=>#?CYX!\:_$T>#O#7@;Q!X5\5ZV^KQOJVLW-K=I
MOL[>W9&58&0?\>^1R?O4 <*?AM\$OAM\6_ .F>&?&/Q(\3>,+K4K"^MM!T3Q
M+>:A'#;&6-A=7R%BL=J%(9O,(W)G -?<5?(?P \(_%GX%KHOA?1?@+X*\/\
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M]XUS+ "3,#L#,^<< <CZ-H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#-M $K6I9QU&Q@-V2!7T%0 4444 %%%% !1110 4444 %%%% !1110 4444
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MCQ5H@\3>&-8T<RF :A9S6AE'5/,0KG\,U\Z_LV?M+^!/#WPST+X?^-_$6D^
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M21.0,[6&1D'()!]T_P"%!>&?^@IXU_\ "[US_P"3*\=_:;_Y2U?!;_L3)O\
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M@ZO7U37EXKXUZ'S69?QEZ?JPHHHKC/)"BBB@ HHHH **** /CWP#XBU#6_\
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M,S,Q)))_/77/^4NWP0_[%6[_ /2?5Z_2JO:H_ C[#"ZT8OR"BBBMCK"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>anab-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:anab="http://www.anaptysbio.com/20210630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="anab-20210630.xsd" xlink:type="simple"/>
    <context id="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4308818b5a0a4b6a9dc093c01b5bf5a2_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i66483ee3f39e44a3aaf565221c3c7873_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie61ef44ef0874171870af019d2a30f6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee911f281b4c476f9c39c369d300a1b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie18fcf4f5df24767b6bbe988f6fdad48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifed6ec8bf45a4cd0aa3ee9a5c90c681c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iad3d053c201649c798018f2b53f729cb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2278fb08662b4d1b8fd10ab11f525ee7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i77b1fdd751a94267ae3ebfa67f9a7b34_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3653550b703940c4a4851c44af5f43b7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i863d80faf8674ff9bb6b825aac12e27b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9d35a18ba42945f887b212ef18ac78b9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5ce013027a2041b0a49e202ddcfe2040_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idcc32bd3c09c4088810c227718709561_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie4d411a7cb224c5ebbb4ac4d0c70b7ac_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i815cd3ad41474aa89bdbc8aac7df75ff_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5af639e68aed46ceaadf61c50fa22b6c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i558e5a32ec2d4a419c4b11583520ee8a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ided6cc631fa347f29afdeec8dc63dfa2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0bdb0c2fd7a1425b88540d8ab89e49ef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7208ae669f5a4129b42fd35dfa7a6c27_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibf4c209b6991485097f5062d7e179388_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idb2028cc405d4c44936f5ed145a50dbf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4641429f60564692a060512d8c74558a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b4663eb93a648168c61a81e9457dc1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i142b163e653d4a9cba36852e354d5a57_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0d07597b3dc4975a4fe06e498a5d3e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bd7946500014e7a935d20e4d9049cab_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i90cec4c950e344009abf72bee3271d18_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i357b6498c5d9488bb080175359e876e9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ida9c210ea8494148835c51d4ce0d58f1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0b05a125a4494bb5ab7cdbe086bdd21c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7bb913f721294b8fbd1c537aae3279a9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic4615342e0d54465853cf7d151fdec12_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i88d8e92fdf0848f5a09451c6582b0d02_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i226bcfccf34e4b0bba7f77efd6749232_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5bd22ef257044497bb6129f2ee1efd43_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia3f83c27a2f24bcf960cbb189259177b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if4d26b66b1c74404b1a4ad9a12346650_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if46ccc6f74854042980a58a0f048852f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i64512e583b524f5fbae03573f01e4425_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if8bf867918fb40f2ade51bfcba942241_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6e42fc0c6ff14036a66064c60d7832a5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0daff577f8ae408693a9f6c34fbe73ce_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i386a0a6a5d9e4bd8ad62ba1339a4e448_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idfc960c533644748967278a36e67af20_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i54e09947d78640e4b9eeb147c43743aa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12ddd91f6523469eb8f7ad820f2b8764_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1487ca8ec2e24d4fba6469fa2aa23d66_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4217decdbe45471ca7c606434d0632c0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8b92baa04c8b4070987a2e921dbaafa4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic8a1dc7356a94c6eb2c2452e7957ebe8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b552c03f74142c287d50400a1538790_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i593bf7da05f24f8a88e6e1f64037cce7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c0631bdcfa94b9182f6f5cfe8b439b3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7c4a40293897411dad729dd8d12a9b9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6bb85d544044f74be91e6c4ded1291a_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="if23f0b3a9c1543389445ca1f2a582eb5_I20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-03-31</instant>
        </period>
    </context>
    <context id="i443e38b29ed84f36aeff8d125942ff3c_I20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="i5c6137734596471eb3bfbea0e8c29f72_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="ia8cde62162f4437eb22081031e78c481_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47989d6424ad4d9ab848e3e615102bac_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedZejulaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="icb9fa8ebdf074b57a099e54ad0196d1d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id40e9b7e255a4b9b918086d940de14a0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedZejulaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:CollaborationAndExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i44529c9832924677ab0905ad04031c28_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i79a47cb5a3684fb9965f688e81d082de_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationFirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i36e884c92e4248ebb969f8b647ff98db_D20150401-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="id039343680da47d7af05ac3697ed6412_D20151001-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i2d312a71cb6944cda527675f2fbd0a55_D20160701-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3GSK40974386Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="ie0f3dd66d4c24741b2a7ded6059d960e_D20160101-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i91888314abeb436d827a581cdd98c07c_D20160401-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i29ad61a6cdfc4838b66812099ad185db_D20170401-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3GSK40974386Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i8d52b0d15c6a49759798e25fe838631e_D20170401-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i69938c04553e464db0b8b7c7704d1867_D20171001-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i97554db485364f75b7e7a0213d8a4225_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3GSK40974386Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7184beea9df1436ba28682c84638c335_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationFirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ib2aeffac54924963b1bf3dc19fca0a21_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationSecondIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7140062cc12f4f01acbb92e93e19466c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingOfBLAFirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4353bed79fb8420982f9675d50f0e0b6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingOfMMAFirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5bc779cbb0dd4b988a625b412a15a49c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingOfBLASecondIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2241e34e4b2493cb520e2f1469c8282_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FirstBLAApprovalDMMRECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8ac11f17d0664ef6b0b60ad3b9f2d76d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FirstMAAApprovalFirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6011ad3b1c6b44a885a7bd57000ca6be_D20110101-20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-01-01</startDate>
            <endDate>2011-12-31</endDate>
        </period>
    </context>
    <context id="ifcb6477f9a49486ab46021a396ff7561_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="i59da14b2fe8548e5870e1779cc0aa9d0_D20160401-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i4a55c463e33c4afab95cb2149af0e3ce_D20161001-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase1ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ifa80869592e640d389371d71f073f337_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70c2ff1aec104594b36f1b5f8e2a3e4a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6413c5f064d49babec39642d4b164a5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id77469bf2efe425dac416b31a411d04b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if9133e4132b240e7bca2e1c95471892e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie5399bd92b9e4cf693eb263ebaa5e180_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia6e2dfb981084eb1a6ddf8ebc09962d3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6e78cb67f53f47f3b1937709b61ee528_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5641bee18d3141bda9c26e4ca72e89b6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i288736d64ff04b0ab6b16af4d6d2b14a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8414801a345a4cd4ab3c203b8ec660a9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icee60ae93525403795b2bac324fca5a6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie3ef14c2603b489b847974efac36accf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec6ade6ba8d441b5a2642b21f097a179_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7ab16caf39c34c8eb91ade5ed0af706b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9275bf5a2daa483ba130b781fc58af8a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id13ee5fb8cf54c68859bac354f7a79d8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iee6704368d964ed69d2439d929ef4748_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i24c4a55ee9124b8bac3e70be46d12bc4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4eeb2688caf9475dacc5b156e4b9ebcc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i61b8a35c442e40f59ff35f5aab9e1ca4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i75a862142bb64348860dc4025bb374fc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0e9b6fa28a604b77aa8d086a61c3002a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2bc0beaf432b417aa88fa1f2d048adb7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifad4b811111a4959a97b530f3e1edc30_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2efedcdd907841bdb7b475cccdb198dc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i16d7c88a334a4713960dc3460eb06106_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibb5ed2e6efa94819b8a0fb85e74275d6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8725cde7bd3b4b58934b4ecdcef2816a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6944b71b72a84436a68e5213fe6df51a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad391a709b144bd48d2872b283602f84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9067efbd18c467aad2eebbaff82cfc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3519bdb64f8b4b6d8efc1c5e46616753_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e3adfb85bf6451c9575bc0e8d008d13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id81d1d57d00941ff976792c032f7c601_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18b9e3d355a14ac49a01d376ea60f2a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2037e57e85fb441b94c20fe503046463_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id812dbcc01ba448783f4b7ace47357b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5c66084d39744f29e968164be5da8b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9802e6239684804a3dc3860a653719b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifea2879f95c041cd895eda44820f8624_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8eae37d2da574506ba4e102853287bd8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3081867d37934fefb8be59e85e8c7a4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i051c714be443417780719d2eb4b53ea9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i674430e3d2c341c8a6df0759fb0fbd73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12aa4229eb9f4c2fa7c9289e272467c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45c3ef9e7fdb4ea2b3bfd0ac0a4f062b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i454b38ab8bdc449cad61e6eb5af78756_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77bdd900a94544d0bbba160586a6eb58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51217ad1af3e4ebda21a0ad07210b827_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ec26d7834be4c8abd097426fd877cb2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if07640a2359445eba2a41ae90501863f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i13528acc7aef4f81ae58f9b16746d0fe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie9b72c1bc28e426696c80f01a5640e80_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i711fd5f10f4e49a58b560bb507d95052_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i45f7ba855861405cbd820fb0f83d8611_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i08c80bb1f49f4b5bafd1241939a88605_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1d163026a6654743b9979520a3af47aa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8b96a7f246684ad1800b51d91e9a69b8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i881cf8050b394e0682d0acff78aa7d9c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i61e188f2a2fc40cdb0ad1ad5fc3d9224_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i03f6372c975642c8b721a357169c41f7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i392569839eab4af895cd18151a8a634b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43d6272b78fc4eaf908301d14bb663d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia309061dd36448469b328ecf3c762679_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a331153831844abb1eef1d1c1087186_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2fdc2c8d4dd1467f8757e49958c27417_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41d5876a7ef54861bdd2687c9d49d1e8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57cbe5ce58ef4a0eb06ff307f39465a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic24b2a7ad667476c99b89caed4bc0d88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia50950aa6de04e559cb7c6cb70e4a3be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4da7cac937d44fb19c0b0d2f90db8d5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i440d9f4d37024e65a225809024ed80f1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i74f2dd192f9145a1bcc410371db79135_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i754f18c3eac04b658b8b6ed077314e68_D20180101-20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="i4866424e06474a119edf3063462a6832_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia3b08700ca1748b2afd4fa071b355893_D20180101-20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="ib69a7ed7bd244d29905de3cacf88167f_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i197e760b801d4f73b5d6e406c4027a35_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifb3a9fe237f347e39f34d734ffdf3d9c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i626d95b570df4e1abdac73a6a2e718d0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib16d46e48de9476ca69ec729d02ab7f7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75b921f1f24c4c54bb6d506c5e62de1f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i79408e23b2ef4790851584643cf1fd31_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a4c03b9afe14b17a08c26f39c61ee23_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i01c0c2bd7cd84e75ba87c7188ac5cb04_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1bf654bbd4e431098303b2f5ba09a92_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie5753215b52c451093ff6ca5ba3c9575_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id7e2add807724d19a9e8cbee0dad3919_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie04286dba40e490ebc78cc7952a23570_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie3b64ce4f6404458b4b4d2e565325a2d_D20201215-20201215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-12-15</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="i84c00b90fbbe46ffbed30a2f2233aea7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10455PacificCenterCourtInSanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1767abcdc9d947d19efb733b02b78b30_I20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="i769956911bf34bc3babeafd4ff7c179c_D20200504-20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="ib2b8bcbccfe046d982471dc4466417f9_I20210405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-05</instant>
        </period>
    </context>
    <context id="ieb17cf126b4e4598b3ace9ab2298bc16_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anab:A10770WateridgeCircleSanDiegoCalifornia92121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>anab:segment</measure>
    </unit>
    <unit id="target">
        <measure>anab:target</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>anab:milestone</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="usdPerSqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF80LTEtMS0xLTA_07a4f7c6-9e30-4642-b781-af6c558747e3">0001370053</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF81LTEtMS0xLTA_b2282552-5558-4723-905e-e0c512318707">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF82LTEtMS0xLTA_778be727-15ef-48fe-9b03-78bf51661d10">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF83LTEtMS0xLTA_eb38e083-bff9-4db7-9ee2-7990922a8265">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80L2ZyYWc6NTBhZWVmM2IyZjM0NGQ3Mzk0MzViYmYxNDg3NjEzZDIvdGFibGU6ZDU5NTk4MDU0MTExNGZmNGJkZThlMGUxNjFmYTc1MDgvdGFibGVyYW5nZTpkNTk1OTgwNTQxMTE0ZmY0YmRlOGUwZTE2MWZhNzUwOF84LTEtMS0xLTA_86ce3f8b-266d-497c-ac69-ad43f4bb7e4f">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_0ace4234-c65a-4b90-89b7-b121fc84c601">http://www.anaptysbio.com/20210630#CollaborationRevenueMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_2f59a2c7-ef6d-4596-9c6c-0bde0d2eb86e">http://www.anaptysbio.com/20210630#CollaborationRevenueMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_48bd1fc1-422b-4ce5-9e49-3270208864cc">http://www.anaptysbio.com/20210630#CollaborationRevenueMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0wLTEtMS0w_a4aa99ec-e447-4b6c-88d1-348a79a7aa89">http://www.anaptysbio.com/20210630#CollaborationRevenueMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i08c80bb1f49f4b5bafd1241939a88605_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU2OQ_2c6af718-21cf-4692-a2d3-b58b8b1319f6">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i881cf8050b394e0682d0acff78aa7d9c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcxNA_0f49c841-e469-4cdb-9e94-1d8fc6721bf2">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="ia309061dd36448469b328ecf3c762679_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwMg_8efbf14a-390d-4a61-8d2e-efb73efed063">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i2fdc2c8d4dd1467f8757e49958c27417_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ1NQ_25069077-64eb-4770-a079-0932cb57d201">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i57cbe5ce58ef4a0eb06ff307f39465a7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyMA_ca5315b3-0237-444d-96a1-9e4abab3f521">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="ia50950aa6de04e559cb7c6cb70e4a3be_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc3NA_1f934835-43a2-4d2e-869c-8b6ff5fa0e3d">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <dei:DocumentType
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjQ0_e83f0dcd-1d51-4f9a-8240-a76d9fcdf0f6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6NDc0ODBkMjYyMzdjNDI3NTlkZGQ2YTU3OGYwMzZiZDEvdGFibGVyYW5nZTo0NzQ4MGQyNjIzN2M0Mjc1OWRkZDZhNTc4ZjAzNmJkMV8wLTAtMS0xLTA_205529f4-b830-4e24-bf2d-3fc3160163bd">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8xMzE_a48adada-b6c7-41be-91ea-d56bd8ba43fa">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6YjFkZWFhZDdhYWFkNGZmMDljY2ViYThlY2FkYjVjYjgvdGFibGVyYW5nZTpiMWRlYWFkN2FhYWQ0ZmYwOWNjZWJhOGVjYWRiNWNiOF8wLTAtMS0xLTA_01098f7f-7c9a-40c2-9b0e-45104aaba450">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjI5_43ebd00d-efab-416c-ad8c-d58fb4da7ded">001-37985</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjI3_af5a3c8c-74a2-4510-813b-38b74b512f7d">ANAPTYSBIO,&#160;INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6MjE0OWZmNTgzYWFlNGFiNDk4MDExNDU1NTkxMzMyNTcvdGFibGVyYW5nZToyMTQ5ZmY1ODNhYWU0YWI0OTgwMTE0NTU1OTEzMzI1N18wLTAtMS0xLTA_59242533-5007-4368-8ea8-22f36ff0517e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6MjE0OWZmNTgzYWFlNGFiNDk4MDExNDU1NTkxMzMyNTcvdGFibGVyYW5nZToyMTQ5ZmY1ODNhYWU0YWI0OTgwMTE0NTU1OTEzMzI1N18wLTItMS0xLTA_8c88a398-bdd2-47fe-a77f-d923be90d120">20-3828755</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM4_9112eb84-4472-44c8-b635-5db8961889ff">10770 Wateridge Circle</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM1_37d6ff45-96cf-4e93-b427-75dc14bbcf17">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM5_a022eda9-2e45-4465-8024-7aa450302517">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM2_28639522-5582-479c-bf10-dfaceb9cbed0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjM0_0552f42f-c76b-4dec-93fc-3235cecccc5f">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjQw_fa2aabfc-6470-4335-803f-3159d4c1f7c1">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjMw_a28dcc9d-3edd-41e7-a0ef-8318e63d2240">362-6295</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6OTFjNGQ5NzY1NjM2NDE3Nzk0N2JjNTlmMTNiMzQ5NDIvdGFibGVyYW5nZTo5MWM0ZDk3NjU2MzY0MTc3OTQ3YmM1OWYxM2IzNDk0Ml8xLTAtMS0xLTA_21c70154-93d5-486e-bcb1-efdd80724d53">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6OTFjNGQ5NzY1NjM2NDE3Nzk0N2JjNTlmMTNiMzQ5NDIvdGFibGVyYW5nZTo5MWM0ZDk3NjU2MzY0MTc3OTQ3YmM1OWYxM2IzNDk0Ml8xLTEtMS0xLTA_66cd6b75-5345-44f4-993b-228916e755ed">ANAB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6OTFjNGQ5NzY1NjM2NDE3Nzk0N2JjNTlmMTNiMzQ5NDIvdGFibGVyYW5nZTo5MWM0ZDk3NjU2MzY0MTc3OTQ3YmM1OWYxM2IzNDk0Ml8xLTItMS0xLTA_e3031a3c-b833-4c0f-b136-0eaaac9af2f5">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjMz_d8e3d1c0-d8c4-42a6-bfd2-7e150b15e537">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjQy_9da0ecc7-2a90-4175-8760-52eebaddb873">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6ODI1NDM2YjM5YTZkNDhiOTk5ZjEyY2EwMTcwZGI0NGYvdGFibGVyYW5nZTo4MjU0MzZiMzlhNmQ0OGI5OTlmMTJjYTAxNzBkYjQ0Zl8yLTAtMS0xLTA_bee65bdf-1981-458a-9a9c-3cebd98bb420">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6ODI1NDM2YjM5YTZkNDhiOTk5ZjEyY2EwMTcwZGI0NGYvdGFibGVyYW5nZTo4MjU0MzZiMzlhNmQ0OGI5OTlmMTJjYTAxNzBkYjQ0Zl8yLTYtMS0xLTA_40c2d9ac-cab1-4b05-bcc2-164c18d5b04e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGFibGU6ODI1NDM2YjM5YTZkNDhiOTk5ZjEyY2EwMTcwZGI0NGYvdGFibGVyYW5nZTo4MjU0MzZiMzlhNmQ0OGI5OTlmMTJjYTAxNzBkYjQ0Zl80LTYtMS0xLTA_0e850884-8d82-4d5c-9e27-67ce4c1b536e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMjQz_e75f2d1f-250d-48b2-9ef7-6ed780322491">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4308818b5a0a4b6a9dc093c01b5bf5a2_I20210805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xL2ZyYWc6ODIyODk1ZGIxY2Q5NDdiOTgyMjg2YWE1OWJlYjE0NGUvdGV4dHJlZ2lvbjo4MjI4OTVkYjFjZDk0N2I5ODIyODZhYTU5YmViMTQ0ZV8yMTY5_9c880692-faee-48e5-aede-dd5d8f3c0fb2"
      unitRef="shares">27433359</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNC0xLTEtMS0w_59cf4a31-f003-42b1-9648-b476f15e833c"
      unitRef="usd">332254000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNC0zLTEtMS0w_33f2f357-4df5-4854-ad4a-3ee09749a198"
      unitRef="usd">250456000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNS0xLTEtMS0w_1496f3c3-f599-401f-bd3a-def821f47eee"
      unitRef="usd">642000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNS0zLTEtMS0w_f6c1e08e-b4ce-482d-9557-874f342fcdcf"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNi0xLTEtMS0w_d65013f5-031b-4722-a790-e9769a908bda"
      unitRef="usd">58597000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNi0zLTEtMS0w_d939e4d4-f614-4bd8-bfc8-6c6b8f59e291"
      unitRef="usd">143197000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNy0xLTEtMS0w_abd18de8-e426-4fe4-a55e-f1271ead430e"
      unitRef="usd">6508000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfNy0zLTEtMS0w_984e556f-7fe6-4213-839b-0d372680b60f"
      unitRef="usd">2908000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfOC0xLTEtMS0w_70e50d64-c8e5-41ad-b7b2-ad3e44e479bc"
      unitRef="usd">60000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfOC0zLTEtMS0w_ea093a8d-241f-4160-b548-5980485866c7"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfOS0xLTEtMS0w_e4553571-3eaf-49ab-84b2-94ef6be3154a"
      unitRef="usd">398061000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfOS0zLTEtMS0w_fc309f62-be9d-4e57-aed9-68a741750271"
      unitRef="usd">396561000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTAtMS0xLTEtMA_aefd1b75-3496-4f6b-b3dd-743038947ce0"
      unitRef="usd">2488000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTAtMy0xLTEtMA_782147c7-bd76-4b67-a672-70e965a95db9"
      unitRef="usd">1783000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTEtMS0xLTEtNzUw_89f8b8d7-dd68-4ca5-a715-49ce5d089cbc"
      unitRef="usd">20278000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTEtMy0xLTEtNzUz_0e1f4528-d6ea-416a-80f4-4b4e257e4aab"
      unitRef="usd">344000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTEtMS0xLTEtMA_c326d040-ecf6-4972-b2bb-e53231472080"
      unitRef="usd">5484000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTEtMy0xLTEtMA_fc6f6b5a-8092-4776-bb59-7da8d0aa2d93"
      unitRef="usd">17546000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTItMS0xLTEtMA_15d36c96-31ae-4f85-b20c-43772d234b4f"
      unitRef="usd">258000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTItMy0xLTEtMA_917753f3-5cf5-4b7c-b19f-950d21331410"
      unitRef="usd">258000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTMtMS0xLTEtMA_e6185ef1-d8dc-4967-ad5f-ac643fbb5c19"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTMtMy0xLTEtMA_8dd3a069-8cc4-4656-b778-b236a4ad1e89"
      unitRef="usd">60000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTUtMS0xLTEtMA_164379b1-0850-4f0a-af4f-d4f562ed73e9"
      unitRef="usd">426569000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTUtMy0xLTEtMA_cfd0fd74-ea75-4e4e-9bb8-dce67f9a4f8a"
      unitRef="usd">416552000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTgtMS0xLTEtMA_9a4e8f92-607f-4bac-99ef-83375d4f184e"
      unitRef="usd">4103000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTgtMy0xLTEtMA_a0aad230-0687-4ae3-a5fd-7265afe2b520"
      unitRef="usd">4217000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTktMS0xLTEtMA_13c9dbe6-1a5b-4c23-be6f-111af68ea332"
      unitRef="usd">15958000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMTktMy0xLTEtMA_c01420cf-d8e1-4001-b61c-98f9ca70689d"
      unitRef="usd">15262000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMjEtMS0xLTEtMA_c1986110-08cc-41ce-a46b-26ba522e27e3"
      unitRef="usd">555000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMjEtMy0xLTEtMA_f20b9924-b443-47bf-8859-179b91d8d5d9"
      unitRef="usd">342000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMjItMS0xLTEtMA_42da8e50-4739-47db-8da2-62c689c22d62"
      unitRef="usd">20616000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMjItMy0xLTEtMA_af600110-0e5a-4b2e-8aed-9508217242a9"
      unitRef="usd">19821000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMS0xLTEtNzU3_ce667c6f-c37e-4e6c-b677-afa07d47e8b2"
      unitRef="usd">20222000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMy0xLTEtNzc1_e75cf819-4fd3-4955-aa25-bda4be9a40b9"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIy_cb3b0e4f-fdeb-4565-b4ae-dc8c2f41f79c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIy_e7a5d0be-437b-4686-9a2f-81acfac6eb1f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzM2_3f39eaa3-e22c-443c-a687-fcdb0b5fe730"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzM2_aa31efac-aa02-481f-b212-38999b6d432f"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIxOTkwMjMyNTU3ODM_529c918b-b398-467c-8217-9ff798ab3bbd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIxOTkwMjMyNTU3ODM_5c9ce06a-efd4-4891-9402-018aeeac096c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIxOTkwMjMyNTU3ODM_a0bf53be-bc56-4590-b900-898c6b3ff93a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjAzMzY0OTZlN2VjMjQ4YWJiYjM5ODRhYmQzNDhiZDE2XzIxOTkwMjMyNTU3ODM_f39ce28f-f661-4566-b6a0-4bf76d815c46"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMS0xLTEtMA_c2abb0db-531e-4942-8c3e-757afaf8b046"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzMtMy0xLTEtMA_28cbf662-8057-406b-8512-5fceabd5316d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzE4_54501a9b-72b7-4d9e-ab92-87cdfa2e1630"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzE4_f5827ec5-190e-4322-9532-4b8664c7a00d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzMy_7d793548-86dd-4ab8-8ab5-808eddd9afca"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzMy_b800a47e-ff06-43f8-9a1e-73fb9e756c76"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzU0_38b0c300-0feb-462d-9001-51b19094e9a3"
      unitRef="shares">27433000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzU0_9db4702e-4e22-4a13-b9bc-e375b75f8a13"
      unitRef="shares">27433000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzY4_dfec6ac9-ba4c-4fe2-bbd7-fbb8b41efcf2"
      unitRef="shares">27356000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMzNhZWM5ZDU2MDQzYTNhNGQ2ODBiNzU3OTFiNWEzXzY4_e6b129a6-27af-4436-9608-17e3a05e889c"
      unitRef="shares">27356000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMS0xLTEtMA_ab98971a-805f-48dc-bb98-a5923d4c4a60"
      unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzQtMy0xLTEtMA_e81930d9-98ef-432b-b28d-f6af01e6e286"
      unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzUtMS0xLTEtMA_f8fb0c8c-82b1-42f6-b2bf-9030483a7034"
      unitRef="usd">668429000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzUtMy0xLTEtMA_dd5cfb69-c592-405b-ac3c-7060ab2e3f35"
      unitRef="usd">660665000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzYtMS0xLTEtMA_7b00d2b7-ecf4-4c7b-a8ff-a6855f9aae63"
      unitRef="usd">-176000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzYtMy0xLTEtMA_ff92597e-fcf3-4976-972d-6ea816402b1b"
      unitRef="usd">-4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzctMS0xLTEtMA_6f7601c4-e5db-4348-8f3c-b7f0d31f4d61"
      unitRef="usd">-282549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzctMy0xLTEtMA_05b98c1e-a0a9-45ef-ab26-68e4cf966fe5"
      unitRef="usd">-263957000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzgtMS0xLTEtMA_f50fb0e4-e1d6-43b0-b177-3ac3db4b72b0"
      unitRef="usd">385731000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzgtMy0xLTEtMA_afda8b14-af95-4c99-8c84-a3c81dd8117d"
      unitRef="usd">396731000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzktMS0xLTEtMA_90dbe814-32dd-4d39-bb9e-2de6d3cbebb4"
      unitRef="usd">426569000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xNi9mcmFnOjU1NmRkNTgxOTczZjRlNzM4YWQ5NzEzYjc5ODdlMjUyL3RhYmxlOjBmYTRjYzA3NzcxZjQ4NWFhYTg5ZjY0NmQ2ZmEyMjdhL3RhYmxlcmFuZ2U6MGZhNGNjMDc3NzFmNDg1YWFhODlmNjQ2ZDZmYTIyN2FfMzktMy0xLTEtMA_20a351b6-4aa2-43dc-bd7b-4263d771c683"
      unitRef="usd">416552000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0xLTEtMS0w_5d43ed17-d214-40ab-909d-6136f80afd97"
      unitRef="usd">30027000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy0zLTEtMS0w_c5d86cf4-6551-4730-93c9-ec56c6ee0dd2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy01LTEtMS0w_efca4da4-2bca-4eb7-a713-f685c9a440ad"
      unitRef="usd">41274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMy03LTEtMS0w_d90537b4-241c-479c-980b-a79fc7fdf487"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfNy0xLTEtMS0w_d028bc33-d510-49ad-ac9b-e32bd4b9c815"
      unitRef="usd">25314000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfNy0zLTEtMS0w_1bab96cb-d75b-4e92-aa48-a30af3765f5d"
      unitRef="usd">17948000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfNy01LTEtMS0w_a685b7ef-4b54-42e0-8e44-6e297ebf28e0"
      unitRef="usd">49499000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfNy03LTEtMS0w_94eedfad-a8d2-4cec-8d47-7af00200bed6"
      unitRef="usd">38916000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOC0xLTEtMS0w_1df034c2-f524-477e-9aff-544b0dd41c14"
      unitRef="usd">5246000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOC0zLTEtMS0w_d4469d94-13cd-48b6-983f-c7af1a7d8ee7"
      unitRef="usd">4687000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOC01LTEtMS0w_a3afd759-cc6c-4717-9908-4bd40cbb3606"
      unitRef="usd">10669000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOC03LTEtMS0w_01325767-cda1-4e30-9bff-14e7bcc11054"
      unitRef="usd">8972000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOS0xLTEtMS0w_45ac841b-1902-4a1e-a05d-ab1f8967870d"
      unitRef="usd">30560000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOS0zLTEtMS0w_2d402631-fed6-4cf5-8642-e21ecb200b7b"
      unitRef="usd">22635000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOS01LTEtMS0w_b947faf3-7922-4254-bf63-b1afe45cb1b9"
      unitRef="usd">60168000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfOS03LTEtMS0w_f6e0ec9e-09c7-4d02-9521-d7c3cd36caba"
      unitRef="usd">47888000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTAtMS0xLTEtMA_e2b7c563-758f-4504-ba7d-bcdb16f471ba"
      unitRef="usd">-533000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTAtMy0xLTEtMA_2086a3a4-136b-4543-91b0-706041815398"
      unitRef="usd">-22635000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTAtNS0xLTEtMA_611c881c-196a-43fa-807a-9dec62ae4118"
      unitRef="usd">-18894000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTAtNy0xLTEtMA_0dcfa988-bbe5-4803-9824-45a163972537"
      unitRef="usd">-32888000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTQtMS0xLTEtMA_25dc1f24-5cf9-4fc7-9f48-780e50bad556"
      unitRef="usd">104000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTQtMy0xLTEtMA_c1062d3c-ea64-4693-b950-faa4f73093d2"
      unitRef="usd">1061000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTQtNS0xLTEtMA_65abaa68-dad8-4b86-8fba-f12abee2b577"
      unitRef="usd">299000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTQtNy0xLTEtMA_deafc396-15a3-4c22-952c-05ba8988d35b"
      unitRef="usd">2958000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTUtMS0xLTEtMA_1e52cc82-ec60-4adb-af5a-1839e5da25b1"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTUtMy0xLTEtMA_89b7946a-90cb-424d-a9bf-bbc57feee390"
      unitRef="usd">26000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTUtNS0xLTEtMA_26717be7-2a32-46a9-8a33-b2f56d2a7966"
      unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTUtNy0xLTEtMA_ef5b4f2f-5227-4b4d-ae1d-a4b290dec7d6"
      unitRef="usd">120000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTYtMS0xLTEtMA_6f32a55c-2fb2-4b8a-b494-0df8f7408e1d"
      unitRef="usd">104000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTYtMy0xLTEtMA_0955ac7a-4031-4f73-8261-efd082d68807"
      unitRef="usd">1087000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTYtNS0xLTEtMA_80836c6a-9299-49c5-bcd4-af4a3d697f04"
      unitRef="usd">302000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMTYtNy0xLTEtMA_8e627bb2-8c14-452e-9b01-61f086ac2098"
      unitRef="usd">3078000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjAtMS0xLTEtMA_9e3eaccb-56b7-46de-840e-31050ed8bd16"
      unitRef="usd">-429000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjAtMy0xLTEtMA_33f836cb-4231-4952-b4e3-ede9c96b3269"
      unitRef="usd">-21548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjAtNS0xLTEtMA_9d948c8e-469c-4d68-a4a0-151698619372"
      unitRef="usd">-18592000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjAtNy0xLTEtMA_6817df05-dcdb-4b83-b80b-258592084567"
      unitRef="usd">-29810000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjMtMS0xLTEtMA_ad8d920a-7fa0-42f9-954a-71016a234ae3"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjMtMy0xLTEtMA_2df7815f-047b-40ba-ab3a-2b292d29f02f"
      unitRef="usd">-392000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjMtNS0xLTEtMA_1e1f19c5-b143-4f63-96e0-a62e8c41821a"
      unitRef="usd">-172000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjMtNy0xLTEtMA_ac97755c-5d89-47a8-af51-0ccc32a9ef26"
      unitRef="usd">415000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjUtMS0xLTEtMA_97d95552-fb2e-462f-8135-cea4569ab7fe"
      unitRef="usd">-494000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjUtMy0xLTEtMA_6ed6f9e0-c9c5-454e-b53b-341772931f9f"
      unitRef="usd">-21940000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjUtNS0xLTEtMA_d7a2538a-ed00-46d1-8506-1df2287778aa"
      unitRef="usd">-18764000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjUtNy0xLTEtMA_376bef57-25d1-4187-aece-1570176494b2"
      unitRef="usd">-29395000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctMS0xLTEtMA_b1a12ee9-4875-4a46-8713-436b704d26de"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctMS0xLTEtMA_bdf68a02-fe5a-43d6-9d17-f161fb444ad5"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctMy0xLTEtMA_36cd4ef6-9379-4f71-a355-0861fa9b4569"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctMy0xLTEtMA_59b4c63e-7ebb-4ce1-8807-e149adf69195"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctNS0xLTEtMA_64e02ec4-13cf-47a7-bd3c-33251cec583a"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctNS0xLTEtMA_8d3d699a-e868-42d3-982d-e44a8835229d"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctNy0xLTEtMA_19e5f7ae-4537-4fc2-b2a2-490430b68187"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMjctNy0xLTEtMA_dc7b24ba-2bc8-43a5-aaba-8059a1b557a0"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtMS0xLTEtMA_fc1c0819-a01d-4b2e-b549-a4db56644cfa"
      unitRef="shares">27391000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtMS0xLTEtMA_fcbd9b68-ed94-4f21-a408-e74189b921b5"
      unitRef="shares">27391000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtMy0xLTEtMA_bb3b9ebe-c3ce-4213-bcc8-bfab6654ba82"
      unitRef="shares">27279000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtMy0xLTEtMA_c387d4c1-bd8d-427a-a52e-2fd95ffede12"
      unitRef="shares">27279000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtNS0xLTEtMA_97a5a81f-1ea3-489d-8403-5751bd663a40"
      unitRef="shares">27377000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtNS0xLTEtMA_c6d2af61-2ff3-4530-861c-29abedf3836a"
      unitRef="shares">27377000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtNy0xLTEtMA_d4bc8a7e-4974-4e9a-a4a6-c8d33012b401"
      unitRef="shares">27271000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8xOS9mcmFnOmI0ZGFkNTIxYTQ4OTQ0ZjU4YjA0ODY4ZDcyN2U2ODAwL3RhYmxlOmVlMTBhMjdiOTA0NzQ3YjA4M2M4MjI5YzIwNDg5MDdmL3RhYmxlcmFuZ2U6ZWUxMGEyN2I5MDQ3NDdiMDgzYzgyMjljMjA0ODkwN2ZfMzAtNy0xLTEtMA_d5002eef-a86e-47e4-81d9-3a5caf35e1af"
      unitRef="shares">27271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i66483ee3f39e44a3aaf565221c3c7873_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi0xLTEtMS0w_a26f783e-2b0e-4342-9f78-7cc339cbe5c8"
      unitRef="shares">27356000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i66483ee3f39e44a3aaf565221c3c7873_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi0zLTEtMS0w_c1a79697-75fe-46ec-b10e-fd7fd22900a1"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie61ef44ef0874171870af019d2a30f6e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi01LTEtMS0w_0852c617-fd7e-407d-a6ff-578875c6e929"
      unitRef="usd">660665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iee911f281b4c476f9c39c369d300a1b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi03LTEtMS0w_b65a8aa6-666e-4b55-ab8c-c8e2fb46d39d"
      unitRef="usd">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie18fcf4f5df24767b6bbe988f6fdad48_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi05LTEtMS0w_1a21fb74-f2c0-43e7-8d61-f6702ee45ad0"
      unitRef="usd">-263957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMi0xMS0xLTEtMA_5dd3e5f2-106f-4693-b470-830e4d23f5f6"
      unitRef="usd">396731000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifed6ec8bf45a4cd0aa3ee9a5c90c681c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfNi0xLTEtMS0w_3832c2ca-f6ff-4637-9773-476dafef3b3e"
      unitRef="shares">11000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iad3d053c201649c798018f2b53f729cb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfNi01LTEtMS0w_3125ad10-4bfc-4980-862d-24201f7d781d"
      unitRef="usd">167000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfNi0xMS0xLTEtMA_9e0e9932-ed39-4e30-a339-14769521407f"
      unitRef="usd">167000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="iad3d053c201649c798018f2b53f729cb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTEtNS0xLTEtMA_0a5ca650-512a-45ce-aa12-239de3eba8df"
      unitRef="usd">3315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTEtMTEtMS0xLTA_642badcc-27c9-4d01-b194-a23dea6965e5"
      unitRef="usd">3315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2278fb08662b4d1b8fd10ab11f525ee7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTItNy0xLTEtMA_a1abfc80-9561-4ff1-8897-4910c735f676"
      unitRef="usd">-107000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTItMTEtMS0xLTA_2aee6455-27aa-46d5-9ebf-fcb70f5390b8"
      unitRef="usd">-107000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i77b1fdd751a94267ae3ebfa67f9a7b34_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTMtOS0xLTEtMA_381bb772-6ae8-4e7a-a6a3-5834b1872dd9"
      unitRef="usd">-18163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic7d94e168fe74f6fa80cec8755f45f47_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTMtMTEtMS0xLTA_073f802f-745e-4206-a9eb-e03dfd177834"
      unitRef="usd">-18163000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3653550b703940c4a4851c44af5f43b7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtMS0xLTEtMA_6ecdba12-2489-4f85-9fef-23b3ffd651a4"
      unitRef="shares">27367000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3653550b703940c4a4851c44af5f43b7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtMy0xLTEtMA_d628d1e0-0099-4238-8a72-ecbe05de391e"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i863d80faf8674ff9bb6b825aac12e27b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtNS0xLTEtMA_fb7adec5-2dff-4b8a-a91d-b66851c31386"
      unitRef="usd">664147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d35a18ba42945f887b212ef18ac78b9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtNy0xLTEtMA_33ac5aa4-eb95-40dc-872f-d767a0960312"
      unitRef="usd">-111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ce013027a2041b0a49e202ddcfe2040_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtOS0xLTEtMA_a6e1e91f-341e-4e62-b4b0-be854db1c792"
      unitRef="usd">-282120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcc32bd3c09c4088810c227718709561_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTQtMTEtMS0xLTA_102519a6-a3dc-44ab-a8ed-70aa5641846d"
      unitRef="usd">381943000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie4d411a7cb224c5ebbb4ac4d0c70b7ac_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTUtMS0xLTEtMA_1d4fb29a-0ecc-49d3-8a47-2590de1c51d7"
      unitRef="shares">66000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i815cd3ad41474aa89bdbc8aac7df75ff_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTUtNS0xLTEtMA_5b3d69cc-c29d-420f-8893-9d1d018d85c0"
      unitRef="usd">592000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTUtMTEtMS0xLTA_bd334241-0ae9-4cca-b544-a48c245fd946"
      unitRef="usd">592000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i815cd3ad41474aa89bdbc8aac7df75ff_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTYtNS0xLTEtMA_694eb3aa-b727-4696-bbcf-f3e334581e3f"
      unitRef="usd">3690000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTYtMTEtMS0xLTA_ed2b0c4f-0fbd-4717-b9e3-b733eb81b638"
      unitRef="usd">3690000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5af639e68aed46ceaadf61c50fa22b6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTctNy0xLTEtMA_aa4ea82c-f5ce-4bb1-ba80-e5d0f998cf88"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTctMTEtMS0xLTA_6a535d5b-d134-453f-b8ea-8f89742cfdf6"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i558e5a32ec2d4a419c4b11583520ee8a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTgtOS0xLTEtMA_e1d9150a-15cc-4f27-a6e6-3b4b8c2b73f3"
      unitRef="usd">-429000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTgtMTEtMS0xLTA_7445c18a-c348-4829-83cf-19d563abd32b"
      unitRef="usd">-429000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ided6cc631fa347f29afdeec8dc63dfa2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktMS0xLTEtMA_3256a131-c4dc-43af-9926-0b3003b7bcf8"
      unitRef="shares">27433000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ided6cc631fa347f29afdeec8dc63dfa2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktMy0xLTEtMA_75e95449-508e-4be4-80cb-e4bb703abf15"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0bdb0c2fd7a1425b88540d8ab89e49ef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktNS0xLTEtMA_c02b6f30-e517-4526-bc4a-07a0bf002065"
      unitRef="usd">668429000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7208ae669f5a4129b42fd35dfa7a6c27_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktNy0xLTEtMA_48c13d2f-f349-4c50-8f59-f6927dee8bdd"
      unitRef="usd">-176000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf4c209b6991485097f5062d7e179388_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktOS0xLTEtMA_877a87dd-efe6-4cf0-8e32-e1f924c214e8"
      unitRef="usd">-282549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yMi9mcmFnOjE4YTY0YzIzYmRmMzQ2OWQ4MzgxNTQwZWIwMDljYWViL3RhYmxlOjVlYmRjM2Y5MDNmMDRlODY5NmEyZTkxNzk3MjBmMTFmL3RhYmxlcmFuZ2U6NWViZGMzZjkwM2YwNGU4Njk2YTJlOTE3OTcyMGYxMWZfMTktMTEtMS0xLTA_5732346e-21fc-47df-9fee-2463cccb9411"
      unitRef="usd">385731000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idb2028cc405d4c44936f5ed145a50dbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi0xLTEtMS0w_9840cf52-98ce-40c0-a527-1ba6790c4380"
      unitRef="shares">27255000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idb2028cc405d4c44936f5ed145a50dbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi0zLTEtMS0w_a96a7aeb-a8ce-4301-b6d5-1d2485ed45bb"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4641429f60564692a060512d8c74558a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi01LTEtMS0w_a3deeea8-5559-41d2-8ba5-b19c256288ac"
      unitRef="usd">648669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b4663eb93a648168c61a81e9457dc1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi03LTEtMS0w_58cdbe2a-e019-41a5-9348-5286e78f7032"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i142b163e653d4a9cba36852e354d5a57_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi05LTEtMS0w_d7e71e3f-2f42-45db-88c6-8743b871a5b0"
      unitRef="usd">-244026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0d07597b3dc4975a4fe06e498a5d3e4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMi0xMS0xLTEtMA_f87b9649-4a64-4245-a965-6019fd5c0177"
      unitRef="usd">405008000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6bd7946500014e7a935d20e4d9049cab_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfNi0xLTEtMS0w_635475d0-725f-4bf5-974e-b01673bdf232"
      unitRef="shares">22000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i90cec4c950e344009abf72bee3271d18_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfNi01LTEtMS0w_06b42e1f-d06a-405b-9b68-f92487f63172"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i357b6498c5d9488bb080175359e876e9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfNi0xMS0xLTEtMA_b23195ef-56d7-4688-aba6-74f611dc0f5e"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i90cec4c950e344009abf72bee3271d18_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTEtNS0xLTEtMA_4aeaabb7-c8a4-4310-bcd8-4e9adb69d599"
      unitRef="usd">2975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i357b6498c5d9488bb080175359e876e9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTEtMTEtMS0xLTA_fbe71e4d-ad1e-4d49-b299-f34556facd87"
      unitRef="usd">2975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ida9c210ea8494148835c51d4ce0d58f1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTItNy0xLTEtMA_1f70a83c-2a78-4f60-9e93-35c1bd654b7a"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i357b6498c5d9488bb080175359e876e9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTItMTEtMS0xLTA_f2218469-cca3-4eb8-ae60-9e1c7ddd4c75"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0b05a125a4494bb5ab7cdbe086bdd21c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTMtOS0xLTEtMA_588e40ba-14b3-405a-b98f-8295181ac534"
      unitRef="usd">-8262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i357b6498c5d9488bb080175359e876e9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTMtMTEtMS0xLTA_519b4195-e9e2-4087-a006-30a2260533ab"
      unitRef="usd">-8262000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7bb913f721294b8fbd1c537aae3279a9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtMS0xLTEtMA_a236421b-3662-4e9d-adb8-1f2cff73f136"
      unitRef="shares">27277000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7bb913f721294b8fbd1c537aae3279a9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtMy0xLTEtMA_35178fa9-7712-4215-a8dc-560367edb6ae"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic4615342e0d54465853cf7d151fdec12_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtNS0xLTEtMA_9e5315b1-67dc-442a-8af1-a9726a6c5b41"
      unitRef="usd">651680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88d8e92fdf0848f5a09451c6582b0d02_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtNy0xLTEtMA_601375c1-a068-46b8-aded-c1401b1efa66"
      unitRef="usd">1145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i226bcfccf34e4b0bba7f77efd6749232_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtOS0xLTEtMA_aa303864-c470-4df1-ba19-ea60410ddec6"
      unitRef="usd">-252288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bd22ef257044497bb6129f2ee1efd43_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTQtMTEtMS0xLTA_9fc80e72-3d58-41a1-8db2-842086d72ad7"
      unitRef="usd">400564000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia3f83c27a2f24bcf960cbb189259177b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTUtMS0xLTEtMA_1f0ec578-5c56-4822-a73e-5a08438bd48b"
      unitRef="shares">10000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if4d26b66b1c74404b1a4ad9a12346650_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTUtNS0xLTEtMA_13d657a5-d895-4533-a073-f1fb47580e6f"
      unitRef="usd">71000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTUtMTEtMS0xLTA_3ea755b3-bedd-48b9-8652-bf50ded62dc3"
      unitRef="usd">71000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="if4d26b66b1c74404b1a4ad9a12346650_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTctNS0xLTEtMA_b121f770-2ace-421b-95e1-352dc19f4914"
      unitRef="usd">2741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTctMTEtMS0xLTA_d90e82d9-15b2-4356-b973-75c8f9f875b9"
      unitRef="usd">2741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if46ccc6f74854042980a58a0f048852f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTgtNy0xLTEtMA_925fee0f-6f61-4a25-9164-39d2cdad47b8"
      unitRef="usd">-392000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTgtMTEtMS0xLTA_7b383dc1-e10f-44d2-b81c-d33b2e00d62e"
      unitRef="usd">-392000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i64512e583b524f5fbae03573f01e4425_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTktOS0xLTEtMA_ac9e979e-42fc-4a38-9785-5db7f2df99d3"
      unitRef="usd">-21548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMTktMTEtMS0xLTA_9e1b9105-b907-4ba3-866b-9d24a54a34cf"
      unitRef="usd">-21548000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="if8bf867918fb40f2ade51bfcba942241_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtMS0xLTEtMA_4fe0208d-e903-451d-a132-ee585cff09cb"
      unitRef="shares">27287000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if8bf867918fb40f2ade51bfcba942241_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtMy0xLTEtMA_dc1389d8-7087-4367-8e1e-0befbde4c449"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e42fc0c6ff14036a66064c60d7832a5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtNS0xLTEtMA_d1e4ca39-6309-49e0-a102-b4c479fb1d37"
      unitRef="usd">654492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0daff577f8ae408693a9f6c34fbe73ce_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtNy0xLTEtMA_9ac96fba-367c-447c-a457-b72d13daff2c"
      unitRef="usd">753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i386a0a6a5d9e4bd8ad62ba1339a4e448_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtOS0xLTEtMA_4bf8cd6f-e00f-4e79-b751-8a0d841fe8e6"
      unitRef="usd">-273836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idfc960c533644748967278a36e67af20_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yNS9mcmFnOjJkN2NmY2Q0ZjQ1NTQ1MWNhMjM0MmMyYmNhNTBjMjY1L3RhYmxlOjRlZTc4NDg3ZDY1ZjQwNTM4OGFlYWY5Y2I1YjNkNDZmL3RhYmxlcmFuZ2U6NGVlNzg0ODdkNjVmNDA1Mzg4YWVhZjljYjViM2Q0NmZfMjAtMTEtMS0xLTA_dd496feb-227a-40c8-b01f-aa4a91f6e894"
      unitRef="usd">381436000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMy0xLTEtMS0w_4c764b84-246b-417a-bb04-2103650c110a"
      unitRef="usd">-18592000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMy0zLTEtMS0w_2b9c5029-62eb-4731-a602-cb35c578a2ea"
      unitRef="usd">-29810000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNS0xLTEtMS0w_2e8a8cff-6679-40c4-b9e9-409ad54e897b"
      unitRef="usd">285000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNS0zLTEtMS0w_1d5e21ae-5cd0-4e80-b19e-d8869281e69f"
      unitRef="usd">277000</us-gaap:DepreciationDepletionAndAmortization>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNi0xLTEtMS0w_c49477c4-f59a-47b5-b7cc-7f91f09c4b56"
      unitRef="usd">7005000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNi0zLTEtMS0w_46ffdc03-a8bc-412f-94c5-6cf648ff3dc4"
      unitRef="usd">5716000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfOC0xLTEtMS0w_eb409479-b35b-40d7-bf6a-350ffe1d5ada"
      unitRef="usd">-293000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfOC0zLTEtMS0w_9692d245-1a60-4ba6-9f3d-705651be14f3"
      unitRef="usd">-61000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTAtMS0xLTEtMjAzNA_0b60a7f7-5a11-4e0a-8a46-7da7482246a7"
      unitRef="usd">751000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTAtMy0xLTEtMjAzOQ_e6d1cafe-0bf4-47c8-9612-09f802d77db5"
      unitRef="usd">382000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTEtMS0xLTEtMA_e5094132-d3d9-4141-a11c-847edf3b161b"
      unitRef="usd">642000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTEtMy0xLTEtMA_98909dbd-5a93-4896-a0e3-b771a9cd8070"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTMtMS0xLTEtMA_d15ce15f-d7a7-429a-923b-8856672e6bff"
      unitRef="usd">3235000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTMtMy0xLTEtMA_db3c1b71-ecf1-4ad7-a57d-13145e845ac5"
      unitRef="usd">2860000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTQtMS0xLTEtMA_bc79ee66-5773-4d6a-9381-4f908023e53f"
      unitRef="usd">772000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTQtMy0xLTEtMA_c5375b0a-a026-474e-8314-6fa7ff23b10c"
      unitRef="usd">-8068000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTctMS0xLTEtODI2_227c1858-5aed-47f6-9df7-a07e41d3b784"
      unitRef="usd">-250000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTctMy0xLTEtODU2_4cdd92c0-5b1d-4f82-aa6c-04ae239522b0"
      unitRef="usd">-420000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTctMS0xLTEtMA_7448acb7-8818-462e-abfe-5c2c987d2140"
      unitRef="usd">-13613000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTctMy0xLTEtMA_ec549815-a35c-477b-9a9e-d29d7a47aa45"
      unitRef="usd">-34722000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTktMS0xLTEtMA_244ba512-fce7-49e6-a547-6211d145a056"
      unitRef="usd">9734000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMTktMy0xLTEtMA_fe060568-4114-40a7-8892-a4a8876d6fd5"
      unitRef="usd">86947000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjAtMS0xLTEtMA_9cc503c3-7287-4b8e-bcda-c52d8e568874"
      unitRef="usd">105604000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjAtMy0xLTEtMA_a9ae8475-9c2e-4454-bc17-5ceffbb89929"
      unitRef="usd">173262000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjEtMS0xLTEtMA_88ec64e5-d8d0-4e55-b0ab-c1c4362b0cd6"
      unitRef="usd">1180000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjEtMy0xLTEtMA_a2c786b8-29a6-48f8-a8f8-38617a66ff78"
      unitRef="usd">170000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjItMS0xLTEtMA_94fdb3d5-72d3-49b2-b7f6-e9be0c74cb46"
      unitRef="usd">94690000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjItMy0xLTEtMA_e27f5673-53d5-4b13-ad85-c5df90e7535f"
      unitRef="usd">86145000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjQtMS0xLTEtMA_69f5265d-8eb6-4ecd-bb49-31515c92dc9c"
      unitRef="usd">721000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjQtMy0xLTEtMA_23d9ff45-adb1-42a2-b61a-51d15acb53c8"
      unitRef="usd">107000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjctMS0xLTEtMA_060d36a1-d271-44cc-aaa5-171687ee1e39"
      unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMjctMy0xLTEtMA_b10d92bb-f456-47e0-924b-8f37c9ab1c05"
      unitRef="usd">1375000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzAtMS0xLTEtMA_33f1b5bb-ec7a-4839-8411-96ad41039e33"
      unitRef="usd">721000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzAtMy0xLTEtMA_7d64876a-6475-4401-a3d1-d40925378977"
      unitRef="usd">-1268000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzEtMS0xLTEtMA_896ce90c-b081-4c59-912a-8a2450ca463f"
      unitRef="usd">81798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzEtMy0xLTEtMA_0a79b60a-c952-4ee7-999c-015605acbe3b"
      unitRef="usd">50155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzItMS0xLTEtMA_c5b1e44e-48d1-4433-abb8-2291d9b2335d"
      unitRef="usd">250516000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0d07597b3dc4975a4fe06e498a5d3e4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzItMy0xLTEtMA_790640a2-ace0-42c9-9212-f11dd3f627d3"
      unitRef="usd">171077000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzMtMS0xLTEtMA_7d0b5415-d944-441d-bdb1-e37dd23817c5"
      unitRef="usd">332314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idfc960c533644748967278a36e67af20_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzMtMy0xLTEtMA_84b2e483-6e1f-4980-8eb1-c7e87571d763"
      unitRef="usd">221232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzUtMS0xLTEtMA_d08bb56f-4399-4dfa-8b1c-4bf20fc592aa"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzUtMy0xLTEtMA_00812def-36a9-4700-90c5-5e3606ee6fe2"
      unitRef="usd">4000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNDAtMS0xLTEtMjA1NA_57c366b5-407f-4111-9a2e-d2ef86807d5c"
      unitRef="usd">20685000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfNDAtMy0xLTEtMjA1Nw_5bf8ee66-d236-499c-a487-c31f0104c1b6"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzgtMS0xLTEtMA_2085d935-74df-4224-933e-2eedc101389b"
      unitRef="usd">89000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzgtMy0xLTEtMA_3e08a92d-df8d-4902-9407-24a0dd5d18a1"
      unitRef="usd">25000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <anab:ReceivablesForStockOptionsExercised
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzktMS0xLTEtMA_2f30a8ca-f667-4e81-a652-945e80ca2847"
      unitRef="usd">38000</anab:ReceivablesForStockOptionsExercised>
    <anab:ReceivablesForStockOptionsExercised
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8yOC9mcmFnOjJlMzBlMzZlNGQ1MTQxOTQ4NThkM2U1NDc2OGM2MTViL3RhYmxlOjJhNTU5NDllOTJmYTRjYjNiZjEyYzM2ZjZmNzk5ZDU3L3RhYmxlcmFuZ2U6MmE1NTk0OWU5MmZhNGNiM2JmMTJjMzZmNmY3OTlkNTdfMzktMy0xLTEtMA_9d805b5d-e7da-4bcd-b46f-a95b24e78fc8"
      unitRef="usd">0</anab:ReceivablesForStockOptionsExercised>
    <us-gaap:NatureOfOperations
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNC9mcmFnOmI0YzkwOWIyMWFlZjRlYTRiYmVhZWQwNjU2MTMxYjZjL3RleHRyZWdpb246YjRjOTA5YjIxYWVmNGVhNGJiZWFlZDA2NTYxMzFiNmNfMTkyMg_775eb912-80e8-4f5f-a5e0-f368180a1773">Description of the Business &lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AnaptysBio, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vitro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We currently generate revenue from milestones and royalties achieved under our collaborative research and development arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTk0Mw_2671b84e-e067-4831-acac-46f78adec24b">Summary of Significant Accounting Policies &lt;div style="margin-top:6pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2020 financial information to conform to the current year presentation of other long-term assets, operating lease right-of-use, or &#x201c;ROU&#x201d; asset, and operating lease liabilities on the Consolidated Balance Sheets and Consolidated Statements of Cash Flows. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities, to date there has not been any material delays in clinical operations. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in one reportable segment, and our functional and reporting currency is the U.S. dollar.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized in accordance with revenue recognition accounting guidance, which utilizes five basic steps to determine whether revenue can be recognized and to what extent: (i)&#160;identify the contract with a customer; (ii)&#160;identify the performance obligation; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price; and (v) determine the recognition period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Obligations.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We evaluate deliverables on a contract-by-contract basis to determine whether each deliverable represents a good or service that is distinct or has the same pattern of transfer as other deliverables. A deliverable is considered distinct if the customer can benefit from the good or service independently of other goods/services either in the contract or that can be obtained elsewhere, without regard to contract exclusivity, and the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contact. If the deliverable is not considered distinct, we combine such deliverables and account for them as a single performance obligation. We allocate the consideration to each deliverable at the inception of the arrangement based on the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;License Arrangements. The performance obligations under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. Licenses for multiple antibodies within a single contract are generally combined as they have substantially the same pattern of transfer to the customer. Historically, our licenses have held no value to the customer, as the antibodies were in the discovery phase and required our expertise for further development. Accordingly, licenses are not considered distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Research and Development Services. The performance obligations under our collaboration and license agreements generally include research and development services we perform on behalf of or with our collaborators. As discussed within license arrangements above, our licenses have historically held no value without the research and development services we provide. As we generally only provide research and development services for internally generated antibodies that require a license to be utilized by a third party, our research and development services are not considered distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Steering Committee Meetings. The performance obligations under our collaboration and license agreements may also include our participation on steering committees, which allows us to direct the progression of our discovery programs. As these steering committees would not occur or benefit the customer without the use of our licenses, these are not considered distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize consideration allocated to a performance obligation as the performance obligation is satisfied, and the determination as to whether consideration is recognized over time or at a point in time is made upon contract inception. For our collaboration agreements, this is generally over the period in which research and development services have been performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction Price. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration and license agreements generally include both fixed and variable consideration. Fixed payments, such as those for upfront fees are included in the transaction price at contract value, while variable consideration such as reimbursement for research and development services, milestone and royalty payments are estimated and then evaluated for constraints upon inception of the contract and evaluated on a quarterly basis thereafter. Research and development services are updated for actual invoices. Given the nature of our agreements, milestones are estimated using the most likely amount and are evaluated on a quarterly basis. Upon commercialization, royalty payments will be recognized in the period incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We receive royalty revenue on sales by our partners of products covered by patents or contract rights that we own and net sales of their approved drugs, where we have concluded the license is the predominant item to which the royalties relate. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of our partners&#x2019; historical experience including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. As of June&#160;30, 2021, there have not been material differences between actual and estimated royalty revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the weighted-average o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkzOQ_8a51c8a0-d550-463b-a026-60e9d35ed21a">Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2020 financial information to conform to the current year presentation of other long-term assets, operating lease right-of-use, or &#x201c;ROU&#x201d; asset, and operating lease liabilities on the Consolidated Balance Sheets and Consolidated Statements of Cash Flows. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities, to date there has not been any material delays in clinical operations. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkxOA_0030f6e9-8999-4cd3-8d91-7bb80981c158">Basis of ConsolidationThe accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in one reportable segment, and our functional and reporting currency is the U.S. dollar.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfMjU4OQ_f7ede7c2-4335-4498-ae1e-2bd2232aeb84"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkxMg_dc713b07-77a9-45b2-b572-bd5575e6637a">&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkxNg_c90dc943-6347-485f-aac8-226da3e7754f">&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized in accordance with revenue recognition accounting guidance, which utilizes five basic steps to determine whether revenue can be recognized and to what extent: (i)&#160;identify the contract with a customer; (ii)&#160;identify the performance obligation; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price; and (v) determine the recognition period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Obligations.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We evaluate deliverables on a contract-by-contract basis to determine whether each deliverable represents a good or service that is distinct or has the same pattern of transfer as other deliverables. A deliverable is considered distinct if the customer can benefit from the good or service independently of other goods/services either in the contract or that can be obtained elsewhere, without regard to contract exclusivity, and the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contact. If the deliverable is not considered distinct, we combine such deliverables and account for them as a single performance obligation. We allocate the consideration to each deliverable at the inception of the arrangement based on the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;License Arrangements. The performance obligations under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. Licenses for multiple antibodies within a single contract are generally combined as they have substantially the same pattern of transfer to the customer. Historically, our licenses have held no value to the customer, as the antibodies were in the discovery phase and required our expertise for further development. Accordingly, licenses are not considered distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Research and Development Services. The performance obligations under our collaboration and license agreements generally include research and development services we perform on behalf of or with our collaborators. As discussed within license arrangements above, our licenses have historically held no value without the research and development services we provide. As we generally only provide research and development services for internally generated antibodies that require a license to be utilized by a third party, our research and development services are not considered distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Steering Committee Meetings. The performance obligations under our collaboration and license agreements may also include our participation on steering committees, which allows us to direct the progression of our discovery programs. As these steering committees would not occur or benefit the customer without the use of our licenses, these are not considered distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize consideration allocated to a performance obligation as the performance obligation is satisfied, and the determination as to whether consideration is recognized over time or at a point in time is made upon contract inception. For our collaboration agreements, this is generally over the period in which research and development services have been performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction Price. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration and license agreements generally include both fixed and variable consideration. Fixed payments, such as those for upfront fees are included in the transaction price at contract value, while variable consideration such as reimbursement for research and development services, milestone and royalty payments are estimated and then evaluated for constraints upon inception of the contract and evaluated on a quarterly basis thereafter. Research and development services are updated for actual invoices. Given the nature of our agreements, milestones are estimated using the most likely amount and are evaluated on a quarterly basis. Upon commercialization, royalty payments will be recognized in the period incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;We receive royalty revenue on sales by our partners of products covered by patents or contract rights that we own and net sales of their approved drugs, where we have concluded the license is the predominant item to which the royalties relate. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of our partners&#x2019; historical experience including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. As of June&#160;30, 2021, there have not been material differences between actual and estimated royalty revenues.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTk0MA_69aa2e2a-8e12-4a59-8b46-557e35aa4e03">&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RleHRyZWdpb246NWM1ZGYzZjg3OGNlNDc4OTlmNmU0Yzg4YmFjZGYwMjVfOTkyMw_9d9cca9b-55cf-4dbb-8632-50cd6c03bcf5">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the weighted-average o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i54e09947d78640e4b9eeb147c43743aa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RhYmxlOmQ3MGUzZTZmNWU4ZTQ3YzViZDMxNGYzZjU3ODgzNDc5L3RhYmxlcmFuZ2U6ZDcwZTNlNmY1ZThlNDdjNWJkMzE0ZjNmNTc4ODM0NzlfMy0xLTEtMS0w_fdc3fcac-74be-42b8-8177-f677d2ceb1f3"
      unitRef="shares">3800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i12ddd91f6523469eb8f7ad820f2b8764_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RhYmxlOmQ3MGUzZTZmNWU4ZTQ3YzViZDMxNGYzZjU3ODgzNDc5L3RhYmxlcmFuZ2U6ZDcwZTNlNmY1ZThlNDdjNWJkMzE0ZjNmNTc4ODM0NzlfMy0zLTEtMS0w_2cd0f41c-29dd-4c76-bed1-3fb961dd5954"
      unitRef="shares">2838000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1487ca8ec2e24d4fba6469fa2aa23d66_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RhYmxlOmQ3MGUzZTZmNWU4ZTQ3YzViZDMxNGYzZjU3ODgzNDc5L3RhYmxlcmFuZ2U6ZDcwZTNlNmY1ZThlNDdjNWJkMzE0ZjNmNTc4ODM0NzlfMy01LTEtMS0w_be9f43e3-fe66-4fea-bdb1-5dd40825b682"
      unitRef="shares">3624000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4217decdbe45471ca7c606434d0632c0_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml8zNy9mcmFnOjVjNWRmM2Y4NzhjZTQ3ODk5ZjZlNGM4OGJhY2RmMDI1L3RhYmxlOmQ3MGUzZTZmNWU4ZTQ3YzViZDMxNGYzZjU3ODgzNDc5L3RhYmxlcmFuZ2U6ZDcwZTNlNmY1ZThlNDdjNWJkMzE0ZjNmNTc4ODM0NzlfMy03LTEtMS0w_afb112b3-e5f4-4311-b4f9-eab1314baac8"
      unitRef="shares">2930000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RleHRyZWdpb246Njg0MjcwNzVlZGRhNDI5NzhlZmUyMTZhMGRlYWQ3OTZfMjE5_44140411-49c5-4a54-bf59-65972630eec5">Balance Sheet Accounts and Supplemental Disclosures &lt;div style="margin-top:6pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research, development and manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RleHRyZWdpb246Njg0MjcwNzVlZGRhNDI5NzhlZmUyMTZhMGRlYWQ3OTZfMjIx_e32391ec-4736-4559-b833-02b642287805">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b92baa04c8b4070987a2e921dbaafa4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMS0xLTEtMS0w_f0ceb1e8-3a7f-471f-a0ce-defd028ee19f"
      unitRef="usd">5660000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic8a1dc7356a94c6eb2c2452e7957ebe8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMS0zLTEtMS0w_c1b360df-9aae-4690-b5db-f97d2754e98d"
      unitRef="usd">5225000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0b552c03f74142c287d50400a1538790_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMi0xLTEtMS0w_6e423b39-fcfa-4c1f-bf4a-cc75746addfb"
      unitRef="usd">1508000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i593bf7da05f24f8a88e6e1f64037cce7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMi0zLTEtMS0w_289dbf33-d295-4fd0-a294-ab7ed6216712"
      unitRef="usd">976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c0631bdcfa94b9182f6f5cfe8b439b3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMy0xLTEtMS0w_59c20530-51d3-48a7-841e-2dd12a312b95"
      unitRef="usd">548000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c4a40293897411dad729dd8d12a9b9b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfMy0zLTEtMS0w_e7340c4d-09ca-429c-bd4f-165f3065564e"
      unitRef="usd">527000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNC0xLTEtMS0w_2c6cb621-cd8c-455c-93b2-b3fc83983ff2"
      unitRef="usd">7716000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNC0zLTEtMS0w_af931585-6848-41c1-bf51-7803308fca3d"
      unitRef="usd">6728000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNS0xLTEtMS0w_81d8e9eb-0cae-4f27-b34d-cd74b2c21aff"
      unitRef="usd">5228000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNS0zLTEtMS0w_e47ed5e6-0f57-46fb-8c6d-f379d99bcacc"
      unitRef="usd">4945000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNi0xLTEtMS0w_b8151192-9310-47af-ba61-90edc54e7977"
      unitRef="usd">2488000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjM4NWMzYTA4NzVlMzRhN2M4YTNhNzRiYTY3YjY0MWI3L3RhYmxlcmFuZ2U6Mzg1YzNhMDg3NWUzNGE3YzhhM2E3NGJhNjdiNjQxYjdfNi0zLTEtMS0w_2b7b83b9-314e-4f1b-a38a-6657cd7eb085"
      unitRef="usd">1783000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RleHRyZWdpb246Njg0MjcwNzVlZGRhNDI5NzhlZmUyMTZhMGRlYWQ3OTZfMjE4_819250a5-7313-4406-82a7-355bf36297a9">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research, development and manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMS0xLTEtMS0w_dadc21dc-7f6e-4d0c-a880-bc0566fb0ba8"
      unitRef="usd">3103000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMS0zLTEtMS0w_7901d5f6-5cb3-4308-82f0-dcc65dbdf254"
      unitRef="usd">3688000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMi0xLTEtMS0w_761eb699-b507-431d-b5ce-ec31981bd686"
      unitRef="usd">447000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMi0zLTEtMS0w_2b64edea-f2d1-44a5-98dc-6410c500dddc"
      unitRef="usd">408000</us-gaap:AccruedProfessionalFeesCurrent>
    <anab:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMy0xLTEtMS0w_a93bb097-7928-485d-b685-5ff6fa7db54e"
      unitRef="usd">11922000</anab:AccruedResearchAndDevelopmentExpensesCurrent>
    <anab:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfMy0zLTEtMS0w_8a2a9d5b-7c98-4086-a4a0-5564c87f2cbf"
      unitRef="usd">10936000</anab:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfNC0xLTEtMS0w_e10c842b-26f4-46f4-8a4e-a78649c0a890"
      unitRef="usd">486000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfNC0zLTEtMS0w_159fd6eb-75fc-41e2-a185-817527fac4b7"
      unitRef="usd">230000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfNS0xLTEtMS0w_992f7aa1-3c9e-4ece-805e-bd4387bab7a6"
      unitRef="usd">15958000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80MC9mcmFnOjY4NDI3MDc1ZWRkYTQyOTc4ZWZlMjE2YTBkZWFkNzk2L3RhYmxlOjQwNzgwODRmZjY1NjQ5Njg4MjI4OWE0ZjhmN2YzOTFiL3RhYmxlcmFuZ2U6NDA3ODA4NGZmNjU2NDk2ODgyMjg5YTRmOGY3ZjM5MWJfNS0zLTEtMS0w_27ab9a0b-4118-4c21-8004-22c43545d91b"
      unitRef="usd">15262000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTE0MTU_1d14c6b8-4b2a-437d-816d-6ac737832f9c">Collaborative Research and Development Agreements&lt;div style="margin-top:6pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GlaxoSmithKline Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2014, we entered into a Collaboration and Exclusive License Agreement (the &#x201c;GSK Agreement&#x201d;) with TESARO, Inc. (&#x201c;Tesaro&#x201d;), an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline (Tesaro and GlaxoSmithKline are hereinafter referred to, collectively, as &#x201c;GSK&#x201d;). Under the terms of the GSK Agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory, and commercial development to be performed by GSK. Under the terms of the GSK Agreement, GSK paid an upfront license fee of $17.0 million in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for three specific targets. In November 2014, Amendment No.&#160;1 to the GSK Agreement was agreed by both parties to add an antibody discovery program against an undisclosed fourth target for an upfront license fee of $2.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each development program, we are eligible to receive milestone payments of up to $18.0 million if certain preclinical and clinical trial events are achieved by GSK, up to an additional $90.0 million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional $165.0 million upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the GSK Agreement will terminate, with respect to each specific developed product, upon the later of the 12th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we determined that the upfront license fees and research funding under the GSK Agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In February 2016, Amendment No.&#160;2 to the GSK Agreement was agreed by both parties to define the effective dates of the development programs of the GSK Agreement. We determined that the research and development services would be extended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;through December 31, 2016. As a result, the period over which the unrecognized license fees and discovery milestones were recognized was extended through December 31, 2016 and have since been recognized in full. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer.&#160;We identified the following material promises under the GSK Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) research and development (&#x201c;R&amp;amp;D&#x201d;) services, and (3) joint steering committee meetings. We considered the research and discovery capabilities of GSK for these specific programs, GSK&#x2019;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the joint steering committee participation would not have been provided without the R&amp;amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 23, 2020, Amendment No. 3 to the GSK Agreement (the &#x201c;Amendment&#x201d;) was agreed to by both parties to permit GSK to conduct development and commercialization of Zejula, an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, which has received U.S. approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, under the Amendment, we were granted increased royalties upon sales of JEMPERLI (dostarlimab), an anti-PD-1 antagonist antibody under development by GSK for multiple oncological disorders. The Amendment also provided for a one-time, non-refundable cash payment of $60.0&#160;million that we received and recognized as revenue in the fourth quarter of 2020. GSK also agreed, starting January 1, 2021, to pay us a 1% royalty less third-party royalty deductions on all GSK net sales of Zejula. The $1.1&#160;billion in cash milestone payments due under the GSK Agreement remain unchanged.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Additionally, under the terms of the Amendment, GSK has agreed to certain diligence commitments with respect to the future development of JEMPERLI, and the parties have agreed to review such commitments under regular joint review committee meetings going forward.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed this Amendment in accordance with ASC 606 and concluded the Amendment was a contract modification to the GSK Agreement. Based on our assessment, we identified the terms of the Amendment to be interrelated to the GSK Agreement&#x2019;s single performance obligation, noting completion and delivery of terms under the Amendment were satisfied by both parties with the execution of the Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the transaction price for the GSK Agreement and Amendment includes the upfront payment, research reimbursement revenue, one-time payment associated with the Amendment, and milestones earned to date, which are allocated in their entirety to the single performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We earned and recognized $1.3 million in royalty revenue during the six months ended June 30, 2021 related to GSK net sales of Zejula and JEMPERLI during the period based on estimates of GSK&#x2019;s sales historical experience. GSK reports sales information to us on a one quarter lag and differences between actual and estimated royalty revenues will be adjusted in the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We earned and recognized three clinical milestones totaling $40.0 million during the six months ended June 30, 2021. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and GSK&#x2019;s efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to GSK and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones recognized through June&#160;30, 2021 under the GSK Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-PD-1 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(JEMPERLI/Dostarlimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-TIM-3 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK4069889A/Cobolimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-LAG-3 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK40974386)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestone Event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Initiated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; toxicology studies using good laboratory practices (GLPs) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q3'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IND clearance from the FDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 2 clinical trial initiation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 3 clinical trial initiation - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q3'18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 3 clinical trial initiation - second indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first BLA - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$10.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first MAA - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first BLA - second indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$10.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;First BLA approval - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$20.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;First MAA approval - first indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$10.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We recognized $30.0 million and $41.3 million in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; revenue under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;GSK Agreement &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;during the three and six months ended June 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;respectively, and $0 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$15.0 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;during the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;six months ended June 30, 2020, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Antibody Generation Agreement with Bristol-Myers Squibb &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2011, we entered into a license and collaboration agreement (the &#x201c;BMS Agreement&#x201d;) with Celgene, now a part of Bristol-Myers Squibb (Celgene and Bristol-Myers Squibb are hereinafter referred to, collectively, as &#x201c;BMS&#x201d;), to develop therapeutic antibodies against multiple targets. We granted BMS the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BMS Agreement provided for an upfront payment of $6.0 million from BMS, which we received in 2011 and recognized through 2014, milestone payments of up to $53.0 million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, BMS, is a customer.&#160;We identified the following material promises under the BMS Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;amp;D services, (3) a written report documenting findings, and (4) steering committee meetings. We considered the research and discovery capabilities of BMS, BMS&#x2019;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the transaction price of the BMS Agreement includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and BMS&#x2019;s efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined to relate predominantly to the intellectual property license granted to BMS and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones achieved through June&#160;30, 2021 under the BMS Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-PD-1 &lt;br/&gt;(CC-90006)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestone Event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completion of first &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; toxicology studies using GLPs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$0.5M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 1 clinical trial initiation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  There was no revenue recognized under this agreement during the three and six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="ib6bb85d544044f74be91e6c4ded1291a_D20140301-20140331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNzQy_7ec55b7e-db23-4add-8445-8a86970d72ab"
      unitRef="usd">17000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets
      contextRef="if23f0b3a9c1543389445ca1f2a582eb5_I20140331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfODc2_f89c7004-a149-41d0-95b1-ec3f3fb9f568"
      unitRef="target">3</anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets>
    <anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets
      contextRef="i443e38b29ed84f36aeff8d125942ff3c_I20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTAzOQ_cfa481de-a1ba-47b2-8d52-45c00aaa3071"
      unitRef="target">4</anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="i5c6137734596471eb3bfbea0e8c29f72_D20141101-20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTA4MQ_fc407157-d1ed-4f3c-b257-0132aed78099"
      unitRef="usd">2000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents
      contextRef="i443e38b29ed84f36aeff8d125942ff3c_I20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTE3MQ_ab9129e1-18f0-49c5-8610-60fc026140ff"
      unitRef="usd">18000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents>
    <anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals
      contextRef="i443e38b29ed84f36aeff8d125942ff3c_I20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTI2NA_68e1030e-9d88-4339-b985-66e267cf4d58"
      unitRef="usd">90000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals>
    <anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales
      contextRef="i443e38b29ed84f36aeff8d125942ff3c_I20141130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTM5NQ_fc8b4dd8-e015-45dc-ab41-0f7292f51e1a"
      unitRef="usd">165000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales>
    <anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent
      contextRef="i5c6137734596471eb3bfbea0e8c29f72_D20141101-20141130"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTc5MQ_b0f7b0e8-c900-444e-a8f0-b5c0aed2ead9">P12Y</anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent>
    <anab:RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees
      contextRef="ia8cde62162f4437eb22081031e78c481_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNDc2Mw_67424fc3-e9c0-4703-912b-516b89d9410d"
      unitRef="usd">60000000.0</anab:RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees>
    <anab:NetSalesRoyaltyPercent
      contextRef="i47989d6424ad4d9ab848e3e615102bac_D20210101-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNDg5NQ_259e552a-0f48-4ca9-aa8e-8c53c9355afe"
      unitRef="number">0.01</anab:NetSalesRoyaltyPercent>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="icb9fa8ebdf074b57a099e54ad0196d1d_D20210101-20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNDk0Mg_9008de5a-d2c6-4bf9-bb52-0411044f28bb"
      unitRef="usd">1100000000</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id40e9b7e255a4b9b918086d940de14a0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQ1NQ_fe2bd775-14e4-4d0c-8002-9d86d3b6aab1"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod
      contextRef="i44529c9832924677ab0905ad04031c28_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNjM0OQ_0299633c-ec1f-40e4-9feb-0928fb81853e"
      unitRef="milestone">3</anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i79a47cb5a3684fb9965f688e81d082de_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfNjM3NQ_9df0fdf7-750f-45ad-8be6-0724e35b94f5"
      unitRef="usd">40000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTE0MTk_200cbb11-c587-4aee-a8c3-9307c59c1bc0">Milestones recognized through June&#160;30, 2021 under the GSK Agreement are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-PD-1 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(JEMPERLI/Dostarlimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-TIM-3 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK4069889A/Cobolimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-LAG-3 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(GSK40974386)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestone Event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Initiated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; toxicology studies using good laboratory practices (GLPs) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q3'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IND clearance from the FDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$4.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 2 clinical trial initiation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 3 clinical trial initiation - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q3'18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 3 clinical trial initiation - second indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first BLA - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$10.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first MAA - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$5.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Filing of the first BLA - second indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$10.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q1'21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;First BLA approval - first indication&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$20.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;First MAA approval - first indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$10.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestones achieved through June&#160;30, 2021 under the BMS Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Anti-PD-1 &lt;br/&gt;(CC-90006)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestone Event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter Recognized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completion of first &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; toxicology studies using GLPs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$0.5M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q2'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Phase 1 clinical trial initiation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.0M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Q4'16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i36e884c92e4248ebb969f8b647ff98db_D20150401-20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMi0xLTEtMS0w_fd123ed8-187e-4ee0-ae75-e6df7ff64a6e"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="id039343680da47d7af05ac3697ed6412_D20151001-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMi00LTEtMS0w_f8b07aac-99c9-4379-8f6f-d0adc0341f08"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i2d312a71cb6944cda527675f2fbd0a55_D20160701-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMi03LTEtMS0w_3c9a7347-4535-4293-9099-184393ffa16a"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="ie0f3dd66d4c24741b2a7ded6059d960e_D20160101-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMy0xLTEtMS0w_eca6e803-dce4-4811-a38a-6da7558ef0bb"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i91888314abeb436d827a581cdd98c07c_D20160401-20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMy00LTEtMS0w_4edf0693-be4d-41d8-8b02-2d3ab6d2c9d9"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i29ad61a6cdfc4838b66812099ad185db_D20170401-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMy03LTEtMS0w_036a5c66-ac26-4675-8a0f-d658c6c8e84b"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i8d52b0d15c6a49759798e25fe838631e_D20170401-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNC0xLTEtMS0w_1ddd7a64-d171-453a-a730-47a0a304100a"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i69938c04553e464db0b8b7c7704d1867_D20171001-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNC00LTEtMS0w_32606265-55aa-4ffc-8e0f-25761bc4c4fd"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i97554db485364f75b7e7a0213d8a4225_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNC03LTEtMS0w_f1a0e653-e637-470a-aefc-1e259b708ed6"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i7184beea9df1436ba28682c84638c335_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNS0xLTEtMS0w_edf29e8d-e4a8-443f-abc3-eab44f96a72e"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="ib2aeffac54924963b1bf3dc19fca0a21_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNi0xLTEtMS0w_7e742a4d-62ec-4a30-8137-a7c945a8f88e"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i7140062cc12f4f01acbb92e93e19466c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfNy0xLTEtMS0w_94c9cad2-4cb5-436e-869a-7a4725e6d017"
      unitRef="usd">10000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i4353bed79fb8420982f9675d50f0e0b6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfOC0xLTEtMS0w_caf3c0c4-dea8-45ad-baa3-821c3924593e"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i5bc779cbb0dd4b988a625b412a15a49c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfOS0xLTEtMS0w_8e0cfc45-0623-435e-bcdd-c49ff8a60a37"
      unitRef="usd">10000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="ia2241e34e4b2493cb520e2f1469c8282_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMTAtMS0xLTEtNTY2_fcfdcc86-96b9-4db3-8a79-267c2e8a63e1"
      unitRef="usd">20000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="i8ac11f17d0664ef6b0b60ad3b9f2d76d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjk3N2MzNjE0MGU5MjRkYzBhMTk3NGNiMmIzNGMxNjFkL3RhYmxlcmFuZ2U6OTc3YzM2MTQwZTkyNGRjMGExOTc0Y2IyYjM0YzE2MWRfMTEtMS0xLTEtNTY2_8930e691-6547-4cee-ae91-8488e67c747c"
      unitRef="usd">10000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQyOQ_1053cac0-e01c-40b9-a964-a2bd0d17fa0e"
      unitRef="usd">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQzNQ_13cc9287-0369-4e06-aa50-1ef706f9c234"
      unitRef="usd">41300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQ0Mw_1881dc1d-719c-4766-b8ef-ccde5d67aedf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMjE5OTAyMzI2NzQ0Nw_455ef548-fac4-4e2d-8bde-a105186f0816"
      unitRef="usd">15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="i6011ad3b1c6b44a885a7bd57000ca6be_D20110101-20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfODU2MQ_25072d1f-558a-4572-b2ae-4171e7bc04cb"
      unitRef="usd">6000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone
      contextRef="ifcb6477f9a49486ab46021a396ff7561_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfODY1Nw_9296c673-119a-438f-aeea-b7c46e2369f6"
      unitRef="usd">53000000.0</anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned
      contextRef="i59da14b2fe8548e5870e1779cc0aa9d0_D20160401-20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjhiMDhjMGMxOGNkZDQzNjBiYTBmMjM1MWM1MGZhYmIyL3RhYmxlcmFuZ2U6OGIwOGMwYzE4Y2RkNDM2MGJhMGYyMzUxYzUwZmFiYjJfMi0xLTEtMS0w_0748750c-6f4d-49d1-8174-077172825cec"
      unitRef="usd">500000</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned
      contextRef="i4a55c463e33c4afab95cb2149af0e3ce_D20161001-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RhYmxlOjhiMDhjMGMxOGNkZDQzNjBiYTBmMjM1MWM1MGZhYmIyL3RhYmxlcmFuZ2U6OGIwOGMwYzE4Y2RkNDM2MGJhMGYyMzUxYzUwZmFiYjJfMy0xLTEtMS0w_13f9c33e-f956-49ac-9150-2eebb3248bf5"
      unitRef="usd">1000000.0</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa80869592e640d389371d71f073f337_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTEzNTA_03cc7e6d-f9c1-48a6-8c5e-4575b63d69dc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70c2ff1aec104594b36f1b5f8e2a3e4a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTEzNTA_809f6a66-6542-4553-ba5b-ebc7fd19c32c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6413c5f064d49babec39642d4b164a5_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTEzNTA_9aa3048e-825f-4840-8c21-6ba7eeb993e5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id77469bf2efe425dac416b31a411d04b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80My9mcmFnOjBhNmU1NDcxZDY3ODQ5NThiMjEyZWY2MjBmYmQwNTg1L3RleHRyZWdpb246MGE2ZTU0NzFkNjc4NDk1OGIyMTJlZjYyMGZiZDA1ODVfMTEzNTA_b47b1241-ee76-47e9-a43b-67df7b0f9566"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTIyNA_349ef4d0-22c4-4e43-8da8-2199e2aa92ca">Fair Value Measurements and Available for Sale Investments &lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, and accounts payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:11.25pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at End of Period Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Market&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prices for&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Identical&#160;Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;At June  30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;At December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:13.5pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Other Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, accrued expenses, and receivables approximate fair value due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of June&#160;30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding agency securities, none have maturity dates of less than one year and $5.0 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU2OQ_2c6af718-21cf-4692-a2d3-b58b8b1319f6"&gt;one&lt;/span&gt; to two years as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding certificates of deposit, $1.1 million have maturity dates of less than one year and $0.5 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcxNA_0f49c841-e469-4cdb-9e94-1d8fc6721bf2"&gt;one&lt;/span&gt; to two years as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our outstanding commercial and corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obligations have maturity dates of less than one year as of June&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our outstanding U.S. Treasury securities have maturity dates of less than one year as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Of our outstanding agency securities, $10.0 million have maturity dates of less than one year and $11.2 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwMg_8efbf14a-390d-4a61-8d2e-efb73efed063"&gt;one&lt;/span&gt; to two years as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding certificates of deposit, $1.1 million have a maturity date of less than one year and $1.3 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ1NQ_25069077-64eb-4770-a079-0932cb57d201"&gt;one&lt;/span&gt; to two years as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Of our outstanding commercial and corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obligations, $29.4 million have maturity dates of less than one year and $0.0 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyMA_ca5315b3-0237-444d-96a1-9e4abab3f521"&gt;one&lt;/span&gt; to two years as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Of our outstanding U.S. Treasury securities, $102.7 million have maturity dates of less than one year and $5.0 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc3NA_1f934835-43a2-4d2e-869c-8b6ff5fa0e3d"&gt;one&lt;/span&gt; to two years as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;June&#160;30, 2021&#160;and&#160;December&#160;31, 2020, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of June&#160;30, 2021 and 2020, unrealized losses on available-for-sale investments were not material, and accordingly, no allowance for credit losses were recorded.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTIyNQ_6aed4d91-8ef5-465a-81c1-329d19d57136">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at End of Period Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Market&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prices for&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Identical&#160;Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;At June  30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;At December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="if9133e4132b240e7bca2e1c95471892e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMy0xLTEtMS0w_1b51a7a0-e370-489a-9c92-1d4902758cd4"
      unitRef="usd">305162000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="ie5399bd92b9e4cf693eb263ebaa5e180_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMy0zLTEtMS0w_7514e730-41f1-4694-98f6-f1c5ef9ed077"
      unitRef="usd">305162000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="ia6e2dfb981084eb1a6ddf8ebc09962d3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMy01LTEtMS0w_d929c364-6e80-4941-81af-4c554a2b08c8"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i6e78cb67f53f47f3b1937709b61ee528_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMy03LTEtMS0w_c9baebec-b83b-482c-879a-f187afd0093b"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i5641bee18d3141bda9c26e4ca72e89b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNC0xLTEtMS0w_66e4fddc-b1f6-4928-a82e-eba17e9b26f3"
      unitRef="usd">26928000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i288736d64ff04b0ab6b16af4d6d2b14a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNC0zLTEtMS0w_de579e96-1f59-428b-9306-ca631804cb62"
      unitRef="usd">26928000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i8414801a345a4cd4ab3c203b8ec660a9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNC01LTEtMS0w_fcad4509-77af-4ab4-abd8-7f8c9ce901f0"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="icee60ae93525403795b2bac324fca5a6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNC03LTEtMS0w_5d18943f-b6b7-42de-8d5e-d181d3563050"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3ef14c2603b489b847974efac36accf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNS0xLTEtMS0w_ae5cba3f-4961-4f39-809a-a53e95d55d98"
      unitRef="usd">45714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec6ade6ba8d441b5a2642b21f097a179_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNS0zLTEtMS0w_95430902-7520-48fa-9860-56bd19f33b32"
      unitRef="usd">45714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ab16caf39c34c8eb91ade5ed0af706b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNS01LTEtMS0w_247f4ede-3205-49a6-a39e-4e95b9e9dbaf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9275bf5a2daa483ba130b781fc58af8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNS03LTEtMS0w_0978b145-0b7c-4bc7-8aa0-b6287e9b51d7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id13ee5fb8cf54c68859bac354f7a79d8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNi0xLTEtMS0w_ed906133-b141-4f84-a9cd-d5745ddadddc"
      unitRef="usd">1591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee6704368d964ed69d2439d929ef4748_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNi0zLTEtMS0w_860605b4-27e6-4f72-a45a-9752c2126a5d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i24c4a55ee9124b8bac3e70be46d12bc4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNi01LTEtMS0w_480ac706-52dc-47bb-b32c-9505fe7c942b"
      unitRef="usd">1591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4eeb2688caf9475dacc5b156e4b9ebcc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNi03LTEtMS0w_3bdefe91-4176-4056-ad34-69384ff6666d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i61b8a35c442e40f59ff35f5aab9e1ca4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNy0xLTEtMS0w_20dec6c6-b4b3-4320-9818-2024a2075d8a"
      unitRef="usd">4997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75a862142bb64348860dc4025bb374fc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNy0zLTEtMS0w_ad9a3572-7dea-4d2b-aa94-06eda454d4c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e9b6fa28a604b77aa8d086a61c3002a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNy01LTEtMS0w_8e745d73-3a25-47c4-a3dc-49b55b483527"
      unitRef="usd">4997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bc0beaf432b417aa88fa1f2d048adb7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfNy03LTEtMS0w_e32dd7f8-7e22-4897-a5e9-59921a4183d0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifad4b811111a4959a97b530f3e1edc30_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfOC0xLTEtMS0w_2807a0e7-ff8b-40a7-8385-8b6bc11b6b38"
      unitRef="usd">11779000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2efedcdd907841bdb7b475cccdb198dc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfOC0zLTEtMS0w_e31dfed2-c25c-450f-9970-1a7306cb4d6b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16d7c88a334a4713960dc3460eb06106_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfOC01LTEtMS0w_9a6bef93-0386-4060-a254-aac831e07c02"
      unitRef="usd">11779000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb5ed2e6efa94819b8a0fb85e74275d6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfOC03LTEtMS0w_45d019bb-e3ea-45e3-aea5-10807c13d67b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i8725cde7bd3b4b58934b4ecdcef2816a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTEtMS0xLTEtMA_032ba3d2-23af-428f-a715-b73c2974e7b4"
      unitRef="usd">188297000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i6944b71b72a84436a68e5213fe6df51a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTEtMy0xLTEtMA_edc70327-b45b-46ce-8d48-f53b5e251bcb"
      unitRef="usd">188297000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="iad391a709b144bd48d2872b283602f84_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTEtNS0xLTEtMA_af5fb622-303d-4967-8422-59452d49947a"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="ie9067efbd18c467aad2eebbaff82cfc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTEtNy0xLTEtMA_566b2aae-d8f6-4c89-bd30-50840ea13e12"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i3519bdb64f8b4b6d8efc1c5e46616753_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTItMS0xLTEtMA_6f59e498-2be9-486d-b990-05962d5da101"
      unitRef="usd">57153000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i5e3adfb85bf6451c9575bc0e8d008d13_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTItMy0xLTEtMA_c9073f03-619b-4469-ad59-afaa3a885016"
      unitRef="usd">57153000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="id81d1d57d00941ff976792c032f7c601_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTItNS0xLTEtMA_a4c9b19a-118e-4597-9684-a442cc1298fd"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="i18b9e3d355a14ac49a01d376ea60f2a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTItNy0xLTEtMA_e85504c4-9add-4fc9-9566-4d867b19c131"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2037e57e85fb441b94c20fe503046463_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTMtMS0xLTEtMA_b74b0905-5435-4753-a322-b2178d5e4cf7"
      unitRef="usd">107697000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id812dbcc01ba448783f4b7ace47357b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTMtMy0xLTEtMA_951ffd4a-a5c6-4e83-9739-60b6f5eebe9d"
      unitRef="usd">107697000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5c66084d39744f29e968164be5da8b7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTMtNS0xLTEtMA_83056ec7-59e6-4bc1-a088-da6388ac5312"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9802e6239684804a3dc3860a653719b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTMtNy0xLTEtMA_0799fcc1-44d5-4e26-b6b6-a72c43f4295a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifea2879f95c041cd895eda44820f8624_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTQtMS0xLTEtMA_1a3dd949-e1b1-4989-8ee2-965a5bf99a44"
      unitRef="usd">2436000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8eae37d2da574506ba4e102853287bd8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTQtMy0xLTEtMA_743d7a6a-9137-4e82-adf1-d7992d9414c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3081867d37934fefb8be59e85e8c7a4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTQtNS0xLTEtMA_f0f3f98c-5a85-4697-9f86-20fd41b6f442"
      unitRef="usd">2436000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i051c714be443417780719d2eb4b53ea9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTQtNy0xLTEtMA_53c9d5ee-bc50-468d-ad18-900b0ac6e248"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i674430e3d2c341c8a6df0759fb0fbd73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTUtMS0xLTEtMA_15fadd48-4a1e-40f4-94a3-43627ef663fe"
      unitRef="usd">21169000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12aa4229eb9f4c2fa7c9289e272467c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTUtMy0xLTEtMA_bc7d190f-3f05-4a2f-a7ea-1291509e0e4c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45c3ef9e7fdb4ea2b3bfd0ac0a4f062b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTUtNS0xLTEtMA_08d9c6ca-a30c-4018-9bcb-d5f3812ab889"
      unitRef="usd">21169000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i454b38ab8bdc449cad61e6eb5af78756_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTUtNy0xLTEtMA_60fd1cc8-1c3e-4696-a06d-2e905a3b0f9f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i77bdd900a94544d0bbba160586a6eb58_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTYtMS0xLTEtMA_c6d0691d-eccf-4d90-b059-ba7133abeefd"
      unitRef="usd">29441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51217ad1af3e4ebda21a0ad07210b827_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTYtMy0xLTEtMA_41283f4e-4ab4-410a-ac40-e9e406528fca"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ec26d7834be4c8abd097426fd877cb2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTYtNS0xLTEtMA_8fbb0358-1214-43de-b975-03ccd955b57d"
      unitRef="usd">29441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if07640a2359445eba2a41ae90501863f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmU4ZDcxODI2MmZmNTQxNzFiYmJhNmUxMzIwODkwOGY2L3RhYmxlcmFuZ2U6ZThkNzE4MjYyZmY1NDE3MWJiYmE2ZTEzMjA4OTA4ZjZfMTYtNy0xLTEtMA_25bba865-600e-4c11-bc42-30fdef8f95c2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTIzNQ_8fb02045-c649-4715-b88f-7274e643faa6">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of June&#160;30, 2021 are as follows:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding agency securities, none have maturity dates of less than one year and $5.0 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU2OQ_2c6af718-21cf-4692-a2d3-b58b8b1319f6"&gt;one&lt;/span&gt; to two years as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding certificates of deposit, $1.1 million have maturity dates of less than one year and $0.5 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcxNA_0f49c841-e469-4cdb-9e94-1d8fc6721bf2"&gt;one&lt;/span&gt; to two years as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our outstanding commercial and corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obligations have maturity dates of less than one year as of June&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our outstanding U.S. Treasury securities have maturity dates of less than one year as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Of our outstanding agency securities, $10.0 million have maturity dates of less than one year and $11.2 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwMg_8efbf14a-390d-4a61-8d2e-efb73efed063"&gt;one&lt;/span&gt; to two years as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of our outstanding certificates of deposit, $1.1 million have a maturity date of less than one year and $1.3 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ1NQ_25069077-64eb-4770-a079-0932cb57d201"&gt;one&lt;/span&gt; to two years as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Of our outstanding commercial and corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obligations, $29.4 million have maturity dates of less than one year and $0.0 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyMA_ca5315b3-0237-444d-96a1-9e4abab3f521"&gt;one&lt;/span&gt; to two years as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Of our outstanding U.S. Treasury securities, $102.7 million have maturity dates of less than one year and $5.0 million have a maturity date of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc3NA_1f934835-43a2-4d2e-869c-8b6ff5fa0e3d"&gt;one&lt;/span&gt; to two years as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMS0xLTEtMS0w_927595f2-6e6b-4de5-96fa-7b6454284203"
      unitRef="usd">5003000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMS0zLTEtMS0w_9b239caa-205c-4d82-a357-0268e9f4f6c9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMS01LTEtMS0w_66c00492-70b0-413c-99e2-17a7c5f02bec"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMS03LTEtMS0w_ade62162-a3de-45a7-8e00-183abafe0adc"
      unitRef="usd">4997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMy0xLTEtMS0w_217386e7-6304-4a72-932e-194f4090c940"
      unitRef="usd">1589000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMy0zLTEtMS0w_19cb5a92-ef5f-4893-b0b5-fe694d7809ad"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMy01LTEtMS0w_3c9b35a5-7499-4aba-b676-7d2a0119abbc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfMy03LTEtMS0w_377ba8ec-68a7-466e-be4c-67aaa4f150c1"
      unitRef="usd">1591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNC0xLTEtMS0w_a47d3837-e724-4b49-8019-dd31da4b4d70"
      unitRef="usd">11778000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNC0zLTEtMS0w_80ea1172-9030-4e65-8432-c984333522bb"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNC01LTEtMS0w_12c3c159-ecba-4764-95bc-67b994451c56"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNC03LTEtMS0w_7a781d6a-8afa-4e72-84f6-057704d6a45a"
      unitRef="usd">11779000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i711fd5f10f4e49a58b560bb507d95052_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNS0xLTEtMS0w_47e62cbc-8bef-463f-85ee-7521662e4346"
      unitRef="usd">45680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i711fd5f10f4e49a58b560bb507d95052_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNS0zLTEtMS0w_84736511-9cf2-4522-bda7-2505dc19e4c2"
      unitRef="usd">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i711fd5f10f4e49a58b560bb507d95052_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNS01LTEtMS0w_ac994fdf-6c62-4904-ae64-90d32282112f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i711fd5f10f4e49a58b560bb507d95052_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNS03LTEtMS0w_8234d411-a9bd-454d-ab53-5aa025522a8f"
      unitRef="usd">45714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNi0xLTEtMS0w_2eb78add-8234-4ea3-b00e-c86fd19c3eaa"
      unitRef="usd">64050000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNi0zLTEtMS0w_64490e11-3370-4467-9638-740ee01598bb"
      unitRef="usd">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNi01LTEtMS0w_e582b5be-f7af-4f53-aca2-42185e312286"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjRlYTc2MmU4OWUzZDQ2MzRhNGQ4MjU5MTc5MjYwYjg0L3RhYmxlcmFuZ2U6NGVhNzYyZTg5ZTNkNDYzNGE0ZDgyNTkxNzkyNjBiODRfNi03LTEtMS0w_c93d0a47-d82e-4851-88fe-53c8c621da53"
      unitRef="usd">64081000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzQ5MQ_17e49653-9ed8-4b8d-a0d0-64c021e78968"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i45f7ba855861405cbd820fb0f83d8611_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzUyNw_7c776d83-4a70-4b48-94cd-5f56dd94476f">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzUzNA_4f5b3f30-87c8-4dd1-9f60-9e0020b90d22"
      unitRef="usd">5000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i1d163026a6654743b9979520a3af47aa_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU3NQ_e3e11b04-bd30-48fe-aa75-c00e53ec8424">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzYzNg_54adb533-b48c-450a-b8c1-528912b02301"
      unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i8b96a7f246684ad1800b51d91e9a69b8_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzY3Mg_e071d5be-42df-4caf-8929-f58902332d1a">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i13528acc7aef4f81ae58f9b16746d0fe_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzY3OQ_fc76f142-e625-47b6-8f33-ef67ca6770c2"
      unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i61e188f2a2fc40cdb0ad1ad5fc3d9224_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcyMA_c798eaf0-3c9c-4420-9142-d74fd2ef713e">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i03f6372c975642c8b721a357169c41f7_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzgzMA_6bf12f54-1ba1-473d-a43f-bbd01e5a42ef">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMS0xLTEtMS0w_c304ca08-7183-413a-840e-33a201b290d0"
      unitRef="usd">21169000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMS0zLTEtMS0w_4a43a700-cefe-4b53-9b0d-92206bac99c2"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMS01LTEtMS0w_11355a4b-4944-44b7-9a25-271fe195ade4"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMS03LTEtMS0w_41e19594-2e5c-4341-bd8d-c63a188e61f5"
      unitRef="usd">21169000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i392569839eab4af895cd18151a8a634b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMi0xLTEtMS0w_4dc8b603-d070-462c-8811-f75d8ba9ce19"
      unitRef="usd">2427000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i392569839eab4af895cd18151a8a634b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMi0zLTEtMS0w_b1b754ca-40cf-4730-896a-e6c7737fede4"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i392569839eab4af895cd18151a8a634b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMi01LTEtMS0w_451555da-63b5-48bc-81ba-1b9f092d352a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i392569839eab4af895cd18151a8a634b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMi03LTEtMS0w_15b15262-0400-4209-bab0-9df97816228e"
      unitRef="usd">2436000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMy0xLTEtMS0w_a2da044e-716b-4832-9e39-277685cfd1e6"
      unitRef="usd">29414000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMy0zLTEtMS0w_0e3ff0a6-a7a4-44ff-bbb9-8ec2786cfd20"
      unitRef="usd">28000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMy01LTEtMS0w_0368480c-13f9-44e2-bcbe-1ed2a4f05d59"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfMy03LTEtMS0w_10cbe75f-09b2-4af3-9b80-4ec638be3ebf"
      unitRef="usd">29441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNC0xLTEtMS0w_b3de3fac-7beb-4627-b583-77e153e7b99d"
      unitRef="usd">107530000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNC0zLTEtMS0w_44b6cf34-469f-4d1f-8154-eebf2ec6f887"
      unitRef="usd">170000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNC01LTEtMS0w_3493d374-374a-4fee-9089-7bd536b09870"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNC03LTEtMS0w_4305a63e-855f-47b5-b46a-0ddd3cf5d41e"
      unitRef="usd">107697000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNS0xLTEtMS0w_90f59043-8ee4-4ba8-98e5-1d9f63a921cd"
      unitRef="usd">160540000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNS0zLTEtMS0w_d003d1e3-7051-4646-885d-935d1454830e"
      unitRef="usd">208000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNS01LTEtMS0w_cea2e789-cf20-469a-8741-e2f4f7382128"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjZlZjY3N2Y2NGYyMTQxOTliMTVlMThiMjI3MzZjOTIxL3RhYmxlcmFuZ2U6NmVmNjc3ZjY0ZjIxNDE5OWIxNWUxOGIyMjczNmM5MjFfNS03LTEtMS0w_0880ca95-e8de-45b4-b826-0219d5de7aec"
      unitRef="usd">160743000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDIxOA_f9d42527-ab0d-4de2-92db-cba5d98904bd"
      unitRef="usd">10000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDI2Nw_592ad217-22f4-4561-b750-a0cfdff11107"
      unitRef="usd">11200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i9a331153831844abb1eef1d1c1087186_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwOA_3b0791c4-c1bc-4dc9-93c5-89ee3004d4ca">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i392569839eab4af895cd18151a8a634b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDM3MA_ba843bf2-acfa-4ac1-80b7-827c547c9834"
      unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i392569839eab4af895cd18151a8a634b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQyMA_377146d0-8d43-4382-86b4-ef334de7a88f"
      unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i41d5876a7ef54861bdd2687c9d49d1e8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ2MQ_c0ec87ff-8ede-4e34-924a-15e43382d649">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDUzNg_7f62f7d9-0bf5-4f38-bf3d-48225b265c03"
      unitRef="usd">29400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDU4NQ_f264b752-09f6-4176-977b-c63db0b9c65d"
      unitRef="usd">0.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="ic24b2a7ad667476c99b89caed4bc0d88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyNg_1d7a5746-f460-44c5-91c4-f180e0903cad">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDY5MA_672cea0e-a7b6-41b8-ae13-ed3b09e8d200"
      unitRef="usd">102700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDczOQ_37780332-234d-42d0-9f37-1971296dbe65"
      unitRef="usd">5000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="i4da7cac937d44fb19c0b0d2f90db8d5a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc4MA_c88450c0-9971-4f61-b74c-3457a8b58235">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTI0Mw_831dd683-9360-44db-ae0f-dc13eff436c4">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;June&#160;30, 2021&#160;and&#160;December&#160;31, 2020, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy0xLTEtMS0w_d8d71ccd-464a-4b5b-9de8-0bef648afe51"
      unitRef="usd">4997000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy0zLTEtMS0w_00908592-c23b-4456-a130-213987ea933b"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy01LTEtMS0w_0026b09d-403c-455e-b3d2-a3b78fe20d71"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy03LTEtMS0w_afab8dd3-2b98-40fe-a1ff-6157f1d6d649"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy05LTEtMS0w_f5541b16-269c-4125-85ff-1c503a5dd1eb"
      unitRef="usd">4997000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ieaa771f324ce4c28ace1cbfe5ba405db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfMy0xMS0xLTEtMA_43010616-fa54-4469-93ad-1363a1ecb161"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC0xLTEtMS0w_eb34a7c9-f731-4d5c-b260-a0766b382204"
      unitRef="usd">3262000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC0zLTEtMS0w_5167cbeb-adff-40e5-9dd0-8892ea532b78"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC01LTEtMS0w_526f5265-5d47-4d9e-afbd-09947701f9d5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC03LTEtMS0w_956bfae0-eeeb-4124-ac71-e0415da87827"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC05LTEtMS0w_2cf20c18-c691-4f56-b53a-c6d77e1eeb96"
      unitRef="usd">3262000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie9b72c1bc28e426696c80f01a5640e80_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNC0xMS0xLTEtMA_9ab0d06b-90ba-4118-ba3a-2b126625654f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi0xLTEtMS0w_c3863f3f-8248-4fa2-b927-842ca6e524a1"
      unitRef="usd">8259000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi0zLTEtMS0w_339321c0-29ca-4c0d-acc3-19b2838a56b4"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi01LTEtMS0w_2cdfe726-cc3a-4828-99f5-27e5788f4e9b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi03LTEtMS0w_e730e87d-bc64-402d-9c2d-dd48917bb154"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi05LTEtMS0w_e34f754d-0535-439d-88dc-a3ff8e9e8f10"
      unitRef="usd">8259000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOjlhMjQ2NTgzMzQwMTRhYzFiZGIzZjA1MWJmYTlkZjEwL3RhYmxlcmFuZ2U6OWEyNDY1ODMzNDAxNGFjMWJkYjNmMDUxYmZhOWRmMTBfNi0xMS0xLTEtMA_8e9fce4b-9070-4d8f-b14b-f672f36c4145"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy0xLTEtMS0w_1a620498-3d18-4e1d-93fa-8188cabec49e"
      unitRef="usd">4999000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy0zLTEtMS0w_2abd80c7-fed7-4665-822a-deef8448cb3e"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy01LTEtMS0w_85d696b6-144b-4bb2-abcf-6a924283d9d6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy03LTEtMS0w_433c39cb-4a29-4c03-a365-1784f3ac8581"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy05LTEtMS0w_b58ea019-c2ce-424a-931d-6a55f5e5556c"
      unitRef="usd">4999000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i31bb4f5a2473478d81fd7fb4dd3c6b80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfMy0xMS0xLTEtMA_6e55a099-87ab-4aca-90b9-8f1461186696"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC0xLTEtMS0w_ae91f651-8da0-4a81-9da3-776dd2ab0100"
      unitRef="usd">6503000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC0zLTEtMS0w_06518870-8a6c-47f8-82f2-9e49c3fb1bf6"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC01LTEtMS0w_43990ba5-0e23-475d-88bd-6b4b68b3a560"
      unitRef="usd">2399000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC03LTEtMS0w_bc61b103-e8e0-4056-9b3b-dec11a37aa20"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC05LTEtMS0w_7fe9d618-0bcc-4111-99f1-c72cb7208b1e"
      unitRef="usd">8902000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i43d6272b78fc4eaf908301d14bb663d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNC0xMS0xLTEtMA_48b2e785-79ea-4734-a3fd-8921336d6718"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS0xLTEtMS0w_b23d3fd0-d47b-4fdb-b5f0-6da22c5175a2"
      unitRef="usd">35211000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS0zLTEtMS0w_6219b1da-165e-4998-8404-5c980644726e"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS01LTEtMS0w_a7443529-3bee-4b9c-a709-72ba83197725"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS03LTEtMS0w_ee731830-31b3-46f4-9e4c-fdc43e19bf04"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS05LTEtMS0w_f8c4d9c1-9660-429f-8d03-603b8954103a"
      unitRef="usd">35211000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i02a8c68df7fa4f6a8aff890ca8ca7b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNS0xMS0xLTEtMA_9933597d-ff0d-433e-993b-365282c916ac"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi0xLTEtMS0w_33a63beb-378c-4494-858f-79b2338c9c19"
      unitRef="usd">46713000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi0zLTEtMS0w_ce921fe8-00e1-438a-8d0f-acbf2a2041b2"
      unitRef="usd">5000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi01LTEtMS0w_1a3bf220-f7c2-4c43-8317-3d36b919c454"
      unitRef="usd">2399000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi03LTEtMS0w_8a3eced7-4a3e-4cc8-864a-66eeea2f5786"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi05LTEtMS0w_d7a263b2-a127-4592-8546-3efd5aea0cfb"
      unitRef="usd">49112000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RhYmxlOmE2OGZjM2IxMDc0MzQ4YTNiOTUyYTJjNjc4N2ZjMTRiL3RhYmxlcmFuZ2U6YTY4ZmMzYjEwNzQzNDhhM2I5NTJhMmM2Nzg3ZmMxNGJfNi0xMS0xLTEtMA_333156e3-0be7-4262-a66a-c156d4169f3a"
      unitRef="usd">5000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTE0Nw_055a7e92-9f38-4dd0-946d-670f7d7cdd6f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTE0Nw_e2e0e937-0fec-4119-8389-4207e74b634f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="idfc960c533644748967278a36e67af20_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTE3OA_07c84060-b9ed-4fd8-948c-c4ed9d4a4064"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNTE3OA_8e478822-affe-46c9-8788-55290eb1b30c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfMjg5_21fc73ae-216e-4666-8ee9-d045ca3547ea">Stockholders&#x2019; Equity &lt;div style="margin-top:12pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the 500,000,000&#160;shares of common stock authorized&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 27,432,609&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares were issued and outstanding as of June&#160;30, 2021. Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at June&#160;30, 2021 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued and Outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares Reserved For:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,195,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfNTE_28f3959c-2714-4278-8753-7df881dc6047"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfODk_892b420f-b7c1-4d20-bb6c-56a98c42d58a"
      unitRef="shares">27432609</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfODk_927b55a4-c5e3-42cd-8f65-3ab5de8ff28c"
      unitRef="shares">27432609</us-gaap:CommonStockSharesIssued>
    <anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RleHRyZWdpb246MDQ3ZjgxNWM3ZTMwNDI0NDk1MTBiODhiN2NmOTJlMjVfMjky_b92c2a74-8972-41b9-a49a-7545935c009e">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at June&#160;30, 2021 are as follows: &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued and Outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares Reserved For:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:1pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,195,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RhYmxlOjk5ZTM1ZWUxYjYwNjQzMTliNzBjZmM0N2E1NGVmOGE0L3RhYmxlcmFuZ2U6OTllMzVlZTFiNjA2NDMxOWI3MGNmYzQ3YTU0ZWY4YTRfMS0xLTEtMS0w_6c2e4c8e-6042-4fb9-b8f9-a1f5bcb0da9b"
      unitRef="shares">3731808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i440d9f4d37024e65a225809024ed80f1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RhYmxlOjk5ZTM1ZWUxYjYwNjQzMTliNzBjZmM0N2E1NGVmOGE0L3RhYmxlcmFuZ2U6OTllMzVlZTFiNjA2NDMxOWI3MGNmYzQ3YTU0ZWY4YTRfNC0xLTEtMS0w_712a6b50-d595-40f5-8968-a0a1256f4a6e"
      unitRef="shares">3192182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i74f2dd192f9145a1bcc410371db79135_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RhYmxlOjk5ZTM1ZWUxYjYwNjQzMTliNzBjZmM0N2E1NGVmOGE0L3RhYmxlcmFuZ2U6OTllMzVlZTFiNjA2NDMxOWI3MGNmYzQ3YTU0ZWY4YTRfNS0xLTEtMS0w_4b770262-050e-4ac5-8915-6e82e23dff90"
      unitRef="shares">1271237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81Mi9mcmFnOjA0N2Y4MTVjN2UzMDQyNDQ5NTEwYjg4YjdjZjkyZTI1L3RhYmxlOjk5ZTM1ZWUxYjYwNjQzMTliNzBjZmM0N2E1NGVmOGE0L3RhYmxlcmFuZ2U6OTllMzVlZTFiNjA2NDMxOWI3MGNmYzQ3YTU0ZWY4YTRfNi0xLTEtMS0w_716fdc31-56c9-46d6-9234-a326ab0780c5"
      unitRef="shares">8195227</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI5NA_e8856edd-e3b1-4e5e-84d6-3012e10d258a">Equity Incentive Plans &lt;div style="margin-top:12pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;). The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017 and replaced our existing 2006 Equity Incentive Plan. Under the 2017 Plan, we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by 4% of the aggregate number of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,094,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares as of January 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by 1% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 273,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares as of January 1, 2021. The initial offering period for the ESPP began in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted to employees and non-employees generally vest over a four-year period while stock options granted to directors vest over a one year period. Each stock option award has a maximum term of 10 years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. A summary of the activity related to stock option awards during the six months ended June 30, 2021 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Subject to&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&#160;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,920,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures and cancellations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,744,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize stock-based compensation expense for awards issued to employees and non-employees over the requisite service period based on the estimated grant-date fair value of such awards. We record the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the appropriate risk-free interest rate, expected term for employee stock-based awards, contractual term for non-employee stock-based awards, and volatility assumptions. The weighted-average expected option term for employee and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;non-employee stock-based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted-average vesting period for all option tranches. Estimated volatility for 2021 incorporates the historical volatility of our stock price, and volatility for 2020 incorporates our stock price as well as similar entities whose share prices are publicly available. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock-based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, there was $36.8 million of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of 2.71 years. At June&#160;30, 2021, there was $0.2 million of unrecognized compensation cost related to the ESPP, which is expected to be recognized over a remaining weighted-average vesting period of 0.38 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding
      contextRef="i754f18c3eac04b658b8b6ed077314e68_D20180101-20180101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNzcw_f13a2ba5-5754-4ea4-8d9f-eab677785657"
      unitRef="number">0.04</anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease
      contextRef="i4866424e06474a119edf3063462a6832_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfOTg3_882832a1-cde5-4e2f-bb95-c9b55e1cdb6a"
      unitRef="shares">1094223</anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding
      contextRef="ia3b08700ca1748b2afd4fa071b355893_D20180101-20180101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTQ4Mg_9d5772de-4b24-4e6f-a9a4-72e14680126b"
      unitRef="number">0.01</anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease
      contextRef="ib69a7ed7bd244d29905de3cacf88167f_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTY5NA_30965e25-cd50-457b-824e-be3f6b7eb8b0"
      unitRef="shares">273555</anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI3OA_5c357e28-0ea8-4a67-a09a-f62a1b454d8a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i197e760b801d4f73b5d6e406c4027a35_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTg4NQ_7acd0a52-109a-414c-99ab-32f7f207eecc">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i197e760b801d4f73b5d6e406c4027a35_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTk0Mg_4d147af5-688a-439a-89f9-54107d958052">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTk0Mg_57665e1f-5af3-4e8a-85ad-d25b2f098b69">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI3Ng_c80f9e55-328d-4c75-b519-f7fccd201d16">A summary of the activity related to stock option awards during the six months ended June 30, 2021 is as follows: &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Subject to&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&#160;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,920,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,037,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeitures and cancellations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,744,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMS0xLTEtMS0w_f81f3a15-dc2b-4b8d-8de9-022a97c2ab50"
      unitRef="shares">2920700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMS0zLTEtMS0w_76c3b56d-353f-4f1a-a5f2-0b57c90cb3f3"
      unitRef="usdPerShare">26.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMi0xLTEtMS0w_977fb535-ce28-4c66-9cc1-3419495245b9"
      unitRef="shares">1037374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMi0zLTEtMS0w_5d017608-0719-4afa-bdb2-e9002b6ba4ae"
      unitRef="usdPerShare">29.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMy0xLTEtMS0w_6585e16b-7e9d-4fc5-90de-6a4785b27359"
      unitRef="shares">77034</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfMy0zLTEtMS0w_74dce53c-2e0f-42df-bfdf-796ead05c1bf"
      unitRef="usdPerShare">9.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNC0xLTEtMS0w_4516a4a5-01a7-4363-b3dc-060dfa2feee2"
      unitRef="shares">149232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNC0zLTEtMS0w_96371a8f-cc71-4349-8f61-84db2b51cc1d"
      unitRef="usdPerShare">29.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNS0xLTEtMS0w_6e785d4e-399e-4386-98db-8481c7d4d15e"
      unitRef="shares">3731808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNS0zLTEtMS0w_b3a7c5bd-3c9d-4083-afa5-f170ecbfd712"
      unitRef="usdPerShare">27.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNS01LTEtMS0w_d8a69119-54e6-4266-8737-472990f09542">P7Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNS03LTEtMS0w_615b0930-e657-4210-ba96-181cea1492ae"
      unitRef="usd">24823000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNi0xLTEtMS0w_3557722b-7af0-4bbf-a540-700d03ab7e0f"
      unitRef="shares">1744975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNi0zLTEtMS0w_c8cc9cb6-ba23-423c-8354-b30331f0bc5a"
      unitRef="usdPerShare">27.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNi01LTEtMS0w_6dff5680-3b5e-483f-9fe9-ba9b30d405b8">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOmZmYjljN2Q3ZjBkYTQyNjhhNmRhZjk5NGMxNTk3NTMwL3RhYmxlcmFuZ2U6ZmZiOWM3ZDdmMGRhNDI2OGE2ZGFmOTk0YzE1OTc1MzBfNi03LTEtMS0w_4e27bb93-158d-4e19-a75a-6b2b5cd1aa8a"
      unitRef="usd">17109000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI4NA_4bcde887-fa0d-49b2-ab5c-4701ef44733e">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfMy0yLTEtMS0w_2fb3acdf-b247-424f-b0c7-cd226c965582"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfMy02LTEtMS0w_a7da947c-7a5b-4454-8f21-5d8e6af3dff4"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNC0yLTEtMS0w_4cb52a6c-4b5b-4a2c-8ebd-dc97ac292ac8"
      unitRef="number">0.931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNC02LTEtMS0w_79aa5d2a-4f6a-4554-8895-327a0a0f1a52"
      unitRef="number">0.918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNS0yLTEtMS0w_6bd47ff1-3997-41da-aa06-d2df4f35961d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNS02LTEtMS0w_d6353260-0cb1-45bd-aeec-676031333ae7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNi0yLTEtMS0w_d8327f95-38aa-41b3-a208-888b4aa46747">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNi02LTEtMS0w_02542f66-5394-4284-acfd-7e55b9e505a2">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNy0yLTEtMS0w_f7ec95a9-4a94-42af-a2d4-df100e98e9d2"
      unitRef="usdPerShare">22.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4d005b42f9404af088a5a0d8bcc3d4ea_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjYyNGY0Y2Y4YzYzMzQ0ZDRhYWFlOTY1MThkNGI2NTczL3RhYmxlcmFuZ2U6NjI0ZjRjZjhjNjMzNDRkNGFhYWU5NjUxOGQ0YjY1NzNfNy02LTEtMS0w_f5c64e8f-fb0d-424a-bd27-d05c66e57a14"
      unitRef="usdPerShare">11.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI5Ng_3603c3bc-22fb-4025-8b88-22e5d63ccb46">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ifb3a9fe237f347e39f34d734ffdf3d9c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMi0xLTEtMS0w_f8cf106f-4711-4027-be21-e661eadb26f7"
      unitRef="usd">1435000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i626d95b570df4e1abdac73a6a2e718d0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMi0zLTEtMS0w_8a53c2a1-cf4a-47ca-ae25-97994669a718"
      unitRef="usd">958000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ib16d46e48de9476ca69ec729d02ab7f7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMi01LTEtMS0w_cd799aa5-3223-4ede-9f4c-f6a5d82891ff"
      unitRef="usd">2629000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i75b921f1f24c4c54bb6d506c5e62de1f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMi03LTEtMS0w_a9f99ab5-63ad-4ad1-a08f-678678147f84"
      unitRef="usd">2104000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i79408e23b2ef4790851584643cf1fd31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMy0xLTEtMS0w_0a9a52cc-12f5-4559-a4d9-a141b3b28212"
      unitRef="usd">2255000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i3a4c03b9afe14b17a08c26f39c61ee23_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMy0zLTEtMS0w_31ca730e-57a4-4f81-b745-d9a385bffe1e"
      unitRef="usd">1783000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i01c0c2bd7cd84e75ba87c7188ac5cb04_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMy01LTEtMS0w_28966e4f-12f4-403f-a9bf-0fc7edc88674"
      unitRef="usd">4376000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ic1bf654bbd4e431098303b2f5ba09a92_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfMy03LTEtMS0w_69779d99-51ea-4250-a75f-f8bf6d972df5"
      unitRef="usd">3612000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfNC0xLTEtMS0w_c1e37953-eda2-4a38-90da-b7cea75849c4"
      unitRef="usd">3690000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ifb2565ff9a1f4b1a8adfce04080b18c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfNC0zLTEtMS0w_09da4a92-c3ae-4351-b2d5-79fc1f415293"
      unitRef="usd">2741000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfNC01LTEtMS0w_3faeadb7-8267-413d-9b3c-943c8df65deb"
      unitRef="usd">7005000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RhYmxlOjgyOTQzZWZlYzBjMjQzMzU4ZGJmNjZhNTNiMjQ0MGM1L3RhYmxlcmFuZ2U6ODI5NDNlZmVjMGMyNDMzNThkYmY2NmE1M2IyNDQwYzVfNC03LTEtMS0w_c4556c55-ae76-470c-a98d-0d5bf50a5394"
      unitRef="usd">5716000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ie5753215b52c451093ff6ca5ba3c9575_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDEwOA_643cd2c5-ba3c-4217-9b10-2bf6123177b1"
      unitRef="usd">36800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfNDI3Mw_24763f26-286b-4834-9eae-bd3b6e2af40f">P2Y8M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id7e2add807724d19a9e8cbee0dad3919_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTY0OTI2NzQ0NzcxMg_2782f152-fffd-4bf0-9304-92cb13652266"
      unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie04286dba40e490ebc78cc7952a23570_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81NS9mcmFnOjc5YmZhMTgwN2RiMjRiMDViMzA3ZWUxYjQ2Nzg1Y2VjL3RleHRyZWdpb246NzliZmExODA3ZGIyNGIwNWIzMDdlZTFiNDY3ODVjZWNfMTY0OTI2NzQ0NzcyNQ_df0d84a1-9899-429a-85ed-fe7d0871400a">P0Y4M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfNTAzNw_e1ec084e-4756-429b-8f59-93f8c3118358">Commitments and Contingencies&lt;div style="margin-top:6pt;text-indent:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On November 11, 2020, we entered into an agreement to terminate our sublease (the &#x201c;Sublease Termination&#x201d;) with Trex Enterprises Corporation, with respect to facilities in the building at 10455 Pacific Center Court in San Diego, California (the &#x201c;10455 Building&#x201d;). The terms of the original sublease with Trex provided for a November 12, 2021 lease expiration. Under the Sublease Termination, we agreed to terminate the sublease agreement on December 15, 2020 with no associated penalty. We recorded a non-cash gain of approximately $0.1&#160;million as other income, in connection with the write-off of the lease liability and corresponding ROU asset. As of June&#160;30, 2021, there was no lease liability and corresponding ROU asset related to the 10455 Building Lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 4, 2020, we entered into a lease agreement with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121 (the &#x201c;Lease Agreement&#x201d;). Under the Lease Agreement, we agreed to lease approximately 45,000 square feet of space for a term of 124 months, beginning on April 5, 2021. The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional five years, as well as a one-time option to terminate the lease after seven years with the payment of a termination fee. The exercise of the lease option is at our sole discretion, which we currently do not anticipate exercising and as such was not recognized as part of our ROU assets and lease liabilities. The monthly base rent will be $4.20 per rentable square foot and will be increased by 3% annually. Under the Lease Agreement, we are also responsible for our pro rata share of real estate taxes, building insurance, maintenance, direct expenses, and utilities. Upon lease commencement, on April 5, 2021, we recognized an ROU asset of $20.6&#160;million, with a corresponding lease liability of $20.7&#160;million on the consolidated balance sheets. The ROU asset includes adjustments for prepayments, initial direct costs, and lease incentives. As of June&#160;30, 2021, we have recorded $0.3&#160;million as a security deposit in accordance with the terms of the Lease Agreement. As of June&#160;30, 2021, we also maintain the non-cancellable office lease for our facilities at 10421 Pacific Center Court in San Diego, California, which expires on August 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our lease payments are fixed, and we recognize lease expense for leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was 4%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following non-cancellable office lease costs are included in our consolidated statements of cash flow (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, the future minimum annual obligations for the Company&#x2019;s operating lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments required&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-indent:15.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;On March 25, 2020, a putative securities class action was filed in the United States District Court for the Southern District of California naming the Company and certain of its current or former officers as defendants. The complaint purports to assert claims under Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), Exchange Act Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019 (the &#x201c;Class Period&#x201d;). An amended complaint was filed on September 30, 2020 alleging that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab product candidate that artificially inflated our stock price. The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses. We believe that the plaintiff&#x2019;s allegations are without merit and intend to vigorously defend against the claims. On May 3, 2021, a shareholder derivative complaint was filed in the same Court based on allegations substantially similar to those in the class action, and purporting to assert claims on the Company&#x2019;s behalf against current or former officers and directors for alleged violation of Sections 14(a) and 20(a) of the Exchange Act, breach of fiduciary duties, unjust enrichment, waste of corporate assets and insider selling. Because the Company is in the early stages of these litigation matters, we are unable to estimate a reasonably possible loss or range of loss, if any, that may result from these matters.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ie3b64ce4f6404458b4b4d2e565325a2d_D20201215-20201215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfNTg2_6c0345e5-dd9e-41dc-a5d6-5157404da2bf"
      unitRef="usd">100000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i84c00b90fbbe46ffbed30a2f2233aea7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMzI5ODUzNDg4ODM5MQ_05605aae-4226-4152-ae4a-52193c803fea"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i84c00b90fbbe46ffbed30a2f2233aea7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMzI5ODUzNDg4ODM5MQ_859ccf39-59ff-4b51-bf6b-0281a47fe1d1"
      unitRef="usd">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i1767abcdc9d947d19efb733b02b78b30_I20200504"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDI0NQ_0f02fb82-01d1-45d7-b903-a523081df8c4"
      unitRef="sqft">45000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i1767abcdc9d947d19efb733b02b78b30_I20200504"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDI4NA_dd0109af-35f3-449b-a515-2920de763dd2">P124M</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="i1767abcdc9d947d19efb733b02b78b30_I20200504"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDQyNg_bb9df583-3ec2-41ba-b6ce-52f83f61c947">P5Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod
      contextRef="i769956911bf34bc3babeafd4ff7c179c_D20200504-20200504"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDQ4OQ_4f45528b-a459-41fc-b19b-46a1fc9a5c45">P7Y</anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod>
    <anab:RentPerSquareFoot
      contextRef="i769956911bf34bc3babeafd4ff7c179c_D20200504-20200504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDU2Mg_4b25f205-b6ac-40d2-949d-cd9439ce8699"
      unitRef="usdPerSqft">4.20</anab:RentPerSquareFoot>
    <anab:AnnualRentIncreasePercent
      contextRef="i769956911bf34bc3babeafd4ff7c179c_D20200504-20200504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDYxNg_bb2dd787-4581-4c1b-88a1-9a8f63f610ff"
      unitRef="number">0.03</anab:AnnualRentIncreasePercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib2b8bcbccfe046d982471dc4466417f9_I20210405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMjE5OTAyMzI2OTI5OA_7660ff87-9de3-4a96-8402-675d4a7d244f"
      unitRef="usd">20600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib2b8bcbccfe046d982471dc4466417f9_I20210405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMjE5OTAyMzI2OTMxMg_87020b6c-cec5-4288-9167-91371f6b5f57"
      unitRef="usd">20700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SecurityDeposit
      contextRef="ieb17cf126b4e4598b3ace9ab2298bc16_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTA5OTUxMTYzNDg0NA_631bc68f-a3c8-4e89-b20a-1ab516f04db2"
      unitRef="usd">300000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfMTQ5NA_409eaeb6-4316-4e8f-9310-3fc03b47ab53"
      unitRef="number">0.04</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfNTAzNQ_036ea024-5dc8-4d57-8897-f1e9fda006ef">&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following non-cancellable office lease costs are included in our consolidated statements of cash flow (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification on the Cash Flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOmQyNDkwYWM5MTIyNTQ0ODA4ODg5YTVjOTM2ZDExYTM2L3RhYmxlcmFuZ2U6ZDI0OTBhYzkxMjI1NDQ4MDg4ODlhNWM5MzZkMTFhMzZfMi00LTEtMS0w_a3a7d5c9-4499-48cf-8493-b22816531b17"
      unitRef="usd">886000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOmQyNDkwYWM5MTIyNTQ0ODA4ODg5YTVjOTM2ZDExYTM2L3RhYmxlcmFuZ2U6ZDI0OTBhYzkxMjI1NDQ4MDg4ODlhNWM5MzZkMTFhMzZfMi02LTEtMS0w_77ffea5e-3eec-4e5d-afca-e333bda5014c"
      unitRef="usd">440000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOmQyNDkwYWM5MTIyNTQ0ODA4ODg5YTVjOTM2ZDExYTM2L3RhYmxlcmFuZ2U6ZDI0OTBhYzkxMjI1NDQ4MDg4ODlhNWM5MzZkMTFhMzZfMy00LTEtMS0w_9f826631-f063-478a-b58d-d2601203bea5"
      unitRef="usd">465000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i5a5af7dbf7884797af9922fd312d166b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOmQyNDkwYWM5MTIyNTQ0ODA4ODg5YTVjOTM2ZDExYTM2L3RhYmxlcmFuZ2U6ZDI0OTBhYzkxMjI1NDQ4MDg4ODlhNWM5MzZkMTFhMzZfMy02LTEtMS0w_f61dcd88-54c7-420a-9143-39c0405261db"
      unitRef="usd">478000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RleHRyZWdpb246NTM3MDlmYTRhZjZiNDdhN2FlNmYwZjY5MTY0OTE2YTVfNTAzMg_7ee209b6-37af-46d2-b678-d4878d8027f0">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, the future minimum annual obligations for the Company&#x2019;s operating lease liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments required&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfMS0xLTEtMS0w_b8d61a06-7dca-481b-8a38-5724e65ed3a0"
      unitRef="usd">239000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfMi0xLTEtMS0w_1c0125df-8a9c-45c7-88d4-b2dcb3575545"
      unitRef="usd">2316000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfMy0xLTEtMS0w_e2847cfb-e09d-4df3-80ef-de821741402f"
      unitRef="usd">2386000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfNC0xLTEtMS0w_7badb4fa-4759-48eb-87f2-2d5bca6f4ea3"
      unitRef="usd">2457000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfNS0xLTEtMS0w_4af3efa6-d538-41c6-9811-9f86ac5cf566"
      unitRef="usd">2531000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <anab:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfNi0xLTEtMS0w_38d1921c-d2b4-4cee-9421-641c958928d7"
      unitRef="usd">15846000</anab:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfNy0xLTEtMS0w_8c16e6d3-aa05-4ad4-a20c-e9e7e5f990fc"
      unitRef="usd">25775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfOC0xLTEtMS0w_caa0dc19-bc4b-47c5-955a-2cf56988b9fd"
      unitRef="usd">4998000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml81OC9mcmFnOjUzNzA5ZmE0YWY2YjQ3YTdhZTZmMGY2OTE2NDkxNmE1L3RhYmxlOjI5YTMzNjVmOGQ3YTRhZGM5NTVlMzg1Yjc0NGE5MGU4L3RhYmxlcmFuZ2U6MjlhMzM2NWY4ZDdhNGFkYzk1NWUzODViNzQ0YTkwZThfOS0xLTEtMS0w_3d3354aa-d893-4f4a-b143-b4af03e379d3"
      unitRef="usd">20777000</us-gaap:OperatingLeaseLiability>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609707431976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAPTYSBIO,&#160;INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3828755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10770 Wateridge Circle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">362-6295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANAB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,433,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001370053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609706412600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 332,254<span></span>
</td>
<td class="nump">$ 250,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivable from collaborative partners</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">58,597<span></span>
</td>
<td class="nump">143,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,508<span></span>
</td>
<td class="nump">2,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">398,061<span></span>
</td>
<td class="nump">396,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">20,278<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">5,484<span></span>
</td>
<td class="nump">17,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">426,569<span></span>
</td>
<td class="nump">416,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,103<span></span>
</td>
<td class="nump">4,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">15,958<span></span>
</td>
<td class="nump">15,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,616<span></span>
</td>
<td class="nump">19,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">20,222<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 500,000 shares authorized, 27,433 shares and 27,356 shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">668,429<span></span>
</td>
<td class="nump">660,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(282,549)<span></span>
</td>
<td class="num">(263,957)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">385,731<span></span>
</td>
<td class="nump">396,731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 426,569<span></span>
</td>
<td class="nump">$ 416,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609707482488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">27,432,609<span></span>
</td>
<td class="nump">27,356,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,432,609<span></span>
</td>
<td class="nump">27,356,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609703621016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 30,027<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,274<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">25,314<span></span>
</td>
<td class="nump">17,948<span></span>
</td>
<td class="nump">49,499<span></span>
</td>
<td class="nump">38,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,246<span></span>
</td>
<td class="nump">4,687<span></span>
</td>
<td class="nump">10,669<span></span>
</td>
<td class="nump">8,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,560<span></span>
</td>
<td class="nump">22,635<span></span>
</td>
<td class="nump">60,168<span></span>
</td>
<td class="nump">47,888<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(533)<span></span>
</td>
<td class="num">(22,635)<span></span>
</td>
<td class="num">(18,894)<span></span>
</td>
<td class="num">(32,888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">2,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(21,548)<span></span>
</td>
<td class="num">(18,592)<span></span>
</td>
<td class="num">(29,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) income on available for sale securities</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (494)<span></span>
</td>
<td class="num">$ (21,940)<span></span>
</td>
<td class="num">$ (18,764)<span></span>
</td>
<td class="num">$ (29,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average number of shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">27,391<span></span>
</td>
<td class="nump">27,279<span></span>
</td>
<td class="nump">27,377<span></span>
</td>
<td class="nump">27,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">27,391<span></span>
</td>
<td class="nump">27,279<span></span>
</td>
<td class="nump">27,377<span></span>
</td>
<td class="nump">27,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">anab:CollaborationRevenueMember<span></span>
</td>
<td class="text">anab:CollaborationRevenueMember<span></span>
</td>
<td class="text">anab:CollaborationRevenueMember<span></span>
</td>
<td class="text">anab:CollaborationRevenueMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609707515624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 405,008<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 648,669<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="num">$ (244,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">400,564<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">651,680<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="num">(252,288)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">405,008<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">648,669<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="num">(244,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">381,436<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">654,492<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="num">(273,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">400,564<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">651,680<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="num">(252,288)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="num">(392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,548)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">381,436<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">654,492<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="num">(273,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">396,731<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">660,665<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(263,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,163)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">381,943<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">664,147<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(282,120)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 396,731<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">660,665<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(263,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="nump">77,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">385,731<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">668,429<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(282,549)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Mar. 31, 2021</a></td>
<td class="nump">381,943<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">664,147<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(282,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">3,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(429)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 385,731<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 668,429<span></span>
</td>
<td class="num">$ (176)<span></span>
</td>
<td class="num">$ (282,549)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609703620696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,592)<span></span>
</td>
<td class="num">$ (29,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">7,005<span></span>
</td>
<td class="nump">5,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Accretion/amortization of investments, net</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets &#8211; operating</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Receivable from collaborative partners</a></td>
<td class="num">(642)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,235)<span></span>
</td>
<td class="num">(2,860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="nump">772<span></span>
</td>
<td class="num">(8,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,613)<span></span>
</td>
<td class="num">(34,722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(9,734)<span></span>
</td>
<td class="num">(86,947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">105,604<span></span>
</td>
<td class="nump">173,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,180)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">94,690<span></span>
</td>
<td class="nump">86,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock, upon the exercise of stock options</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,375)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">721<span></span>
</td>
<td class="num">(1,268)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">81,798<span></span>
</td>
<td class="nump">50,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">250,516<span></span>
</td>
<td class="nump">171,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">332,314<span></span>
</td>
<td class="nump">221,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">20,685<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for property and equipment</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_ReceivablesForStockOptionsExercised', window );">Receivable related to issuance of common stock, upon exercise of stock options</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_ReceivablesForStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables for Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_ReceivablesForStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609701163800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text">Description of the Business <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AnaptysBio, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We currently generate revenue from milestones and royalties achieved under our collaborative research and development arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609703246872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2020 financial information to conform to the current year presentation of other long-term assets, operating lease right-of-use, or &#8220;ROU&#8221; asset, and operating lease liabilities on the Consolidated Balance Sheets and Consolidated Statements of Cash Flows. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities, to date there has not been any material delays in clinical operations. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K. </span></div><div style="margin-top:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in one reportable segment, and our functional and reporting currency is the U.S. dollar.  </span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with revenue recognition accounting guidance, which utilizes five basic steps to determine whether revenue can be recognized and to what extent: (i)&#160;identify the contract with a customer; (ii)&#160;identify the performance obligation; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price; and (v) determine the recognition period. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We evaluate deliverables on a contract-by-contract basis to determine whether each deliverable represents a good or service that is distinct or has the same pattern of transfer as other deliverables. A deliverable is considered distinct if the customer can benefit from the good or service independently of other goods/services either in the contract or that can be obtained elsewhere, without regard to contract exclusivity, and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contact. If the deliverable is not considered distinct, we combine such deliverables and account for them as a single performance obligation. We allocate the consideration to each deliverable at the inception of the arrangement based on the transaction price. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations may include the following: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">License Arrangements. The performance obligations under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. Licenses for multiple antibodies within a single contract are generally combined as they have substantially the same pattern of transfer to the customer. Historically, our licenses have held no value to the customer, as the antibodies were in the discovery phase and required our expertise for further development. Accordingly, licenses are not considered distinct. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and Development Services. The performance obligations under our collaboration and license agreements generally include research and development services we perform on behalf of or with our collaborators. As discussed within license arrangements above, our licenses have historically held no value without the research and development services we provide. As we generally only provide research and development services for internally generated antibodies that require a license to be utilized by a third party, our research and development services are not considered distinct. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Steering Committee Meetings. The performance obligations under our collaboration and license agreements may also include our participation on steering committees, which allows us to direct the progression of our discovery programs. As these steering committees would not occur or benefit the customer without the use of our licenses, these are not considered distinct.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize consideration allocated to a performance obligation as the performance obligation is satisfied, and the determination as to whether consideration is recognized over time or at a point in time is made upon contract inception. For our collaboration agreements, this is generally over the period in which research and development services have been performed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and license agreements generally include both fixed and variable consideration. Fixed payments, such as those for upfront fees are included in the transaction price at contract value, while variable consideration such as reimbursement for research and development services, milestone and royalty payments are estimated and then evaluated for constraints upon inception of the contract and evaluated on a quarterly basis thereafter. Research and development services are updated for actual invoices. Given the nature of our agreements, milestones are estimated using the most likely amount and are evaluated on a quarterly basis. Upon commercialization, royalty payments will be recognized in the period incurred. </span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We receive royalty revenue on sales by our partners of products covered by patents or contract rights that we own and net sales of their approved drugs, where we have concluded the license is the predominant item to which the royalties relate. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of our partners&#8217; historical experience including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. As of June&#160;30, 2021, there have not been material differences between actual and estimated royalty revenues. </span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the weighted-average o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609701146376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Accounts and Supplemental Disclosures</a></td>
<td class="text">Balance Sheet Accounts and Supplemental Disclosures <div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,660&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,225&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,716&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,728&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,228)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,945)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,688&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research, development and manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,922&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,958&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,262&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609703249928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Research and Development Agreements</a></td>
<td class="text">Collaborative Research and Development Agreements<div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GlaxoSmithKline Collaboration </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, we entered into a Collaboration and Exclusive License Agreement (the &#8220;GSK Agreement&#8221;) with TESARO, Inc. (&#8220;Tesaro&#8221;), an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline (Tesaro and GlaxoSmithKline are hereinafter referred to, collectively, as &#8220;GSK&#8221;). Under the terms of the GSK Agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory, and commercial development to be performed by GSK. Under the terms of the GSK Agreement, GSK paid an upfront license fee of $17.0 million in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for three specific targets. In November 2014, Amendment No.&#160;1 to the GSK Agreement was agreed by both parties to add an antibody discovery program against an undisclosed fourth target for an upfront license fee of $2.0 million. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each development program, we are eligible to receive milestone payments of up to $18.0 million if certain preclinical and clinical trial events are achieved by GSK, up to an additional $90.0 million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional $165.0 million upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the GSK Agreement will terminate, with respect to each specific developed product, upon the later of the 12th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that the upfront license fees and research funding under the GSK Agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In February 2016, Amendment No.&#160;2 to the GSK Agreement was agreed by both parties to define the effective dates of the development programs of the GSK Agreement. We determined that the research and development services would be extended </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through December 31, 2016. As a result, the period over which the unrecognized license fees and discovery milestones were recognized was extended through December 31, 2016 and have since been recognized in full. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer.&#160;We identified the following material promises under the GSK Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) research and development (&#8220;R&amp;D&#8221;) services, and (3) joint steering committee meetings. We considered the research and discovery capabilities of GSK for these specific programs, GSK&#8217;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the joint steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 23, 2020, Amendment No. 3 to the GSK Agreement (the &#8220;Amendment&#8221;) was agreed to by both parties to permit GSK to conduct development and commercialization of Zejula, an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, which has received U.S. approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, and is under development for additional cancer indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under the Amendment, we were granted increased royalties upon sales of JEMPERLI (dostarlimab), an anti-PD-1 antagonist antibody under development by GSK for multiple oncological disorders. The Amendment also provided for a one-time, non-refundable cash payment of $60.0&#160;million that we received and recognized as revenue in the fourth quarter of 2020. GSK also agreed, starting January 1, 2021, to pay us a 1% royalty less third-party royalty deductions on all GSK net sales of Zejula. The $1.1&#160;billion in cash milestone payments due under the GSK Agreement remain unchanged.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, under the terms of the Amendment, GSK has agreed to certain diligence commitments with respect to the future development of JEMPERLI, and the parties have agreed to review such commitments under regular joint review committee meetings going forward.  </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed this Amendment in accordance with ASC 606 and concluded the Amendment was a contract modification to the GSK Agreement. Based on our assessment, we identified the terms of the Amendment to be interrelated to the GSK Agreement&#8217;s single performance obligation, noting completion and delivery of terms under the Amendment were satisfied by both parties with the execution of the Amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the transaction price for the GSK Agreement and Amendment includes the upfront payment, research reimbursement revenue, one-time payment associated with the Amendment, and milestones earned to date, which are allocated in their entirety to the single performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We earned and recognized $1.3 million in royalty revenue during the six months ended June 30, 2021 related to GSK net sales of Zejula and JEMPERLI during the period based on estimates of GSK&#8217;s sales historical experience. GSK reports sales information to us on a one quarter lag and differences between actual and estimated royalty revenues will be adjusted in the following quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earned and recognized three clinical milestones totaling $40.0 million during the six months ended June 30, 2021. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and GSK&#8217;s efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property license granted to GSK and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones recognized through June&#160;30, 2021 under the GSK Agreement are as follows:</span></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(JEMPERLI/Dostarlimab)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-TIM-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4069889A/Cobolimab)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-LAG-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK40974386)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initiated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using good laboratory practices (GLPs) </span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IND clearance from the FDA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2 clinical trial initiation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'19</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - second indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'19</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first BLA - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$10.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first MAA - first indication</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first BLA - second indication</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$10.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">First BLA approval - first indication</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$20.0M</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">First MAA approval - first indication</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$10.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:13pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized $30.0 million and $41.3 million in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> revenue under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GSK Agreement </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the three and six months ended June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively, and $0 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$15.0 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">six months ended June 30, 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody Generation Agreement with Bristol-Myers Squibb </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2011, we entered into a license and collaboration agreement (the &#8220;BMS Agreement&#8221;) with Celgene, now a part of Bristol-Myers Squibb (Celgene and Bristol-Myers Squibb are hereinafter referred to, collectively, as &#8220;BMS&#8221;), to develop therapeutic antibodies against multiple targets. We granted BMS the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BMS Agreement provided for an upfront payment of $6.0 million from BMS, which we received in 2011 and recognized through 2014, milestone payments of up to $53.0 million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, BMS, is a customer.&#160;We identified the following material promises under the BMS Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;D services, (3) a written report documenting findings, and (4) steering committee meetings. We considered the research and discovery capabilities of BMS, BMS&#8217;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the transaction price of the BMS Agreement includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and BMS&#8217;s efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined to relate predominantly to the intellectual property license granted to BMS and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved through June&#160;30, 2021 under the BMS Agreement are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 <br/>(CC-90006)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of first </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using GLPs</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$0.5M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1 clinical trial initiation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'16</span></td></tr></table></div><div style="margin-top:7pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  There was no revenue recognized under this agreement during the three and six months ended June 30, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702573944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Available for Sale Investments</a></td>
<td class="text">Fair Value Measurements and Available for Sale Investments <div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, and accounts payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:12pt;padding-left:11.25pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices for</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identical&#160;Assets</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At June  30, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,697&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,697&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div><div style="margin-top:2pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. </span></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Other Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, accrued expenses, and receivables approximate fair value due to their short-term nature. </span></div><div style="margin-top:18pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of June&#160;30, 2021 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding agency securities, none have maturity dates of less than one year and $5.0 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU2OQ_2c6af718-21cf-4692-a2d3-b58b8b1319f6">one</span> to two years as of June&#160;30, 2021.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $1.1 million have maturity dates of less than one year and $0.5 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcxNA_0f49c841-e469-4cdb-9e94-1d8fc6721bf2">one</span> to two years as of June&#160;30, 2021.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations have maturity dates of less than one year as of June&#160;30, 2021. </span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding U.S. Treasury securities have maturity dates of less than one year as of June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of December&#160;31, 2020 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,414&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,441&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,540&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,743&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Of our outstanding agency securities, $10.0 million have maturity dates of less than one year and $11.2 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwMg_8efbf14a-390d-4a61-8d2e-efb73efed063">one</span> to two years as of December&#160;31, 2020.</span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $1.1 million have a maturity date of less than one year and $1.3 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ1NQ_25069077-64eb-4770-a079-0932cb57d201">one</span> to two years as of December&#160;31, 2020.</span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations, $29.4 million have maturity dates of less than one year and $0.0 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyMA_ca5315b3-0237-444d-96a1-9e4abab3f521">one</span> to two years as of December&#160;31, 2020. </span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Of our outstanding U.S. Treasury securities, $102.7 million have maturity dates of less than one year and $5.0 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc3NA_1f934835-43a2-4d2e-869c-8b6ff5fa0e3d">one</span> to two years as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;June&#160;30, 2021&#160;and&#160;December&#160;31, 2020, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:26.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:26.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,112&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of June&#160;30, 2021 and 2020, unrealized losses on available-for-sale investments were not material, and accordingly, no allowance for credit losses were recorded.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702733896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 500,000,000&#160;shares of common stock authorized</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 27,432,609</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of June&#160;30, 2021. Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at June&#160;30, 2021 are as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued and Outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares Reserved For:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Equity Incentive Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609701301304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">Equity Incentive Plans <div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;). The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017 and replaced our existing 2006 Equity Incentive Plan. Under the 2017 Plan, we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by 4% of the aggregate number of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,094,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares as of January 1, 2021.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by 1% of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 273,555</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares as of January 1, 2021. The initial offering period for the ESPP began in May 2021.</span></div><div style="margin-top:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees and non-employees generally vest over a four-year period while stock options granted to directors vest over a one year period. Each stock option award has a maximum term of 10 years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. A summary of the activity related to stock option awards during the six months ended June 30, 2021 is as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;(in</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,920,700&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.67&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,034)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.86&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and cancellations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731,808&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.70&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.51</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,823&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744,975&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for awards issued to employees and non-employees over the requisite service period based on the estimated grant-date fair value of such awards. We record the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.39</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.97</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate risk-free interest rate, expected term for employee stock-based awards, contractual term for non-employee stock-based awards, and volatility assumptions. The weighted-average expected option term for employee and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-employee stock-based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted-average vesting period for all option tranches. Estimated volatility for 2021 incorporates the historical volatility of our stock price, and volatility for 2020 incorporates our stock price as well as similar entities whose share prices are publicly available. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock-based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,376&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,005&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,716&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, there was $36.8 million of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of 2.71 years. At June&#160;30, 2021, there was $0.2 million of unrecognized compensation cost related to the ESPP, which is expected to be recognized over a remaining weighted-average vesting period of 0.38 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702515720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 11, 2020, we entered into an agreement to terminate our sublease (the &#8220;Sublease Termination&#8221;) with Trex Enterprises Corporation, with respect to facilities in the building at 10455 Pacific Center Court in San Diego, California (the &#8220;10455 Building&#8221;). The terms of the original sublease with Trex provided for a November 12, 2021 lease expiration. Under the Sublease Termination, we agreed to terminate the sublease agreement on December 15, 2020 with no associated penalty. We recorded a non-cash gain of approximately $0.1&#160;million as other income, in connection with the write-off of the lease liability and corresponding ROU asset. As of June&#160;30, 2021, there was no lease liability and corresponding ROU asset related to the 10455 Building Lease. </span></div><div style="margin-top:12pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 4, 2020, we entered into a lease agreement with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121 (the &#8220;Lease Agreement&#8221;). Under the Lease Agreement, we agreed to lease approximately 45,000 square feet of space for a term of 124 months, beginning on April 5, 2021. The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional five years, as well as a one-time option to terminate the lease after seven years with the payment of a termination fee. The exercise of the lease option is at our sole discretion, which we currently do not anticipate exercising and as such was not recognized as part of our ROU assets and lease liabilities. The monthly base rent will be $4.20 per rentable square foot and will be increased by 3% annually. Under the Lease Agreement, we are also responsible for our pro rata share of real estate taxes, building insurance, maintenance, direct expenses, and utilities. Upon lease commencement, on April 5, 2021, we recognized an ROU asset of $20.6&#160;million, with a corresponding lease liability of $20.7&#160;million on the consolidated balance sheets. The ROU asset includes adjustments for prepayments, initial direct costs, and lease incentives. As of June&#160;30, 2021, we have recorded $0.3&#160;million as a security deposit in accordance with the terms of the Lease Agreement. As of June&#160;30, 2021, we also maintain the non-cancellable office lease for our facilities at 10421 Pacific Center Court in San Diego, California, which expires on August 31, 2021. </span></div><div style="margin-top:12pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our lease payments are fixed, and we recognize lease expense for leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was 4%.</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following non-cancellable office lease costs are included in our consolidated statements of cash flow (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Cash Flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, the future minimum annual obligations for the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments required</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:13pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div>On March 25, 2020, a putative securities class action was filed in the United States District Court for the Southern District of California naming the Company and certain of its current or former officers as defendants. The complaint purports to assert claims under Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), Exchange Act Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019 (the &#8220;Class Period&#8221;). An amended complaint was filed on September 30, 2020 alleging that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab product candidate that artificially inflated our stock price. The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses. We believe that the plaintiff&#8217;s allegations are without merit and intend to vigorously defend against the claims. On May 3, 2021, a shareholder derivative complaint was filed in the same Court based on allegations substantially similar to those in the class action, and purporting to assert claims on the Company&#8217;s behalf against current or former officers and directors for alleged violation of Sections 14(a) and 20(a) of the Exchange Act, breach of fiduciary duties, unjust enrichment, waste of corporate assets and insider selling. Because the Company is in the early stages of these litigation matters, we are unable to estimate a reasonably possible loss or range of loss, if any, that may result from these matters.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609708855592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2020 financial information to conform to the current year presentation of other long-term assets, operating lease right-of-use, or &#8220;ROU&#8221; asset, and operating lease liabilities on the Consolidated Balance Sheets and Consolidated Statements of Cash Flows. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions, including the issuance of stay-at-home orders and social distancing guidelines, which have resulted in some businesses suspending operations or experiencing a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business, and delay our development programs and regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;the COVID-19 pandemic on the costs and timing associated with the conduct of our clinical trials and other related business activities, to date there has not been any material delays in clinical operations. The financial statements should be read in conjunction with our audited financial statements for the year ended December&#160;31, 2020 included in our Annual Report on Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">Basis of ConsolidationThe accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in one reportable segment, and our functional and reporting currency is the U.S. dollar.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with revenue recognition accounting guidance, which utilizes five basic steps to determine whether revenue can be recognized and to what extent: (i)&#160;identify the contract with a customer; (ii)&#160;identify the performance obligation; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price; and (v) determine the recognition period. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We evaluate deliverables on a contract-by-contract basis to determine whether each deliverable represents a good or service that is distinct or has the same pattern of transfer as other deliverables. A deliverable is considered distinct if the customer can benefit from the good or service independently of other goods/services either in the contract or that can be obtained elsewhere, without regard to contract exclusivity, and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contact. If the deliverable is not considered distinct, we combine such deliverables and account for them as a single performance obligation. We allocate the consideration to each deliverable at the inception of the arrangement based on the transaction price. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations may include the following: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">License Arrangements. The performance obligations under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. Licenses for multiple antibodies within a single contract are generally combined as they have substantially the same pattern of transfer to the customer. Historically, our licenses have held no value to the customer, as the antibodies were in the discovery phase and required our expertise for further development. Accordingly, licenses are not considered distinct. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and Development Services. The performance obligations under our collaboration and license agreements generally include research and development services we perform on behalf of or with our collaborators. As discussed within license arrangements above, our licenses have historically held no value without the research and development services we provide. As we generally only provide research and development services for internally generated antibodies that require a license to be utilized by a third party, our research and development services are not considered distinct. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Steering Committee Meetings. The performance obligations under our collaboration and license agreements may also include our participation on steering committees, which allows us to direct the progression of our discovery programs. As these steering committees would not occur or benefit the customer without the use of our licenses, these are not considered distinct.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize consideration allocated to a performance obligation as the performance obligation is satisfied, and the determination as to whether consideration is recognized over time or at a point in time is made upon contract inception. For our collaboration agreements, this is generally over the period in which research and development services have been performed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and license agreements generally include both fixed and variable consideration. Fixed payments, such as those for upfront fees are included in the transaction price at contract value, while variable consideration such as reimbursement for research and development services, milestone and royalty payments are estimated and then evaluated for constraints upon inception of the contract and evaluated on a quarterly basis thereafter. Research and development services are updated for actual invoices. Given the nature of our agreements, milestones are estimated using the most likely amount and are evaluated on a quarterly basis. Upon commercialization, royalty payments will be recognized in the period incurred. </span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div>We receive royalty revenue on sales by our partners of products covered by patents or contract rights that we own and net sales of their approved drugs, where we have concluded the license is the predominant item to which the royalties relate. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a sales-based royalty to be recorded when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of our partners&#8217; historical experience including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. As of June&#160;30, 2021, there have not been material differences between actual and estimated royalty revenues.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702795192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the weighted-average o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">utstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702582296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,660&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,225&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,716&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,728&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,228)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,945)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,688&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research, development and manufacturing expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,922&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,958&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,262&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702511112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Milestones Achieved</a></td>
<td class="text">Milestones recognized through June&#160;30, 2021 under the GSK Agreement are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(JEMPERLI/Dostarlimab)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-TIM-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK4069889A/Cobolimab)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-LAG-3 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(GSK40974386)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Initiated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using good laboratory practices (GLPs) </span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'15</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IND clearance from the FDA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$4.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2 clinical trial initiation</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'17</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'19</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q3'18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3 clinical trial initiation - second indication</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'19</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first BLA - first indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$10.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first MAA - first indication</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.0M</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filing of the first BLA - second indication</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$10.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1'21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">First BLA approval - first indication</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$20.0M</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">First MAA approval - first indication</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$10.0M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones achieved through June&#160;30, 2021 under the BMS Agreement are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Anti-PD-1 <br/>(CC-90006)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestone Event</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter Recognized</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of first </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> toxicology studies using GLPs</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$0.5M</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2'16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1 clinical trial initiation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.0M</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q4'16</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609700945960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at End of Period Using:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Market</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices for</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identical&#160;Assets</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At June  30, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,928&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">At December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,697&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,697&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div>(2)&#160;&#160;&#160;&#160;Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Available-for-sale Investments</a></td>
<td class="text">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of June&#160;30, 2021 are as follows:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding agency securities, none have maturity dates of less than one year and $5.0 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzU2OQ_2c6af718-21cf-4692-a2d3-b58b8b1319f6">one</span> to two years as of June&#160;30, 2021.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $1.1 million have maturity dates of less than one year and $0.5 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfMzcxNA_0f49c841-e469-4cdb-9e94-1d8fc6721bf2">one</span> to two years as of June&#160;30, 2021.</span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations have maturity dates of less than one year as of June&#160;30, 2021. </span></div><div style="margin-top:3pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our outstanding U.S. Treasury securities have maturity dates of less than one year as of June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of December&#160;31, 2020 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,169&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,414&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,441&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,540&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,743&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Of our outstanding agency securities, $10.0 million have maturity dates of less than one year and $11.2 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDMwMg_8efbf14a-390d-4a61-8d2e-efb73efed063">one</span> to two years as of December&#160;31, 2020.</span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our outstanding certificates of deposit, $1.1 million have a maturity date of less than one year and $1.3 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDQ1NQ_25069077-64eb-4770-a079-0932cb57d201">one</span> to two years as of December&#160;31, 2020.</span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Of our outstanding commercial and corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations, $29.4 million have maturity dates of less than one year and $0.0 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDYyMA_ca5315b3-0237-444d-96a1-9e4abab3f521">one</span> to two years as of December&#160;31, 2020. </span></div><div style="margin-top:2pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Of our outstanding U.S. Treasury securities, $102.7 million have maturity dates of less than one year and $5.0 million have a maturity date of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyNzg5MjQ3MTk4ZjRjZjFiNjBiMDQ4ZGE0MjBlYjUyL3NlYzplMjc4OTI0NzE5OGY0Y2YxYjYwYjA0OGRhNDIwZWI1Ml80OS9mcmFnOjRhYmQ2YTk2NmYwZDQxOGJhZTQ2ZTNiN2M2MmVjMjEyL3RleHRyZWdpb246NGFiZDZhOTY2ZjBkNDE4YmFlNDZlM2I3YzYyZWMyMTJfNDc3NA_1f934835-43a2-4d2e-869c-8b6ff5fa0e3d">one</span> to two years as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Unrealized Loss and Fair Values in a Loss Position</a></td>
<td class="text">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;June&#160;30, 2021&#160;and&#160;December&#160;31, 2020, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:<div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:26.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:26.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,112&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702792168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at June&#160;30, 2021 are as follows: <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued and Outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares Reserved For:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Equity Incentive Plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609701296616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Related to Stock Option Awards</a></td>
<td class="text">A summary of the activity related to stock option awards during the six months ended June 30, 2021 is as follows: <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;(in</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,920,700&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.67&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,034)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.86&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures and cancellations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731,808&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.70&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.51</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,823&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744,975&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions used to Estimate Fair Value</a></td>
<td class="text">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.39</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.97</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,376&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,005&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,716&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609701158376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Costs in Cash Flow Statement</a></td>
<td class="text"><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following non-cancellable office lease costs are included in our consolidated statements of cash flow (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification on the Cash Flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Annual Obligations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, the future minimum annual obligations for the Company&#8217;s operating lease liabilities are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments required</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702742456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609708997688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock (in shares)</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">2,838<span></span>
</td>
<td class="nump">3,624<span></span>
</td>
<td class="nump">2,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609704267800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,716<span></span>
</td>
<td class="nump">$ 6,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,228)<span></span>
</td>
<td class="num">(4,945)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,660<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609708866056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="nump">$ 3,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research, development and manufacturing expenses</a></td>
<td class="nump">11,922<span></span>
</td>
<td class="nump">10,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 15,958<span></span>
</td>
<td class="nump">$ 15,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609691231992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="16">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,274,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Collaborative Research And Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived', window );">Upfront license fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets', window );">Number of outstanding research and development targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents', window );">Milestone payments, contingent upon preclinical and clinical trial events (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals', window );">Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales', window );">Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent', window );">Agreement term following first commercial sale or expiration of the last to expire patent (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod', window );">Number of milestones achieved during period | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-TIM-3 (GSK4069889A/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-LAG-3 (GSK40974386)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | IND clearance from the FDA | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | IND clearance from the FDA | Anti-TIM-3 (GSK4069889A/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | IND clearance from the FDA | Anti-LAG-3 (GSK40974386)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Phase 2 clinical trial initiation | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Phase 2 clinical trial initiation | Anti-TIM-3 (GSK4069889A/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Phase 2 clinical trial initiation | Anti-LAG-3 (GSK40974386)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Phase 3 clinical trial initiation - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Phase 3 clinical trial initiation - second indication | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Filing of the first BLA - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Filing of the first MAA - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Filing of the first BLA - second indication | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | First BLA approval - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | First MAA approval - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Amendment | Anti-PD-1 (JEMPERLI/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees', window );">Revenue recognition multiple deliverable arrangements upfront fee receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember', window );">GSK | Amendment | AnaptysBio-generated Zejula</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_NetSalesRoyaltyPercent', window );">Royalty percent on net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_BristolMyersSquibbMember', window );">Celgene Corporation | Collaborative Research And Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived', window );">Upfront license fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone', window );">Maximum milestone payments per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_BristolMyersSquibbMember', window );">Celgene Corporation | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (CC-90006)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned', window );">Milestone payment earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_BristolMyersSquibbMember', window );">Celgene Corporation | Phase 1 clinical trial initiation | Anti-PD-1 (CC-90006)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned', window );">Milestone payment earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_NetSalesRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_NetSalesRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition Multiple Deliverable Arrangements Upfront Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognized, Milestone Method, Milestone Payment Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationFirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationFirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationSecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationSecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FilingOfBLAFirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FilingOfBLAFirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FilingOfMMAFirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FilingOfMMAFirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FilingOfBLASecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FilingOfBLASecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FirstBLAApprovalDMMRECMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FirstBLAApprovalDMMRECMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FirstMAAApprovalFirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FirstMAAApprovalFirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_CollaborationAndExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_CollaborationAndExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedZejulaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedZejulaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anab_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anab_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase1ClinicalTrialInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase1ClinicalTrialInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609707504232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">$ 64,081<span></span>
</td>
<td class="nump">$ 160,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">45,714<span></span>
</td>
<td class="nump">107,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">21,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">11,779<span></span>
</td>
<td class="nump">29,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">45,714<span></span>
</td>
<td class="nump">107,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">21,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">11,779<span></span>
</td>
<td class="nump">29,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">305,162<span></span>
</td>
<td class="nump">188,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">26,928<span></span>
</td>
<td class="nump">57,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">45,714<span></span>
</td>
<td class="nump">107,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">305,162<span></span>
</td>
<td class="nump">188,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted&#160;Market Prices for Identical&#160;Assets (Level 1) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">26,928<span></span>
</td>
<td class="nump">57,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other&#160;Observable Inputs (Level 2) | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other&#160;Observable Inputs (Level 2) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other&#160;Observable Inputs (Level 2) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">21,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other&#160;Observable Inputs (Level 2) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">11,779<span></span>
</td>
<td class="nump">29,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other&#160;Observable Inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other&#160;Observable Inputs (Level 2) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609706728024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 64,050<span></span>
</td>
<td class="nump">$ 160,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">64,081<span></span>
</td>
<td class="nump">160,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">58,597<span></span>
</td>
<td class="nump">143,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">5,484<span></span>
</td>
<td class="nump">17,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">21,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">21,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,589<span></span>
</td>
<td class="nump">$ 2,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 11,778<span></span>
</td>
<td class="nump">$ 29,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 11,779<span></span>
</td>
<td class="nump">29,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 45,680<span></span>
</td>
<td class="nump">$ 107,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 45,714<span></span>
</td>
<td class="nump">107,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Debt Securities, Remaining Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AvailableforsaleDebtSecuritiesRemainingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609706119160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 8,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,713,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">8,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,112,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses on available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">4,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,999,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">4,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,999,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">3,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,503,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">3,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,902,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,211,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,211,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609699666040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">27,432,609<span></span>
</td>
<td class="nump">27,356,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,432,609<span></span>
</td>
<td class="nump">27,356,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609706181688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options issued and outstanding (in shares)</a></td>
<td class="nump">3,731,808<span></span>
</td>
<td class="nump">2,920,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance (in shares)</a></td>
<td class="nump">8,195,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future award grants (in shares)</a></td>
<td class="nump">3,192,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future award grants (in shares)</a></td>
<td class="nump">1,271,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609704572168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period remaining for amortization of unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period remaining for amortization of unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock | Director Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding', window );">Annual increase in number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease', window );">Capital shares reserved for future issuance, increase (in shares)</a></td>
<td class="nump">1,094,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member', window );">ESPP | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding', window );">Annual increase in number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease', window );">Capital shares reserved for future issuance, increase (in shares)</a></td>
<td class="nump">273,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved For Future Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609791336120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,920,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,037,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises (in shares)</a></td>
<td class="num">(77,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeitures and cancellations (in shares)</a></td>
<td class="num">(149,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, ending balance (in shares)</a></td>
<td class="nump">3,731,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable, ending balance (in shares)</a></td>
<td class="nump">1,744,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 26.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">29.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercises (in dollars per share)</a></td>
<td class="nump">9.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeitures and cancellations (in dollars per share)</a></td>
<td class="nump">29.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">27.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable, ending balance (in dollars per share)</a></td>
<td class="nump">$ 27.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding (in years)</a></td>
<td class="text">7 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options exercisable (in years)</a></td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding</a></td>
<td class="nump">$ 24,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, options exercisable</a></td>
<td class="nump">$ 17,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609703295800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Weighted Average Assumptions used to Estimate Fair Value (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">93.10%<span></span>
</td>
<td class="nump">91.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 22.39<span></span>
</td>
<td class="nump">$ 11.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609706900440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,690<span></span>
</td>
<td class="nump">$ 2,741<span></span>
</td>
<td class="nump">$ 7,005<span></span>
</td>
<td class="nump">$ 5,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,255<span></span>
</td>
<td class="nump">$ 1,783<span></span>
</td>
<td class="nump">$ 4,376<span></span>
</td>
<td class="nump">$ 3,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609706098088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 04, 2020 </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of tenant improvements and certain equipment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember', window );">10455 Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=anab_A10770WateridgeCircleSanDiegoCalifornia92121Member', window );">Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">124 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod', window );">Lease termination term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RentPerSquareFoot', window );">Monthly base rate (usd per sqft) | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AnnualRentIncreasePercent', window );">Increase in annual rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AnnualRentIncreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Rent Increase, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AnnualRentIncreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent Per Square Foot</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=anab_A10770WateridgeCircleSanDiegoCalifornia92121Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=anab_A10770WateridgeCircleSanDiegoCalifornia92121Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609702614904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Costs Included in Cash Flow Statement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 20,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140609703268920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">2,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">15,846<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments required</a></td>
<td class="nump">25,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(4,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 20,777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *Z!"5,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "N@0E32Z+S .\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O:1%T=#U9<,G!<&!XEM(;EM8TX3DI-VW-ZU;A^@'\#%W__SN
M=W"-#E+[B"_1!XQD,=V,KNN3U&'%#D1! B1]0*=2F1-];NY\=(KR,^XA*'U4
M>X2*\SMP2,HH4C !B[ 06=L8+75$13Z>\48O^/ 9NQEF-&"'#GM*($H!K)TF
MAM/8-7 %3##"Z-)W <U"G*M_8N<.L'-R3'9)#<-0#O6<RSL(>']^>IW7+6R?
M2/4:\Z]D)9T"KMAE\EN]WFP?65OQ2A3\ON /VXI+44MQ^S&Y_O"["CMO[,[^
M8^.+8-O K[MHOP!02P,$%     @ KH$)4YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MLQX1G**([Y$>;, R;%F&3I8WDA]9EB#^';97Q56]%(1.N80:[J\U&_%PFM<
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M*[%J3WK;&\%VS5'FD@E9-<WEEB8IK11 _G_-F#C>J %.Y^W3?P!02P,$%
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M?_?;LY1IRY?H>GEO%ZP=)9Q\W!I4+)X#\'SM<*SY"S<87^1^]4]02P,$%
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M-?6EN2^Y0V +&CP""5G'M56R#M6R3)&U""8U0SZ#O$SO:"$:Z9+*S8R0&-2
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M."4MP/<+8^KPAABT/_9[^3]02P,$%     @ KH$)4Z*!>CH$"@  P"$  !D
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M9F##<1!'$=%<+P.[1S7\HPEHVV&SLSA;'<?G013%KL.A#[N7K:_J$-6*_G<
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MIJIE&<X]ZBJ%\@F]5]3OWTWB*/W8'P!7HFGH:[8(N"M EPCC,/1#]X J&=&
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MK_#;Y 9"!V1I ^^4T %P/]ME3WH [D4R&9VW^ME(@CC1JE,U:[9==+)KHEI
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MTVIV.U>[J.%^76RL5.3X^Y03J9'=?!?$KZQ,3-&(1HEQ6+.U "V>&?:(B%Y
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M$&-\B%%I%'!])83>#HR#^FDW_ E02P,$%     @ KH$)4TUQ\4C>!@  UQ<
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M1A=87-KF/2X#!$<VT[0S@D(K1J4)PUG8=N& F21X5C9+:7,QKATSO63,KL0
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M6-@(9BVGN"P<1.V]\*0"7E'_2>!#@X9Y&4X(GDQ^"_/YE+Y9EG3N#>,E)6N
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MW'H=[ZKYD?KI'E,_YP7:JY52+I6VL4@%=744]/5:00E[23\'Y&2%8SZ)XH'
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M8= !;!>"(I/MU9! S29.'ZDD4/X)[IC*[0&.2&(-ZK FDD)O;Q>'(H]M])%
M^2:TEPQ"V2?V%OP9&&1-]+$&9=%' JI [*I0VHI/TTH"E9R(7K(*&D#L+?HS
ML.HVTLH:F$4K"6@$L6M$D=;K))8/*/+5=ZG1;%5Q%<J'@").1GTDD4+UI_:.
MO6C7^&;F6;[K+-_:RWBG0@1U.!9D_T*^BL.>1PYI(@4IH'8I*#&VTBNS"8]Q
M1:%0TWZZ, 4;QMZFM^.*5C>-&!%OGZHJS#0Y_(#G0J'D4WO)+S+UYRK1<OKS
M3U@XOUQO=MB-"B9F/3/7\&IJ)F1:FW #V*[\RT]R+4.$7YW2QU*H[+27'@X%
M%:!=NSBTF8U3 [/UL11D@MIEXCG/A/9], 4UH+WTA2AH">W:&:)5U\?9/PUL
MD++_"AK#[!KSG&= FPZ:@:ZP7CI,#+2)=>TPL:IWM,^]%5).'#2+V37K67?_
MTUIO5OC%H)<V%0/98EW;5*SJ/U5.!QNDG#C(&6MN3SWU=&C5LC/0*]9+:XN!
M4#'[94NK-I!5[:G:EKT&9VO9&:@6:VYC/9GQ9BT_!V7BO?2^. @3MU_PM.*:
MUQA8-2U_#<S2\G/0*-[<Z+H-YG'>J,4:?=8+J3:<?AZG4JWS&P:NXN4*Z"4G
M]?D<9(CWTB+C(#F\:XN,5\VO_8INA903+_P(WMP;.XGU]CT]![GAO?30.(@-
M[]I#XS4>6M7;KD$=]K8Y2!%O[J"=1'Z;=IZ#YO!>NFX"=$<<^9W\Z?=F5"VV
M&D.\!F4QQ 7(DFCNPYVVZ9_6R@L0)=%+4T^ ,HFN;ZX250NOSD6O@5E<= '*
M)9H[?2>="ZWZ> '")'II[8G"_5GV:Z%6O9VHVG/[ZFZ%E',$?1+-S;O3R&W6
ML@N0'-%+FTZ ^ C[!4\[6H\[<E9(^=XZT!^WN2-7I/4N3@ZQ24_JT%V0%+>7
M%IP+2N)V;<&YQRTX*Z2<."B,V]R":T-V^\;<!=%P>^FPN: >;M<.FWO<8;-"
MRHF#JKC-';8V;+?IQ-W"7;R]---<D!.WZ_O$W*IS5N'9!BDG#C+C-O?56NWJ
MIW7>'FB,UTMOS0/%\;J^K\RK.FG[U%LAY<1!B;S3C+9CU+=JM#W0%Z^7WIH'
M8N/9KU!:=63><1O-"BGG"'KCG6:C'>6T67_M@7YXO;3,/) 4SWY)TH[-32QA
M8],&V>0X+#P]ESVZ>.VK>1"G*)0S,\9YF^FXVCP-N'FCDV7^0-TXT3J)\I<+
MZ4^ER@#F^UF2Z,<WV3-ZNV<R+_X'4$L#!!0    ( *Z!"5,)W/3GTP8  - I
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;+V:7V_;-A# OPIA]*$%
MFEJD2,HND@"ILW8=&J!HFNYAV(-B,[902?0D.FF&??A1LB)*(G526L-]:"S[
M_I$G_^Y\U.F#S+[G&R$4^I'$:7XVV2BU?3N=YLN-2,+\C=R*5']R)[,D5/HR
M6T_S;2;"5:F4Q%/B>7R:A%$Z.3\MW_N<G9_*G8JC5'S.4+Y+DC![?"=B^7 V
MP9.G-[Y$ZXTJWIB>GV[#M;@6ZF;[.=-7T]K**DI$FD<R19FX.YM<X+<+'A0*
MI<2W2#SDC=>H6,JME-^+BX^KLXE71"1BL52%B5#_N1<+$<>%)1W'/Y712>VS
M4&R^?K+^OER\7LQMF(N%C/^,5FIS-IE-T$K<A;M8?9$/OXMJ0:RPMY1Q7OZ/
M'BI9;X*6NUS)I%+6$211NO\;_J@VHJ&@[;@52*5 N@J\1\&O%/QRH?O(RF5=
MABH\/\WD \H*:6VM>%'N3:FM5Q.E11JO5:8_C;2>.G\?1AGZ%L8[@:Y$F.\R
MH7.D<A2F*W1Q'T9Q>!L+I&\7=!WJ%Q_3>Y&KO<B)$3C1 B=Y5^#EI5!:('^E
M16^N+]'+%Z_0"Q2EZ.M&[G+M(3^=*KV&(I+ILHKWW3Y>TA,O1U<R59L<_9:N
MQ,JAOX#U,0$,3/7FU3M(GG;P'0$M_K%+WR#?>XV(1[ K(%C]4BRU.B[5/2 <
MOTZH7]KS>^W=*G0MEKLL4I'(7[N2]-<GK80^*I'D?P,N:>V2EBYIC\N+1&8J
M^E>LT$+FRI73O3XO]0NPW)]SZC&]W/OF1ME2F'N,&K%6=*R.CH'1?<ADGJ.;
M5$,N+H/\H.'FO//V=EC#OQ]T0K1%B#=SQ\?K^/CSXONDKX4S0&YY/^&= !TB
MS!U?4,<7@/%]E2J,D>&$*[# \JKS.\.=V&PIG=^ ^N[X9G5\,S"^ZXV^^TZ4
MR!*-EAH^KBAGEG\V8_-NBFTI3'W<$&M%.:^CG(-1?I+I>E20<SM(.J.=&&TA
M'##*W2%BS]0"#_XBKT6Z?$1Y30\ #KA18?"QB(2)<4I^D4F5@=9.>Y[?V6F'
M%,&8SWNVVE :^P>B4F6H&4$7G X1W!.@83J&H?X,+%660"ZY9/IB-&3',-K'
MH G;R*9SZTOOD(+2;-B.8;B/AU-EB$-IMN&./?VO)T@#> P3OMFSZ4X_5[HU
MB]+U:]UGJN)+^XA6H1(H"].U0"]U__8HPBQ_Y5P%[ F7JM 7W% ?P]@?#=3*
M#F]_SZV]M:4P)KU[:["/8>Y;2$7_H:LHC9)= O6>!MG$.Q9<B2$ZP<>Z808\
MN6Z8JJM^OF)[M::4D(%2XDIA^&,HA:84D*-U[,3@G<!X/V0*84]DK^K,X4]H
MMM=K2@6!2\5"Z';@+EKJ1>D%W^E?^EN91PJR;2!/^-$2:*!-8)0.-SB5@1;2
MV&S> 9]#BE#2T^T2@V<"XWE\?T/LAIMT8[1%>BHS,6 F,)B?T=\0N]WNE@]0
MI/T[WJ#=A[OQ,=U-9:+5$K!Y]X>70XI0O^?G@F_*@ \S=GQS4QEJ5U>K!E=2
MK$^J':;AMP_S^X"H&_ T6'3\QA0'_GTPNKVI['3:F^[.VD+8[]U94T1\&- ]
M4!W5XO@&W3X[%EY]PW0?;MP/>=/ GOI;G)]0;*_6%!,?+B9 (@<;'=_4!']V
MM$0:SOLPYP^92-@3T.C\C&9[%&NJ!H6KQD(FB<B6D2X=Q0Q_*;.MS(H5RMLX
M6H?%V0GHR-"?'FVL0PW+Z:^.=2H#[5(3!+,.$1UB9$XQ=2.1&F[30\UU*#2T
MJ8*T14C/M)DVAO4'&^Q0>VACS>S'SW6H(3[]];E.9:*;YVY[2QV#G3FE?2&:
M^D /--A94'MJHR/H*[[4,)O"S![;(2RHW>'W.3<HIW![/X8RH]H :D!.Y\?B
M#3,T93!-#U<]%@.>!JLY,V1F<%\^-CF#I9T9+C-RM.08UC*8M0<L[0.>^GNT
M <7ARLX,N!D,[IMK]#4KS^@?&UL-F6X<D1ZMQ68&H0Q&Z' M9_9,G#(^Z]8@
MAQCV N;W'1P;Q#(8L<\X.K;/-OWNH9U#!@=],1H2LV<.6OK+.;/'*-96VB(G
M/>>SS)";P>WMF')>F6BG.L#6'CI./KV ]YW.<@-Z#N-W?#WGCI&+1X*^@LX-
MMCF,[=$%G=O3%-9[#,0-PSG<6[OY,JJ*<\-L?K1A-S?DY,<:=B\&/ U6<6Z8
MS.$FN#\=@W6;-YX].=KHFANL\F.=-RX&/ 'E=]IX9DYW2^OR4<)<-TN[5.T?
MGZO?K1]7O"@?TIL:\?VSCE=AMM9U <7B3JMZ;P*=V&S_^.#^0LEM^03>K51*
M)N7+C0A7(BL$].=W4JJGB\)!_1#G^?]02P,$%     @ KH$)4_DB]-73!
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M$@+?3$/@82+29-;>K<BH"'*KR(2E*>5A3!+]?1$ROF9<]0%@\R1>DORKPD6
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M;HM%, L@QRVKA;U3A]^PU7/I^#(EC'_"H;6- \AJ8U79@LF#DLOFS9[:.)P
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M%=3.@/:W2MGGB3N@^_U9_@-02P,$%     @ KH$)4X@4A1HJ P  L0H  !D
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MKK'Q!6DFX/>E$/IE8/J8II6>_0M02P,$%     @ KH$)4RC(D6.I @  EP8
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MYBX%:3>8]RLA]/O$MO?N=I[\ 5!+ P04    " "N@0E3A].KD1L#   N$@
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M5=D<_%GW5V#V!5!+ 0(4 Q0    ( *Z!"5,'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ KH$)4TNB
M\P#O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ KH$)4YE<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "N@0E3B#5/0D\%  #\
M%0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ KH$)4_UHL628!0  FA4  !@              ("!DPT
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *Z!"5/M]E>/
MU0(  +T)   8              " @6$3  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "N@0E3_R L*:0%  ![%P  &
M@(%L%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ KH$)
M4U^MCHTQ!P  O"T  !@              ("!1AP  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( *Z!"5.2^%=V?08  )08   8
M      " @:TC  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "N@0E32GI&,I %   ]#   &               @(%@*@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ KH$)4_@@9OUZ$   U"T  !@
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M970Q,BYX;6Q02P$"% ,4    " "N@0E3I<%OFUL)  #-&0  &0
M    @('18@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M *Z!"5/V%3_+I0<  +02   9              " @6-L  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ KH$)4W@G*9";#@  7RD  !D
M             ("!/W0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "N@0E3_EOV:NP"  !/!@  &0              @($1@P  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( *Z!"5,I=+JT;0,
M .$'   9              " @32&  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ KH$)4[N5D0*S P  Y@D  !D              ("!
MV(D  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "N@0E3
M37'Q2-X&  #7%P  &0              @('"C0  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( *Z!"5/V%-JLN@(  +D%   9
M      " @=>4  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ KH$)4U-'R9(<!0  :@L  !D              ("!R)<  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "N@0E3$**JPH #  #$!P
M&0              @($;G0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( *Z!"5/#5Q$U' (  ( $   9              " @=*@  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ KH$)4Q_FIT'$
M @  A <  !D              ("!):,  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "N@0E3,B^I\RH#  "&"@  &0
M@($@I@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *Z!
M"5,[U=<>O0(  %L'   9              " @8&I  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ KH$)4](#;6<5"0  &3@  !D
M         ("!=:P  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " "N@0E3I1SVUQ0'  "?.0  &0              @('!M0  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *Z!"5,)W/3GTP8  - I
M   9              " @0R]  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ KH$)4_DB]-73!   JQ@  !D              ("!%L0
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "N@0E3RS7C
M6$4"    !@  &0              @($@R0  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( *Z!"5-]]Z;*O@(  /X'   9
M  " @9S+  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MKH$)4T*2$R[\ P  J!   !D              ("!D<X  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "N@0E3RTS"#1T$   J#P  &0
M            @('$T@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( *Z!"5-0B"B<00,   H)   9              " @1C7  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ KH$)4X@4A1HJ P
ML0H  !D              ("!D-H  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "N@0E3,WX-NR<$  !6#P  &0              @('Q
MW0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *Z!"5,H
MR)%CJ0(  )<&   9              " @4_B  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ KH$)4\6L+@VU @  J0<  !D
M     ("!+^4  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M" "N@0E3A].KD1L#   N$@  #0              @ $;Z   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( *Z!"5.7BKL<P    !,"   +              "
M 6'K  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *Z!"5.J 79&>0,  ,$:   /
M              "  4KL  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "N
M@0E30+O#+8<!  "\%P  &@              @ 'P[P  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "N@0E3_WEJDI\!   =&   $P
M            @ &O\0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +P O
+ , ,  !_\P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>278</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statement of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Collaborative Research and Development Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements</Role>
      <ShortName>Collaborative Research and Development Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Fair Value Measurements and Available for Sale Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Collaborative Research and Development Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables</Role>
      <ShortName>Collaborative Research and Development Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2324306 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/EquityIncentivePlans</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Collaborative Research and Development Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails</Role>
      <ShortName>Collaborative Research and Development Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Equity Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Equity Incentive Plans - Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Equity Incentive Plans - Summary of Weighted Average Assumptions used to Estimate Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Weighted Average Assumptions used to Estimate Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails</Role>
      <ShortName>Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="anab-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="anab-20210630.htm">anab-20210630.htm</File>
    <File>anab-20210630.xsd</File>
    <File>anab-20210630_cal.xml</File>
    <File>anab-20210630_def.xml</File>
    <File>anab-20210630_lab.xml</File>
    <File>anab-20210630_pre.xml</File>
    <File>anab-6302021x10qxexx311.htm</File>
    <File>anab-6302021x10qxexx312.htm</File>
    <File>anab-6302021x10qxexx321.htm</File>
    <File>anab-6302021x10qxexx322.htm</File>
    <File>anaptysbio-firstamendmentx.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>anab-20210630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "anab-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "anab-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "anab-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "anab-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "anab-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anab-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "anab-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 344,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 4,
    "http://www.anaptysbio.com/20210630": 6,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 15
   },
   "keyCustom": 24,
   "keyStandard": 254,
   "memberCustom": 25,
   "memberStandard": 23,
   "nsprefix": "anab",
   "nsuri": "http://www.anaptysbio.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.anaptysbio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Collaborative Research and Development Agreements",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements",
     "shortName": "Collaborative Research and Development Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Fair Value Measurements and Available for Sale Investments",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments",
     "shortName": "Fair Value Measurements and Available for Sale Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Stockholders' Equity",
     "role": "http://www.anaptysbio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Equity Incentive Plans",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Commitments and Contingencies",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Collaborative Research and Development Agreements (Tables)",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables",
     "shortName": "Collaborative Research and Development Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables",
     "shortName": "Fair Value Measurements and Available for Sale Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324306 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i54e09947d78640e4b9eeb147c43743aa_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i54e09947d78640e4b9eeb147c43743aa_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment, net (Details)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Collaborative Research and Development Agreements (Details)",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
     "shortName": "Collaborative Research and Development Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i5c6137734596471eb3bfbea0e8c29f72_D20141101-20141130",
      "decimals": "INF",
      "lang": "en-US",
      "name": "anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ie3ef14c2603b489b847974efac36accf_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ie04286dba40e490ebc78cc7952a23570_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Equity Incentive Plans - Narrative (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ie04286dba40e490ebc78cc7952a23570_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i0d8c08adf39c4e31b110d3c3dffd9d36_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Equity Incentive Plans - Option Activity (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails",
     "shortName": "Equity Incentive Plans - Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Equity Incentive Plans - Summary of Weighted Average Assumptions used to Estimate Fair Value (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails",
     "shortName": "Equity Incentive Plans - Summary of Weighted Average Assumptions used to Estimate Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ib2f731f1d7f645a0884d48194de88b83_D20210101-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ifb3a9fe237f347e39f34d734ffdf3d9c_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ie3b64ce4f6404458b4b4d2e565325a2d_D20201215-20201215",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ie3b64ce4f6404458b4b4d2e565325a2d_D20201215-20201215",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails",
     "shortName": "Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i742e1380ee1b4cf9a0bddfe8e8e2be62_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ia0631536fcce419a94967e30da4ebc8c_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "idb2028cc405d4c44936f5ed145a50dbf_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statement of Stockholders\u2019 Equity",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity",
     "shortName": "Consolidated Statement of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "i6bd7946500014e7a935d20e4d9049cab_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of the Business",
     "role": "http://www.anaptysbio.com/role/DescriptionoftheBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-20210630.htm",
      "contextRef": "ibac457effe62404b80cca6b3d4ebd85c_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "anab_A10455PacificCenterCourtInSanDiegoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "10455 Pacific Center Court in San Diego, California",
        "label": "10455 Pacific Center Court in San Diego, California [Member]",
        "terseLabel": "10455 Building"
       }
      }
     },
     "localname": "A10455PacificCenterCourtInSanDiegoCaliforniaMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_A10770WateridgeCircleSanDiegoCalifornia92121Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "10770 Wateridge Circle, San Diego, California 92121",
        "label": "10770 Wateridge Circle, San Diego, California 92121 [Member]",
        "terseLabel": "Lease Agreement"
       }
      }
     },
     "localname": "A10770WateridgeCircleSanDiegoCalifornia92121Member",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Expenses, Current",
        "label": "Accrued Research And Development Expenses, Current",
        "terseLabel": "Accrued research, development and manufacturing expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_AnaptysBioGeneratedAntiLAG3GSK40974386Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AnaptysBio Generated Anti-LAG-3 (GSK40974386)",
        "label": "AnaptysBio Generated Anti-LAG-3 (GSK40974386) [Member]",
        "terseLabel": "Anti-LAG-3 (GSK40974386)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiLAG3GSK40974386Member",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]",
        "label": "AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]",
        "terseLabel": "Anti-PD-1 (CC-90006)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab)",
        "label": "AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) [Member]",
        "terseLabel": "Anti-PD-1 (JEMPERLI/Dostarlimab)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab)",
        "label": "AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member]",
        "terseLabel": "Anti-TIM-3 (GSK4069889A/Cobolimab)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBioGeneratedZejulaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AnaptysBio-generated Zejula",
        "label": "AnaptysBio-generated Zejula [Member]",
        "terseLabel": "AnaptysBio-generated Zejula"
       }
      }
     },
     "localname": "AnaptysBioGeneratedZejulaMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnnualRentIncreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Rent Increase, Percent",
        "label": "Annual Rent Increase, Percent",
        "terseLabel": "Increase in annual rent"
       }
      }
     },
     "localname": "AnnualRentIncreasePercent",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_AvailableforsaleDebtSecuritiesRemainingMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sale Debt Securities, Remaining Maturity",
        "label": "Available-for-sale Debt Securities, Remaining Maturity",
        "terseLabel": "Investments outstanding, maturity date range (in years)"
       }
      }
     },
     "localname": "AvailableforsaleDebtSecuritiesRemainingMaturity",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb",
        "label": "Bristol-Myers Squibb [Member]",
        "terseLabel": "Celgene Corporation"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure",
        "label": "Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure",
        "terseLabel": "Investments at fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_ClearanceOfInvestigationalNewDrugFromFDAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clearance Of Investigational New Drug From FDA [Member]",
        "label": "Clearance Of Investigational New Drug From FDA [Member]",
        "terseLabel": "IND clearance from the FDA"
       }
      }
     },
     "localname": "ClearanceOfInvestigationalNewDrugFromFDAMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CollaborationAndExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Exclusive License Agreement",
        "label": "Collaboration and Exclusive License Agreement [Member]",
        "terseLabel": "Amendment"
       }
      }
     },
     "localname": "CollaborationAndExclusiveLicenseAgreementMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CommercialAndCorporateObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Corporate Obligations [Member]",
        "label": "Commercial And Corporate Obligations [Member]",
        "verboseLabel": "Commercial and corporate obligations"
       }
      }
     },
     "localname": "CommercialAndCorporateObligationsMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding",
        "label": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding",
        "terseLabel": "Annual increase in number of shares available for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Increase",
        "label": "Common Stock, Capital Shares Reserved For Future Issuance, Increase",
        "terseLabel": "Capital shares reserved for future issuance, increase (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceIncrease",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "anab_EmployeeStockPurchasePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, 2017 [Member]",
        "label": "Employee Stock Purchase Plan, 2017 [Member]",
        "terseLabel": "2017 Employee Stock Purchase Plan",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2017Member",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_EquityIncentivePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan, 2017 [Member]",
        "label": "Equity Incentive Plan, 2017 [Member]",
        "terseLabel": "2017 Equity Incentive Plan",
        "verboseLabel": "2017 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2017Member",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FilingOfBLAFirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Filing of BLA - First Indication",
        "label": "Filing of BLA - First Indication [Member]",
        "terseLabel": "Filing of the first BLA - first indication"
       }
      }
     },
     "localname": "FilingOfBLAFirstIndicationMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FilingOfBLASecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Filing of BLA - Second Indication",
        "label": "Filing of BLA - Second Indication [Member]",
        "terseLabel": "Filing of the first BLA - second indication"
       }
      }
     },
     "localname": "FilingOfBLASecondIndicationMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FilingOfMMAFirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Filing of MMA - First Indication",
        "label": "Filing of MMA - First Indication [Member]",
        "terseLabel": "Filing of the first MAA - first indication"
       }
      }
     },
     "localname": "FilingOfMMAFirstIndicationMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FirstBLAApprovalDMMRECMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First BLA Approval - dMMREC",
        "label": "First BLA Approval - dMMREC [Member]",
        "terseLabel": "First BLA approval - first indication"
       }
      }
     },
     "localname": "FirstBLAApprovalDMMRECMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FirstMAAApprovalFirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First MAA Approval - First Indication",
        "label": "First MAA Approval - First Indication [Member]",
        "terseLabel": "First MAA approval - first indication"
       }
      }
     },
     "localname": "FirstMAAApprovalFirstIndicationMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline",
        "label": "GlaxoSmithKline [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_InVivoToxicologyStudiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In Vivo Toxicology Studies [Member]",
        "label": "In Vivo Toxicology Studies [Member]",
        "terseLabel": "Initiated in vivo toxicology studies using good laboratory practices (GLPs)"
       }
      }
     },
     "localname": "InVivoToxicologyStudiesMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period",
        "terseLabel": "Lease termination term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_NetSalesRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Royalty, Percent",
        "label": "Net Sales Royalty, Percent",
        "terseLabel": "Royalty percent on net sales"
       }
      }
     },
     "localname": "NetSalesRoyaltyPercent",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_Phase1ClinicalTrialInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 1 Clinical Trial Initiation [Member]",
        "label": "Phase 1 Clinical Trial Initiation [Member]",
        "verboseLabel": "Phase 1 clinical trial initiation"
       }
      }
     },
     "localname": "Phase1ClinicalTrialInitiationMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase2ClinicalTrialInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 2 Clinical Trial Initiation [Member]",
        "label": "Phase 2 Clinical Trial Initiation [Member]",
        "terseLabel": "Phase 2 clinical trial initiation"
       }
      }
     },
     "localname": "Phase2ClinicalTrialInitiationMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase3ClinicalTrialInitiationFirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 3 Clinical Trial Initiation - First Indication",
        "label": "Phase 3 Clinical Trial Initiation - First Indication [Member]",
        "terseLabel": "Phase 3 clinical trial initiation - first indication"
       }
      }
     },
     "localname": "Phase3ClinicalTrialInitiationFirstIndicationMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase3ClinicalTrialInitiationSecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 3 clinical Trial Initiation - Second Indication [Member]",
        "label": "Phase 3 clinical Trial Initiation - Second Indication [Member]",
        "terseLabel": "Phase 3 clinical trial initiation - second indication"
       }
      }
     },
     "localname": "Phase3ClinicalTrialInitiationSecondIndicationMember",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_ReceivablesForStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables for Stock Options Exercised",
        "label": "Receivables for Stock Options Exercised",
        "terseLabel": "Receivable related to issuance of common stock, upon exercise of stock options"
       }
      }
     },
     "localname": "ReceivablesForStockOptionsExercised",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RentPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent Per Square Foot",
        "label": "Rent Per Square Foot",
        "terseLabel": "Monthly base rate (usd per sqft)"
       }
      }
     },
     "localname": "RentPerSquareFoot",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent",
        "label": "Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent",
        "terseLabel": "Agreement term following first commercial sale or expiration of the last to expire patent (in years)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales",
        "terseLabel": "Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals",
        "terseLabel": "Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events",
        "terseLabel": "Milestone payments, contingent upon preclinical and clinical trial events (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone",
        "label": "Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone",
        "terseLabel": "Maximum milestone payments per target"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount",
        "label": "Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount",
        "terseLabel": "Milestones achieved, amount"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period",
        "label": "Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period",
        "terseLabel": "Number of milestones achieved during period"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets",
        "label": "Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets",
        "terseLabel": "Number of outstanding research and development targets"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition Multiple Deliverable Arrangements Upfront Fees",
        "label": "Revenue Recognition Multiple Deliverable Arrangements Upfront Fees",
        "terseLabel": "Revenue recognition multiple deliverable arrangements upfront fee receivable"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsUpfrontFees",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received",
        "terseLabel": "Upfront license fee received"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognized, Milestone Method, Milestone Payment Earned",
        "label": "Revenue Recognized, Milestone Method, Milestone Payment Earned",
        "terseLabel": "Milestone payment earned"
       }
      }
     },
     "localname": "RevenueRecognizedMilestoneMethodMilestonePaymentEarned",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims",
        "label": "Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://www.anaptysbio.com/20210630",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r40",
      "r91",
      "r92",
      "r205",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director Stock options"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r204",
      "r215",
      "r259",
      "r260",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r396",
      "r398",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r204",
      "r215",
      "r259",
      "r260",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r396",
      "r398",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r144",
      "r247",
      "r248",
      "r374",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r144",
      "r247",
      "r248",
      "r374",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r204",
      "r215",
      "r250",
      "r259",
      "r260",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r396",
      "r398",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r204",
      "r215",
      "r250",
      "r259",
      "r260",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r396",
      "r398",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r39",
      "r40",
      "r91",
      "r92",
      "r205",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r147",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r341"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails",
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r31"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r185"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r44",
      "r45",
      "r46",
      "r386",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r53",
      "r54",
      "r55",
      "r94",
      "r95",
      "r96",
      "r302",
      "r399",
      "r400",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r289",
      "r341"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r286",
      "r287",
      "r288",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Options to purchase common stock (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property (sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r134",
      "r137",
      "r142",
      "r167",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r299",
      "r303",
      "r317",
      "r339",
      "r341",
      "r375",
      "r385"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r37",
      "r89",
      "r167",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r299",
      "r303",
      "r317",
      "r339",
      "r341"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r152",
      "r174"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "terseLabel": "Unrealized losses on available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r149",
      "r153",
      "r174",
      "r377"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total Fair Value",
        "verboseLabel": "Available-for-sale securities, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r151",
      "r174"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r151",
      "r174"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r26",
      "r78"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r72",
      "r78",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r318"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r295",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Research and Development Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Research And Development Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Common stock, shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Issued and Outstanding:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r341"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 500,000 shares authorized, 27,433 shares and 27,356 shares issued and outstanding at June\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r59",
      "r380",
      "r393"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r154",
      "r174",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r162",
      "r178",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r162",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Greater, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r162",
      "r178",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r162",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less than 12 Months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r159",
      "r175",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r160",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Revenue Arrangement [Line Items]",
        "terseLabel": "Deferred Revenue Arrangement [Line Items]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r76",
      "r133"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r60",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r107",
      "r109",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r307",
      "r308",
      "r381",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average number of shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r60",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r109",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r307",
      "r308",
      "r381",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period remaining for amortization of unrecognized compensation cost (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails",
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r118",
      "r168",
      "r229",
      "r236",
      "r286",
      "r287",
      "r288",
      "r293",
      "r294",
      "r306",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r399",
      "r400",
      "r401",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r206",
      "r208",
      "r209",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r310",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r309",
      "r310",
      "r312",
      "r313",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Available for Sale Investments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r206",
      "r251",
      "r252",
      "r257",
      "r258",
      "r310",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Market Prices for Identical\u00a0Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r206",
      "r208",
      "r209",
      "r251",
      "r252",
      "r257",
      "r258",
      "r310",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other\u00a0Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r206",
      "r208",
      "r209",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r310",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r206",
      "r208",
      "r209",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r177",
      "r179",
      "r182",
      "r183",
      "r207",
      "r227",
      "r305",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Loss on disposal of tenant improvements and certain equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedTerseLabel": "Receivable from collaborative partners"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r75",
      "r332"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r71",
      "r73",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Costs in Cash Flow Statement"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Annual Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum payments required"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r89",
      "r167",
      "r317",
      "r341",
      "r376",
      "r388"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r89",
      "r167",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r300",
      "r303",
      "r304",
      "r317",
      "r339",
      "r340",
      "r341"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r121",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/DescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r50",
      "r55",
      "r57",
      "r77",
      "r89",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r106",
      "r110",
      "r134",
      "r136",
      "r138",
      "r141",
      "r143",
      "r167",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r308",
      "r317",
      "r378",
      "r391"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r136",
      "r138",
      "r141",
      "r143"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r331",
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails",
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r328",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesCostsIncludedinCashFlowStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets \u2013 operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r334",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r9",
      "r31"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r51",
      "r53",
      "r54",
      "r56",
      "r58",
      "r229",
      "r319",
      "r324",
      "r325",
      "r379",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Comprehensive income (loss), net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) income on available for sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r65",
      "r67",
      "r150"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r341"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at June\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r65",
      "r66",
      "r150"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r285"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock, upon the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r184"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r186",
      "r341",
      "r383",
      "r390"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails",
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r16",
      "r23",
      "r341",
      "r389",
      "r405"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivable from collaborative partners"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r292",
      "r373",
      "r419"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r5",
      "r13",
      "r78",
      "r83",
      "r406"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r10",
      "r83"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r236",
      "r289",
      "r341",
      "r387",
      "r402",
      "r404"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r168",
      "r286",
      "r287",
      "r288",
      "r293",
      "r294",
      "r306",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r131",
      "r132",
      "r135",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146",
      "r246",
      "r247",
      "r374"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]",
        "terseLabel": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r333",
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Available-for-sale Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Milestones Achieved"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosuresPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r266",
      "r272",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions used to Estimate Fair Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r33",
      "r87",
      "r119",
      "r120",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r222",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of Unrealized Loss and Fair Values in a Loss Position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationofSharebasedCompensationExpenseDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares reserved for future award grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options exercisable, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeitures and cancellations (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeitures and cancellations (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r268",
      "r284"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock options outstanding, ending balance (in shares)",
        "periodStartLabel": "Stock options outstanding, beginning balance (in shares)",
        "terseLabel": "Stock options issued and outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Stock options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Stock options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercises (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r277",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansSummaryofWeightedAverageAssumptionsusedtoEstimateFairValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Stockholders' Equity, Ending Balance (in shares)",
        "periodStartLabel": "Stockholders' Equity, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r53",
      "r54",
      "r55",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r118",
      "r168",
      "r229",
      "r236",
      "r286",
      "r287",
      "r288",
      "r293",
      "r294",
      "r306",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r399",
      "r400",
      "r401",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r118",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r229",
      "r236",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercises (in shares)",
        "terseLabel": "Shares issued under employee stock plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r229",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued under employee stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r89",
      "r148",
      "r167",
      "r317",
      "r341"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Stockholders' Equity, Ending Balance",
        "periodStartLabel": "Stockholders' Equity, Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/ConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Accounts and Supplemental Disclosures"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsandSupplementalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r164",
      "r165",
      "r166",
      "r207",
      "r227",
      "r305",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchandDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r90",
      "r251",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r90",
      "r251",
      "r258",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsAvailableforsaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsandAvailableforSaleInvestmentsScheduleofUnrealizedLossandFairValuesinaLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Accretion/amortization of investments, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r108",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r107",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r422": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r423": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r424": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r425": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r426": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r427": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r428": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r429": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r431": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r432": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001370053-21-000056-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001370053-21-000056-xbrl.zip
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M0=?6VZNNW<P[! F*QN?7SW_4#IQZ!%H2$F"N3N_=??[5J2]['=/JQG:G:7J
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M6%(:99H\X8B2G@/]0@9SJJ1&2Z)+XY-W8DS;V15,E;BF-DIO$(^$1664"B(
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M"Z/*?;,K<WCS_W[4&UY_LTZZZR*]VI_U\V1IWW2,R]>G[+?JO=V4I.EW_0K
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M:>[6]B=E0)/&N,]=-:?#&2Y"I^V!$Y0*^P0*>T4/HG X(!4@3G$!Z 'QF>;
M%I1DD3(2G7=Q93W?D8'\L4!*N^P)H;WC=J>7]4*G6:FWOH5NKWE7-F@BFS-I
M!%9DFS.#_,G&-U-O)+OSIMU)"XI<S3C?#+9W]:TT20\P2?5K',(+CC"%8 6!
M[\B8)"0S4J,L:"FTT4A9;U;6N7K!M5R@@&7:997/7:5GD'HH5?I)5?J*97A-
M=6">95%@EC'K56:C4YEPPBH(%0))LX<QHR_P0NGTLB<AWG?"J:G[2C@_#:WN
M:#FL=C[3T]T862SS$/,C'B,A;0UEM-'R^53<C5PNI65Z@&4:7",;QGJL?%!9
M8$1D+ :6&<Y#%C&1.!C/*$H)BQ<<J06*?LJ41>&X1JG%4]?B*WZA%0N<BYC)
M&$"+"::9HMIF($1)A$)6H+BR3E[HA=+B9<]A[(9NKU-WJ50[E;64R8LG'\L8
M]W<:3"V-ROV-RL[UB@Z) D=>L,RIP#.&C<^LM"0SG@;& I/:.J &:('BE3('
ML8B\X,=#&:6^/EI?KTA ,$A3HWQ&&(Z@KP)EEC.5<:T04UP)X>34AC(6+\F0
M/YOA5;[ C&"_W3.-*:86?EU'OY1F:1:C'65@\E";=+T>(C#.*9<XH\& 3=+&
M9HH!A] L1&'!HW!F5M:I5B^0P%,*3293B@*E'IZIEL]B *34\H=K^;4B"D>1
MCH)D-FB?L<!E9H+7F5!&,BPY(A(G+1<O>$&T?-E3$^\[[5-HRB ?\$C3;4Y3
M?<6+2BOTRC3%/(<ZAF)YWS"MWD;+;XTE4PNE>;J/>:KN;R33-"0B&U],B!Y;
MR3/*=!KE$#:SU/M,,HJHTDRZ@%)^E*E'YT?+;,;"*O!,1CE*!9Z> @\N%5@J
M@D%+96:]! 6V AB&D"23*&C!C>;>ZI5U_$(JND *O.SE$SN ==.#EE8:P71#
M)>^2K!VS/GPI"R?FS28NQ?,N26<WM7,G?NR&/.HIK=&]K-'6)9VH77P\^Z)T
M5%9YF7DO5,:<X9F1F&=,N\ ]4MJEL1&"7A"Y2".N9=W$HC"*4E.?4%,'EYIZ
M\04%'!DG*O,BF#0J8C*%8BK"9(%P&9@Q=F6=LD?/22\+(R;6L'?MUE$YMV.!
MF,*DA>"U=LN5R=)'T0<(9APEPB.&LN B!#,:XAA+K,T"I^ IF"1(H95U_H*I
M)5PHHU3KQ9O?4:KUH[D&J'5T(@K+$[_0)&-2BLQ:KC/IC?+(&.(U75G'\@5G
MY4(3,TQ2Y-,Y&I>4H\Q+S*08\UIY=VE>'FA>MJ^S!LS!*3@M,HI-R%A4'%@#
M<AFC4A)/* 0TJ<:;E_F&Y57.J>4;2N6<AG)>^7Z-I>0TTHR[M,J4E2ZS6,=,
M<^0)IL#JTRX,BZ6<RYYE**=?S#*_,%F1]_<+W97VYX'VIWJ=' 2!%0\19UYY
MH 0ZC8]Z'C/C!*,1PA"']2+6?I=)A<4D"*76/IW67K$&Y3TU2.A,.<<R)KC(
MK)0*>#T5AAF/@](+-L/J29?BG]GR_@^<74+4 M.=X=R2N[,;$Q;3CC;1H/"Z
MOMU/2W..6_V($O3B+FP\Y<Y9%A\SL]DWI6NYEVOY>"-;!+Q/:HLSI#C*6$0F
M,Y'%S+/(!0E>T@"NA9%4DJ^G6Y+_6$69<[*IM)6EK5P /E[:RB>VE5<TW$6/
MHI<L"T;RC 46,FVMRKP+0H)_8U$9L)48;"6?UL+-<[:5O]KTZBGW+;Z^&>@L
M]@*=;/.L=]L;K[;?;>]O;^U5-FJ;E;W]G=?_^N?.N\VMW;T\;R+_J&Q]^+B]
M?S"-O<4+-H8ZWF:K43>VWLAK!LJ]MHJ:%]]P#EK?ZU9.S2 5AY1;;#V+K6QF
M$;:-D/5^"*QR7O5#J,G1]3 .R$=049-,(!DS!HC-M XQ4Y1*#K$<5BP -7F!
MT2+->RKWU"H-T7QCHM(03<407<5(!AGC"449$DIFS 2:&1Y])HG@)H('X00E
M0P0\>8$,T;+S<L!YIQ^NUJ\NJQKG2GZ2+-Y=A4BEV7F(V?EZ(XU-G?8@H P;
M;C/F",W@6\PPQB8*%0RE9&4=\Q=ZH4JKRKK'(E*&4GVGH[[7,JL(,X)<S+P*
M. ,8X,P*##$,Q#3.2. 2VN?J2\0B[8BW_$4.!4M9C?./I^U.;BK:L=*^M?;$
M.#4Y*.L\GWIFQXW)ZF.#.2C-Y0/,Y<G-B:%8*P&N+4/*N8QA%S+#A,V(L(83
M$H@,=&6=<[Y (599P;DH5*?4TJ?4TFOS/ FR6A.66<9HQJ2-F5)<9UAJJ[%7
MGGN=5I1X-*-9O$1(\=;8OC9B^20+;4]4UE-D>S2#S$D9<SW2/-V8)\J(-RJD
MHC])-?SE;::\(9D@#L(M1X@7)%^:2N!'3T._KW84*)_R?#5^!LF64N,?K_'7
MQF:B0"@/&P(W&;,D9,J$M)$Y2G5+A!&3%L?4+^!;431^V5(P98/+!I<-+AM<
M-KA,A4]US>7+O'>^>4/*C+N;R?(R'[XH*S!?)N'*V=,/H[T7U>NK,-,O+@@A
MG8B9HS)D+ B762%E9J)!TC,9E!V&NH0L4C*N3)DO8L#ZHP5,2AV>N@Y?KL_L
M\)<@N8L*ZXQ%3S.F.<^,(3RSWC ;M&'(+N3*)<M>6KC7:[NOQ^T&A/G=\?RG
MM%%4;U#._)D*=_SAC+CYR/M])\0 ]BQI#TC^1>6_?V:!WX?.WK'IA*E0JNW:
MF^_WT1FU)H?A>]/9Z>SU3"_X3Z;1#U=/'UE>5%K>R2SO>'_OUQH=_OL8N>:G
MEOFL^SLG&Q?5BP.TLW_8J)%/)]!/T.:_ZP<G56AO>N:'B]KF<?UP<XO\^V)[
M\,59:E%@,8L^V(QQ 0:;F9!YIQR)#$>IW<]]^ \0]#!?7B*H< @*TG"/;$CK
MEP*"A!*9-B1F"AL7C1/!XKBRCE81^CYG_=T/E5/3J7Q+@GU1^2'HNDG@W>E9
MK'ML"G8=BCGNNAO]WG&[ ^;9E_1Q+A"LDB\4C$PPAF:!$)<Q1EUFTNR6Z+Q%
MEL<@0>H_-F)WXND1]JO$4\'Q!%#" 6P7!#"(9$SAF%F(6C*JM-96>$8)F#2,
M7@"1F\"F#?%5,9>2S3=KG8=Y TKI$B3/VAW?#:U)\+C=[?:O8;%TKS-UK_!N
M7\^J)]5!;?\CW=FL?N%$.XU5VO94*_"VTF4II,MT!*:F#+ YZ^=CZDIL%1Y;
M3KN Q/]G[TV;VDJ6+="_HN#=>-$=H:)K'MPWB*"-NR\=!VC;N/WL+XZLR0AK
MX&BPC7_]J]H2("8C(2&VH,Z 0=K:JEU9N6KE4)F 0O0\P9XAR/ $@)AH" $<
M-O)GMD"]<.M@-!P,$\XF<[XLL)HLL"3\*%@R%:P3,AF;!B-K,$;::"<MB]$P
M6!OP*@NL?@LL+X) =4112I*]&1)9"1AQ&Y7TF@C'Y<96MW<W:9N9UC4;K6H7
M:_3ZC=[%DFC L/'WJ!O&?FV&FXV,<Q7QVPDN=&SH3]XBU5OI@G2SDY#N_36T
M3V\H354"1:NJ=']9VRLW4['%[AG>S8>A*%B+O44B656(&TZ1=BP@)11$B-KB
MK)3U"PR5Z.XZ17>+TBXOGIN4EFIGTR::5!4+A3B6%FE!*!+1!; ^J;+T=53:
ME49SJ\WY,4Y1]SJ=7K<6\;WQ4$IH9GEJ^/IV=MSY>+SW8__HX_L]\7'G'4US
M\N/#X7ZZ]VMZL/-'*Z=2'1RF^7K_ZL?_]^,5_R2XP 2,18K:I,3>! 36))U6
MSD=(*T#^U"^^@N!>63XU7CY1:*J"$X@8G,-[E"(C&$W6E):2.P48^Q5$]E81
MB9E:AR4,4XOUMW?Z27EEF. ::>D]XF#3;V!%HB0Z>.\-1#>WNV@58>*RF&JX
MF*S&&+@**$8L$YA%C0PD>U2Q:$U00CJ5K%"![QW46TW"PEQ9Z]<6XI6 2UF$
MJUR$[_ GIBUV#&.$8\ZVDM0CDVMIB;2I&6QX,,!6@VB+K:.;?-]E,:UX,1EO
MN<(TGY=(S(P#8<@:ZU!@2E@EHDZO;&Q1U>3L>DWIVP%M[M2$%1PS+T!6I[7W
M@7]* .,D.(,L<(=X#!19ZQ6*UFK+28@NTM5$\@J0K?UB"M(2:D BJB#F]#V)
MC,0:$1488!&TSCG("<B8N%[HY%8@FX3E,I[5(B[W',J[+JLRX92>%D_^O73S
M(OP&UFBC"&1/?M*NW%;:II<0"$.9YXZ#S!WM%Z[V7JHNUU8MEU6*L*CEHFIY
M$6 +FAB&O4%&AYB=JQ99JCV*$B(F00:J9<W4\JE79-A.P\Q3#.W&";1\H]5M
M.#AI#:%=2B\\8CN&<ZG\DX2RVWTY%DG!GKFPYU)/X:BCQ4[GU'%+$*=1)NRQ
M$1G,,-<,%&9\8TM*W>1TX9[")2.GMMJ[BFX,17N7H[T7S,%[X:*5!KG$X!''
MPB)PS"&%)09+ XM,9.W%32GK5&#\J1=:V'9NU!FU<P)#HS<\"OWTE)V3?C@*
MW4'K:VBT>X-GUM?IEY4PB4%ZS/3;#7U@SL1QD*7Q<EH8N]TDF_"?))'],#R(
MA_"](-)<B/1AFD\HB['/*4;!18ZX4PF1=(SY$*X02900)-O8(NJZ]^[7XEYX
M KI[?QY1=/=Q='>J"4(T5)B<%^%B+MND)#**>B0#:"(Y3A:"W=CB]=#<)^^!
MF*(0/L26:PV?E^MAQ8QA9C/F31A"&JQ_!?UNFM'!E*!VQG(J&#07!KEI_B"C
MDI@XCH+P%G&64_YBLFBLBFD?(9%[23:VJ*9-P:_[(V9'HN**J*\V+X%#%&U^
M1&V^8!186*,="0@P&,1%2(: I1))'3),2QF#2-HL6=.(Z^&-1]'F9795(GP-
MNBH-;BT*69HKU30.,EW'\U4EJ@)2<X'4YTLA$(%C+GR( O$Y'=QB9(E2B$':
M<BRWBEJ\L<6T:"JV-KU62G>EIQ4\*2J_N,I/=U?RH"WA"*(1B#MCD'8Z_<F<
M)MYK0I1/*F_D.JG\DCPBU7=377O>,M4%LLK9O)W'-.;ED1-1C:?W!4MSXGLC
MVP[GXEH,ZFZ:S,=$NO]YQ/EY*EO :EMJ;G=]V1 6W!"^3'- @[T-.FT(C.;S
MI9Z9G!D;$/5!IIW<!FOYQA:GLBGDLM)@EJ=%C^RY*G!:X'3]&'6!TV7#Z53)
M( Q,$)NL:0":3.I\T,#GDO!4,J\4<5*S!*<DP:E85A>GQX?3BH#_-H3TI6?'
M@FYI",(N(Y@+:>GWEZV4!-^EE31KY7BVWX;0 )>SE*![F@]'=7O#]!W#7M)2
M&/E6#D,F#:TFK8I)QE87NJY5.1#3"YWT"(/-QN5#45-//_E*)M.83GJ#*A'P
M13^T(1^F^OU;RP^/SE!BZE,38>*+CX!-0Q@-;__(]#33&DTSN7)>;.IG'GV%
M,($J;2A7Q.B82&12(&PQUQXXQ<$*^HF8C;,/'?7/GN $/@=D^P&^)',V/> +
M:'^#T\'&;Y?G)4W*9$"<;JKLE[XZA>.)V?I?VT\?O6&T4W=;_:RJ&V=UNPLG
MP]/!'ZU>L[';=3]9@'49\<MI)7I[KCJYR>.D*UFZH#)H+V6Z-/XSG3)8UX?[
MI=5M#(]ZHW0//V@VPG<7$I:FQQJ?Q&RDIX9?ZR^C7\XQ[]=;QSJ%,Z)BPQ7N
M7P!7M=>D ;?A9!!>G/WR^UE[TU:W^MKJ0[]/[C5!NZR:5UTM>6+&;U]H[28>
M:^[$Y3/YYLG;F]5;5_;.\7L";PJL;WT;;Y);W_O9;0G>Y-S<Z[8_?T^PV[^T
M#+:.@Q5BIMO>X;"\,R9A-JZHVT2![F1WUTG!:LPD?1?ZC-V;1_U$QO;2=4>#
MQJNN#[[:D?-1]0;#S1DZ]3W7F7O;^C[CO"VZ]-C5"9S)JJCW[&4'Y2QM(&=Y
MX.<V<7@96OE$YZ8LJJ4LJCL@ZXQ8=GO=\/,Y*E=>OG+^C*\8<71KDTE^Z3MS
M=Q/4^HZ.6MZ'[HM'<VH>O)TX-3N[^.-??W[9/]S]_N'P=?K\:_SQ^!VO/K/S
M@7_<<:?[]!T]V-G^=N[4[/S;WCO\XVCOV+<.#K?3][UFZ7J^1_?XWO&N^/!C
M]]O^3AK[CN]<=6I^?/_N^]Y?K](]=]/[K]G^CD_/\_G'AQ^?3_>.V\=[U?=^
M^;9//\:]4_RM<FB^Q=\^87"!4\:1DP(0MR;WJK$*64))=)H[B4F9Z^7,-8W"
M '4*A2A];@XDD7'2(6Q]P)X&JV4H<[V<N>;:^K2 \]E_:A%W02 3N$&,JK0#
M:2VY<V6NES/7P &,29,7.%<)0]*2UMH3Q+@&94 !:),]A.TV)")3N0(;_? U
M=$?AG K\[)\[,Y'&&]=S#;?._?A/)9H*6#(BF(PN[6'$@.%&JL"P!QZLT^[3
M3I6<PC%!"V>IO!FOUS_[O<[+-(8\NO>MX='+T2#-5.B_^N[:HSS#VX-!2/_S
M=3JSN2: \OT<4(3G+'BBD*>$(X[!(H.-1Y(D86L,T1NUL<5P$R^A>M2<VO/@
MF<N76?C,22D%!)\G"$9+A10Q&B"16P(YN\2%!'H:6Z(=KD 0GX$@OF_'N()_
M#XY_/\[QSPFO92XT(85(#%8QC QS!@4GI),A&0N>+JTU50'  H#K#(!I*KA0
M(<8@*<?<:NP<2,M\(H%>BS,62 H+7 L4).<H&*(#GK@\HM8!2M)4"!1A*,HD
M50,\\4*?L^V:5%TOWE% L(#@,P)! 0*B\C8JK;DR"J(QE$;/"/5$2CMA@61&
M%EA \'%!D)V#H#=8,&43"'+B$A4T#IG$[!,2FNA4])'K9 H3<6-/IYJ"8 GY
M/4[(KWX#7I<KGWI5KDF*;O=S(WP_"=V$VR]FR6ZXX\S"=029*^?AWI6&R@CK
M.,(EY2.L0P6:-V$0H.^.JGQWG^A2NW>2T^'O5WGF^C0\N4H3JXWDC(6SW?4[
M%Z)Y-<:]0E3G(*K[TS$;CZFVCC'D!<&(&_ (G+$H,&H]M\9IDFMBB28CR[+6
M:V20%TU^F'!$T>15:?)%](%8L$8ZB[P2%O%@* +@&@'#$)E*TA4^U[IN&JZ+
M)C]935ZM7[UH\M(T^<*#GJO36Y6;;UG!$:<!(QTX1S)0HX*-5 >\L<5-DYN%
MJW\43:ZM)J_6.5PT>6F:?.$&-CP$'S.GUI[F=%:'M.<*)5GB+#(;O,S%')N&
M7&]!\7B:O,S:;36W^?\*W="'=F7R@^^TNJW!L%^5@7A>]>UK:O5/Q)-@:?N2
M< HRS8],!R^G['[B(V;<410%31Q#J8 ,Q(@$YQ9[SXDC?&-+-"E?&)A*<?O:
MJO(JS?ZBRDM5Y0O#WW,NC3<<$>8\XMI*9#2+R"6604!Y'8)*YD)3ZH6SKHLJ
MUU:55VGW%U5>JBI/6?X,HE?"()</&')%%#(&:\2MY]A9RR1.]@+)#31+^]NG
MJ\NKM/R++B]5ER]L?TP8%4HJY#P0Q$,^#6 3PR8\*.L<(5@DAIU,?[6LFI./
MTW#F=K?#&I1M[UW+H%DDV/]\>TZLTB=PGO4T@:A!P:AY,.KME!> "W":$XN(
MP11QJ'IC"8_ DJB3!+7"OCJQ*>3:I*D^0ACB^>K]*AT(1>\7U/L+EP%-Y@1-
MB(UBR$VF7!1(2TY1H"0XFP,3RFYL4=J43!2]+WK_J-Z&HO<+ZOV%?\$:KB)$
MAE2R)Q&G@B,;)4,)N6/@PEEBS<:6Q$TBEY4C5/3^*>G]*CT31>\7U/L+7T24
M 0=G L+&*<1](OM&4(*\<LQY)AU8V-CBJJGUVNC],I,4.*EUDD*NMM^(_5[G
MS%_1Z][/3W'7$9#UQ*]YNGDOP5%QWM;[%KC:[;I>)V29%<":Y_SLX?9T#[1
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M3BR$*D"0^^_1Z$V2=O"!T&ISH;/$WLOF4C:7Y9X/+9A1$\R8[HJA0( F$9$
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MS\6A]X8'%XD93!-KE:)(0M"(!P4()# D-..6:$6]-XE"ZR:1;/'"<46!:ZC
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M_FCH<!.P/B8X_,]C"'\.H=<)+V^H"'5OL"QEGY8-B1>17B6"$9P;)+#.D=[
MD<;.HL!M+IT--A*QC(+,!0X+'!8XG()#;+W%CD:O@' JK-:"8Z_!:A.X"7$9
MW+$@Y:)(.75(R&%J960Y"88HQ$7BC=9Q0%@!MA%CBJ7(1:%T\R9CM\!E@<L"
MEXLT!Z180Y#21 &<4&-YPDXF$G-4(!U5M^-E*0K^8.AXP2.Y=H1YFL],\ERX
M06"DHS H2D-5XOG:>K^Q1=3UFGESI[044"R@6$"Q D4;N:/86&D,X5I@HZ+
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MA!6E+=!:I%2G?+8"K0\ K9=,8$J)YM(@YX A'JQ&$"J )4YYGW9%)>J&K26
M?9.:)G5HM)-:E(!U\=06*14I%2D5*14IK4\5.6RQ $(%<&ZXM0*LR@48L9;6
M>TK<#-QY_G)RB31<$.I"I.<BTGO#@XMD#:%UX-@"(MRR?# 2D#4Z(DV-()J
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MKU75/PV3-78\.EM!E8P[&5*J-1GR'I4%D!;+MS$3&77/%M:Y>B1M@<;GWF0
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MX;W5SM\O^/EP^\[G _KF\^[ASO8!W_W[]>?=YT_YF\^'ASOL*=]]_OOA[OL
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M@3)#+:HX*BJ>51S^<-9@?;'[[+I9W9=  @"_E]&/#F ^,*^=V6#:/Q[$$ ?
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M2YKGX0DLGXP#+-HLNX)%3<>VGS^8-Q+8^3:=9@K#EF)N&D,GG9(J%Z<GN'E
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MUP"".39M6>*STL!UH L7C?_$?V*[06#R3L_ZO?7!I)WU6VUX1^._9YVL,Z<
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M0/ P0+&[H/DG;&*TQGX>=8>M.;6'$;ENM-^13=#8=[9];B]Z:S]=[R-T<'Q
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MB+8[6<BQ.E_^?UY:]^=#HIJ=$__FM?_K9?/] 3BDCB6&D58>M#\$@DR2&,
M8XJ=P8'2M4VQ,;V(TP![T\Y37H& O0X#&05<[)_'"!@P;KFRTJ+6#W34"D P
MWKVEX:8[GP^HES8IHA$E/N^ -A19&AAR0COM"",P^)7*#:Q^+EI_%X:20$!?
MJ+12"JXX<\8H(RBVS":NK"T8^HP3RIJ?#R*+A#C,D0OY:&_V)P#F!/(81\&B
MUYSRM<W^>:?"T-XTB-Y21G?C(86_P:'X^752>/KO%:'#_N8<LNLS6<9')D9Z
M#LM82/'>9?/P0' ;G&  S%Q[Q 6VR&E/$,R3(=1ARG#.<K0Q'2BX;A8?RXVU
M,]*J!(V7&II"-,9.D&!(-%8:IPNN/Z, L.W#@X@5"3ELSVD 0^UM0MI0@Y+0
M!F:?T4#L'+GQ$B% X<:5# !92QX<(,(IBI(*Q)632"? A)BD\E8JA?/Y%KPA
M"C=^XG#['^"*X,0-\"6"(O!B4+G@P LQ')&@DY>*$I?H+-Q8DDBT3M32Y#F&
MQV$ 4AM$\BP82GG!T&><T(OM]P=>&1UMPHAY T:44W KLSH%Q5.@$?P@%@LW
M?D0NO&7DQN_;[3Q;4_SXEGR$+]/4J9K055,;BQRGL3R,3Z.(F"7)%/5&"<FI
MUPX0,E?[(])X3I(J\/9\\'9X"? F72(T"3!0SA*@!RP@RUE"S@5,HK <(.XN
MBG@;NC7>-KSQLGKWO)!\6_Z4^^%H*,M/L\R$3H@I(\\AI0\<I-TC(.B'A]UX
MF*DY-/-[[#?^L>VSN YXV^LW7#XHLEY9K\.\0P[<N.$6N<8AX&"O^JH-W]3#
M=?=)JX:[&O*+1O_B-+^E;7N]5FK!\UHG#6][1XWXW[,6M"'?L-[H'76Z?=2/
MW>/!FT#EJ[_&'UO/R%;T\=C%[F!62#4KN&&[,5^0.NUVY[SW[J&3!#-2;1RX
MVN90;U: F6G;TUY\-_SEYV$5J=9)-;[533\/'C;8^W"#SE<B4'_]\WDK](_>
M&;.A!<M;<P;G_08OKK\E&]6NG8F]%_5W7 #ZT5N_QAODUN_N>BPA&V!C'_78
MN[\3K#1VM1K+']:@>TZK+L6Q4GT?2Z[W*@,8]8\Z9_"(T)O:C3I;WSQ@5.PN
M4^^NS@+^K^O^M)D/!#ZMA\LV>S?O5UOU6:NVJ%<S-MJGWLAGAZ9.,)?96Y'9
M^T]%G,KT+?_T58D$JNG[S;:ZC;\R1[[6QS=39./]Y![(%4P]26Y)/7G[9*6$
MDW_#QR-F[?^K.?W B',\"4NY8ESIH$D**CD> O/2#;(:8T(9*8D;9CL%L=_>
M_[;'FG2/-C_N76SOPCV[[=;V[E_M[=VCUO:W3VS[<O\;M.7'U"F(X[^.F]\\
M@_OQ_K=//YI;T-:_X;]_?X7W?KJ /EPVC[>AW[_E2N"CQ V>8>XMUDB1O/.3
M,(LTQQ$Q9F$.'34XX+5-2M:)?'IVXQE5YMD/GMW5GD>?*RNX6'!Q1EPL21,6
MCHBCI G<<F:!\B(?4T0\IT0S#@=D*,72Y1R(>9O'TX^$%3 L8+AB8#A+OH)%
MH^%KS%?P8F@X5LN&,"$L=X@;SA'G3B%CJ4!4D12)$39$?A,:SI"OH !A <(5
M \+E]I9?>:Z %T/!4:X 3C+6&8YH%!YQQ@ER08-T2V:)UE&2)%;-2WXS!8)^
MO?E,S@H&:6FI#W0?VAHJI-',1.NX3=H('X@F@EAM)>.NQ":7''7'D\KRX+63
MF*& \X%T23W2FA"4E C:6>,!E %UUSE]<@;#4FW@->ITB:LM7)M'<35'G!+<
M6\1Q/NNN<I(!(RV*TBO%5(J5)_ED^E0T^35J<JD.M*3Z/8H4<4&$$,$BR9Q
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MI!7&]N:O8Z$,3R)31C 4@Z6(@VN$#,PRN$H^ LAK;CROL-W@^49:YZ!NJ[%
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MA>]!'PZ\3:JGM&XHWGS;L^4M_-OKG$-:DQ$N9E@X^<,X !S\Q,L@*8W+RZ/
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MFFC5)\@T0' @+<CEH+CE55PHZKTJ=TEV5A7PFX5IMSI-@^5J7?P:9YO]3-2
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MZM%O1-LJR(GSD(#;'4._AC7@-M;<V%X0E!DBNIBH6/5I#G?[M0.M-#J<8_<
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MP ?,";(=P>LLV9_BJ,O*E"^05VQVTY1@!L++I('T&@R]8P)F>P*F?TS 7)^
MD0OOPY/O#X#SNC$LCHW&G=]%"5X59M(+H[BP='V3>1N<WYKK4T.U>GR=OW_=
M@=4H/\9FGCS\?S\$:3!MH3KHC/J=?U]TVW\M+W[P0,1M^U.5CX>#\?+3D^H:
MAO#.2Y53-;F\EY; ?Q8B'8T'RT](SC?<T/@^** 9DU"WUN\[!NH0(C$N(J%$
MJ25V!S07B,6$/4\Q1T4C-X$09CG8=Y=Q7EHC61^"]=U8"<*VL.T\9/ 9ZHNW
M$T;P80:80'_2HWJ@N3(NK68AB:B1OMR.CXGAE"SE!L9:HY -#>F)L>M*B'Z*
M(5%=HB'N!1I%)??E95@?H@J9;((C+-?>E,MG?$&/8H"'!9@O\!T-Y+4LJ9V)
M*AG@P.&;7&=WE>5)]-#"ZT;F;=X;UE$22D>$R.6,;X)3VBJ#8Z2_! .=UG9&
M%-8J BO:YW#I%&OF_A5X$LU>62R3;(VS,[!U%+&LLDNA7"(N+%]?T=E^Y$LF
M@YD[[;FWGX@R%Y=%>R$<7<4>V$ME1H;AQ I!C/U)0RI<*4U%%Z4@/K006HMV
M:2CDJI;[0?6PN3294$,#-F:81%*$FDLAP,#,7G#G6UP@1F;*?C1'/]@^SCDI
MC2@END.56%LLN*DJ&.H^)P >P4_41TG]EZ;A#V%\S64)0N)7C#)/@_#C!?%
M2ZAU1O_WY"YI5\86B02Z3A[)["-I0$QBN(Y((_48,&RD*CM5@Q-MW &+WV\
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M=OS^X#.[#8XW>\@W>^(/1@=YL5\I4GW0QK[!>/]\,__A.I-#?SPZQLX._)+
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M00R+O\H"K1H"3HDB9"8N=0%*:K$MI"N9J$?1%K/56A$+CT!1I,UGHZ0S6&3
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M'::%531P3HD40?&3\ <MD3!'!7?MPY]X_GS&.)NY6N#\RZLL_^CK>T8$FMB
MQKJ>EYX[B!Y%3!,T9=:>6#A2R5;\!!;"'&,4&CMM"KJ)ZCMRU0*J9 [*4#,)
M7H?+N@%&*%C9;BQ/"GY6B(:NZ]LTN01F;H2K\B^P"2YE7\;J=QY?PJ6$D6*/
M4+E] %.>/0A_@7^8B+4%=G)E.@W\@\\M,YS:*I- -RZ<]FEM 8,M:$Z".HIQ
MT@MC6=AWZ9(+N!/3O;-N3<GA7078]P>D(L6L@G#A>KXRW(!\7ZE8-I_75<N.
MYJ*BJYQ,4AX=;ZY$?$BS+I1+<#.ZP%IV04%#+3JPMCTHI9XW1:,P5!M5O=SK
MEA9DWKJGK%,W$OEB D@2:FX"-UW>41G9X=*;$!LQ1<JUH;D"P2>46( A)5^2
MZG\=1Z"UHD@SEQ@&&M&1O  2:A+]QL]1>3\<-3P25D3DHK_:]A@;(,5##6CJ
M#FQ3[@'.>-T*5JTY$+N^BLK"9#<X@3B>,>X@+\':Q+PTYXTD662*9.2SQXXF
MYV4<E6@3 U/AL?&]H-B=8OLR&A$+"CJB'\!,PD,L40H1GX-[T"*P:!VQOXS!
MK0#R/S5P%V@FW_2$.-AS8<UAF=V =X<S%F !##D=KQAM6.O[2KF?^QGL2X"7
MPI<=[G?/M>UY&A0R1M["#^#A+KF9#ST)H3EM;OA.Y/2B!(L?]V:B,T\9Q0A-
M\6<2J,'!P6!<FPM[$X;E4B.$OK<$_7<&X3Z-X/!C/!U&%7M;YD6I$6>6/,9U
M\[W/_X/)Z>?$+[3)-P;5?\VCC*FRSM<NETHO@@M.;AL!1/SN;#Q.47C&3%.6
MV6VENJV<-S>H/BTS8E\62F)81W'.+4P4CJ*K)8HRG\9+E$8.+;A0H C(U)\U
MM1!%.=6-DA2"+?ZGQ-#LJJQZ4C3WFT#/*X_3+-YL0J$A38S4FJY;^%_<2%PX
M:DS+*BV[B'90#:65PS/6*0).L43#-PK2NA9@+6[/K"L58IV<6Z*F!,&%K0(Y
M7GEAVP?,*RQDB''Q:M %51Q".0Z2P282L-8ZDRZ%C0ES/B 7:!J7;@W5WV:
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MT=ZZ:<.;];T8T ]4.4%"V%STLP#YZ-I?IWB:6V(]>,+'UE2E"J<U@>@GE8]
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M@A^W"C&(0E*NJG.'YQ\^K]$R1&(S2YQY!9$S'\?)E?%OSY7Q,Q_'?0)<J.N
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M;\P:N\L2WJ6E)UOD#10\1^EDABMNV>,6FX-#1!=*(B_J\"7GMHM[73%'V '
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MA%S,5=DVV-=@B#D\%!4>\#\T1-(/PMFPB84,Q)C[&8)L/\P6P52LZR9^@R+
MIJ&>-*A(MV0M67%I<2"NTS;#&:1K*.X.UXH6$V/#G=2&A6NT)1$5+6,O7:'A
M!5%$HAYWQN%2HCG\;0=%/#^.0QJ)V%RK[<_N+OK\^L#K@I5H8H>D;(-PN#;]
M7G)R8</ORE53+T$*?5,VG'/B'R03(J4!89/EKE2X;OE*,XNRP;RI$*2J^Q+<
M/SGUE@1-AFSN1I06W@G]1N0DH*(/L_BJP)(VP0?+?E!E0+]P?#\R:[]/]C-:
M2H$.B>3\\(0#'%$@U6=5!/$8AN^JC?THFI"B 9)V<![IY]O\5A-_FD@<D-T@
MX0UL$-HW)65^5==#7NH]+44D$A6BN_KIY>LV8G1]0288H ,X,<PS9B8:3L)P
M#7-5"LG&J@XW17Z%:G:4D^1<;)>>1HUF3^BZ(JR0?*R<"<E8/$3G8]"L*F3X
M,'N+O&WK%5-5N$Y@L@+%8,(FCK8T?2V_LM60A"Z0R"!_,BR-IJ\\/0AM]V!2
M=Q*DJ)G'U2[Z?69_"1,)PU"R:<NH05:M7-OV488C+MIC"R\+EEO83\2$PIGG
M NT0--?DMU'K,S;'Q_1O;+&&FAJ?\7.$!4=S^8ZWI:II@GI.G6,]ICZ,EF,T
M"O3.5F32<IUCE'N6 % M8M1==.6F2<J%6 _(XOG'G$25QQ+\5T]T+5I+44VX
M5#9.*Y%Q%6SSO@HV;U JY;  UXA?%9:A=1'>=^TM79@.IO1?*$&27"Z9/MAN
M,=AS?AR4(/H.@FA0:[A\<[EXZH)'5'W0N>QDTFA>C2%)SBI01^EIA=H/:*^8
MR<F8P:P\]^S5?[YX?O'X+\&M"[8C'&QR"JQR"N5P$J573&0N<!H.C7H[R!7H
MQ$U/V<P^3_M&I6:3C?^D6*L8P!#S%6,C1#?#\4E5$SQ2_AC+HMY##*(S\2+X
MM-Y;]@*XU*:^92/"K%,/T%Z_$1>LWSN.J&FWBKF=S(<3>2%=^UW>OA5BGB,Z
M/Q#XV80%-8BXT48#?FT-])/34:^'>>0T@+88IYH0+C$@6G&._VRD@&".YHNI
MVHB@I,*N4N ,HAHY*08/Z<<)AP',M'@DR?[(##B02#"1P@_%:S"$@PTE34#V
M6NEMY>F<YVPN74X$,8MM45UUUP>Y3ML1+4-\XV/OBRCF[A<^8ML8 5.S/.?<
M0# 'DPY'55S5'7D)_&-8H>DKQ")X.VXU)WLH6*A./4UCLBM&IQD09C0,5E>G
M6GWP7X>G5G\F/S]2ZGIR+G5]\J01O\ 9_T4H_<.2)A:)'^WH>ZW<4K1WGN6
M?X9;%^OVQ$S.QY-DP_E ]&8(R$R=4/&F"&.C5J$[S\DEK%O-H \QD&3V^[;S
MR%/XZE%WJZICFBQA>_<F*2?8'=Q^]LL2STX1L^S7Z1-SSZ?!ZQAN_C\(5OF;
MG$%50D<UI7AD>H3CZ94)369C&(RTC@26^0MY@*^I)YA(OO9-&0:I!$2F04U$
MW/*&A&,P;=^_?!,EG!S+E6P5U4R*AY+Y0WDS5+KBPJH<,W+$^9A.0Q;G/@T
M(!.'+7OGX,YR#]<R\9W+\QHZVV\, 5E':+45?_N].,JYQL+Y%E20C7-U_--G
M(]A1XKZ<AF11IT+DM7R#MNPAB7NC+S@E7?9A/OF3+R^_^8A.>0D<8D]9(R2!
MD:63Q5TR-C05*XR;0<Q8&)<"JE_@;BW>T65">$/.'/_IR:/'7\J.62_^].7C
MRR\6X4VVM)B1@_*KVR\3>JJJD$0TL5__Z?&WEU_;;VW=EN\6N_"BUU3[H/CW
MKWU8,5\\RL*-GSP62VS7":O@3T_^<OGM^UWF4<;K[T^/O[I\=.?3@R\YW(BN
M\+_^K\=?/_I.GR8S8=L*^K<[R>%SLJ_CI_OVR>57>H\'&.>I:>0(M^!Y=.%L
M-']*X\?+K^2D&9II2"M(:J4H\N[ ?5"OWM*8_S4XYK0'P[KZADWL)LQ"?7M!
M84GZ\W;J]Z]674U<0O1[+(\W8<46._G3MY28*V_(9B&_RCZ_&0\BH\66P-5R
M%M)$GDZAUNMBV<4#(EB@&G)&1$&;*V^PB-'1)36O !BKTR),2/?U:G6U/0!8
M(=3\9<<Y3DML>(/'*UO(F.;H+@F'\X[5R)$7[BQ< 2$G"-&1:F?JY4@"*L39
MXW::X&ROAWQ<QHOZ6V&WXZI26?520UB1<K0S-"I)+$TF1+7<8D4,#9#N8!$S
MQH'"::/,)DCW?P$Y5;X9^5Z;;7AX="BEAR9.9!)JZ#A8EO_D\VUTHK-;('I=
MR:&>[T@ZXE]6 .OWS':XSP]R;L]-.L&S.=T<]F@1KE])<:4^0,M4KR#<VJ<X
M"3-GZ/RA+0E)G>.DF<IG'>IF^%6WQ!)@5Z3Q<FB*,:-74B[^K(:*@/#\0P1Z
M^ IH"OCF._W)Y^$M/@PD_,709[WX0Z*GAP$3^Y)/%=NVR=(-IG'2"LW:G@_K
M(#Y/T-T39'BD%+%T'O\_:/RI<13Q@DF9X)@%*"=\0GG'VZ'!-B-]GI9[M%O8
M LFNB$:K[?IU:>X&>U:CBM%\_OD\;_<U;P-Z>U=DG2@"%+X';4I0;;#O'&?X
M>0;O:P:-^QQ<9ELJM#N8(.!:Q+2W9(&.LMHT>?AW+P7_M*FNF .=QU;V5!9A
M#$@\3_1]GWP916_(O, SA&:ZA/E=L:7>KYY]DA#+42P3@J00PY?U>6;N:V:N
M"3GO3K[B7;'J641%S[B,)0V@Y4+4L5LIRIJX@:D9G*?IOJ8I_,V7BCQ.9" M
M$:PD 5,=GJ%5]D&5G(CAM/V1T^60[4G\&!^Q#?5X$OS+>>K_@$,2,RTQA,"M
M9/8=)$(9"$D:UAJAAGQV!71T(@\/$D,D!JF5DC)/4".2<CV[N!_%Q9VF,(SI
M-T]E*(Q&L0V$B9+\KG=DAOSA>0+OS6ZS(#$%'6$8-?7*$*N9M+O7E_GPWM;S
MY)PR.9Y@RE.0:3@_!7;6G')*\UV=V)WVJ97DAE!94.XLO&Y 0\6*GC.V4FXI
MUE:%01,7R;+B/ZB!=P+9YE L=GXE,!8J_>?2NXFR3!^\#&HK%=2^QWD*04N*
MXY_P5R84YZQTQ!AC?9M!C6=9'&HK?RDANX$5C;S(,<K< 1_W%#N:39I '9?Q
M<1F;3LTEJ+Z%6T?^G:@-&G'Y"253"KCG!SOC!6?Q@E^<\8(GX@6??+1GG>H:
M*>_"N=&&M;TBH!40!25:@FTWMB;2 JZ7BZT:DRFFARC&*)8_6A4@"*2W8K)>
MUS)?O9Z,H. 3+;TII298W[I9<YE<D%W2!)CR9R(MU[?="9@NKPR+GO)> Q:?
M!O3-- :)9"#W6,#5NFQ(I:I4L3]VVGI5@4X["/(%<L. D%R3IF5UA2PB<99(
MNU#TM05V-A9W/ *BS"8)L_1J$[P&'":4)LZ:D&I(5KR=S(N/PL=A!K8MMMO8
MZI@T8I^65 6V@SM(;[CY?%4P324_5!PVNE^&>97C=EUG[I=#R*!7 ?8XM$::
M^HH*("+G?@R0LR_D)M.?9X,NDLAEQC!<>/3B/Z2^#  - @RAG47'<45YS67>
MEH*JD/[HN_>&M,3*C6AWD@B,07<4F<JY&3@U:#\:]M4W>4F@3(929]$+8THU
M1=7-8DXDR9/Y+QMU@RC8H/2?8KHN%]2"2^N^4-LR^?3\EJ"'9#?P4/?TU%NL
M.; 6-KPP!"!UX)PQM1?#U?O$B2%^$Y=8#8MG'1%T>WA; <8-QG!"M4>:-;49
M! O.-8A0QPA[@1V-%U"'N?20):MZ%A([G>F;1XO%DAI*V/\38.$Z9M/[019N
M-L0P OQ&+;8A?DFP?1)#,>XP;^DH&@%L/0KN^&[4,(;Q<1+#)$!"9@&N"D<"
MC$>MKNKA694H*$/U+=W.RA]P. KG\70W@#'HE_RQIEATL2 IWES+\.-C,I.3
MJ'@[<[[-L0P-0D!I8)X[J4YI5;[U.,4Q-G$B/:YSU<1F%[WPL.29#1*NPPKH
MY>+'OJ%PCEB:L@A8') 8C?W9"(T$J[" 86418]DI-Y2Q)!A$A59KQFN6K!<3
M0RD:0@VPM&83-#$% -J-P4@;KKT-B[5CM,N31T^^O%S\7-\RA'15-JM^UW:L
MSDPVBL^"7IHJL:G,7DZ*WD\'R0GG]&"!4[,UJ8S/&#9%(D_@0<A)6^[*;O'B
M'\^U8QB4LL-1&JUKMVW,'#-J5GJ#M=V7CPOTQK9R0*SG#.SBZ03A$EW9# 3V
M<F+#:*E@''7\>&D[CXW7*SL/'IC9 [@IR85;^E1VE8!3IY38$S13 O,]"1;X
M --K[&#J*+;%JD_/?JGAT<9G<<!TA&G8G9H',X.488D8CXG6_ QXN\X/81PN
MUD2V[4Q\]""&K*Q#/]%'6&E8=9*%I:T5G%UJ)NN) ;DKQ*0(#-C>.*8(S9=)
M217LO&SFNV Y\RI.CGGSH(0;KE@U&Y2I=*J'S;3O=)NL_S-B^+X2\,.&M&U.
M+">@55GFJ[?P*\G[4&,][-R::"4X[J6NV!(Z#H5M5U\59,7.-;![FV5RW$2A
M% 2<S%C#2819)U>E*K#!N3FSI/P!VC/UP.+ ,9Y").K U38S&EO0 Y@H#WZY
MHR=V/_-VZ+P.[FL=-*1G&RPO^9.4I=%B:+7PJDD:OE( 1!=L66(BUD2/=Y5H
MO21.+J\1+,)C2@0U5="W-U1SK9OS&K@O, OU3E?HJ^J"!Z*>?='<P.T%F='#
M=_4F$.7>H4M3GJ>X+1_B&XD3LV0^7RJQ2>_9/JST'JHAIX*[C,J(G#9I\#/>
MI[L8C3P) L<U OX4QB+.AX8P9)5' MXAF:"$$_P8:.TT_)LM&WX\1R+C 6WN
MS >)4+CA;=ZL+[9U_19%H2[\QD8B1+8UV8*Y^C-G)'*&J^IK<?[UAEI0\YAQ
M8Y6=V-\VT=0FG(S(@I"_T[>HL&_;XI:9T2#9TBY4VYNTP'_D[PM_( 47ED+"
M!"U1I<?/B(-Q!^Z@"O1J.^7F8H(U5+1N)!6]N&UJ4-GQNN17ZB5ZC+ZZKLLX
M]FU=5TPB.(C$-:;$+$L4($&B9TC+%LN:*C37-&% HX7GN*"UG?&\<KL@O0,:
M4,?#..^FGVO<7YYKW!\H_W ^U.\^U-'ISIU1R + =8?M9PQ1IFG):KUP5'9S
M35:G]U:QE-.L+R@GH!QS9\?^/N=?#C@DZN%.;T;S*#24E J[KF^A]T%EUH+\
MFESH2/,D'4.G[Y]5W0]5T6UQ=Y;^/-'W.=%UWU&]6O>V4?I!BS@$6?JWB$F8
MXL11F/*IBFQ#=\F1H];":#\ W"42C+>% ?"0\'8H/%F<<%SF('?LPYS7U7VN
MJX0Y<;428('B)"+;%+F:6U-L&0"$>"&TB[_^\/+U#[_\_056UO]7_!Y6%/WB
MIS=_B]0?LGY!/EQOSI-[;ST,:87AW 3_2<X2;T'6WK6.HP@42AHW2:= -E&[
M"H&U'L5W-'$.;;C RH6%7#J,@+!4"IN8PO"2L;O\;9$Q22\;:L;L04<HFT(^
M<*81CFCP.?<YX]R",R%_JEOT/-(_^-7BJ@Q'QBIYLJ[0S MPU=.OS(G+\V*]
MS\6JZ286>V(D1TP3KZPQ$BA/E^DZ3\L]=GD/^VADVXQX^<_.^A]GT1%K<Q\:
M3)Q90X:PWJ@*7.43SYJ^+:(\C1.J.=:Q=I[/^SZA29ZC6#5]:=Y34VBL];8(
MT<INOZT/Q4.?BV^^_.AS$1[AKKV%T+68Z$@CNR<2U9!S#^90U*^P(;7@40S;
MMY=YM[I^Z'/W(/91ZGBR]#0L9-ZOX]ZR3$-4)>!&"S]I;6EJ>!;&7DRH"IW[
M>?\H"VDQ#*;G3FZA1,/CF%#.L.]%U6RGI(\XT\ QBBF1C7F+#'G !_(@^)WA
MYGRH)7*!![H^$E>931"E4F/$"*4UY? 3"BK[BJ=+M CSQ1:8L4UL<[E36F=8
MDG#/8GJ28R'[3[W=Y!?%&8R!!!%6O2ZWO;8:)X!O,!A?U]LU!%+"X(1=LAH5
MT0'=\FUR$=WC<#MS2+P)R,]=PB9'&D4^+E6Z@*4!,)IJ[!'H0@Z9RH+EU79%
M/E02%*"Y\%0W1C9-@TQE$J*/COA9EX*0"KR_6K^_2.F$.18VOF#[,TLZ&#0O
M)>W/IJB"/=5P_#.D#1"5DQID9U9O%M"B[XL<$AV3(@+:':2=C&#.)4L A/<&
M=EH* >C]JF^KL#RORSVK@X7W,D0Q%C;);UFB%\M+L/!AA$B?(]QJ':5(A8Z#
M.+P+(!.YLW"(E3XX4!H0'FZK7"[>0#73 ,Y\.*CZI]]MZ08K=XHO4))PT+V$
MRW0\IT*XL"G?40#-,[>HPS*YTFER] .\65-XAT-Z1[E,ML8SR'Z=G?$Z(@:'
M\3("HBCG+J"YU33!1)1V/Z0VA/H$I09XES%I%E<$-=?5VD90E#6(TI'C[ TL
MS0BY?FP7RQD3KR&YCJATSGK#\=TKTM+3=W=-K=IIHU3I#M?%@Z_>QYA$.^VF
M.=$'^(1$?EY2QP(]_D]0K<L6KU(QNY?YJJF+,'0UZ0 ^LZ']Y$5_J'U]D7>L
M#Q8#<A-2?AM,$R&Z-#"'%*OVQDM'],/RZ!Y_12K5]O"9-O%K9B*3(<BD384/
MH+KC,PU\@IO2"11DCD\PXX22R^%:HXLCL1.$VH:D;@<M>)0-[E3#P^M5VL^E
MV1_@.-('91H!.F%PTY9MXVY/HH2T%Z^Y#>N,,)M%F'UU1IA]RBPJV*\$P&FY
MU,H97VJQ)QBOB%Y-D3[.]^.E'5>.UT$,X3@Y&;>]V\=I^W&G&H^ZX[?T+)"/
MY8#LK@8VYB\MTGB1CLLLBH9/(Y+ONO)03>JTWKCX>ID__:W/5HYVA3P$BR2'
M1I3G@OB5BJ9KQL+H0]JB*FO?#3@84OK.Z_">Z,YF0;WKLM@L?E"BU\4K<D"H
M Q=V;PO[YZXLAKF%EQ^>0N62"+0/07,I\ECS*>EDW93K,-D CM<@;6#4>%B@
MY*7S0<AH:T>TS2YB#UWKJ 2/6 @ ]CODR/PL[,L]^9)%9@0LKC4LK(:J&.,,
MA3W\/5K*N %1BEL\.L/C9V+-*Q5&JC$7OD/L'2T"&@1=Q(:23U W+#UCF^]D
MGO! IFX?U<J4,'UB(#V[!SQS'.MA](681%3FTU-YX%.KUND.(DKS*S:<]_F.
M5\AM'=QJ<A:Y*8^=8:(FRA=ZG))#!91XVB-@0JLR1%$EF*P"P@EFNB@;J1V'
M:TF' N6!W++E$!1E_9*A]*4B_J,Y"*_9H+6,-[ R 146JEBL]: <.QQJ+^-^
MELAR2@^Q=.U6O.PI4Q FO.UFESXF^2IX  3W23F,+835? ;-8($0B'"@BO\4
M8XW^@*(Q*4W94V'T@A?:1$J =8U]>6!V&>UV()ES  '13XV64)]1S"%&V-$S
MAGFU7L55""4)X\JL5\PQ^(:X>\STA6_3#@RC#F8F78NX5; 3!2M=AP5"1O["
M:+63]K7PV#*H&A9#M6Q:(OJ.[9_<QAVZK!&O\LIR]M!--;5-NLU*_.%;,^=*
MP(G)T$R,Z&2>O $^4@#W:ZKU3;.9+G=#'I:M'"?OL@%S%INW8+B#>[4B6%/1
M1 M4<L07A<9U+E,DLR?M3:\<KTE?UP.820!:K%(ZMI=Y]99K")OWO2SO/?_
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MU:B^8XR8/TUVZZXHN@5*5N3?R[Z$B"$>A)8BE,"#WU0F%!Z(B<"@2;D(^=Z
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M2G6I9=G.C3D#[IP.MB(<,0CH9(PMQ3!#"9-S=079D6BZ8''U<>!(T, @0N^
MJ^ZZK:J0[O*.T6V+5ZNN)H@+#\RR[^Z'1_K)28?:XI[N?MJ1"GE7XMI8 F./
M%DG.,PETT[H7(WX*YX5T2<YF+<Q9CO2F,=!W#9 ?=>@_\=#YM^A9.G:SA%B<
MC_O8Z.?*>G>W+8T\65<ONHN,3 .?X96GG(V'%PZZ@T:C=&5#C>HE8SQ]&NMC
MQ5LW&KL^!_+?4J2MF[+H'TTQX9TRB>GN\H[(X'M$C-#4^5J26H3TV/+18J'1
M\-Z^TG1R!YPU+1[ER:3>2Y5N]/5Z?_Z&P:P*YSDMJN*J%LE7(P"AT1V#\(6D
MY'+QLFZ*&AWUMY-["XA'<=.3)H3!Z)E1\WYKLAX&(J%2J]7,43U"]@[HC P[
ML"R8+9TN0DG(O$%2<8 P$;(YK?]3N4!K!]D<5B"YC0$'" (@K!G$A5C75!8$
M_5FK%4Q_YTV=6/X;C9(R36"DE74=\ILR[--3GBM'G*;!%?HH*+7KUB)LT8Y[
MW<DQ@J@K5Q14UY49Y):^L8"T-$H*(R\7/T1JY+P9-K;,+HB12"!'<I[W^59\
M$\83.(=^0 0]U5XS2N--!&GAH3-AF!6?+_&9FA@SPG\:(W#+-B$LXMZ:#=S
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M88WD 9:Y?Z.AZ(0O>H+D^DA)5U=V2M/(G :;AIC,>[F,(R-+:5W\S?S@SF3
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M49B=;!$12HQ38HL'&/__,@S=9O3IPOR1I$5T%J@0,FKZ,6&>")L?BUM%V+P
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MA_PALF#7C5D4=O\Z2\B.3B=BRA)?R2;B(<9Q"86UW^)=NO('F-:!<6:;H:1
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M3U6VS*J[%5%0:0_B/I%(UV]V0I<*2'L0A>DT#5-9XVTF3_O#R^DO__!/(0?
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M_A'2L7G\)5L*7]=^2G;X;V*'4=7IN>OZNER6@(-,6,T0D+5*86H=D$AGDO
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M-,P3IEXJ*994^QMM;BF,F@/L(":9J*,I4U\S=\TMC"TJ:&9-Q&.<[( 5UR:
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M%,SKQ7UO^WH6X#-2$$BN>/V%A$'0!+6SUP&00I"QP<BD=-,-\PJHSQOZ?6S
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M"& 1]?^I*TO)B%ISB?Y:@RN'']@'LK(0FD/$*)RAE$T5.GX%>J=N7]>I1!"
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M-X]QSJH(Z5=ANBAF[YO> 8MW;KG#=^*E@?96Y?NEU:0W&7-F<L%FGHP/Z,=
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M8[1M!3?W#N!Q!7%;#RCV7A3[HP'%?I^)L]!PL]!FYSG9L5D^B1GF8K5,M0-
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MEKD"&AE8V84 @/(E5JH@7PJE3H<R0)2.&JSPE[E>+[.I]Y#LB>+F'A\?794
MQL2@I\(4!P&9%!.(B]?ZIE!_D<HF2K+RR@Y7[)TL+E= H*!+]^MVXI4!5_/=
M@*O9'5<SG,M/3RI JF<&NLG0>A&76R&. =X>(21&*=$%-TAQV9_#V9+Z>X W
M!IMYI%&1,F-4!4HPZ8#("D"21$"\M6"GK2V7R_@ 2W81XIYQKJ/3XP=2;=($
M[\_<#_3,! VODJO1U^PW/O_YV2MQ&"E!]WEIPDGG:/R/(%4TP(BY90O#EC+C
MZ]1_?NG*"X1TF![0Y50WAQ&;M^BFJ5M?(<40 VM#YO'DT9^;2K^'A.=X.6]
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MO8STQ>(8UII#?5(9QD<_&HRHE#I1A??I;O/6-M8V5J.BVV[Z"P6=[\-?.L*
MKGHHP1.8.)2@'O36?$$Q_:)U>LI]=9UD Y85M=+J6'2Q+A85\L "3*N["LV4
M@O00>?%89/[55.KI[=?IEE"!BE(>-E4(;:OKR_^^O.U=WM]<7W#P7E'^3+2=
M585M<--Y'Q_F;A^WFB?EZO0K>%2AU^\9?N']$56//T,>NJ9:NJ+Q-^V'^<9&
MPHIAA-_]\']02P,$%     @ KH$)4^I6U<P#%   [+@  !4   !A;F%B+3(P
M,C$P-C,P7V-A;"YX;6S=75ES&[>6?L^OT/B^#B+L2RK)+7G+N,J)7'8RN?/$
MPG)@=84B=;M)V;J_?@XHT=HHF1(!BDZ538EDJ_L#SH>SX0#X\9^?C\=[I] /
MW73RTS/V/7VV!Y,X3=WDXT_/_OC]-;'/_OGS=]_]^%^$_.OY^[=[+Z=Q?@R3
MV=Z+'OP,TMZG;G:T]V>"X:^]W$^/]_Z<]G]UIYZ0GQ=_]&)Z<M9W'X]F>YQR
M=O/;_H=HM%*94L*4M$1JKHB-R9'HA&7X)SI*]M\??\A:@= ,2!;&$.F2)I;R
M3)+./@DM@Y-Y<=-Q-_GKA_(2_ ![V+C)L'C[T[.CV>SDA_W]3Y\^??\Y]./O
MI_W'?4ZIV%]>_>SB\L^WKO\D%E<SY]S^XMLOEP[=J@OQMFS_7[^^_1"/X-B3
M;C+,_"26!PS=#\/BP[?3Z&>+/O\JKKT[KRCOR/(R4CXBC!/!OO\\I&<_?[>W
M=]X=_70,[R'OE9]_O']S[9%^XD]F9T/HIM_'Z?%^N63_Q70R3,==*O)][L<%
M^H<C@-F #5C<<'9V C\]&[KCDS$L/SOJ(?_T#&\72)$TU8(6&/^X^V;[EPBC
M'\?Y>-$A;_']Q2T+F%I@X?,,)@G.NV7YV/$T7KMH7(0R[9=_.?8!QHM/1_.!
M?/3^9/2V\Z$;=[,.AA?SOL>!,/(V><IC(C3J2*1EF3A#@3@OK8Q>:9;]]4XJ
M+1JP20MA9C^$A40O'K%?>F\?QK-A^<FB/PEE%X+]Q]U8SKOT\:T[B'$ZG\R&
M=_[,AS$L6\@5HSR$0!P/DD@:#<'QQHF,R; @HLU)-6GA:CS76WF%.@=]W)OV
M"7I49,_V/D%1.Q<Z[1R<[^,M3ET?41=7[ _SX^/%/4DW@^/EWQ<%5Y4/LVEU
M 9S+&MM1@0S]'-**%@:1$N.@B X2E;&W0+P40"*@$F="V91S*SZLAK0.)?@W
M2XD*8JC&BL,3Z+$7)A_? MJ<):JS)2:0+F>O*0'A,F*20!!F)B&JX+71U%#:
MA!KWXUJ''^+;Y$=%@50CR94F'DS2A]DT_G4T'6,O#Z_^/4=P(^&BH-0( A19
M*X-UQ%HOB-$&E&$V>V%;V\R5R"JV_%("&9P(Z-(*AAZN")IX:A*Q0?/$#-,F
MZB?Q#W;&<F[.D9N#8D,Q5!L(*YHE;7924HE/UXI((S5Q@GI$Q)/D0"4SJ0D=
MOD;VG;&:]>FPH1A:&\_?II.XM 2)"0_)$I$D)9)[2:S)C,1,<W \B>S--NWG
M);0=-:'UR5)72/7<\6' H/9+1!"D8,X@?;&AZ#%82IR#2#A:>&:<3EJV,2K7
M8&S:IO<0H3LMD<[P&\R6;9-)ZDQE)A1[%:,=A=%.<(X$FIWB&K1C;7S(E7!V
MR68^G@,W2;YYSU<C]@L_'.$H+C_*Z#WU8X0R',Q>^+X_PV'XOWX\AQ&&.-XY
MY8BQ'K5TEA'''%,$=$C"2RF4<4U(L1:\7;*D]4A27S+UM.&I[\:%OJ^G_0?$
M]0%0.2\,PDL(L\MWRVY0@@:AD=G"%'//HR8A<TX<TCLQ+0&@#7T>"'27K&P]
M(K645C5*O>OAQ'?IU><3F R O#^<'4%_O1.D!1-]TL10CX%ZBA8#=8-:DN$(
MB%(QC*V;T&@-<.M01WYSU*DME6IT>0_#K._B#!;Z\9*YBVDK1UA&_U!&\"1H
MC\HP!N4,3QA8M/'+5L)9AQ+JFZ/$YCU?V2D?V2PT8PC?1.U(L7C$*@PF=712
M1^,X,K2A-UZ7RK<M_I70)Z.XT$E$?>R#P*&6 _$A8\.SY\G)G,&T2=RMCW'W
M'/8'\>-^ME<33D6S.<6 >7;V;NPG,X17H)V4"@&,*T:<&6Y51-\P.!SFV:!F
MSE(1!<(PCE;<,]G(7MZ-:O><]8T(4DT C5(5.?ADE==$62AM<XS8J#010H'E
MWE T!-M.5>R"8[V1T!_?Q5L/P:XH*,M4Q/C0DF 2XF1,D*"8)LPZY=%0A^#9
MDT9A#[,BV_6F-^-+6V'5RY!?>O=7H&#4IU74@6B;3>%W(,$&CTHM96JCI!(:
M9<57P=D]KWHC:FS>Y8WF1]Z7_CO,?V#85]"-0*>40M0DAS*#)Q&2\X&29"FC
MPOO@TC9J"V[ 6H<-^AMB0S41M)Q$U4$!NK?(3@<!/5V)!@]=7Z(58TZ$;#BT
MH4+]BH$7T^/CZ61QW_-\*@:J(D2!0ZUDXB77F5@=),E&0%0VZ- H57D3R2X%
M4AMRX%9F>Y-.K^=!I=25MOOQ.]^E-Y,7_J2;^?%(*>$YSX(HK3R1 :7EF,\$
M!YBU@@H1?:/)O=6 =BE@JDR$&B*H67$Y/RY="^=93F3I20]',!FZ4W@SB=-C
M>#L=RH3=8?[=?QY9"+;DRXB/&D$"TM?&D(AW-%.?,XVM)H$?!G278J_:_&DH
MLHJIZIGO)I!>^7Z"EGVX OHEY"YV&$&:I$$I2UQ99"&U$B5[;HF7.C N63!>
M-,KK?0W;+D5BE=E363 UI\(R8!R0KEA(%:1GX(%$S1&(Y9988*@1N5+1!4IY
M(V6S LPN16"5*;%IU]_@P(_[-[OH+;ZOLS3HPPQ?2Z)QF.:+L &_]9-T30D6
M]7<=W,/7#3W@2?47%3VVF956'*VP*%^LB=,Q:Y4P'+-*HS5QJ!R\BOB;<H+:
M8%AL,QMS#ZA-=0_>Y])NCK(R5G%38E? @).+4KDN&(DR.!><#A;:S*Q=@[%+
MD5 M/MQ4/(_O][K)OQ7M^V/2@Q]W_X'T/ZAGT5#^@E:SP#R<7&8N#_INP*]>
MXMO)QW?0=]/TI5^B,5+[;(D"?)$,77IK(R569@:@:8)&>>=6+=JEB*P5(7>"
M#?53FQ>5+,,H,.2,3,6SXYQ(&CBQ(0"A7BOE*8M*-$YG+J%4J!\ [*(R.?T2
M3F$\74P_7MQ]E*3+D6F*471&#G"NB6=,$L6C%28DQW6;P7<OK%U2Z9MQ8T7!
M0"5I5"/_+S#!%HX1T4$Z[B;=,"OM/84EJ%*VD+QWQ.A%O9^.I7!!$@Q\:.(2
M V,;FE#D*\!V2<W6)4E-B52CR6_3R739RG-=OX3CLA,VX?,Y#XE(:0,IK4>Q
M1@<B!6URF_3$G9 V;>N;R0QZ&&;7;GKU::5ZPVAA-&>A3.2@A(U'+RQK3[S#
MF#)*D\"V:?8ZZ'9)@]9ASLU!4EU&=3WENQL=E"@EE4"4=NALH9]#+#6<1&&#
MU#E$5 [M_-TUQ\S3JM,VC*DHE_J>YY7P+GA@)AE#! =)I)6!>&DT"1992P-X
MZ]O4Y:T 4]^S]I)E <X3;A)V,Y6)N) D<<GA5Y%1RAHOHESM67]51Y+M>!"/
M),*=I0*/ZOB*LQNG,)G#:VSOB^D$_9@X^[.;';V8#S-L9?_J<QS/2YA8*ACP
M7RHAH$#7QG+IB4!G"4/ TF(PY3=MT!O..4,;!?D(L+ND-6M3J+7LZKFFU[)C
M()V,-BG"A"X)>4H)MI*2;" 9=).Y5&WH<T]6LJJ[C5%@Q-B"H"VD)5G#B5..
MDY2ULCZA2?1MMK3:R'78FK/Y:"[<RKE6D4!33X$F<#8!(XPE!"+!$<M=V7_*
MY2PEIY+RI_$4GMA_K$:"37O]B6;\RC*4U^/IIZJ3>Y<W;3N/=P?X2E-V944]
M/N!=/SWM\&[/S_Y T_5F\F9RBL%DL69QUITNTM0CS2S3C@8B8ED\;719M989
M<4YDZR,7UK5) J^/<>-B G^VZ/7?IP?QW_.NA_MKT4?,@=?9:@*0?:D[E]@E
M@9>W.F;)T-BWJ7]\(-"=\NT;4>Y6=4)#6=9<D18!TE"\RH+I8))^];,"Z^PP
MWPUXY)2GH+P@06+@(B$(C%XR)]3;(#+CV*]MO+I' MXQ<[@5_FU!M/5X>'.P
MW+E2;Y2C--)%3Q GQE!!:^(]"X3&J$4TE.'_[>B\.S$^L(CS[ZGNZDBP9E2Z
MJAM>=Q,_B=>[(3$NN!*H?R&',A/OT4--0&(.5',%+(LV4VSK8ZRJ]TOUW.')
MHE3KU6?H8X=/'?F2V,5_Q'BNB,P"B!,*O7:# K.927QIK^%70=NQ^+8%J^[5
MY1N+JV(Z\>1BU!_FWZ8S6.[%/ I6Y6@Y)9R7M4\T8DSFA2L3KUE3Z:5);4;0
M78@>:/^?1"/7)DT5Z;36OU\B^BN-=AIXQ&:3( 0K"TK0 ]$($DV15MQE&T,;
MU;,^QMHYTEBV''8(J6RK6>JMK(C8?BYRHBSPH-I,,>ULY68CMMQ?R/D0,50;
M%R_AI(?8+3H%?Q_#HL<GZ>!XVL^Z_RP^'VEJI0H8#!J74 UH&\YS7+:L@@DZ
M2:7:G"JP#KIO(+:JS9OJ0MN83B5O./IPY'LHYYLLZNUA,O@+7&^&85Y.^SC,
M"^\!/_G3]SWZY4.)_Z _[2(,A_V+L>^.AY%RAD%TE-"R+8X,%(AGD CCRGKK
M@(J;.[?=SEI6Q+-+2^(:\^NII%A-FUT6'%]6&I]'F@M'9*0BITZ ) @B$LFX
M15 17QR.%<\-BXVJ;;X"[($+YY[$/ZRMQ&K*:CO;6EQ5KU]F_X++"0("Y*9L
M:$@-<< T288;X%Y3IIY@IXL52'=I(=Z6&-94F-4HAQY@7_"]A/.?;R:KZBO.
M-_7(("1%B,0:MSA')A$/U!&3!/<"%:Z3;38U?0#(!^ZR\K?09:UDV)!D%[NU
MOKQ8P[IRU]:145(&4U:^!YZP3T19@N M8<)X%SWH9-M$AH_#NP[US-^>>M4E
MVY"%-TY1*S',K4.T1M@-+@OKB3#<$8DJF?@L(@G94 ;*@85M:;UU\*[#0OOW
MLK1;$&Q#$MYQC,C(9\.UM9:86%8?)NR;<H(IL=Y8GJW6PK2)%M:&N [5W-^=
M:C7$5_6(C!O;_M[:%OCZ!U>N/%_]>KN%%Z6UKS['(S_Y"._]#%Z5VMG9*&7+
MC4Z:<.[+DI88T6,U@7#T8E/.5'#>9M']=MNYQ>R_%MY 2)&HK/AYS;(S7A'.
M1(PI2 '0IHKRL=G_)][C8'?YOB+;WH($K:>H5E5*4&$R3\DC*IM1M;%%D8PD
MAC.&<6K(O-$>4(^M17SB?0^^>9)N2H*GJ&,1*DJF+39>!D#O#@-=FU4B7.><
M0P*;<IM9H\?6L3QM;O_;)^FF)&A<'G_UR/EE>.(GZ</\Y&2\J#;WXY?=$,?3
M8=[#L*P?\U=*QR8P>UGV@1L_JI*^ZO/K%-VWZY)*]?GWGIB@4H#@I2.*ELW;
M1!3$"V90%8HD?/#>FV8U8FL>65&QQ;_TI4B 2T@B"([#MG@F)EEBK9/$66ML
MS$:%1I;_?ER[Y))6X\S:QW<\7#0M-J)=IRK@[JI8K1E#CR&0(",J:NFQ8Z+C
MA&GPS.3(E&ET,%*E%NQ4C5TS#CZ)O'?*,%_D$9<KV;=FD.]X[E,8XG6ZH)(!
MOIVU_7**FP0?94C$\5@F2RT0ER(E5)K@ 6,0"\VVM%X-:5-=^@I),ST#Y.YB
M?*UHLP]*"1K+67AE:SR5T9LMBPBLA2 @Z21-FY#FJ]!VR0#7X<Q-S5=7.C4-
M<&DL*MH,P[#8G_XU7,$$4CNO.3$E4I?"HC_ I2$Q&)<%\QAKM2E%OQ_7+F5G
MVM"EHESJ5$=> +IWS[_+<U)I9!:U-U&QG ^H%"7644M"V<)*E(7EFG[-O#WX
MJ;N4#:E+BK8"J'RDUITMCU8(B)&C0E.NG$B020#&B+)1484?YM!H@X=[<>W2
MKO]M=$E%N31VI5_[KE_L1/\K^.(J+DHIT9'\LN VGR^XO5)H>?6KX?I7&_C6
M;8#4<;:WT$FUO.\;ZZ2OGP!X$>B50NUA]MP/75D]G932VA*@0A)I9"".@B8<
M.5CH+HS9SK&-7T-:^TC+&\^[C)(7N9GKM<;/BQ1A<<:+Y:@)3"3)154V;]'$
M<F/*!E6.>\T\-,H@5H&_4]M:-*7JU\[(;"_]9F>QK@N]%,A?@>Z4 .\R06<U
M$UGV[? 8]1"#QD=SKZRP;;;]J@)_IZ*/;X&WCQ?^UL\0'B4 0\N2#="9$ND,
M>LY0EA ;JA7SE(-OLR)B780[%>8\)?NJB+"Q0WO[S*8/I6O[LVF^<C)DB>GZ
M4T@X0E[/9^C2+=>J;>#!5GIR'9>U13?4._5H^?R+(QD7*PB')9C7-\&,RE'G
MR;M C,.!++E6Q&DA"(T&=)*"4]W\V-3UH&Y\'FZY_?-;:RG+JLF/B[#C^=GE
M)1=;V!Q\\GVZV&#C<#X;9AB9E W,Y\<!^A&C2CF;$@F<F_-C?:V$4DD;G,]4
M!QRG3?JN>E-V*6/=EL,W]?#3LJ+>8<^/;<8YZ,-\WL=7K=(O93GQR$7):):6
MJ$5YN,9V.98=R3D)P9,!GAL=&=VH1;OD[WXC5*_)D>;;KAX?=[-E$JDL_,.!
M"9.(GM2'> 1I/H9I/N_37[M)=SP_/IA,YGY\&,;=Q\7S-TFT57QZK8U<VW1'
M)7?E;=F='.Y8,[+<1>[E'$:<2Z$]523IA:>M,_')E%/1!,U!&N\:Y8;61;BI
M_E[W.?\'OG\]G?<C%04-@GH"TEHB;<[$>N0CY,"SL\J#:)-T>"C277(MFO#M
MIIIM*LIJ#L.Z*'_#H?[[)QB?PJ^H/8Z&D<E)N:0"R9Z6Q?D)@UXA@&@1-<]@
M&--M%N(]%O$N&?R=(N!&HMTZ$<MP^?W3=.0MY\QG350VE$B:@ 2JRK2PMU$H
MZFRC [4?"'27,EL[1;O'"'*[;'L/Q[Y#]P9=WM?=@*(KD$<,M':49:*#2D1F
M'4@H^Y-X;Q5+.C+AVF1*'H]YEZH!=H>#FXNW3A'2O6!_GSZ'=[Y+!WD&_1=7
M(0;E%AN4>%[.(HW82T%Y2I)1D=EL5,[\:T'*(Y^]2WL6->72-F3S--83&0&C
M9%UD+*.R-=J4P\84\3%18I),&,1+)G2;4]X>#/6!FQ=]NXS;CC#7S+Q<?%Y>
MRL:#/W_W_U!+ P04    " "N@0E3@?&',V<P  "%! ( %0   &%N86(M,C R
M,3 V,S!?9&5F+GAM;.U]67=;.9+F>_T*3_;KH(Q]J=-9?91><CQMIWUL9V7/
MO/!@"5B<HGA57)Q6__H)D)0L4Z+$!2!IR7VZG!))\7Z(^!"( "("__X?7\X&
M3S[#:-SOAC__Q/Y*?WH"P]BE_O#3SS_]_O$EL3_]Q]__\I=__Q^$_-<O[U\_
M>=[%Z1D,)T^>C<!/(#WYLS\Y??)'@O$_G^11=_;DCV[TS_YG3\C?9W_TK#N_
M&/4_G4Z><,K9\KNCOT6CE<J4$J:D)5)S16Q,CD0G+,,_T5&R__GI;UDK$)H!
MR<(8(EW2Q%*>2=+9)Z%E<#+/OG30'_[S;^6?X,?P! <W',]^_?FGT\GD_&]/
MG_[YYY]__1)&@[]VHT]/.:7BZ>6G?UI\_,N-S_\I9I]FSKFGLW>O/CKNW_9!
M_%KV]+_>O/X03^',D_YP//'#^/4!^/@TN?K#ZVC4T_F;^-%Q_V_CV=^_[J*?
MS-1S[Q">K/Q$^8U<?HR4EPCC1+"_?AFGG_[^ER=/YI+SHSCJ!O >\I/%C[^_
M?W43:7\X>9KZ9T\7GWGJ!P-$//N&R<4Y_/S3N']V/H#+UTY'D%>BOQQR :4*
MG'\KW_9T9TRG"&04IP$(O@K#0O"*&&_[]MTQ7WT729#]=#"IB/CF=U?%VYWY
M?DT!W_CJ"FAG7T3.X"S J";4;[[W&LY+D,L(RU?ZH3^?7(Q#O_MK[,Z>S@ ^
MZX;C;M!/Q;!^F."_Q=)V^<.DB_\\[08)S?2+?TW[DXO[P>/7!U),+M6"SE"N
M_^771H!4Z0_[Q?J\QE\73RA86XT%ODQ@F"#]]*2??OZI3R7SD!E(196$G+P(
MV@7)E "K-:>]]1]3!G4YK$$7OWGJH)C8[HH3 Q]@,'NU-QV33]Z?]ZZ^&^4
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MLA9&F+:[HS,<%:?NM4.NYOM^.PCSMKV<)_,CB[_%08?^Q<\_3493^/IB-YS
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MB<85><B2LFK*H9\P7&JN5?#':-OO&M3!SA4.2-6ZUK\:95IL5]R*[#=_!HM
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M:=8.2)\-P(]* \:W^=7P,XPG_4]^?OW6;_#G\]'T4SD ?_G\9 %56^J%+!>
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MO47TI0Z$.2 AB4 2S8%SAB:'KK7ONY;^OGGT?J]RVUKX70W)58SR9D#\EVM
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MYT;Q;&G6[$<URTZ\:::/_5Z6(+5/1N4R=%L2!RT0%]'E]0F,+$VN(;3J2OY
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M0'OR"9SYU!KG&."5L!N36_BIBL-A\T5/U8]G3=XZJOR]7:YD::4#SE!$YNF
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MLL4<$:RU8DL8V"C$T18<ZZ!-\G^'436=N8). [KP7_BZ'C9$]!O_>'A$(%N
M 1H\OZG0HW"79Z*A (:$+C- +.:+L#0&:.P ;&(.50QM"XHH/AU/DF[C_(X+
M2&(J;]+#OB0\P?9>4F]RR8>C?PXB/[.X^T6L]K&"CNQ.:Q9>ZG8?1 9AUZ1]
M_CJLHO<U_\L"F7D7L6@U:CJT TSAV^.B20<1H6]11*:"?Z5S ="<)2 ?$LWM
MC2BZ54WU6*&1W6=&1(G&3SSAT$])0\>&>%%*C0WZN'@U!N@"5,9(_K"!SL<
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M>\1EU03(.ZJLGT]UQ)ZGZ)W?@^YP><'Y2[-G^"6T9!*UH7BN, R?,<4LX%X
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M=?A"*V> [F))6W2T6Y&AK&"]E^<RLVVM\/FR0W&,!@/4$LF\/7 UH%ZD7V>
MLH7G452! "0#E)*\"9X"[_8PH8D!6C?_G\5 8.+!ZIE@!N@4-@Z[$@$L,T G
M1)FWBWG@_]"H6J0[<DB!&LP E1B0NVB*_RP1'0X'/V*M?,],\.^3F_^+,H,C
M_V>^_Z4P](?_;L/_M]MPGP&"Z=+&J)'  .&9:)]T./(_-2:QDW\8(%\&2)RN
MC/SO_/^=__^_^566D<0!T?,,$$K.@DXS8)JE;)!YF0.]3ZT\UD _N6ZZU OW
MG[%J/\B_*^82 Q3QCKA,/7!#[:]!Z!KVX(>=2 E%,@!?5M\"3*C,VF^K=4&
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M^.1]^QHD3T@POG5>I6J)FDT#2-G/F".;OJ4U>F\=(:@P1#6F"^;&.KDQU6U
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M8><8!XZ?Z\W',2\,FV4^Z:O,+4)WW4=PET>[FI)_Q(KG_\#40P)Q?T:GZAN
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MP].Z]V>OJ-SRE@%\BJN[*PZX7@&AAU/@+=G'L2#D)0Q%-QWX8H::G%5);'I
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MZ1;HE^*?>GP&9Y]FS^'*>%,;71BRRRR-?I!KL+R=7Z=Q DE]*W,NU9-SQ_K
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MU6_$K[+[5/&DIX 7QW._"$#5P?RJ/JD]#B(Z=+X5+:X-I_(ML0%NNN<&-QG
M%4+5,P9H['8H^GWCVN2<S[A*?.%E*^L+FUZ,NF<XR4Q-'ES@9 [6W1(=:3ZK
M.B5'?\,XR'3N1]K,Z+@SS"F^+$R!;)V+YQ\[=[XQIQS;6MYWY;J6$E8(N:MR
M+@^K!E$G6%TXGF?J"0GV"A33Y$\\-C$QDV7%T%22C8^#@_/9CZZ.^M*'GP1_
M$C0$9##0$6S TR 8D&BYCT(Y[*'K4]:(&?/A&FZ/Z1J^+E=,*Z?ZX0P5\)JX
MRR]+K@"&!&)@XQL;P$O>#YL^=G@Z&_ MJ;=>. ;&U/$H%LRHE-$?MU&=/7=
MFB/@6=;TD#MI!^.>N7=_&R<6X+H]-IRJ6M6OE;*)YOTQ:C<\^FE=>2R2I%&2
MRQJQ!H=N*HLP'U'E7JHW'5U=ND&UYE(U].0Y_F6L6[YDI1GPXM/5>4]I>"ZJ
M$WN<"FHSCF))([))\%C? WGT2.O!_:1S0K9HN:"IWL[TQ:2^UV!]*BSO\]'B
MDR_#RB.)A!4T*>$8T^\7ZB*B:H:S<(9P<LS*=G';<VKQ$M[&^-"K0VYP<5,A
M/-0Y_<!V$E-.9A?W#1T&I.0U"@=\0$/1L.!<2]PPJI\&EX:/>TC"E3UHO9,,
M?Y<,%XY\]ZQ*>)[S]H8;&Y!(6%=+GNV9/[=]OIH-6'?L+\J)#OD7Y(TU^B]U
MV6.36/9(G/FW'E1GWU\+*M@/E)O_J_%)4Q5QE!E5C][;E[$_SE[N'W?62*NQ
MCF[MB2Y,HU_M@;XO*LS@QI=;T#Q,-X8!4G$0JP0NL*$;,[@>):'*/M5F\F;)
M5/_6'DY4RQ!J69W/NE)1J=#"DF?RQY#\R3S3BH[VE(+W)#CG8J!L,=Q/W55Q
MU2%ZSDHQ%E27))-X\NXE\UCQ-UFH^V9S&9?W7X_-]VCCG[M'?O2G-.$V\_<"
M@=JNVY C+ #SR< :ZL#RO25K'4SD5IQE>YIL3'EWL=O<^!3^9T2 :-:]Q)UF
M/H>JB,4^W?!IX._N_00OIBV<0U\C,990FM2.)A?)@NU$=XP&97'*/>JDV*./
M;P1/7OK!>:/K?A )&S6 XJ4#6[&2(Y=U>%NLE2,WF^R%0W8)!I^C>SP$7W^<
MG)7_0WZBAE>?1HDU['UD'5A(R3H\@!5;S!;:5%15@>8A4D#\-_*-4DK:#'V/
M?3+64A)XUWL$8IX6:%<,S<&DE"]W(_#]Y,_N*R1R.390 :2+V;*^9OL':154
M1@=/P\EJE!*K426F,92HR$,^K5M8#'KO]TRIS,F5^'Z?WN>Z3MZ2O-/YN0)$
M-6C)_KW1 CH"U[Y%7!-82 /&*U[.KAZ#(- =YGU%[<BS/P*>EW7/QE#T>U4#
M?27)1:@^UM5Z.B\U9\8F9=">7DP]V@+1ZC/Q%,S'_CYF,?*\,0]9Q'UX(C9%
M9C?[(06XLD8AM/BE26SA6N'<;FE[;_DP>)B/\8.OT<XW4JP>JC5<W7G)=!?4
ME%-R<7%5V(((KC#*E'8;=/.]B];'[.RM?1C7=G2>-;C]6E][X:\U/$\6_&2+
M>'-:F:^;0FBM*,K=(WHYU:N&?IOW"[+$(?6HO9F4OF]IV]%;_F.%KC2O*9/O
MAT,NG-%'1\4+G/@330&^*J%Z$^?)%\KIW<U ;AS1T74<%_GL\D@JZZ2QB?+W
M%-%RB8ASW9HG*R@O5X/,J2-OJ#:T# HA$BDQ@PX_B>!JU<1*Q8/Y<^@I(TSC
M@NLAC].)3KZJ/_DOO7C-E_B W_*"49GN(U=\ZH^-%&S4M5W^(QT9:SKWC>==
M%2HLGS;=!8]%X-NR#V//NUE#8CUD EB*;F"2U=V?*ISUL0.3-D42H/X_,>(S
M>^(DK!^E@JG22?NKX+DG&_!]BPW@MJBD9>\<8P-*&,^PELQ UMKJ3*%NX^@
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MA2,)O'+<]%M8:Z?/;,(XX$F['_.#7Y]<+].2P4OOU9%KMEZ+;A1UI.+-*P>
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M[[*I9'A%>L'_%I?+Y*^Q[#H\F8N;7H[ A[  ;8,'65DL@ \WG8*@I>V#G%B
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MEK%@]'?7=K##GH]:,I&JF!G#(0;3 /&#7)C] WV:X4@QCU'S(W*?6!:_4-U
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MNE3;C]\;RT]PEO2(+YS*T^+Q9$A+F'\!LP#-.FHG"B8Z2[MF$9&Z/]=7V.-
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MHFGJY+:#Y)9Q!/)3U,-G?%P&OW9O7GUS;_I6:D78P]-?9LWD'&Z$\A1.-VV
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M(HUBL@E9( ",O=@# 8"?,\=K<4[LV@[#;A3W@>4^>-4,/E.H2[1Y_5D"R"3
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M'SY8JL0/,!$$F(J5M]/ 31Y@XT*5#QY-M1U>EFT#J)#;YT8O)&O$+2?^[/$
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M*K*,F5-:+'J6^/MTI)V=A3FF/GJT>&C>%H-GK$Y@LY>VC'F SO.?^J:'BA@
MW!O4<_*@$[XX6IS\C 'H,:)9%3( 'BOTBTG?IPWI(\E$"S?ODOHWEL?;:WYO
MJ-DC3F=1DD7=FA ][$ES0%)/7>=]4E+VA[SSB3H!GAN_12%756"A._K,Q)6M
MA 5A*],B^B#HK Q,'ES0/Y_,[L#_?&)X0WQD7I7SR?&W9[(#(5J!KC>6E7M^
MPDZ0/V8?30&GCMIB)Z+1B^(V+I=!RB9[>R**,_9D?S\*:YCEV%2L*Q$37[CK
M-E;D]M!^V%35J\FF%4;4"&RV37KTY,%<^&) ?2OO&D2ZA^Y&=#[,I0&?X!D
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MS7A&ZXI94CU>4OP;I:P84KCQ5T7;#ES.O4B:7&<F:%]CZI46DQCIN:<\^DR
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MW S=QM^A7VVGDMPWUL.PH6., 5^Z*,J*EO/V8K)Q=W9M<9^*4";6N,\@X7*
M'WP6<0,^4E.Z5OGBB&"1/%$3=3?E4#0D!S%% >/Z$@=D9%T<+ +_QLZ.X\JM
MWT6&!O);WE:7+N@I)D$^@&"5OU&L]-(F-!>]']^(XP'N3<"$-7<=/GY%.@P\
MZ"V<1HZCNZ76+W_ZD 3*W7EP^1P/<DW>L8[$K:E('Z6@@R8_N=PNH2>',@5J
M:Z)M3[GT*D99G>W6-+W_/#_X.Z7/O4U!_Q2_\)Z>0&G%A%D^F3DR3E(JFZF>
MQS3U&F^2UXI[3?;,4$:TP;<,MPPDMI[)U\N40CJLM,FFMI;'/3V$O.+QE;5R
M%JDEJ;6^C//AQH9VKBPR1W.6R'LV0,L4:[2FXZ1=#3F4>8XNCLVXGI.]J,T=
MOUF&4_:(T@6GL52(Q47J&XYXJ.>+7]F/14L"/<T(85BZ%"V]E/X$[MYN"=?>
MJK?1O'ZN/,3U:\F0E^2Y]>F$7Y(^U!O'$$4-DSEUI(AT,6#E ,2M&9 '*%F[
M:]X8D=B"!,.S*T(:X/7&@F]OSNJ!"7*=.L=?@5XWZ:C?Z5T_!!F5G76?Q4"_
MYV_<KZB%)C,3\S?*EV?@BC[([1\2L>FJ ._>Y89O0)+B:?+#9Q/253V$&]F[
M=H;!C<EX_07CO7"B(=7 1LA0\M)G'L'9&BP(/9*2%/KMF3"B,1I&(86_ZE'T
MCK37I?B4(.*.?T,_3UIOD$RV<F)OVQGQB1MXCVY!*P]H\RUH'Q\HAYZ&N'T!
MXDTP/[;-K6NI=Z12_*1"S2L247A+WL0=Y:BY^ PEE-9^+$.GX)GMV\-!!=.2
M&VX^KWXZD5(!Y4"I5*Q#ML*B]*UJ4J[)Z5FD'0_+A9.O209%;!4IP0(.Y>(K
M6=0.;O>/FZ)+E\_&K.\J';]]8Y2^X#>XS#_5%3.AL(^='B X3I)/#R%%'&IZ
M#C&O>]4EX4&/&>Y\_,6:"<TJ750NZMN9ASQ73TI\9GUG< ?H;3H E<8N<T\A
M0N@,C7Z"UV1-+-L\PDD.)U_H#E\M-UR>#4]$G+(RK'O0M?):KJWJW%E<B8(F
M^0)$ZGRJVY"4E,*29YI/A[>VQ:D7RSZ# ;8:.W^\BIP'KV]9+0?4QD81M1C'
M 2W:($5K+@A.4&2-(EX&/H\IA'M[L_N*GZ_MN^B#**^MOU*MQUNQG3"C]^!'
MIX>OM@A#NAM]&15 9TCPOFSG$G4 U/1_;XC\U4^QJW%RDV,L?HQ7/R(R'5=:
M&3W$$O=P]5"LO,&4RS20>6 3TL%$]D6T[.!%EUKZB=*+A:J+^J;FXS9FEC?N
M'6<3OH)K4XY7=@BF(MYB152@ @93JR 8^C2>CJ[)M+4&< 8#U!KX1;M<ON"J
M<M<#D/_)B9_\NT6G9K^_,3.J7.VMB!G8,&DBJ7:+&*T;%6P/$O-J]@<=8@O4
MN=Y@CA+$IF0AW$! X]_)SLCL*$2!3N8?VZAVA=1I K?A&ZHZWZHU:M[':=)=
MO>L9B1/-#BA/*<80K^!?+15IGJ?YVO; RT0BL1S49K)-;82/WVS9O2QV;>B*
ML-X]B9>I7NWFJ%O[\4QYDT-"0SM$4CT*]$SD^)/%1@<5*)^1+QQ>.-'6UBID
M_/00;EIV:Q<X&W]*7JB.Q)UD]J>$-NS[-IA-H"1IQ0EW[>0OS#7(F.-A%\G"
MC)JIIWIG=K[X%.D^;P9E)G[%B93SD1IWS.';Q#SHX'>'50.G\7T!-24\S'VY
MXF<+7: !$PJE=4MP,,"TR/H4_5AJ[.EGNF9T<1QE40\?T@ Y4ZV:U1<'$G=K
M/V=-5@QVOL$JL[B[ Y[$-'"-R% XB*&44;CB9$7R)% T%6CH!AWI"-1\FMR5
MC$HSTK@$UGP[_3K]>.!C>^Z'W_&I&"TP%Z"8%SE@A?^+:,N\R33\K[%T_YD>
M^!\.GOZ[%%Q\P:+MSA5BAM2A=,(J]M&4H<7K^X<]P^5JGOGWJO1?;<Q_DQ'A
M'TZ"_/QUB .U&'W_&Q)4,&3MYIU+7XE.V__=<<IU0TOT;*@K3O>^'#71-MX+
MJ:D)L#XKZ:5^Y&X)/TO NWPVT;1+&P4;__:]@@<B#;L/4Z;]1]TJHK^UN ^$
MYW[@&Y-C_Y%R_J+:,;G\)J\WM[3R]_G\7OUG&K)_8QJR?Y?R'WJ?R1\0R<HN
MGQRVI=J /7UHS;R@XR/1\PO+.X-Q*6XZ:MWI,2RV%6NJN45X)K<L>&<>O+]!
MHA@P+EABUGLP>_.8>B)DI'%7PD7R[_P%P%_?#D!SF0>@[9Y#$2%!"[<Y '4=
M]GHUZP!T6NN;[O#/Z7_]0;&P,ULO_LX[<*CJ[W0Q_0_=+U 1,#O468E8Q@:6
MN0NE98PT:J7%_)WB@,)SJ +3$PY 9&,F'Z9>VN4 I'6H@(G)C$M;Q5S_V9K_
M;,U_MN8_:FL64=('H'/#X,6\ ]!OR]A_^4C7^9&7_D[R?'=_?1LEOCCUAS6G
MW,4\\ZG(!0JK@(_MUPC9#W_^[\1._3]5-/\)R_IG86.N_QK=8&G2%CP M9H"
M\X=_#\8S,T:T_/7\2 T2.Y?)8N ECXH#4%^  <[PWX\_$N_@"F'3^;M1"4P'
M%.E^70>ZI6OCL&_$S[3;_[.Y;&TI99 17HW9+SL =4<[R/S+V4E2F7EZ<U_H
MSR0F;!_\<_Z0N.XDC/TO&_U_:;95_V#&Q06TE%X@NOK2U\J8_W/6___9A>6?
MQ"OB_HE<^-<M_/X_,B.K5,9_<P[WWQY?6:36C!4DB-"VFQSX:>2P\J&7M; F
M-2Y8QDA;C$E?OH!LU8/\P!E0%2@)Y)1F]51_8?'1\/!_Y9W\H5.Q(JYD3DW)
M B2V4<W$\<O\/=7^F1X=J=E+R:O7?_9_>-TW*:Y>R"%B74+GC'/,=\-?FY@?
M_"W=4=YH<%G._4OBZXUS04!W+8,$!5RV61&+NV-5>EX.)X X"CG\ZK-UX,5^
MN:#*ISN!%U80I>T\\GU2<KG?%K[>RISR=W_XYL@-U9Z-V9CDG5"[X_R=*"T@
MG'( BDCGKZ#+!&]R+9N<I1I]C5ALC1?KX"OD"WH>\>WJGX:X3B6EJ[",_]W8
MYU05P](ENAG>7X&;J_?64 ;?1A_:#PW[*:E]XA-!#4P(/%F>("@?]6KV*XJ)
M26;6L-K]K\BL\=\M_WAYN>D_>+"^"X-_<5>YN^X Q+V+B>LQT^-?EZG\9\?#
M^:<P9:'+TH_W-.:9XNE3!JD.V <UGO+EA.SK%<7!FNTU#6O79\*OQQ/<Y4[H
M!4C_G9V5'S@ 4:V6C]-9[&CX'V3 3IRCIVR'P(:0!.)'[T3(/,+E4IQ;?9R=
MHDI>73NK],(SVLA()8.(6UF='O^Z;_*8K_?%*(*$3[%*K![:)5/5FA0Y&7)
M8"ZRRZ%V;4/CAB5"B;MV3NY6S(UDX--PX@-?N9N<L/I5$@P1AN8O1? "^*U
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M5#CRQ\3[L![56IORN$(D9@]DN\ S:HVMR.H:A3]0:,>^0Z^B[;;A/T>[;!D
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MK R>B;$>;E._3X0DZMP7D E*C9Q];V7<? !25T7\V/)?]E(/R-L>($NE'X#
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MH1<ZAVYH\:W)XO8_HCG::3*3Q""*QF)97WGE@'$M])Z!BX!5KWJ\'\M5]H:
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M<6FH22F^# ]1F#@Y<*E7:ME"D$4FH6[509'>-348R11%KM=/G*%!&J" =?5
MU5-?S#0&H9NUPUW7+2O6T]PVO&[@@?P3X((4V$JG'\.>44&<0)D#CW-1\@.J
ME M_!KGR=?*M)]J"O'3GZD%&/FO\H3<DU>N43V31-AEP[_6!K9VA/!FQ7;1
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MWL+E_9GH^C3Y1HRI\L)5OV:NB7X*M,R@SD@3E=$H?,RSJ.8T/'V,HD?E3#L
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MXEE+OJE?1R+MV XCFDGHQ+QE0EJR\5:W<O0+9P>1$V=P/IGR6[^'V-TEP'*
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MS-#=KC3U[QPCSF[2265/I>CG@[SF)@&Q;G&!?N>;8:<I'L62+-C0[E(-@\K
MMK:9CIHX33#X>K18K$-2EO@/ $#M@A^=(=];+F^]TW69)F&A$X7FU3?9$;?_
MPT*?_RKN^5^Y!FHZ3N$9EO3<;/K )_Z;SW&'#5D[FH/4JDL5$LI6]7>Q?=GO
M_^SB,^7Q*!@>3T/(QFNA.IS=6P48U%D=,]D\,UE\'IG5*9<VQUG;[]WP"+?[
M>E4HS53ON1+M!Y^V^GI+'6>>-=_2P9"#S_T?^LQJATL*QIVLXWDLM?4]P)^A
M2]U?XWJTEXVGZP#^KK+#614XN]"#)O&CI[_^5LVH*9R8VC54!@[(A6#U].XU
MAEWD^A;_.E;_V@"XO_DB_.\PS'A"_FP*0V-:3Y+;=P7LK[8KY&!.M>UW.'\G
MWQ0)Q&HDV?>^5 3<W[;J?+5HNWP*1X7?WEP]A6<&]!*],0(!C0(BF2)!"R@6
M^Y@"KM3>JFUQ!G='6\!3:[&@MZY%/"Z*%[@&)"#ZN/FX[_..)A]=$FT+YAP-
M_?)/?,T]PG?R+K/I28A=F+&G<;=9.&<F]Y*K"]F*".W'%N#OXT1#@.$VL;]/
M>H>V*9,#'RO2WN_Y[9M,8%"?3%JI -S9HEOU F-9DCEI_2QT2T6?0[!GIO)"
MN)!UH4B]\FUS?0\!\\/[:&;R?5QFT,[-VK\PZ>RUA'9[.6+>2!71>5KES7+'
MY1>:5T/?S=!Q"2W*:Z\NK/I#5"TRQ&MQ&B&K^(>ZO\J0(@DN$T6+.?2_(;1>
M]\O:(HHWX;G'7+^@$-VTCBN;PP[&P+)'+N-QCLXN(2M*ID%R^E**M'?.B3/3
M T:<R!+9ZR<AI7[@G$ESJXU.YAQWIE]"R7DF[U*^,O8&'VMO+;@-5TOX$T%X
M^ AV( ';,"=@4/>91&?>]+>Q.%\+'%Y:4WRW]:;1U]A['P'/9 .43<MZ48EC
M5 !'Q(3.7-Y^)7(A)0^!"VU)S0_*L_=NOHS;7@G/_>FG8E [G.4+5N!CE/DR
MP\5?=,$I\_):5*GE)IW.3^6FN5]3%J#31-7CTM'XGXU?9WL89"X_NP?D'0.=
MV^1>#5,5R'-4%\8=D6^E;G?<W)4#U73[$/3NP8'*=SF>R?1<7T$6Y:9/(R8>
M&M8;("R?Z;1IT)$OX*B E[6CJM(+,<Q0R/-:RTI+!VZ#II)?D:N,^"PAN]$)
M2RVVQI#_8Z-_S\@/#!(V&;7)W-M?/LFX"":H([)>:+$?T@7^KQX:_%?;OSMG
MQBL3!D-!>R)GI)MP]IVVO ]7)LZD?&U0AX:LLT[1T=-B,_F3L? ?9Q<M3XTI
MY[RTOGB0),.QF]2J$^,"\]*PL["77-E6-*A5@/$ !=A4EQH].-Y9R>PX*2!4
M8V?K?W5+)_":6T]G!<^P?F/M%MJ?KH6PP7_/L^.]*K&^I#F@V2N\2&4^6#GO
MB^'#&^DEKRYEW>@P[WU7-*#H(JS-I:WE<[BZ?9KO,)V1F3]'9B4.@G]L7-2T
M<U#\-"9<-]F0V?=('>2XYQ44T%O^\2S2&"@<B*#M0RJ J-VHA9%6UA.D].&U
M0B?+$\#LLT,N3C2101E:8E-3W5MY1Q+F.[](H1+%Z%(J@ =]J*!JA$ECX89:
M&_^5UVW<5GQ5E?1[17V;-^R%_U&K?#M9FDB3318?3S"J&#LL-3[TX)%F/DZM
MPNN:38_EVG_=BOI !33=R/@DCF/6.YA^Z$J?H]L,V7R/$J'@U4PD*#6(;%*,
M.EZTE8^A W2M:I>_=/Y[[B9AVN-$J\]A3SMN0R'^PZU:8^W9J[]Z7A72'@I&
MS!#MSN+N&='P[/,!+B1!?JPK)7M:.+$165(J>XOQ_+*1IL8#]<0!J/5B6<JB
M]'FH76>J1BCY$:)@LSZ38.,Z,W4GP2Q363?5IZV._G*5366@ZZ7%ZH]&2KD)
MRY3ZLX#H)[>90"RI@+P3\Z5(@2M0((65"=P^'4,8*#TC^-:S38-3<J1R\?DC
M#P.!Y ]?U=\QS00NO4T$.H9B=0+NJ(M!Z3KXKXZ]KT..>!;?=G(1KK0U3;K/
M5LQVIX3F#3Y6I]KCR\LOK[*Q!.N7;H[Z'D;#!\2#]'O#71SO0\;9 K@?,K ;
M7:9OV0RP6(3)C_!@BZ#D0>_37_4R?SMX)K8HFE\-&ESF9HX8[;QD9IK<,GDT
M')RE%Y+#JI@N0NB@W5T?:ZHA;IX0.PR3)&3Y-4:,+YTQHN6]UM)Y-;=7S9R4
M\0P.8N*BF*JP3Q:TLH7_=GWPSIVJ&.YUI@(#7^X/*[R5$HF\<=\61:_3L>5M
MB_ZI_D@II*#"51OCEFM2X5'PD/QBTCVBAB5.)UI5XD=-CG<^%/DZP;+!W945
M#"ZPGS*CT^)1D-/M2Y\-BF_!U@%IX9WJ'#A(!Q-=UQ&_#'[BLRHPARN)[U''
M"7HF55<H?!'LS72=_S7SG_/!*@UQG7[TKPVA:*V@KO'FJ[Y_51^YOQ4I9,_H
M$IK1N:4][-(UM*^;0[NTWWTQ6T8OMXFS%Q%/0OXM\!%%*% 0.!!Z!?KB- C&
M.#'(0,SIABR,I_53 9^N45AO:W^ZN#W_&DGCU3^[C8YICQC'%VPY8$!L1.3S
MB8-,=B*ZY9YC/+VG/LO%S=*"J8U[%RY;V0?^['T1:.+R06]II6DOXKXU^/7]
M/*^=MT2!5F7%]LQ+ZU9<N,/X]1.I% "R&FDL6:U3S*K/JB<4KR>4,-YX<9_
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MIIHFK!]?H^@/@T*'C^/)\%C'JWH2/<.%L3I5.3XEN<YT ,;#P3ICEF"8*15
M;P@6)/$8#VM4>M)[D#=JFA_43[(=XSYXM\TTFRPJJ;J]C!^6R$=%40$'!:[>
M8\WU< YRE6H[5G$K9F$WO'XB3#[]T4O\Q<Q2QPECSB%',X.]&0L')$><Z@M]
MQXT4[=N"(7.UO$OG @R(.B0AHO4"%=#!!7.VQFIP$(,ZD,J^ZT@D17 ,/B>\
MY;2V,9STP%LTJ:CAB;]L[,<)Y-#C=UG'.:<.D+X'"1^,$6,Q])6G460&" ;!
M#G7$DCJX0T,/^Y\ZXAR.S.*FLN?H^35%,HR,LE1F*X[3U/;HSUXN$Q5@4\X(
M9;!*,!]3U<-2 6'3R*GW%<AZ?->OZ;BJP.<<]EC+HB)>QFN!NCT#].P;9I"H
M TOSSNG!$$GIQ]/S,1>:.@]_:/,_ :)^"X=->_M 6H0B&0_9&_0>WC:5E(2T
MH9,R4ME%):9V4>ARLD#'<> JA7X;1]CHK9J"Z2V&5XG91EA*/ZJ=>$I05A&*
M.*Z*>/SF4["8OHN*I;_@_?*"M3)%S#^.,+#5T0V>N>;SYMTY8,6/?"U-CU^.
MS/PTL9GN_R*$>\;R@UW_F+-\J?SX"A60<@*'D =5B7$D 2*P.T.\&2^5C)7F
M)"M/R$L?T\\1!4R=54@Z-("!--/K,;L7:(]$:N<4*?2;"X,L1)V.9I8A57-L
MOT K1;@F1,W< %D?L)0!S34V'7>X]2[8W]:3!GR1E]&DR4'CFER3'=8N#,;"
MR DNMD\R3CZ2U8VX =UA##A_I?,SR^W*1)JX0-^7=<3>K-?D9V.J5[T)G_5/
M937Y;]6COMV:RBM,S+GO1PHZG_NM#+"J5BQEYF">@YHM0_>:HN(*Y'972H\:
MS%>+2(-W<9E;=@*?//L%7H0N@KHD'_+=PW*-&(RJ&@M5IEB_>?Q2^R9/S@UG
MB;A8W?(7Q#%<L@%Q&8<VQAE7%CJF6B47AHUC_?AM(A:*ZIM;!J(;])Y?$O]
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M2S=C!\7,W3E?9G+<\,A1X^W/)3W=D?=_PV3-,!W] E5I\A)T&EX#VVM&Z9*
MBS<)><*.=K-=LF1!U"7 HYZ+NG_<S8I>$4$<V"/795UQE61OGH0);UP/(&.[
MH .4?Q3S.L!>$"=EE#A^X*V]@XI_/AO01HK;H41Q?%H6'?AG(_V?C[_W<J!R
M"EJ!8R<4RW-;P'MX@+E+N38%/_Y18"\8B?A/-8U64>'@E9N$\ZB?%"\>((^!
M=HS[[W^9@<#YT'X@+O(AC'P((<PDYL%%FD3G(O@<9?ZY.XE;']P.[U.;#TXT
M-C[S!JIS8KAMEX:A]KHB'-PD\I-<1Q1E>P5,J(+OT%T:B!+DRY_('B#! :A9
M^OI!0,;=0XFO=DB3XL_$/SIS?E6)\X0UZ/=KRW8@5A4%I0%=YFK>.V.;EH'%
MY";@"[+X8H401M26J3/CV+O>M6^SE#1F6]:Z1ZSAV,/(&Q-* OF"T4Y*G:#C
M#A>)- @*\-"UY=T]RN?>TZ"'DM9#%G-P_>##6Q[CY(5VONM[SJB9O]U:"$^P
M&ZS/*:6*B).UN1_S3N7?,G6^"[JQ1^J&8'&@"UL/1<GO<>XF-R+/I5Z(I*A5
M%$M,.&K>_A5;OL>T/.Q'@<04Y*S_\.+S/2<J<ET[? -"86RQ!'96<BLAQ]<F
MRH*[GLS,/$0L@'63/GYG!S&=,MGW^09%A0(6'7,PH<PO T92.>=[IHH[<P^/
MA;,T:PY0A'8^/O <@7<1&'S-OO?C*!-,PS&*F&84TGPA>ONO(.^( C=K75US
M7T[LAD:H:@$^VM[M9]E.I:<CD_'F-8@G',P4LXOE#'_LP=2'9/U*(NSY+,%5
MH;'+;=MSH4)UY6TU-VXI_NQ:>3]UFYUE!94C.G/T*)@%#[IY U*@MW)9 IX,
MO;VTC,7*F9G?'E#39Y:M?'+HK#.D6&U;/?*@5+_U[ _K7NHFES[,*2:&%&>Z
M6-G!P^9%$C-E."P$V1EITL(#".B#67JX>E24G/" GZU^<#$<8]J[_L5XPBK%
MB?H*>WTH_DK4IFV=VL=#MRX^.FMI$$J)CN+S02N]4G?_3,/6-J%TGZH)3-]-
MKA2WD2M(<XG4-Z#F5P(/>< RFLM^(>4&UR/4*CIV65^0&K;_M+G[UPX)TE/C
MO?DR1 D^8F#VLN_0U['19"C=Y87^Y:2HW#$')L0VQ*!2Y@(I[$OSCX 3OAO^
MZ4&T,_WJ_J:JU=DKUW5, Y5*TD;C6D2",)S:0W-]U:FLBL'254_=/;H+>JR;
MY@)1"EY4C%C9E1<:<=,YNPWFR^G)=<MAF!U$E]JTJ]R9YD]SW'/)9F;W5^L'
MXT<\QI0(=Q](M.(_0;4J:I/43Q_Z]NW0PF'@0M0X:C];E/ZROE@CQ+JKGG#B
M<^WG-*<4]?.#7:2:LU(M3PL.[APK"C$M2: 2OXKL0SQ@>CF/=P2N[_9<VU1=
M.JTM"YKY]J7\\]/[RM37^TX_=4G+>@PO2MGPK.Q)V30*)B/3S;)#8I+*:WOM
MT#S =K<F'L"N) 4#F$5NZR'((GN@NX'U4$']6S28,5VG$)28#RF&O^DX40U3
M$,!K#$M/^>TX-_H9<(6KFA6,6M"DV=1A1-CR]$S;'UJP3^ZF5#./"[:$?JVW
MI3C42%/E"#I9:;IY8B1E^0GPITA=D'D,7G="U:09<P!A0R6+D)N"G8OA"5"6
M)T7<AW5F5(ZL&/7@Z<?/E/#KP3S 2V*Y=2BMJUE.=V#-"]5(?D#W3+CCZ"II
M]RK9#)?^</0T[?)-9?DCDTGZ1YP =^.1G1;VE8H;*Z25^%EOE]$JI>5Z!_$H
M5C5VLVESR-\4D<S2RV4KC^Y@W&>F2ORJ@!YT;1]''TB$OM&*-SV!T90+%=\5
MC3'9,5Q9&6/?@-2F89M@4<@_^O7M)1(F@*(DYLT&?\+N%D8Z/XZJ5;"N^FQY
M=>2[FG15V=(M5H,^1].'=9H)6F7XX)BJ/CX%YI3@8*V*</I4U&+WPFO3(X5'
MT7?C;F\7_N[3DTJ%#IE_'3O)E*'P &').RPK?K!!52T08FG- ?*P.: Q0/E4
MB0"^5,E[CU.3VZW\JS"_ )@I) 4*CASLZ2G_T1D=Z+0;Y^*,NEVHGMQ0-9)L
M5TX%[V<:MU#4%XUH]C=H)G4\P"&$1._ZJ+N]$"G&H_%AH'9>RO&.@U4Q6D7;
M,:D^7A_BXFK=@+GKJR="6=N8ZJ9T7#C;.8_92Q6)9-M36$RL9R56S(,'\'I_
MW!O\4"^3-%GJ^?J@[I$_6KMZGRRS*B5K8$MEN'G2^L/5FN%6Q!(/,(ZR.QYY
M,N_D[VTE*I,%6P.$J]B\5O#43/NZ_K[!!00/<"$C4F5.1."_-W?2_]=#A022
M17U+S>4!2.8<J7ZJWW_<A0'^MUT8Z%YV;'SD2>P[@Z__Z#/K>M 95&L'8AL/
M4%(SPWT=6<^L<Z&"HU$5!KGU+'/9>0* -H:AE&+'S"A1B15]?GL>?':UL+Q?
M9'F6\6#\,53@B?P0&T(;O$8WC\4?H]96+TWT(=0&S5P.JF4H@[HEWW#OGC*M
M7QNV2:^>O8-K1@^U-! /8]?2[)9OT07#$)!L^087*G#OG-D]U,'KAG#<4T/C
MEHNYTF>;S>Y3.:3"K-'! G]6&N9;/R183T\5^2^I?:=00'@J5:DAN!A&N?6R
ML0-J@3&ENX0+)U"+KSJIKDEL]%PI]@IJN[FX-^=HHXYNX6OX5[G<'#BT"5B.
M;4&]K'%EIE$Q0%?'<_&,]AN]^K;P9$M#GT.U(ZH=^7L)5G<_WI0:%Y2%-P?P
MS<@0^"(-5[\HTF GD8J%?UDG'OFUD2[?5RD4@5T7^O6BSCF%ZEQWZW9K^_Z"
M#PEU"H.%"%5.(OX,GX0MX25F 4V.6O3M7QE)NF/J T"+$)W13D<9KZ\"-Y]J
M//[Y;?3Y8XJD&[369GG)!(*4'&7;?[3R<"ZW#QRSXU:1%A:Z=C,#L7-!(@M$
MVM'9E)BQ]S#0T4MNC[V47/&_@#=J^$P@_UAGEQ7-I\-E3DZ(OM$H*SDQ&)7!
M;)DPV\:6IQK85NQ7@O3IUU[IP"NKM=99]ER^?M#H\_&G5P1]#JWEI+&TF2[7
M:,!0O.(A1M%P0%AEQ6!1=F"&INEY,X6Z!R#'O=Z)X0>5OQ[9T#ML4V<@8D(C
MHY]<\5[?54E/6UQD?%@QE89GU42;''WQHCX/X#4B%=J7TGD#<WHDH*)XKE\/
M-:O!?>=N,1,5[ #M65?G ;(O;V(88<Q9ZCQY!UNDQY/4'(>6GE6Z-:@&.O*S
MN+/J5]*/<A-O_.Y0_;H4HZF+T<)72EXR].BXJ-26E.4PF!8YRA>NSCH'*_(#
M1YTWC=R2^7C4]J[D)953&C5EX0UJS0#1!,<O$^"AY'K'L\P "G2OPZB'A C%
M]7Z4T>!:;:]'P>VRR\?%3#1.;HM\]MEK^+KPV"Y%YCG6>5?@KG59$YN7]G2E
M*+9IWL6D\GFN6K_,C2]_J$C<OO5MVPVQZX>,KVN^WSO7;?V^1H<[4Y6FFCL:
M0C(!LZM?!&416/,;&YN![\E_F_XWGV5OZB273W-^4T\X!I6];7JW<]=ZV*74
M\O2/ GI1_A3?X1KS&$SY]60ZKM%NUQ?=:(33>(>]$>YS)0Y/"\^K$JOP/:A6
M,JUS7_,P;;=<=0%F'^H!>2_B//TB,X5E3[=I%!%K$DBJ&B;&5+[L>U@9;A@A
M_^I WL>7 HN=&IK/?7]G *YI(B^EQK/6'.WG2XO>PY38;62$%71S<W$:83&!
M?H416]2R!:DP88TH2>U:N/;):;FC?6JJ%6@A,\\-R)&'LB<KXB'B*CLM;XN_
MGI$5[.:J,;UKDA=9E%%O<TEFZO4K[&-J)0-)-<G);J_4/D23WI!X +GEM)43
MR(> R?M%<V#:=?ZCEI,(B@%'(8_JAB=^3PEXB7[UKH*CN"%A4Q7Q^JF-DLP&
M9^)]NL<@PH<F=)D^B,;+3RBOA_A"!MCG9.P+9P.B]@6%E6N4DQSR+RI$1&ZW
M\NHTK]K=U!+7A%#]@J!2JQ;6/5:/3&9W31?S  E*FP[(5TR5%J H2''8M0QA
M0R._XJIY^-/<+;[K&^;=L7>3DT@96DHZ^_V\A9M"T@GKO5F?E(YUGA?IVTUZ
MXMX2'3W8MH5FBV,H2_G9YIGF5/*K_91LWQ-IE GJ"2^P:4A3XF+&@Z.'6ILY
M/ !\1BEER\6ZN[.0,M]Q$NI@*Q-E4\7R*S7TD9A4F3[FK()WD3]E;'*IIT0W
M1NUVL37Y,<>&>BTE#?*EAC]Z<#. /<^,HVMR)<9JZ9DWS</)XOKF:ME3KND'
MZ))A"/W!)(G2V57-%GW?<$N(8Z&>E^#4+>E.HP!^(.X2 ?: 13CNQI4QPZ@H
MP*^-L>W!7X):&@)0#S]+TATW-9JS^_')MH;M8>32BS2IP9_ ?5RY6?!>_1T?
MX9<NB:.<71GY'CON_.%V1[AD$B!4JA@!V&XZ;B-$6V4XTG(;U*,=3S)C,LGS
M2E;T[=_+9W&2HI71NVPM;0]+-=Y[4YXSD61@7G5"J\]%2A=>R&&XN7&FE]@]
M1V8Z)!6*E6 U]/G)C/A-C#K[<CE=,@)\CP>(#A*,T'<IF=MPW$67G4Z#%7#R
M5)L_>NUHF3+Q)_F>/ Y-U8\O\&T*#B_T*D"H,=$L$-.RMPDD/U"Q*E>&2W ?
M#C7WR5NH6!5?%/ 22W1:F?1Y%KG&CP==4$*.<'FJ2)A:5I]:!5:&/.I^/OF=
MQI[C27X7QDRM9"Z^L:P-/6"BL);9P .4<Q,S(+05ZD0CZ/@@%G$ %^447.2H
MV+AQD;(7/ QMW\G(KU\D1>^;3LR9(!0;+[/:5'4W.-0$L]DR7URF1_+6+WCR
M5]1+$(C9Q.>;?6QGS 0X4FO4UQK/_8$2N=BJ]DSV[?O\<A80J)N4O:]V8WO
MW;B$[TQ2BYQ.ZM>QTV9*S79)<04\0/WL2Z/R/L7J^%L5.+=[%J)F$T\ 5=?.
M[34VG'>L0=TC;T/56_OM[&?; L-C> #&.]HIC^OZ^MX!FZG<UMATERZ<_P@]
MVN<VL$)W8?4!0L0K8];.OYBJ!Q9'7/U-1C]5KMZ/M8WSOG+F5,6C K4 \<16
MQ7R%S8_.SD^*D:NY@R$)@S.USFVFJWH; 3P SJ77:[AWJLPH!-R0?H*3BCR/
M )>B(D%*],&7;,^-@90D#'6^L2;8C5(5'%9==<RF+=KS5#?ZS2Y9>$L'W\9&
MT-5ZC?B\'LXVH?O:XT(M8^]1]U^DDJ[0*@:ZGI0VW^N),E4HU?AT2_'9.6&?
M'R&5M':&!0W;@)(TIP;'P)KD= >178J):3/1?@%]]M>K4,3]G^]N5QX7^Q?7
M.+0Z:L+=TT7;L.K)[<ZEPQIWT7JJ$Z[3Z'1Q'4P6@=K&Z-8XL'=R LD#X'T3
M.N[<M(S&F*_60OW'BAU;A=YI]<X3T]%051Y : CG%)%@_)D)91DCNXFBQ0@(
MU>'B<@-2IG+@?O=2I?[/$?S X/52B%Q7RME($67?%6_O:JPR#=,$C+#3#P)&
M5["@PY!&I-:[Q27UA76TL"#MRZ1GFTNL"KSUCX_7%N*VR0,FIL^RXEF, !KC
M(_T>&[&55)&,LX,RC/.SLGMX@(=S/UX\N>FW[=*T1E%,] '!W#NT(),%I?$8
ME9L58O#,EB!,V.GIV&"HP)S<\20OX1TR@C%&U3*1A8"+Y7'S<4VG?!Z]MQ^R
MGWR3C?JB/5]^PM(RBO OV8)I;IP-8[EB"N8@LILL2S@Z:T;7; )M^Z$OS-!)
M.HQZX3W0 XF8QMD.!^><&KO/KKO\P*L^_>6Y?D[HPG(%/Q0A@"K[UL_Z%5\5
MD9T_<V?NAK$\)-_ZLLA)B_JEHVF9S][;0.GV#&M:2Y.YE'HD"H>W&5\,NB+6
MR=BHMVN87<PC?52\]QEP8$Y7[L+^6,VO+68TFW'T2]!VYGT>H($KP;*<M;%[
ML_4V?+:?G93L[616\-EH+T!0J2^E0+EY@VM=.[IJ1&YCD*;*+N9MQD-J4&K6
M1-VMI:'5C4@B!<:?XA[B$C^6,.<!=ING\?\LQ7 ^\@![,"2=Q5'?J4VPRW+:
MYNAB[+ID_7[=EIJ6Q3#JO$BT#D&$T.>-WW90Q(.2MZ3P*:4#>]LST=OP=..[
M'2(UAG+K:YT)M"Y(-^$$_&7+@2[_X:IJ9[=[OOMB<P1B1[[=^+!7ZLRJ_;G[
M9Z5V$,$3(D_/ Z/QME28J%G!_'ED+I;IAE=]M(6@-Q^KU-#<C'NH87VG>C-"
M7FHSN,]8[4BQAW<(NV]Q$]M8K0UR#H8FT!X1)WF '6ULY\(6EJ46>#\(^+,(
MM6^MEO6$+A(9KW[J>W91P?R]G/'[-F2QPBN9[3$F.Z/VA9S)=ZL*:D[SNY=G
M5Q=RST_<T,?#5RI>.?/N)?G"[=)7% [ CPY^3P$N[,^%>T J>I]@^*;BL%:'
M1H> -<,:>?KVAS!!H\NW ;?DGMK\X&K1WH!T:8[EE,+4^7FA$,LV>VG8:46K
MZAB%B]'?OA?MN/M>3*2GF#Q46=L_WS\4T@ZQS[6OQ>T=F<]@$SLVN5>_;2XW
MV^%1E?*7:+T43F0+7WE$G/D!9O[QE:(VN[:2JL/>NQ1#Z*<J(O4_]SVZ_:G%
MB'4J4(:@R2EL9P6P3\O:+P:7UK8W(JUY )B*MT%AR@\>X*Z77H.=0TYJ%AO&
M[,YQ2W(]CBLKI]]O$CAY_M3QK]OSUK;7_"X92'P!4H37L!JAM-?PVGJ<799%
M0[$]T\G60R7$3=3_F?^SZWRG/Z7@I0!LSNFQ6QIV(]=.!:QM>'F/CI)RVWIB
M6[6X4XHP:#!*+7)@U7R(3-4-!>WC=A .T$]DYPCQ *+NON[GK4/=,G\6-Q<6
MV,=<G+[BY54?TR$EH*MP?%+,.' 9(3C>#MOV:TSK=^5R61%(_[J#L2QR>LPK
M66=XK_VE2;O3CP]MEDAH&,:=<WDL'NU,.,]YQ5:F+HNY'NY,G! Y M]N)FAB
M)G(=1_,O23I#&LY7<CUQ E$J[S.ZZG5G147S-N?%$[0H\[Z#D!VSENYB5^7!
M\KIZKE)=S,1'&_]CCX[4NW&]7<XCCS1KSG8:#QM,?1]@J3!J!OM)[SAMPU7!
MQ:/K_:2NW(POR>0A5=3+@>'E%E34L'J3F8E)-:TE5!_L[.=!"38PW&<7GC&H
M9^W1.J'?)'JE[_++Z:/+G@_V;HGA-2G$!2P/L'>FV0[U"D6!L:WI)C\W>(#&
MPL;T$RR':%9<PD9<(*16!B<,=Q:L#$[SR(B$Y&Z2M]ABQM[LCD__:"_._R$5
MK_Y;Q_^B6D5\'Y\JK8941/@YGP+08S[Q#4#?ETR;'![@00=GDMW%O+'SU*EE
MQC7RF/EWOG4##FFB L&:W(/;KD;6<A)T-Q)6P123?V\&6&:4_/M(BW]KOW P
MKY#X;P-1?\W[?^*\V/C"!?6%=T0\YAW_^:(M,UU0HCQ UU(R#X!ZP -,^*V=
MNWX\41CEIN)(SI]XJ.5^:W+2II('N-2>A[7@ <(#Z$ V=Q:UP3#GZIJP-8FO
M>("9#0@/0"Q#T6NV1+ 48IJ<;K\*#R"O7Q.Y#OR/TS]!->@QT5S4$R*+I<0#
MR&3.,V$SANM7>8!O76H97TRXTN1&U"HKFP<@#X&9HT!:)U>>!\",JG.YK3Q
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ME]D\$.)-7"W_+\D#^AC.O0RTQ[(7^.CZ'Z[V#:KA,AS-15006>M\=#V"5<M
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MC!QY)VQZ_P_![>6@DPC!'TAE9GD=Z&3-E[XUJ"CSXCI6:_2F2=+9Z>'Y*OM
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M+8F6;R]]<<]X7S'NY"- IWO!F 4>BL_H"4F-=R<KK@RYGK*VW"#(/2"GF.;
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M!9>*=\Z&"M[=WU+?Q%4[V-[VVWE%/W(%-CS?LH5IX &>#9?_NBF#$O4(T"$
M>T]8)!QJFFP'O [.J#V[87$;7)$<54$><F% ^KP0!EJ']9-J$""Y']=*\DI'
MK@J<.?=PW'-G]D-OD/&)#,L*1<7NH4 ".3H$-FD7,R5%#H'&+V]NV7]G\ #[
MF=C+]/2WVNHB\X>1M;G2<L<"<D85&^U_)/J-O8C.%Q!]_URY%$Z\B&E<A7L;
M>%Q/:+QA']7Z)*PV>K1EVUFQBG-C!Q)B&IVTZ9@%<RIP)UN1.43%ACH>H/NC
MJ=A]<^>-DE]5I!;+6\2N2RP>MP]F#DWX;QO*-*UZ?T J/3&4WMLP=K*<4Z$/
MHRO5J1JT1"!V4HKE;YZ_]MC+S+HNG0+SNE+7K@6I!@\;M9QMCI^*_I"ZX1P2
M;*M'O$SEVA6^:UZ)7JBT+EMW;^_/(;B,;H 4>DZOMZM*3-PJ"[4EQ)H6/YE5
M$_56DT?+.;5(Z[VS>3SY],*W+KM)O!'+D*U*0U;Z9<Z3Q?#',MP96:I-X9E8
M.U+7GJ-_B,A\DS85D#.YJ-*H1)]&TR\Q2CCI;%L*ZV-@IH><Z*#:8K94YX!$
MKH?P]]Q3#:4"_E@I/!W\3 LXC)KH0ZIQ,'@C>ORTF7?K!T(W0G)731*$L=M7
M1O^%5*O^HFQ03[F9L9V>*0\PKCF%FSO2FC-1@$=)^:*^@G@ 6DO4$[",FZ@[
M07;@"0<%>1,GRTCVD_TN;')#=L_-S0%[A WM(O,KW SO1*%3XQ]I:188,J@^
M[P-E-M88V CN-GC[E1_:V&&7YO1]M.\\P-[33Y9%6GP$&SA7^VRA)CX[*\ID
M-DJE;HN6O?JX1Z!0/#1ZP9;;"A8I(=[M+H)01@W8@;IAYA%=4=%0NA:WYX\0
M;"?+47\D,*T\VB?R9K*"@RGBC"EA:]6KUQ6WH>02?.?^E.).?"JDZGTM_WI,
M0Y8KN3UTF^@*D>VNRX7PY#N]"(-LXSHYUJW:V(&=3E]W3AXS!-LE-R!/=N.=
M,^L*F2B;TL$GA=%O816D-Y^?7SLB6W;L5.":]FH16)BM3>^EF#> HX$'U@Q,
M6G!!-B_D^^1IT?YT1[O1.^:P(_'?JDHR.]-**R\1QH)V= 0"OZI+N"'W?.;D
ML"&4&&'S,"KY"K>OC E#N2EF3[W#52;K+KI_-8Y2\?SZM.R>E83@P3GN5%_T
M1LQ8.G3FX1JI9]$,/)9WEI.33.;:S!/-/#%#BW1HG=#$-HH.'?VR)=+TZX_.
M?$%21+//)(S<.XQ375_46+V-[[G;YW6BWS,SUKY0:L8Z72 A(*GSZ=(-$M!-
M7M##Z2/VU<+OO<DO!Z&?7 <4:4OI7/W4^MS&F:9F=68*RDT*-#@3@I7SUN\<
M:C[;Y'=^.79]O^Y%SENN]C=_=SOJ+$&.+I+\N;BC)'/[)S5!J!K%8O!'N;^3
MW>.S'3U)LWF$P<0>' =?Q*Y<D4]-D>O1TQI>BTDEML[.Y+YC[#_4]@M%2^7'
MX\%4Z"*&:<*/N?<.P3AA#""898+L6D-7>G/&=#E=ZCA'CX*BK1-0^__AK(>(
M1*C=8.NM=6DE-GX3F?LLA8/&_.);V1##\?]9F1AE<?7036DUU'PW<4T+:T+7
M94<%X3A!$'[D?W@5_8*XHG&'!QC,1/UR<\S,'^(!W-QP_JEL(D@I"JF)>QSW
M/F >*OO>J/-F=(#'&BA!-3XR.KT5LY_;R0-46J4 %R;&,4)&-$TJ)C+KI5%D
MJ[<J0@L((>CY3UY_4!=1OA$Y(4"W!0IS#[(M: &-Q.UP^89A F8<)LY?6C'H
MG*9=2][^P\K:-IAOSV7KSSE LFP52G;(P;$5R'WL\SQ F FML'YL'_<'=X#;
M\"FV97',)&'&4VJTW->K*V=BO6"11@QH.<D]SA=[PN5EJB&W@P6^,[('3]8,
MJ!JM#5D=_CS]IE 95EA+NFZKB//GKV3E^?O#F>W>46;</I0"ABTK<HB&;E&7
M=8.6PQK3;C8=Y@'",^B8YW[!H_O91H5-BE68<V$3>WP5'JE43=ONDH]!/AS^
ML&\PC=N%J8 U"I&'Q>NYXOULGP+V95I7A!=6&K8.VX$6N23PNFD:74:X=!T<
MAL,"\N<\1BJQ0XXD1V8P7:A!G)DR-PP]"$]DFWODVY)>3?5ZZW][\ )@^R)5
M[I!"6NTS^;V!1> ]R#;N61RS<GSY%4B'V8V:*+9O")\^6^S\XT-IA>N)L$SG
M*QD(A7>GFLW??C*ZXY/2F9KPWEF[&UJYZ=?+=HA?@=V?:6]7E%O!A7#(B?BM
MH>Q:&CD*6"G2:+Z'[4HW3BUFW\0QC3TKE8_2>("7?LN[M <2BDC*VY6S^FX^
MR2MSF7&6NL8Z8L>DL%Q&,)$U+\/N,_LSV4=Z*H)EE,.S72CO]"]O-:[6GW@8
M\5S+P[M@MO*SO_Z$(-J+^8SU!Y,':*IIKO;*9OL.5&!VS#]N55U^J;W_,,DJ
M3N#=JCRNYGURN+[8H0O']*QT,67"I>.D*'MT*.:@'SAL!>4R[#9(Z\BN*[(G
MJU9</)GCFG-*S.N95<WZWET[G:6ZXI77<,6+Q>L</ZZ5E[)A1R4/L,//&>>Q
MQ@/@TCHS&<;,!3*0>\BTJ"O8N0 Z6Q.]9=:9F7M)06*C6&[ M$<9 &]H_M4D
M]4 L^#Y^AM'.U/T@) -[91/O?AC[BDA1^.&U@!SU[[&?]4EE/8CSND]Q6M69
M(NV,4'KO _WM_A3)#<0])MGNH)/];*=\K9X[H^Y;?:2I)!//UP6@VYFR$EK;
MK$3RM0A:;#XFA1''YT,$6>8LI=9^3VUP10BFLVNHQ GS<+1] _^ENDNZ4_B,
M@P:3HMC=S .<J,:8@]*MSV72.@WZDF><-_W670(=15FW42VX>A3KI)TN]Z5B
M\)='& F0)-\Z_4#7NW%R.>\XH509@V"PRRJ"!SA:ND)861RM7?:-?J(-=A>I
MR.!>-25^13WTP#\@,"MB51@OZ"TQO4UC.YE^M%7+4MK&*WW+P80N+'E8J+*W
M:#'N&OK(Z8NM\EJO#NH>.3*11P='D"4)&MRN(!&TOBK5_/ 0DV@+%2*^PNM1
M22%R0LJ9\)+[X? 35=NH9\6/6=>-'YE,!T4P9VD@\Z@("@=B0C=8?HYPIK1'
MJ#U!';C]->'MX<M#"H\O\P"G2\\V3RJXN,Y("\Z@T/P0<[IX'/44**GO-8$"
M0A%7Z%]F7@Y>=;A.K9?9K>JULQ$V=0DF<4OHCYVI^HFRYSK5WRF#E1%KB*JQ
M 7]BYACCO-M*VPWT>]1:=O!&#P\PU3=?:2Z*\&7J4D5VPXG-2*UN?7.*^8%Y
MG93KN91@55G506/6S5?48(_WFPD+_C>:+VCLJ5]=V=J%85FS3S-CJ#!1IF##
MF#+W!]TK[<N"[RP/,+1AX>EZZ73F=WB29D5H=_5BRE?:S$(I=A1>WI#,U69B
MBYD3]2"9ZJ@;/Q#:@?=@@G'Z'J\<YZ;/$'ZUO,^_F_M(8.8U,K2/[]8J*DBU
M9EPH1KR)*$VJOM*IMYYK+6SEO',PI;TXQ=J,_&69$.-^S]@C11PU6CM;"S.'
M^*_I1S$T>8"$6TQ['N"N#(RS"Q_0##V"/(G>-^_48#>5XM% ':>EA<Y)6&C7
MV/YQX]CK4^&G]K3>17Q_XCY <UDHI ]2EL.>8/?_ E8,_M1R4-M96<%_;E[L
MJC<_I2TE5#UU&IF5X%",72C7\O<XU!*%['V$" '&9F%86B<8-SZ0%L7&'Y0@
MZGK!CZLPRRJK7XX/\P ]XV/D44MVS;NFX/.G5&P]>( L4W7V.VS7QU0:NI$L
MCM]/)SDP ^GBS3J8 Z<?T'[13V *#3.;<MJ%E58>X,XT-UV-W:T0'Q)LT\9?
ML;H+?B&V,/P#S)$UL/#HI=,]0^P_4NN2=0]TB.GMIF L;K>?+OG@_/K-/A/#
M]R$;NO65J1./V1>]+FN@A:N>/BF'O3;\+!Y(>+CL5>O/FJD,%$"5F<<B#&9<
MY829RU21/6R=N$EE2GO(J6&/VBNC45K6PZ'(E4/2]7?%/O@9>,A8N9\?XON^
MV>L=&QM>W9MS,'CPX/#\TI0-#A;$L4EZ^4-N%]T9A]:7_ !/:KUJYR%QP/U
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M (QHIW=T .K/*/)G09S12'-@-!+^B:'^)[]?6*U)_JACM52$;PI_"J3\I /
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MY5+EE-VW/+LVNH'J5^C5XPWYKXQ7^*NPP#\N+/#?$A(VV%=;2.NG:$&M1*Y
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M/=RIWYNCIB4O/+>+S5,90J2Q].JL6'4'!N,7MZ_#BL,^0+J C&75JQ+WN"_
ME??<65K$F=,$OF54(W'.7\5[0G0?\$X%S^#<!]Q0:1Z&31%W#UL=^%CX+8E'
MYC03)Z1^$N\]:X>[_XMLV?\;GT/_H*S1\#^(T/NGL=-B%_\>CLMUL?Y]%#P
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M'"I*3#0<#URB E9YC+)CID%-\+;4'4V&PV0(G/9HAI>.+.,29X-W?D)$E/H
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MXP]55C1S=.&!5XA13^&75B9G1H\[.GX^"8@;L>P?!@3[8W)$;T\L?)''60H
MR_6B8 \F=4,(=/,%X8V>^'G-VE#L5.N.8\U^A:6O*)?PEL3%3^)/6#D9SSZB
MN_K&>6WMIIJ;]/R@  HWT[R)>)W<F!+@0CFF4 H&4)=1ME3 16?@%0FR.QZ-
MC<W#(TW&2C!5XUG50[@]A@!U^2##]QKB9]Q#%%1S! "W[RW@F3=\LXG:<Z#8
M0)8U\[W]AFR?? IE4WM<)_E)2>?TZ8V!I4<A#WW?,?5UZP\UO\U.OK7X>F48
M?&,+VG2!LIUL.'R8]Y(RO\@$W!<AP([0;3-ZG6!N&3TNN: ]?W_<C<EYM= Q
MVIJ(\Q^M;!*DM-!"1ZHAX>?5T1]3ULD!I.N.Z,LRX&CWM>9K=9'#6,&D9.>%
MB:GPQ>'<<D:;Q)?BL)]UQE/5K]DY[_XX.AU9)R=H?RP'@:+52@_&735FO!'Q
MI/3Q:2J@UV8>SAG8!KH<>'/5S[,  7+HLVC/_'WPVGKU21>FP5G!=#%B9+,V
M\NZI6H6' +.@IQ/+[P/".H" O9*'^Y&_*+>(\*ZG/CYM^5TYZ_=$5O6MU(K,
M<ON$8U[:,9V:[EJRZ@K:9*X<?.!5:<4-E_UZ[%(U8JPC?50,2ZC?K1RUL%G4
M'OB-[&@&UHUYE(6!>,@J<\QA1WTCXR:!G&&/D0W^7I^BM&I,=%63BK0OGPY^
MJ]DM,]-%NK62(I;<TG2GK3XZ11>!GSW>>H9, 59IPNOIKT.V7:Q*^T0>F=X\
MLT#+.3\MG ?T%*B7I@+PO,V;4<][9R'-2+(WB;3Y#\^&PG&">.OE^>76!M2Y
M"9\PRB6+;@DQB6>C@>T2BI^NIM\ S[#?GQ"F$^+KRO,5SR()DU\21J./@ @J
MP#'& HR/V8!<R,IWF+U2/B14%Q'*!:KJ-$LTO7QNTHV>=<^()5YK;5+)OS0*
M&L\[BRBBH(Q])3J@$^N/"0<M31*8_BAO8(A'C-2R3M)P;XT< XNQ>]>M=I;Z
MA+B+5AT5=S+\,>0G1&:"D#4A;SF\F9?L,48!,JGP6_3=VM$*MBQGC*HVGQ4)
M!=H+N+5<X-B)/'"ZV8#T.D(O#>EMJ^8F154W:]:@9&$#<AL*.<RA7N9BF=&>
MO4#NB?5AGWP@S\-O5C'&KR)L)0'\VY]>YU]Z8W@J;2&C&"/T'0TD@CO0^#BR
M*G&XA/RH_NT,[FL5T8/H875/!N;B"RGY_76;\;G90 _]]_YS^VLW#W9(-351
MMODI'K^X].#K%N0][SUE4.5Q",PQE^A%^NZG=Q+1+SH"Z5U>IDF$0J0M]'U9
M+C<HM-8'W=#)K:39GGNK?EO'ZQYX(P>+8("QX]G?*8H0@LWQR' RD+%F?W(I
M\V6,O2]WN8)+U2%O3K+3>Y:D'U??^W8$ -5TJI %I:G.*&/#3.FZC".*PFHY
M!D@/M_LC29)8;$F MT-Y9V!/":$E>?!GO0&N^2KY4QH%6_:W2ZI XJ;(G^WQ
MKR5CW=M6@>69[<STO\O>-4J05(DY?Q#1N,B'&*)TL?T(!-+='<JD@TCEX&4)
M.=1@W0M@M3*@ D*WBB;6IL:+ R9 XQAHM^"V%8*56((7Z0P4&/%(-\$L=P(O
MPNZ.;'PUT8V_^]G*J7.)]>Z%_7&Q8)"-K/>E<1GXG,1WLT#F/BS$V8)@M1RK
M",%&8&K'/->+'7!L[HR!EIJ\C6"!1\499S5%W?0X]NJ%HUR;ZJF ="K@=L6@
MU['T"75__]\*S/_O>HY-18W%Y*/W'WB!,T-H9'$0)E?L=/&6XEA2@N7U'_1/
M?X2\D>>/1I@O4)B(5, 38A@>U!HH-?*\.MA@M,K4DQ-3;6QJK!%^]SQG%&WW
M9CMI_.'\UN$E10TJX-E4YC'+*&'@.WR"G7(9,;'<8KY%%B^+.M*;\F#P+]N8
MD>BPUOG G<6TV,'^P:OS!"V<KEN^*3R*5 ,F=U' 054ORIA/D.H^>H>L9T?T
M)SW1<"7)$$%8C6A1VV33\5Z5LW&88D[[I.UU6-959)0[;\<+(=$6=7I1VA/
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MJ "U*2P=!4 \68")AJ?05,#+ON,%\@!1_SA![B!A!X2QI"/?1+'#![V(053
M&V4^*F#1"/A7U[^Z_M7UKZ[_?^IJ$@9O4R B*' /%(ET$K"Y2WLI+.@HU$H#
M[/[):0=DAF\7(8@&@>)40#:.0$,% &!*5$!/$:X-NX:!;ARE57_;); MK[BB
M\/T4?BH@<T:"0NFF CI73HB%-P%(IJS"#_;U*')6R7]F:D83QR41F\WSJ:1[
M8?8':5#R'=0)SEP^T*8"4!5P0CWH[P5T;:F \] .]*Y5\U7X"?=&'1II_!OC
M3/[.6-]DWECCS9S])TW4$.[\PK^L%E3YQ0ONVTD%_*T3<RB<Z';X#ND/0<D)
M$''&"_QO&&A-)7@?LT/#@40:S!;%2/^_?O,Y2G_6Q/$R]W^H8>DY\0\&_M$5
M^S5"]:3@OWSYER__\N5?OOR_QI?I<_#@>^A03T>7TM*O C%SDJ<88W6U;VX&
MQS)Y@_Y[H==%*@"C0VR@1"';F<FG\ =4P*TO5$"('';K2!Q]$82G:T.3BTIO
MU18EY@TH]1?Y^'GD]%[Y\N^KN):"_]3AUC7Y8WBB?>W?UY$52?Z'6>3\HV7G
MJ_NN][01M'K>4($KQTD.+Y\B>#[9>O*?N6CR7L.I)(\L%_5P"%)5<F]<;WBW
MU^'=13/SSNNAPM^_JZD]*?KL^D;2-/,_7E)/]RN8[:_8J!!MH1BK&U-:@Z\\
M9OBU:VB?57P+5V&\'__(T.A\CD &W5-'#W"H%X6G.GY*LV+8H\'W1OPBIB+\
M 4(TVESSG!&@4E+4HE @P13]'P]IL#_4U#;1]5S1E@3RL<!*)U7X5+9F<!%4
MDX*29O;2[XE4GGOE<NYE3$UP4)KG]R^*_"0YGSL82MZ-' R4EFC09OXNCH-O
M_=%05G5BCL#ED/GHR[E%:?:<-$-?_^/EKFD8_SNP3ZD#_X>7&7UTJ0#]YE]D
M,4P3U\'3,];3JT<>3S0]Z 4BS/AIMS5!LG[C,B>[S!Z?0XDP::,"R$(0$+'/
MXT^Y-?KNI1!?TC78[1&[*U9D*;S82+9TN*9LD-/&)9;KXH^M6(T,+WP'R+..
M^(#F:J+P!SK)>OB:X"RB4ZO9XVWSE7U'QRL_[M/V=+YA:_W2?^>-TJV"/P6
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M!,R2 '\;R-.21:2SJL7O-PCFC=5]<6*S?_7+<;_E8LCS'LX;&6<8SX'\5\W
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MG<>,4^NZ9@7>**F8MMW-W'*2>-8G+_+9]YR<J*M&P<]"SSR+'B\D2T;>!+F
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MG:X^?\):F3S)LM!Z^R_ZX$SPJ;VM< K-<4$C70ZXCV#.?)Y8,:YOEDW,*;4
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M:TW09Q&Z'K]9OJ%KW8K)!J#:=5#BQ,[(TZO7]&UMW-!D;50C\,<:FI4BUA_
M3++UY[Q;AQX,&/IJXYS\*B27V- ]U-V2JR_RKBVLIN/<]:QS!6KFW$4!'536
M8;2*->5^QOWA!).8%>S]!)T8_.7<1S:-].^T/$1TKBS<T3]_YL6-PG:^+=61
M]8,99DZ+>KKF=.5!=6%[[V%S6_5OOP5<3YYEW],S_.F2:'Y@(,&:_I%OI)!B
M1=J<005BSN<24>&['Z1WGK"D.E_V<H*-ELS%3.D+V'U;.M&F(G)-1+)3W'2G
M>OG0>MXUPOG&R^S#:1H 11%L^4VJ(=3IDOH(^Q8$[_K]^\NU\1+U>S+Y[HR2
MA=EQY9*GO.R-SS+$]==&,IJ5EE950<-+QKF&Y=Q?W(J_#>#]\/KT[.#,B83^
MC]DK#Z \-FD4B57F07%5J=>GSW5RT07Z-A9ZIKC70W;:4N*-;_VM;KEGRK\Z
MP& ]&N = A*[K?"R(05Y<D?=.8/W#Z>B0NZ_$SK[/S%#IH8ERI:W@9C<=.P@
M\MBY#'H97MSK'"O3N1K/<$?=[UL).J(G6R.;3]#TZ7+W0$K*<CY.L-2AQ96A
M+:,<&22]0X[T\]=J/GS$HU.:RZ0KD^;E%BANER3WR^&E+&^HT )J*:.B/1!]
M!0[#5QX%KG"BV0EZ*=C[PVL_R1H;7792JTXB;MP?&4Z%3-]-M/L4@;T$>@IZ
M\T<-U@=B8113PF$;V?K]1LK&-![?G0?;O"L41Q]-'3@)OC?RE>2 VPQ!<.+.
M("0SEU0#DG'?OSAR&E15FU:/CDV?LV.N$W-7D=(74U$H=E+M?)G<*G(D<W@(
MRZG=S"TUE#"2A9RK+DX&VU126+J0,9J<E:E[!K5$@5B"( [2##HU;2E2:UM9
MZ+R*1$UF77>\=^E.ZK@WW[JO-=UE$I/D4H,U+B,$?3U@2)"NN-XA>X*4U-F+
M*TIY5S[X#LQ4'G[Y9G_6,SU983Y%G1=^YE_':(!&-1K  <I;?!L/"E'UT_?G
MB[M;;C-U-Z+DC!V/?,[3)^D\UW/@XSJG7O7$$OR:5%G"*OB]V_5EG<<YHFF
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M32E'Y,DBM Q\6YO0$XY+)I[:JTKY ;O@O&T()WY);;L7AI^@2$;=R.<_,ZL
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M $*6"ZMXH04 7XS>3N\$MSP-&5.;6I6EBZ/.X(WK@YW&2<?)P=O1Y.!=.0:
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M_**)9BEZ(IUF4_;8#"/[;9,RB.PG(]CK82.RU_AL1GP6Z"X^PV"OD(!>]2)
MHOCHYV,7D.=(V5A""=_0&DV-F"7W8^G:D,P=13W;$ED?4>%)@UY%UIE-,.6<
M?DO60Y_#LYY(Q4\DS$<?@AG_Y$)LG4IC]QL7G$/*0^;H#E>?$]%?:#^8XYTU
MUK@0ON2:6(R,(X4-<N!NA *_V*>&>?%'EUKW60YYO(IRK#ST*M_\^6<YI,NN
MP.[CC5*V=HP:Y1-5G*(S'9%""FE-]-[#1RHO2Y)5ADX!.77<O@GP8[TYNY]>
M '[#G0$S29RHNV\17!HZ"9KL@0T:%/Y$?HNVK'%2&9E\*3)Y;W8D S>>8PYE
M *I4G^327)()6>APF@.1DZOI@0?OMWZ_ML\U5=$$'?GN@:"PKO"'3$J AW#V
MI_KB:"3>^5"_2JB)"PD?[Y]SPLO&PFY)6WF@04MB3S(SL7I,;>(H<[@OZZT[
M7]NO]L!H,J2 @GQZ?XX@6N$#Z,W@VH=*V1 M"T\!KN7.JA1(UXO8RQ9!39>D
MTTE]+)2=#OQ1).LD[43:M$VLICXQQB&D1]ITN'+\&+YE[]G#AFRGUE'=YK;/
MVO/6 GT6:@]24OL=>T>K1]?7:Z;60E/BSHY3&H?]ZL?WJ)6_^MYK\I.[6K0O
M8\@%C1E]]S#<2:#J"2?F=?>G#OZ?H^?X]6]_;_!YT<$2UA8T4DKUH1B;D?#/
MJMA QRCX5ON.J$W\:@:(;4']0N,PUQ?,<%WJI=ESB9_:61%9+;&SG )D!N +
MIS!"ZSOM" '$-N;L+=[NS#M(.T)<U3>+FHW_YC,E-UG+-&M6H;5Y-5Z]72G3
M&KNJF[MLK]^ZSV(TA) A&[<"C\DW@'FS7^?39!.'=8E?N\Y"Y'SC+3M//I-\
M^J0>D/2CO_G,B.G2]H$DR_J#YZ]QI-$>;WFI%Y&6-/)M?]7AUTXRUFW[^XIF
M*/6: ^(F"=0"/$E1W7#\SHP_5=G#?VOPUXBQT(_3!LTA&D4MJ/I:UO/P98BE
MS;Q'$RH<<_X[G6]1T)#B3P2R"<'BK-/K/'=N=OEMUP59W9')8>F)8^D<]!"P
M3$ZGHF; ,5N00[3S9+W&-PL[=?1Z#U=QKSW?'"_)H5%^"9^HZP^>ML)D,SEX
MN.X?4E&Q"%<EHDM7EX_[XD,'SJ>I&!5K'[B>W^;0.PZ%7W<36O&""!M7ZK4)
MFGZ,30/DF2#G<Q_:H9#;Y>HX#4.!C:VC%M?F9&M%([L[CI?)CM$O((>S!2A*
M,QE@%@@<U>8L3I:DO\(5Q&<1LB3P/7XQ8GIQO+8GIX\^^GP$5SC7>X@TR4UG
M+?$*(<4#.;T9 'YMZ:M:6R\RS/NG1Y.IHOA+7$;(GEE"<J_D1U,SI[&Y&O!=
M/,4484(N:4:*DM'A5:6R5H/:P#["OA$#8#XX%RT#$QNZ92Q7]AFF<M+H O+V
MV)GC&(,I931IBHZ<"4:-+S$ V^O7+W?VOK<W.C#S2Y*-TZXP=G5\2X <N4V,
MPG##^=OH@'Z$74!=88Q\9:G1 /XZEQ-NU[(0=T\R+IZ+>&7*_HCT(RXFII[@
M?6RKTU&S.%4+/ 1>>+TQ^<N\?8;1T$\#Y1('LTJ9(.EGU;/UUP*2OY^[D[Z[
MUC;%0G:.(:UUX$H+PU1Z3$V49C2=99P4FIMZ)K=B'XW7&_L(,/5,1HBB64X\
M:BK;(:H]\<?'YO!51:THQ]GH?2*#FF4;%84:C7H-^$:6B/<MI@*:6,^Q;^@G
M?3GZH:PQ_:5U'=:XW\)X,'UY=J_"Q'%"8M/:N;JT$X^6S^GQTS<GS6__(.FW
M]@EZV1_)#I]A/SOH&'3V>X/NAP48M  J%]VK^V$VJ_6]$GMG;;OZM+5T! /@
MC0;0SE/TIX6HRWA!J#TL"J0B9**]8V^%&<I/%Y!R/5,/E+,;[8RZ>?%RG.EE
M,>0Q&IQ<-4\3PW/\I @1]]G,!U;??AQ5"76YM*H,-2 \%^^"WF>+^5#^N.CM
M0R&-Q\RCD8O+1%@XG7L_30)UU#OX7>.[9?K9;#..!M3=QB3%M'MM7$Y8\,OV
MZY9QL^=8YHY698H+%34J5/TJVZ)7*L497MHP]$X.6%F9Q)8B-T/U237;Y:3
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M*:TYQ[. 6OO?_[3@L_[5T- '%GYUI\32_%G9VMCN+L]":0)%GP%8G&$ SAP
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MG"-KOZ7J4/2)>H6JR3R"J&?2_?YL#G8_ ZEN%;HR%^]>$!3[%#%W?E(;8AI
MW?8950E9PRD[>@>'5A6V=MG*5XZY*AI*EG4QW>M1Y+VI[?J"-T/\.QFBTW\]
MZ:6CNO)HI\4<ZKGN9T-#WW34PW(:9[*F$U699DYY307!79M$I(8:>/EC&^2+
MQR9_=,".M/5&%35Y9YR-6+]L\^BH1>#C?/>K3(/IR=L0ROP,)Y!VF:P66X6*
MP#G'$>2=?'.:D9R?ZFHJDH[J&;[C6' JQ%W[X,;<!%;<J%^-/I\_D3^[XTNW
M&80T06C?#,^=AUY/ALC[[3J-TQ*^,0""B&O#FI>I:I2*+]I'*&ND-2N*PZRS
M_6* VL4)_1G5J*RGB[D]S23'76?7<QJG/W[Y O2@=&V'D,UB,*=IP"&:/%J'
MP!F5??CCDP_2V&HEW%?[?K':JBQMDC[NT&TUA:FC02)MP"8\H(4X1W9$LI!P
M\+?YBED^?AD/@AVW8."[-.J\RNB S4^O1J>LO<40Z&A@R-IH8" H?MF]IY!2
MBNHJW'68PT="F)&RE+R9H^%DH1F;Y[2+6J,1/K_$OM,TIKN"1MH%/*XD37R3
M[U@3Z'0/F'Z2^?3R43,6>J^VY!_)30DSP/ :?IPE)<PNQMXXY-6[E[CBAG2/
MF)#3+2=8;0).3H?%CO8/6?6>?_ @Q Z='(B*,D^.?5GW+F?2#V-/K\]FR4<P
MD=DC6W.>TD5#5B_944#-@?9\;SYUSME))PGYV3P[3?IZ0CZIS4P\K%>SA9BV
M\I-ZA79K$(3@)YK ". 8FNS]\O$V8D](RX8P<D1&B?KU;2R;>\JA0W9&"2]%
MV$/3=!T9 /B:?"#-(9GFH/1TV_O[(*Q) LN<D($41_8AU0<;=$D.CA2/$D^E
M21JX/,,@%<@?1/!=E8PXY]3RA77C6NO]8VRI??> ^46Y&<FI^^/4+50<OEN<
M5^C<MO$O!N!)X=>#)S#IZ=]3%*QAF<['_QR\(,8 O'!E (C0?FC;\L^-NF&9
M$+"'%#HTJQYHEM1?:(,+,2B$^J(G%A@ PAUX&/TI</<HF"Z50+%U%F4 WD32
MKQZ\**/*'D;O)I2YH.9G,=NA:D,D_,8O\$-U\%\2Y?TSB9FY_]@%:-F"ZON\
M__7_*$2[-NH MR51?X2:L3, VC,[XGD,0'@XD7/O&&KV- - 20?_.8/:SG-[
M<])TI/':G2U--1HU82(^X2^5\/QGW>?/Y2V_RMG=!35&_K;BMQ6_K?AMQ?]
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M%_QZ4';=L -%D0&GV^R6UIVA5Y4B[N^GN9:3S>(;4'?(85_D X^45:(^B@V
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MX5WWR[*=^_A43.;'3S4#*SX?2L_:ROO,V-Z).LI[ZLKQO!^ ([:YZ-?KZPP
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MHVH7G7>-*K"M"?3AF//A+?BGLSRHVQ.H YQQ(%&D/31L7*<V0]?K3^> /]2
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M)=E2J8>6-@EIN^G-0O7M)W8EO%X:/P8'#N6! A;&%D).7@F]I,YA, , <[%
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M4ZU:DP:UB1".:<C$Y-A4Z[W5]%.R&E++-+AG\ZGDKG,%@XBY<R),P$%J&.1
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MTPMM@;#-#L."R"RV51DFD4;Q!G6U22V%YJ+& 7(#>7IB8;'2TFE=L.&-&":
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MH-X3G:]R*U;!XLIY8\J)WVK?*>CQW8=K\+7#B4@#.'CRC;J SC?"9J)3OEO
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M+%B-[L)_RLZ3PDNL?@=.UL^)J=C5;L66EPN/E*IEEM3%VXXP2W]\]10C_.[
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MG[$K'&C-,1#_F(',\-JUE'FC/Z6L6^51-JL1PCN?%@QT<45>TK@$33J0K$D
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MRW!;'%LK&$]I_43'573H@]:BOGG\KZZS?P4NR/[_YS[;_\B&E:>T2)#H +E
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ML"XY<G*\%'.IZ/UV-J*[YETB)U*895R$4I2DUI0_6=E, S [STA4DR[D9+7
M\W\OL[^2[WK33^IYMED_^RIR:\*R)J&Z@Z^#*S4QYHF%A?C^\#S8'=T5+CT)
MR0P^RNNE[I*1J36L+3![G%'K0%"&4CDQ-VU6'\5.1AB5IQBGM.^KC-47-=WJ
M+;IUVF52V>1\*$?8\_83J'(:X#D-0*:01VF %SR/:(!?5W+)+_>8R2RSQR8"
M^CID?^>7WS3]+WP]C9DJGGDL'MD:7_9Z*"'PQJE\G.$-S<L6*+)18RHP"&L%
M8^]8,RARNKF"6>Q/,%)9N?-U[F!\O=/LP.*<7&/Q=[-HPY[LE)S?E\ '4I,]
M-MR%B[&2-LK3T+7<-!J@*P56"3+:2QF]7L=%2INUB*'<N^[5<''8T^9N\]8>
M].SK#=<B:*WE<_M]GK<UKB 62KP-?%V+Q- \PW*,I-C[XIE[+*^72POA^X=&
MJAQ&1%.%XEO8=^,_UA!<?6XOR=LFX358EFUO_-KTL'$W+!\M2QOO55:RB+]>
M\B#\VPOA,W5PW.*:%E$#!XX6(BF'!0#')YS?H#^QC+:UM6'>3_0O#3D*V-N-
M?SOE5:S#.Q*2IU8^57KLC1DVN% N:9KZG85RA!KN(8T<%.!8U[*^0)^2(PE&
MK!1C U-C%X[F#*ZR%'W$PXPAKKI+;N89]R,QT(B'^1N=_,B0#&EK<J(91L,>
M%=1PF<03M<NBH4GBB43C^$FL$>HC@[\58]QM\N\/<WQ@__@LHL+OLH>(Q=2D
M4>".-&M;*@T0^?HU-!9B:^TQXEJWS#_ =E6WP:3-PJD$*,$W<!LE26XB>MGP
MS)[*8")[SAJQD@OTX@BPCG<4+4^)N+V).5\'75>^;<X%[0L)MZ_JK@?%KI@O
M>CMKXR>7LS";]?7*XXMY.@E*1H]2C5 M+Z;RC7+K3;U!IBW(DP&" 0/8"DQ+
MD11NV.!YI:W Z(9KW:W)]$KCJ1^/@_\JD"K5?G$0)(*K^QJHE#H'XB**XSK:
M$!.U5N0I IC=R9ET2^L;V(9<>>2ZP%3&WSF7Z%+GQG126_CJ(VT+$64!"X&!
MM;PCZ17UB^1J.X)> )LC^%093+!Y8U):#,CV^2T-8%Q5)1<B4LGWM$3HZN2G
M3@=Q7K'ZE%9X"4\CEIN\9<3GA+W@4=L78-DPJ)"S\%CL?8)^EVOQU?<)>J+O
M-]3<S92S+53K,^HMZL5SZU-7!WV_Y.PA95*LG%^^RBG"P*4@#3'D;5O2F7+"
M0! -4':A%"5OO3I9&0KB<?<5RFWGT#O'#<OBUQ/WNM7N9HO-I9PE;JZM'IE"
MK]827_2C(,K11;O61A?KJ=_=O"9KVYQ$XWQCXMRO0#, ?* 3X'O.V!-0)OP+
MDI63U;G^#,FX(0$;\Q6?MFYK>$=-8#&H'KGF,@ =HY;,2C.#2<KA4$VX_>(*
M55"^XI/;HB[ZI;S.?,]6V+D)0_6G;B-/AY->]"^>=L9NS)?7:\RJ#8DI6 6_
M^[Q^L(S"'=L@N9>PIP,$J8/Z)'@'EG-W"D< LJX>9B!9?HWE_*0!WIF/341-
M^>H67]2\(_I[I2F: ^,%V][CH0$2=<AV83,:/RT6U&@ 'PHFA.)+7V76!%2,
M57L!_$C11Q4OL$9'!ZUY[6[DSSM5PN&\X4=W.ZN=/PD#SEQAZP8 +C". 0'4
M2_I$[]F!$ J/FZ? >G]L7H>+6NN5B!G;8M,K K61[=IN,2.:4ZS.-(!81I0%
M;&.S"-.7)$+],8U. YL7UEI:&W@M"\0=_H--E )64O1%BOR#* G4PZWF_ZJD
MHO\;&NM_D *DKF OF09(\,R&CR_B-(YU/59VK0#_\_[/OVTDHW\7B&D+^;<5
MCO^U>,DB>$JV184&:#, -@&9/6)E#@DZ)*]:=G*T266PZ>F,%$CD@J689D3J
MW6^15;$=5_Q]-3IDQXT:L:?K.("M&D$SIVK*R=$X@[L8BY^5I0T-]0E[M^;!
M*K_O;S6L=UJ'VG3P"CAO7)/4)HZIJ,Y0DW_N#$.4?[M\=Q3U=+;>1/?-8+9L
M$)_GALO!;-1QZBF2APIW$>1+URQSU5QM34FR2&6J_C>!IQ]^(F1LJH^G[!I,
M.[A:5C58**:%3L *K7)4^.Z9Q-9D[A]+?:*U.H)?:( ) SZV6@ J7-60E3$$
M_-3X@;%)2&Z%DSX-<#)%&?<#)\Z7CS!/!U,9!,&MY-IVP6OD>#QJ'-5\KZF!
MDQR$<]'7KQK>0;(M>^W!)V:$7-3/)LG8-BH1JB/NQIS1G6Y<J!,:P,50)<BK
M1&2K.@]9D01Y,.2B6%XY!C(CG=/_M,LZT[YTHL(1W!,:L&T0*!^H2_!>T5(<
M?*ZM\["[Y;1NI_!0L5&&:];8!@V0-+I?6C$]A7TF5"V9;SS4C95!*F*[7*H/
MFO#P2'4-LM01T <U&U9$A+=9J/1'9H(=X<0DZRE9BO"0(_G]<>%T,B]$(G'>
M7C3P,D>9/T\<2)X@P-&$+O5N8SU'MEIL-_4!ZCW>U6"U["R9T7?VS&OC3+C+
MO]G%=^<^S/K6/O\8#4 T H97[,LZ@(P("T35WXI-Q!.DRR%WYBG-R)?G>'-I
M@+33A[NHO*+9J+&SN##%,-X1(9U+H68/;P 8OIQ$RCOVH7W+-I?[T :^G]<7
M*Y(OFZ3&6-1\2* !*HNVA[!CFW/H"ZNV,L=YZ%>H\  9&B#4&8\(SSA+O 3^
M78Z-*0H-W3V>;A6\VR+PP^%I5'8)]/T;'0%^#=QF$$C_!0UPBDI7K"D$J],/
MG^ 55O9HF)BUI/F*O71;5X2(EK<2L=N"8>&\7#IF?,?<-"K]LE*-\Z8W&K=_
MZ:ZA?,Q,A>,Q9I@$P6RHFQ#W0Z!:$%+6G@O:A=%8WT"\T6+,>Y_=2K?$\K=B
M_9?'N;"JV"[M$]:,\R WL#)4C^SLZ(XW<%AL!I;NMVN$(B^YBJ2WY/M<V%0Y
MA;FN%YM=+U-RG26P[^<M4E6P?%\ TMBJ[TAO&[WI=S3T=I#2Z]@QT9'D3-P\
M'O]6I&Y!9\QT0,54&10@%=#?H#A6)XGRF;$!_M4P#+JG\:Y0?9(X\V2JB>]#
M>ZUNM%]GVP\ 0^X;J54GB:_=JPLT (\_;/V=?<_S6M%]1WA-DQ;GHW\JZIP+
MO[M.;UN6- "EYH :/O9<8VM__C"4TQ@L!'OZGUVPW>)O;P3VKPZ"Q&D H6,4
MA9D&N*>X.H]L#T#F@])[R%*8'8=Z^A -H;_^V:[,_[9B5(CU)"O%%WWLH=%I
M80@DW"X!MBA\RXS:9;W^C^SH?X>VA9JTINJ-Q=, ]LAW-,#NU>&"4>?_H"35
M/_8VG/]N=YV+KGK_ML9$;9'?UK[1KUW^(F4CZMB(766"OC/K;;NCO[[JZ=:U
MXY39>-QF7RJDS5O8/]AH6Y$B%+GOM9*7<6A>'TAS#6*M:0_FW_IL;MD+2?QQ
MG7\=^/+.-G25Z=%D(6NOMGN[\VCV<:;BP D*^Q@(3GJ)FUX,W+PNDSPCR^HX
MF7YIM&]A+_;J5@9;08.>R#@G@;?KE@)U0-F(K#3<4&/)G&]# Z"6,[!:T+SO
M >- #A#S4ZHH.>1(936#BPSGQE1CI$&:+[_]GFQM?699^)Y1"S!_T+T]5C,0
M2P=SE9$41H(1@P\8M]GB2?[ZG5Q@5#.R/JI(]BC7M=N*?#K4WMT8J7G42/HU
M.#5 2<-41&Z.@VB HJ'AAB*7:> =8[#L1, 8DHTBBI<^QQH-/NG)&FXK,":+
M&\)AUD$ZSH4M++U%%:*?KSRTUW[&X[OA9S'">0@^I);S6,/!8T%:T&42P]XW
MDA:ZU07>1&=\#>Q.8,Y-D(+0I=TYO[)++\K3$\1VPY0_ E4>5HGR\'8668,G
M[]F20XE&>B1L,R*<)T!E9 -EU;W=HA)6<";6/:_.?\Q-JO?<1MQ]L\G;JDWK
M)JD??).QBYCA <C-(L>W]31 '@0L/>"5V:!7?HQJD%W^$U+/,0OF#.C/:]G/
M$*^6O/R>/#ET/%NA#5:?SPICOZM=E%[RL-6%4:P&$0DLP[1*2Q$$:V>!833
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M <0!'$O7VL.++'T2[P_OPI0@9<N3H77>7L.O7VP+Q=\3M@L4OJ;9!,"D4<>
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MVT*<MU'D+<R\QDGK[MNHI5['KNYS1F_HV.IF<W6?.UX\O$Z9P,I"MC8>41]
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M_W@_1BXQW1[P_+UHGXS9#&9IJCPEH, 38_M5JEW9.<MKRZ*6(C@U91@^1+U
MCL1M @?P9ST$[JUOO5))3U7/;O@K_H#'+;^T8_O;=.#JMLRCQ9"Q&A6R:@L-
MP%UWCXALP5YB#%E;@X#L\."8;1]O'>K(=6FAJJHP[/[/];G\_-N-FW'UK!!?
MO&P<N-0B!LKB2V+ R\23=)H"),;6=YCG53BMS,:2W-SBF1N?W4I6(YQ_OLC;
MR"<BX;_">O !3I34EL$>W-P:=:XV4^L0G4JC 4Y$.]$ (=N#2S!/+6A(-GF
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MZ\8B7BGOI10Y[A\V]O8A<QXZ#DCO#"C+R5K+3U30Q^H1A<^=ON#VO4EUK'1
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M1[0)V300[FB]"0O$L1R>HH'F'&D@X//07Q*!(2CL_1%'56L88BLM'M"&*-)
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MKGKVH*]X:N"/HWDA#?*_&*IK\/=_>U;:.N/ZY_G/%F+&/K[Z(:+?'[I9<7]
M2W:#OZA<<4(&NMB W!_/7D\1VI[6)ZT-RQGTD"*NK/TM<1Q>$.Q_GK"9P:F<
M\LB/T=?Z=/@S\FH_+\O%'YQJ V@@62MS^\FIOC_NW3O3UB61U<C>]Y]];?D_
M]<KTT%[H\,(@_%2N_C'+^IIH^#4Z+H6!OGK;,5?A)^<U'G%+)I:>G'M4FOO
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M??Z&V+ VV,;V0]7>?"2;_KB/%!V5S65[08SRMA3Q)/7DIS16(('R]L?UR4=
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M_'>5%GT#2+)[[PG!9<3C>T% !+;DV-#ZX71)YM2#<<Q!I%"Z9+N)F=>;HL2
M\N/3=3,1AU9]D;-0IN6Q<G_%Y "WJ@;B!M/7.Y$FX;<NS(9VWB@P6-B+7#M
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M;C:$ 9_S2VU0RIRT-J>/Z[UXQD/F0SAE,WD^V^"[* /D'2>ZG>7UCRRX7N.
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M_GLIVH0SD&]K,%]@]B1^=L1_VAU-_H"]S 1<!M(#0$P G_;O$0@7-4$6C4Q
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MZ%O+ODIK8 QUE%+8L@GA45,GMT]J/4D=I\X:]ED/K)ZBWU;,S72(O4XZW7N
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M@'PH3@HDJ.P ^.200T4L 2?F?-CLKF^W);Z4OIQD%IG.<*$'6A1<$MY8AK=
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M&!'.A">C'H7_!Q?<Z*,<OUW EMR5M<%TXL%\7LO^#@%+QN_!P#X(I]/ZN_%
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MA=TRTYL1QN620\KM??T'+[*O=?NA"13^J,Q',O^;(/E']9-B%@4($<E2R%F
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MIW&TMK$LD'%J(9F,.ZI]8P'$KG5B<VN/+.!-<O%6XRR])\_5&_)QF7]<Z>X
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MB$(>0<R""!(:^@E+<<*(4>3!N8),;0U1'TTP3*?UO2DPH_LQ@!V8SNTZL5^
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M8B^%*?43&%(N4D]2AE.K B^'AYD:)51&@FYH4Q4])$]UU85LH1NZU.ZJ\E&
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M!])>J#FUT.PD&-5PZP7.KCW7[R%N>AQ_R.:K4E>_1XC$ J>0R*J32QI 2F@
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M4!EG?*,$*&LM7+8LMIY@@YW)NT[;P"N#89/B9F)OY79=7= J6144VU(3?)O
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M$'?J70H\/VD^$\S#B",?P2CU)$2$>S#U<0HY"\(T$@D.D#2V'@T&G!I7:<E
M*W?=, "TD@,MNH718X)W$"/NI:$'6:)SHGUEK5,_99 )W_<9#?R(!;,7D=/E
M>R"^/?!PF%_?W]TYAM7 (G<,U< DW_5*7H#JK>UAEIM :6&9.X9T)./<!;1V
M=KH%3IVFNLESQK/6+;1Z8[#;W-?/9M]J$E)W!]FJ'#CS<9 D<<)A(--$F>F!
MA%3HPKL!CWTFHS#PC%8\D\&FMMHU?7&*NB_.?@L^^W911I";V>*N@!R8F=_V
M%JHEO=BN9^K.]C9!Q*FYW3G@J!:VB>J[1K71/?T8I6HS*M47JOV\(G_)6.5S
M:+H,D_G-HBCS:O$JOJD1BL._^K!\(MEBE@1$IE$<P!!+JJM^)S E"8(B020)
M4RP\NYP1E\)-C;'6DH(M4<&OM;"6X51.)]&,T]YK:@9W&?>:%6L"' (^IX3I
M5,!1"78(:'<)>9 Q>E9:?1:Z.]#BX?J[3GK>Z@?,)&*"I@@2#PN(/-VLC:,8
MIK%/J<"8<+O6S4='FAJUK@4%HI'4L@/S<4S-R-$)4@,SW0:D5LA!#N=/0N&V
MLNK1T<8MJGI*Z;UZJB=OZ.$EO5R0Y_*U^"E;_BP6^OF"7R[*[.Z#K_Y#'I:+
MK"CU#^B2OUY=8<_SXL93X@D9^5AM'5/BZ^H#"8$T%<J8"R,<)D*&D33*H#E/
MC*G1BA82WGV /OCAZ@I6@MJT'NX_'08^P%% 'OKX9ZT#7"L!-J!O% &M)EL3
MT<=IV']&+%R)H\S,2 [&@6?(SO=X-K"='LG^3Q_/3WDV F^\E^<_S=T:]>GR
MY_#G^_]"'DY0F+9?78P"7?4MA,PG:EE* J86J#"&<4)8Q#QESX;HW&7IX,B3
M7(F4I# $/VP)ZV U.@Q\_P7H;#A'6W/ #J,=@-?A&G,8Y_.7E;/Q'GTE,<!]
MV 6C$[(^:\3A![[[LM"II\E*T/V ?MZ+KT+M<S*F1K@BA6YZI?^C8XQ?R%R[
M2 [_M TY"'!,9!I /_$X1)&?0BJPA"GV:9B0)(YI;./@.$>8J2T16L@J\+[Z
MRY:X/5W,9TV4F==D+/B'/D;KC[RU=\4%9$X=,&<)-*J/Q@5TNVX<)\_LF4"L
M#P=OBF(E^(=5OFX+7.6C5;_;*7+)9RSQ8QRGBBZ)D!!YB$-"HA2F/HH2GWLI
M$G9)PK823(TRZZ-5D%4J@-5"@0]$&U)311: 9W6#;5*O]<28L>6@< ],D75\
M4BT\J*5?%Q5N\G3K2QH=UH6%7;9.[XN?V^Q::RG&S:#M"])>EFSO!]G189&7
ML\_9(GM:/36VAR2*SCQ$((YTP7C=.8SXJ0?]$ <I#B.$0B.:VWORU.BK$<Z,
MG?9QZF:=L[0?F$T:N1SZ%X]JV_7MJYNVOGOUK]UO?O^IHWS+1Y5IO]'C%_1,
M+%)[19[-5V7VLM5DYOH[FZ^XX+HWC4X*6-4NAEMY3?*%(H1",4*U G]:5P#"
M:9!PP83:T$D/HH#'ZM,5">2$IJE/94@#J_V=*\&F]N5OZ[5=,+'5K&X/M:6;
MSM]KM=,+;QWL=T8])V=3;F;[O,=$#NZ(''$.[7.E' /N-I7*E7#C9EHYAG0O
M$<OU\\\IU+F.;ZA*^;75!5Z;)@S%AY7XFR#YM]^6LR@@,8U\!H.0$;4KC1"D
M:4B@\-(44Q;[4OKVQ3N-QY\:M:M7/NQ3LM,<<#/&'1#&@8FU+>VYB7=JBGRN
MQ;_0::945'7,+X#6 "@57!?\M,9N@"*@YC*\0V%0:X .%PNU?\Q ?<].=)O9
M"N'_NIS//RYS_<M91 ,O#GRL)E 0W34Q@MB/&&0I\P...4&)5:[],&).C28;
MU]W]BOX?P4K]/3?B.VY@UF].#1UZ[SY30WO]#!J2F?8CVU(6_*K5!8V^+FOS
M#3HAXW87ZR?JM+J(G06W=;>P\T9[GS5%22%%5NH6Z9<+?OW].<NK)YCU4V0^
M2R7R(_5R<0R1,K<A(<*'W L0I0'U&;)RM[RK-E-;H;:4J0Z'&5$?Q7Q>*S1.
M]\U!7YYQUKC17HG?T5*X^V9MH3+-9IUCS/&D5M?S-/I=+<).)L_U6NU&*(?^
M+_W'EV7Y-U'JS&ZA9H9_%0OQ&YE_$_F3/XN]A$4AYC *4*HV@4A G"0(\AAS
M%'!?QCP]VPEV0HBI+:"5O""O)01J1,.3SK,FX@SGF$-XW\U#5D&NE "OH@1K
M-2Y HPCXUC4+;OQDAC .[RP[)<C[>\P,H3)RFYD^JQ\IWN5+-5SYJFOCE)J2
M_['*GC5K;[H7X$ FOD<#&*<DA(AC!(E ,?01]OZ_[KZU-W)<3>][?@6!!-D9
MP#PK4I1$;8  ;G?WK).^.-T]>["9#P5>V]J4JYQ2E<_X_/J0DJI*=2=5E*P3
M8/>,VY;(]WTH/GQ)OI>(H@A+[E5<\'*78R.\M<2;]-F5N#=@II9^S.> MAO/
MA<6P9U9;"WM3I;]:[J+8:TT'=YB"LI9#MX-RE#L,^XSD\697_FD*^K12ZMRN
MEH_S1?%W)2<\C[!*X\R K# D:9)#+E,&A18D2R*=IYF79^SY[L;'.^LB5;O9
MM-A&XN[)M"X [TI#H>#LG8+62.[DU );84.2C@LH@0GG;)<#DXV+^H=$X_16
M-Y*ID]U^7[)E72EL7N?N;K(L<8'BC'("!<YM3NT\AS2)8R@UCZ(T0:E07H>M
M9WL;&\74PH*-M& M;L?@I/-0N[%*, ![)I4KL/,F%2=,@G+*^1X'I10GY?<9
MQ>VE#H'R9D;.%W:X7C?64..XS2(N,L8SB D19J>$!&09SV$6J8PR*E#"G6HY
MG>]F;!2R%12HM:0>8=FGX3S/%N% ZOM09XM/:]?C'[]^&BB/8/4@@ T4F=X-
M.+](](MXG T[/_WV<#'F%S78"2B__'3'2(,75DSM1O[C?/&=3=5NH?E6*8+?
M%O.R_'VV4&QJ+;O?#!F_4WJ^4#_8GQ.42BV3F$+,A2%0;E/DY0C#!,4R%[&A
MU<PIK4A0J<;&MY6L8"LLL-)ZNE>%&2XW<V[P0>B9SZW\K;B &[!1$!IA86E4
M-+]KU:<Y.F W@%>Z :-<P.B D%B'#0T((MFP<0$AP3P("@C:>#?2WNMS3Z+J
M7':"=,992CCDJ9*0Z(C8$S@.,XY1FD:1H!3[4+)#GV,C7(<)WYQB>VZ67?!W
MX]C J+X]@UX$U)L:/2 *2GPN_0Y*:QY [).6SZL=RVJP\O'C=/ZW+T87\^/]
M[$65]B[T=B:;O,WF9[$L7BH)WA>EF,YM->=-6N X%EDN%(8RJA*FQ@ED<<1@
M1B.4,"Y2DGO=5EXKT-C(S.@!K2*@6&M2W<?IM2Z ;93Q3-5\]="Y4=V0 ](S
M#U9IB:PN-Z#1!MSOC,I&(;#5"&Q5ZB5-="A\PQ8-N5:H80N+!(+PH/A(J';[
M,!?OYC,CRVJ^:AFKM@CGP[PL[#D1PI_-$X_EU\6G^>RG/;42,E,,QS#**(,$
MFVU_'O'$;/9)CEDF19X[G9;V(][8>!MA4 MHALSL*)79&BQNP$=6+.H\/2$M
M3^^A#&&D]CE ;V_/WH"M?NVC *LA6*MX W9&N=9S* NX*_X#&LO>(H[(KNX*
MKY\)WKD7OQ5!JL(67K$A5]]?G_A\.HG36(F(Q%"+"$,B;<4")1"D489B)!&2
ML=,QP4'+8^/A1CA02^?&NH=PG2?,JT#HF>L<]7<FIY.Z'N&54HF__)R__+-Y
MIZ84\T/%)!6''+8TR/0_J<!ZYIY^(+#+[A>UG$@4R5@G'%*4*)N(5T">$&UK
M+1.DM$X1]4K:<:ZSL4W-'3==U8>;KD58T QSFN8PU:E!6.,,,HPH9#F-N):(
M"FP0GB_9=&"$-UWV./EM'^!Y$)S=;,I0Z/7,FF==H,WN_PQRX9R>6Y ,X^YL
M.QR'HW-+=6<7Y_8[@0K"36+SI21*YC"2J89$I-2829GU9S;&DDHIS:@7>1ST
M,$[&F!^4@;NR"ES7ZF\CHH3#JF\]EGKK9=X?]O*VI=U.S?#3#W8,)&TR&9G]
MU]UJL; AKNLC;)XF.I*)K7Z@F=D&"099DF"8&6LLSY20&?<J_'VZJ[$97XUX
M8+J5V//^X RL;K,]#%@]3_N6D#=@#5H?Y_B7T0@;J7FZNV'C,2^J?1!U>?F-
MSF$'"QN]^5[5_[V?G<B(-LFR7,@X1Y#%F3$+I#;;":IMO'D6*\RS&,5>1^'.
M/8^-1;:+XK2*>&ZQB7<<@B/V;MS2"Z(]4\U:9O#+6NI?;1J2O>#R;?;%H-$*
M?FB%CEQP['WH* 8_4(Y$-'@VT$\E*'O]6!/E)",)II&Q=U!&,T-75$+&XPBF
M)*=Q(GF<95Z%K=V['AMS;24']FXV;$FG%N)N=-4/CCWS50O"DY6;:D^)6O3A
MBC<=PC5HJ:96]Z,JS'0(BV\9IB,MA"E=^K_5?ZRF;%U$.R<IIRR#&4L))").
M89X8EJ((XYB37"3$Z7+*I;.Q\5*K4/#/37G'6N#K:F?N('R>E4+CUC,/G8$L
M4-W1'>RN*S7:%</AZU0[?WY7UQ(]AHEO^="=-MZT8N@Q;2X5"3WZ3C=KL&YS
M:KC[5CX5MO2T-3E?5'.8-M$9(3*+"912<DAB&4&;&@WF>98:@Y#@./$*G[_0
MW]CXM1&W,E;8CL!^)N EF-WLOH#@]4RR;=QV95V?AX<S[QQ1"6K37>IS4$/.
M$8!]Z\WUM2M2++>S-T]4HED2\1P2F2:09+RJ-\5AFDECPD6$$BDGSU6>R.]+
MMEBZ$<I!/SZS8+^W_B9$E?CD<3XU );_5&UY['7Q._6SF-ER,. =F]I$Q=TS
M_ASBS25*DC@34&5F"T\(SB!53,$$(9:*5!.>10W>'V9R,+37?0V-]8<ZB7T/
M0+N1]U70]4S7M6P[V?X#YRD^IGCXW,$[O0R?S_>8DD=S[!Y]\&U2V3<Y>*V7
MZ=F\XYAK1J-<&R))8DB27$"&L+$+>9Q&.*(JEUZN9P/)/3:#LBZW.V_*[:JM
M$C= U03%6P3UUJGJ73\.#P8<UY /P:N!TL]_:'\K_S!)YCW';%3IY%UE_X=*
M'.\Y(*%3Q/MVWS'.V/)FE0K'[&=:PC5G<IP@D25I#D6&S4Z$\!32B*60L"R*
M-4$IEUZUO\YW-[8E:$=:\$V5RN#[",P^$+Q7+VHZKU,QW?Y<*.6>[<L1>K>5
M(AR@/1/\+I9M5@^7R<H/E+"!N>>['#;LUDG]@Z!:M[<ZALQN8G"_ZC8=?E-5
M;I>[>;DL#]BP;.5>CW%"HTQ"1A&")"?F)\40I"(3"$5)C/QJ$%XIS]B(JMZY
M@WOS><RJ^66=N#T]A:X=(C>^&A#X 2W6C27:IK5>,KD'PB]LL.J5,@T;G1H&
MP(-PU$#-=J-7&_Y>1;_?SYY7R_*3-4[BQH[ *-8RIA3&L6%-DC,"69YBF'%$
MTYPG"@NOQ%5G^AH;+7XO?LX*70@;:?3[;,Y+M7BIBBS4HH-?*N%!['E6< YM
M-Q8,A&'/#+=-JG#3(&8+\%2(]6"T.6 2E+7.]3<H(SDHOL\V+J\$#JJMTN]-
M=,1CE" .629MW);Y'Q:I%$J,99S0)%:15V+2\]V-C4].!=;^M,(&"OFL<7:C
MD7#H]<PD%\(^?SN+7[C SQU8A@G]K+L<1_#GCOK.X9^[;W7,BBS$?&4S<OQ\
MF$\+81-VK$.:C'F2<&+,$Q$E:7WA36.9P)3&/%;$;.PRZ97J^&178V.3K:1@
M+:I+ )0OP&Y4$@:VGFFD(V+^V8,O@A$V)?#I[H;-\WM1[8/DO9??\$^H\[[Q
MR/Q?*[8P\W#Z^DT]SQ?+"8L92V.<V3(2 A*6&-N#D1QBA5/K'L-U[,049_H8
M&T6LQ00;.4$MJ'N^G5-HGJ>%0!CUS ?^\'BEX[D 0*?$/*?:'"Q%SP6EVLEZ
M+CW:1_;$X^FZ6FG [:\G4I,H$Y3 /,H))+G"D",M8)ZDA"FA<9:@R4S]M"_\
M")4YT4DTI]F1U[/C0,#^9LI!ZGTKJV\L:8B1<SPE'F@@1I06\70NQ'8)A4]!
M-TH!81XP^Z&;7"-*>>@%I%^>0[^FK_";XY<=&?@)1X:6!]^>(\,W96N0F=_;
M=(W6:ES5Q9SQ),\2+C F,"&IV14*GMER\S%4F4YS))*8*>;M0S>L#F.S)3>.
M4*QQA%JL)0=B*WI5QOYFXW8WW^I=N=F]*K;HY 8\\/?CMLR,_*L8\ +S6I>[
M%A)'7.XV:( 6',#B$=C][FW&,KPKWL!Z#.^6]S8#==1%[XU$Z;86?UG9.YZO
MNMZ)64/@N_I9725/,")<$JQJ[Q@2169WI#([<6D2YYPD:>:5<NMT5V-;V6I)
MP5R;)6TM*R@;8?W6JC/XNBTI85#KF?FW@&W%!-\O >9-R9>Q",J<9[H;E. N
MJ[W/0PYO=+YW6:P,=2WF6I6EH2PV_:@VZ;TF]M8VIYF$*1+$4$::V6.4#,J4
MDSC.<II'7B'+Y[L;&VTTTMHTOAMQ@5:^IR(7,':^?@F$7/]7,!5H;4F!%763
MQ"_H-8P#**&O8LYU.?1UC(/Z1ZYD7-ZZ,I'O7NXXKG+)XHS#.$4Y)"DAD&H1
MP43EC&>9B**$3(QEQ.>N5!(@JUR[O_XFQ*>=_'RG<\=YX1E+R3 5&J8I3B'!
M'$,6)8FAZ"S&66H@55[NSO\@60^K),EA$'2CW?'G+MQ+4GC31Y;"(7,2CB(#
MH6>^P7ZR"UX;'W9Z\[D;<9KR6&.%8JAUS"%!:0X9CA.8*H$%0CD7*>J83*)_
MZ7UFXL I*HZ=D=IBUNL\%6.*3G;]5A@R'TN$$S-Q*8*$4FW6<:YA1!6UZWA,
M4=XI$<88OY2!TFL<_TY&&,+N^I%XG*V/:]C_OSE/'VL(N^>8C2J$W57V?Z@0
M=L\!"1W"[MM]UQ#VIZ?YK.+:*B9BDK&82<08U!Q'9C?*!,P1IY#&.DD(123.
MO(ZU]CL8V[:IE@^45L ;\%^BOT01 L]L 5[JV)TDBFZB*&J2. &V6C[.%]9G
MX ;@[(;$\>8O,VE_$R?I^C=%6=K3'ON']E4P6X+_L9JI__J?41K]MS@R[9A)
M63WU7HDJ#*7Y$ZK^9!XPC3TK6Y)733WWR ?#Z[;^7#-H/2\4S7A]K\=K'6!5
M(1TR!OZX_H&CWO<Z&3C._;B*AY'M)Y[S]TW^,%N:G5^KP<,<9P@SG6:$P00;
MP @6QH;&"L.$:Y&GN<*:45<WY<O=C8V+:HG![B=>2^V4,ZT+XN<)(3R./=/#
MM1!Z^3B[(]/)W=FA^<$\G]U5;3M!>[S5\4I_/MN4A;N?B?G3)M5M@K A$\1A
MCA&!A",$.=<8:D42)71$XXSY%,D[V9,7B0Q7+&_Y:';"125HAZ*:IW%UO,D/
M@5;?%_DM&4$M)/BE$?/TZ8'_1?XE*,+>XY_L;=AK_$M*']SB7WRA&T%\>'J>
MSE^5^JX6+V:W='Q39CI_4:7=8-G]5UG-H/;?;0**+_/EOZOE-R7F/V?6_'^H
MCL$^SA?-KZK"Z).<1YAGPM!,PB0D.D:0YED,(Z85%5DDI/0*\1Y6_+'90P=>
MM_798\OY5L\7@#W-%\OB[_5QT5R#U6RQ41.(]EF2,$!T]L0=^$MRX]GQ?A\#
MGA<>22!45?BIE5X?#UHMS6^79O"78*OH#:A5K3ZEEK+A%H"W&:.@J\K *@RZ
M5+W-\.RO?V\D18<Z20^/1BQT9_Y<"#;]L2C8]-XV6TG0)/(1**:$$P[-HJ<@
M89I!RE@$*<6I4C&6223=7%I<NQR?;TLE-$! -&*#I97;F.1KP3VJ_[A@?G[!
MZ /'GBE^#>!:7E )#+82=ZFCY(*D1RVEP(@.5$\I +)^Y94\8#I;8LFEG>'*
M+'EHM5-JR>>]#@3]L5B4RW>?;F^?GQ?S%S9]__GSMP]WS;>M9!IIR6*((I)
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MZ]7==OYN>_?>BF7Q4BQ?]W++V[@1EJH(8I;84IAI!&D42TATC 4B*L*\8SF
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M 5?"-Z<PHJ64Y\WP0(/N>'<\OJ'LF<YO'^[O;HZ?J&T/-VY K=D-V+"_GB_
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M.?T,U1-@NEFFUT/4,[77Z-02@DK$'O:ZYU$(:FJ>Z&I0V_*\NOO&Y(6G_1A
MJF+R8;8LEJ]FMVR^$UM<R^R1_W?Q?#>7:J)RS+5F*8PICR")"8<LBQEDUI^9
MHDPD*7-A@//=C(T!:DE!(ZK-#&*%!49:8,5UHX,+R)ZG@W!X]4P'7:%RI@0W
M)(Y00JG$7W[.7_[9-%"S@?FA(H%J^E]H=I#I[Z;:>OH[/MUA\WBQ3/UF5V3]
M83_.I]/YW\RF]6.Q*)>V;)=:B()-;<S:U\6'/Y^+.I?U5_WCT4S4<OEC7OU2
M/1A[9K:<T$Q&4L3*F!+,&!4Q,S]E6,$<YXFFB?F;=$H4-[SH8Z.IC6YUZ(1>
M:P>T5<]>^3;Z@2I1R'P!U$9%F^5@^:C U&@)EO/Z+PH\5XIZ1V&\P6?DL(4>
M[<?1,R<W>K<O?F_ 1G50ZWZS/>NH0B[ 1G]0 0"V"  + ?BZ %L0P%<-# S
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M 0:B$1HLK=3&*%B+[7'3XX*WP_U;8!1[IH,U@&MY024PV$K<):S0!4F/^[#
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MU6W2MVWD?^S#!FOLWXK: QO]3U?P*80ODTWE6]7WV_+S=$Z+36G?+\Y;^Z[
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M\=N :R<M= BE"P%-7/#(E0E@- 4[2D<#M.DHF&:2. A:R=@F3_L(0>.F-,:
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MQFC[B;D#H)"!7-;'!5_A^9]OYO<S(>\7L]G/B^4?89DG/N2052G ?!VQ45P
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MU0'^[O2=:Y]BMH0#78=#F?J.MW0&HN-6<";I)&KC2^S>W=^R-?5HB-I?^AU
MYWZN@0L5,F<.K*FY!LT*^,0%6,UM2L8[SQMEI_N:(S]NQF<7+1P8H;^>YU;Y
M'IEUU#%8$#8[4-$E.M&U!1.]%)DEXJ35:Y)[Y7M:-F:-F>_910^#HNEH+Q.\
M#*O//\\6?PSZ",'UAS9^;^ 1ZH<ONKY:Z,9X))70$C1\?4)3)1/ 2V_IT)(Y
M8A0&59O@["FJ!G"(ZF>^6RZ^3DE^/YW]E<*1-_.K49HOTGKZ]7QXR94<<F+*
M>0%D63TH"CSJ>Z(>C!7>&*<E*ZF5U[0CK9W<J!V*I@?\J)9*Z\#9NNTI"I&D
MT5:!B[*^8%LTQ$Q!;@D8:_2AN6MS@;N[G]YN]&1CG3_IJN^B@ [0<ROY4K,E
M\S2=X2V6/BYVE6;TJ8X1R& 3<:Z$DN"U3>1H<"695H[K-F:O!3<C#[@\+I9'
MAT,'6^(5TLIINE$Q_7V&&UW/\XN3Q7(]_<_-]R>9<UUR<J!SS<JS$B#Z&"%B
M+E([Q[-KT]NP#77CFM_Q,;1HK- 105KCC//(/M[-AA-']6(IS!->-+S1=_X6
MELM FJ 8\"(QOGJ[?#D+TY/5I(Y!MHYE$%YO C@!(5@-23#)N<.B,'TKRAF0
MGG$-;3>H'4O#'5C>Z\F0UR,AW\R_XH5>)L&PH+A H)U:*! ("(XQ\JV$-:64
MY&UIX]Q^@[!QRRRZ06X+->Z.2G^.RCE^J@F18=\G^;6FV=[7,1MO"\FP/DZW
MOGF*7 YRS@JM,I$BUJPM**S]?"$68#9IEYV2IE&;R*Z4CEMXT1URFRJZ P-[
M/V-\Q?'%1?N5&'FV,0@7H&030"F*)WS$!#I@)C9Y]*+-C<WV-(Y;(M$=>!LI
MMTO8/C0X9K-))SH[8PJ=)@:-JA+,$&,=J<\#S]&F5$2;=Z-V(+*WJO-A</)-
M. ZCM$,]@H\-8?ENB5_"-+^Z(.ORU8CY>>OBAM?51 N*GER.D)GBM=G?0B G
M"%BQOKXD00?'L1"Z#;V]U;0?":R#J[)GW+Y(:7%*!]F[<%:;YFIN)*7E*1$X
M#7$ZVYQ1$X<AT"EDH7A&FU09"2X)#Q15&H5><F_:#(39C][>:M^/A-O!5=GE
M^7_;4;]D[6SB6/!!&0>VSH53EEQQ[YD$)EA"5+S8TJ9[>FL2>RMU/Q(LAU!8
M!TC<_CIF(K%(FVN)E;.QO@XF('I>2)RRH"E:Q-AFR/3V-([\RM;1KVE;J*Z#
M-T$>X>P\Y?:(("770I0(WH1$VTXY<)$9",Q:CP:5;O4TZLZT=C)-X$B%*4,I
MK0-;21[(95-'^H_3Z1)?? W3675*ZE5%F.'U:T^O,-;!KH*V'?%CM-0D37)/
MHK((5@I._R>1-QI_OB.A71:W#(:;Q?&4V$5NGP1)CD9>U7'$E1]RF'\+Z\K2
MV=OR.+,3;DTJG-@CQXA"/\;K'&WCP::DLPLZQT8/T.U)<)=E+,U0>P2E]FAA
MB6]R9]9G[V9A7B=HUTKM+_57)MJQ**,0D'.NB67!('!I((OB@Y'"!'4DX_HH
MC5UZHT>SJ\.HKI\DT_;RI$@S:V2Y@*#=!TIN'B(H 9P-FGON5&@TL7%[&L>-
MVH^,S4:JZS=2^GDZ#_/TL""E#!0$4AC(M$[U10Y77\,R@$'RE!TRWLAP[D[K
MN ;TV)'24$KKX1R_Z:X\. 2".YU-] F2R )J%Q_)K]3BF6*29MKPZZ?FVWF;
M>X_N.'8T-!@VGO(K#U94!\A[CU\N')&WY??%&B^O#2;**YD#N;XF!Z*>=B]$
M'>N+XQ3A&99D$6U>RWB,HB[CEU8X&T0MW?N"#TAO$B-3S(@$D5FLH\A-??M*
M0&$Q1H]6)^-'/FZ[C%-:(;&1ZCKP!2M;]7\UT/H:9G6SO2?_=CE-A/WZ PK"
M;G_CQF^>3Y>Y?\V59J>UT_[UG^ESF'_"][2/7I>"]<4LS,(:7L@_C@I4B1K(
M#Z>@#CF70CFN1)N>J./R.6Z@U,P'[1@LSWTK3339!LXC0DG1T9E&EBE*&2%P
M;YWS4FG7IECZ(++'+3[M$^@[J;*;$:"'L6PY[4>!"+QH$K;/=2J/%<"R3X5;
M(21OTPC8'KW-1G-UBMY=5-G+>)S3+U]F&U&&V:4HW\S+8GERKLRK8AXI<G!.
M@BNZSCK-&IQU#(I562(=*[:$)BC=DL!Q!WLUPV,+]720-7@SI\^B;51'-%*
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MFFD/_8SM6;V9_]OTZ^+CXL]I6LP6G\X^K$_S%*_:%IT2S&A/@, ,BHD,,<M
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MW=M,[KZ^TTW,&.$*AQPTJR(B!T=E!$V'I1/>!LO;I-AW(G/<F*EUXKV=QCJ
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MBAZ"D.%,P]]P^NESO=CYBLOP"2_=V'?+:<)JR<J%)0O&!B?(=&FA8WT.24)
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M9RW3SB@60AUEB4IJZ[3VN5%4\)]9VAWQVVZ6=A<0C,#5^GQ6G11(#J'S++L
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MMDGW?RWU$KEP+X)!YGTII.*6,R]JB:\KX$PQPKI&&;U_ZB4ZXK==O407$(S
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MCT:GR<ZX10S@;39GM[F>I5*,93T$I0J%T-@QUZ!\*.0J9SR?LS)WII0P&$W
M]P/$B+,,5P!.RA+P)=.&Z4PYYG20VQ#(92RM!:622,9O)?9=TVEQ3\ 8;)GZ
M9H(]2"!6!LT#8CF6PQ(A#9M-5#QAMJ2/U?J9-+)20@YDRJ;H,M2P9LI-X* M
M9.P-)+T%3-,";DZQ3+#1?#T,KR+AW3])N&2)RA%2RLXJA'5D&^)X;-:>JSQ!
M<7":*/ ]3DL!G4C36KSJ2+&B@BH090(( 2=-5PBH@F\?; V0"3^JU$FB3"&
MM&ODQF]GO3TQMQ.6I'IF%Y@P<JPLVC0VXG0SV TKZVNIM0MC-JQ]%=G=:[+A
MO5"\?8,YZ?V1K?)7L3G!7R>)PJ4/TH!Q(WTZ$%XU2B6%C4E@8)0J.R%Q$LM0
M^E3^="V4C5-M2ZPC4C Z#7DIC(ZEP&W+=I &(9'7$.O^73SA^5BR4]3;39E"
M(NKR1K2_(W?]TFA?A*MPJ:B'YP$/I)]14:[!)*2-;'EVH[=OHG?MHVJW9#=<
MKFV98$OR^"&,($&=XOO[7J?3W'\YZ."[[$):#$B(D^?)YY-8)PJ/>6FW7T)<
M.I)(2+538&==&BA $4Z5]:4-*9E[/31:K$AAG5B,3+G/<$7/J]S4*]*AAPH$
M 5NL3G%8<-[0D55"<:/( 16:B*>ZG#25EHC=%X3U7< 3 4X\, A'$;^HP#"@
MXC+EQ%]PRQNQ:A!8$=K->I?$MY$D05 ,UDOQ_93RLG S>HB;K4MS S[;%_76
M* +RIDH0.+C%\9;8BUL BV8#0@PW8I$]X$GQD4J5FU/7>&Q;PK)/M,]A@.$]
MT;79PI/D7>5049H"&+*^R\6Q-L(;X*>,L<S1O%) "4]D01@E$4Q0 2[ LBH\
M3[T.P,2[K#_E:>FKD:(IDP2-7DT1!_M(PUYVJ2W8)5P^WL,]/K 0S&##I##2
MI7O:@FWXCR^E)8U!R?-S(ALM!BP/>1DB 7M\>FF#5Y!B 4X(T=O, IT.JA;L
MGSR:ZH=,$)KRTW1 34+'<6DHX&N,_(CJ3%N'^_0K '39&(JJTQW;>6)) N2@
M4!](5]9CUI3^=$,'G[Q<VK4;K)IPNVQ?Z;P:+CS<I/ $Z"-3D=,<!YE;F5;G
MG<4B%N3KVP;K2=K\WR#V@B;9_>^=9/W17BR@65\5(W'#.C)6=4FY_8:6MC&,
M+$WC&$B<-G;91?P-J,QP"'92_@GSC33Z%#T7"O9Y)3N #HC&$I'A7QJ+%J"7
MOY<*YGN EWGLCT6[KVA,/<4QD1J_0F9I$J?I/E82J:@ZP')<G$E^2Y0>&J\G
M=3\R^)\>%D?&;TIP-=F%$]$C5<L%%EJY+-HGP5 -&EB"C&(>J(>^8M%4PN_(
MB(EWIJ+-1P_7KZEG8(X\16M(#,JBCC!+7\E(E/]EILIH/9"JRJ<ZG4IBUIR/
MJQ^83%7\,BM2/9=X.IOH4/'\'EZ0WV_I/4]BH?ER?ZWU$;U T'S9L]-R7%H7
MFL]A/;QTV3#^QQ@9C'HNDB/MG,YZ!->UV"[1>_]EB_-C?J5@A-J2I@%W4EY8
MV5M\.4(7*%(^[ZG<&^47'4VI<:#)5QJQ2?5RJ'O8/&QWZ?V0,_@K%NJK5T=-
M_^JHY<3FL\,#K'SZ<;L9+9^UO.Z@'W;:@N<?:MW:8D%5O+U.<<>B^ZY3/3]B
M_/\?>.V0TST4DO]<?U^P3/(6OE9I\Q54P $ZOK.%Y7^;0'RG\R_)/Z^QIQRV
MBK?P^'RB9,+Z=S(NZ3S%KL+X]9=[_R/XRSN\<QT.Z&@,3WK],E*S^^!=]C(5
M+<]]CY#O^COR0H?_(= +/[M-Y<9;\U7I>JYNKY;P$>JW=)M+GGG17GV&=_[^
M?Q^<_!=02P,$%     @ KH$)4Y;:-(/I!P  42   !L   !A;F%B+38S,#(P
M,C%X,3!Q>&5X>#,Q,BYH=&W=66MOVS@6_;Z_@N-B.PG@EVSGY:0!$L=%#722
MK.M!9SXM:)&RB5"BAJ3L>G[]'I+R(W'2N%WL-DV!.I9(7M['N>=>FF>_7-WT
M1G_>]LG4II+<_G[Y<= CE5JC\;G=:S2N1E?DP^BWCZ13;T9DI&EFA!4JH[+1
MZ%]72&5J;=YM-.;S>7W>KBL]:8R&#2>JTY!*&5YGEE7.S]P;?'+*SO]Q]DNM
M1JY47*0\LR36G%K.2&%$-B&?&3=WI%8K9_54OM!B,K6DU6Q%Y+/2=V)&P[@5
M5O+SI9RS1G@^:_A-SL:*+<[/F)@1P=Y51+/59D>'+<X['=;IM,?CUF'4BN@)
M3YIQS*+C?T=0LH'I88VQ"\G?55*1U:;<[=\]:N7V="Z8G7:C9O.?%3_O_"Q1
MF<5F&HO#UR!C2U+-\+C&OUA-8]LU19I2O3BU>%&C4DRRKC>R$N0MU\1**MU]
MT_3_3MU(+:&ID(ONKR.1<D.N^9P,54JS7ZL&@<$>6B1AHA%_<R@*G?WCO#0"
M<J3(^-*HJ.4LZ?_Q87 Y&)%V5&^1^W9L^H+J"=QA58YED+NA? S_<_V#M._U
MAZ/!^T'O8C2XN28W[\EM?SBXN0*(A_W;F^&(_'Y]U1^23_V>G]!NMMRD)\U\
M*6:-/O3)IXOAY<5U_U/MYH^/_3_)16_D5&\UF[N'Z7^N?>>A]D<=:#^HDBN>
M9<*0WPJIU:)*8JZM2!;$3JE]^^;@^'07"PZQ64X9 S/4)$]L]V0)/)$Q1*=;
M._EA)D9U,B!3.N-$\YG@<U"8G<+@OPJJ 1NYP/M<:4M41MXKG9*H6?L740FY
MR&AN%^92J"H99'$=WCCYF;WAX=JJDTMJX -8FR[(7:;FDK,)KP:GE*Y@"CMF
M"J0/@51DA&8+4F16%QP*HPSXB@ ?49+B20LJ20+&)$H3E0I+K KSMB9D/.;&
M@%3=E)3><>R[(=/@'8,RV%+Z<H(]W(18:)0/3,NP')HPKLE\*N(I,87[6*^?
M<\U+(<Z 5!B).N-*UES8*0PT.8^]@DYN#M44@YDS+&-DO-ATPZL(>/LK ><D
M$1E<ZJ*S=F$5T<9T#.N-<9$E2 [J>@I\CV7!(!-AVO!7%2$6+J%R>-D!Q %'
MRC4"2N>;!UL#9,PW*U4WHY"8@+ KQ,9O9[P^,353DD@U-TM,:#X1!H4:&U'W
M,N@-+:L;H35+9;:T?171[=3)Z)XKWKXY;D5'IZ:,7\GF#OXJ200>O9,&A&KN
MPP'WBK'DSFV$ P-C*<S437?34J2^2W_WS(2)I3(%UCE2T$J&N.1:Q9SAM2%[
M" /CB&OP=?]+/*79A),+Y-NPD)@1M6DM.MCC^WYI=,#"4W@4KHIG 0]./G%)
MN0&3$#:GR[,;O7T3'39/R]V2_?"XL66"+9W%#V&$&:Y2?'_=:[7J!R\''70?
MU=V@18*?/$\^'\2JH_"8%F;W)8Y+QQP!*7<*[*P*#0%(PIDP/K4QBV=>CFLM
MUJ2P22R:2^HC7-+S.C;5DG3<H !!0!>CI&#^2&**L1%,4"V< 2(4$4]UF9-4
M&$?L/B&,KP*>"'#F@4(XC/A%.9H!$1>2.OZ"65Z)=8' BE!N-JLDOHVYFPB*
MP7K.OI]27A9NQ@]QLW-J;L%G]Z3>&45 WDPP!PYJ<,!U[$4-@.5Z X<8JMDR
M>L"3H&,AA5VXJO'8M@[+/M ^A@&&]Z9N]!:>)+^4!N6%SH$AXZM<'"O-O *^
MRYCP#,5+ DH8X;G#J)N"#BK !5@6N>>IUP&8>)_T9U06/AN=-WF2H-"+&?Q@
M'BG8JRJU [N$Q\=KN,<'%H(93.@4QJJP3VNP"__1U6SNVJ#D^3Z1C)<-EH<\
M#YZ /CZ\;H-7$&(&3@C>VXZ".QV4)=B//!KJATP0BO+3=."*A(KC0CN';S#R
M(Z)392S>N]\!(,O$$%2>[LC>$TL2( >)^F!VJ3UZ3>Y/-^[@DQ4KO?:#5E-J
M5N5++LKFPL.-,T^ WC,E.2UPD+GCLCSO+!>1,+^ZJ[.>I,W_#F(OJ),]^-Y.
MUA_MV1*:U74R.F[81,8Z+UULOZ&D;34C*]4H&A*KM%E5$?\"(E,<@BWG7V&^
ML4*=<N-,0#\O9 _0 =$81V3XZ]JB)>CY7X6 ^A[@11;[8]'^*VI3+W!,=(5?
M(+*N$W?=?2PX0E%6@%6[..?TSE%Z*+R>U'W+X']Z6!X9ORG 96<73D2/9"UE
M6&CX*FF?!$/9:& )(HI^H!KJBD%1";\DPR?>F)(V'SU<OZ::@3[R J4AT4B+
M*MS,?28C4/Z7F3*BU4"J(ILI.>..63,Z*7]@TF7R\S27:L$Q.I^JD/'T'EX0
MWV^I/4]BH?YR?Z_U'KV"TWS:DXMB4A@;BL])-5R[;"G_8Y0,2CWGR;&R5J5=
M!]<-WZ[0>_^ZQ?HVOQ0P1FYQ78,YDN:&=Y=?3E$%<DD779%YI?RBTYDK'"CR
MI41L4EX/'3;KQR='[H;(:OQG2_'EY5'=7QXU+-L>.SFNGS2?'F[6H]58P\L.
M\J&GR6GVKM*N+!>4R=MMY5](=-]TE\\/E0\^^_]CKQG"VD$N^<_[EP:K2.]@
M<!D[GT8Y3'!G>++4_6?RQG=[X(49Z25VA<5N\0YF]Z:")^3]BCEO0B_V$SO@
MJ^;NW8:S.BS=LGE_V^B&IYQ'.&_S<CI7X6J^&W[MFO&MZ^IULGB*;*Z7T#$R
MIK#;2YZYX2X_PV6[O_8__P]02P,$%     @ KH$)4Z.Z'@S*!   11,  !L
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M/'+-IZ='K)3D+%N'KR*64PE7= 4W/"?%JZ;$QF .P=+:4+*O%($B9O.XVI#
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M(S*2OZ@K; SFD#RI!BK^%T.@B-G>KC8D,$[*<[8E%30,D_&'R\GY)()FPVW
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M$-9U!KL(([G%T"I4J5RQYGQP.?KM^GAX42+#\Y-*8=3'$3(4DB)++H3:C%A
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M8BTR,#(Q,#8S,"YH=&U02P$"% ,4    " "N@0E3CFI7/+@.  #@B   $0
M            @ '/;0( 86YA8BTR,#(Q,#8S,"YX<V102P$"% ,4    " "N
M@0E3ZE;5S ,4  #LN   %0              @ &V? ( 86YA8BTR,#(Q,#8S
M,%]C86PN>&UL4$L! A0#%     @ KH$)4X'QAS-G,   A00" !4
M     ( ![) " &%N86(M,C R,3 V,S!?9&5F+GAM;%!+ 0(4 Q0    ( *Z!
M"5.QN1-8H7L$ !PQ!@ 4              "  8;! @!A;F%B+3(P,C$P-C,P
M7V<Q+FIP9U!+ 0(4 Q0    ( *Z!"5/H(%L@4Z0  "3?!@ 5
M  "  5D]!P!A;F%B+3(P,C$P-C,P7VQA8BYX;6Q02P$"% ,4    " "N@0E3
M$<_4>P];  #K( 0 %0              @ '?X0< 86YA8BTR,#(Q,#8S,%]P
M<F4N>&UL4$L! A0#%     @ KH$)4_=LR*_T!P  V"   !L
M ( !(3T( &%N86(M-C,P,C R,7@Q,'%X97AX,S$Q+FAT;5!+ 0(4 Q0    (
M *Z!"5.6VC2#Z0<  %$@   ;              "  4Y%" !A;F%B+38S,#(P
M,C%X,3!Q>&5X>#,Q,BYH=&U02P$"% ,4    " "N@0E3H[H>#,H$  !%$P
M&P              @ %P30@ 86YA8BTV,S R,#(Q>#$P<7AE>'@S,C$N:'1M
M4$L! A0#%     @ KH$)4R[NN!#"!   LA(  !L              ( !<U((
M &%N86(M-C,P,C R,7@Q,'%X97AX,S(R+FAT;5!+ 0(4 Q0    ( *Z!"5-=
MI0^6IPX  *]G   >              "  6Y7" !A;F%P='ES8FEO+69I<G-T
D86UE;F1M96YT>"YH=&U02P4&      P #  \ P  468(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
